<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Interventions for mycosis fungoides - Valipour, A - 2020 | Cochrane Library</title> <meta content="Interventions for mycosis fungoides - Valipour, A - 2020 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008946.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Interventions for mycosis fungoides - Valipour, A - 2020 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008946.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD008946.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Interventions for mycosis fungoides" name="citation_title"/> <meta content="Arash Valipour&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="arash.valipour@kgu.de" name="citation_author_email"/> <meta content="Manuel Jäger&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="Peggy Wu" name="citation_author"/> <meta content="University of California Davis" name="citation_author_institution"/> <meta content="Jochen Schmitt" name="citation_author"/> <meta content="Faculty of Medicine Carl Gustav Carus, Technischen Universität (TU) Dresden" name="citation_author_institution"/> <meta content="Charles Bunch" name="citation_author"/> <meta content="The University of Nottingham" name="citation_author_institution"/> <meta content="Tobias Weberschock" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="7" name="citation_issue"/> <meta content="10.1002/14651858.CD008946.pub3" name="citation_doi"/> <meta content="2020" name="citation_date"/> <meta content="2020/07/07" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008946.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008946.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008946.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Acitretin [adverse effects, therapeutic use]; Antineoplastic Agents [administration &amp; dosage, adverse effects]; Bexarotene [therapeutic use]; Combined Modality Therapy [methods]; Immunologic Factors [therapeutic use]; Interferon-alpha [therapeutic use]; Mycosis Fungoides [pathology, *therapy]; Neoplasm Staging [methods]; Photochemotherapy [methods]; Photopheresis [methods]; PUVA Therapy [methods]; Randomized Controlled Trials as Topic; Skin Neoplasms [pathology, *therapy]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008946.pub3&amp;doi=10.1002/14651858.CD008946.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008946.pub3&amp;doi=10.1002/14651858.CD008946.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008946.pub3&amp;doi=10.1002/14651858.CD008946.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008946.pub3&amp;doi=10.1002/14651858.CD008946.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008946.pub3&amp;doi=10.1002/14651858.CD008946.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008946.pub3&amp;doi=10.1002/14651858.CD008946.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008946.pub3&amp;doi=10.1002/14651858.CD008946.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008946.pub3&amp;doi=10.1002/14651858.CD008946.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008946.pub3&amp;doi=10.1002/14651858.CD008946.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008946.pub3&amp;doi=10.1002/14651858.CD008946.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008946.pub3&amp;doi=10.1002/14651858.CD008946.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008946.pub3&amp;doi=10.1002/14651858.CD008946.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008946.pub3&amp;doi=10.1002/14651858.CD008946.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008946.pub3&amp;doi=10.1002/14651858.CD008946.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008946.pub3&amp;doi=10.1002/14651858.CD008946.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008946.pub3&amp;doi=10.1002/14651858.CD008946.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008946.pub3&amp;doi=10.1002/14651858.CD008946.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008946.pub3&amp;doi=10.1002/14651858.CD008946.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008946.pub3&amp;doi=10.1002/14651858.CD008946.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008946.pub3&amp;doi=10.1002/14651858.CD008946.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008946.pub3&amp;doi=10.1002/14651858.CD008946.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008946.pub3&amp;doi=10.1002/14651858.CD008946.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008946.pub3&amp;doi=10.1002/14651858.CD008946.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="z6k50IFd";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD008946\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD008946\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008946\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008946\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","ko","ms","ja","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD008946.pub3",title:"Interventions for mycosis fungoides",firstPublishedDate:"Jul 7, 2020 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Skin Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=z6k50IFd&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008946.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008946.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD008946.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD008946.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008946.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD008946.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD008946.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD008946.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD008946.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD008946.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4509 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD008946.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008946.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008946.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008946.pub3/full#CD008946-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008946.pub3/full#CD008946-sec-0205"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008946.pub3/full#CD008946-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008946.pub3/full#CD008946-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008946.pub3/full#CD008946-sec-0034"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008946.pub3/full#CD008946-sec-0035"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008946.pub3/full#CD008946-sec-0064"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008946.pub3/full#CD008946-sec-0199"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008946.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008946.pub3/appendices#CD008946-sec-0210"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008946.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008946.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/table_n/CD008946StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/table_n/CD008946StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008946.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008946.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008946.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008946.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008946.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD008946.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Interventions for mycosis fungoides</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author custom-tooltip" title="These authors contributed equally to this work"><a href="/cdsr/doi/10.1002/14651858.CD008946.pub3/information#CD008946-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Arash Valipour</a><sup>a</sup></li> <li class="author custom-tooltip" title="These authors contributed equally to this work"><a href="/cdsr/doi/10.1002/14651858.CD008946.pub3/information#CD008946-cr-0005">Manuel Jäger</a><sup>a</sup></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008946.pub3/information#CD008946-cr-0006">Peggy Wu</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008946.pub3/information#CD008946-cr-0007">Jochen Schmitt</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008946.pub3/information#CD008946-cr-0008">Charles Bunch</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008946.pub3/information#CD008946-cr-0009">Tobias Weberschock</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/information/en#CD008946-sec-0227">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 07 July 2020 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD008946.pub3">https://doi.org/10.1002/14651858.CD008946.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD008946-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008946-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008946-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008946-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD008946-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD008946-abs-0005">한국어</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD008946-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD008946-abs-0001" lang="en"> <section id="CD008946-sec-0001"> <h3 class="title" id="CD008946-sec-0001">Background</h3> <p>Mycosis fungoides (MF) is the most common type of cutaneous T‐cell lymphoma, a malignant, chronic disease initially affecting the skin. Several therapies are available, which may induce clinical remission for a time. This is an update of a Cochrane Review first published in 2012: we wanted to assess new trials, some of which investigated new interventions. </p> </section> <section id="CD008946-sec-0002"> <h3 class="title" id="CD008946-sec-0002">Objectives</h3> <p>To assess the effects of interventions for MF in all stages of the disease.</p> </section> <section id="CD008946-sec-0003"> <h3 class="title" id="CD008946-sec-0003">Search methods</h3> <p>We updated our searches of the following databases to May 2019: the Cochrane Skin Specialised Register, CENTRAL, MEDLINE, Embase, and LILACS. We searched 2 trials registries for additional references. For adverse event outcomes, we undertook separate searches in MEDLINE in April, July and November 2017. </p> </section> <section id="CD008946-sec-0004"> <h3 class="title" id="CD008946-sec-0004">Selection criteria</h3> <p>Randomised controlled trials (RCTs) of local or systemic interventions for MF in adults with any stage of the disease compared with either another local or systemic intervention or with placebo. </p> </section> <section id="CD008946-sec-0005"> <h3 class="title" id="CD008946-sec-0005">Data collection and analysis</h3> <p>We used standard methodological procedures expected by Cochrane. The primary outcomes were improvement in health‐related quality of life as defined by participants, and common adverse effects of the treatments. Key secondary outcomes were complete response (CR), defined as complete disappearance of all clinical evidence of disease, and objective response rate (ORR), defined as proportion of patients with a partial or complete response. We used GRADE to assess the certainty of evidence and considered comparisons of psoralen plus ultraviolet A (PUVA) light treatment as most important because this is first‐line treatment for MF in most guidelines. </p> </section> <section id="CD008946-sec-0006"> <h3 class="title" id="CD008946-sec-0006">Main results</h3> <p>This review includes 20 RCTs (1369 participants) covering a wide range of interventions. The following were assessed as either treatments or comparators: imiquimod, peldesine, hypericin, mechlorethamine, nitrogen mustard and intralesional injections of interferon‐α (IFN‐α) (topical applications); PUVA, extracorporeal photopheresis (ECP: photochemotherapy), and visible light (light applications); acitretin, bexarotene, lenalidomide, methotrexate and vorinostat (oral agents); brentuximab vedotin; denileukin diftitox; mogamulizumab; chemotherapy with cyclophosphamide, doxorubicin, etoposide, and vincristine; a combination of chemotherapy with electron beam radiation; subcutaneous injection of IFN‐α; and intramuscular injections of active transfer factor (parenteral systemics). </p> <p>Thirteen trials used an active comparator, five were placebo‐controlled, and two compared an active operator to observation only. In 14 trials, participants had MF in clinical stages IA to IIB. All participants were treated in secondary and tertiary care settings, mainly in Europe, North America or Australia. Trials recruited both men and women, with more male participants overall. Trial duration varied from four weeks to 12 months, with one longer‐term study lasting more than six years. We judged 16 trials as at high risk of bias in at least one domain, most commonly performance bias (blinding of participants and investigators), attrition bias and reporting bias. </p> <p>None of our key comparisons measured quality of life, and the two studies that did presented no usable data. Eighteen studies reported common adverse effects of the treatments. Adverse effects ranged from mild symptoms to lethal complications depending upon the treatment type. More aggressive treatments like systemic chemotherapy generally resulted in more severe adverse effects. </p> <p>In the included studies, CR rates ranged from 0% to 83% (median 31%), and ORR ranged from 0% to 88% (median 47%). Five trials assessed PUVA treatment, alone or combined, summarised below. </p> <p>There may be little to no difference between intralesional IFN‐α and PUVA compared with PUVA alone for 24 to 52 weeks in CR (risk ratio (RR) 1.07, 95% confidence interval (CI) 0.87 to 1.31; 2 trials; 122 participants; low‐certainty evidence). Common adverse events and ORR were not measured. </p> <p>One small cross‐over trial found once‐monthly ECP for six months may be less effective than twice‐weekly PUVA for three months, reporting CR in two of eight participants and ORR in six of eight participants after PUVA, compared with no CR or ORR after ECP (very low‐certainty evidence). Some participants reported mild nausea after PUVA but no numerical data were given. One participant in the ECP group withdrew due to hypotension. However, we are unsure of the results due to very low‐certainty evidence. </p> <p>One trial comparing bexarotene plus PUVA versus PUVA alone for up to 16 weeks reported one case of photosensitivity in the bexarotene plus PUVA group compared to none in the PUVA‐alone group (87 participants; low‐certainty evidence). There may be little to no difference between bexarotene plus PUVA and PUVA alone in CR (RR 1.41, 95% CI 0.71 to 2.80) and ORR (RR 0.94, 95% CI 0.61 to 1.44) (93 participants; low‐certainty evidence). </p> <p>One trial comparing subcutaneous IFN‐α injections combined with either acitretin or PUVA for up to 48 weeks or until CR indicated there may be little to no difference in the common IFN‐α adverse effect of flu‐like symptoms (RR 1.32, 95% CI 0.92 to 1.88; 82 participants). There may be lower CR with IFN‐α and acitretin compared with IFN‐α and PUVA (RR 0.54, 95% CI 0.35 to 0.84; 82 participants) (both outcomes: low‐certainty evidence). This trial did not measure ORR. </p> <p>One trial comparing PUVA maintenance treatment to no maintenance treatment, in participants who had already had CR, did report common adverse effects. However, the distribution was not evaluable. CR and OR were not assessable. </p> <p>The range of treatment options meant that rare adverse effects consequently occurred in a variety of organs. </p> </section> <section id="CD008946-sec-0007"> <h3 class="title" id="CD008946-sec-0007">Authors' conclusions</h3> <p><i>​</i>​There is a lack of high‐certainty evidence to support decision making in the treatment of MF. Because of substantial heterogeneity in design, missing data, small sample sizes, and low methodological quality, the comparative safety and efficacy of these interventions cannot be reliably established on the basis of the included RCTs. PUVA is commonly recommended as first‐line treatment for MF, and we did not find evidence to challenge this recommendation. There was an absence of evidence to support the use of intralesional IFN‐α or bexarotene in people receiving PUVA and an absence of evidence to support the use of acitretin or ECP for treating MF. </p> <p>Future trials should compare the safety and efficacy of treatments to PUVA, as the current standard of care, and should measure quality of life and common adverse effects. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD008946-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008946-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008946-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008946-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD008946-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/ja#CD008946-abs-0008">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD008946-abs-0006">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD008946-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD008946-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD008946-abs-0002" lang="en"> <h3>Treatments for mycosis fungoides (a malignant cancerous condition of immune cells in the blood that affects the skin) </h3> <p><b>What was the aim of this review?</b> </p> <p>This Cochrane Review compared treatments for mycosis fungoides (also called cutaneous T‐cell lymphoma, Alibert‐Bazin syndrome or granuloma fungoides). </p> <p><b>What was studied in the review?</b> </p> <p>Mycosis fungoides (MF) typically starts as flat and scaly pink or red areas (patches) on the torso, upper thighs or buttocks. At this stage, life expectancy is unaffected. As the disease develops, life expectancy reduces. Patches can turn into raised, itchy plaques. Plaques can become thicker, deeper, and develop into tumours. In rare cases, the disease spreads to other organs. </p> <p>Many treatments exist for MF; these target specific body areas (local therapy) or the entire body (systemic therapy). Treatments include creams, ointments, oral or injected medicines, light therapy, radiotherapy (radiation that kills cancer cells) and chemotherapy (medicines that kill cancer cells). </p> <p>We compared the benefits and harms of different treatments in adults, at different disease stages. We identified 20 studies published up to May 2019. </p> <p>The studies included 1369, mainly male, adults. Most ran from 4 weeks to 12 months. Only five studies investigated the later stages of disease. All were set in specialised healthcare centres in Europe (12 studies), North America (11 studies), Australia (three studies), Brazil and Japan (one study each; satellite centres for studies already listed). Treatments were compared with another treatment (13 studies); an inactive treatment (placebo) (five studies); or no treatment (two studies). </p> <p>Five studies did not report their funding. Eleven studies were funded by pharmaceutical companies and four by academic institutions or hospitals. </p> <p><b>Key results</b> </p> <p>We do not know how different treatments for MF affect quality of life. Very few studies assessed this outcome and they presented no usable data. </p> <p>Unwanted (adverse) effects ranged from mild symptoms to severe life‐threatening complications. More aggressive treatments (such as chemotherapy) generally caused more severe adverse effects. </p> <p>PUVA (a light treatment) is the first treatment used for MF. Results from five studies provided low‐certainty evidence: </p> <p>There may be little to no difference between giving PUVA alone and PUVA plus injected interferon‐α (IFN‐ α) (a messenger substance of the immune system) for 24 to 52 weeks for making the disease disappear completely. No studies investigated adverse events in these treatments or disappearance of at least 50% of the disease. </p> <p>There may be little to no difference between an oral vitamin A derivative (bexarotene) plus PUVA, and PUVA alone, for complete or at least 50% disease disappearance (treatment duration: up to 16 weeks). Extreme sensitivity to ultraviolet (UV) rays occurred in some people who received bexarotene and PUVA, but not PUVA alone. </p> <p>There may be little to no difference between IFN‐ α plus PUVA and IFN‐α plus acitretin (another oral vitamin A derivative) on flu‐like symptoms, when treatment is given for up to 48 weeks or until complete disease disappearance. However, there may be a lower rate of complete disease disappearance with IFN‐α plus acitretin. No studies investigated the effect on partial disappearance. </p> <p>It is not clear how PUVA maintenance treatment (to prevent the disease from reappearing after it has disappeared) compares with no maintenance treatment, since the only study on this reported very limited information. </p> <p>One small trial (eight people) compared extracorporeal photopheresis (ECP, a light therapy) once monthly for six months with twice‐weekly PUVA for three months. It reported complete or at least 50% disappearance of MF in some participants treated with PUVA and none who received ECP. Common side effects were reported with each treatment (PUVA may be associated with mild nausea, and ECP with hypotension). However, the very‐low certainty evidence means we are not sure of these results. </p> <p><b>How confident are we in the results of this review?</b> </p> <p>Our confidence in the results of this review is mainly low, but very low for one set of key results. The review is based on small and poorly designed studies. Further research is likely to change its message. </p> <p><b>Conclusion</b> </p> <p>We found no evidence to challenge or support the standard treatment (PUVA). In the absence of a cure, treatment of MF should be based on disease stage, with a focus on limiting severe adverse effects. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD008946-sec-0205" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD008946-sec-0205"></div> <h3 class="title" id="CD008946-sec-0206">Implications for practice</h3> <section id="CD008946-sec-0206"> <p>At this point, no exact cause for the disease has been found and no curative treatment for mycosis fungoides (MF) has been established. </p> <p>Our review found the following key findings.</p> <p> <ul id="CD008946-list-0032"> <li> <p>There may be little to no difference between psoralen plus ultraviolet A (PUVA) alone versus PUVA plus interferon‐α (IFN‐α) in complete response (low‐certainty evidence). This comparison did not report the objective response rate (ORR). </p> </li> <li> <p>Very low‐certainty evidence means that we are uncertain of the effects of extracorporeal photopheresis (ECP) compared with PUVA on the reported outcomes of complete response (CR) and ORR with PUVA. </p> </li> <li> <p>There may be little to no difference in CR and ORR in participants given bexarotene in combination with PUVA compared to PUVA alone (low‐certainty‐evidence). </p> </li> <li> <p>Low‐certainty evidence indicates that IFN‐α + acitretin may lead to a lower complete response rate than IFN‐α + PUVA. This comparison did not report the ORR. </p> </li> <li> <p>One study compared PUVA maintenance versus no maintenance in patients with CR, but our key outcomes were not assessable or data were not provided. </p> </li> <li> <p>Mild nausea was reported by some participants after PUVA, and one participant withdrew from the ECP group due to hypotension (very‐low certainty evidence). In the bexarotene plus PUVA group, one participant reported photosensitivity compared to no participants in the PUVA‐alone group (low‐certainty evidence). There may be little to no difference between IFN‐α combined with either PUVA or acitretin in the occurrence of flu‐like symptoms (low‐certainty evidence). Common adverse events were not measured in the comparison of PUVA alone versus PUVA plus IFN‐α (low‐certainty evidence). </p> </li> </ul> </p> <p>The interventions in our review showed a wide range of adverse effects, some of them potentially life‐threatening. Generally, the studies suggested that more aggressive therapeutic approaches led to substantially increased, and more severe, adverse effects. </p> <p>When treating MF, the clinician should be aware of the limited evidence supporting the different types of treatments. Despite a wide variety of existing treatments for MF, the data we extracted from the 20 randomised controlled trials (RCTs) in this systematic review did not provide us with much useful evidence. The studies included only, on average, 68 participants and showed heterogeneous designs, making it difficult to draw firm conclusions. Only five trials assessed PUVA treatment, either given alone or combined. </p> <p>In the early stages of this disease, skin‐directed treatment approaches are more often recommended than systemic or combination therapies because progression of the disease is slow, and in the very early stages life expectancy is similar to age‐matched control groups. In this review, we were not able to include RCTs investigating the effect of topical corticosteroids versus placebo. Despite its widespread use, no RCTs could be included in this review investigating the effect of UVB or localised radiotherapy. </p> <p>Even if the majority of the reviewed trials compared an intervention to an active comparator, clinicians and people with early stage MF should consider what is called 'watchful waiting' or 'expectant policy' as one of their treatment options. Treating patients at early stages of disease might temporary improve their condition. Nevertheless, potential adverse effects can negatively affect quality of life resulting in lower therapeutic value. </p> <p>Clinicians should motivate people with MF to enter multicentre RCTs, especially for advanced stages of MF as they represent an unmet medical need, in order to facilitate evidence‐based recommendations. </p> </section> <h3 class="title" id="CD008946-sec-0207">Implications for research</h3> <section id="CD008946-sec-0207"> <p>Research should be based on commonly‐accepted diagnostic and staging criteria. With the publication of the joint consensus statement of the ISCL, EORTC and the United States Cutaneous Lymphoma Consortium (USCLC) by <a href="./references#CD008946-bbs2-0157" title="OlsenEA , WhittakerS , KimYH , DuvicM , PrinceHM , LessinSR , et al. Clinical end points and response criteria in mycosis fungoides and Sezary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. Journal of Clinical Oncology2011;29(18):2598-607. [PMID: 21576639]">Olsen 2011</a>, commonly‐accepted criteria have been established regarding the conduct of MF studies and their outcome measurements. The consensus statement emphasised the RCT as the ideal and a goal that may be reached by co‐operative studies. </p> <p>For all studies, the stage of the disease and its activity are needed in order to refer treatments under investigation to a suitable group of participants. The inclusion of subtypes of MF should be clearly stated, and it is recommended that the results are stratified according to the different MF entities. A joint commitment of the specialised centres to high‐quality multicentre RCTs would be helpful to gain sufficient sample sizes. </p> <p>Regarding the two primary outcome measures chosen for this review, it is surprising that while quality of life measurements are paid attention to in an extra chapter in the consensus statement, no end points were proposed on how to measure or address adverse effects. This might be due to the fact that many clinicians do not consider adverse effects to be a relevant end point for studies at all, but still we remain of the opinion that they should be reported in all further trials regarding the treatment of MF. </p> <p>The first‐line treatment options already recommended for early stages (i.e. topical application of corticosteroids, nitrogen mustard, hypericin, intralesional injection of IFN‐α, or PUVA) should be a primary target for further research, since they apply to the largest group of people with MF. Treatment options often used as concomitant therapy, such as topical corticosteroids, should be investigated for their inherent efficacy. </p> <p>Comparable, clearly‐defined, and standardised end points have been proposed by international societies, and they should be consistently used in further research in order to gain comparability (<a href="https://mail.yahoo.com/Olsen%202011?soc_src=mail&amp;soc_trk=ma" target="_blank">Olsen 2011</a>). Furthermore, involvement of patients at the stage of study design would lead to adequate evaluations of their desires and needs. In addition to efficacy measures, toxicities should be reported not only by physicians but also by patients in order to facilitate the decision for treatment allocation. Quality of life should be addressed based on different treatment arms and not according to response as has been done in the included studies. A measure of the quality of life was often not implemented in the RCTs under investigation, but is essential in order to balance the risks and benefits of treatments. This is particularly applicable to early stage disease where life expectancy is not likely to be affected. </p> <p>Validated patient‐reported outcome measures are crucial for the comparison of different interventions. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD008946-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD008946-sec-0008"></div> <div class="table" id="CD008946-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">IFN‐α + PUVA compared to PUVA alone for mycosis fungoides</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>IFN‐α + PUVA compared to PUVA alone for mycosis fungoides</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with mycosis fungoides<br/><b>Setting:</b> tertiary care setting<br/><b>Intervention:</b> IFN‐α + PUVA<br/><b>Comparison:</b> PUVA alone </p> <p><b>Number of trials included:</b> 2 (<a href="./references#CD008946-bbs2-0014" title="BohmeyerJ , OtteHG , StadlerR , LugerT , SterryW . Therapy of cutaneous T-cell lymphoma with PUVA versus interferon alfa plus PUVA: first results. Journal of the European Academy of Dermatology &amp; Venereology1999;12(Suppl 2):S268. [CENTRAL: CN-00478472] BohmeyerJ , StadlerR , LugerT , SterryW . Prospective randomized multicentre therapy optimizing protocol for therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α + PUVA [Prospectiv randomisiertes, multizentrisches Therapieoptimierungsprotokoll zur Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α + PUVA]. Zeitschrift für Hautkrankheiten2001;76(Suppl 1):S55. [CENTRAL: CN-01446038] KremerA , BohmeyerJ , StadlerR , LugerT , SterryW . Prospective randomized multicentre therapy optimizing protocol for therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α + PUVA [Prospectiv randomisiertes, multizentrisches Therapieoptimierungsprotokoll zur Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α + PUVA]. Journal der Deutschen Dermatologischen Gesellschaft2003;1(Suppl 1):S99. [CENTRAL: CN-01446037] OtteHG , StadlerR , LugerT , SterryW . Therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α plus PUVA: first results of a prospective randomized multicentre therapy optimizing protocol [Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α plus PUVA: Erste Ergebnisse des prospektiven randomisierten multizentrischen Therapieoptimierungsprotokolls]. Der Hautarzt1999;50(Suppl 1):S2. [CENTRAL: CN-01457423] OtteHG , StadlerR . Combination therapy of cutaneous t-cell-lymphoma with interferon alfa 2a and PUVA [Kombinationstherapie kutaner T-Zell-Lymphome mit Interferon Alfa 2a und PUVA]. Zentralblatt Haut- und Geschlechtskrankheiten1993;162(Suppl):P2.03.08. [CENTRAL: CN-01457422] StadlerM , KremerA , LugerT , SterryW . Prospective, randomized, multicentre clinical trial on the use of interferon a 2a plus PUVA versus PUVA monotherapy in patients with cutaneous T-cell lymphoma, stages I and II [Abstract 7541]. ASCO annual meeting proceedings. Journal of Clinical Oncology2006;24(18S Pt 1):432. [CENTRAL: CN-00625001] ">Stadler 2006</a>; <a href="./references#CD008946-bbs2-0020" title="WozniakMB , TraceyL , Ortiz-RomeroPL , MontesS , AlvarezM , FragaJ , et al. Psoralen plus ultraviolet A +/- interferon-alpha treatment resistance in mycosis fungoides: the role of tumour microenvironment, nuclear transcription factor-kappaB and T-cell receptor pathways. British Journal of Dermatology2008;160(1):92-102. [CENTRAL: CN-00668828] [PMID: 18945306]">Wozniak 2008</a>) </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with PUVA alone</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with IFN‐α + PUVA</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement of quality of life</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Common adverse effects</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Complete response (CR)<br/>assessed with: outcome assessment not described </p> <p>Time point of measurement</p> <p><a href="./references#CD008946-bbs2-0014" title="BohmeyerJ , OtteHG , StadlerR , LugerT , SterryW . Therapy of cutaneous T-cell lymphoma with PUVA versus interferon alfa plus PUVA: first results. Journal of the European Academy of Dermatology &amp; Venereology1999;12(Suppl 2):S268. [CENTRAL: CN-00478472] BohmeyerJ , StadlerR , LugerT , SterryW . Prospective randomized multicentre therapy optimizing protocol for therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α + PUVA [Prospectiv randomisiertes, multizentrisches Therapieoptimierungsprotokoll zur Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α + PUVA]. Zeitschrift für Hautkrankheiten2001;76(Suppl 1):S55. [CENTRAL: CN-01446038] KremerA , BohmeyerJ , StadlerR , LugerT , SterryW . Prospective randomized multicentre therapy optimizing protocol for therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α + PUVA [Prospectiv randomisiertes, multizentrisches Therapieoptimierungsprotokoll zur Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α + PUVA]. Journal der Deutschen Dermatologischen Gesellschaft2003;1(Suppl 1):S99. [CENTRAL: CN-01446037] OtteHG , StadlerR , LugerT , SterryW . Therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α plus PUVA: first results of a prospective randomized multicentre therapy optimizing protocol [Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α plus PUVA: Erste Ergebnisse des prospektiven randomisierten multizentrischen Therapieoptimierungsprotokolls]. Der Hautarzt1999;50(Suppl 1):S2. [CENTRAL: CN-01457423] OtteHG , StadlerR . Combination therapy of cutaneous t-cell-lymphoma with interferon alfa 2a and PUVA [Kombinationstherapie kutaner T-Zell-Lymphome mit Interferon Alfa 2a und PUVA]. Zentralblatt Haut- und Geschlechtskrankheiten1993;162(Suppl):P2.03.08. [CENTRAL: CN-01457422] StadlerM , KremerA , LugerT , SterryW . Prospective, randomized, multicentre clinical trial on the use of interferon a 2a plus PUVA versus PUVA monotherapy in patients with cutaneous T-cell lymphoma, stages I and II [Abstract 7541]. ASCO annual meeting proceedings. Journal of Clinical Oncology2006;24(18S Pt 1):432. [CENTRAL: CN-00625001] ">Stadler 2006</a>: up to week 52 </p> <p><a href="./references#CD008946-bbs2-0020" title="WozniakMB , TraceyL , Ortiz-RomeroPL , MontesS , AlvarezM , FragaJ , et al. Psoralen plus ultraviolet A +/- interferon-alpha treatment resistance in mycosis fungoides: the role of tumour microenvironment, nuclear transcription factor-kappaB and T-cell receptor pathways. British Journal of Dermatology2008;160(1):92-102. [CENTRAL: CN-00668828] [PMID: 18945306]">Wozniak 2008</a>: up to week 24 </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.07<br/>(0.87 to 1.31) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>122<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low <sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>731 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>783 per 1000<br/>(636 to 958) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Objective response rate (ORR)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The assumed risk is based on the number of events/number of participants in the control groups in <a href="./references#CD008946-fig-0015" title="">Analysis 5.1</a>.<br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded by two levels to low‐certainty evidence. One level because of low internal validity (risk of bias ‐ performance bias in both studies, attrition bias in <a href="./references#CD008946-bbs2-0014" title="BohmeyerJ , OtteHG , StadlerR , LugerT , SterryW . Therapy of cutaneous T-cell lymphoma with PUVA versus interferon alfa plus PUVA: first results. Journal of the European Academy of Dermatology &amp; Venereology1999;12(Suppl 2):S268. [CENTRAL: CN-00478472] BohmeyerJ , StadlerR , LugerT , SterryW . Prospective randomized multicentre therapy optimizing protocol for therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α + PUVA [Prospectiv randomisiertes, multizentrisches Therapieoptimierungsprotokoll zur Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α + PUVA]. Zeitschrift für Hautkrankheiten2001;76(Suppl 1):S55. [CENTRAL: CN-01446038] KremerA , BohmeyerJ , StadlerR , LugerT , SterryW . Prospective randomized multicentre therapy optimizing protocol for therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α + PUVA [Prospectiv randomisiertes, multizentrisches Therapieoptimierungsprotokoll zur Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α + PUVA]. Journal der Deutschen Dermatologischen Gesellschaft2003;1(Suppl 1):S99. [CENTRAL: CN-01446037] OtteHG , StadlerR , LugerT , SterryW . Therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α plus PUVA: first results of a prospective randomized multicentre therapy optimizing protocol [Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α plus PUVA: Erste Ergebnisse des prospektiven randomisierten multizentrischen Therapieoptimierungsprotokolls]. Der Hautarzt1999;50(Suppl 1):S2. [CENTRAL: CN-01457423] OtteHG , StadlerR . Combination therapy of cutaneous t-cell-lymphoma with interferon alfa 2a and PUVA [Kombinationstherapie kutaner T-Zell-Lymphome mit Interferon Alfa 2a und PUVA]. Zentralblatt Haut- und Geschlechtskrankheiten1993;162(Suppl):P2.03.08. [CENTRAL: CN-01457422] StadlerM , KremerA , LugerT , SterryW . Prospective, randomized, multicentre clinical trial on the use of interferon a 2a plus PUVA versus PUVA monotherapy in patients with cutaneous T-cell lymphoma, stages I and II [Abstract 7541]. ASCO annual meeting proceedings. Journal of Clinical Oncology2006;24(18S Pt 1):432. [CENTRAL: CN-00625001] ">Stadler 2006</a>) and one level because of low sample size (imprecision) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008946-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Extracorporeal photopheresis compared to PUVA for mycosis fungoides</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Extracorporeal photopheresis compared to PUVA for mycosis fungoides</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with mycosis fungoides<br/><b>Setting:</b> tertiary care setting<br/><b>Intervention:</b> Extracorporeal photopheresis (ECP)<br/><b>Comparison:</b> PUVA </p> <p><b>Number of trials included:</b> 1 (<a href="./references#CD008946-bbs2-0002" title="ChildFJ , MitchellTJ , WhittakerSJ , ScarisbrickJJ , SeedPT , Russel-JonesR . A randomized cross-over study to compare PUVA and extracorporeal photopheresis in the treatment of plaque stage (T2) mycosis fungoides. Clinical &amp; Experimental Dermatology2004;29(3):231-6. [CENTRAL: CN-00468455] [PMID: 15115499]ChildFJ , MitchellTJ , WhittakerSJ , WatkinsP , SeedP , Russell-JonesR . A randomised cross-over study to compare Puva and extracorporeal photopheresis (ECP) in the treatment of plaque stage (T2) mycosis fungoides. British Journal of Dermatology2001;145(Suppl 59):16. [CENTRAL: CN-00430854] ">Child 2004</a>) </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with PUVA</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with Extracorporeal photopheresis</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement of quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Common adverse effects</p> <p>(Time point of measurement:</p> <p>three months of PUVA or six months of ECP<sup>c</sup>) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Some participants reported mild nausea after PUVA. However, incidences and time points were not stated. One participant starting in the ECP group had hypotension leading to withdrawal from the study. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16<br/>(1 RCT) <sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low <sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Complete response</p> <p>(Time point of measurement: three months of PUVA or six months of ECP<sup>c</sup>) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.20<br/>(0.01 to 3.61) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>16<br/>(1 RCT) <sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low <sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>250 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>50 per 1000<br/>(3 to 903) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Objective response rate</p> <p>(Time point of measurement: three months of PUVA or six months of ECP<sup>c</sup>) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.08<br/>(0.01 to 1.17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>16<br/>(1 RCT) <sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low <sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Additionally computed 95% CI by the use of the method described by Miettinen 1985 (adverse effects requiring discontinuation): 95% CI by Miettinen 0.00 to 0.40, Fisher test P = 0.002 </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>750 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>53 per 1000<br/>(0 to 750) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded by three levels to very low‐certainty evidence. One level because of low internal validity (risk of bias ‐ high risk of attrition bias) and two levels because of very low sample size (imprecision) </p> <p><sup>b</sup> Cross‐over design, no carry‐over effect suspected due to long washout phase of three months </p> <p><sup>c</sup> The PUVA‐first group was given PUVA twice a week for 3 months followed by ECP once monthly for 6 months (doses not reported). The ECP‐first group was given ECP once monthly for 6 months followed by PUVA twice a week for 3 months (doses not reported). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008946-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Bexarotene + PUVA compared to PUVA alone for mycosis fungoides</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Bexarotene + PUVA compared to PUVA alone for mycosis fungoides</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with mycosis fungoides<br/><b>Setting:</b> tertiary care setting<br/><b>Intervention:</b> Bexarotene + PUVA<br/><b>Comparison:</b> PUVA alone </p> <p><b>Number of trials included:</b> 1 (<a href="./references#CD008946-bbs2-0018" title="NCT00056056. Ultraviolet light therapy using methoxsalen with or without Bexarotene in treating patients with mycosis fungoides. clinicaltrials.gov/ct2/show/NCT00056056 (first received 7 March 2003). WhittakerS , OrtizP , DummerR , RankiA , HasanB , MeulemansB , et al. Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial 21011 (NCT00056056). British Journal of Dermatology2012;167(3):678-87. [CENTRAL: CN-00856432] [PMID: 22924950]WhittakerS , Ortiz-RomeroPL , DummerR , RankiA , HasanB , MeulemansB , et al. Efficacy and safety of bexarotene combined with psoralen/ultraviolet A light (PUVA) compared to PUVA treatment alone in stage IB-IIa mycosis fungoides (MF): Final results from EORTC cutaneous lymphoma task force (CLTF) phase III clinical trial 21011. Journal of Clinical Oncology2012;30(15 Suppl 1):8076. ">Whittaker 2012</a>) </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with PUVA alone</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with Bexarotene + PUVA</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement of quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Common adverse effects ‐ Photosensitivity (Time point of measurement: up to 16 weeks)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Zero events in with PUVA alone, so unable to calculate absolute effects.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.68<br/>(0.11 to 64.04) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low <sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Complete response (Time point of measurement: up to 16 weeks)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.41<br/>(0.71 to 2.80) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>93<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low <sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>222 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>313 per 1000<br/>(158 to 622) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Objective response rate (Time point of measurement: up to 16 weeks)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.94<br/>(0.61 to 1.44) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>93<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low <sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>489 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>460 per 1000<br/>(298 to 704) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded by two levels to low‐certainty evidence. One level because of low internal validity (risk of bias ‐ high risk of performance bias) and one level because of low sample size (imprecision) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008946-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">IFN‐α + acitretin compared to IFN‐α + PUVA for mycosis fungoides</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>IFN‐α + acitretin compared to</b> <b>IFN‐α + PUVA for mycosis fungoides</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with mycosis fungoides<br/><b>Setting:</b> tertiary care setting<br/><b>Intervention:</b> IFN‐α + acitretin<br/><b>Comparison:</b> IFN‐α + PUVA </p> <p><b>Number of trials included:</b> 1 (<a href="./references#CD008946-bbs2-0013" title="OtteHG , KuhlS , StadlerR , LugerT , HenzB , SterryW . Treatment of cutaneous T-cell lymphoma with Interferon alpha and PUVA versus Interferon alpha and Acitretin - results of a prospective randomised multi-centre study [Behandlung des kutanen T-Zell-Lymphoms mit Interferon alpha und PUVA versus Interferon alpha und Acirentin - Ergebnisse einer prospektiv-randomisierten Multicenter-Studie]. Der Hautarzt1997;48(Suppl):S97. [CENTRAL: CN-00495120] OtteHG , StadierR , LugerT , HenzB , SterryW . Open controlled clinical trial on the use of interferon plus acitretin versus interferon plus PUVA in patients with cutaneous T-cell lymphoma (CTCL). Annals of Oncology1996;7(Suppl 3):66. [CENTRAL: CN-00308243] StadlerR , OtteHG , LugerT , HenzBM , KuhlP , ZwingersT , et al. Prospective randomized multicenter clinical trial on the use of interferon -2a plus acitretin versus interferon -2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood1998;92(10):3578-81. [CENTRAL: CN-00156682] [PMID: 9808550]">Stadler 1998</a>) </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with IFN‐α + PUVA</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with IFN‐α + acitretin</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement of quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Common adverse effects ‐ Flu‐like symptoms</p> <p>(Time point of measurement: up to 48 weeks or until complete response)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.32<br/>(0.92 to 1.88) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>82<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low <sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>525 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>693 per 1000<br/>(483 to 987) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Complete response</p> <p>(Time point of measurement: up to 48 weeks or until complete response)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.54<br/>(0.35 to 0.84) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>82<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low <sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>700 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>378 per 1000<br/>(245 to 588) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Objective response rate</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate;the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded by two levels to low‐certainty evidence. One level because of low internal validity (risk of bias ‐ high risk of attrition bias) and one level because of low sample size (imprecision) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008946-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">PUVA maintenance compared to no maintenance for mycosis fungoides</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>PUVA maintenance compared to no maintenance for mycosis fungoides</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> mycosis fungoides<br/><b>Setting:</b> tertiary care setting<br/><b>Intervention:</b> PUVA maintenance<br/><b>Comparison:</b> no maintenance </p> <p><b>Number of trials included:</b> 1 (<a href="./references#CD008946-bbs2-0016" title="NCT01686594. A multi-center, randomized study on oral 8-methoxypsoralen plus UVA with or without maintenance therapy in mycosis fungoides EORTC/ISCL stage IA to IIB. clinicaltrials.gov/ct2/show/NCT01686594 (first received 18 September 2012). Vieyra-GarciaP , Fink-PuchesR , PorkertS , LangR , PöchlauerS , RatzingerG , et al. Evaluation of low-dose, low-frequency oral psoralen-UV-A treatment with or without maintenance on early-stage mycosis fungoides: A randomized clinical trial. JAMA Dermatology2019;155(5):538-47. [PMID: 30892603]">Vieyra‐Garcia 2019</a>) </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with no maintenance</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with PUVA maintenance</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Improvement of quality of life</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1.000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Common adverse effects</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Measured but distribution in treatment arms was not reported</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1.000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Complete response</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Complete response was a condition for randomisation and not an outcome</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0 per 1.000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0 per 1.000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Objective response rate</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0 per 1.000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0 per 1.000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD008946-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD008946-sec-0009"></div> <p>Please see <a href="#CD008946-tbl-0006">Table 1</a> for definitions of the clinical stages of the disease, our glossary in <a href="#CD008946-tbl-0007">Table 2</a> for an explanation of medical terms used throughout the text, and <a href="#CD008946-tbl-0008">Table 3</a> for definitions of acronyms. </p> <div class="table" id="CD008946-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Clinical staging system</span></div> <tbody> <tr> <th align="center" class="headercell" colspan="2" rowspan="2" scope="col" valign="middle"> <p><b>2007</b> </p> <p><b>MF and Sézary syndrome</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="2" scope="col" valign="middle"> <p><b>1979</b> </p> <p><b>CTCL</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="middle"> <p><b>Disease‐specific survival rates in % (</b><a href="./references#CD008946-bbs2-0089" title="AgarNS , WedgeworthE , CrichtonS , MitchellTJ , CoxM , FerreiraS , et al. Survival outcomes and prognostic factors in mycosis fungoides/Sezary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. Journal of Clinical Oncology2010;28(31):4730-9. [PMID: 20855822]">Agar 2010</a>) </p> </th> </tr> <tr> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="middle"> <p><b>5 year</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="middle"> <p><b>10 year</b> </p> </th> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="middle"> <p><b>IA</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>T1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="middle"> <p><b>IA</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>T1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="middle"> <p>98</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="middle"> <p>95</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>N0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>N0</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>M0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>M0</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>B0‐1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>‐</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="middle"> <p><b>IB</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>T2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="middle"> <p><b>IB</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>T2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="middle"> <p>89</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="middle"> <p>77</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>N0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>N0</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>M0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>M0</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>0‐1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>‐</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="middle"> <p><b>IIA</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>T1‐2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="middle"> <p><b>IIA</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>T1‐2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="middle"> <p>89</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="middle"> <p>67</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>N1‐2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>N1</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>M0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>M0</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>B0‐1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>‐</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="middle"> <p><b>IIB</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>T3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="middle"> <p><b>IIB</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>T3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="middle"> <p>56</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="middle"> <p>42</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>N0‐2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>N0,1</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>M0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>M0</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>B0‐1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>‐</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="middle"> <p><b>III</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>T4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="middle"> <p><b>III</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>T4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="middle"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="middle"></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>N0‐2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>N0,1</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>M0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>M0</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>B0‐1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>‐</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="middle"> <p><b>IIIA</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>T4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="middle"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="middle"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="middle"> <p>54</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="middle"> <p>45</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>N0‐2</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>M0</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>B0</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="middle"> <p><b>IIIB</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>T4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="middle"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="middle"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="middle"> <p>48</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="middle"> <p>45</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>N0‐2</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>M0</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>B1</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="middle"> <p><b>IVA1</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>T1‐4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="8" valign="middle"> <p><b>IVA</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="middle"> <p>T1‐4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="middle"> <p>41</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="middle"> <p>20</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>N0‐2</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>M0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="middle"> <p>N2‐3</p> <p>‐</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>B2</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="middle"> <p><b>IVA2</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>T1‐4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="middle"> <p>M0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>23</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>20</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>N3</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>M0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="middle"> <p>‐</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>B0‐2</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="middle"> <p><b>IVB</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>T1‐4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="middle"> <p><b>IVB</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>T1‐4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>18</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>not reached</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>N0‐3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>N0‐3</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>M1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>M1</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>B0‐2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>‐</p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD008946-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Glossary of terms</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>General medical terms</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Explanation</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Apoptosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Programmed cell death</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cutaneous T‐cell lymphoma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group of skin‐directed T‐cell neoplasms with diverse clinical and histological features and prognosis </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cutaneous B‐cell lymphoma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group of skin‐directed B‐cell neoplasms with diverse clinical and histological features and prognosis </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lesional skin atrophy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death of the cells in the damaged area of skin</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lymph nodes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Small organs in the human body which are part of the immune system</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Neoplasm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Any new and abnormal growth</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NK‐cell lymphoma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group of neoplasms derived from the natural killer cells (NK‐cells) with diverse clinical and histological features and prognosis </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Plaques</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A solid elevated area on the skin that is more broad than it is high</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pleomorphic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Variability in size and shape</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Poikiloderma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Skin that demonstrates adjacent hyper‐ and hypopigmented areas with widened capillaries (telangiectasia) in the affected area </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Precursor haematologic neoplasm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Clinically‐aggressive neoplasm with a high incidence of cutaneous involvement and risk of leukaemic dissemination </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Primary cutaneous lymphoma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Cutaneous T‐ and B‐cell lymphoma that primarily affect the skin</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>T‐cell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>A type of lymphocyte (white cell)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Adverse effects</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Explanation</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Acute myocardial infarction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Death of myocardial tissue due to blocked blood supply</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Acute non‐lymphatic leukaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>A quickly progressive malignant disease of too many immature non‐lymphatic leucocytes cells in the blood and bone marrow </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>ALT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>The alanine transaminase is a liver enzyme (SGPT)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Anaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Low count of red blood cells</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Anaemia hypochromic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Low count of red blood cells with low amount of haemoglobin, the red molecule that transports oxygen within the blood vessels </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Anaphylactoid reactions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Very acute systemic allergic reaction often accompanied with flushing, angioedema,urticaria, difficulty breathing, lowered blood pressure, nausea </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Arthralgia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Joint pain</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>AST</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>The aspartate transaminase is an enzyme mainly present in the liver but also in the blood, muscle cells, and bones (SGOT) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Asthenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Lack of energy or physical weakness or both</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Cardiomyopathy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Structural or functional disease of the cardiac muscle</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Cardiopulmonary syndrome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Adverse effect where the heart and the lung are involved</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Chill</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Feeling of cold, resulting in shivering</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>CNS syndrome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Adverse effect where the central nervous system (brain, spinal cord) is involved</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Cutaneous hypersensitivity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Altered reactivity to a specific antigen leading to cutaneous alterations</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Cutaneous toxicity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Cutaneous adverse effect of an agent used in therapeutic dosages</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Constipation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Hard and/or difficult bowel movements</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Dermatitis exfoliation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Inflammation and detachment of the skin</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Many fluid stools</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Dyspnea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Bad breathing</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Erythema</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Redness of the skin</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>To be exhausted</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Flu‐like symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Symptoms which are often seen with influenza, such as fever, chills, and muscular pain </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Gastrointestinal syndromes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Adverse effects affecting the digestive system (oesophagus, stomach, bowel)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Hair loss</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Pathological increased loss of hair</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Hepatotoxicity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Capacity of a substance to have damaging effects on the liver</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Hospitalisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Admission of a patient in a hospital</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Hypercholesterolaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Elevated levels of cholesterol in the blood</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Hyperlipidaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Elevated levels of lipids in the blood</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Hypotension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Low blood pressure</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Hypothyroidism</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Low function of thyroid gland</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Impotentia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Inability to engage in sexual intercourse</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Not being able to sleep</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>LDH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Lactate dehydrogenase, an enzyme which helps to produce energy in the body when oxygen is absent </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Leukopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Low count of white blood cells</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Malaise</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>To feel ill</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Mucositis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Inflammation of mucosa</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Myalgia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Muscle pain</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Nasopharyngitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Inflammation of the inner nose and the throat</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>An unpleasant sensation associated with the feeling one is going to vomit</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Neuropathy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>A problem of the nervous system or nerves, which can result in abnormal sensations, pain, or muscle weakness </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Non‐melanoma skin cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Skin cancer which does not originate from melanocytes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Photosensitivity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Enhanced responsibility to light or ultraviolet light</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Pruritus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Itching of the skin</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Radiodermatitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Dermatitis resulting from overexposure to sources of radiant energy</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>An abnormal change in the skin often affecting colour (increased redness), texture, and/or sensation </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>SGOT/SGPT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Liver enzymes, see also AST and ALT</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>T4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Enzyme of the thyroid gland</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Thrombopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Low count of thrombocytes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Thrombotic syndrome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Blood coagulation and clotting within blood vessels, obstructing blood flow</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Triglycerid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Lipid</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Vascular leak syndrome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>When the blood vessels dilate and become more porous, allowing blood components to leak into the surrounding tissue </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Vasodilatation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Widening of the blood vessels</p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD008946-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">List of abbreviations and acronyms</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Acronym</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Description (letters used for acronym in capitals)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ADF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Arbeitsgemeinschaft Dermatologische Forschung</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BCNU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Carmustine, a nitrogen mustard related alkylating agent</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CENTRAL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cochrane Central Register of Controlled Trials</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Confidence interval</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CTCL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cutaneous T‐Cell Lymphoma</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DDG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>German Dermatologic Society</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EORTC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>European Organization of Research and Treatment of Cancer</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ISCL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>International Society for Cutaneous Lymphoma (ISCL)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ITT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intention‐to‐treat</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LILACS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Latin American and Caribbean Health Science Information database</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mycosis Fungoides</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PICOS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants, Interventions, Controls, Outcomes and Study</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PRISMA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Preferred Reporting Items of Systematic Reviews and Meta‐Analyses</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Randomised‐Controlled Trial</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk Ratio</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TSEB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total Skin Electron Beam</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TNMB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tumour, lymph Node, Metastasis and Blood</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>United Kingdom</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>United States of America</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USCLC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>United States Cutaneous Lymphoma Consortium</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WHO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>World Health Organization</p> </td> </tr> </tbody> </table> </div> <section id="CD008946-sec-0010"> <h3 class="title" id="CD008946-sec-0010">Description of the condition</h3> <p>Mycosis fungoides (MF) is the most common type of cutaneous T‐cell lymphoma (<a href="./references#CD008946-bbs2-0139" title="KorgavkarK , XiongM , WeinstockM . Changing incidence trends of cutaneous T-cell lymphoma. JAMA Dermatology2013;149(11):1295-9. [DOI: 10.1001/jamadermatol.2013.5526]">Korgavkar 2013</a>). It is a malignant condition with clonal T‐helper cells primarily affecting the skin. The course of the condition is chronic, so its description depends upon the stage at which it presents for clinical examination. </p> <p>Typically, at first there are multiple eczematous patches on the trunk and extremities, which may be accompanied by lesional skin atrophy. After some years, these patches frequently develop into plaques and may progress to solid skin tumours (<a href="#CD008946-fig-0001">Figure 1</a>). Skin tumours can also develop on the face and head region, but these are uncommon locations for mycosis fungoides at the early patch or plaque stage. In the more advanced stages, lymph nodes and eventually solid organs may also be involved, but progress is usually slow. Pruritus (itching) is infrequent at the patch stage but can become more frequent at the plaque and skin‐tumour stages. Clinical diagnosis needs to be confirmed by histology, but often multiple skin biopsies are necessary to establish diagnosis since histological findings are often ambiguous (<a href="./references#CD008946-bbs2-0101" title="CerroniL . Mycosis fungoides - clinical and histopathologic features, differential diagnosis, and treatment. Seminars in Cutaneous Medicine and Surgery2018;37(1):2-10. [DOI: 10.12788/j.sder.2018.002]">Cerroni 2018</a>). </p> <div class="figure" id="CD008946-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Skin changes in mycosis fungoides. Left: Patch; Middle: Plaque; Right: TumourCopyright © 2018. Department of Dermatology, University Hospital Frankfurt am Main: reproduced with permission." data-id="CD008946-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-FIG-01.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Skin changes in mycosis fungoides. Left: Patch; Middle: Plaque; Right: Tumour</p> <p>Copyright © 2018. Department of Dermatology, University Hospital Frankfurt am Main: reproduced with permission. </p> </div> </div> </div> <section id="CD008946-sec-0011"> <h4 class="title">Incidence and demographics</h4> <p>Mycosis fungoides accounts for about half of all cutaneous T‐cell lymphomas (CTCL), but it still remains a rare disease due to the low incidence of CTCL (<a href="./references#CD008946-bbs2-0184" title="WillemzeR , JaffeES , BurgG , CerroniL , BertiE , SwerdlowSH , et al. WHO-EORTC classification for cutaneous lymphomas. Blood2005;105(10):3768-85. [PMID: 15692063]">Willemze 2005</a>). Age‐adjusted incidence rates for CTCL have been reported for several countries. These equate to a yearly incidence per 10 million people of 13 in Norway and England/Wales, 14 in the Netherlands, 15 in Western Australia, and 41 to 64 in the USA (<a href="./references#CD008946-bbs2-0095" title="BradfordPT , DevesaSS , AndersonWF , ToroJR . Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood2009;113(21):5064-73. [PMID: 19279331]">Bradford 2009</a>; <a href="./references#CD008946-bbs2-0104" title="CriscioneVD , WeinstockMA . Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002. Archives of Dermatology2007;143(7):854-9. [PMID: 17638728]">Criscione 2007</a>; <a href="./references#CD008946-bbs2-0153" title="Morales Suárez-VarelaMM , Llopis GonzálezA , Marquina VilaA , BellJ . Mycosis fungoides: Review of epidemiological observations. Dermatology2000;201(1):21-8. [PMID: 10971054]">Morales 2000</a>). Differences between countries have been assumed to be a result of variable diagnostic criteria in the past (<a href="./references#CD008946-bbs2-0153" title="Morales Suárez-VarelaMM , Llopis GonzálezA , Marquina VilaA , BellJ . Mycosis fungoides: Review of epidemiological observations. Dermatology2000;201(1):21-8. [PMID: 10971054]">Morales 2000</a>). </p> <p>Onset of symptoms, generally, occurs in late middle age with a median of 50 to 60 years (<a href="./references#CD008946-bbs2-0137" title="KimYH , LiuHL , Mraz-GernhardS , VargheseA , HoppeRT . Long-term outcome of 525 patients with mycosis fungoides and Sézary syndrome: Clinical prognostic factors and risk for disease progression. Archives of Dermatology2003;139(7):857-66. [PMID: 12873880]">Kim 2003</a>; <a href="./references#CD008946-bbs2-0144" title="LorinczAL . Cutaneous T-cell lymphoma (mycosis fungoides). Lancet1996;347(9005):871-6. [PMID: 8622396]">Lorincz 1996</a>; <a href="./references#CD008946-bbs2-0174" title="vanDoornR , Van HaselenCW , vanVoorst VaderPC , GeertsML , HeuleF , deRieM , et al. Mycosis fungoides: Disease evolution and prognosis of 309 Dutch patients. Archives of Dermatology2000;136(4):504-10. [PMID: 10768649]">van Doorn 2000</a>; <a href="./references#CD008946-bbs2-0190" title="ZackheimHS , AminS , Kashani-SabetM , McMillanA . Prognosis in cutaneous T-cell lymphoma by skin stage: Long-term survival in 489 patients. Journal of the American Academy of Dermatology1999;40(3):418-25. [PMID: 10071312]">Zackheim 1999</a>), but cases in children and adolescents are also known (<a href="./references#CD008946-bbs2-0104" title="CriscioneVD , WeinstockMA . Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002. Archives of Dermatology2007;143(7):854-9. [PMID: 17638728]">Criscione 2007</a>; <a href="./references#CD008946-bbs2-0179" title="WainEM , OrchardGE , WhittakerSJ , SpittleMF , Russell-JonesR . Outcome in 34 patients with juvenile-onset mycosis fungoides: A clinical, immunophenotypic, and molecular study. Cancer2003;98(10):2282-90. [PMID: 14601100]">Wain 2003</a>; <a href="./references#CD008946-bbs2-0181" title="WeinstockMA , ReynesJF . The changing survival of patients with mycosis fungoides: A population-based assessment of trends in the United States. Cancer1999;85(1):208-12. [PMID: 9921994]">Weinstock 1999</a>). The disease occurs more often in men than in women with a ratio of 2:1 (<a href="./references#CD008946-bbs2-0095" title="BradfordPT , DevesaSS , AndersonWF , ToroJR . Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood2009;113(21):5064-73. [PMID: 19279331]">Bradford 2009</a>; <a href="./references#CD008946-bbs2-0180" title="WeinstockMA , HormJW . Mycosis fungoides in the United States. Increasing incidence and descriptive epidemiology. JAMA1988;260(1):42-6. [PMID: 3379722]">Weinstock 1988</a>). Ethnicity also affects incidence rates. Black populations have the highest reported incidence rates, followed by white populations. The lowest incidence rates have been reported in Asian and Hispanic populations (<a href="./references#CD008946-bbs2-0093" title="BernsteinL , DeapenD , RossRK . Mycosis fungoides. JAMA1989;261(13):1882. [PMID: 2784510]">Bernstein 1989</a>; <a href="./references#CD008946-bbs2-0095" title="BradfordPT , DevesaSS , AndersonWF , ToroJR . Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood2009;113(21):5064-73. [PMID: 19279331]">Bradford 2009</a>; <a href="./references#CD008946-bbs2-0180" title="WeinstockMA , HormJW . Mycosis fungoides in the United States. Increasing incidence and descriptive epidemiology. JAMA1988;260(1):42-6. [PMID: 3379722]">Weinstock 1988</a>). Moreover, African‐American race seems to be associated with a poorer overall survival (<a href="./references#CD008946-bbs2-0154" title="NathSK , YuJB , WilsonLD . Poorer prognosis of African-American patients with mycosis fungoides: an analysis of the SEER dataset, 1988 to 2008. Clinical Lymphoma, Myeloma &amp; Leukemia2014;14(5):419-23. [PMID: 24508350]">Nath 2014</a>). </p> <p>The median time to diagnosis is found to be about four years. This may be due to its pleomorphic presentation and often slow disease progression with non‐specific eczematous patch lesions for some years (<a href="./references#CD008946-bbs2-0137" title="KimYH , LiuHL , Mraz-GernhardS , VargheseA , HoppeRT . Long-term outcome of 525 patients with mycosis fungoides and Sézary syndrome: Clinical prognostic factors and risk for disease progression. Archives of Dermatology2003;139(7):857-66. [PMID: 12873880]">Kim 2003</a>). </p> </section> <section id="CD008946-sec-0012"> <h4 class="title">Classification</h4> <p>The classification specific for primary cutaneous lymphoma made by the European Organization of Research and Treatment of Cancer (EORTC) was published in 1997 (<a href="./references#CD008946-bbs2-0183" title="WillemzeR , KerlH , SterryW , BertiE , CerroniL , ChimentiS , et al. EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood1997;90(1):354-71. [PMID: 9207472]">Willemze 1997</a>). Together with the 2001 Classification of Tumours by the World Health Organization (WHO) (<a href="./references#CD008946-bbs2-0133" title="JaffeES , HarrisNL , SteinH , VardimanJW , editors. Pathology and Genetics: Tumours of Hematopoetic and Lymphoid Tissues (World Health Organization Classification of Tumours). Lyon: IARC Press, 2001.">Jaffe 2001</a>), this classification was succeeded in 2004 by the commonly‐used WHO‐EORTC classification for cutaneous lymphoma, which constituted the standard classification (<a href="./references#CD008946-bbs2-0184" title="WillemzeR , JaffeES , BurgG , CerroniL , BertiE , SwerdlowSH , et al. WHO-EORTC classification for cutaneous lymphomas. Blood2005;105(10):3768-85. [PMID: 15692063]">Willemze 2005</a>) until 2018. This classification was updated in 2018 and was published in the 4th edition of the WHO classification for Skin Tumours Blue Book (<a href="./references#CD008946-bbs2-0116" title="ElderDE , MassiD , ScolyerRA , WillemzeR . WHO Classification of Skin Tumours (4th edition). IARC Press, 2018. [ISBN-13 9789283224402]">Elder 2018</a>). </p> <section id="CD008946-sec-0013"> <h5 class="title">WHO‐EORTC classification</h5> <p>The WHO‐EORTC classification for cutaneous lymphoma distinguishes two main entities: cutaneous T‐cell and cutaneous B‐cell lymphomas. </p> <p>Cutaneous T‐cell lymphomas are further grouped into different subcategories, of which classical mycosis fungoides is one. Mycosis fungoides represents the most common type and is usually defined as classical 'Alibert‐Bazin' type with evolution of patches, plaques, and tumours. Mycosis fungoides variants and subtypes, as well as Sézary syndrome, are distinctive conditions with separate clinical, histological, and haematological findings. Therefore, they are not included in analyses done for this review (<a href="./references#CD008946-bbs2-0185" title="WillemzeR , CerroniL , KempfW , BertiE , FacchettiF , SwerdlowSH , et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood 2019 Jan 11 [Epub ahead of print]. [DOI: 10.1182/blood-2018-11-881268]">Willemze 2019</a>). </p> </section> <section id="CD008946-sec-0014"> <h5 class="title">TNMB (tumour, lymph node, metastasis, and blood) classifications for mycosis fungoides</h5> <p>In 2007, the International Society for Cutaneous Lymphoma (ISCL) and the cutaneous lymphoma task force of the EORTC revised the 1979 TNMB classification for CTCL to adapt to recent advances and develop a more specific classification of mycosis fungoides, as well as Sézary syndrome (<a href="./references#CD008946-bbs2-0097" title="Bunn PA Jr, LambergSI . Report of the committee on staging and classification of cutaneous T-cell lymphomas. Cancer Treatment Reports1979;63(4):725-8. [PMID: 445521]">Bunn 1979</a>; <a href="./references#CD008946-bbs2-0156" title="OlsenE , VonderheidE , PimpinelliN , WillemzeR , KimY , KnoblerR , et al. Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood2007;110(6):1713-22. [PMID: 17540844]">Olsen 2007</a>). In 2011, Olsen and colleagues further updated this classification (<a href="./references#CD008946-bbs2-0157" title="OlsenEA , WhittakerS , KimYH , DuvicM , PrinceHM , LessinSR , et al. Clinical end points and response criteria in mycosis fungoides and Sezary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. Journal of Clinical Oncology2011;29(18):2598-607. [PMID: 21576639]">Olsen 2011</a>). Because of overall similarity and the fact that only the most recent articles have incorporated the revised TNMB classification, both classifications are accepted in this review. <a href="#CD008946-tbl-0009">Table 4</a> shows the original and currently‐revised TNMB classification. </p> <div class="table" id="CD008946-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">TNMB classifications</span></div> <tbody> <tr> <td align="center" class="headercell" colspan="2" rowspan="1" valign="middle"></td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="middle"> <p><b>Modified ISCL/EORTC classification of MF and Sézary Syndrome according to</b><a href="./references#CD008946-bbs2-0157" title="OlsenEA , WhittakerS , KimYH , DuvicM , PrinceHM , LessinSR , et al. Clinical end points and response criteria in mycosis fungoides and Sezary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. Journal of Clinical Oncology2011;29(18):2598-607. [PMID: 21576639]"><b>Olsen 2011</b> </a> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="middle"> <p><b>CTCL 1979</b> </p> </th> </tr> <tr> <th align="center" class="headercell" colspan="4" rowspan="1" scope="col" valign="middle"> <p><b>T: Skin<sup>1</sup> </b> </p> </th> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>T<sub>0</sub> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>N.E.</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Clinically and/or histopathologically suspicious lesions</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>T<sub>1</sub> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Limited patches, papules, and/or plaques covering &lt; 10% of the skin surface; may further stratify into T1a (patch only) vs. T1b (plaque ± patch) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Limited plaques, papules, or eczematous patches<br/>covering &lt; 10% of the skin surface </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>T<sub>2</sub> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Patches, papules, or plaques covering ≥ 10% of the skin surface; may further stratify into T2a (patch only) vs. T2b (plaque patch) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Generalised plaques, papules, or erythematous<br/>patches covering ≥ 10% of the skin surface </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>T<sub>3</sub> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>One or more tumours (≥ 1 cm diameter)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Tumours, 1 or more</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>T<sub>4</sub> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Confluence of erythema covering ≥ 80% body surface area</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Generalised erythroderma</p> </td> </tr> <tr> <th align="center" class="headercell" colspan="4" rowspan="1" scope="col" valign="middle"> <p><b>N: Node<sup>2</sup> </b> </p> </th> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>N<sub>0</sub> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>No clinically abnormal peripheral lymph nodes; biopsy not required</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>No clinically abnormal peripheral lymph nodes palpable,<br/>histopathology negative for CTCL </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>N<sub>1</sub> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Clinically abnormal lymph nodes; histopathology Dutch grade 1 or NCI LN<sub>0-2</sub> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Palpable Clinically abnormal peripheral lymph nodes, histopathology<br/>negative for CTCL </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>N<sub>1a</sub> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Clone negative</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>‐</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>N<sub>1b</sub> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Clone positive</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>‐</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>N<sub>2</sub> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Clinically abnormal peripheral lymph nodes, histopathology Dutch grade 2 or NCI LN<sub>3</sub> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>No clinically abnormal peripheral lymph nodes,<br/>histopathology positive for CTCL </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>N<sub>2a</sub> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Clone negative</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>‐</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>N<sub>2b</sub> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Clone positive</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>‐</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>N<sub>3</sub> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Clinically abnormal lymph nodes; histopathology Dutch grade 3‐4 or NCI LN<sub>4</sub>; </p> <p>clone positive or negative</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Palpable clinically abnormal peripheral lymph nodes, pathology<br/>positive for CTCL </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>N<sub>x</sub> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Clinically abnormal lymph nodes without histologic confirmation or inability to fully characterize the histologic subcategories </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>‐</p> </td> </tr> <tr> <th align="center" class="headercell" colspan="4" rowspan="1" scope="col" valign="middle"> <p><b>M: Visceral</b> </p> </th> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>M<sub>0</sub> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>No visceral organ involvement</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>No visceral organ involvement</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>M<sub>1</sub> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Visceral involvement (must have pathology confirmation and organ involved should be specified) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Visceral involvement (must have pathology<br/>confirmation and organ involved should be<br/>specified) </p> </td> </tr> <tr> <th align="center" class="headercell" colspan="4" rowspan="1" scope="col" valign="middle"> <p><b>B: Blood</b> </p> </th> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>B<sub>0</sub> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Absence of significant blood involvement: ≤ 5% of peripheral blood lymphocytes are atypical (Sézary) cells </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Atypical circulating cells not present (less than 5%)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>B<sub>0a</sub> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Clone negative</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>‐</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>B<sub>0b</sub> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Clone positive</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>‐</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>B<sub>1</sub> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Low blood tumour burden: &gt; 5% of peripheral blood lymphocytes are atypical (Sézary) cells but does not meet the criteria of B<sub>2</sub> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Atypical circulating cells present (more than 5%), record total<br/>white blood count and total lymphocyte counts, and<br/>number of atypical cells/100 lymphocytes </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>B<sub>1a</sub> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Clone negative</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>‐</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>B<sub>1b</sub> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Clone positive</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>‐</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>B<sub>2</sub> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>High blood tumour burden: ≥ 1,000/L Sézary cells with positive clone<sup>3</sup>; one of the following can be substituted for Sézary cells: CD4/CD8 ≥ 10,<br/>CD4CD7‐ cells ≥ 40% or CD4CD26‐ cells ≥ 30% </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>‐</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup> Patch any size lesion without induration or significant elevation above the surrounding uninvolved skin: poikiloderma may be present. Plaque any size lesion that is elevated or indurated: crusting or poikiloderma may be present. Tumour any solid or nodular lesion ≥ 1 cm in diameter with evidence of deep infiltration in the skin and/or vertical growth. </p> <p><sup>2</sup> Lymph node classification has been modified from 2007 ISCL/EORTC consensus revisions1 to include central nodes. Lymph nodes are qualified as abnormal if ≥ 1.5 cm in diameter. </p> <p><sup>3</sup> The clone in the blood should match that of the skin. The relevance of an isolated clone in the blood or a clone in the blood that does not match the clone in the skin remains to be determined. </p> </div> </div> </section> </section> <section id="CD008946-sec-0015"> <h4 class="title">Staging and Prognosis</h4> <p>Clinical staging of mycosis fungoides was derived from the TNMB classification and can help when predicting survival (<a href="./references#CD008946-bbs2-0163" title="SausvilleEA , EddyJL , MakuchRW , FischmannAB , SchechterGP , MatthewsM , et al. Histopathologic staging at initial diagnosis of mycosis fungoides and the Sézary syndrome. Definition of three distinctive prognostic groups. Annals of Internal Medicine1988;109(5):372-82. [PMID: 3408055]">Sausville 1988</a>; <a href="./references#CD008946-bbs2-0174" title="vanDoornR , Van HaselenCW , vanVoorst VaderPC , GeertsML , HeuleF , deRieM , et al. Mycosis fungoides: Disease evolution and prognosis of 309 Dutch patients. Archives of Dermatology2000;136(4):504-10. [PMID: 10768649]">van Doorn 2000</a>; <a href="./references#CD008946-bbs2-0178" title="VonderheidEC , PenaJ , NowellP . Sézary cell counts in erythrodermic cutaneous T-cell lymphoma: Implications for prognosis and staging. Leukemia &amp; Lymphoma2006;47(9):1841-56. [PMID: 17064997]">Vonderheid 2006</a>). Independent prognostic factors are described as age; gender; T‐cell classification; presence of extracutaneous disease; response to initial treatment; the presence of follicular mucinosis, poikilodermatous or hypopigmented mycosis fungoides; or the association with lymphomatoid papulosis (<a href="./references#CD008946-bbs2-0089" title="AgarNS , WedgeworthE , CrichtonS , MitchellTJ , CoxM , FerreiraS , et al. Survival outcomes and prognostic factors in mycosis fungoides/Sezary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. Journal of Clinical Oncology2010;28(31):4730-9. [PMID: 20855822]">Agar 2010</a>; <a href="./references#CD008946-bbs2-0137" title="KimYH , LiuHL , Mraz-GernhardS , VargheseA , HoppeRT . Long-term outcome of 525 patients with mycosis fungoides and Sézary syndrome: Clinical prognostic factors and risk for disease progression. Archives of Dermatology2003;139(7):857-66. [PMID: 12873880]">Kim 2003</a>; <a href="./references#CD008946-bbs2-0174" title="vanDoornR , Van HaselenCW , vanVoorst VaderPC , GeertsML , HeuleF , deRieM , et al. Mycosis fungoides: Disease evolution and prognosis of 309 Dutch patients. Archives of Dermatology2000;136(4):504-10. [PMID: 10768649]">van Doorn 2000</a>). The risk for disease progression is also related to the clinical stage of the disease. In stage IA, the risk is reported to be 12% within 10 years. In stage IB, the risk for progression increases to 38%, and in stage IIA, to 33% within the same period of time. In stage IIB, the risk elevates markedly to 58% within 10 years, and in stages IIIA and IIIB, it rises to 62% and 73%, respectively. Stages IVA1 and IVA2 show the highest risk for disease progression within 10 years at 83% and 80%, respectively (<a href="./references#CD008946-bbs2-0089" title="AgarNS , WedgeworthE , CrichtonS , MitchellTJ , CoxM , FerreiraS , et al. Survival outcomes and prognostic factors in mycosis fungoides/Sezary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. Journal of Clinical Oncology2010;28(31):4730-9. [PMID: 20855822]">Agar 2010</a>). </p> </section> </section> <section id="CD008946-sec-0016"> <h3 class="title" id="CD008946-sec-0016">Description of the intervention</h3> <p>Treatment of mycosis fungoides is stage‐adapted aiming at the following:</p> <p> <ol id="CD008946-list-0001"> <li> <p>complete response of lesions (i.e. remission induction);</p> </li> <li> <p>maintaining or improving quality of life; and</p> </li> <li> <p>prolonging disease‐free survival and overall survival (<a href="./references#CD008946-bbs2-0131" title="HwangST , JanikJE , JaffeES , WilsonWH . Mycosis fungoides and Sézary syndrome. Lancet2008;371(9616):945-57. [PMID: 18342689]">Hwang 2008</a>). </p> </li> </ol> </p> <p>In early stages of the disease skin‐directed treatment approaches, including topical therapies, skin‐directed phototherapies, and radiotherapy, are favoured (<a href="./references#CD008946-bbs2-0110" title="DummerR , DreylingM . Primary cutaneous lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Annals of Oncology2008;19(Suppl 2):ii72-6. [PMID: 18456777]">Dummer 2008</a>; <a href="./references#CD008946-bbs2-0172" title="TrautingerF , KnoblerR , WillemzeR , PerisK , StadlerR , LarocheL , et al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. European Journal of Cancer2006;42(8):1014-30. [PMID: 16574401]">Trautinger 2006</a>; <a href="./references#CD008946-bbs2-0182" title="WhittakerSJ , MarsdenJR , SpittleM , Russell JonesR . Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas. British Journal of Dermatology2003;149(6):1095-107. [PMID: 14696593]">Whittaker 2003</a>). Also, an expectant policy with careful monitoring is recommended, since life expectancy is similar to age‐matched control groups (<a href="./references#CD008946-bbs2-0136" title="KimYH , JensenRA , WatanabeGL , VargheseA , HoppeRT . Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-term outcome analysis. Archives of Dermatology1996;132(11):1309-13. [PMID: 8915308]">Kim 1996</a>; <a href="./references#CD008946-bbs2-0190" title="ZackheimHS , AminS , Kashani-SabetM , McMillanA . Prognosis in cutaneous T-cell lymphoma by skin stage: Long-term survival in 489 patients. Journal of the American Academy of Dermatology1999;40(3):418-25. [PMID: 10071312]">Zackheim 1999</a>). </p> <p>In later stages of the disease, systemic treatment approaches are recommended. These include chemotherapy, extracorporeal photochemotherapy, biological response modifiers and combinations of these therapies (<a href="./references#CD008946-bbs2-0110" title="DummerR , DreylingM . Primary cutaneous lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Annals of Oncology2008;19(Suppl 2):ii72-6. [PMID: 18456777]">Dummer 2008</a>; <a href="./references#CD008946-bbs2-0118" title="GilsonD , WhittakerSJ , ChildFJ , ScarisbrickJJ , IllidgeTM , ParryEJ , et al. British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018. British Journal of Dermatology2019;180(3):496-526. [PMID: 30561020]">Gilson 2019</a>; <a href="./references#CD008946-bbs2-0172" title="TrautingerF , KnoblerR , WillemzeR , PerisK , StadlerR , LarocheL , et al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. European Journal of Cancer2006;42(8):1014-30. [PMID: 16574401]">Trautinger 2006</a>; <a href="./references#CD008946-bbs2-0182" title="WhittakerSJ , MarsdenJR , SpittleM , Russell JonesR . Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas. British Journal of Dermatology2003;149(6):1095-107. [PMID: 14696593]">Whittaker 2003</a>). Extracorporeal photochemotherapy is a procedure by which leucocytes are first sensitised to ultraviolet‐A light (UVA) via 8‐methoxypsoralen followed by irradiation with UVA leading to modulation of the immune system. Biological response modifiers represent a group of substances which modify the immune response in manifold ways. </p> </section> <section id="CD008946-sec-0017"> <h3 class="title" id="CD008946-sec-0017">How the intervention might work</h3> <p>Mycosis fungoides is a rare disease affecting the skin, lymph nodes and blood. Based on severity of the disease (clinical stage), there are different treatment options (<a href="./references#CD008946-bbs2-0173" title="TrautingerF , EderJ , AssafC , BagotM , CozzioA , DummerR , et al. European organisation for research and treatment of cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017. European Journal of Cancer2017;77:57-74. [DOI: 10.1016/j.ejca.2017.02.027] [PMID: 28365528]">Trautinger 2017</a>). Since most people present with early stage disease, with the disease appearing as patches and plaques on the skin, topical and skin‐directed therapies are commonly used. Disease progression with involvement of the blood, lymph nodes, or other organs is possible. At this stage of disease more aggressive therapies are often required. Potential mechanisms of action are induction of apoptosis (programmed cell death) in malignant T‐lymphocytes (<a href="./references#CD008946-bbs2-0187" title="YooEK , RookAH , ElenitsasR , GasparroFP , VowelsBR . Apoptosis induction of ultraviolet light A and photochemotherapy in cutaneous T-cell Lymphoma: relevance to mechanism of therapeutic action. Journal Investigative Dermatology1996;107(2):235-42. [PMID: 8757769]">Yoo 1996</a>) and modulation of the immune system (<a href="./references#CD008946-bbs2-0168" title="SpaccarelliN , RookAH . The use of interferons in the treatment of cutaneous T-cell lymphoma. Dermatologic Clinics2015;33(4):731-45. [PMID: 26433845]">Spaccarelli 2015</a>). </p> <p>We hereby present a brief overview of the different treatment options, which were investigated in the included trials. </p> <section id="CD008946-sec-0018"> <h4 class="title">Topical glucocorticoids</h4> <p>Topical glucocorticoids are commonly used for early stage disease. Glucocorticoids are known for their manifold effects in the human body. Treatment with topical glucocorticoids may lead to the induction of apoptosis in neoplastic lymphocytes (<a href="./references#CD008946-bbs2-0165" title="SchwartzmanR , CidlowskiJ . Glucocorticoid-induced apoptosis of lymphoid cells. International Archives of Allergy and Immunology1994;105(4):347-54. [PMID: 7981603]">Schwartzman 1994</a>). </p> </section> <section id="CD008946-sec-0019"> <h4 class="title">Topical peldesine</h4> <p>Peldesine is a pyrimidine analogue and inhibitor of nucleoside phosphorylase. By acting as a pyrimidine analogue, it inhibits T‐cell proliferation, which presumably eases the symptoms of mycosis fungoides patients (<a href="./references#CD008946-bbs2-0005" title="DuvicM , OlsenEA , OmuraGA , MaizeJC , VonderheidEC , et al. A phase III, randomized, double-blind, placebo-controlled study of peldesine (BCX-34) cream as topical therapy for cutaneous T-cell lymphoma. Journal of the American Academy of Dermatology2001;44(6):940-7. [CENTRAL: CN-00348073] [PMID: 11369904]">Duvic 2001a</a>). </p> </section> <section id="CD008946-sec-0020"> <h4 class="title">Topical imiquimod</h4> <p>Topical treatment with imiquimod causes a local immune response modification by acting as an agonist of toll‐like receptor 7. This leads to a local cytokine shift and modification of the immune response. The stimulated immune system then eliminates the altered T‐cells causing mycosis fungoides (<a href="./references#CD008946-bbs2-0162" title="SauderDN . Imiquimod: modes of action. British Journal of Dermatology2003;149(s66):5-8.">Sauder 2003</a>). </p> </section> <section id="CD008946-sec-0021"> <h4 class="title">Topical hypericin</h4> <p>Hypericin is a photosensitising agent which produces oxidative stress via superoxide radicals. In combination with visible light or UVA, it induces apoptosis in malignant T‐cells (<a href="./references#CD008946-bbs2-0012" title="RookAH , WoodGS , DuvicM , VonderheidEC , TobiaA , CabanaB . A phase II placebo-controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis. Journal of the American Academy of Dermatology2010;63(6):984-90. [CENTRAL: CN-00772559] [PMID: 20889234]">Rook 2010</a>). </p> </section> <section id="CD008946-sec-0022"> <h4 class="title">Interferon‐α</h4> <p>Interferon‐α is known to have antiproliferative effects on malignant T‐cells (<a href="./references#CD008946-bbs2-0019" title="WolffJM , ZitelliJA , RabinBS , SmilesKA , AbellE . Intralesional interferon in the treatment of early mycosis fungoides. Journal of the American Academy of Dermatology1985;13(4):604-12. [CENTRAL: CN-00040943] [PMID: 2934438]">Wolff 1985</a>). It is approved by European Medicines Agency (EMA) for the treatment of CTCL. </p> </section> <section id="CD008946-sec-0023"> <h4 class="title">Mechlorethamine/nitrogen mustard</h4> <p>Mechlorethamine is an alkylating agent with cytotoxic effects preventing cell duplication via binding to deoxyribonucleic acid (DNA) (<a href="./references#CD008946-bbs2-0017" title="VonderheidEC , ThompsonR , SmilesKA , LattanandA . Recombinant interferon alfa-2b in plaque-phase mycosis fungoides. Intralesional and low-dose intramuscular therapy. Archives of Dermatology1987;123(6):757-63. [CENTRAL: CN-00047990] [PMID: 3579357]">Vonderheid 1987</a>; <a href="./references#CD008946-bbs2-0019" title="WolffJM , ZitelliJA , RabinBS , SmilesKA , AbellE . Intralesional interferon in the treatment of early mycosis fungoides. Journal of the American Academy of Dermatology1985;13(4):604-12. [CENTRAL: CN-00040943] [PMID: 2934438]">Wolff 1985</a>). </p> </section> <section id="CD008946-sec-0024"> <h4 class="title">Psoralen + UVA (PUVA)</h4> <p>There are several modes of action attributed to PUVA like generation of reactive oxygen species, inhibition of DNA synthesis and mitochondrial dysfunction (<a href="./references#CD008946-bbs2-0020" title="WozniakMB , TraceyL , Ortiz-RomeroPL , MontesS , AlvarezM , FragaJ , et al. Psoralen plus ultraviolet A +/- interferon-alpha treatment resistance in mycosis fungoides: the role of tumour microenvironment, nuclear transcription factor-kappaB and T-cell receptor pathways. British Journal of Dermatology2008;160(1):92-102. [CENTRAL: CN-00668828] [PMID: 18945306]">Wozniak 2008</a>). </p> </section> <section id="CD008946-sec-0025"> <h4 class="title">Total skin electron beam therapy (TSEBT)</h4> <p>TSEBT results in cytotoxic effects such as DNA damage, which ultimately induces cellular death within the radiation field (<a href="./references#CD008946-bbs2-0007" title="KayeF , EddyJ , IhdeDC , SteinbergS , FischmannAB , GlatsteinE , et al. Conservative vs. aggressive therapy in mycosis fungoides. Proceedings of the American Society of Clinical Oncology1989;8:257. [CENTRAL: CN-00694960] KayeF , IhdeD , FischmannA , GlatsteinE , MinnaJ , SchechterG , et al. A randomized trial comparing conservative and aggressive therapy in mycosis fungoides (MF). Proceedings of the American Society of Clinical Oncology1986;5:195. [CENTRAL: CN-00695166] KayeFJ , BunnPA , SteinbergSM , StockerJL , IhdeDC , FischmannAB , et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. New England Journal of Medicine1989;321(26):1784-90. [CENTRAL: CN-00064211] [PMID: 2594037]">Kaye 1989</a>). </p> </section> <section id="CD008946-sec-0026"> <h4 class="title">Denileukin diftitox</h4> <p>Denileukin diftitox influences protein synthesis in cells that express the IL‐2 receptor, which in the case of T‐cell leads to downregulation of proliferation and differentiation (<a href="./references#CD008946-bbs2-0010" title="DuvicM , KuzelTM , OlsenEA , MartinAG , FossFM , KimYH , et al. Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK). Clinical Lymphoma2002;2(4):222-8. [CENTRAL: CN-00514479] [PMID: 11970761]KuzelT , OlsenE , MartinA , KimY , DuvicM , FrankelA , et al. Pivotal phase III trial of two dose levels of DAB389IL-2 (Ontak®) for the treatment of mycosis fungoides (MF). Blood1997;90(10 Suppl 1 (Pt 1)):586a. [CENTRAL: CN-00518069] NTC00050999. Study of ONTAK (Denileukin Diftitox) in cutaneous T-Cell lymphoma (CTCL) patients. clinicaltrials.gov/ct2/show/NCT00050999 (first received 3 January 2003). OlsenE , DuvicM , FrankelA , KimY , MartinA , VonderheidE , et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. Journal of Clinical Oncology2001;19(2):376-88. [CENTRAL: CN-00328506] [PMID: 11208829]OlsenE , DuvicM , MartinA . Pivotal phase III trial of two dose levels of DAB 389 IL-2 (ONTAK) for the treatment of cutaneous T-cell lymphoma (CTCL). Journal of Investigative Dermatology1998;110(4):678. [CENTRAL: CN-00353452] ">Olsen 2001</a>). </p> </section> <section id="CD008946-sec-0027"> <h4 class="title">Bexarotene</h4> <p>Bexarotene belongs to the group of retinoids which modify cellular differentiation and growth via activation of retinoid X receptors (<a href="./references#CD008946-bbs2-0018" title="NCT00056056. Ultraviolet light therapy using methoxsalen with or without Bexarotene in treating patients with mycosis fungoides. clinicaltrials.gov/ct2/show/NCT00056056 (first received 7 March 2003). WhittakerS , OrtizP , DummerR , RankiA , HasanB , MeulemansB , et al. Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial 21011 (NCT00056056). British Journal of Dermatology2012;167(3):678-87. [CENTRAL: CN-00856432] [PMID: 22924950]WhittakerS , Ortiz-RomeroPL , DummerR , RankiA , HasanB , MeulemansB , et al. Efficacy and safety of bexarotene combined with psoralen/ultraviolet A light (PUVA) compared to PUVA treatment alone in stage IB-IIa mycosis fungoides (MF): Final results from EORTC cutaneous lymphoma task force (CLTF) phase III clinical trial 21011. Journal of Clinical Oncology2012;30(15 Suppl 1):8076. ">Whittaker 2012</a>). It was approved by the EMA for CTCL because its benefits were evaluated greater than its risks. </p> </section> <section id="CD008946-sec-0028"> <h4 class="title">Lenalidomide</h4> <p>Lenalidomide is an immunomodulator and has multiple mechanisms of action, e.g. inhibition of proliferation of certain haematopoietic tumour cells (<a href="./references#CD008946-bbs2-0001" title="BagotM , HasanB , WhittakerS , Beylot-BarryM , KnoblerR , ShahE , et al. A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma - EORTC 21081 (NCT01098656): results and lessons learned for future trial designs. European Journal of Dermatology2017;27(3):286–94. [CENTRAL: CN-01395486] [PMID: 28468739]NCT01098656. A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-Cell lymphoma. clinicaltrials.gov/ct2/show/NCT01098656 (first received 5 April 2010). [NCT01098656]">Bagot 2017</a>). </p> </section> <section id="CD008946-sec-0029"> <h4 class="title">Brentuximab vedotin</h4> <p>CD30 is frequently expressed in cutaneous T‐cell lymphoma making it targetable by the CD30‐antibody brentuximab vedotin (<a href="./references#CD008946-bbs2-0011" title="HorwitzS , WhittakerS , DuvicM , DummerR , KimYH , ScarisbrickJ , et al. Response by stage in CD30-positive (CD30+) cutaneous T cell lymphoma (CTCL) patients receiving brentuximab vedotin (BV) vs physician's choice (PC) in the phase 3 ALCANZA study. In: Hematological oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:245–7. [CENTRAL: CN-01408605] [DOI: 10.1002/hon.2438]HorwitzSM , AkilovOE , FisherD , KuzelTM , WangY , Palanca-WesselsMC , et al. Brentuximab vedotin or physician’s choice in CD30-positivecutaneous T-cell lymphoma (ALCANZA): an international,open-label, randomised, phase 3, multicentre trial. Lancet2017;390(10094):555-66. [CENTRAL: CN-01403731] HorwitzSM , ScarisbrickJJ , DummerR , DuvicM , KimYH , WalewskiJ , et al. Updated analyses of the international, open-label, randomized, phase 3 alcanza study: longer-term evidence for superiority of brentuximab vedotin versus methotrexate or bexarotene for CD30-positive cutaneous T-cell lymphoma (CTCL). In: Blood. Conference: 59th annual meeting of the american society of hematology, ASH 2017. United states. Vol. 130. 2017. [CENTRAL: CN-01450312] KimYH , PrinceHM , WhittakerS , HorwitzSM , DuvicM , ScarisbrickJ , et al. Brentuximab vedotin vs physician's choice in CTCL patients from the phase 3 ALCANZA study: analysis of outcomes by CD30 expression. In: Hematological Oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:77–8. [CENTRAL: CN-01408482] [DOI: 10.1002/hon.2437]KimYH , PrinceHM , WhittakerS , HorwitzSM , DuvicM , ScarisbrickJ , et al. Outcomes by CD30 expression in patients with CTCL receiving brentuximab vedotin (BV) vs physician's choice (PC) in the Phase 3 ALCANZA study. Journal of Clinical Oncology2017;35(15 Supplement 1):7517. [EMBASE: 617388795]KimYH , WhittakerS , DummerR , GeskinLJ , GauthierP , LittleM , et al. Phase 3 study of brentuximab vedotin versus physician's choice of methotrexate or bexarotene in patients (PTS) with CD30-positive (CD30+) cutaneous T-cell lymphoma (CTCL). The alcanza study. Hematological Oncology2013;31(Suppl 1):278. [CENTRAL: CN-01531598] [EMBASE: 71147875]KimYH , WhittakerS , HorwitzSM , DuvicM , DummerR , ScarisbrickJ , et al. Brentuximab vedotin demonstrates superior activity to standard therapy in CD30-expressing (CD30+) cutaneous T-cell lymphoma (CTCL) in the randomized phase 3 ALCANZA study. Journal of Investigative Dermatology2017;137(5 Suppl 1):S45. [CENTRAL: CN-01375469] [EMBASE: 616393777]KimYH , WhittakerS , HorwitzSM , DuvicM , DummerR , ScarisbrickJJ , et al. Brentuximab vedotin demonstrates significantly superior clinical outcomes in patients with CD30-expressing cutaneous T cell lymphoma versus physician's choice (Methotrexate or Bexarotene): the phase 3 alcanza study. In: Blood. Conference: 58th annual meeting of the american society of hematology, ASH 2016. United states. Conference start: 20161203. Conference end: 20161206. Vol. 128. 2016. [CENTRAL: CN-01303081] [EMBASE: 614225065]NCT01578499. A randomised, open-label, phase 3 trial of brentuximab vedotin (SGN-35) versus physician's choice (methotrexate or bexarotene) in patients with CD30-positive cutaneous T-cell lymphoma. clinicaltrials.gov/ct2/show/NCT01578499 (first received 17 April 2012). PrinceHM , DummerR , WhittakerS , HorwitzS , DuvicM , ScarisbrickJ , et al. Patient-reported outcomes and quality of life in patients with cutaneous T cell lymphoma: results from the phase 3 ALCANZA study. In: Hematological Oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:247–8. [CENTRAL: CN-01408603] [DOI: 10.1002/hon.2438]ZagadailovE , PrinceHM , WhittakerS , HorwitzS , DuvicM , KimY , et al. Phase 3 alcanza study of brentuximab vedotin (BV) or physician's choice (PC) of methotrexate (MTX) or bexarotene (BEX) in CD30-positive cutaneous T-cell lymphoma (CTCL): number needed to treat analysis. In: Haematologica. Conference: 22th congress of the european hematology association. Spain. Vol. 102. 2017:251. [CENTRAL: CN-01399195] ">Prince 2017</a>). Its approval was based on a significant benefit over treatment with bexarotene or methotrexate with an acceptable safety profile. </p> </section> <section id="CD008946-sec-0030"> <h4 class="title">Mogamulizumab</h4> <p>Mogamulizumab is a monoclonal antibody targeting C‐C chemokine receptor 4. The mechanisms of action include antibody opsonisation of malignant T‐cells leading to the elimination of said cells by Natural killer cells. Mogamulizumab is FDA and EMA approved for patients with mycosis fungoides or Sézary syndrome who received a previous systemic treatment (<a href="./references#CD008946-bbs2-0008" title="BagotM , DalleS , SokolL , TsianakasA , MusiekA , Ortiz-RomeroP , et al. Long-term clinical benefit to anti-CCR4 mogamulizumab: results from the phase 3 mavoric study in previously treated cutaneous t-cell lymphoma (CTCL). Blood2018;132(Supp 1):2901. [DOI: 10.1182/blood-2018-99-118473]CowanR , ScarisbrickJ , DwyerK , LeoniM , GrebennikD , MorrisS . Mogamulizumab demonstrates significant improvement in PFS compared to vorinostat in patients with previously treated cutaneous T-cell lymphoma (CTCL). British Journal of Haematology2018;181(S1):77–8. [DOI: 10.1111/bjh.15226]KimYH , BagotM , Pinter-BrownL , RookAH , PorcuP , HorwitzSM , et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncology2018;19(9):1192-1204. [PMID: 30100375]NCT01728805. Study of KW-0761 versus vorinostat in relapsed/refractory CTCL. clinicaltrials.gov/ct2/show/NCT01728805 (first received 20 November 2012). PorcuP , HudgensS , QuaglinoP , CowanR , FlodenL , LeoniM , et al. Quality of life in cutaneous T-cell lymphoma subjects treated with anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat: results from the phase 3 MAVORIC trial. Journal of Clinical Oncology2018;36(15):-. [DOI: 10.1097/HS9.0000000000000060]QuaglinoP , HudgensS , PorcuP , CowanR , FlodenL , TsianakasA , et al. Quality of life in cutaneous t-cell lymphoma subjects treated with the anti-ccr4 monoclonal antibody mogamulizumab versus vorinostat: results from the phase 3 mavoric trial. Hemasphere2018;2(S1):85. ScarisbrickJ , ZinzaniPL , HorwitzS , KimYH , MoskowitzAJ , PorcuP , et al. Efficacy of mogamulizumab by prior systemic therapy in patients with previously treated cutaneous T-cell lymphoma: Post hoc analysis from the phase 3 MAVORIC study. British Journal of Haematology2019;185(Suppl 1):94. TsianakasA , QuaglinoP , HudgensS , FlodenL , LeoniM , DaleS , et al. Quality of life in cutaneous T-cell lymphoma subjects treated with the anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat: Results from the phase 3 MAVORIC trial. Oncology Research and Treatment2018;41(Suppl 4):272. ZinzaniPL , HorwitzSM , KimYH , MoskowitzAJ , PorcuP , ScarisbrickJ , et al. Efficacy of mogamulizumab by prior systemic therapy in patients with previously treated cutaneous T-cell lymphoma: post hoc analysis from the phase 3 mavoric study. Blood2018;132(Suppl 1):1619. [DOI: 10.1182/blood-2018-99-114819]">Kim 2018</a>). </p> </section> <section id="CD008946-sec-0031"> <h4 class="title">Extracorporeal photopheresis</h4> <p>Extracorporeal photopheresis is a procedure by which leucocytes are first sensitised to ultraviolet‐A light (UVA ) via 8‐methoxypsoralen followed by irradiation with UVA leading to modulation of the immune system (<a href="./references#CD008946-bbs2-0002" title="ChildFJ , MitchellTJ , WhittakerSJ , ScarisbrickJJ , SeedPT , Russel-JonesR . A randomized cross-over study to compare PUVA and extracorporeal photopheresis in the treatment of plaque stage (T2) mycosis fungoides. Clinical &amp; Experimental Dermatology2004;29(3):231-6. [CENTRAL: CN-00468455] [PMID: 15115499]ChildFJ , MitchellTJ , WhittakerSJ , WatkinsP , SeedP , Russell-JonesR . A randomised cross-over study to compare Puva and extracorporeal photopheresis (ECP) in the treatment of plaque stage (T2) mycosis fungoides. British Journal of Dermatology2001;145(Suppl 59):16. [CENTRAL: CN-00430854] ">Child 2004</a>). </p> </section> <section id="CD008946-sec-0032"> <h4 class="title">Stem cell transplantation</h4> <p>Stem cell transplantation is a complex therapy where bone marrow containing healthy lymphocytes is implanted in the patient. When stem cells from other people are used (allogeneic stem cell transplantation), there is a possibility that the donor lymphocytes eliminate the neoplastic lymphocytes causing mycosis fungoides (<a href="./references#CD008946-bbs2-0108" title="DuarteR , CanalsC , OnidaF , GabrielI , ArranzR , ArceseW , et al. Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.. Journal of Clinical Oncology2010;28(29):4492-9. [PMID: 20697072]">Duarte 2010</a>). </p> </section> </section> <section id="CD008946-sec-0033"> <h3 class="title" id="CD008946-sec-0033">Why it is important to do this review</h3> <p>As described above, there is a wide variety of available treatment options for mycosis fungoides. However, published reports on treatment options differ in terms of trial design, risk of bias, internal and external validity of the results and assessment of adverse effects. A systematic evaluation of these different characteristics is therefore warranted. As <a href="./references#CD008946-bbs2-0130" title="HummeD , NastA , ErdmannR , VanderseeS , BeyerM . Systematic review of combination therapies for mycosis fungoides. Cancer Treatment Reviews2014;40(8):927-33. [PMID: 24997678]">Humme 2014</a> pointed out, mycosis fungoides is an uncommon disease, which leads to difficulties recruiting patients for well‐designed randomised controlled trials (RCTs). Furthermore, it is likely that costs and logistical difficulties discourage investigators to initiate new RCTs. For these reasons, it is particularly important to assess the already available evidence. A systematic review of the evidence for benefits and harms will help decision‐making in individual clinical situations. It will also help in the process of developing evidence‐based clinical guidelines for the treatment of this disease. Since the initial review (<a href="./references#CD008946-bbs2-0192" title="WeberschockT , StrametzR , LorenzM , RölligC , BunchC , BauerA , et al. Interventions for mycosis fungoides. Cochrane Database of Systematic Reviews2012, Issue 9. [DOI: 10.1002/14651858.CD008946.pub2]">Weberschock 2012</a>), several potentially relevant RCTs have been published investigating new interventions, which makes an update necessary. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD008946-sec-0034" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD008946-sec-0034"></div> <p>To assess the effects of interventions for mycosis fungoides in all stages of the disease. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD008946-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD008946-sec-0035"></div> <section id="CD008946-sec-0036"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD008946-sec-0037"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs) of adults in which at least 90% were diagnosed with histologically‐confirmed mycosis fungoides (classical "Alibert‐Bazin" type). In contrast to the protocol (<a href="./references#CD008946-bbs2-0191" title="WeberschockT , RehbergerP , RoelligC , BunchC , SchmittJ , BauerA . Interventions for mycosis fungoides. Cochrane Database of Systematic Reviews2011, Issue 1. [DOI: 10.1002/14651858.CD008946]">Weberschock 2011</a>), we included studies with different investigated diseases (e.g. mycosis fungoides and other lymphomas), but separate outcome data for the mycosis fungoides cohort meeting our inclusion criteria had to be available. </p> <p>For the analysis of the efficacy of interventions for mycosis fungoides, we excluded quasi‐randomised studies (e.g. alternate treatment allocation or by date of birth), as we considered this study design to be poor quality and likely to lead to unreliable study results. However, for the qualitative analysis of the safety of interventions, we included quasi‐randomised RCTs or non‐randomised studies since RCTs are known to have limited statistical power to detect rare adverse effects (<a href="./references#CD008946-bbs2-0127" title="HigginsJP , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>). For these studies we did not perform a formal qualitative assessment. A tabulated presentation of the rare adverse effects can be found in <a href="#CD008946-tbl-0010">Table 5</a>. </p> <div class="table" id="CD008946-tbl-0010"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Rare adverse effects detected by separate adverse event search</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Intervention</b>  </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Rare severe adverse effects</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PUVA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>transient lymphomatoid papulosis (<a href="./references#CD008946-bbs2-0091" title="AronssonA , JonssonN , TegnerE . Transient lymphomatoid papulosis in mycosis fungoides. Acta Dermato-Venereologica1982;62(6):529-31.">Aronsson 1982</a>)<br/>basal cell carcinoma/squamous cell carcinoma (<a href="./references#CD008946-bbs2-0126" title="HerrmannJJ , Roenigk HH Jr, HurriaA , KuzelTM , SamuelsonE , RademakerAW , et al. Treatment of mycosis fungoides with photochemotherapy (PUVA): long-term follow-up. Journal of the American Academy of Dermatology1995;33(2 Pt 1):234-42.">Herrmann 1995</a>)<br/>squamous cell carcinoma (<a href="./references#CD008946-bbs2-0152" title="MolinL , ThomsenK , VoldenG , GrothO . Photochemotherapy (PUVA) in the pretumour stage of mycosis fungoides: a report from the Scandinavian Mycosis Fungoides Study Group. Acta Dermatovenereologica (Stockholm)1981;61(1):47-51.">Molin 1981</a>)<br/>cataract (<a href="./references#CD008946-bbs2-0160" title="RupoliS , GoteriG , PuliniS , FilosaA , TassettiA , OffidaniM , et al. Long-term experience with low-dose interferon-alpha and PUVA in the management of early mycosis fungoides. European Journal of Haematology2005;75(2):136-45.">Rupoli 2005</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>extracorporeal photopheresis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>sarcoma (<a href="./references#CD008946-bbs2-0140" title="KorpusikD , HomeyB , StegeH , Bruch-GerharzD , SchulteKW . Mycosis fungoides: Complications of long-term treatment with PUVA and ECP [Mycosis fungoides: Komplikationen einer Langzeitbehandlung mit PUVA und ECP]. Hautarzt2007;58(4):298-9. [EMBASE: 46623430]">Korpusik 2007</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>imiquimod</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no reported SAEs found</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>electron beam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total epilation (<a href="./references#CD008946-bbs2-0096" title="BravermanIM , YagerNB , ChenM , CadmanEC , HaitWN , MaynardT . Combined total body electron beam irradiation and chemotherapy for mycosis fungoides. Journal of the American Academy of Dermatology1987;16(1 Pt 1):45-60.">Braverman 1987</a>, <a href="./references#CD008946-bbs2-0107" title="DesaiKR , PeznerRD , LipsettJA , VoraNL , LukKH , WongJY , et al. Total skin electron irradiation for mycosis fungoides: relationship between acute toxicities and measured dose at different anatomic sites. International Journal of Radiation Oncology, Biology, Physics1988;15(3):641-5.">Desai 1988</a>),<br/>nail dystrophy/oedema of hands and feet/bullae dorsum and feet/conjunctivitis/hospitalisation due to skin ulcers (<a href="./references#CD008946-bbs2-0107" title="DesaiKR , PeznerRD , LipsettJA , VoraNL , LukKH , WongJY , et al. Total skin electron irradiation for mycosis fungoides: relationship between acute toxicities and measured dose at different anatomic sites. International Journal of Radiation Oncology, Biology, Physics1988;15(3):641-5.">Desai 1988</a>)<br/>diffuse permanent telangiectasia/linear sclerosis/Ischaemic ulceration of finger tips (<a href="./references#CD008946-bbs2-0146" title="MicailyB , VonderheidEC , BradyLW . Combined moderate dose electron beam radiotherapy and topical chemotherapy for cutaneous T-Cell lymphoma. International Journal of Radiation Oncology, Biology, Physics1983;9(4):475-9.">Micaily 1983</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>cyclophosphamide, doxorubicin, etoposide, vincristine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>haematological toxicity: febrile neutropenia/staphylococcal bacteraemia/disseminated herpes infection/pneumocystis carinii pneumonia/neurologic toxicity grade 3/decreased left ventricular ejection fraction (<a href="./references#CD008946-bbs2-0090" title="AkpekG , KohHK , BogenS , O'HaraC , FossFM . Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma. Cancer1999;86(7):1368-76.">Akpek 1999</a>) </p> <p>pulmonary embolism and death due to drug‐related cardiac infarction reported for doxorubicin monotherapy (<a href="./references#CD008946-bbs2-0111" title="DummerR , QuaglinoP , BeckerJC , HasanB , KarraschM , WhittakerS , et al. Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012. Journal of Clinical Oncology2012;30(33):4091-7.">Dummer 2012</a>) </p> <p>nephrotic syndrome (<a href="./references#CD008946-bbs2-0135" title="KairouaniM , SekkateS , IsmailiN , AbahssainH , ErrihaniH . A rare case of nephrotic syndrome revealing mycosis fungoide managed successfully with chemotherapy. Pan African Medical Journal2012;12:67.">Kairouani 2012</a>) </p> <p>acute nonlymphocytic leukaemia reported for combination of CHOP with TSEBT (<a href="./references#CD008946-bbs2-0007" title="KayeF , EddyJ , IhdeDC , SteinbergS , FischmannAB , GlatsteinE , et al. Conservative vs. aggressive therapy in mycosis fungoides. Proceedings of the American Society of Clinical Oncology1989;8:257. [CENTRAL: CN-00694960] KayeF , IhdeD , FischmannA , GlatsteinE , MinnaJ , SchechterG , et al. A randomized trial comparing conservative and aggressive therapy in mycosis fungoides (MF). Proceedings of the American Society of Clinical Oncology1986;5:195. [CENTRAL: CN-00695166] KayeFJ , BunnPA , SteinbergSM , StockerJL , IhdeDC , FischmannAB , et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. New England Journal of Medicine1989;321(26):1784-90. [CENTRAL: CN-00064211] [PMID: 2594037]">Kaye 1989</a>) </p> <p>reticulated generalised skin pigmentation reported for combination of cyclophosphamide with prednisone (<a href="./references#CD008946-bbs2-0188" title="YoussefM , MokniS , BelhadjaliH , AouemK , MoussaA , LaatiriA , et al. Cyclophosphamide-induced generalised reticulated skin pigmentation: a rare presentation. International Journal of Clinical Pharmacy2013;35(3):309-12.">Youssef 2013</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>active transfer factor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no reported SAEs found</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>methotrexate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>severe oedematous erythroderma/denudation on the trunk and extremities/Interstitial pulmonary fibrosis (<a href="./references#CD008946-bbs2-0189" title="ZackheimHS , Kashani-SabetM , HwangST . Low-dose methotrexate to treat erythrodermic cutaneous T-cell lymphoma: results in twenty-nine patients. Journal of the American Academy of Dermatology1996;34(4):626-31.">Zackheim 1996</a>) </p> <p>epidermal necrosis (<a href="./references#CD008946-bbs2-0148" title="MnaAB , SouissiA , HalouaniS , El EuchD , ZahaniA , KchirN , et al. Methotrexate-induced necrolysis in tumoral-stage mycosis fungoides: a challenging diagnosis. Dermatology Online Journal2016;22(1):16.">Mna 2016</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>interferon‐alpha</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>acrocyanosis (<a href="./references#CD008946-bbs2-0098" title="Campo-VoegeliA , EstrachT , MartiRM , CorominasN , TusetM , MascaróJM . Acrocyanosis induced by interferon alpha(2a). Dermatology1998;196(3):361-3.">Campo‐Voegeli 1998</a>)<br/>oropharyngeal lichen planus (<a href="./references#CD008946-bbs2-0141" title="KüttingB , BöhmM , LugerTA , BonsmannG . Oropharyngeal lichen planus associated with interferon-alpha treatment for mycosis fungoides: a rare side-effect in the therapy of cutaneous lymphomas. British Journal of Dermatology1997;137(5):836-7.">Kütting 1997</a>)<br/>seizures (<a href="./references#CD008946-bbs2-0142" title="Legroux-CrespelE , LafayeS , MahéE , Picard-DahanC , CrickxB , SassolasB , et al. Seizures during interferon alpha therapy: three cases in dermatology. Annales de Dermatologie et de Venereologie2003;130(2 Pt 1):202-4.">Legroux‐Crespel 2003</a>)<br/>fatal neutropenia and sepsis (<a href="./references#CD008946-bbs2-0176" title="VegnaML , PapaG , DefazioD , PisaniF , CoppolaG , De PitàO , et al. Interferon alpha-2a in cutaneous T-cell lymphoma. European Journal of Haematology. Supplementum1990;52:32-5.">Vegna 1990</a>)<br/>liver toxicity (<a href="./references#CD008946-bbs2-0160" title="RupoliS , GoteriG , PuliniS , FilosaA , TassettiA , OffidaniM , et al. Long-term experience with low-dose interferon-alpha and PUVA in the management of early mycosis fungoides. European Journal of Haematology2005;75(2):136-45.">Rupoli 2005</a>, <a href="./references#CD008946-bbs2-0166" title="SimoniR , CavalieriR , CoppolaG , RicciottiL , De PitàO , CriscuoloD , et al. Recombinant leukocyte interferon alfa-2a in the treatment of mycosis fungoides. Journal of Biological Regulators and Homeostatic Agents1987;1(2):93-9.">Simoni 1987</a>, <a href="./references#CD008946-bbs2-0176" title="VegnaML , PapaG , DefazioD , PisaniF , CoppolaG , De PitàO , et al. Interferon alpha-2a in cutaneous T-cell lymphoma. European Journal of Haematology. Supplementum1990;52:32-5.">Vegna 1990</a>) </p> <p>generalised urticaria in association with angio‐oedema (<a href="./references#CD008946-bbs2-0132" title="HüskenAC , TsianakasA , HensenP , NashanD , LoquaiC , BeissertS , et al. Comparison of pegylated interferon α-2b plus psoralen PUVA versus standard interferon α-2a plus PUVA in patients with cutaneous T-cell lymphoma. Journal of the European Academy of Dermatology and Venereology : JEADV2012;26(1):71-8.">Hüsken 2012</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>bexarotene</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>neutropenia/non‐ST‐elevation myocardial infarction/elevated liver enzymes (<a href="./references#CD008946-bbs2-0088" title="AbbottRA , WhittakerSJ , MorrisSL , Russell-JonesR , HungT , BashirSJ , et al. Bexarotene therapy for mycosis fungoides and Sézary syndrome. British Journal of Dermatology2009;160(6):1299-307.">Abbott 2009</a>)<br/>lethal sepsis (<a href="./references#CD008946-bbs2-0094" title="BohmeyerJ , StadlerR , KremerA , NashanD , MucheM , GellrichS , et al. Bexarotene--an alternative therapy for progressive cutaneous T-cell lymphoma? First experiences. Journal der Deutschen Dermatologischen Gesellschaft [Journal of the German Society of Dermatology]2003;1(10):785-9.">Bohmeyer 2003</a>) </p> <p>pancreatitis (<a href="./references#CD008946-bbs2-0112" title="DuvicM , HymesK , HealdP , BrenemanD , MartinAG , MyskowskiP , et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. Journal of Clinical Oncology2001;19(9):2456-71.">Duvic 2001b</a>) </p> <p>bleeding gastric ulcer (<a href="./references#CD008946-bbs2-0167" title="Sokolowska-WojdyloM , FlorekA , ZauchaJM , ChmielowskaE , GizaA , Knopinska-PoslusznyW , et al. Polish lymphoma research group experience with bexarotene in the treatment of cutaneous T-cell lymphoma. American Journal of Therapeutics2016;23(3):e749-56.">Sokolowska‐Wojdylo 2016</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>peldesine (BCX‐34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no reported SAEs found</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>denileukin diftitox (ONTAK)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>capillary leak syndrome (<a href="./references#CD008946-bbs2-0113" title="DuvicM , KuzelTM , OlsenEA , MartinAG , FossFM , KimYH , et al. Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK). Clinical Lymphoma2002;2(4):222-8.">Duvic 2002</a> and <a href="./references#CD008946-bbs2-0114" title="DuvicM , MartinAG , OlsenEA , FivensonDP , PrinceHM . Efficacy and safety of denileukin diftitox retreatment in patients with relapsed cutaneous T-cell lymphoma. Leukemia &amp; Lymphoma2013;54(3):514-9.">Duvic 2013</a>, <a href="./references#CD008946-bbs2-0170" title="TalpurR , DuvicM . Pilot study of denileukin diftitox alternate dosing regimen in patients with cutaneous peripheral T-cell lymphomas. Clinical Lymphoma, Myeloma &amp; Leukemia2012;12(3):180-5.">Talpur 2012</a>) </p> <p>lethal vascular leak syndrome with rhabdomyolysis (<a href="./references#CD008946-bbs2-0092" title="AvarbockAB , LorenAW , ParkJY , Junkins-HopkinsJM , ChoiJ , LitzkyLA , et al. Lethal vascular leak syndrome after denileukin diftitox administration to a patient with cutaneous gamma/delta T-cell lymphoma and occult cirrhosis. American Journal of Hematology2008;83(7):593-5.">Avarbock 2008</a>)<br/>grade 4 infusion event (<a href="./references#CD008946-bbs2-0117" title="FossFM , BachaP , OsannKE , DemierreMF , BellT , KuzelT . Biological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication. Clinical Lymphoma2001;1(4):298-302.">Foss 2001</a>) </p> <p>visual changes (<a href="./references#CD008946-bbs2-0145" title="McCannS , AkilovOE , GeskinL . Adverse effects of denileukin diftitox and their management in patients with cutaneous T-cell lymphoma. Clinical Journal of Oncology Nursing2012;16(5):E164-72.">McCann 2012</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nitrogen mustard</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>urticaria and anaphylactoid reaction (<a href="./references#CD008946-bbs2-0105" title="DaughtersD , ZackheimH , MaibachH . Urticaria and anaphylactoid reactions after topical application of mechlorethamine. Archives of Dermatology1973;107(3):429-30.">Daughters 1973</a>, <a href="./references#CD008946-bbs2-0122" title="GrunnetE . Contact urticaria and anaphylactoid reaction induced by topical application of nitrogen mustard. British Journal of Dermatology1976;94(1):101-3.">Grunnet 1976</a>, <a href="./references#CD008946-bbs2-0161" title="Sánchez YusE , Surárez MartínE . Contact urticaria and anaphylactic reactions induced by topical application of nitrogen mustard. Actas Dermo-Sifiliograficas1977;68(12):39-44.">Sanchez 1977</a>)<br/>local bullous reaction (<a href="./references#CD008946-bbs2-0119" title="GodayJJ , AguirreA , RatónJA , Díaz-PérezJL . Local bullous reaction to topical mechlorethamine (mustine). Contact Dermatitis1990;22(5):306-7.">Goday 1990</a>)<br/>perforating follicular mucinosis (<a href="./references#CD008946-bbs2-0123" title="GuilhouJJ , BarnéonG , MalbosS , PeyronJL , MichelB , MeynadierJ . Perforating follicular mucinosis and immediate hypersensitivity to mechlorethamine in a patient with mycosis fungoides. Annales de Dermatologie et de Venereologie1980;107(1-2):59-62.">Guilhou 1980</a>)<br/>Stevens‐Johnson‐Syndrome (<a href="./references#CD008946-bbs2-0155" title="NewmanJM , RindlerJM , BergfeldWF , BrydonJK . Stevens-Johnson syndrome associated with topical nitrogen mustard therapy. Journal of the American Academy of Dermatology1997;36(1):112-4.">Newman 1997</a>)<br/>cutaneous squamous/basal cell carcinoma (<a href="./references#CD008946-bbs2-0129" title="HoppeRT , AbelEA , DeneauDG , PriceNM . Mycosis fungoides: management with topical nitrogen mustard. Journal of Clinical Oncology1987;5(11):1796-803.">Hoppe 1987</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>brentuximab vedotin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>peripheral neuropathy (<a href="./references#CD008946-bbs2-0115" title="DuvicM , TetzlaffMT , GangarP , ClosAL , SuiD , TalpurR . Results of a phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis. Journal of Clinical Oncology2015;33(32):3759-65.">Duvic 2015</a>, <a href="./references#CD008946-bbs2-0103" title="CorbinZA , Nguyen-LinA , LiS , RahbarZ , TavallaeeM , VogelH , et al. Characterization of the peripheral neuropathy associated with brentuximab vedotin treatment of Mycosis Fungoides and Sézary Syndrome. Journal of Neuro-oncology2017;132(3):439-46.">Corbin 2017</a>) </p> <p>unstable angina or myocardial infarction, pulmonary embolism (<a href="./references#CD008946-bbs2-0115" title="DuvicM , TetzlaffMT , GangarP , ClosAL , SuiD , TalpurR . Results of a phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis. Journal of Clinical Oncology2015;33(32):3759-65.">Duvic 2015</a>) </p> <p>progressive multifocal leukoencephalopathy (<a href="./references#CD008946-bbs2-0099" title="CarsonKR , NewsomeSD , KimEJ , Wagner-JohnstonND , vonGeldernG , MoskowitzCH , et al. Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project. Cancer2014;120(16):2464-71.">Carson 2014</a>) </p> <p>acute renal failure (<a href="./references#CD008946-bbs2-0138" title="KimYH , TavallaeeM , SundramU , SalvaKA , WoodGS , LiS , et al. Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and Sézary syndrome with variable CD30 expression level: a multi-institution collaborative project. Journal of Clinical Oncology2015;33(32):3750–8.">Kim 2015</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>lenalidomide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>thrombocytopenia, pneumonitis, fatigue, dyspnoea, cognitive disturbance, respiratory failure, seizure (<a href="./references#CD008946-bbs2-0109" title="DueckG , ChuaN , PrasadA , FinchD , StewartD , WhiteD , et al. Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma. Cancer2010;116(19):4541-8.">Dueck 2010a</a>) </p> <p>anaemia, lymphopenia, neutropenia, cardiac ischaemia/infarction‐acute myocardial infarction, hypoxia‐respiratory failure, rash, supraventricular arrhythmia (<a href="./references#CD008946-bbs2-0171" title="ToumisheyE , PrasadA , DueckG , ChuaN , FinchD , JohnstonJ , et al. Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma. Cancer2015;121(5):716-23.">Toumishey 2015</a>) </p> <p>pneumonitis, fatigue, cognitive disturbance, dyspnoea (<a href="./references#CD008946-bbs2-0109" title="DueckG , ChuaN , PrasadA , FinchD , StewartD , WhiteD , et al. Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma. Cancer2010;116(19):4541-8.">Dueck 2010a</a>, <a href="./references#CD008946-bbs2-0171" title="ToumisheyE , PrasadA , DueckG , ChuaN , FinchD , JohnstonJ , et al. Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma. Cancer2015;121(5):716-23.">Toumishey 2015</a>) </p> </td> </tr> </tbody> </table> </div> </section> <section id="CD008946-sec-0038"> <h4 class="title">Types of participants</h4> <p>We included studies of adults (aged 18 years or more) diagnosed with histologically‐confirmed mycosis fungoides of the classical "Alibert‐Bazin" type. </p> <p>We excluded studies from this review that included more than 10% of participants with variants and subtypes of mycosis fungoides, such as folliculotropic mycosis fungoides, pagetoid reticulosis, or granulomatous slack skin. </p> </section> <section id="CD008946-sec-0039"> <h4 class="title">Types of interventions</h4> <p>We were interested in comparisons of any local or systemic therapy with either another local or systemic therapy or with placebo. Types of interventions included the following: </p> <p> <ul id="CD008946-list-0002"> <li> <p>topical therapies;</p> </li> <li> <p>skin‐directed phototherapies;</p> </li> <li> <p>total skin electron beam;</p> </li> <li> <p>radiotherapy;</p> </li> <li> <p>chemotherapy;</p> </li> <li> <p>extracorporeal photochemotherapy;</p> </li> <li> <p>biological response modifiers;</p> </li> <li> <p>combination therapies (of the interventions listed above);</p> </li> <li> <p>other skin‐directed treatment approaches; and</p> </li> <li> <p>other systemic treatment approaches.</p> </li> </ul> </p> <p>We made comparisons according to the stage of the disease, whereas the TNMB (tumour, lymph node, metastasis, and blood) classification was used primarily for consideration of the applicability of interventions to be used at a certain disease stage. </p> </section> <section id="CD008946-sec-0040"> <h4 class="title">Types of outcome measures</h4> <p>We investigated the following primary and secondary outcomes.</p> <section id="CD008946-sec-0041"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD008946-list-0003"> <li> <p>Improvement in health‐related quality of life as defined by participant questionnaires (all self‐completed). </p> </li> <li> <p>Common adverse effects of the treatments, presented as proportions of participants.</p> </li> </ol> </p> </section> <section id="CD008946-sec-0042"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD008946-list-0004"> <li> <p>Percentage of participants demonstrating complete response (CR), defined as complete disappearance of all clinical evidence of disease. </p> </li> <li> <p>Relapse defined as recurrence of the disease in prior CR.</p> </li> <li> <p>Disease‐free survival.</p> </li> <li> <p>Overall survival.</p> </li> <li> <p>Objective response rate (ORR) defined as proportion of patients with CR or partial response (PR). A PR is considered as a regression of measurable disease of at least 50% in one of the categories T, N, M and B without any progression of disease. </p> </li> <li> <p>Rare adverse effects.</p> </li> </ol> </p> </section> </section> </section> <section id="CD008946-sec-0043"> <h3 class="title">Search methods for identification of studies</h3> <p>We aimed to identify all relevant randomised controlled trials (RCTs) regardless of language or publication status (published, unpublished, in press, and in progress). </p> <section id="CD008946-sec-0044"> <h4 class="title">Electronic searches</h4> <p>For this update, we revised all our search strategies in line with current Cochrane Skin practices. Details of the previous search strategies are available in <a href="./references#CD008946-bbs2-0192" title="WeberschockT , StrametzR , LorenzM , RölligC , BunchC , BauerA , et al. Interventions for mycosis fungoides. Cochrane Database of Systematic Reviews2012, Issue 9. [DOI: 10.1002/14651858.CD008946.pub2]">Weberschock 2012</a>. </p> <p>The Cochrane Skin Information Specialist searched the following databases up to 13 May 2019: </p> <p> <ul id="CD008946-list-0005"> <li> <p>the Cochrane Skin Group Specialised Register using the search strategy in <a href="./appendices#CD008946-sec-0211">Appendix 1</a>; </p> </li> <li> <p>the Cochrane Central Register of Controlled Trials (CENTRAL); 2019, Issue 5, in the Cochrane Library using the strategy in <a href="./appendices#CD008946-sec-0212">Appendix 2</a>; </p> </li> <li> <p>MEDLINE via Ovid (from 1946) using the strategy in <a href="./appendices#CD008946-sec-0213">Appendix 3</a>; </p> </li> <li> <p>Embase via Ovid (from 1974) using the strategy in <a href="./appendices#CD008946-sec-0214">Appendix 4</a>; and </p> </li> <li> <p>LILACS (Latin American and Caribbean Health Science Information database, from 1982) using the strategy in <a href="./appendices#CD008946-sec-0215">Appendix 5</a>. </p> </li> </ul> </p> <section id="CD008946-sec-0045"> <h5 class="title">Trials registers</h5> <p>Review authors (AV and MJ) searched the following trials registers for reports of trials using the terms 'mycosis fungoides' and 'cutaneous T‐cell lymphoma' on 20 May 2019: </p> <p> <ul id="CD008946-list-0006"> <li> <p>ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>); and </p> </li> <li> <p>the World Health Organization International Clinical Trials Registry Platform (ICTRP) (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch/</a>). </p> </li> </ul> </p> </section> <section id="CD008946-sec-0046"> <h5 class="title">Adverse effects</h5> <p>We examined the included and excluded RCTs for common adverse effects.</p> <p>To find rare but potentially serious side‐effects in non‐RCTs, we conducted a separate search in MEDLINE (using the strategy in <a href="./appendices#CD008946-sec-0216">Appendix 6</a>) up to 13 April 2017. We qualitatively summarised findings from non‐RCTs in <a href="#CD008946-tbl-0010">Table 5</a>. </p> <p>We ran two separate additional searches for specific drugs not included in the April 2017 searches: brentuximab vedotin on 18 July 2017, and lenalidomide on 8 November 2017. We used the same terms as in <a href="./appendices#CD008946-sec-0216">Appendix 6</a> combined with these drug terms. </p> </section> </section> <section id="CD008946-sec-0047"> <h4 class="title">Searching other resources</h4> <section id="CD008946-sec-0048"> <h5 class="title">Searching reference lists and handsearching</h5> <p>We examined the citation lists of the reports of identified trials and other relevant review articles to identify further references to relevant trials. </p> <p>We examined the conference proceedings of the German Dermatologic Society (DDG) for the years 2013, 2015 and 2017, and the Arbeitsgemeinschaft Dermatologische Forschung (ADF) between 2012 and 2018. These conferences are not covered by online database searches. </p> </section> <section id="CD008946-sec-0049"> <h5 class="title">Correspondence with trialists/experts/organisations</h5> <p>We contacted the corresponding authors of potentially relevant studies for additional information. </p> </section> </section> </section> <section id="CD008946-sec-0050"> <h3 class="title" id="CD008946-sec-0050">Data collection and analysis</h3> <section id="CD008946-sec-0051"> <h4 class="title">Selection of studies</h4> <p>At least two review authors (MJ and AV) independently screened titles and abstracts of studies identified from the above sources for the eligibility criteria stated previously. If this could not be done satisfactorily from the title and abstract, we obtained a full‐text version for assessment. </p> <p>We assessed studies that displayed characteristics meeting the inclusion criteria by screening for eligibility using an eligibility form. This eligibility form contained the following questions. </p> <p> <ul id="CD008946-list-0007"> <li> <p>Is the study described as randomised?</p> </li> <li> <p>Did at least 90% of the participants in the study have biopsy‐proven classical mycosis fungoides? </p> </li> <li> <p>Is the stage of the mycosis fungoides given?</p> </li> <li> <p>Are the participants under investigation 18 years of age or older?</p> </li> </ul> </p> <p>To be eligible, studies had to meet all of the criteria stated above. We included abstracts and unpublished data if sufficient information on study design, characteristics of participants, interventions and outcomes was available; otherwise, we excluded them or included them with reservations following discussion with the review authors. If there was insufficient information to judge eligibility, we tried to contact the first author of the report for clarification. This process is described in more detailed in the section '<a href="#CD008946-sec-0057">Dealing with missing data</a>'. We resolved any disagreements between the review authors (AV and MJ) by discussion and consensus with a third party (TW). We identified any duplicate reports. We obtained full‐text versions of all eligible studies for quality assessment and data collection, where available. At every stage of searching and screening of the literature, we documented ‐ with reasons ‐ the overall number of studies identified and the number excluded and included in a flow diagram (<a href="#CD008946-fig-0002">Figure 2</a>) as suggested by the Preferred Reporting Items of Systematic Reviews and Meta‐Analyses (PRISMA) (<a href="./references#CD008946-bbs2-0150" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG , PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Journal of Clinical Epidemiology2009;62(10):1006-12. [PMID: 19631508]">Moher 2009</a>). </p> <div class="figure" id="CD008946-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD008946-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-FIG-02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD008946-sec-0052"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (AV, MJ) independently extracted the following data from the studies which met the inclusion criteria of this review. </p> <p> <ul id="CD008946-list-0008"> <li> <p>information about the treatment and outcome for each participant, which included information on the diagnosis and stage of mycosis fungoides, received treatment, additional therapy, quality of life, objective response rate/complete response, duration of remission, overall survival, and toxicity and adverse effects; </p> </li> <li> <p>potentially significant participant‐related prognostic factors, which included information on age (birth date) and gender; and </p> </li> <li> <p>potentially significant tumour‐related prognostic factors, which included information on histological subtype, clinical stage (patch, plaque, tumour), blood tumour burden: atypical T lymphocytes (Lutzner cells), elevated eosinophilic cells, and systemic involvement (lymph nodes, bone marrow, internal organs). </p> </li> </ul> </p> <p>We tried to obtain any missing data from the trial authors, where possible. We developed a data collection form and piloted it in order to summarise the trials. </p> </section> <section id="CD008946-sec-0053"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>At least two review authors (MJ, AV and TW) independently assessed quality by doing a 'Risk of bias' assessment using the new features of Review Manager 5 and as described in Table 8.5c of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD008946-bbs2-0127" title="HigginsJP , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>). The same authors assessed the domains, which included the following: </p> <p>(a) sequence generation (selection bias);<br/>(b) allocation concealment (selection bias);<br/>(c) blinding (performance and detection bias);<br/>(d) whether incomplete outcome data were addressed (attrition bias);<br/>(e) whether the study was free of selective reporting (reporting bias); and<br/>(f) whether the study was free of other bias. </p> <p>We discussed any disagreements until consensus was obtained. We assessed quality using an assessment form designed for the topic of this review (sources used: <a href="./references#CD008946-bbs2-0128" title="HollisS , CampbellF . What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ1999;319(7211):670-4. [PMID: 10480822]">Hollis 1999</a>; <a href="./references#CD008946-bbs2-0134" title="JüniP , AltmanDG , EggerM . Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ2001;323(7303):42-6. [PMID: 11440947]">Jüni 2001</a>; <a href="./references#CD008946-bbs2-0149" title="MoherD , JadadAR , NicholG , PenmanM , TugwellP , WalshS . Assessing the quality of randomized controlled trials: An annotated bibliography of scales and checklists. Controlled Clinical Trials1995;16(1):62-73. [PMID: 7743790]">Moher 1995</a>; <a href="./references#CD008946-bbs2-0177" title="VerhagenAP , deVetHC , deBieRA , KesselsAG , BoersM , BouterLM , et al. The Delphi list: A criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. Journal of Clinical Epidemiology1998;51(12):1235-41. [PMID: 10086815]">Verhagen 1998</a>). </p> <section id="CD008946-sec-0054"> <h5 class="title">Assessment of external validity</h5> <p>The 'Risk of bias' domains described so far help to investigate the potentially lowered internal validity of studies. But when study data need to be incorporated into daily practice, there is also considerable risk of bias that potentially influences the external validity. </p> <p>We assessed external validity of all included trials by addressing: study population and eligibility criteria; temporal, ethnic, socio‐economic and geographical aspects; and generalisability as proposed by <a href="./references#CD008946-bbs2-0106" title="DekkersOM , vonElmE , AlgraA , RomijnJA , VandenbrouckeJP . How to assess the external validity of therapeutic trials: a conceptual approach. International Journal of Epidemiology2010;39(1):89-94. [PMID: 19376882]">Dekkers 2010</a>. </p> <p>The reference population for this aspect was the middle‐aged population between 50 and 60 years old with mycosis fungoides (classical "Alibert Bazin" type) treated in secondary and tertiary referral centres, since this seemed most likely to represent the overall largest group of people with the disease and possible access to the treatment options (<a href="./references#CD008946-bbs2-0137" title="KimYH , LiuHL , Mraz-GernhardS , VargheseA , HoppeRT . Long-term outcome of 525 patients with mycosis fungoides and Sézary syndrome: Clinical prognostic factors and risk for disease progression. Archives of Dermatology2003;139(7):857-66. [PMID: 12873880]">Kim 2003</a>; <a href="./references#CD008946-bbs2-0180" title="WeinstockMA , HormJW . Mycosis fungoides in the United States. Increasing incidence and descriptive epidemiology. JAMA1988;260(1):42-6. [PMID: 3379722]">Weinstock 1988</a>; <a href="./references#CD008946-bbs2-0181" title="WeinstockMA , ReynesJF . The changing survival of patients with mycosis fungoides: A population-based assessment of trends in the United States. Cancer1999;85(1):208-12. [PMID: 9921994]">Weinstock 1999</a>). </p> <p>More details can be found in <a href="./appendices#CD008946-sec-0217">Appendix 7</a>. </p> </section> </section> <section id="CD008946-sec-0055"> <h4 class="title">Measures of treatment effect</h4> <p>The effect measures of choice were the mean difference (MD) for continuous outcomes and the risk ratio (RR) for binary outcomes. For time‐to‐event effect measures we used the hazard ratio (HR). For all measures of effect, we reported 95% confidence intervals (CIs) and corresponding P values. In order to gain more accurate analyses for smaller sample sizes, we added Fisher tests, which is a deviation from the review protocol. This change was made in order to avoid spurious (non‐)significance in studies with small sample sizes or low numbers of events. P values ≤ 0.05 were considered to be significant. </p> </section> <section id="CD008946-sec-0056"> <h4 class="title">Unit of analysis issues</h4> <p>The standard unit of analysis in the review is the participant. This also applies to cross‐over trials. In case of within‐participant trials with lesional treatments, comparable lesions of participants were also accepted as the unit of analysis, thus, allowing us to include within‐participant trials. For cross‐over trials and within‐participant trials, we extracted the data as reported in the trials. This approach is prone to a carry‐over effect and to over‐ or underestimation of the precision of results. </p> </section> <section id="CD008946-sec-0057"> <h4 class="title">Dealing with missing data</h4> <p>We attempted to obtain data that were not reported directly from the original researchers.</p> <p>We dealt with missing data by contacting the corresponding author of the paper with missing data and asking him or her to provide these data. This was done for inclusion and exclusion criteria, possible sources of bias (as described in the section <a href="#CD008946-sec-0053">Assessment of risk of bias in included studies</a>), and for outcome data. If the corresponding author did not reply after the third approach via letter or email within four weeks, or they did not provide the requested data, we classified the data as missing. Because of the low number of comparable trials, we could not perform reliable sensitivity analyses to assess the potential effects of missing data on the meta‐analysis. </p> </section> <section id="CD008946-sec-0058"> <h4 class="title">Assessment of heterogeneity</h4> <p>In order to address clinical diversity between studies, we tabulated the included studies in terms of study characteristics and outcomes, and then carefully examined them for quality, similarities and differences. We addressed statistical heterogeneity between individual studies reporting on outcomes for the same intervention using the I² statistic. Pooling data was considered in case of two or more trials reporting on the same intervention with clinical similarity, and comparable study quality. In such case, we planned to use a fixed‐effect model for meta‐analysis. If clinically and methodological heterogeneity was suspected, then we would use the random‐effects model. Substantial statistical heterogeneity was defined as an I² statistic with a value greater than or equal to 50% and we would undertake subgroup analyses to investigate the clinical and methodological heterogeneity in these circumstances. If extreme levels of statistical heterogeneity existed between the studies (I² statistic &gt; 80%) which could not be explained by subgroup analyses, we intended to report the results of the studies individually and explore heterogeneity using subgroup analyses.. </p> </section> <section id="CD008946-sec-0059"> <h4 class="title">Assessment of reporting biases</h4> <p>In order to assess for possible reporting bias, we planned to examine a funnel plot for asymmetry where feasible (e.g. more than 10 studies for an outcome). Because of the low number of comparable trials, we could not reliably investigate reporting bias. </p> </section> <section id="CD008946-sec-0060"> <h4 class="title">Data synthesis</h4> <p>In case of clinical and methodological similarity we pooled data for meta‐analysis using the fixed‐effect model. Meta‐analysis comprised risk ratios (RR) with corresponding confidence intervals (95% CIs) and were presented as forest plots. Where HRs were available we used the generic inverse variance method (and random‐effects model) to report the pooled estimates and 95% CIs. If meta‐analysis was not possible, we used a narrative approach. <a href="./references#CD008946-bbs2-0159" title="Nordic Cochrane Centre, The Cochrane Collaboration.Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration., 2014.">Review Manager 2014</a> was used to conduct the analyses. For continuous outcomes we used the mean difference (MD) or the standardised mean difference (SMD) as appropriate in order to establish comparability among different scales. </p> </section> <section id="CD008946-sec-0061"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to explore potential causes of heterogeneity by performing subgroup analyses: stage of mycosis fungoides (patch, plaque, or tumour) and different interventions. However, we were unable to undertake any subgroup analyses due to low number of comparable trials. </p> </section> <section id="CD008946-sec-0062"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to perform sensitivity analyses to explore the influence of the following factors on effect size. </p> <p> <ul id="CD008946-list-0009"> <li> <p>Study quality according to risk of bias (sequentially).</p> </li> <li> <p>Largest trials in the review measured by number of randomised participants.</p> </li> <li> <p>Excluding studies using the following filters: language of publication (English versus other), funding sources (yes/no), etc. </p> </li> <li> <p>Investigation of the origin (individual participant data or publication) of the data/information.</p> </li> </ul> </p> <p>Because of the low number of comparable trials, we could not perform reliable sensitivity analyses. </p> </section> <section id="CD008946-sec-0063"> <h4 class="title">'Summary of findings' tables</h4> <p>The "Summary of findings tables" provide key outcomes, the magnitude of effects and the certainty of the evidence presented in Cochrane systematic reviews. For creating our 'Summary of findings tables' we used the GRADE approach (<a href="./references#CD008946-bbs2-0120" title="McMaster University (developed by Evidence Prime)GRADEpro GDT. Version accessed prior to 29 March 2019. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015.Available at gradepro.org.">GRADE pro GDT 2015</a>). In order to evaluate the certainty of the evidence, we assessed the data in the categories risk of bias, inconsistency, indirectness, imprecision and publication bias. Based on these criteria the quality of evidence was rated as high, moderate, low or very low (<a href="./references#CD008946-bbs2-0124" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck-YtterY , Alonso-CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924-6. [PMID: 18436948]">Guyatt 2008</a>). </p> <p>Due to the variety of the interventions, a rational summarisation of all interventions proved to be difficult. Therefore, we focused on a treatment which is essential for the therapy of mycosis fungoides. Patients with mycosis fungoides are mostly treated by dermatologists in a tertiary care setting in which PUVA is readily available. The treatment is easy to perform and has manageable adverse effects. Reflecting the importance of PUVA therapy, current international guidelines recommend PUVA as a first‐line therapy in early stage of disease (<a href="./references#CD008946-bbs2-0158" title="OlsenEA , HodakE , AndersonT , CarterJB , HendersonM , CooperK , et al. Guidelines for phototherapy of mycosis fungoides and Sézary syndrome: A consensus statement of the United States Cutaneous Lymphoma Consortium. Journal of the American Academy of Dermatology2015;74(1):27-58. [DOI: 10.1016/j.jaad.2015.09.033] [PMID: 26547257]">Olsen 2016</a>). Furthermore, PUVA is combined with systemic therapies in more advanced stages of disease (<a href="./references#CD008946-bbs2-0173" title="TrautingerF , EderJ , AssafC , BagotM , CozzioA , DummerR , et al. European organisation for research and treatment of cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017. European Journal of Cancer2017;77:57-74. [DOI: 10.1016/j.ejca.2017.02.027] [PMID: 28365528]">Trautinger 2017</a>). For these reasons we focused on RCTs comparing PUVA with other interventions. </p> <p>The primary end points of this review (quality of life, common adverse events) were not adequately measured, thus the following secondary end points were also reported in the tables: complete response (CR), and objective response rate (ORR). </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD008946-sec-0064" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD008946-sec-0064"></div> <section id="CD008946-sec-0065"> <h3 class="title">Description of studies</h3> <p>Please see the '<a href="./references#CD008946-sec-0233" title="">Characteristics of included studies</a>', <a href="./references#CD008946-sec-0234" title="">Characteristics of excluded studies</a>', '<a href="./references#CD008946-sec-0235" title="">Characteristics of studies awaiting classification'</a>, and <a href="./references#CD008946-sec-0236" title="">Characteristics of ongoing studies</a>' tables for full descriptions. </p> <section id="CD008946-sec-0066"> <h4 class="title">Results of the search</h4> <p>In this update, the <a href="#CD008946-sec-0044">Electronic searches</a> retrieved 702 records. We searched a number of other sources: handsearching (no records identified), examination of the reference lists of relevant studies and reviews (one record identified), and searches of trials databases (12 records identified). We therefore had a total of 715 records. </p> <p>We excluded 655 records based on titles and abstracts. We obtained the full text of the remaining 60 records. We excluded 23 studies (see <a href="./references#CD008946-sec-0234" title="">Characteristics of excluded studies</a>). We added three records to two studies awaiting classification (see <a href="./references#CD008946-sec-0235" title="">Characteristics of studies awaiting classification</a>). We identified 13 ongoing studies (see <a href="./references#CD008946-sec-0236" title="">Characteristics of ongoing studies</a>). </p> <p>We included six new studies reported in 21 references (see <a href="./references#CD008946-sec-0233" title="">Characteristics of included studies</a>). We combined these studies with the 14 previously included in this review, and for this update we included a total of 20 trials (1369 participants). We have excluded a total of 52 studies (23 new, 29 from the previous review). <a href="#CD008946-fig-0002">Figure 2</a> shows a flow diagram summarising our study selection process. </p> <section id="CD008946-sec-0067"> <h5 class="title">Dealing with missing data</h5> <p>After inclusion of all publications, we tried to contact the authors of included publications by sending an individualised missing data contact form to them via email. </p> </section> </section> <section id="CD008946-sec-0068"> <h4 class="title">Included studies</h4> <section id="CD008946-sec-0069"> <h5 class="title">Designs</h5> <p>In the initial review we included 14 randomised controlled trial (RCTs) (<a href="./references#CD008946-bbs2-0002" title="ChildFJ , MitchellTJ , WhittakerSJ , ScarisbrickJJ , SeedPT , Russel-JonesR . A randomized cross-over study to compare PUVA and extracorporeal photopheresis in the treatment of plaque stage (T2) mycosis fungoides. Clinical &amp; Experimental Dermatology2004;29(3):231-6. [CENTRAL: CN-00468455] [PMID: 15115499]ChildFJ , MitchellTJ , WhittakerSJ , WatkinsP , SeedP , Russell-JonesR . A randomised cross-over study to compare Puva and extracorporeal photopheresis (ECP) in the treatment of plaque stage (T2) mycosis fungoides. British Journal of Dermatology2001;145(Suppl 59):16. [CENTRAL: CN-00430854] ">Child 2004</a>; <a href="./references#CD008946-bbs2-0003" title="ChongA , LooWJ , BanneyL , GrantJW , NorrisPG . Imiquimod 5% cream in the treatment of mycosis fungoides - a pilot study. Journal of Dermatological Treatment2004;15(2):118-9. [CENTRAL: CN-00467258] [PMID: 15204164]">Chong 2004</a>; <a href="./references#CD008946-bbs2-0004" title="DuvicM , MartinAG , KimY , OlsenE , WoodGS , CrowleyCA , et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Archives of Dermatology2001;137(5):581-93. [CENTRAL: CN-00347816] [PMID: 11346336]PrinceHM , McCormackC , RyanG , BakerC , RotsteinH , DavisonJ , et al. Bexarotene capsules and gel for previously treated patients with cutaneous T-cell lymphoma: results of the Australian patients treated on phase II trials. Australasian Journal of Dermatology2001;42(2):91-7. [CENTRAL: CN-00442169] [PMID: 11309029]">Duvic 2001</a>; <a href="./references#CD008946-bbs2-0005" title="DuvicM , OlsenEA , OmuraGA , MaizeJC , VonderheidEC , et al. A phase III, randomized, double-blind, placebo-controlled study of peldesine (BCX-34) cream as topical therapy for cutaneous T-cell lymphoma. Journal of the American Academy of Dermatology2001;44(6):940-7. [CENTRAL: CN-00348073] [PMID: 11369904]">Duvic 2001a</a>; <a href="./references#CD008946-bbs2-0006" title="GuitartJ , TuckerR , StevensV . Low dose bexarotene (Targretin®) capsules and phototherapy for early stage cutaneous T-Cell lymphoma. Journal of Investigative Dermatology2002;119(1):241. [CENTRAL: CN-00794450] NCT00030589. A muliticenter, dose-randomized evaluation of Targretin capsules plus PUVA in patients with stage IB - IIA cutaneous T-Cell lymphoma. clinicaltrials.gov/ct/show/NCT00030589 (first received 27 Jaunry 2003). ">Guitart 2002</a>; <a href="./references#CD008946-bbs2-0007" title="KayeF , EddyJ , IhdeDC , SteinbergS , FischmannAB , GlatsteinE , et al. Conservative vs. aggressive therapy in mycosis fungoides. Proceedings of the American Society of Clinical Oncology1989;8:257. [CENTRAL: CN-00694960] KayeF , IhdeD , FischmannA , GlatsteinE , MinnaJ , SchechterG , et al. A randomized trial comparing conservative and aggressive therapy in mycosis fungoides (MF). Proceedings of the American Society of Clinical Oncology1986;5:195. [CENTRAL: CN-00695166] KayeFJ , BunnPA , SteinbergSM , StockerJL , IhdeDC , FischmannAB , et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. New England Journal of Medicine1989;321(26):1784-90. [CENTRAL: CN-00064211] [PMID: 2594037]">Kaye 1989</a>; <a href="./references#CD008946-bbs2-0010" title="DuvicM , KuzelTM , OlsenEA , MartinAG , FossFM , KimYH , et al. Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK). Clinical Lymphoma2002;2(4):222-8. [CENTRAL: CN-00514479] [PMID: 11970761]KuzelT , OlsenE , MartinA , KimY , DuvicM , FrankelA , et al. Pivotal phase III trial of two dose levels of DAB389IL-2 (Ontak®) for the treatment of mycosis fungoides (MF). Blood1997;90(10 Suppl 1 (Pt 1)):586a. [CENTRAL: CN-00518069] NTC00050999. Study of ONTAK (Denileukin Diftitox) in cutaneous T-Cell lymphoma (CTCL) patients. clinicaltrials.gov/ct2/show/NCT00050999 (first received 3 January 2003). OlsenE , DuvicM , FrankelA , KimY , MartinA , VonderheidE , et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. Journal of Clinical Oncology2001;19(2):376-88. [CENTRAL: CN-00328506] [PMID: 11208829]OlsenE , DuvicM , MartinA . Pivotal phase III trial of two dose levels of DAB 389 IL-2 (ONTAK) for the treatment of cutaneous T-cell lymphoma (CTCL). Journal of Investigative Dermatology1998;110(4):678. [CENTRAL: CN-00353452] ">Olsen 2001</a>; <a href="./references#CD008946-bbs2-0012" title="RookAH , WoodGS , DuvicM , VonderheidEC , TobiaA , CabanaB . A phase II placebo-controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis. Journal of the American Academy of Dermatology2010;63(6):984-90. [CENTRAL: CN-00772559] [PMID: 20889234]">Rook 2010</a>; <a href="./references#CD008946-bbs2-0013" title="OtteHG , KuhlS , StadlerR , LugerT , HenzB , SterryW . Treatment of cutaneous T-cell lymphoma with Interferon alpha and PUVA versus Interferon alpha and Acitretin - results of a prospective randomised multi-centre study [Behandlung des kutanen T-Zell-Lymphoms mit Interferon alpha und PUVA versus Interferon alpha und Acirentin - Ergebnisse einer prospektiv-randomisierten Multicenter-Studie]. Der Hautarzt1997;48(Suppl):S97. [CENTRAL: CN-00495120] OtteHG , StadierR , LugerT , HenzB , SterryW . Open controlled clinical trial on the use of interferon plus acitretin versus interferon plus PUVA in patients with cutaneous T-cell lymphoma (CTCL). Annals of Oncology1996;7(Suppl 3):66. [CENTRAL: CN-00308243] StadlerR , OtteHG , LugerT , HenzBM , KuhlP , ZwingersT , et al. Prospective randomized multicenter clinical trial on the use of interferon -2a plus acitretin versus interferon -2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood1998;92(10):3578-81. [CENTRAL: CN-00156682] [PMID: 9808550]">Stadler 1998</a>; <a href="./references#CD008946-bbs2-0014" title="BohmeyerJ , OtteHG , StadlerR , LugerT , SterryW . Therapy of cutaneous T-cell lymphoma with PUVA versus interferon alfa plus PUVA: first results. Journal of the European Academy of Dermatology &amp; Venereology1999;12(Suppl 2):S268. [CENTRAL: CN-00478472] BohmeyerJ , StadlerR , LugerT , SterryW . Prospective randomized multicentre therapy optimizing protocol for therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α + PUVA [Prospectiv randomisiertes, multizentrisches Therapieoptimierungsprotokoll zur Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α + PUVA]. Zeitschrift für Hautkrankheiten2001;76(Suppl 1):S55. [CENTRAL: CN-01446038] KremerA , BohmeyerJ , StadlerR , LugerT , SterryW . Prospective randomized multicentre therapy optimizing protocol for therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α + PUVA [Prospectiv randomisiertes, multizentrisches Therapieoptimierungsprotokoll zur Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α + PUVA]. Journal der Deutschen Dermatologischen Gesellschaft2003;1(Suppl 1):S99. [CENTRAL: CN-01446037] OtteHG , StadlerR , LugerT , SterryW . Therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α plus PUVA: first results of a prospective randomized multicentre therapy optimizing protocol [Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α plus PUVA: Erste Ergebnisse des prospektiven randomisierten multizentrischen Therapieoptimierungsprotokolls]. Der Hautarzt1999;50(Suppl 1):S2. [CENTRAL: CN-01457423] OtteHG , StadlerR . Combination therapy of cutaneous t-cell-lymphoma with interferon alfa 2a and PUVA [Kombinationstherapie kutaner T-Zell-Lymphome mit Interferon Alfa 2a und PUVA]. Zentralblatt Haut- und Geschlechtskrankheiten1993;162(Suppl):P2.03.08. [CENTRAL: CN-01457422] StadlerM , KremerA , LugerT , SterryW . Prospective, randomized, multicentre clinical trial on the use of interferon a 2a plus PUVA versus PUVA monotherapy in patients with cutaneous T-cell lymphoma, stages I and II [Abstract 7541]. ASCO annual meeting proceedings. Journal of Clinical Oncology2006;24(18S Pt 1):432. [CENTRAL: CN-00625001] ">Stadler 2006</a>; <a href="./references#CD008946-bbs2-0015" title="Thestrup-PedersenK , GrunnetE , ZachariaeH . Transfer factor therapy in mycosis fungoides: a double-blind study. Acta Dermato-Venereologica1982;62(1):47-53. [CENTRAL: CN-00027377] [PMID: 6175137]">Thestrup‐Pedersen 1982</a>; <a href="./references#CD008946-bbs2-0017" title="VonderheidEC , ThompsonR , SmilesKA , LattanandA . Recombinant interferon alfa-2b in plaque-phase mycosis fungoides. Intralesional and low-dose intramuscular therapy. Archives of Dermatology1987;123(6):757-63. [CENTRAL: CN-00047990] [PMID: 3579357]">Vonderheid 1987</a>; <a href="./references#CD008946-bbs2-0019" title="WolffJM , ZitelliJA , RabinBS , SmilesKA , AbellE . Intralesional interferon in the treatment of early mycosis fungoides. Journal of the American Academy of Dermatology1985;13(4):604-12. [CENTRAL: CN-00040943] [PMID: 2934438]">Wolff 1985</a>; <a href="./references#CD008946-bbs2-0020" title="WozniakMB , TraceyL , Ortiz-RomeroPL , MontesS , AlvarezM , FragaJ , et al. Psoralen plus ultraviolet A +/- interferon-alpha treatment resistance in mycosis fungoides: the role of tumour microenvironment, nuclear transcription factor-kappaB and T-cell receptor pathways. British Journal of Dermatology2008;160(1):92-102. [CENTRAL: CN-00668828] [PMID: 18945306]">Wozniak 2008</a>). Two were within‐participant designs assessing efficacy of topically applied agents (<a href="./references#CD008946-bbs2-0012" title="RookAH , WoodGS , DuvicM , VonderheidEC , TobiaA , CabanaB . A phase II placebo-controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis. Journal of the American Academy of Dermatology2010;63(6):984-90. [CENTRAL: CN-00772559] [PMID: 20889234]">Rook 2010</a>) or intralesional injections (<a href="./references#CD008946-bbs2-0017" title="VonderheidEC , ThompsonR , SmilesKA , LattanandA . Recombinant interferon alfa-2b in plaque-phase mycosis fungoides. Intralesional and low-dose intramuscular therapy. Archives of Dermatology1987;123(6):757-63. [CENTRAL: CN-00047990] [PMID: 3579357]">Vonderheid 1987</a>), one had a cross‐over design (<a href="./references#CD008946-bbs2-0002" title="ChildFJ , MitchellTJ , WhittakerSJ , ScarisbrickJJ , SeedPT , Russel-JonesR . A randomized cross-over study to compare PUVA and extracorporeal photopheresis in the treatment of plaque stage (T2) mycosis fungoides. Clinical &amp; Experimental Dermatology2004;29(3):231-6. [CENTRAL: CN-00468455] [PMID: 15115499]ChildFJ , MitchellTJ , WhittakerSJ , WatkinsP , SeedP , Russell-JonesR . A randomised cross-over study to compare Puva and extracorporeal photopheresis (ECP) in the treatment of plaque stage (T2) mycosis fungoides. British Journal of Dermatology2001;145(Suppl 59):16. [CENTRAL: CN-00430854] ">Child 2004</a>), and 11 had a parallel‐group design. In this update we identified six more parallel RCTs (<a href="./references#CD008946-bbs2-0001" title="BagotM , HasanB , WhittakerS , Beylot-BarryM , KnoblerR , ShahE , et al. A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma - EORTC 21081 (NCT01098656): results and lessons learned for future trial designs. European Journal of Dermatology2017;27(3):286–94. [CENTRAL: CN-01395486] [PMID: 28468739]NCT01098656. A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-Cell lymphoma. clinicaltrials.gov/ct2/show/NCT01098656 (first received 5 April 2010). [NCT01098656]">Bagot 2017</a>; <a href="./references#CD008946-bbs2-0008" title="BagotM , DalleS , SokolL , TsianakasA , MusiekA , Ortiz-RomeroP , et al. Long-term clinical benefit to anti-CCR4 mogamulizumab: results from the phase 3 mavoric study in previously treated cutaneous t-cell lymphoma (CTCL). Blood2018;132(Supp 1):2901. [DOI: 10.1182/blood-2018-99-118473]CowanR , ScarisbrickJ , DwyerK , LeoniM , GrebennikD , MorrisS . Mogamulizumab demonstrates significant improvement in PFS compared to vorinostat in patients with previously treated cutaneous T-cell lymphoma (CTCL). British Journal of Haematology2018;181(S1):77–8. [DOI: 10.1111/bjh.15226]KimYH , BagotM , Pinter-BrownL , RookAH , PorcuP , HorwitzSM , et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncology2018;19(9):1192-1204. [PMID: 30100375]NCT01728805. Study of KW-0761 versus vorinostat in relapsed/refractory CTCL. clinicaltrials.gov/ct2/show/NCT01728805 (first received 20 November 2012). PorcuP , HudgensS , QuaglinoP , CowanR , FlodenL , LeoniM , et al. Quality of life in cutaneous T-cell lymphoma subjects treated with anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat: results from the phase 3 MAVORIC trial. Journal of Clinical Oncology2018;36(15):-. [DOI: 10.1097/HS9.0000000000000060]QuaglinoP , HudgensS , PorcuP , CowanR , FlodenL , TsianakasA , et al. Quality of life in cutaneous t-cell lymphoma subjects treated with the anti-ccr4 monoclonal antibody mogamulizumab versus vorinostat: results from the phase 3 mavoric trial. Hemasphere2018;2(S1):85. ScarisbrickJ , ZinzaniPL , HorwitzS , KimYH , MoskowitzAJ , PorcuP , et al. Efficacy of mogamulizumab by prior systemic therapy in patients with previously treated cutaneous T-cell lymphoma: Post hoc analysis from the phase 3 MAVORIC study. British Journal of Haematology2019;185(Suppl 1):94. TsianakasA , QuaglinoP , HudgensS , FlodenL , LeoniM , DaleS , et al. Quality of life in cutaneous T-cell lymphoma subjects treated with the anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat: Results from the phase 3 MAVORIC trial. Oncology Research and Treatment2018;41(Suppl 4):272. ZinzaniPL , HorwitzSM , KimYH , MoskowitzAJ , PorcuP , ScarisbrickJ , et al. Efficacy of mogamulizumab by prior systemic therapy in patients with previously treated cutaneous T-cell lymphoma: post hoc analysis from the phase 3 mavoric study. Blood2018;132(Suppl 1):1619. [DOI: 10.1182/blood-2018-99-114819]">Kim 2018</a>; <a href="./references#CD008946-bbs2-0009" title="LessinS , DuvicM , GuitartJ , PandyaA , StroberB , OlsenE , et al. Positive results of a pivotal phase ii trial testing a manufactured 0.02% Mechlorethamine gel in mycosis fungoides (mf). Journal of Investigative Dermatology2011;131(Suppl 1):S84. [CENTRAL: CN-00843792] LessinSR , DuvicM , GuitartJ , PandyaAG , StroberBE , OlsenEA , et al. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatology2013;149(1):25-32. [CENTRAL: CN-00859487] [PMID: 23069814]NCT00168064. Safety and efficacy of nitrogen mustard in treatment of mycosis fungoides. clinicaltrials.gov/ct2/show/NCT00168064 (first received 14 September 2005). ">Lessin 2013</a>; <a href="./references#CD008946-bbs2-0011" title="HorwitzS , WhittakerS , DuvicM , DummerR , KimYH , ScarisbrickJ , et al. Response by stage in CD30-positive (CD30+) cutaneous T cell lymphoma (CTCL) patients receiving brentuximab vedotin (BV) vs physician's choice (PC) in the phase 3 ALCANZA study. In: Hematological oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:245–7. [CENTRAL: CN-01408605] [DOI: 10.1002/hon.2438]HorwitzSM , AkilovOE , FisherD , KuzelTM , WangY , Palanca-WesselsMC , et al. Brentuximab vedotin or physician’s choice in CD30-positivecutaneous T-cell lymphoma (ALCANZA): an international,open-label, randomised, phase 3, multicentre trial. Lancet2017;390(10094):555-66. [CENTRAL: CN-01403731] HorwitzSM , ScarisbrickJJ , DummerR , DuvicM , KimYH , WalewskiJ , et al. Updated analyses of the international, open-label, randomized, phase 3 alcanza study: longer-term evidence for superiority of brentuximab vedotin versus methotrexate or bexarotene for CD30-positive cutaneous T-cell lymphoma (CTCL). In: Blood. Conference: 59th annual meeting of the american society of hematology, ASH 2017. United states. Vol. 130. 2017. [CENTRAL: CN-01450312] KimYH , PrinceHM , WhittakerS , HorwitzSM , DuvicM , ScarisbrickJ , et al. Brentuximab vedotin vs physician's choice in CTCL patients from the phase 3 ALCANZA study: analysis of outcomes by CD30 expression. In: Hematological Oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:77–8. [CENTRAL: CN-01408482] [DOI: 10.1002/hon.2437]KimYH , PrinceHM , WhittakerS , HorwitzSM , DuvicM , ScarisbrickJ , et al. Outcomes by CD30 expression in patients with CTCL receiving brentuximab vedotin (BV) vs physician's choice (PC) in the Phase 3 ALCANZA study. Journal of Clinical Oncology2017;35(15 Supplement 1):7517. [EMBASE: 617388795]KimYH , WhittakerS , DummerR , GeskinLJ , GauthierP , LittleM , et al. Phase 3 study of brentuximab vedotin versus physician's choice of methotrexate or bexarotene in patients (PTS) with CD30-positive (CD30+) cutaneous T-cell lymphoma (CTCL). The alcanza study. Hematological Oncology2013;31(Suppl 1):278. [CENTRAL: CN-01531598] [EMBASE: 71147875]KimYH , WhittakerS , HorwitzSM , DuvicM , DummerR , ScarisbrickJ , et al. Brentuximab vedotin demonstrates superior activity to standard therapy in CD30-expressing (CD30+) cutaneous T-cell lymphoma (CTCL) in the randomized phase 3 ALCANZA study. Journal of Investigative Dermatology2017;137(5 Suppl 1):S45. [CENTRAL: CN-01375469] [EMBASE: 616393777]KimYH , WhittakerS , HorwitzSM , DuvicM , DummerR , ScarisbrickJJ , et al. Brentuximab vedotin demonstrates significantly superior clinical outcomes in patients with CD30-expressing cutaneous T cell lymphoma versus physician's choice (Methotrexate or Bexarotene): the phase 3 alcanza study. In: Blood. Conference: 58th annual meeting of the american society of hematology, ASH 2016. United states. Conference start: 20161203. Conference end: 20161206. Vol. 128. 2016. [CENTRAL: CN-01303081] [EMBASE: 614225065]NCT01578499. A randomised, open-label, phase 3 trial of brentuximab vedotin (SGN-35) versus physician's choice (methotrexate or bexarotene) in patients with CD30-positive cutaneous T-cell lymphoma. clinicaltrials.gov/ct2/show/NCT01578499 (first received 17 April 2012). PrinceHM , DummerR , WhittakerS , HorwitzS , DuvicM , ScarisbrickJ , et al. Patient-reported outcomes and quality of life in patients with cutaneous T cell lymphoma: results from the phase 3 ALCANZA study. In: Hematological Oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:247–8. [CENTRAL: CN-01408603] [DOI: 10.1002/hon.2438]ZagadailovE , PrinceHM , WhittakerS , HorwitzS , DuvicM , KimY , et al. Phase 3 alcanza study of brentuximab vedotin (BV) or physician's choice (PC) of methotrexate (MTX) or bexarotene (BEX) in CD30-positive cutaneous T-cell lymphoma (CTCL): number needed to treat analysis. In: Haematologica. Conference: 22th congress of the european hematology association. Spain. Vol. 102. 2017:251. [CENTRAL: CN-01399195] ">Prince 2017</a>; <a href="./references#CD008946-bbs2-0016" title="NCT01686594. A multi-center, randomized study on oral 8-methoxypsoralen plus UVA with or without maintenance therapy in mycosis fungoides EORTC/ISCL stage IA to IIB. clinicaltrials.gov/ct2/show/NCT01686594 (first received 18 September 2012). Vieyra-GarciaP , Fink-PuchesR , PorkertS , LangR , PöchlauerS , RatzingerG , et al. Evaluation of low-dose, low-frequency oral psoralen-UV-A treatment with or without maintenance on early-stage mycosis fungoides: A randomized clinical trial. JAMA Dermatology2019;155(5):538-47. [PMID: 30892603]">Vieyra‐Garcia 2019</a>; <a href="./references#CD008946-bbs2-0018" title="NCT00056056. Ultraviolet light therapy using methoxsalen with or without Bexarotene in treating patients with mycosis fungoides. clinicaltrials.gov/ct2/show/NCT00056056 (first received 7 March 2003). WhittakerS , OrtizP , DummerR , RankiA , HasanB , MeulemansB , et al. Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial 21011 (NCT00056056). British Journal of Dermatology2012;167(3):678-87. [CENTRAL: CN-00856432] [PMID: 22924950]WhittakerS , Ortiz-RomeroPL , DummerR , RankiA , HasanB , MeulemansB , et al. Efficacy and safety of bexarotene combined with psoralen/ultraviolet A light (PUVA) compared to PUVA treatment alone in stage IB-IIa mycosis fungoides (MF): Final results from EORTC cutaneous lymphoma task force (CLTF) phase III clinical trial 21011. Journal of Clinical Oncology2012;30(15 Suppl 1):8076. ">Whittaker 2012</a>). All studies randomly assigned participants or comparable lesions of participants to one of the treatment groups. </p> </section> <section id="CD008946-sec-0070"> <h5 class="title">Sample Size</h5> <p>The number of participants evaluated in the studies varied from four to 260 participants. Seven of the included RCTs consisted of a very small sample size of less than 20 participants (<a href="./references#CD008946-bbs2-0002" title="ChildFJ , MitchellTJ , WhittakerSJ , ScarisbrickJJ , SeedPT , Russel-JonesR . A randomized cross-over study to compare PUVA and extracorporeal photopheresis in the treatment of plaque stage (T2) mycosis fungoides. Clinical &amp; Experimental Dermatology2004;29(3):231-6. [CENTRAL: CN-00468455] [PMID: 15115499]ChildFJ , MitchellTJ , WhittakerSJ , WatkinsP , SeedP , Russell-JonesR . A randomised cross-over study to compare Puva and extracorporeal photopheresis (ECP) in the treatment of plaque stage (T2) mycosis fungoides. British Journal of Dermatology2001;145(Suppl 59):16. [CENTRAL: CN-00430854] ">Child 2004</a>; <a href="./references#CD008946-bbs2-0003" title="ChongA , LooWJ , BanneyL , GrantJW , NorrisPG . Imiquimod 5% cream in the treatment of mycosis fungoides - a pilot study. Journal of Dermatological Treatment2004;15(2):118-9. [CENTRAL: CN-00467258] [PMID: 15204164]">Chong 2004</a>; <a href="./references#CD008946-bbs2-0012" title="RookAH , WoodGS , DuvicM , VonderheidEC , TobiaA , CabanaB . A phase II placebo-controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis. Journal of the American Academy of Dermatology2010;63(6):984-90. [CENTRAL: CN-00772559] [PMID: 20889234]">Rook 2010</a>; <a href="./references#CD008946-bbs2-0015" title="Thestrup-PedersenK , GrunnetE , ZachariaeH . Transfer factor therapy in mycosis fungoides: a double-blind study. Acta Dermato-Venereologica1982;62(1):47-53. [CENTRAL: CN-00027377] [PMID: 6175137]">Thestrup‐Pedersen 1982</a>; <a href="./references#CD008946-bbs2-0016" title="NCT01686594. A multi-center, randomized study on oral 8-methoxypsoralen plus UVA with or without maintenance therapy in mycosis fungoides EORTC/ISCL stage IA to IIB. clinicaltrials.gov/ct2/show/NCT01686594 (first received 18 September 2012). Vieyra-GarciaP , Fink-PuchesR , PorkertS , LangR , PöchlauerS , RatzingerG , et al. Evaluation of low-dose, low-frequency oral psoralen-UV-A treatment with or without maintenance on early-stage mycosis fungoides: A randomized clinical trial. JAMA Dermatology2019;155(5):538-47. [PMID: 30892603]">Vieyra‐Garcia 2019</a>; <a href="./references#CD008946-bbs2-0017" title="VonderheidEC , ThompsonR , SmilesKA , LattanandA . Recombinant interferon alfa-2b in plaque-phase mycosis fungoides. Intralesional and low-dose intramuscular therapy. Archives of Dermatology1987;123(6):757-63. [CENTRAL: CN-00047990] [PMID: 3579357]">Vonderheid 1987</a>; <a href="./references#CD008946-bbs2-0019" title="WolffJM , ZitelliJA , RabinBS , SmilesKA , AbellE . Intralesional interferon in the treatment of early mycosis fungoides. Journal of the American Academy of Dermatology1985;13(4):604-12. [CENTRAL: CN-00040943] [PMID: 2934438]">Wolff 1985</a>). Three studies had a sample size of 20 to 49 participants (<a href="./references#CD008946-bbs2-0001" title="BagotM , HasanB , WhittakerS , Beylot-BarryM , KnoblerR , ShahE , et al. A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma - EORTC 21081 (NCT01098656): results and lessons learned for future trial designs. European Journal of Dermatology2017;27(3):286–94. [CENTRAL: CN-01395486] [PMID: 28468739]NCT01098656. A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-Cell lymphoma. clinicaltrials.gov/ct2/show/NCT01098656 (first received 5 April 2010). [NCT01098656]">Bagot 2017</a>; <a href="./references#CD008946-bbs2-0006" title="GuitartJ , TuckerR , StevensV . Low dose bexarotene (Targretin®) capsules and phototherapy for early stage cutaneous T-Cell lymphoma. Journal of Investigative Dermatology2002;119(1):241. [CENTRAL: CN-00794450] NCT00030589. A muliticenter, dose-randomized evaluation of Targretin capsules plus PUVA in patients with stage IB - IIA cutaneous T-Cell lymphoma. clinicaltrials.gov/ct/show/NCT00030589 (first received 27 Jaunry 2003). ">Guitart 2002</a>; <a href="./references#CD008946-bbs2-0020" title="WozniakMB , TraceyL , Ortiz-RomeroPL , MontesS , AlvarezM , FragaJ , et al. Psoralen plus ultraviolet A +/- interferon-alpha treatment resistance in mycosis fungoides: the role of tumour microenvironment, nuclear transcription factor-kappaB and T-cell receptor pathways. British Journal of Dermatology2008;160(1):92-102. [CENTRAL: CN-00668828] [PMID: 18945306]">Wozniak 2008</a>), seven studies enrolled 50 to 99 participants (<a href="./references#CD008946-bbs2-0004" title="DuvicM , MartinAG , KimY , OlsenE , WoodGS , CrowleyCA , et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Archives of Dermatology2001;137(5):581-93. [CENTRAL: CN-00347816] [PMID: 11346336]PrinceHM , McCormackC , RyanG , BakerC , RotsteinH , DavisonJ , et al. Bexarotene capsules and gel for previously treated patients with cutaneous T-cell lymphoma: results of the Australian patients treated on phase II trials. Australasian Journal of Dermatology2001;42(2):91-7. [CENTRAL: CN-00442169] [PMID: 11309029]">Duvic 2001</a>; <a href="./references#CD008946-bbs2-0005" title="DuvicM , OlsenEA , OmuraGA , MaizeJC , VonderheidEC , et al. A phase III, randomized, double-blind, placebo-controlled study of peldesine (BCX-34) cream as topical therapy for cutaneous T-cell lymphoma. Journal of the American Academy of Dermatology2001;44(6):940-7. [CENTRAL: CN-00348073] [PMID: 11369904]">Duvic 2001a</a>; <a href="./references#CD008946-bbs2-0010" title="DuvicM , KuzelTM , OlsenEA , MartinAG , FossFM , KimYH , et al. Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK). Clinical Lymphoma2002;2(4):222-8. [CENTRAL: CN-00514479] [PMID: 11970761]KuzelT , OlsenE , MartinA , KimY , DuvicM , FrankelA , et al. Pivotal phase III trial of two dose levels of DAB389IL-2 (Ontak®) for the treatment of mycosis fungoides (MF). Blood1997;90(10 Suppl 1 (Pt 1)):586a. [CENTRAL: CN-00518069] NTC00050999. Study of ONTAK (Denileukin Diftitox) in cutaneous T-Cell lymphoma (CTCL) patients. clinicaltrials.gov/ct2/show/NCT00050999 (first received 3 January 2003). OlsenE , DuvicM , FrankelA , KimY , MartinA , VonderheidE , et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. Journal of Clinical Oncology2001;19(2):376-88. [CENTRAL: CN-00328506] [PMID: 11208829]OlsenE , DuvicM , MartinA . Pivotal phase III trial of two dose levels of DAB 389 IL-2 (ONTAK) for the treatment of cutaneous T-cell lymphoma (CTCL). Journal of Investigative Dermatology1998;110(4):678. [CENTRAL: CN-00353452] ">Olsen 2001</a>; <a href="./references#CD008946-bbs2-0011" title="HorwitzS , WhittakerS , DuvicM , DummerR , KimYH , ScarisbrickJ , et al. Response by stage in CD30-positive (CD30+) cutaneous T cell lymphoma (CTCL) patients receiving brentuximab vedotin (BV) vs physician's choice (PC) in the phase 3 ALCANZA study. In: Hematological oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:245–7. [CENTRAL: CN-01408605] [DOI: 10.1002/hon.2438]HorwitzSM , AkilovOE , FisherD , KuzelTM , WangY , Palanca-WesselsMC , et al. Brentuximab vedotin or physician’s choice in CD30-positivecutaneous T-cell lymphoma (ALCANZA): an international,open-label, randomised, phase 3, multicentre trial. Lancet2017;390(10094):555-66. [CENTRAL: CN-01403731] HorwitzSM , ScarisbrickJJ , DummerR , DuvicM , KimYH , WalewskiJ , et al. Updated analyses of the international, open-label, randomized, phase 3 alcanza study: longer-term evidence for superiority of brentuximab vedotin versus methotrexate or bexarotene for CD30-positive cutaneous T-cell lymphoma (CTCL). In: Blood. Conference: 59th annual meeting of the american society of hematology, ASH 2017. United states. Vol. 130. 2017. [CENTRAL: CN-01450312] KimYH , PrinceHM , WhittakerS , HorwitzSM , DuvicM , ScarisbrickJ , et al. Brentuximab vedotin vs physician's choice in CTCL patients from the phase 3 ALCANZA study: analysis of outcomes by CD30 expression. In: Hematological Oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:77–8. [CENTRAL: CN-01408482] [DOI: 10.1002/hon.2437]KimYH , PrinceHM , WhittakerS , HorwitzSM , DuvicM , ScarisbrickJ , et al. Outcomes by CD30 expression in patients with CTCL receiving brentuximab vedotin (BV) vs physician's choice (PC) in the Phase 3 ALCANZA study. Journal of Clinical Oncology2017;35(15 Supplement 1):7517. [EMBASE: 617388795]KimYH , WhittakerS , DummerR , GeskinLJ , GauthierP , LittleM , et al. Phase 3 study of brentuximab vedotin versus physician's choice of methotrexate or bexarotene in patients (PTS) with CD30-positive (CD30+) cutaneous T-cell lymphoma (CTCL). The alcanza study. Hematological Oncology2013;31(Suppl 1):278. [CENTRAL: CN-01531598] [EMBASE: 71147875]KimYH , WhittakerS , HorwitzSM , DuvicM , DummerR , ScarisbrickJ , et al. Brentuximab vedotin demonstrates superior activity to standard therapy in CD30-expressing (CD30+) cutaneous T-cell lymphoma (CTCL) in the randomized phase 3 ALCANZA study. Journal of Investigative Dermatology2017;137(5 Suppl 1):S45. [CENTRAL: CN-01375469] [EMBASE: 616393777]KimYH , WhittakerS , HorwitzSM , DuvicM , DummerR , ScarisbrickJJ , et al. Brentuximab vedotin demonstrates significantly superior clinical outcomes in patients with CD30-expressing cutaneous T cell lymphoma versus physician's choice (Methotrexate or Bexarotene): the phase 3 alcanza study. In: Blood. Conference: 58th annual meeting of the american society of hematology, ASH 2016. United states. Conference start: 20161203. Conference end: 20161206. Vol. 128. 2016. [CENTRAL: CN-01303081] [EMBASE: 614225065]NCT01578499. A randomised, open-label, phase 3 trial of brentuximab vedotin (SGN-35) versus physician's choice (methotrexate or bexarotene) in patients with CD30-positive cutaneous T-cell lymphoma. clinicaltrials.gov/ct2/show/NCT01578499 (first received 17 April 2012). PrinceHM , DummerR , WhittakerS , HorwitzS , DuvicM , ScarisbrickJ , et al. Patient-reported outcomes and quality of life in patients with cutaneous T cell lymphoma: results from the phase 3 ALCANZA study. In: Hematological Oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:247–8. [CENTRAL: CN-01408603] [DOI: 10.1002/hon.2438]ZagadailovE , PrinceHM , WhittakerS , HorwitzS , DuvicM , KimY , et al. Phase 3 alcanza study of brentuximab vedotin (BV) or physician's choice (PC) of methotrexate (MTX) or bexarotene (BEX) in CD30-positive cutaneous T-cell lymphoma (CTCL): number needed to treat analysis. In: Haematologica. Conference: 22th congress of the european hematology association. Spain. Vol. 102. 2017:251. [CENTRAL: CN-01399195] ">Prince 2017</a>; <a href="./references#CD008946-bbs2-0013" title="OtteHG , KuhlS , StadlerR , LugerT , HenzB , SterryW . Treatment of cutaneous T-cell lymphoma with Interferon alpha and PUVA versus Interferon alpha and Acitretin - results of a prospective randomised multi-centre study [Behandlung des kutanen T-Zell-Lymphoms mit Interferon alpha und PUVA versus Interferon alpha und Acirentin - Ergebnisse einer prospektiv-randomisierten Multicenter-Studie]. Der Hautarzt1997;48(Suppl):S97. [CENTRAL: CN-00495120] OtteHG , StadierR , LugerT , HenzB , SterryW . Open controlled clinical trial on the use of interferon plus acitretin versus interferon plus PUVA in patients with cutaneous T-cell lymphoma (CTCL). Annals of Oncology1996;7(Suppl 3):66. [CENTRAL: CN-00308243] StadlerR , OtteHG , LugerT , HenzBM , KuhlP , ZwingersT , et al. Prospective randomized multicenter clinical trial on the use of interferon -2a plus acitretin versus interferon -2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood1998;92(10):3578-81. [CENTRAL: CN-00156682] [PMID: 9808550]">Stadler 1998</a>; <a href="./references#CD008946-bbs2-0014" title="BohmeyerJ , OtteHG , StadlerR , LugerT , SterryW . Therapy of cutaneous T-cell lymphoma with PUVA versus interferon alfa plus PUVA: first results. Journal of the European Academy of Dermatology &amp; Venereology1999;12(Suppl 2):S268. [CENTRAL: CN-00478472] BohmeyerJ , StadlerR , LugerT , SterryW . Prospective randomized multicentre therapy optimizing protocol for therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α + PUVA [Prospectiv randomisiertes, multizentrisches Therapieoptimierungsprotokoll zur Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α + PUVA]. Zeitschrift für Hautkrankheiten2001;76(Suppl 1):S55. [CENTRAL: CN-01446038] KremerA , BohmeyerJ , StadlerR , LugerT , SterryW . Prospective randomized multicentre therapy optimizing protocol for therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α + PUVA [Prospectiv randomisiertes, multizentrisches Therapieoptimierungsprotokoll zur Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α + PUVA]. Journal der Deutschen Dermatologischen Gesellschaft2003;1(Suppl 1):S99. [CENTRAL: CN-01446037] OtteHG , StadlerR , LugerT , SterryW . Therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α plus PUVA: first results of a prospective randomized multicentre therapy optimizing protocol [Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α plus PUVA: Erste Ergebnisse des prospektiven randomisierten multizentrischen Therapieoptimierungsprotokolls]. Der Hautarzt1999;50(Suppl 1):S2. [CENTRAL: CN-01457423] OtteHG , StadlerR . Combination therapy of cutaneous t-cell-lymphoma with interferon alfa 2a and PUVA [Kombinationstherapie kutaner T-Zell-Lymphome mit Interferon Alfa 2a und PUVA]. Zentralblatt Haut- und Geschlechtskrankheiten1993;162(Suppl):P2.03.08. [CENTRAL: CN-01457422] StadlerM , KremerA , LugerT , SterryW . Prospective, randomized, multicentre clinical trial on the use of interferon a 2a plus PUVA versus PUVA monotherapy in patients with cutaneous T-cell lymphoma, stages I and II [Abstract 7541]. ASCO annual meeting proceedings. Journal of Clinical Oncology2006;24(18S Pt 1):432. [CENTRAL: CN-00625001] ">Stadler 2006</a>; <a href="./references#CD008946-bbs2-0018" title="NCT00056056. Ultraviolet light therapy using methoxsalen with or without Bexarotene in treating patients with mycosis fungoides. clinicaltrials.gov/ct2/show/NCT00056056 (first received 7 March 2003). WhittakerS , OrtizP , DummerR , RankiA , HasanB , MeulemansB , et al. Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial 21011 (NCT00056056). British Journal of Dermatology2012;167(3):678-87. [CENTRAL: CN-00856432] [PMID: 22924950]WhittakerS , Ortiz-RomeroPL , DummerR , RankiA , HasanB , MeulemansB , et al. Efficacy and safety of bexarotene combined with psoralen/ultraviolet A light (PUVA) compared to PUVA treatment alone in stage IB-IIa mycosis fungoides (MF): Final results from EORTC cutaneous lymphoma task force (CLTF) phase III clinical trial 21011. Journal of Clinical Oncology2012;30(15 Suppl 1):8076. ">Whittaker 2012</a>), and three studies (<a href="./references#CD008946-bbs2-0007" title="KayeF , EddyJ , IhdeDC , SteinbergS , FischmannAB , GlatsteinE , et al. Conservative vs. aggressive therapy in mycosis fungoides. Proceedings of the American Society of Clinical Oncology1989;8:257. [CENTRAL: CN-00694960] KayeF , IhdeD , FischmannA , GlatsteinE , MinnaJ , SchechterG , et al. A randomized trial comparing conservative and aggressive therapy in mycosis fungoides (MF). Proceedings of the American Society of Clinical Oncology1986;5:195. [CENTRAL: CN-00695166] KayeFJ , BunnPA , SteinbergSM , StockerJL , IhdeDC , FischmannAB , et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. New England Journal of Medicine1989;321(26):1784-90. [CENTRAL: CN-00064211] [PMID: 2594037]">Kaye 1989</a>; <a href="./references#CD008946-bbs2-0008" title="BagotM , DalleS , SokolL , TsianakasA , MusiekA , Ortiz-RomeroP , et al. Long-term clinical benefit to anti-CCR4 mogamulizumab: results from the phase 3 mavoric study in previously treated cutaneous t-cell lymphoma (CTCL). Blood2018;132(Supp 1):2901. [DOI: 10.1182/blood-2018-99-118473]CowanR , ScarisbrickJ , DwyerK , LeoniM , GrebennikD , MorrisS . Mogamulizumab demonstrates significant improvement in PFS compared to vorinostat in patients with previously treated cutaneous T-cell lymphoma (CTCL). British Journal of Haematology2018;181(S1):77–8. [DOI: 10.1111/bjh.15226]KimYH , BagotM , Pinter-BrownL , RookAH , PorcuP , HorwitzSM , et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncology2018;19(9):1192-1204. [PMID: 30100375]NCT01728805. Study of KW-0761 versus vorinostat in relapsed/refractory CTCL. clinicaltrials.gov/ct2/show/NCT01728805 (first received 20 November 2012). PorcuP , HudgensS , QuaglinoP , CowanR , FlodenL , LeoniM , et al. Quality of life in cutaneous T-cell lymphoma subjects treated with anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat: results from the phase 3 MAVORIC trial. Journal of Clinical Oncology2018;36(15):-. [DOI: 10.1097/HS9.0000000000000060]QuaglinoP , HudgensS , PorcuP , CowanR , FlodenL , TsianakasA , et al. Quality of life in cutaneous t-cell lymphoma subjects treated with the anti-ccr4 monoclonal antibody mogamulizumab versus vorinostat: results from the phase 3 mavoric trial. Hemasphere2018;2(S1):85. ScarisbrickJ , ZinzaniPL , HorwitzS , KimYH , MoskowitzAJ , PorcuP , et al. Efficacy of mogamulizumab by prior systemic therapy in patients with previously treated cutaneous T-cell lymphoma: Post hoc analysis from the phase 3 MAVORIC study. British Journal of Haematology2019;185(Suppl 1):94. TsianakasA , QuaglinoP , HudgensS , FlodenL , LeoniM , DaleS , et al. Quality of life in cutaneous T-cell lymphoma subjects treated with the anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat: Results from the phase 3 MAVORIC trial. Oncology Research and Treatment2018;41(Suppl 4):272. ZinzaniPL , HorwitzSM , KimYH , MoskowitzAJ , PorcuP , ScarisbrickJ , et al. Efficacy of mogamulizumab by prior systemic therapy in patients with previously treated cutaneous T-cell lymphoma: post hoc analysis from the phase 3 mavoric study. Blood2018;132(Suppl 1):1619. [DOI: 10.1182/blood-2018-99-114819]">Kim 2018</a>; <a href="./references#CD008946-bbs2-0009" title="LessinS , DuvicM , GuitartJ , PandyaA , StroberB , OlsenE , et al. Positive results of a pivotal phase ii trial testing a manufactured 0.02% Mechlorethamine gel in mycosis fungoides (mf). Journal of Investigative Dermatology2011;131(Suppl 1):S84. [CENTRAL: CN-00843792] LessinSR , DuvicM , GuitartJ , PandyaAG , StroberBE , OlsenEA , et al. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatology2013;149(1):25-32. [CENTRAL: CN-00859487] [PMID: 23069814]NCT00168064. Safety and efficacy of nitrogen mustard in treatment of mycosis fungoides. clinicaltrials.gov/ct2/show/NCT00168064 (first received 14 September 2005). ">Lessin 2013</a>) had more than 100 participants. </p> </section> <section id="CD008946-sec-0071"> <h5 class="title">Population</h5> <p>Fourteen of the included trials exclusively assessed participants with cutaneous T‐cell lymphomas (CTCL) in clinical stages IA to IIB (<a href="./references#CD008946-bbs2-0002" title="ChildFJ , MitchellTJ , WhittakerSJ , ScarisbrickJJ , SeedPT , Russel-JonesR . A randomized cross-over study to compare PUVA and extracorporeal photopheresis in the treatment of plaque stage (T2) mycosis fungoides. Clinical &amp; Experimental Dermatology2004;29(3):231-6. [CENTRAL: CN-00468455] [PMID: 15115499]ChildFJ , MitchellTJ , WhittakerSJ , WatkinsP , SeedP , Russell-JonesR . A randomised cross-over study to compare Puva and extracorporeal photopheresis (ECP) in the treatment of plaque stage (T2) mycosis fungoides. British Journal of Dermatology2001;145(Suppl 59):16. [CENTRAL: CN-00430854] ">Child 2004</a>; <a href="./references#CD008946-bbs2-0003" title="ChongA , LooWJ , BanneyL , GrantJW , NorrisPG . Imiquimod 5% cream in the treatment of mycosis fungoides - a pilot study. Journal of Dermatological Treatment2004;15(2):118-9. [CENTRAL: CN-00467258] [PMID: 15204164]">Chong 2004</a>; <a href="./references#CD008946-bbs2-0004" title="DuvicM , MartinAG , KimY , OlsenE , WoodGS , CrowleyCA , et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Archives of Dermatology2001;137(5):581-93. [CENTRAL: CN-00347816] [PMID: 11346336]PrinceHM , McCormackC , RyanG , BakerC , RotsteinH , DavisonJ , et al. Bexarotene capsules and gel for previously treated patients with cutaneous T-cell lymphoma: results of the Australian patients treated on phase II trials. Australasian Journal of Dermatology2001;42(2):91-7. [CENTRAL: CN-00442169] [PMID: 11309029]">Duvic 2001</a>; <a href="./references#CD008946-bbs2-0005" title="DuvicM , OlsenEA , OmuraGA , MaizeJC , VonderheidEC , et al. A phase III, randomized, double-blind, placebo-controlled study of peldesine (BCX-34) cream as topical therapy for cutaneous T-cell lymphoma. Journal of the American Academy of Dermatology2001;44(6):940-7. [CENTRAL: CN-00348073] [PMID: 11369904]">Duvic 2001a</a>; <a href="./references#CD008946-bbs2-0006" title="GuitartJ , TuckerR , StevensV . Low dose bexarotene (Targretin®) capsules and phototherapy for early stage cutaneous T-Cell lymphoma. Journal of Investigative Dermatology2002;119(1):241. [CENTRAL: CN-00794450] NCT00030589. A muliticenter, dose-randomized evaluation of Targretin capsules plus PUVA in patients with stage IB - IIA cutaneous T-Cell lymphoma. clinicaltrials.gov/ct/show/NCT00030589 (first received 27 Jaunry 2003). ">Guitart 2002</a>; <a href="./references#CD008946-bbs2-0009" title="LessinS , DuvicM , GuitartJ , PandyaA , StroberB , OlsenE , et al. Positive results of a pivotal phase ii trial testing a manufactured 0.02% Mechlorethamine gel in mycosis fungoides (mf). Journal of Investigative Dermatology2011;131(Suppl 1):S84. [CENTRAL: CN-00843792] LessinSR , DuvicM , GuitartJ , PandyaAG , StroberBE , OlsenEA , et al. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatology2013;149(1):25-32. [CENTRAL: CN-00859487] [PMID: 23069814]NCT00168064. Safety and efficacy of nitrogen mustard in treatment of mycosis fungoides. clinicaltrials.gov/ct2/show/NCT00168064 (first received 14 September 2005). ">Lessin 2013</a>; <a href="./references#CD008946-bbs2-0012" title="RookAH , WoodGS , DuvicM , VonderheidEC , TobiaA , CabanaB . A phase II placebo-controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis. Journal of the American Academy of Dermatology2010;63(6):984-90. [CENTRAL: CN-00772559] [PMID: 20889234]">Rook 2010</a>; <a href="./references#CD008946-bbs2-0013" title="OtteHG , KuhlS , StadlerR , LugerT , HenzB , SterryW . Treatment of cutaneous T-cell lymphoma with Interferon alpha and PUVA versus Interferon alpha and Acitretin - results of a prospective randomised multi-centre study [Behandlung des kutanen T-Zell-Lymphoms mit Interferon alpha und PUVA versus Interferon alpha und Acirentin - Ergebnisse einer prospektiv-randomisierten Multicenter-Studie]. Der Hautarzt1997;48(Suppl):S97. [CENTRAL: CN-00495120] OtteHG , StadierR , LugerT , HenzB , SterryW . Open controlled clinical trial on the use of interferon plus acitretin versus interferon plus PUVA in patients with cutaneous T-cell lymphoma (CTCL). Annals of Oncology1996;7(Suppl 3):66. [CENTRAL: CN-00308243] StadlerR , OtteHG , LugerT , HenzBM , KuhlP , ZwingersT , et al. Prospective randomized multicenter clinical trial on the use of interferon -2a plus acitretin versus interferon -2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood1998;92(10):3578-81. [CENTRAL: CN-00156682] [PMID: 9808550]">Stadler 1998</a>; <a href="./references#CD008946-bbs2-0014" title="BohmeyerJ , OtteHG , StadlerR , LugerT , SterryW . Therapy of cutaneous T-cell lymphoma with PUVA versus interferon alfa plus PUVA: first results. Journal of the European Academy of Dermatology &amp; Venereology1999;12(Suppl 2):S268. [CENTRAL: CN-00478472] BohmeyerJ , StadlerR , LugerT , SterryW . Prospective randomized multicentre therapy optimizing protocol for therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α + PUVA [Prospectiv randomisiertes, multizentrisches Therapieoptimierungsprotokoll zur Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α + PUVA]. Zeitschrift für Hautkrankheiten2001;76(Suppl 1):S55. [CENTRAL: CN-01446038] KremerA , BohmeyerJ , StadlerR , LugerT , SterryW . Prospective randomized multicentre therapy optimizing protocol for therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α + PUVA [Prospectiv randomisiertes, multizentrisches Therapieoptimierungsprotokoll zur Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α + PUVA]. Journal der Deutschen Dermatologischen Gesellschaft2003;1(Suppl 1):S99. [CENTRAL: CN-01446037] OtteHG , StadlerR , LugerT , SterryW . Therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α plus PUVA: first results of a prospective randomized multicentre therapy optimizing protocol [Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α plus PUVA: Erste Ergebnisse des prospektiven randomisierten multizentrischen Therapieoptimierungsprotokolls]. Der Hautarzt1999;50(Suppl 1):S2. [CENTRAL: CN-01457423] OtteHG , StadlerR . Combination therapy of cutaneous t-cell-lymphoma with interferon alfa 2a and PUVA [Kombinationstherapie kutaner T-Zell-Lymphome mit Interferon Alfa 2a und PUVA]. Zentralblatt Haut- und Geschlechtskrankheiten1993;162(Suppl):P2.03.08. [CENTRAL: CN-01457422] StadlerM , KremerA , LugerT , SterryW . Prospective, randomized, multicentre clinical trial on the use of interferon a 2a plus PUVA versus PUVA monotherapy in patients with cutaneous T-cell lymphoma, stages I and II [Abstract 7541]. ASCO annual meeting proceedings. Journal of Clinical Oncology2006;24(18S Pt 1):432. [CENTRAL: CN-00625001] ">Stadler 2006</a>; <a href="./references#CD008946-bbs2-0016" title="NCT01686594. A multi-center, randomized study on oral 8-methoxypsoralen plus UVA with or without maintenance therapy in mycosis fungoides EORTC/ISCL stage IA to IIB. clinicaltrials.gov/ct2/show/NCT01686594 (first received 18 September 2012). Vieyra-GarciaP , Fink-PuchesR , PorkertS , LangR , PöchlauerS , RatzingerG , et al. Evaluation of low-dose, low-frequency oral psoralen-UV-A treatment with or without maintenance on early-stage mycosis fungoides: A randomized clinical trial. JAMA Dermatology2019;155(5):538-47. [PMID: 30892603]">Vieyra‐Garcia 2019</a>; <a href="./references#CD008946-bbs2-0017" title="VonderheidEC , ThompsonR , SmilesKA , LattanandA . Recombinant interferon alfa-2b in plaque-phase mycosis fungoides. Intralesional and low-dose intramuscular therapy. Archives of Dermatology1987;123(6):757-63. [CENTRAL: CN-00047990] [PMID: 3579357]">Vonderheid 1987</a>; <a href="./references#CD008946-bbs2-0018" title="NCT00056056. Ultraviolet light therapy using methoxsalen with or without Bexarotene in treating patients with mycosis fungoides. clinicaltrials.gov/ct2/show/NCT00056056 (first received 7 March 2003). WhittakerS , OrtizP , DummerR , RankiA , HasanB , MeulemansB , et al. Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial 21011 (NCT00056056). British Journal of Dermatology2012;167(3):678-87. [CENTRAL: CN-00856432] [PMID: 22924950]WhittakerS , Ortiz-RomeroPL , DummerR , RankiA , HasanB , MeulemansB , et al. Efficacy and safety of bexarotene combined with psoralen/ultraviolet A light (PUVA) compared to PUVA treatment alone in stage IB-IIa mycosis fungoides (MF): Final results from EORTC cutaneous lymphoma task force (CLTF) phase III clinical trial 21011. Journal of Clinical Oncology2012;30(15 Suppl 1):8076. ">Whittaker 2012</a>; <a href="./references#CD008946-bbs2-0019" title="WolffJM , ZitelliJA , RabinBS , SmilesKA , AbellE . Intralesional interferon in the treatment of early mycosis fungoides. Journal of the American Academy of Dermatology1985;13(4):604-12. [CENTRAL: CN-00040943] [PMID: 2934438]">Wolff 1985</a>; <a href="./references#CD008946-bbs2-0020" title="WozniakMB , TraceyL , Ortiz-RomeroPL , MontesS , AlvarezM , FragaJ , et al. Psoralen plus ultraviolet A +/- interferon-alpha treatment resistance in mycosis fungoides: the role of tumour microenvironment, nuclear transcription factor-kappaB and T-cell receptor pathways. British Journal of Dermatology2008;160(1):92-102. [CENTRAL: CN-00668828] [PMID: 18945306]">Wozniak 2008</a>). Three studies also included participants with CTCL in clinical stage III (<a href="./references#CD008946-bbs2-0007" title="KayeF , EddyJ , IhdeDC , SteinbergS , FischmannAB , GlatsteinE , et al. Conservative vs. aggressive therapy in mycosis fungoides. Proceedings of the American Society of Clinical Oncology1989;8:257. [CENTRAL: CN-00694960] KayeF , IhdeD , FischmannA , GlatsteinE , MinnaJ , SchechterG , et al. A randomized trial comparing conservative and aggressive therapy in mycosis fungoides (MF). Proceedings of the American Society of Clinical Oncology1986;5:195. [CENTRAL: CN-00695166] KayeFJ , BunnPA , SteinbergSM , StockerJL , IhdeDC , FischmannAB , et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. New England Journal of Medicine1989;321(26):1784-90. [CENTRAL: CN-00064211] [PMID: 2594037]">Kaye 1989</a>; <a href="./references#CD008946-bbs2-0010" title="DuvicM , KuzelTM , OlsenEA , MartinAG , FossFM , KimYH , et al. Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK). Clinical Lymphoma2002;2(4):222-8. [CENTRAL: CN-00514479] [PMID: 11970761]KuzelT , OlsenE , MartinA , KimY , DuvicM , FrankelA , et al. Pivotal phase III trial of two dose levels of DAB389IL-2 (Ontak®) for the treatment of mycosis fungoides (MF). Blood1997;90(10 Suppl 1 (Pt 1)):586a. [CENTRAL: CN-00518069] NTC00050999. Study of ONTAK (Denileukin Diftitox) in cutaneous T-Cell lymphoma (CTCL) patients. clinicaltrials.gov/ct2/show/NCT00050999 (first received 3 January 2003). OlsenE , DuvicM , FrankelA , KimY , MartinA , VonderheidE , et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. Journal of Clinical Oncology2001;19(2):376-88. [CENTRAL: CN-00328506] [PMID: 11208829]OlsenE , DuvicM , MartinA . Pivotal phase III trial of two dose levels of DAB 389 IL-2 (ONTAK) for the treatment of cutaneous T-cell lymphoma (CTCL). Journal of Investigative Dermatology1998;110(4):678. [CENTRAL: CN-00353452] ">Olsen 2001</a>; <a href="./references#CD008946-bbs2-0015" title="Thestrup-PedersenK , GrunnetE , ZachariaeH . Transfer factor therapy in mycosis fungoides: a double-blind study. Acta Dermato-Venereologica1982;62(1):47-53. [CENTRAL: CN-00027377] [PMID: 6175137]">Thestrup‐Pedersen 1982</a>), and five studies (<a href="./references#CD008946-bbs2-0001" title="BagotM , HasanB , WhittakerS , Beylot-BarryM , KnoblerR , ShahE , et al. A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma - EORTC 21081 (NCT01098656): results and lessons learned for future trial designs. European Journal of Dermatology2017;27(3):286–94. [CENTRAL: CN-01395486] [PMID: 28468739]NCT01098656. A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-Cell lymphoma. clinicaltrials.gov/ct2/show/NCT01098656 (first received 5 April 2010). [NCT01098656]">Bagot 2017</a>; <a href="./references#CD008946-bbs2-0007" title="KayeF , EddyJ , IhdeDC , SteinbergS , FischmannAB , GlatsteinE , et al. Conservative vs. aggressive therapy in mycosis fungoides. Proceedings of the American Society of Clinical Oncology1989;8:257. [CENTRAL: CN-00694960] KayeF , IhdeD , FischmannA , GlatsteinE , MinnaJ , SchechterG , et al. A randomized trial comparing conservative and aggressive therapy in mycosis fungoides (MF). Proceedings of the American Society of Clinical Oncology1986;5:195. [CENTRAL: CN-00695166] KayeFJ , BunnPA , SteinbergSM , StockerJL , IhdeDC , FischmannAB , et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. New England Journal of Medicine1989;321(26):1784-90. [CENTRAL: CN-00064211] [PMID: 2594037]">Kaye 1989</a>; <a href="./references#CD008946-bbs2-0008" title="BagotM , DalleS , SokolL , TsianakasA , MusiekA , Ortiz-RomeroP , et al. Long-term clinical benefit to anti-CCR4 mogamulizumab: results from the phase 3 mavoric study in previously treated cutaneous t-cell lymphoma (CTCL). Blood2018;132(Supp 1):2901. [DOI: 10.1182/blood-2018-99-118473]CowanR , ScarisbrickJ , DwyerK , LeoniM , GrebennikD , MorrisS . Mogamulizumab demonstrates significant improvement in PFS compared to vorinostat in patients with previously treated cutaneous T-cell lymphoma (CTCL). British Journal of Haematology2018;181(S1):77–8. [DOI: 10.1111/bjh.15226]KimYH , BagotM , Pinter-BrownL , RookAH , PorcuP , HorwitzSM , et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncology2018;19(9):1192-1204. [PMID: 30100375]NCT01728805. Study of KW-0761 versus vorinostat in relapsed/refractory CTCL. clinicaltrials.gov/ct2/show/NCT01728805 (first received 20 November 2012). PorcuP , HudgensS , QuaglinoP , CowanR , FlodenL , LeoniM , et al. Quality of life in cutaneous T-cell lymphoma subjects treated with anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat: results from the phase 3 MAVORIC trial. Journal of Clinical Oncology2018;36(15):-. [DOI: 10.1097/HS9.0000000000000060]QuaglinoP , HudgensS , PorcuP , CowanR , FlodenL , TsianakasA , et al. Quality of life in cutaneous t-cell lymphoma subjects treated with the anti-ccr4 monoclonal antibody mogamulizumab versus vorinostat: results from the phase 3 mavoric trial. Hemasphere2018;2(S1):85. ScarisbrickJ , ZinzaniPL , HorwitzS , KimYH , MoskowitzAJ , PorcuP , et al. Efficacy of mogamulizumab by prior systemic therapy in patients with previously treated cutaneous T-cell lymphoma: Post hoc analysis from the phase 3 MAVORIC study. British Journal of Haematology2019;185(Suppl 1):94. TsianakasA , QuaglinoP , HudgensS , FlodenL , LeoniM , DaleS , et al. Quality of life in cutaneous T-cell lymphoma subjects treated with the anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat: Results from the phase 3 MAVORIC trial. Oncology Research and Treatment2018;41(Suppl 4):272. ZinzaniPL , HorwitzSM , KimYH , MoskowitzAJ , PorcuP , ScarisbrickJ , et al. Efficacy of mogamulizumab by prior systemic therapy in patients with previously treated cutaneous T-cell lymphoma: post hoc analysis from the phase 3 mavoric study. Blood2018;132(Suppl 1):1619. [DOI: 10.1182/blood-2018-99-114819]">Kim 2018</a>; <a href="./references#CD008946-bbs2-0010" title="DuvicM , KuzelTM , OlsenEA , MartinAG , FossFM , KimYH , et al. Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK). Clinical Lymphoma2002;2(4):222-8. [CENTRAL: CN-00514479] [PMID: 11970761]KuzelT , OlsenE , MartinA , KimY , DuvicM , FrankelA , et al. Pivotal phase III trial of two dose levels of DAB389IL-2 (Ontak®) for the treatment of mycosis fungoides (MF). Blood1997;90(10 Suppl 1 (Pt 1)):586a. [CENTRAL: CN-00518069] NTC00050999. Study of ONTAK (Denileukin Diftitox) in cutaneous T-Cell lymphoma (CTCL) patients. clinicaltrials.gov/ct2/show/NCT00050999 (first received 3 January 2003). OlsenE , DuvicM , FrankelA , KimY , MartinA , VonderheidE , et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. Journal of Clinical Oncology2001;19(2):376-88. [CENTRAL: CN-00328506] [PMID: 11208829]OlsenE , DuvicM , MartinA . Pivotal phase III trial of two dose levels of DAB 389 IL-2 (ONTAK) for the treatment of cutaneous T-cell lymphoma (CTCL). Journal of Investigative Dermatology1998;110(4):678. [CENTRAL: CN-00353452] ">Olsen 2001</a>; <a href="./references#CD008946-bbs2-0011" title="HorwitzS , WhittakerS , DuvicM , DummerR , KimYH , ScarisbrickJ , et al. Response by stage in CD30-positive (CD30+) cutaneous T cell lymphoma (CTCL) patients receiving brentuximab vedotin (BV) vs physician's choice (PC) in the phase 3 ALCANZA study. In: Hematological oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:245–7. [CENTRAL: CN-01408605] [DOI: 10.1002/hon.2438]HorwitzSM , AkilovOE , FisherD , KuzelTM , WangY , Palanca-WesselsMC , et al. Brentuximab vedotin or physician’s choice in CD30-positivecutaneous T-cell lymphoma (ALCANZA): an international,open-label, randomised, phase 3, multicentre trial. Lancet2017;390(10094):555-66. [CENTRAL: CN-01403731] HorwitzSM , ScarisbrickJJ , DummerR , DuvicM , KimYH , WalewskiJ , et al. Updated analyses of the international, open-label, randomized, phase 3 alcanza study: longer-term evidence for superiority of brentuximab vedotin versus methotrexate or bexarotene for CD30-positive cutaneous T-cell lymphoma (CTCL). In: Blood. Conference: 59th annual meeting of the american society of hematology, ASH 2017. United states. Vol. 130. 2017. [CENTRAL: CN-01450312] KimYH , PrinceHM , WhittakerS , HorwitzSM , DuvicM , ScarisbrickJ , et al. Brentuximab vedotin vs physician's choice in CTCL patients from the phase 3 ALCANZA study: analysis of outcomes by CD30 expression. In: Hematological Oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:77–8. [CENTRAL: CN-01408482] [DOI: 10.1002/hon.2437]KimYH , PrinceHM , WhittakerS , HorwitzSM , DuvicM , ScarisbrickJ , et al. Outcomes by CD30 expression in patients with CTCL receiving brentuximab vedotin (BV) vs physician's choice (PC) in the Phase 3 ALCANZA study. Journal of Clinical Oncology2017;35(15 Supplement 1):7517. [EMBASE: 617388795]KimYH , WhittakerS , DummerR , GeskinLJ , GauthierP , LittleM , et al. Phase 3 study of brentuximab vedotin versus physician's choice of methotrexate or bexarotene in patients (PTS) with CD30-positive (CD30+) cutaneous T-cell lymphoma (CTCL). The alcanza study. Hematological Oncology2013;31(Suppl 1):278. [CENTRAL: CN-01531598] [EMBASE: 71147875]KimYH , WhittakerS , HorwitzSM , DuvicM , DummerR , ScarisbrickJ , et al. Brentuximab vedotin demonstrates superior activity to standard therapy in CD30-expressing (CD30+) cutaneous T-cell lymphoma (CTCL) in the randomized phase 3 ALCANZA study. Journal of Investigative Dermatology2017;137(5 Suppl 1):S45. [CENTRAL: CN-01375469] [EMBASE: 616393777]KimYH , WhittakerS , HorwitzSM , DuvicM , DummerR , ScarisbrickJJ , et al. Brentuximab vedotin demonstrates significantly superior clinical outcomes in patients with CD30-expressing cutaneous T cell lymphoma versus physician's choice (Methotrexate or Bexarotene): the phase 3 alcanza study. In: Blood. Conference: 58th annual meeting of the american society of hematology, ASH 2016. United states. Conference start: 20161203. Conference end: 20161206. Vol. 128. 2016. [CENTRAL: CN-01303081] [EMBASE: 614225065]NCT01578499. A randomised, open-label, phase 3 trial of brentuximab vedotin (SGN-35) versus physician's choice (methotrexate or bexarotene) in patients with CD30-positive cutaneous T-cell lymphoma. clinicaltrials.gov/ct2/show/NCT01578499 (first received 17 April 2012). PrinceHM , DummerR , WhittakerS , HorwitzS , DuvicM , ScarisbrickJ , et al. Patient-reported outcomes and quality of life in patients with cutaneous T cell lymphoma: results from the phase 3 ALCANZA study. In: Hematological Oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:247–8. [CENTRAL: CN-01408603] [DOI: 10.1002/hon.2438]ZagadailovE , PrinceHM , WhittakerS , HorwitzS , DuvicM , KimY , et al. Phase 3 alcanza study of brentuximab vedotin (BV) or physician's choice (PC) of methotrexate (MTX) or bexarotene (BEX) in CD30-positive cutaneous T-cell lymphoma (CTCL): number needed to treat analysis. In: Haematologica. Conference: 22th congress of the european hematology association. Spain. Vol. 102. 2017:251. [CENTRAL: CN-01399195] ">Prince 2017</a>) also assessed participants in stage IV. </p> <p><a href="./references#CD008946-bbs2-0002" title="ChildFJ , MitchellTJ , WhittakerSJ , ScarisbrickJJ , SeedPT , Russel-JonesR . A randomized cross-over study to compare PUVA and extracorporeal photopheresis in the treatment of plaque stage (T2) mycosis fungoides. Clinical &amp; Experimental Dermatology2004;29(3):231-6. [CENTRAL: CN-00468455] [PMID: 15115499]ChildFJ , MitchellTJ , WhittakerSJ , WatkinsP , SeedP , Russell-JonesR . A randomised cross-over study to compare Puva and extracorporeal photopheresis (ECP) in the treatment of plaque stage (T2) mycosis fungoides. British Journal of Dermatology2001;145(Suppl 59):16. [CENTRAL: CN-00430854] ">Child 2004</a>, <a href="./references#CD008946-bbs2-0003" title="ChongA , LooWJ , BanneyL , GrantJW , NorrisPG . Imiquimod 5% cream in the treatment of mycosis fungoides - a pilot study. Journal of Dermatological Treatment2004;15(2):118-9. [CENTRAL: CN-00467258] [PMID: 15204164]">Chong 2004,</a><a href="./references#CD008946-bbs2-0006" title="GuitartJ , TuckerR , StevensV . Low dose bexarotene (Targretin®) capsules and phototherapy for early stage cutaneous T-Cell lymphoma. Journal of Investigative Dermatology2002;119(1):241. [CENTRAL: CN-00794450] NCT00030589. A muliticenter, dose-randomized evaluation of Targretin capsules plus PUVA in patients with stage IB - IIA cutaneous T-Cell lymphoma. clinicaltrials.gov/ct/show/NCT00030589 (first received 27 Jaunry 2003). ">Guitart 2002,</a><a href="./references#CD008946-bbs2-0007" title="KayeF , EddyJ , IhdeDC , SteinbergS , FischmannAB , GlatsteinE , et al. Conservative vs. aggressive therapy in mycosis fungoides. Proceedings of the American Society of Clinical Oncology1989;8:257. [CENTRAL: CN-00694960] KayeF , IhdeD , FischmannA , GlatsteinE , MinnaJ , SchechterG , et al. A randomized trial comparing conservative and aggressive therapy in mycosis fungoides (MF). Proceedings of the American Society of Clinical Oncology1986;5:195. [CENTRAL: CN-00695166] KayeFJ , BunnPA , SteinbergSM , StockerJL , IhdeDC , FischmannAB , et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. New England Journal of Medicine1989;321(26):1784-90. [CENTRAL: CN-00064211] [PMID: 2594037]">Kaye 1989,</a><a href="./references#CD008946-bbs2-0009" title="LessinS , DuvicM , GuitartJ , PandyaA , StroberB , OlsenE , et al. Positive results of a pivotal phase ii trial testing a manufactured 0.02% Mechlorethamine gel in mycosis fungoides (mf). Journal of Investigative Dermatology2011;131(Suppl 1):S84. [CENTRAL: CN-00843792] LessinSR , DuvicM , GuitartJ , PandyaAG , StroberBE , OlsenEA , et al. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatology2013;149(1):25-32. [CENTRAL: CN-00859487] [PMID: 23069814]NCT00168064. Safety and efficacy of nitrogen mustard in treatment of mycosis fungoides. clinicaltrials.gov/ct2/show/NCT00168064 (first received 14 September 2005). ">Lessin 2013</a>, <a href="./references#CD008946-bbs2-0010" title="DuvicM , KuzelTM , OlsenEA , MartinAG , FossFM , KimYH , et al. Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK). Clinical Lymphoma2002;2(4):222-8. [CENTRAL: CN-00514479] [PMID: 11970761]KuzelT , OlsenE , MartinA , KimY , DuvicM , FrankelA , et al. Pivotal phase III trial of two dose levels of DAB389IL-2 (Ontak®) for the treatment of mycosis fungoides (MF). Blood1997;90(10 Suppl 1 (Pt 1)):586a. [CENTRAL: CN-00518069] NTC00050999. Study of ONTAK (Denileukin Diftitox) in cutaneous T-Cell lymphoma (CTCL) patients. clinicaltrials.gov/ct2/show/NCT00050999 (first received 3 January 2003). OlsenE , DuvicM , FrankelA , KimY , MartinA , VonderheidE , et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. Journal of Clinical Oncology2001;19(2):376-88. [CENTRAL: CN-00328506] [PMID: 11208829]OlsenE , DuvicM , MartinA . Pivotal phase III trial of two dose levels of DAB 389 IL-2 (ONTAK) for the treatment of cutaneous T-cell lymphoma (CTCL). Journal of Investigative Dermatology1998;110(4):678. [CENTRAL: CN-00353452] ">Olsen 2001</a>, <a href="./references#CD008946-bbs2-0015" title="Thestrup-PedersenK , GrunnetE , ZachariaeH . Transfer factor therapy in mycosis fungoides: a double-blind study. Acta Dermato-Venereologica1982;62(1):47-53. [CENTRAL: CN-00027377] [PMID: 6175137]">Thestrup‐Pedersen 1982,</a><a href="./references#CD008946-bbs2-0016" title="NCT01686594. A multi-center, randomized study on oral 8-methoxypsoralen plus UVA with or without maintenance therapy in mycosis fungoides EORTC/ISCL stage IA to IIB. clinicaltrials.gov/ct2/show/NCT01686594 (first received 18 September 2012). Vieyra-GarciaP , Fink-PuchesR , PorkertS , LangR , PöchlauerS , RatzingerG , et al. Evaluation of low-dose, low-frequency oral psoralen-UV-A treatment with or without maintenance on early-stage mycosis fungoides: A randomized clinical trial. JAMA Dermatology2019;155(5):538-47. [PMID: 30892603]">Vieyra‐Garcia 2019</a>, <a href="./references#CD008946-bbs2-0017" title="VonderheidEC , ThompsonR , SmilesKA , LattanandA . Recombinant interferon alfa-2b in plaque-phase mycosis fungoides. Intralesional and low-dose intramuscular therapy. Archives of Dermatology1987;123(6):757-63. [CENTRAL: CN-00047990] [PMID: 3579357]">Vonderheid 1987,</a><a href="./references#CD008946-bbs2-0018" title="NCT00056056. Ultraviolet light therapy using methoxsalen with or without Bexarotene in treating patients with mycosis fungoides. clinicaltrials.gov/ct2/show/NCT00056056 (first received 7 March 2003). WhittakerS , OrtizP , DummerR , RankiA , HasanB , MeulemansB , et al. Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial 21011 (NCT00056056). British Journal of Dermatology2012;167(3):678-87. [CENTRAL: CN-00856432] [PMID: 22924950]WhittakerS , Ortiz-RomeroPL , DummerR , RankiA , HasanB , MeulemansB , et al. Efficacy and safety of bexarotene combined with psoralen/ultraviolet A light (PUVA) compared to PUVA treatment alone in stage IB-IIa mycosis fungoides (MF): Final results from EORTC cutaneous lymphoma task force (CLTF) phase III clinical trial 21011. Journal of Clinical Oncology2012;30(15 Suppl 1):8076. ">Whittaker 2012</a>, <a href="./references#CD008946-bbs2-0019" title="WolffJM , ZitelliJA , RabinBS , SmilesKA , AbellE . Intralesional interferon in the treatment of early mycosis fungoides. Journal of the American Academy of Dermatology1985;13(4):604-12. [CENTRAL: CN-00040943] [PMID: 2934438]">Wolff 1985,</a> and <a href="./references#CD008946-bbs2-0020" title="WozniakMB , TraceyL , Ortiz-RomeroPL , MontesS , AlvarezM , FragaJ , et al. Psoralen plus ultraviolet A +/- interferon-alpha treatment resistance in mycosis fungoides: the role of tumour microenvironment, nuclear transcription factor-kappaB and T-cell receptor pathways. British Journal of Dermatology2008;160(1):92-102. [CENTRAL: CN-00668828] [PMID: 18945306]">Wozniak 2008</a> enrolled participants with mycosis fungoides (MF) only. </p> <p>All studies except one (<a href="./references#CD008946-bbs2-0003" title="ChongA , LooWJ , BanneyL , GrantJW , NorrisPG . Imiquimod 5% cream in the treatment of mycosis fungoides - a pilot study. Journal of Dermatological Treatment2004;15(2):118-9. [CENTRAL: CN-00467258] [PMID: 15204164]">Chong 2004</a>), enrolled men and women, although most of the studies enrolled more men than women. When information on participants' origin was available, most enrolled participants were white. Participants' ages ranged from 18 to &gt;75 years. In <a href="./references#CD008946-bbs2-0009" title="LessinS , DuvicM , GuitartJ , PandyaA , StroberB , OlsenE , et al. Positive results of a pivotal phase ii trial testing a manufactured 0.02% Mechlorethamine gel in mycosis fungoides (mf). Journal of Investigative Dermatology2011;131(Suppl 1):S84. [CENTRAL: CN-00843792] LessinSR , DuvicM , GuitartJ , PandyaAG , StroberBE , OlsenEA , et al. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatology2013;149(1):25-32. [CENTRAL: CN-00859487] [PMID: 23069814]NCT00168064. Safety and efficacy of nitrogen mustard in treatment of mycosis fungoides. clinicaltrials.gov/ct2/show/NCT00168064 (first received 14 September 2005). ">Lessin 2013</a>, one of 260 participants was a minor (11 years old). In an effort to not withhold the interested reader of this review from the results of this trial, we sought further information to exclude this patient from our analysis. Unfortunately, we did not receive a reply within four weeks. After careful consideration, we still included this trial. No other published RCT was excluded because of this criterion. </p> </section> <section id="CD008946-sec-0072"> <h5 class="title">Setting</h5> <p>All included studies took place in secondary and tertiary care skin tumour settings. Twelve studies enrolled participants in Europe (<a href="./references#CD008946-bbs2-0001" title="BagotM , HasanB , WhittakerS , Beylot-BarryM , KnoblerR , ShahE , et al. A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma - EORTC 21081 (NCT01098656): results and lessons learned for future trial designs. European Journal of Dermatology2017;27(3):286–94. [CENTRAL: CN-01395486] [PMID: 28468739]NCT01098656. A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-Cell lymphoma. clinicaltrials.gov/ct2/show/NCT01098656 (first received 5 April 2010). [NCT01098656]">Bagot 2017</a>; <a href="./references#CD008946-bbs2-0002" title="ChildFJ , MitchellTJ , WhittakerSJ , ScarisbrickJJ , SeedPT , Russel-JonesR . A randomized cross-over study to compare PUVA and extracorporeal photopheresis in the treatment of plaque stage (T2) mycosis fungoides. Clinical &amp; Experimental Dermatology2004;29(3):231-6. [CENTRAL: CN-00468455] [PMID: 15115499]ChildFJ , MitchellTJ , WhittakerSJ , WatkinsP , SeedP , Russell-JonesR . A randomised cross-over study to compare Puva and extracorporeal photopheresis (ECP) in the treatment of plaque stage (T2) mycosis fungoides. British Journal of Dermatology2001;145(Suppl 59):16. [CENTRAL: CN-00430854] ">Child 2004</a>; <a href="./references#CD008946-bbs2-0003" title="ChongA , LooWJ , BanneyL , GrantJW , NorrisPG . Imiquimod 5% cream in the treatment of mycosis fungoides - a pilot study. Journal of Dermatological Treatment2004;15(2):118-9. [CENTRAL: CN-00467258] [PMID: 15204164]">Chong 2004</a>; <a href="./references#CD008946-bbs2-0004" title="DuvicM , MartinAG , KimY , OlsenE , WoodGS , CrowleyCA , et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Archives of Dermatology2001;137(5):581-93. [CENTRAL: CN-00347816] [PMID: 11346336]PrinceHM , McCormackC , RyanG , BakerC , RotsteinH , DavisonJ , et al. Bexarotene capsules and gel for previously treated patients with cutaneous T-cell lymphoma: results of the Australian patients treated on phase II trials. Australasian Journal of Dermatology2001;42(2):91-7. [CENTRAL: CN-00442169] [PMID: 11309029]">Duvic 2001</a>; <a href="./references#CD008946-bbs2-0008" title="BagotM , DalleS , SokolL , TsianakasA , MusiekA , Ortiz-RomeroP , et al. Long-term clinical benefit to anti-CCR4 mogamulizumab: results from the phase 3 mavoric study in previously treated cutaneous t-cell lymphoma (CTCL). Blood2018;132(Supp 1):2901. [DOI: 10.1182/blood-2018-99-118473]CowanR , ScarisbrickJ , DwyerK , LeoniM , GrebennikD , MorrisS . Mogamulizumab demonstrates significant improvement in PFS compared to vorinostat in patients with previously treated cutaneous T-cell lymphoma (CTCL). British Journal of Haematology2018;181(S1):77–8. [DOI: 10.1111/bjh.15226]KimYH , BagotM , Pinter-BrownL , RookAH , PorcuP , HorwitzSM , et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncology2018;19(9):1192-1204. [PMID: 30100375]NCT01728805. Study of KW-0761 versus vorinostat in relapsed/refractory CTCL. clinicaltrials.gov/ct2/show/NCT01728805 (first received 20 November 2012). PorcuP , HudgensS , QuaglinoP , CowanR , FlodenL , LeoniM , et al. Quality of life in cutaneous T-cell lymphoma subjects treated with anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat: results from the phase 3 MAVORIC trial. Journal of Clinical Oncology2018;36(15):-. [DOI: 10.1097/HS9.0000000000000060]QuaglinoP , HudgensS , PorcuP , CowanR , FlodenL , TsianakasA , et al. Quality of life in cutaneous t-cell lymphoma subjects treated with the anti-ccr4 monoclonal antibody mogamulizumab versus vorinostat: results from the phase 3 mavoric trial. Hemasphere2018;2(S1):85. ScarisbrickJ , ZinzaniPL , HorwitzS , KimYH , MoskowitzAJ , PorcuP , et al. Efficacy of mogamulizumab by prior systemic therapy in patients with previously treated cutaneous T-cell lymphoma: Post hoc analysis from the phase 3 MAVORIC study. British Journal of Haematology2019;185(Suppl 1):94. TsianakasA , QuaglinoP , HudgensS , FlodenL , LeoniM , DaleS , et al. Quality of life in cutaneous T-cell lymphoma subjects treated with the anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat: Results from the phase 3 MAVORIC trial. Oncology Research and Treatment2018;41(Suppl 4):272. ZinzaniPL , HorwitzSM , KimYH , MoskowitzAJ , PorcuP , ScarisbrickJ , et al. Efficacy of mogamulizumab by prior systemic therapy in patients with previously treated cutaneous T-cell lymphoma: post hoc analysis from the phase 3 mavoric study. Blood2018;132(Suppl 1):1619. [DOI: 10.1182/blood-2018-99-114819]">Kim 2018</a>; <a href="./references#CD008946-bbs2-0011" title="HorwitzS , WhittakerS , DuvicM , DummerR , KimYH , ScarisbrickJ , et al. Response by stage in CD30-positive (CD30+) cutaneous T cell lymphoma (CTCL) patients receiving brentuximab vedotin (BV) vs physician's choice (PC) in the phase 3 ALCANZA study. In: Hematological oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:245–7. [CENTRAL: CN-01408605] [DOI: 10.1002/hon.2438]HorwitzSM , AkilovOE , FisherD , KuzelTM , WangY , Palanca-WesselsMC , et al. Brentuximab vedotin or physician’s choice in CD30-positivecutaneous T-cell lymphoma (ALCANZA): an international,open-label, randomised, phase 3, multicentre trial. Lancet2017;390(10094):555-66. [CENTRAL: CN-01403731] HorwitzSM , ScarisbrickJJ , DummerR , DuvicM , KimYH , WalewskiJ , et al. Updated analyses of the international, open-label, randomized, phase 3 alcanza study: longer-term evidence for superiority of brentuximab vedotin versus methotrexate or bexarotene for CD30-positive cutaneous T-cell lymphoma (CTCL). In: Blood. Conference: 59th annual meeting of the american society of hematology, ASH 2017. United states. Vol. 130. 2017. [CENTRAL: CN-01450312] KimYH , PrinceHM , WhittakerS , HorwitzSM , DuvicM , ScarisbrickJ , et al. Brentuximab vedotin vs physician's choice in CTCL patients from the phase 3 ALCANZA study: analysis of outcomes by CD30 expression. In: Hematological Oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:77–8. [CENTRAL: CN-01408482] [DOI: 10.1002/hon.2437]KimYH , PrinceHM , WhittakerS , HorwitzSM , DuvicM , ScarisbrickJ , et al. Outcomes by CD30 expression in patients with CTCL receiving brentuximab vedotin (BV) vs physician's choice (PC) in the Phase 3 ALCANZA study. Journal of Clinical Oncology2017;35(15 Supplement 1):7517. [EMBASE: 617388795]KimYH , WhittakerS , DummerR , GeskinLJ , GauthierP , LittleM , et al. Phase 3 study of brentuximab vedotin versus physician's choice of methotrexate or bexarotene in patients (PTS) with CD30-positive (CD30+) cutaneous T-cell lymphoma (CTCL). The alcanza study. Hematological Oncology2013;31(Suppl 1):278. [CENTRAL: CN-01531598] [EMBASE: 71147875]KimYH , WhittakerS , HorwitzSM , DuvicM , DummerR , ScarisbrickJ , et al. Brentuximab vedotin demonstrates superior activity to standard therapy in CD30-expressing (CD30+) cutaneous T-cell lymphoma (CTCL) in the randomized phase 3 ALCANZA study. Journal of Investigative Dermatology2017;137(5 Suppl 1):S45. [CENTRAL: CN-01375469] [EMBASE: 616393777]KimYH , WhittakerS , HorwitzSM , DuvicM , DummerR , ScarisbrickJJ , et al. Brentuximab vedotin demonstrates significantly superior clinical outcomes in patients with CD30-expressing cutaneous T cell lymphoma versus physician's choice (Methotrexate or Bexarotene): the phase 3 alcanza study. In: Blood. Conference: 58th annual meeting of the american society of hematology, ASH 2016. United states. Conference start: 20161203. Conference end: 20161206. Vol. 128. 2016. [CENTRAL: CN-01303081] [EMBASE: 614225065]NCT01578499. A randomised, open-label, phase 3 trial of brentuximab vedotin (SGN-35) versus physician's choice (methotrexate or bexarotene) in patients with CD30-positive cutaneous T-cell lymphoma. clinicaltrials.gov/ct2/show/NCT01578499 (first received 17 April 2012). PrinceHM , DummerR , WhittakerS , HorwitzS , DuvicM , ScarisbrickJ , et al. Patient-reported outcomes and quality of life in patients with cutaneous T cell lymphoma: results from the phase 3 ALCANZA study. In: Hematological Oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:247–8. [CENTRAL: CN-01408603] [DOI: 10.1002/hon.2438]ZagadailovE , PrinceHM , WhittakerS , HorwitzS , DuvicM , KimY , et al. Phase 3 alcanza study of brentuximab vedotin (BV) or physician's choice (PC) of methotrexate (MTX) or bexarotene (BEX) in CD30-positive cutaneous T-cell lymphoma (CTCL): number needed to treat analysis. In: Haematologica. Conference: 22th congress of the european hematology association. Spain. Vol. 102. 2017:251. [CENTRAL: CN-01399195] ">Prince 2017</a>; <a href="./references#CD008946-bbs2-0013" title="OtteHG , KuhlS , StadlerR , LugerT , HenzB , SterryW . Treatment of cutaneous T-cell lymphoma with Interferon alpha and PUVA versus Interferon alpha and Acitretin - results of a prospective randomised multi-centre study [Behandlung des kutanen T-Zell-Lymphoms mit Interferon alpha und PUVA versus Interferon alpha und Acirentin - Ergebnisse einer prospektiv-randomisierten Multicenter-Studie]. Der Hautarzt1997;48(Suppl):S97. [CENTRAL: CN-00495120] OtteHG , StadierR , LugerT , HenzB , SterryW . Open controlled clinical trial on the use of interferon plus acitretin versus interferon plus PUVA in patients with cutaneous T-cell lymphoma (CTCL). Annals of Oncology1996;7(Suppl 3):66. [CENTRAL: CN-00308243] StadlerR , OtteHG , LugerT , HenzBM , KuhlP , ZwingersT , et al. Prospective randomized multicenter clinical trial on the use of interferon -2a plus acitretin versus interferon -2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood1998;92(10):3578-81. [CENTRAL: CN-00156682] [PMID: 9808550]">Stadler 1998</a>; <a href="./references#CD008946-bbs2-0014" title="BohmeyerJ , OtteHG , StadlerR , LugerT , SterryW . Therapy of cutaneous T-cell lymphoma with PUVA versus interferon alfa plus PUVA: first results. Journal of the European Academy of Dermatology &amp; Venereology1999;12(Suppl 2):S268. [CENTRAL: CN-00478472] BohmeyerJ , StadlerR , LugerT , SterryW . Prospective randomized multicentre therapy optimizing protocol for therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α + PUVA [Prospectiv randomisiertes, multizentrisches Therapieoptimierungsprotokoll zur Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α + PUVA]. Zeitschrift für Hautkrankheiten2001;76(Suppl 1):S55. [CENTRAL: CN-01446038] KremerA , BohmeyerJ , StadlerR , LugerT , SterryW . Prospective randomized multicentre therapy optimizing protocol for therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α + PUVA [Prospectiv randomisiertes, multizentrisches Therapieoptimierungsprotokoll zur Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α + PUVA]. Journal der Deutschen Dermatologischen Gesellschaft2003;1(Suppl 1):S99. [CENTRAL: CN-01446037] OtteHG , StadlerR , LugerT , SterryW . Therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α plus PUVA: first results of a prospective randomized multicentre therapy optimizing protocol [Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α plus PUVA: Erste Ergebnisse des prospektiven randomisierten multizentrischen Therapieoptimierungsprotokolls]. Der Hautarzt1999;50(Suppl 1):S2. [CENTRAL: CN-01457423] OtteHG , StadlerR . Combination therapy of cutaneous t-cell-lymphoma with interferon alfa 2a and PUVA [Kombinationstherapie kutaner T-Zell-Lymphome mit Interferon Alfa 2a und PUVA]. Zentralblatt Haut- und Geschlechtskrankheiten1993;162(Suppl):P2.03.08. [CENTRAL: CN-01457422] StadlerM , KremerA , LugerT , SterryW . Prospective, randomized, multicentre clinical trial on the use of interferon a 2a plus PUVA versus PUVA monotherapy in patients with cutaneous T-cell lymphoma, stages I and II [Abstract 7541]. ASCO annual meeting proceedings. Journal of Clinical Oncology2006;24(18S Pt 1):432. [CENTRAL: CN-00625001] ">Stadler 2006</a>; <a href="./references#CD008946-bbs2-0015" title="Thestrup-PedersenK , GrunnetE , ZachariaeH . Transfer factor therapy in mycosis fungoides: a double-blind study. Acta Dermato-Venereologica1982;62(1):47-53. [CENTRAL: CN-00027377] [PMID: 6175137]">Thestrup‐Pedersen 1982</a>; <a href="./references#CD008946-bbs2-0016" title="NCT01686594. A multi-center, randomized study on oral 8-methoxypsoralen plus UVA with or without maintenance therapy in mycosis fungoides EORTC/ISCL stage IA to IIB. clinicaltrials.gov/ct2/show/NCT01686594 (first received 18 September 2012). Vieyra-GarciaP , Fink-PuchesR , PorkertS , LangR , PöchlauerS , RatzingerG , et al. Evaluation of low-dose, low-frequency oral psoralen-UV-A treatment with or without maintenance on early-stage mycosis fungoides: A randomized clinical trial. JAMA Dermatology2019;155(5):538-47. [PMID: 30892603]">Vieyra‐Garcia 2019</a>; <a href="./references#CD008946-bbs2-0018" title="NCT00056056. Ultraviolet light therapy using methoxsalen with or without Bexarotene in treating patients with mycosis fungoides. clinicaltrials.gov/ct2/show/NCT00056056 (first received 7 March 2003). WhittakerS , OrtizP , DummerR , RankiA , HasanB , MeulemansB , et al. Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial 21011 (NCT00056056). British Journal of Dermatology2012;167(3):678-87. [CENTRAL: CN-00856432] [PMID: 22924950]WhittakerS , Ortiz-RomeroPL , DummerR , RankiA , HasanB , MeulemansB , et al. Efficacy and safety of bexarotene combined with psoralen/ultraviolet A light (PUVA) compared to PUVA treatment alone in stage IB-IIa mycosis fungoides (MF): Final results from EORTC cutaneous lymphoma task force (CLTF) phase III clinical trial 21011. Journal of Clinical Oncology2012;30(15 Suppl 1):8076. ">Whittaker 2012</a>; <a href="./references#CD008946-bbs2-0020" title="WozniakMB , TraceyL , Ortiz-RomeroPL , MontesS , AlvarezM , FragaJ , et al. Psoralen plus ultraviolet A +/- interferon-alpha treatment resistance in mycosis fungoides: the role of tumour microenvironment, nuclear transcription factor-kappaB and T-cell receptor pathways. British Journal of Dermatology2008;160(1):92-102. [CENTRAL: CN-00668828] [PMID: 18945306]">Wozniak 2008</a>), 11 studies in North America (<a href="./references#CD008946-bbs2-0004" title="DuvicM , MartinAG , KimY , OlsenE , WoodGS , CrowleyCA , et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Archives of Dermatology2001;137(5):581-93. [CENTRAL: CN-00347816] [PMID: 11346336]PrinceHM , McCormackC , RyanG , BakerC , RotsteinH , DavisonJ , et al. Bexarotene capsules and gel for previously treated patients with cutaneous T-cell lymphoma: results of the Australian patients treated on phase II trials. Australasian Journal of Dermatology2001;42(2):91-7. [CENTRAL: CN-00442169] [PMID: 11309029]">Duvic 2001</a>; <a href="./references#CD008946-bbs2-0005" title="DuvicM , OlsenEA , OmuraGA , MaizeJC , VonderheidEC , et al. A phase III, randomized, double-blind, placebo-controlled study of peldesine (BCX-34) cream as topical therapy for cutaneous T-cell lymphoma. Journal of the American Academy of Dermatology2001;44(6):940-7. [CENTRAL: CN-00348073] [PMID: 11369904]">Duvic 2001a</a>; <a href="./references#CD008946-bbs2-0006" title="GuitartJ , TuckerR , StevensV . Low dose bexarotene (Targretin®) capsules and phototherapy for early stage cutaneous T-Cell lymphoma. Journal of Investigative Dermatology2002;119(1):241. [CENTRAL: CN-00794450] NCT00030589. A muliticenter, dose-randomized evaluation of Targretin capsules plus PUVA in patients with stage IB - IIA cutaneous T-Cell lymphoma. clinicaltrials.gov/ct/show/NCT00030589 (first received 27 Jaunry 2003). ">Guitart 2002</a>; <a href="./references#CD008946-bbs2-0007" title="KayeF , EddyJ , IhdeDC , SteinbergS , FischmannAB , GlatsteinE , et al. Conservative vs. aggressive therapy in mycosis fungoides. Proceedings of the American Society of Clinical Oncology1989;8:257. [CENTRAL: CN-00694960] KayeF , IhdeD , FischmannA , GlatsteinE , MinnaJ , SchechterG , et al. A randomized trial comparing conservative and aggressive therapy in mycosis fungoides (MF). Proceedings of the American Society of Clinical Oncology1986;5:195. [CENTRAL: CN-00695166] KayeFJ , BunnPA , SteinbergSM , StockerJL , IhdeDC , FischmannAB , et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. New England Journal of Medicine1989;321(26):1784-90. [CENTRAL: CN-00064211] [PMID: 2594037]">Kaye 1989</a>; <a href="./references#CD008946-bbs2-0008" title="BagotM , DalleS , SokolL , TsianakasA , MusiekA , Ortiz-RomeroP , et al. Long-term clinical benefit to anti-CCR4 mogamulizumab: results from the phase 3 mavoric study in previously treated cutaneous t-cell lymphoma (CTCL). Blood2018;132(Supp 1):2901. [DOI: 10.1182/blood-2018-99-118473]CowanR , ScarisbrickJ , DwyerK , LeoniM , GrebennikD , MorrisS . Mogamulizumab demonstrates significant improvement in PFS compared to vorinostat in patients with previously treated cutaneous T-cell lymphoma (CTCL). British Journal of Haematology2018;181(S1):77–8. [DOI: 10.1111/bjh.15226]KimYH , BagotM , Pinter-BrownL , RookAH , PorcuP , HorwitzSM , et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncology2018;19(9):1192-1204. [PMID: 30100375]NCT01728805. Study of KW-0761 versus vorinostat in relapsed/refractory CTCL. clinicaltrials.gov/ct2/show/NCT01728805 (first received 20 November 2012). PorcuP , HudgensS , QuaglinoP , CowanR , FlodenL , LeoniM , et al. Quality of life in cutaneous T-cell lymphoma subjects treated with anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat: results from the phase 3 MAVORIC trial. Journal of Clinical Oncology2018;36(15):-. [DOI: 10.1097/HS9.0000000000000060]QuaglinoP , HudgensS , PorcuP , CowanR , FlodenL , TsianakasA , et al. Quality of life in cutaneous t-cell lymphoma subjects treated with the anti-ccr4 monoclonal antibody mogamulizumab versus vorinostat: results from the phase 3 mavoric trial. Hemasphere2018;2(S1):85. ScarisbrickJ , ZinzaniPL , HorwitzS , KimYH , MoskowitzAJ , PorcuP , et al. Efficacy of mogamulizumab by prior systemic therapy in patients with previously treated cutaneous T-cell lymphoma: Post hoc analysis from the phase 3 MAVORIC study. British Journal of Haematology2019;185(Suppl 1):94. TsianakasA , QuaglinoP , HudgensS , FlodenL , LeoniM , DaleS , et al. Quality of life in cutaneous T-cell lymphoma subjects treated with the anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat: Results from the phase 3 MAVORIC trial. Oncology Research and Treatment2018;41(Suppl 4):272. ZinzaniPL , HorwitzSM , KimYH , MoskowitzAJ , PorcuP , ScarisbrickJ , et al. Efficacy of mogamulizumab by prior systemic therapy in patients with previously treated cutaneous T-cell lymphoma: post hoc analysis from the phase 3 mavoric study. Blood2018;132(Suppl 1):1619. [DOI: 10.1182/blood-2018-99-114819]">Kim 2018</a>; <a href="./references#CD008946-bbs2-0009" title="LessinS , DuvicM , GuitartJ , PandyaA , StroberB , OlsenE , et al. Positive results of a pivotal phase ii trial testing a manufactured 0.02% Mechlorethamine gel in mycosis fungoides (mf). Journal of Investigative Dermatology2011;131(Suppl 1):S84. [CENTRAL: CN-00843792] LessinSR , DuvicM , GuitartJ , PandyaAG , StroberBE , OlsenEA , et al. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatology2013;149(1):25-32. [CENTRAL: CN-00859487] [PMID: 23069814]NCT00168064. Safety and efficacy of nitrogen mustard in treatment of mycosis fungoides. clinicaltrials.gov/ct2/show/NCT00168064 (first received 14 September 2005). ">Lessin 2013</a>; <a href="./references#CD008946-bbs2-0010" title="DuvicM , KuzelTM , OlsenEA , MartinAG , FossFM , KimYH , et al. Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK). Clinical Lymphoma2002;2(4):222-8. [CENTRAL: CN-00514479] [PMID: 11970761]KuzelT , OlsenE , MartinA , KimY , DuvicM , FrankelA , et al. Pivotal phase III trial of two dose levels of DAB389IL-2 (Ontak®) for the treatment of mycosis fungoides (MF). Blood1997;90(10 Suppl 1 (Pt 1)):586a. [CENTRAL: CN-00518069] NTC00050999. Study of ONTAK (Denileukin Diftitox) in cutaneous T-Cell lymphoma (CTCL) patients. clinicaltrials.gov/ct2/show/NCT00050999 (first received 3 January 2003). OlsenE , DuvicM , FrankelA , KimY , MartinA , VonderheidE , et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. Journal of Clinical Oncology2001;19(2):376-88. [CENTRAL: CN-00328506] [PMID: 11208829]OlsenE , DuvicM , MartinA . Pivotal phase III trial of two dose levels of DAB 389 IL-2 (ONTAK) for the treatment of cutaneous T-cell lymphoma (CTCL). Journal of Investigative Dermatology1998;110(4):678. [CENTRAL: CN-00353452] ">Olsen 2001</a>; <a href="./references#CD008946-bbs2-0011" title="HorwitzS , WhittakerS , DuvicM , DummerR , KimYH , ScarisbrickJ , et al. Response by stage in CD30-positive (CD30+) cutaneous T cell lymphoma (CTCL) patients receiving brentuximab vedotin (BV) vs physician's choice (PC) in the phase 3 ALCANZA study. In: Hematological oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:245–7. [CENTRAL: CN-01408605] [DOI: 10.1002/hon.2438]HorwitzSM , AkilovOE , FisherD , KuzelTM , WangY , Palanca-WesselsMC , et al. Brentuximab vedotin or physician’s choice in CD30-positivecutaneous T-cell lymphoma (ALCANZA): an international,open-label, randomised, phase 3, multicentre trial. Lancet2017;390(10094):555-66. [CENTRAL: CN-01403731] HorwitzSM , ScarisbrickJJ , DummerR , DuvicM , KimYH , WalewskiJ , et al. Updated analyses of the international, open-label, randomized, phase 3 alcanza study: longer-term evidence for superiority of brentuximab vedotin versus methotrexate or bexarotene for CD30-positive cutaneous T-cell lymphoma (CTCL). In: Blood. Conference: 59th annual meeting of the american society of hematology, ASH 2017. United states. Vol. 130. 2017. [CENTRAL: CN-01450312] KimYH , PrinceHM , WhittakerS , HorwitzSM , DuvicM , ScarisbrickJ , et al. Brentuximab vedotin vs physician's choice in CTCL patients from the phase 3 ALCANZA study: analysis of outcomes by CD30 expression. In: Hematological Oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:77–8. [CENTRAL: CN-01408482] [DOI: 10.1002/hon.2437]KimYH , PrinceHM , WhittakerS , HorwitzSM , DuvicM , ScarisbrickJ , et al. Outcomes by CD30 expression in patients with CTCL receiving brentuximab vedotin (BV) vs physician's choice (PC) in the Phase 3 ALCANZA study. Journal of Clinical Oncology2017;35(15 Supplement 1):7517. [EMBASE: 617388795]KimYH , WhittakerS , DummerR , GeskinLJ , GauthierP , LittleM , et al. Phase 3 study of brentuximab vedotin versus physician's choice of methotrexate or bexarotene in patients (PTS) with CD30-positive (CD30+) cutaneous T-cell lymphoma (CTCL). The alcanza study. Hematological Oncology2013;31(Suppl 1):278. [CENTRAL: CN-01531598] [EMBASE: 71147875]KimYH , WhittakerS , HorwitzSM , DuvicM , DummerR , ScarisbrickJ , et al. Brentuximab vedotin demonstrates superior activity to standard therapy in CD30-expressing (CD30+) cutaneous T-cell lymphoma (CTCL) in the randomized phase 3 ALCANZA study. Journal of Investigative Dermatology2017;137(5 Suppl 1):S45. [CENTRAL: CN-01375469] [EMBASE: 616393777]KimYH , WhittakerS , HorwitzSM , DuvicM , DummerR , ScarisbrickJJ , et al. Brentuximab vedotin demonstrates significantly superior clinical outcomes in patients with CD30-expressing cutaneous T cell lymphoma versus physician's choice (Methotrexate or Bexarotene): the phase 3 alcanza study. In: Blood. Conference: 58th annual meeting of the american society of hematology, ASH 2016. United states. Conference start: 20161203. Conference end: 20161206. Vol. 128. 2016. [CENTRAL: CN-01303081] [EMBASE: 614225065]NCT01578499. A randomised, open-label, phase 3 trial of brentuximab vedotin (SGN-35) versus physician's choice (methotrexate or bexarotene) in patients with CD30-positive cutaneous T-cell lymphoma. clinicaltrials.gov/ct2/show/NCT01578499 (first received 17 April 2012). PrinceHM , DummerR , WhittakerS , HorwitzS , DuvicM , ScarisbrickJ , et al. Patient-reported outcomes and quality of life in patients with cutaneous T cell lymphoma: results from the phase 3 ALCANZA study. In: Hematological Oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:247–8. [CENTRAL: CN-01408603] [DOI: 10.1002/hon.2438]ZagadailovE , PrinceHM , WhittakerS , HorwitzS , DuvicM , KimY , et al. Phase 3 alcanza study of brentuximab vedotin (BV) or physician's choice (PC) of methotrexate (MTX) or bexarotene (BEX) in CD30-positive cutaneous T-cell lymphoma (CTCL): number needed to treat analysis. In: Haematologica. Conference: 22th congress of the european hematology association. Spain. Vol. 102. 2017:251. [CENTRAL: CN-01399195] ">Prince 2017</a>; <a href="./references#CD008946-bbs2-0012" title="RookAH , WoodGS , DuvicM , VonderheidEC , TobiaA , CabanaB . A phase II placebo-controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis. Journal of the American Academy of Dermatology2010;63(6):984-90. [CENTRAL: CN-00772559] [PMID: 20889234]">Rook 2010</a>; <a href="./references#CD008946-bbs2-0017" title="VonderheidEC , ThompsonR , SmilesKA , LattanandA . Recombinant interferon alfa-2b in plaque-phase mycosis fungoides. Intralesional and low-dose intramuscular therapy. Archives of Dermatology1987;123(6):757-63. [CENTRAL: CN-00047990] [PMID: 3579357]">Vonderheid 1987</a>; <a href="./references#CD008946-bbs2-0019" title="WolffJM , ZitelliJA , RabinBS , SmilesKA , AbellE . Intralesional interferon in the treatment of early mycosis fungoides. Journal of the American Academy of Dermatology1985;13(4):604-12. [CENTRAL: CN-00040943] [PMID: 2934438]">Wolff 1985</a>), and three studies in Australia (<a href="./references#CD008946-bbs2-0004" title="DuvicM , MartinAG , KimY , OlsenE , WoodGS , CrowleyCA , et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Archives of Dermatology2001;137(5):581-93. [CENTRAL: CN-00347816] [PMID: 11346336]PrinceHM , McCormackC , RyanG , BakerC , RotsteinH , DavisonJ , et al. Bexarotene capsules and gel for previously treated patients with cutaneous T-cell lymphoma: results of the Australian patients treated on phase II trials. Australasian Journal of Dermatology2001;42(2):91-7. [CENTRAL: CN-00442169] [PMID: 11309029]">Duvic 2001</a>; <a href="./references#CD008946-bbs2-0008" title="BagotM , DalleS , SokolL , TsianakasA , MusiekA , Ortiz-RomeroP , et al. Long-term clinical benefit to anti-CCR4 mogamulizumab: results from the phase 3 mavoric study in previously treated cutaneous t-cell lymphoma (CTCL). Blood2018;132(Supp 1):2901. [DOI: 10.1182/blood-2018-99-118473]CowanR , ScarisbrickJ , DwyerK , LeoniM , GrebennikD , MorrisS . Mogamulizumab demonstrates significant improvement in PFS compared to vorinostat in patients with previously treated cutaneous T-cell lymphoma (CTCL). British Journal of Haematology2018;181(S1):77–8. [DOI: 10.1111/bjh.15226]KimYH , BagotM , Pinter-BrownL , RookAH , PorcuP , HorwitzSM , et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncology2018;19(9):1192-1204. [PMID: 30100375]NCT01728805. Study of KW-0761 versus vorinostat in relapsed/refractory CTCL. clinicaltrials.gov/ct2/show/NCT01728805 (first received 20 November 2012). PorcuP , HudgensS , QuaglinoP , CowanR , FlodenL , LeoniM , et al. Quality of life in cutaneous T-cell lymphoma subjects treated with anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat: results from the phase 3 MAVORIC trial. Journal of Clinical Oncology2018;36(15):-. [DOI: 10.1097/HS9.0000000000000060]QuaglinoP , HudgensS , PorcuP , CowanR , FlodenL , TsianakasA , et al. Quality of life in cutaneous t-cell lymphoma subjects treated with the anti-ccr4 monoclonal antibody mogamulizumab versus vorinostat: results from the phase 3 mavoric trial. Hemasphere2018;2(S1):85. ScarisbrickJ , ZinzaniPL , HorwitzS , KimYH , MoskowitzAJ , PorcuP , et al. Efficacy of mogamulizumab by prior systemic therapy in patients with previously treated cutaneous T-cell lymphoma: Post hoc analysis from the phase 3 MAVORIC study. British Journal of Haematology2019;185(Suppl 1):94. TsianakasA , QuaglinoP , HudgensS , FlodenL , LeoniM , DaleS , et al. Quality of life in cutaneous T-cell lymphoma subjects treated with the anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat: Results from the phase 3 MAVORIC trial. Oncology Research and Treatment2018;41(Suppl 4):272. ZinzaniPL , HorwitzSM , KimYH , MoskowitzAJ , PorcuP , ScarisbrickJ , et al. Efficacy of mogamulizumab by prior systemic therapy in patients with previously treated cutaneous T-cell lymphoma: post hoc analysis from the phase 3 mavoric study. Blood2018;132(Suppl 1):1619. [DOI: 10.1182/blood-2018-99-114819]">Kim 2018</a>; <a href="./references#CD008946-bbs2-0011" title="HorwitzS , WhittakerS , DuvicM , DummerR , KimYH , ScarisbrickJ , et al. Response by stage in CD30-positive (CD30+) cutaneous T cell lymphoma (CTCL) patients receiving brentuximab vedotin (BV) vs physician's choice (PC) in the phase 3 ALCANZA study. In: Hematological oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:245–7. [CENTRAL: CN-01408605] [DOI: 10.1002/hon.2438]HorwitzSM , AkilovOE , FisherD , KuzelTM , WangY , Palanca-WesselsMC , et al. Brentuximab vedotin or physician’s choice in CD30-positivecutaneous T-cell lymphoma (ALCANZA): an international,open-label, randomised, phase 3, multicentre trial. Lancet2017;390(10094):555-66. [CENTRAL: CN-01403731] HorwitzSM , ScarisbrickJJ , DummerR , DuvicM , KimYH , WalewskiJ , et al. Updated analyses of the international, open-label, randomized, phase 3 alcanza study: longer-term evidence for superiority of brentuximab vedotin versus methotrexate or bexarotene for CD30-positive cutaneous T-cell lymphoma (CTCL). In: Blood. Conference: 59th annual meeting of the american society of hematology, ASH 2017. United states. Vol. 130. 2017. [CENTRAL: CN-01450312] KimYH , PrinceHM , WhittakerS , HorwitzSM , DuvicM , ScarisbrickJ , et al. Brentuximab vedotin vs physician's choice in CTCL patients from the phase 3 ALCANZA study: analysis of outcomes by CD30 expression. In: Hematological Oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:77–8. [CENTRAL: CN-01408482] [DOI: 10.1002/hon.2437]KimYH , PrinceHM , WhittakerS , HorwitzSM , DuvicM , ScarisbrickJ , et al. Outcomes by CD30 expression in patients with CTCL receiving brentuximab vedotin (BV) vs physician's choice (PC) in the Phase 3 ALCANZA study. Journal of Clinical Oncology2017;35(15 Supplement 1):7517. [EMBASE: 617388795]KimYH , WhittakerS , DummerR , GeskinLJ , GauthierP , LittleM , et al. Phase 3 study of brentuximab vedotin versus physician's choice of methotrexate or bexarotene in patients (PTS) with CD30-positive (CD30+) cutaneous T-cell lymphoma (CTCL). The alcanza study. Hematological Oncology2013;31(Suppl 1):278. [CENTRAL: CN-01531598] [EMBASE: 71147875]KimYH , WhittakerS , HorwitzSM , DuvicM , DummerR , ScarisbrickJ , et al. Brentuximab vedotin demonstrates superior activity to standard therapy in CD30-expressing (CD30+) cutaneous T-cell lymphoma (CTCL) in the randomized phase 3 ALCANZA study. Journal of Investigative Dermatology2017;137(5 Suppl 1):S45. [CENTRAL: CN-01375469] [EMBASE: 616393777]KimYH , WhittakerS , HorwitzSM , DuvicM , DummerR , ScarisbrickJJ , et al. Brentuximab vedotin demonstrates significantly superior clinical outcomes in patients with CD30-expressing cutaneous T cell lymphoma versus physician's choice (Methotrexate or Bexarotene): the phase 3 alcanza study. In: Blood. Conference: 58th annual meeting of the american society of hematology, ASH 2016. United states. Conference start: 20161203. Conference end: 20161206. Vol. 128. 2016. [CENTRAL: CN-01303081] [EMBASE: 614225065]NCT01578499. A randomised, open-label, phase 3 trial of brentuximab vedotin (SGN-35) versus physician's choice (methotrexate or bexarotene) in patients with CD30-positive cutaneous T-cell lymphoma. clinicaltrials.gov/ct2/show/NCT01578499 (first received 17 April 2012). PrinceHM , DummerR , WhittakerS , HorwitzS , DuvicM , ScarisbrickJ , et al. Patient-reported outcomes and quality of life in patients with cutaneous T cell lymphoma: results from the phase 3 ALCANZA study. In: Hematological Oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:247–8. [CENTRAL: CN-01408603] [DOI: 10.1002/hon.2438]ZagadailovE , PrinceHM , WhittakerS , HorwitzS , DuvicM , KimY , et al. Phase 3 alcanza study of brentuximab vedotin (BV) or physician's choice (PC) of methotrexate (MTX) or bexarotene (BEX) in CD30-positive cutaneous T-cell lymphoma (CTCL): number needed to treat analysis. In: Haematologica. Conference: 22th congress of the european hematology association. Spain. Vol. 102. 2017:251. [CENTRAL: CN-01399195] ">Prince 2017</a>). <a href="./references#CD008946-bbs2-0011" title="HorwitzS , WhittakerS , DuvicM , DummerR , KimYH , ScarisbrickJ , et al. Response by stage in CD30-positive (CD30+) cutaneous T cell lymphoma (CTCL) patients receiving brentuximab vedotin (BV) vs physician's choice (PC) in the phase 3 ALCANZA study. In: Hematological oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:245–7. [CENTRAL: CN-01408605] [DOI: 10.1002/hon.2438]HorwitzSM , AkilovOE , FisherD , KuzelTM , WangY , Palanca-WesselsMC , et al. Brentuximab vedotin or physician’s choice in CD30-positivecutaneous T-cell lymphoma (ALCANZA): an international,open-label, randomised, phase 3, multicentre trial. Lancet2017;390(10094):555-66. [CENTRAL: CN-01403731] HorwitzSM , ScarisbrickJJ , DummerR , DuvicM , KimYH , WalewskiJ , et al. Updated analyses of the international, open-label, randomized, phase 3 alcanza study: longer-term evidence for superiority of brentuximab vedotin versus methotrexate or bexarotene for CD30-positive cutaneous T-cell lymphoma (CTCL). In: Blood. Conference: 59th annual meeting of the american society of hematology, ASH 2017. United states. Vol. 130. 2017. [CENTRAL: CN-01450312] KimYH , PrinceHM , WhittakerS , HorwitzSM , DuvicM , ScarisbrickJ , et al. Brentuximab vedotin vs physician's choice in CTCL patients from the phase 3 ALCANZA study: analysis of outcomes by CD30 expression. In: Hematological Oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:77–8. [CENTRAL: CN-01408482] [DOI: 10.1002/hon.2437]KimYH , PrinceHM , WhittakerS , HorwitzSM , DuvicM , ScarisbrickJ , et al. Outcomes by CD30 expression in patients with CTCL receiving brentuximab vedotin (BV) vs physician's choice (PC) in the Phase 3 ALCANZA study. Journal of Clinical Oncology2017;35(15 Supplement 1):7517. [EMBASE: 617388795]KimYH , WhittakerS , DummerR , GeskinLJ , GauthierP , LittleM , et al. Phase 3 study of brentuximab vedotin versus physician's choice of methotrexate or bexarotene in patients (PTS) with CD30-positive (CD30+) cutaneous T-cell lymphoma (CTCL). The alcanza study. Hematological Oncology2013;31(Suppl 1):278. [CENTRAL: CN-01531598] [EMBASE: 71147875]KimYH , WhittakerS , HorwitzSM , DuvicM , DummerR , ScarisbrickJ , et al. Brentuximab vedotin demonstrates superior activity to standard therapy in CD30-expressing (CD30+) cutaneous T-cell lymphoma (CTCL) in the randomized phase 3 ALCANZA study. Journal of Investigative Dermatology2017;137(5 Suppl 1):S45. [CENTRAL: CN-01375469] [EMBASE: 616393777]KimYH , WhittakerS , HorwitzSM , DuvicM , DummerR , ScarisbrickJJ , et al. Brentuximab vedotin demonstrates significantly superior clinical outcomes in patients with CD30-expressing cutaneous T cell lymphoma versus physician's choice (Methotrexate or Bexarotene): the phase 3 alcanza study. In: Blood. Conference: 58th annual meeting of the american society of hematology, ASH 2016. United states. Conference start: 20161203. Conference end: 20161206. Vol. 128. 2016. [CENTRAL: CN-01303081] [EMBASE: 614225065]NCT01578499. A randomised, open-label, phase 3 trial of brentuximab vedotin (SGN-35) versus physician's choice (methotrexate or bexarotene) in patients with CD30-positive cutaneous T-cell lymphoma. clinicaltrials.gov/ct2/show/NCT01578499 (first received 17 April 2012). PrinceHM , DummerR , WhittakerS , HorwitzS , DuvicM , ScarisbrickJ , et al. Patient-reported outcomes and quality of life in patients with cutaneous T cell lymphoma: results from the phase 3 ALCANZA study. In: Hematological Oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:247–8. [CENTRAL: CN-01408603] [DOI: 10.1002/hon.2438]ZagadailovE , PrinceHM , WhittakerS , HorwitzS , DuvicM , KimY , et al. Phase 3 alcanza study of brentuximab vedotin (BV) or physician's choice (PC) of methotrexate (MTX) or bexarotene (BEX) in CD30-positive cutaneous T-cell lymphoma (CTCL): number needed to treat analysis. In: Haematologica. Conference: 22th congress of the european hematology association. Spain. Vol. 102. 2017:251. [CENTRAL: CN-01399195] ">Prince 2017</a> also included patients from South America (Brazil). <a href="./references#CD008946-bbs2-0008" title="BagotM , DalleS , SokolL , TsianakasA , MusiekA , Ortiz-RomeroP , et al. Long-term clinical benefit to anti-CCR4 mogamulizumab: results from the phase 3 mavoric study in previously treated cutaneous t-cell lymphoma (CTCL). Blood2018;132(Supp 1):2901. [DOI: 10.1182/blood-2018-99-118473]CowanR , ScarisbrickJ , DwyerK , LeoniM , GrebennikD , MorrisS . Mogamulizumab demonstrates significant improvement in PFS compared to vorinostat in patients with previously treated cutaneous T-cell lymphoma (CTCL). British Journal of Haematology2018;181(S1):77–8. [DOI: 10.1111/bjh.15226]KimYH , BagotM , Pinter-BrownL , RookAH , PorcuP , HorwitzSM , et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncology2018;19(9):1192-1204. [PMID: 30100375]NCT01728805. Study of KW-0761 versus vorinostat in relapsed/refractory CTCL. clinicaltrials.gov/ct2/show/NCT01728805 (first received 20 November 2012). PorcuP , HudgensS , QuaglinoP , CowanR , FlodenL , LeoniM , et al. Quality of life in cutaneous T-cell lymphoma subjects treated with anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat: results from the phase 3 MAVORIC trial. Journal of Clinical Oncology2018;36(15):-. [DOI: 10.1097/HS9.0000000000000060]QuaglinoP , HudgensS , PorcuP , CowanR , FlodenL , TsianakasA , et al. Quality of life in cutaneous t-cell lymphoma subjects treated with the anti-ccr4 monoclonal antibody mogamulizumab versus vorinostat: results from the phase 3 mavoric trial. Hemasphere2018;2(S1):85. ScarisbrickJ , ZinzaniPL , HorwitzS , KimYH , MoskowitzAJ , PorcuP , et al. Efficacy of mogamulizumab by prior systemic therapy in patients with previously treated cutaneous T-cell lymphoma: Post hoc analysis from the phase 3 MAVORIC study. British Journal of Haematology2019;185(Suppl 1):94. TsianakasA , QuaglinoP , HudgensS , FlodenL , LeoniM , DaleS , et al. Quality of life in cutaneous T-cell lymphoma subjects treated with the anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat: Results from the phase 3 MAVORIC trial. Oncology Research and Treatment2018;41(Suppl 4):272. ZinzaniPL , HorwitzSM , KimYH , MoskowitzAJ , PorcuP , ScarisbrickJ , et al. Efficacy of mogamulizumab by prior systemic therapy in patients with previously treated cutaneous T-cell lymphoma: post hoc analysis from the phase 3 mavoric study. Blood2018;132(Suppl 1):1619. [DOI: 10.1182/blood-2018-99-114819]">Kim 2018</a> included patients from Japan. Fifteen RCTs were multicentre trials (<a href="./references#CD008946-bbs2-0001" title="BagotM , HasanB , WhittakerS , Beylot-BarryM , KnoblerR , ShahE , et al. A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma - EORTC 21081 (NCT01098656): results and lessons learned for future trial designs. European Journal of Dermatology2017;27(3):286–94. [CENTRAL: CN-01395486] [PMID: 28468739]NCT01098656. A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-Cell lymphoma. clinicaltrials.gov/ct2/show/NCT01098656 (first received 5 April 2010). [NCT01098656]">Bagot 2017</a>; <a href="./references#CD008946-bbs2-0004" title="DuvicM , MartinAG , KimY , OlsenE , WoodGS , CrowleyCA , et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Archives of Dermatology2001;137(5):581-93. [CENTRAL: CN-00347816] [PMID: 11346336]PrinceHM , McCormackC , RyanG , BakerC , RotsteinH , DavisonJ , et al. Bexarotene capsules and gel for previously treated patients with cutaneous T-cell lymphoma: results of the Australian patients treated on phase II trials. Australasian Journal of Dermatology2001;42(2):91-7. [CENTRAL: CN-00442169] [PMID: 11309029]">Duvic 2001</a>; <a href="./references#CD008946-bbs2-0005" title="DuvicM , OlsenEA , OmuraGA , MaizeJC , VonderheidEC , et al. A phase III, randomized, double-blind, placebo-controlled study of peldesine (BCX-34) cream as topical therapy for cutaneous T-cell lymphoma. Journal of the American Academy of Dermatology2001;44(6):940-7. [CENTRAL: CN-00348073] [PMID: 11369904]">Duvic 2001a</a>; <a href="./references#CD008946-bbs2-0006" title="GuitartJ , TuckerR , StevensV . Low dose bexarotene (Targretin®) capsules and phototherapy for early stage cutaneous T-Cell lymphoma. Journal of Investigative Dermatology2002;119(1):241. [CENTRAL: CN-00794450] NCT00030589. A muliticenter, dose-randomized evaluation of Targretin capsules plus PUVA in patients with stage IB - IIA cutaneous T-Cell lymphoma. clinicaltrials.gov/ct/show/NCT00030589 (first received 27 Jaunry 2003). ">Guitart 2002</a>; <a href="./references#CD008946-bbs2-0007" title="KayeF , EddyJ , IhdeDC , SteinbergS , FischmannAB , GlatsteinE , et al. Conservative vs. aggressive therapy in mycosis fungoides. Proceedings of the American Society of Clinical Oncology1989;8:257. [CENTRAL: CN-00694960] KayeF , IhdeD , FischmannA , GlatsteinE , MinnaJ , SchechterG , et al. A randomized trial comparing conservative and aggressive therapy in mycosis fungoides (MF). Proceedings of the American Society of Clinical Oncology1986;5:195. [CENTRAL: CN-00695166] KayeFJ , BunnPA , SteinbergSM , StockerJL , IhdeDC , FischmannAB , et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. New England Journal of Medicine1989;321(26):1784-90. [CENTRAL: CN-00064211] [PMID: 2594037]">Kaye 1989</a>; <a href="./references#CD008946-bbs2-0008" title="BagotM , DalleS , SokolL , TsianakasA , MusiekA , Ortiz-RomeroP , et al. Long-term clinical benefit to anti-CCR4 mogamulizumab: results from the phase 3 mavoric study in previously treated cutaneous t-cell lymphoma (CTCL). Blood2018;132(Supp 1):2901. [DOI: 10.1182/blood-2018-99-118473]CowanR , ScarisbrickJ , DwyerK , LeoniM , GrebennikD , MorrisS . Mogamulizumab demonstrates significant improvement in PFS compared to vorinostat in patients with previously treated cutaneous T-cell lymphoma (CTCL). British Journal of Haematology2018;181(S1):77–8. [DOI: 10.1111/bjh.15226]KimYH , BagotM , Pinter-BrownL , RookAH , PorcuP , HorwitzSM , et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncology2018;19(9):1192-1204. [PMID: 30100375]NCT01728805. Study of KW-0761 versus vorinostat in relapsed/refractory CTCL. clinicaltrials.gov/ct2/show/NCT01728805 (first received 20 November 2012). PorcuP , HudgensS , QuaglinoP , CowanR , FlodenL , LeoniM , et al. Quality of life in cutaneous T-cell lymphoma subjects treated with anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat: results from the phase 3 MAVORIC trial. Journal of Clinical Oncology2018;36(15):-. [DOI: 10.1097/HS9.0000000000000060]QuaglinoP , HudgensS , PorcuP , CowanR , FlodenL , TsianakasA , et al. Quality of life in cutaneous t-cell lymphoma subjects treated with the anti-ccr4 monoclonal antibody mogamulizumab versus vorinostat: results from the phase 3 mavoric trial. Hemasphere2018;2(S1):85. ScarisbrickJ , ZinzaniPL , HorwitzS , KimYH , MoskowitzAJ , PorcuP , et al. Efficacy of mogamulizumab by prior systemic therapy in patients with previously treated cutaneous T-cell lymphoma: Post hoc analysis from the phase 3 MAVORIC study. British Journal of Haematology2019;185(Suppl 1):94. TsianakasA , QuaglinoP , HudgensS , FlodenL , LeoniM , DaleS , et al. Quality of life in cutaneous T-cell lymphoma subjects treated with the anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat: Results from the phase 3 MAVORIC trial. Oncology Research and Treatment2018;41(Suppl 4):272. ZinzaniPL , HorwitzSM , KimYH , MoskowitzAJ , PorcuP , ScarisbrickJ , et al. Efficacy of mogamulizumab by prior systemic therapy in patients with previously treated cutaneous T-cell lymphoma: post hoc analysis from the phase 3 mavoric study. Blood2018;132(Suppl 1):1619. [DOI: 10.1182/blood-2018-99-114819]">Kim 2018</a>; <a href="./references#CD008946-bbs2-0009" title="LessinS , DuvicM , GuitartJ , PandyaA , StroberB , OlsenE , et al. Positive results of a pivotal phase ii trial testing a manufactured 0.02% Mechlorethamine gel in mycosis fungoides (mf). Journal of Investigative Dermatology2011;131(Suppl 1):S84. [CENTRAL: CN-00843792] LessinSR , DuvicM , GuitartJ , PandyaAG , StroberBE , OlsenEA , et al. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatology2013;149(1):25-32. [CENTRAL: CN-00859487] [PMID: 23069814]NCT00168064. Safety and efficacy of nitrogen mustard in treatment of mycosis fungoides. clinicaltrials.gov/ct2/show/NCT00168064 (first received 14 September 2005). ">Lessin 2013</a>; <a href="./references#CD008946-bbs2-0010" title="DuvicM , KuzelTM , OlsenEA , MartinAG , FossFM , KimYH , et al. Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK). Clinical Lymphoma2002;2(4):222-8. [CENTRAL: CN-00514479] [PMID: 11970761]KuzelT , OlsenE , MartinA , KimY , DuvicM , FrankelA , et al. Pivotal phase III trial of two dose levels of DAB389IL-2 (Ontak®) for the treatment of mycosis fungoides (MF). Blood1997;90(10 Suppl 1 (Pt 1)):586a. [CENTRAL: CN-00518069] NTC00050999. Study of ONTAK (Denileukin Diftitox) in cutaneous T-Cell lymphoma (CTCL) patients. clinicaltrials.gov/ct2/show/NCT00050999 (first received 3 January 2003). OlsenE , DuvicM , FrankelA , KimY , MartinA , VonderheidE , et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. Journal of Clinical Oncology2001;19(2):376-88. [CENTRAL: CN-00328506] [PMID: 11208829]OlsenE , DuvicM , MartinA . Pivotal phase III trial of two dose levels of DAB 389 IL-2 (ONTAK) for the treatment of cutaneous T-cell lymphoma (CTCL). Journal of Investigative Dermatology1998;110(4):678. [CENTRAL: CN-00353452] ">Olsen 2001</a>; <a href="./references#CD008946-bbs2-0011" title="HorwitzS , WhittakerS , DuvicM , DummerR , KimYH , ScarisbrickJ , et al. Response by stage in CD30-positive (CD30+) cutaneous T cell lymphoma (CTCL) patients receiving brentuximab vedotin (BV) vs physician's choice (PC) in the phase 3 ALCANZA study. In: Hematological oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:245–7. [CENTRAL: CN-01408605] [DOI: 10.1002/hon.2438]HorwitzSM , AkilovOE , FisherD , KuzelTM , WangY , Palanca-WesselsMC , et al. Brentuximab vedotin or physician’s choice in CD30-positivecutaneous T-cell lymphoma (ALCANZA): an international,open-label, randomised, phase 3, multicentre trial. Lancet2017;390(10094):555-66. [CENTRAL: CN-01403731] HorwitzSM , ScarisbrickJJ , DummerR , DuvicM , KimYH , WalewskiJ , et al. Updated analyses of the international, open-label, randomized, phase 3 alcanza study: longer-term evidence for superiority of brentuximab vedotin versus methotrexate or bexarotene for CD30-positive cutaneous T-cell lymphoma (CTCL). In: Blood. Conference: 59th annual meeting of the american society of hematology, ASH 2017. United states. Vol. 130. 2017. [CENTRAL: CN-01450312] KimYH , PrinceHM , WhittakerS , HorwitzSM , DuvicM , ScarisbrickJ , et al. Brentuximab vedotin vs physician's choice in CTCL patients from the phase 3 ALCANZA study: analysis of outcomes by CD30 expression. In: Hematological Oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:77–8. [CENTRAL: CN-01408482] [DOI: 10.1002/hon.2437]KimYH , PrinceHM , WhittakerS , HorwitzSM , DuvicM , ScarisbrickJ , et al. Outcomes by CD30 expression in patients with CTCL receiving brentuximab vedotin (BV) vs physician's choice (PC) in the Phase 3 ALCANZA study. Journal of Clinical Oncology2017;35(15 Supplement 1):7517. [EMBASE: 617388795]KimYH , WhittakerS , DummerR , GeskinLJ , GauthierP , LittleM , et al. Phase 3 study of brentuximab vedotin versus physician's choice of methotrexate or bexarotene in patients (PTS) with CD30-positive (CD30+) cutaneous T-cell lymphoma (CTCL). The alcanza study. Hematological Oncology2013;31(Suppl 1):278. [CENTRAL: CN-01531598] [EMBASE: 71147875]KimYH , WhittakerS , HorwitzSM , DuvicM , DummerR , ScarisbrickJ , et al. Brentuximab vedotin demonstrates superior activity to standard therapy in CD30-expressing (CD30+) cutaneous T-cell lymphoma (CTCL) in the randomized phase 3 ALCANZA study. Journal of Investigative Dermatology2017;137(5 Suppl 1):S45. [CENTRAL: CN-01375469] [EMBASE: 616393777]KimYH , WhittakerS , HorwitzSM , DuvicM , DummerR , ScarisbrickJJ , et al. Brentuximab vedotin demonstrates significantly superior clinical outcomes in patients with CD30-expressing cutaneous T cell lymphoma versus physician's choice (Methotrexate or Bexarotene): the phase 3 alcanza study. In: Blood. Conference: 58th annual meeting of the american society of hematology, ASH 2016. United states. Conference start: 20161203. Conference end: 20161206. Vol. 128. 2016. [CENTRAL: CN-01303081] [EMBASE: 614225065]NCT01578499. A randomised, open-label, phase 3 trial of brentuximab vedotin (SGN-35) versus physician's choice (methotrexate or bexarotene) in patients with CD30-positive cutaneous T-cell lymphoma. clinicaltrials.gov/ct2/show/NCT01578499 (first received 17 April 2012). PrinceHM , DummerR , WhittakerS , HorwitzS , DuvicM , ScarisbrickJ , et al. Patient-reported outcomes and quality of life in patients with cutaneous T cell lymphoma: results from the phase 3 ALCANZA study. In: Hematological Oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:247–8. [CENTRAL: CN-01408603] [DOI: 10.1002/hon.2438]ZagadailovE , PrinceHM , WhittakerS , HorwitzS , DuvicM , KimY , et al. Phase 3 alcanza study of brentuximab vedotin (BV) or physician's choice (PC) of methotrexate (MTX) or bexarotene (BEX) in CD30-positive cutaneous T-cell lymphoma (CTCL): number needed to treat analysis. In: Haematologica. Conference: 22th congress of the european hematology association. Spain. Vol. 102. 2017:251. [CENTRAL: CN-01399195] ">Prince 2017</a>; <a href="./references#CD008946-bbs2-0012" title="RookAH , WoodGS , DuvicM , VonderheidEC , TobiaA , CabanaB . A phase II placebo-controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis. Journal of the American Academy of Dermatology2010;63(6):984-90. [CENTRAL: CN-00772559] [PMID: 20889234]">Rook 2010</a>; <a href="./references#CD008946-bbs2-0013" title="OtteHG , KuhlS , StadlerR , LugerT , HenzB , SterryW . Treatment of cutaneous T-cell lymphoma with Interferon alpha and PUVA versus Interferon alpha and Acitretin - results of a prospective randomised multi-centre study [Behandlung des kutanen T-Zell-Lymphoms mit Interferon alpha und PUVA versus Interferon alpha und Acirentin - Ergebnisse einer prospektiv-randomisierten Multicenter-Studie]. Der Hautarzt1997;48(Suppl):S97. [CENTRAL: CN-00495120] OtteHG , StadierR , LugerT , HenzB , SterryW . Open controlled clinical trial on the use of interferon plus acitretin versus interferon plus PUVA in patients with cutaneous T-cell lymphoma (CTCL). Annals of Oncology1996;7(Suppl 3):66. [CENTRAL: CN-00308243] StadlerR , OtteHG , LugerT , HenzBM , KuhlP , ZwingersT , et al. Prospective randomized multicenter clinical trial on the use of interferon -2a plus acitretin versus interferon -2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood1998;92(10):3578-81. [CENTRAL: CN-00156682] [PMID: 9808550]">Stadler 1998</a>; <a href="./references#CD008946-bbs2-0014" title="BohmeyerJ , OtteHG , StadlerR , LugerT , SterryW . Therapy of cutaneous T-cell lymphoma with PUVA versus interferon alfa plus PUVA: first results. Journal of the European Academy of Dermatology &amp; Venereology1999;12(Suppl 2):S268. [CENTRAL: CN-00478472] BohmeyerJ , StadlerR , LugerT , SterryW . Prospective randomized multicentre therapy optimizing protocol for therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α + PUVA [Prospectiv randomisiertes, multizentrisches Therapieoptimierungsprotokoll zur Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α + PUVA]. Zeitschrift für Hautkrankheiten2001;76(Suppl 1):S55. [CENTRAL: CN-01446038] KremerA , BohmeyerJ , StadlerR , LugerT , SterryW . Prospective randomized multicentre therapy optimizing protocol for therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α + PUVA [Prospectiv randomisiertes, multizentrisches Therapieoptimierungsprotokoll zur Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α + PUVA]. Journal der Deutschen Dermatologischen Gesellschaft2003;1(Suppl 1):S99. [CENTRAL: CN-01446037] OtteHG , StadlerR , LugerT , SterryW . Therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α plus PUVA: first results of a prospective randomized multicentre therapy optimizing protocol [Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α plus PUVA: Erste Ergebnisse des prospektiven randomisierten multizentrischen Therapieoptimierungsprotokolls]. Der Hautarzt1999;50(Suppl 1):S2. [CENTRAL: CN-01457423] OtteHG , StadlerR . Combination therapy of cutaneous t-cell-lymphoma with interferon alfa 2a and PUVA [Kombinationstherapie kutaner T-Zell-Lymphome mit Interferon Alfa 2a und PUVA]. Zentralblatt Haut- und Geschlechtskrankheiten1993;162(Suppl):P2.03.08. [CENTRAL: CN-01457422] StadlerM , KremerA , LugerT , SterryW . Prospective, randomized, multicentre clinical trial on the use of interferon a 2a plus PUVA versus PUVA monotherapy in patients with cutaneous T-cell lymphoma, stages I and II [Abstract 7541]. ASCO annual meeting proceedings. Journal of Clinical Oncology2006;24(18S Pt 1):432. [CENTRAL: CN-00625001] ">Stadler 2006</a>; <a href="./references#CD008946-bbs2-0016" title="NCT01686594. A multi-center, randomized study on oral 8-methoxypsoralen plus UVA with or without maintenance therapy in mycosis fungoides EORTC/ISCL stage IA to IIB. clinicaltrials.gov/ct2/show/NCT01686594 (first received 18 September 2012). Vieyra-GarciaP , Fink-PuchesR , PorkertS , LangR , PöchlauerS , RatzingerG , et al. Evaluation of low-dose, low-frequency oral psoralen-UV-A treatment with or without maintenance on early-stage mycosis fungoides: A randomized clinical trial. JAMA Dermatology2019;155(5):538-47. [PMID: 30892603]">Vieyra‐Garcia 2019</a>; <a href="./references#CD008946-bbs2-0018" title="NCT00056056. Ultraviolet light therapy using methoxsalen with or without Bexarotene in treating patients with mycosis fungoides. clinicaltrials.gov/ct2/show/NCT00056056 (first received 7 March 2003). WhittakerS , OrtizP , DummerR , RankiA , HasanB , MeulemansB , et al. Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial 21011 (NCT00056056). British Journal of Dermatology2012;167(3):678-87. [CENTRAL: CN-00856432] [PMID: 22924950]WhittakerS , Ortiz-RomeroPL , DummerR , RankiA , HasanB , MeulemansB , et al. Efficacy and safety of bexarotene combined with psoralen/ultraviolet A light (PUVA) compared to PUVA treatment alone in stage IB-IIa mycosis fungoides (MF): Final results from EORTC cutaneous lymphoma task force (CLTF) phase III clinical trial 21011. Journal of Clinical Oncology2012;30(15 Suppl 1):8076. ">Whittaker 2012</a>; <a href="./references#CD008946-bbs2-0020" title="WozniakMB , TraceyL , Ortiz-RomeroPL , MontesS , AlvarezM , FragaJ , et al. Psoralen plus ultraviolet A +/- interferon-alpha treatment resistance in mycosis fungoides: the role of tumour microenvironment, nuclear transcription factor-kappaB and T-cell receptor pathways. British Journal of Dermatology2008;160(1):92-102. [CENTRAL: CN-00668828] [PMID: 18945306]">Wozniak 2008</a>). Fifty‐five per cent of the included trials were completely or partially funded by pharmaceutical companies. Non‐commercial sponsors funded 20% of the studies. Further details are provided in the <a href="./references#CD008946-sec-0233" title="">Characteristics of included studies</a> section. </p> </section> <section id="CD008946-sec-0073"> <h5 class="title">Interventions</h5> <p>The studies were conducted with a wide range of interventions including:</p> <p> <ul id="CD008946-list-0010"> <li> <p>invasive and non‐invasive topical treatments;</p> </li> <li> <p>light therapies, including extracorporeal photopheresis;</p> </li> <li> <p>oral treatments;</p> </li> <li> <p>parenteral applied systemic agents; and</p> </li> <li> <p>radiation therapies.</p> </li> </ul> </p> <p>Comparators comprised of active ingredients, placebo or observation after having achieved complete response (CR). </p> <p>Nine RCTs combined two or more therapies for at least one treatment group (<a href="./references#CD008946-bbs2-0006" title="GuitartJ , TuckerR , StevensV . Low dose bexarotene (Targretin®) capsules and phototherapy for early stage cutaneous T-Cell lymphoma. Journal of Investigative Dermatology2002;119(1):241. [CENTRAL: CN-00794450] NCT00030589. A muliticenter, dose-randomized evaluation of Targretin capsules plus PUVA in patients with stage IB - IIA cutaneous T-Cell lymphoma. clinicaltrials.gov/ct/show/NCT00030589 (first received 27 Jaunry 2003). ">Guitart 2002</a>; <a href="./references#CD008946-bbs2-0007" title="KayeF , EddyJ , IhdeDC , SteinbergS , FischmannAB , GlatsteinE , et al. Conservative vs. aggressive therapy in mycosis fungoides. Proceedings of the American Society of Clinical Oncology1989;8:257. [CENTRAL: CN-00694960] KayeF , IhdeD , FischmannA , GlatsteinE , MinnaJ , SchechterG , et al. A randomized trial comparing conservative and aggressive therapy in mycosis fungoides (MF). Proceedings of the American Society of Clinical Oncology1986;5:195. [CENTRAL: CN-00695166] KayeFJ , BunnPA , SteinbergSM , StockerJL , IhdeDC , FischmannAB , et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. New England Journal of Medicine1989;321(26):1784-90. [CENTRAL: CN-00064211] [PMID: 2594037]">Kaye 1989</a>; <a href="./references#CD008946-bbs2-0012" title="RookAH , WoodGS , DuvicM , VonderheidEC , TobiaA , CabanaB . A phase II placebo-controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis. Journal of the American Academy of Dermatology2010;63(6):984-90. [CENTRAL: CN-00772559] [PMID: 20889234]">Rook 2010</a>; <a href="./references#CD008946-bbs2-0013" title="OtteHG , KuhlS , StadlerR , LugerT , HenzB , SterryW . Treatment of cutaneous T-cell lymphoma with Interferon alpha and PUVA versus Interferon alpha and Acitretin - results of a prospective randomised multi-centre study [Behandlung des kutanen T-Zell-Lymphoms mit Interferon alpha und PUVA versus Interferon alpha und Acirentin - Ergebnisse einer prospektiv-randomisierten Multicenter-Studie]. Der Hautarzt1997;48(Suppl):S97. [CENTRAL: CN-00495120] OtteHG , StadierR , LugerT , HenzB , SterryW . Open controlled clinical trial on the use of interferon plus acitretin versus interferon plus PUVA in patients with cutaneous T-cell lymphoma (CTCL). Annals of Oncology1996;7(Suppl 3):66. [CENTRAL: CN-00308243] StadlerR , OtteHG , LugerT , HenzBM , KuhlP , ZwingersT , et al. Prospective randomized multicenter clinical trial on the use of interferon -2a plus acitretin versus interferon -2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood1998;92(10):3578-81. [CENTRAL: CN-00156682] [PMID: 9808550]">Stadler 1998</a>; <a href="./references#CD008946-bbs2-0014" title="BohmeyerJ , OtteHG , StadlerR , LugerT , SterryW . Therapy of cutaneous T-cell lymphoma with PUVA versus interferon alfa plus PUVA: first results. Journal of the European Academy of Dermatology &amp; Venereology1999;12(Suppl 2):S268. [CENTRAL: CN-00478472] BohmeyerJ , StadlerR , LugerT , SterryW . Prospective randomized multicentre therapy optimizing protocol for therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α + PUVA [Prospectiv randomisiertes, multizentrisches Therapieoptimierungsprotokoll zur Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α + PUVA]. Zeitschrift für Hautkrankheiten2001;76(Suppl 1):S55. [CENTRAL: CN-01446038] KremerA , BohmeyerJ , StadlerR , LugerT , SterryW . Prospective randomized multicentre therapy optimizing protocol for therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α + PUVA [Prospectiv randomisiertes, multizentrisches Therapieoptimierungsprotokoll zur Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α + PUVA]. Journal der Deutschen Dermatologischen Gesellschaft2003;1(Suppl 1):S99. [CENTRAL: CN-01446037] OtteHG , StadlerR , LugerT , SterryW . Therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α plus PUVA: first results of a prospective randomized multicentre therapy optimizing protocol [Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α plus PUVA: Erste Ergebnisse des prospektiven randomisierten multizentrischen Therapieoptimierungsprotokolls]. Der Hautarzt1999;50(Suppl 1):S2. [CENTRAL: CN-01457423] OtteHG , StadlerR . Combination therapy of cutaneous t-cell-lymphoma with interferon alfa 2a and PUVA [Kombinationstherapie kutaner T-Zell-Lymphome mit Interferon Alfa 2a und PUVA]. Zentralblatt Haut- und Geschlechtskrankheiten1993;162(Suppl):P2.03.08. [CENTRAL: CN-01457422] StadlerM , KremerA , LugerT , SterryW . Prospective, randomized, multicentre clinical trial on the use of interferon a 2a plus PUVA versus PUVA monotherapy in patients with cutaneous T-cell lymphoma, stages I and II [Abstract 7541]. ASCO annual meeting proceedings. Journal of Clinical Oncology2006;24(18S Pt 1):432. [CENTRAL: CN-00625001] ">Stadler 2006</a>; <a href="./references#CD008946-bbs2-0015" title="Thestrup-PedersenK , GrunnetE , ZachariaeH . Transfer factor therapy in mycosis fungoides: a double-blind study. Acta Dermato-Venereologica1982;62(1):47-53. [CENTRAL: CN-00027377] [PMID: 6175137]">Thestrup‐Pedersen 1982</a>; <a href="./references#CD008946-bbs2-0018" title="NCT00056056. Ultraviolet light therapy using methoxsalen with or without Bexarotene in treating patients with mycosis fungoides. clinicaltrials.gov/ct2/show/NCT00056056 (first received 7 March 2003). WhittakerS , OrtizP , DummerR , RankiA , HasanB , MeulemansB , et al. Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial 21011 (NCT00056056). British Journal of Dermatology2012;167(3):678-87. [CENTRAL: CN-00856432] [PMID: 22924950]WhittakerS , Ortiz-RomeroPL , DummerR , RankiA , HasanB , MeulemansB , et al. Efficacy and safety of bexarotene combined with psoralen/ultraviolet A light (PUVA) compared to PUVA treatment alone in stage IB-IIa mycosis fungoides (MF): Final results from EORTC cutaneous lymphoma task force (CLTF) phase III clinical trial 21011. Journal of Clinical Oncology2012;30(15 Suppl 1):8076. ">Whittaker 2012</a>; <a href="./references#CD008946-bbs2-0019" title="WolffJM , ZitelliJA , RabinBS , SmilesKA , AbellE . Intralesional interferon in the treatment of early mycosis fungoides. Journal of the American Academy of Dermatology1985;13(4):604-12. [CENTRAL: CN-00040943] [PMID: 2934438]">Wolff 1985</a>; <a href="./references#CD008946-bbs2-0020" title="WozniakMB , TraceyL , Ortiz-RomeroPL , MontesS , AlvarezM , FragaJ , et al. Psoralen plus ultraviolet A +/- interferon-alpha treatment resistance in mycosis fungoides: the role of tumour microenvironment, nuclear transcription factor-kappaB and T-cell receptor pathways. British Journal of Dermatology2008;160(1):92-102. [CENTRAL: CN-00668828] [PMID: 18945306]">Wozniak 2008</a>). </p> <p>The topical treatments, used as interventions or comparators, consisted of:</p> <p> <ul id="CD008946-list-0011"> <li> <p>topical application of hypericin (<a href="./references#CD008946-bbs2-0012" title="RookAH , WoodGS , DuvicM , VonderheidEC , TobiaA , CabanaB . A phase II placebo-controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis. Journal of the American Academy of Dermatology2010;63(6):984-90. [CENTRAL: CN-00772559] [PMID: 20889234]">Rook 2010</a>); </p> </li> <li> <p>imiquimod 5% (<a href="./references#CD008946-bbs2-0003" title="ChongA , LooWJ , BanneyL , GrantJW , NorrisPG . Imiquimod 5% cream in the treatment of mycosis fungoides - a pilot study. Journal of Dermatological Treatment2004;15(2):118-9. [CENTRAL: CN-00467258] [PMID: 15204164]">Chong 2004</a>); </p> </li> <li> <p>intralesional injections of IFN‐α without (<a href="./references#CD008946-bbs2-0017" title="VonderheidEC , ThompsonR , SmilesKA , LattanandA . Recombinant interferon alfa-2b in plaque-phase mycosis fungoides. Intralesional and low-dose intramuscular therapy. Archives of Dermatology1987;123(6):757-63. [CENTRAL: CN-00047990] [PMID: 3579357]">Vonderheid 1987</a>) or with the combined use of topical steroids (<a href="./references#CD008946-bbs2-0019" title="WolffJM , ZitelliJA , RabinBS , SmilesKA , AbellE . Intralesional interferon in the treatment of early mycosis fungoides. Journal of the American Academy of Dermatology1985;13(4):604-12. [CENTRAL: CN-00040943] [PMID: 2934438]">Wolff 1985</a>); </p> </li> <li> <p>mechlorethamine 0.02% gel versus mechlorethamine 0.02% ointment (comparator) (<a href="./references#CD008946-bbs2-0009" title="LessinS , DuvicM , GuitartJ , PandyaA , StroberB , OlsenE , et al. Positive results of a pivotal phase ii trial testing a manufactured 0.02% Mechlorethamine gel in mycosis fungoides (mf). Journal of Investigative Dermatology2011;131(Suppl 1):S84. [CENTRAL: CN-00843792] LessinSR , DuvicM , GuitartJ , PandyaAG , StroberBE , OlsenEA , et al. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatology2013;149(1):25-32. [CENTRAL: CN-00859487] [PMID: 23069814]NCT00168064. Safety and efficacy of nitrogen mustard in treatment of mycosis fungoides. clinicaltrials.gov/ct2/show/NCT00168064 (first received 14 September 2005). ">Lessin 2013</a>); </p> </li> <li> <p>nitrogen mustard (comparator: <a href="./references#CD008946-bbs2-0007" title="KayeF , EddyJ , IhdeDC , SteinbergS , FischmannAB , GlatsteinE , et al. Conservative vs. aggressive therapy in mycosis fungoides. Proceedings of the American Society of Clinical Oncology1989;8:257. [CENTRAL: CN-00694960] KayeF , IhdeD , FischmannA , GlatsteinE , MinnaJ , SchechterG , et al. A randomized trial comparing conservative and aggressive therapy in mycosis fungoides (MF). Proceedings of the American Society of Clinical Oncology1986;5:195. [CENTRAL: CN-00695166] KayeFJ , BunnPA , SteinbergSM , StockerJL , IhdeDC , FischmannAB , et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. New England Journal of Medicine1989;321(26):1784-90. [CENTRAL: CN-00064211] [PMID: 2594037]">Kaye 1989</a>; intervention: <a href="./references#CD008946-bbs2-0015" title="Thestrup-PedersenK , GrunnetE , ZachariaeH . Transfer factor therapy in mycosis fungoides: a double-blind study. Acta Dermato-Venereologica1982;62(1):47-53. [CENTRAL: CN-00027377] [PMID: 6175137]">Thestrup‐Pedersen 1982</a>); or </p> </li> <li> <p>peldesine (<a href="./references#CD008946-bbs2-0005" title="DuvicM , OlsenEA , OmuraGA , MaizeJC , VonderheidEC , et al. A phase III, randomized, double-blind, placebo-controlled study of peldesine (BCX-34) cream as topical therapy for cutaneous T-cell lymphoma. Journal of the American Academy of Dermatology2001;44(6):940-7. [CENTRAL: CN-00348073] [PMID: 11369904]">Duvic 2001a</a>). </p> </li> </ul> </p> <p>The light therapies investigated, as interventions or comparators were:</p> <p> <ul id="CD008946-list-0012"> <li> <p>psoralen plus ultraviolet A light (PUVA) used as intervention and comparator (<a href="./references#CD008946-bbs2-0002" title="ChildFJ , MitchellTJ , WhittakerSJ , ScarisbrickJJ , SeedPT , Russel-JonesR . A randomized cross-over study to compare PUVA and extracorporeal photopheresis in the treatment of plaque stage (T2) mycosis fungoides. Clinical &amp; Experimental Dermatology2004;29(3):231-6. [CENTRAL: CN-00468455] [PMID: 15115499]ChildFJ , MitchellTJ , WhittakerSJ , WatkinsP , SeedP , Russell-JonesR . A randomised cross-over study to compare Puva and extracorporeal photopheresis (ECP) in the treatment of plaque stage (T2) mycosis fungoides. British Journal of Dermatology2001;145(Suppl 59):16. [CENTRAL: CN-00430854] ">Child 2004</a>; <a href="./references#CD008946-bbs2-0007" title="KayeF , EddyJ , IhdeDC , SteinbergS , FischmannAB , GlatsteinE , et al. Conservative vs. aggressive therapy in mycosis fungoides. Proceedings of the American Society of Clinical Oncology1989;8:257. [CENTRAL: CN-00694960] KayeF , IhdeD , FischmannA , GlatsteinE , MinnaJ , SchechterG , et al. A randomized trial comparing conservative and aggressive therapy in mycosis fungoides (MF). Proceedings of the American Society of Clinical Oncology1986;5:195. [CENTRAL: CN-00695166] KayeFJ , BunnPA , SteinbergSM , StockerJL , IhdeDC , FischmannAB , et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. New England Journal of Medicine1989;321(26):1784-90. [CENTRAL: CN-00064211] [PMID: 2594037]">Kaye 1989</a>; <a href="./references#CD008946-bbs2-0013" title="OtteHG , KuhlS , StadlerR , LugerT , HenzB , SterryW . Treatment of cutaneous T-cell lymphoma with Interferon alpha and PUVA versus Interferon alpha and Acitretin - results of a prospective randomised multi-centre study [Behandlung des kutanen T-Zell-Lymphoms mit Interferon alpha und PUVA versus Interferon alpha und Acirentin - Ergebnisse einer prospektiv-randomisierten Multicenter-Studie]. Der Hautarzt1997;48(Suppl):S97. [CENTRAL: CN-00495120] OtteHG , StadierR , LugerT , HenzB , SterryW . Open controlled clinical trial on the use of interferon plus acitretin versus interferon plus PUVA in patients with cutaneous T-cell lymphoma (CTCL). Annals of Oncology1996;7(Suppl 3):66. [CENTRAL: CN-00308243] StadlerR , OtteHG , LugerT , HenzBM , KuhlP , ZwingersT , et al. Prospective randomized multicenter clinical trial on the use of interferon -2a plus acitretin versus interferon -2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood1998;92(10):3578-81. [CENTRAL: CN-00156682] [PMID: 9808550]">Stadler 1998</a>; <a href="./references#CD008946-bbs2-0014" title="BohmeyerJ , OtteHG , StadlerR , LugerT , SterryW . Therapy of cutaneous T-cell lymphoma with PUVA versus interferon alfa plus PUVA: first results. Journal of the European Academy of Dermatology &amp; Venereology1999;12(Suppl 2):S268. [CENTRAL: CN-00478472] BohmeyerJ , StadlerR , LugerT , SterryW . Prospective randomized multicentre therapy optimizing protocol for therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α + PUVA [Prospectiv randomisiertes, multizentrisches Therapieoptimierungsprotokoll zur Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α + PUVA]. Zeitschrift für Hautkrankheiten2001;76(Suppl 1):S55. [CENTRAL: CN-01446038] KremerA , BohmeyerJ , StadlerR , LugerT , SterryW . Prospective randomized multicentre therapy optimizing protocol for therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α + PUVA [Prospectiv randomisiertes, multizentrisches Therapieoptimierungsprotokoll zur Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α + PUVA]. Journal der Deutschen Dermatologischen Gesellschaft2003;1(Suppl 1):S99. [CENTRAL: CN-01446037] OtteHG , StadlerR , LugerT , SterryW . Therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α plus PUVA: first results of a prospective randomized multicentre therapy optimizing protocol [Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α plus PUVA: Erste Ergebnisse des prospektiven randomisierten multizentrischen Therapieoptimierungsprotokolls]. Der Hautarzt1999;50(Suppl 1):S2. [CENTRAL: CN-01457423] OtteHG , StadlerR . Combination therapy of cutaneous t-cell-lymphoma with interferon alfa 2a and PUVA [Kombinationstherapie kutaner T-Zell-Lymphome mit Interferon Alfa 2a und PUVA]. Zentralblatt Haut- und Geschlechtskrankheiten1993;162(Suppl):P2.03.08. [CENTRAL: CN-01457422] StadlerM , KremerA , LugerT , SterryW . Prospective, randomized, multicentre clinical trial on the use of interferon a 2a plus PUVA versus PUVA monotherapy in patients with cutaneous T-cell lymphoma, stages I and II [Abstract 7541]. ASCO annual meeting proceedings. Journal of Clinical Oncology2006;24(18S Pt 1):432. [CENTRAL: CN-00625001] ">Stadler 2006</a>; <a href="./references#CD008946-bbs2-0015" title="Thestrup-PedersenK , GrunnetE , ZachariaeH . Transfer factor therapy in mycosis fungoides: a double-blind study. Acta Dermato-Venereologica1982;62(1):47-53. [CENTRAL: CN-00027377] [PMID: 6175137]">Thestrup‐Pedersen 1982</a>; <a href="./references#CD008946-bbs2-0016" title="NCT01686594. A multi-center, randomized study on oral 8-methoxypsoralen plus UVA with or without maintenance therapy in mycosis fungoides EORTC/ISCL stage IA to IIB. clinicaltrials.gov/ct2/show/NCT01686594 (first received 18 September 2012). Vieyra-GarciaP , Fink-PuchesR , PorkertS , LangR , PöchlauerS , RatzingerG , et al. Evaluation of low-dose, low-frequency oral psoralen-UV-A treatment with or without maintenance on early-stage mycosis fungoides: A randomized clinical trial. JAMA Dermatology2019;155(5):538-47. [PMID: 30892603]">Vieyra‐Garcia 2019</a>; <a href="./references#CD008946-bbs2-0020" title="WozniakMB , TraceyL , Ortiz-RomeroPL , MontesS , AlvarezM , FragaJ , et al. Psoralen plus ultraviolet A +/- interferon-alpha treatment resistance in mycosis fungoides: the role of tumour microenvironment, nuclear transcription factor-kappaB and T-cell receptor pathways. British Journal of Dermatology2008;160(1):92-102. [CENTRAL: CN-00668828] [PMID: 18945306]">Wozniak 2008</a>), or PUVA combined with bexarotene (<a href="./references#CD008946-bbs2-0006" title="GuitartJ , TuckerR , StevensV . Low dose bexarotene (Targretin®) capsules and phototherapy for early stage cutaneous T-Cell lymphoma. Journal of Investigative Dermatology2002;119(1):241. [CENTRAL: CN-00794450] NCT00030589. A muliticenter, dose-randomized evaluation of Targretin capsules plus PUVA in patients with stage IB - IIA cutaneous T-Cell lymphoma. clinicaltrials.gov/ct/show/NCT00030589 (first received 27 Jaunry 2003). ">Guitart 2002</a>; <a href="./references#CD008946-bbs2-0018" title="NCT00056056. Ultraviolet light therapy using methoxsalen with or without Bexarotene in treating patients with mycosis fungoides. clinicaltrials.gov/ct2/show/NCT00056056 (first received 7 March 2003). WhittakerS , OrtizP , DummerR , RankiA , HasanB , MeulemansB , et al. Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial 21011 (NCT00056056). British Journal of Dermatology2012;167(3):678-87. [CENTRAL: CN-00856432] [PMID: 22924950]WhittakerS , Ortiz-RomeroPL , DummerR , RankiA , HasanB , MeulemansB , et al. Efficacy and safety of bexarotene combined with psoralen/ultraviolet A light (PUVA) compared to PUVA treatment alone in stage IB-IIa mycosis fungoides (MF): Final results from EORTC cutaneous lymphoma task force (CLTF) phase III clinical trial 21011. Journal of Clinical Oncology2012;30(15 Suppl 1):8076. ">Whittaker 2012</a>), </p> </li> <li> <p>extracorporeal photopheresis (intervention and comparator) (<a href="./references#CD008946-bbs2-0002" title="ChildFJ , MitchellTJ , WhittakerSJ , ScarisbrickJJ , SeedPT , Russel-JonesR . A randomized cross-over study to compare PUVA and extracorporeal photopheresis in the treatment of plaque stage (T2) mycosis fungoides. Clinical &amp; Experimental Dermatology2004;29(3):231-6. [CENTRAL: CN-00468455] [PMID: 15115499]ChildFJ , MitchellTJ , WhittakerSJ , WatkinsP , SeedP , Russell-JonesR . A randomised cross-over study to compare Puva and extracorporeal photopheresis (ECP) in the treatment of plaque stage (T2) mycosis fungoides. British Journal of Dermatology2001;145(Suppl 59):16. [CENTRAL: CN-00430854] ">Child 2004</a>); and </p> </li> <li> <p>visible light (intervention and comparator) (<a href="./references#CD008946-bbs2-0012" title="RookAH , WoodGS , DuvicM , VonderheidEC , TobiaA , CabanaB . A phase II placebo-controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis. Journal of the American Academy of Dermatology2010;63(6):984-90. [CENTRAL: CN-00772559] [PMID: 20889234]">Rook 2010</a>). </p> </li> </ul> </p> <p>The oral treatments assessed included:</p> <p> <ul id="CD008946-list-0013"> <li> <p>acitretin (comparator) (<a href="./references#CD008946-bbs2-0013" title="OtteHG , KuhlS , StadlerR , LugerT , HenzB , SterryW . Treatment of cutaneous T-cell lymphoma with Interferon alpha and PUVA versus Interferon alpha and Acitretin - results of a prospective randomised multi-centre study [Behandlung des kutanen T-Zell-Lymphoms mit Interferon alpha und PUVA versus Interferon alpha und Acirentin - Ergebnisse einer prospektiv-randomisierten Multicenter-Studie]. Der Hautarzt1997;48(Suppl):S97. [CENTRAL: CN-00495120] OtteHG , StadierR , LugerT , HenzB , SterryW . Open controlled clinical trial on the use of interferon plus acitretin versus interferon plus PUVA in patients with cutaneous T-cell lymphoma (CTCL). Annals of Oncology1996;7(Suppl 3):66. [CENTRAL: CN-00308243] StadlerR , OtteHG , LugerT , HenzBM , KuhlP , ZwingersT , et al. Prospective randomized multicenter clinical trial on the use of interferon -2a plus acitretin versus interferon -2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood1998;92(10):3578-81. [CENTRAL: CN-00156682] [PMID: 9808550]">Stadler 1998</a>); </p> </li> <li> <p>bexarotene (intervention and comparator) (<a href="./references#CD008946-bbs2-0004" title="DuvicM , MartinAG , KimY , OlsenE , WoodGS , CrowleyCA , et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Archives of Dermatology2001;137(5):581-93. [CENTRAL: CN-00347816] [PMID: 11346336]PrinceHM , McCormackC , RyanG , BakerC , RotsteinH , DavisonJ , et al. Bexarotene capsules and gel for previously treated patients with cutaneous T-cell lymphoma: results of the Australian patients treated on phase II trials. Australasian Journal of Dermatology2001;42(2):91-7. [CENTRAL: CN-00442169] [PMID: 11309029]">Duvic 2001</a>; <a href="./references#CD008946-bbs2-0006" title="GuitartJ , TuckerR , StevensV . Low dose bexarotene (Targretin®) capsules and phototherapy for early stage cutaneous T-Cell lymphoma. Journal of Investigative Dermatology2002;119(1):241. [CENTRAL: CN-00794450] NCT00030589. A muliticenter, dose-randomized evaluation of Targretin capsules plus PUVA in patients with stage IB - IIA cutaneous T-Cell lymphoma. clinicaltrials.gov/ct/show/NCT00030589 (first received 27 Jaunry 2003). ">Guitart 2002</a>; <a href="./references#CD008946-bbs2-0018" title="NCT00056056. Ultraviolet light therapy using methoxsalen with or without Bexarotene in treating patients with mycosis fungoides. clinicaltrials.gov/ct2/show/NCT00056056 (first received 7 March 2003). WhittakerS , OrtizP , DummerR , RankiA , HasanB , MeulemansB , et al. Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial 21011 (NCT00056056). British Journal of Dermatology2012;167(3):678-87. [CENTRAL: CN-00856432] [PMID: 22924950]WhittakerS , Ortiz-RomeroPL , DummerR , RankiA , HasanB , MeulemansB , et al. Efficacy and safety of bexarotene combined with psoralen/ultraviolet A light (PUVA) compared to PUVA treatment alone in stage IB-IIa mycosis fungoides (MF): Final results from EORTC cutaneous lymphoma task force (CLTF) phase III clinical trial 21011. Journal of Clinical Oncology2012;30(15 Suppl 1):8076. ">Whittaker 2012</a>); </p> </li> <li> <p>lenalidomide (<a href="./references#CD008946-bbs2-0001" title="BagotM , HasanB , WhittakerS , Beylot-BarryM , KnoblerR , ShahE , et al. A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma - EORTC 21081 (NCT01098656): results and lessons learned for future trial designs. European Journal of Dermatology2017;27(3):286–94. [CENTRAL: CN-01395486] [PMID: 28468739]NCT01098656. A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-Cell lymphoma. clinicaltrials.gov/ct2/show/NCT01098656 (first received 5 April 2010). [NCT01098656]">Bagot 2017</a>); </p> </li> <li> <p>vorinostat (comparator) (<a href="./references#CD008946-bbs2-0008" title="BagotM , DalleS , SokolL , TsianakasA , MusiekA , Ortiz-RomeroP , et al. Long-term clinical benefit to anti-CCR4 mogamulizumab: results from the phase 3 mavoric study in previously treated cutaneous t-cell lymphoma (CTCL). Blood2018;132(Supp 1):2901. [DOI: 10.1182/blood-2018-99-118473]CowanR , ScarisbrickJ , DwyerK , LeoniM , GrebennikD , MorrisS . Mogamulizumab demonstrates significant improvement in PFS compared to vorinostat in patients with previously treated cutaneous T-cell lymphoma (CTCL). British Journal of Haematology2018;181(S1):77–8. [DOI: 10.1111/bjh.15226]KimYH , BagotM , Pinter-BrownL , RookAH , PorcuP , HorwitzSM , et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncology2018;19(9):1192-1204. [PMID: 30100375]NCT01728805. Study of KW-0761 versus vorinostat in relapsed/refractory CTCL. clinicaltrials.gov/ct2/show/NCT01728805 (first received 20 November 2012). PorcuP , HudgensS , QuaglinoP , CowanR , FlodenL , LeoniM , et al. Quality of life in cutaneous T-cell lymphoma subjects treated with anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat: results from the phase 3 MAVORIC trial. Journal of Clinical Oncology2018;36(15):-. [DOI: 10.1097/HS9.0000000000000060]QuaglinoP , HudgensS , PorcuP , CowanR , FlodenL , TsianakasA , et al. Quality of life in cutaneous t-cell lymphoma subjects treated with the anti-ccr4 monoclonal antibody mogamulizumab versus vorinostat: results from the phase 3 mavoric trial. Hemasphere2018;2(S1):85. ScarisbrickJ , ZinzaniPL , HorwitzS , KimYH , MoskowitzAJ , PorcuP , et al. Efficacy of mogamulizumab by prior systemic therapy in patients with previously treated cutaneous T-cell lymphoma: Post hoc analysis from the phase 3 MAVORIC study. British Journal of Haematology2019;185(Suppl 1):94. TsianakasA , QuaglinoP , HudgensS , FlodenL , LeoniM , DaleS , et al. Quality of life in cutaneous T-cell lymphoma subjects treated with the anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat: Results from the phase 3 MAVORIC trial. Oncology Research and Treatment2018;41(Suppl 4):272. ZinzaniPL , HorwitzSM , KimYH , MoskowitzAJ , PorcuP , ScarisbrickJ , et al. Efficacy of mogamulizumab by prior systemic therapy in patients with previously treated cutaneous T-cell lymphoma: post hoc analysis from the phase 3 mavoric study. Blood2018;132(Suppl 1):1619. [DOI: 10.1182/blood-2018-99-114819]">Kim 2018</a>); and </p> </li> <li> <p>methotrexate (comparator) (<a href="./references#CD008946-bbs2-0007" title="KayeF , EddyJ , IhdeDC , SteinbergS , FischmannAB , GlatsteinE , et al. Conservative vs. aggressive therapy in mycosis fungoides. Proceedings of the American Society of Clinical Oncology1989;8:257. [CENTRAL: CN-00694960] KayeF , IhdeD , FischmannA , GlatsteinE , MinnaJ , SchechterG , et al. A randomized trial comparing conservative and aggressive therapy in mycosis fungoides (MF). Proceedings of the American Society of Clinical Oncology1986;5:195. [CENTRAL: CN-00695166] KayeFJ , BunnPA , SteinbergSM , StockerJL , IhdeDC , FischmannAB , et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. New England Journal of Medicine1989;321(26):1784-90. [CENTRAL: CN-00064211] [PMID: 2594037]">Kaye 1989</a>; <a href="./references#CD008946-bbs2-0011" title="HorwitzS , WhittakerS , DuvicM , DummerR , KimYH , ScarisbrickJ , et al. Response by stage in CD30-positive (CD30+) cutaneous T cell lymphoma (CTCL) patients receiving brentuximab vedotin (BV) vs physician's choice (PC) in the phase 3 ALCANZA study. In: Hematological oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:245–7. [CENTRAL: CN-01408605] [DOI: 10.1002/hon.2438]HorwitzSM , AkilovOE , FisherD , KuzelTM , WangY , Palanca-WesselsMC , et al. Brentuximab vedotin or physician’s choice in CD30-positivecutaneous T-cell lymphoma (ALCANZA): an international,open-label, randomised, phase 3, multicentre trial. Lancet2017;390(10094):555-66. [CENTRAL: CN-01403731] HorwitzSM , ScarisbrickJJ , DummerR , DuvicM , KimYH , WalewskiJ , et al. Updated analyses of the international, open-label, randomized, phase 3 alcanza study: longer-term evidence for superiority of brentuximab vedotin versus methotrexate or bexarotene for CD30-positive cutaneous T-cell lymphoma (CTCL). In: Blood. Conference: 59th annual meeting of the american society of hematology, ASH 2017. United states. Vol. 130. 2017. [CENTRAL: CN-01450312] KimYH , PrinceHM , WhittakerS , HorwitzSM , DuvicM , ScarisbrickJ , et al. Brentuximab vedotin vs physician's choice in CTCL patients from the phase 3 ALCANZA study: analysis of outcomes by CD30 expression. In: Hematological Oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:77–8. [CENTRAL: CN-01408482] [DOI: 10.1002/hon.2437]KimYH , PrinceHM , WhittakerS , HorwitzSM , DuvicM , ScarisbrickJ , et al. Outcomes by CD30 expression in patients with CTCL receiving brentuximab vedotin (BV) vs physician's choice (PC) in the Phase 3 ALCANZA study. Journal of Clinical Oncology2017;35(15 Supplement 1):7517. [EMBASE: 617388795]KimYH , WhittakerS , DummerR , GeskinLJ , GauthierP , LittleM , et al. Phase 3 study of brentuximab vedotin versus physician's choice of methotrexate or bexarotene in patients (PTS) with CD30-positive (CD30+) cutaneous T-cell lymphoma (CTCL). The alcanza study. Hematological Oncology2013;31(Suppl 1):278. [CENTRAL: CN-01531598] [EMBASE: 71147875]KimYH , WhittakerS , HorwitzSM , DuvicM , DummerR , ScarisbrickJ , et al. Brentuximab vedotin demonstrates superior activity to standard therapy in CD30-expressing (CD30+) cutaneous T-cell lymphoma (CTCL) in the randomized phase 3 ALCANZA study. Journal of Investigative Dermatology2017;137(5 Suppl 1):S45. [CENTRAL: CN-01375469] [EMBASE: 616393777]KimYH , WhittakerS , HorwitzSM , DuvicM , DummerR , ScarisbrickJJ , et al. Brentuximab vedotin demonstrates significantly superior clinical outcomes in patients with CD30-expressing cutaneous T cell lymphoma versus physician's choice (Methotrexate or Bexarotene): the phase 3 alcanza study. In: Blood. Conference: 58th annual meeting of the american society of hematology, ASH 2016. United states. Conference start: 20161203. Conference end: 20161206. Vol. 128. 2016. [CENTRAL: CN-01303081] [EMBASE: 614225065]NCT01578499. A randomised, open-label, phase 3 trial of brentuximab vedotin (SGN-35) versus physician's choice (methotrexate or bexarotene) in patients with CD30-positive cutaneous T-cell lymphoma. clinicaltrials.gov/ct2/show/NCT01578499 (first received 17 April 2012). PrinceHM , DummerR , WhittakerS , HorwitzS , DuvicM , ScarisbrickJ , et al. Patient-reported outcomes and quality of life in patients with cutaneous T cell lymphoma: results from the phase 3 ALCANZA study. In: Hematological Oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:247–8. [CENTRAL: CN-01408603] [DOI: 10.1002/hon.2438]ZagadailovE , PrinceHM , WhittakerS , HorwitzS , DuvicM , KimY , et al. Phase 3 alcanza study of brentuximab vedotin (BV) or physician's choice (PC) of methotrexate (MTX) or bexarotene (BEX) in CD30-positive cutaneous T-cell lymphoma (CTCL): number needed to treat analysis. In: Haematologica. Conference: 22th congress of the european hematology association. Spain. Vol. 102. 2017:251. [CENTRAL: CN-01399195] ">Prince 2017</a>). </p> </li> </ul> </p> <p>Treatment with parenteral systemic agents consisted of:</p> <p> <ul id="CD008946-list-0014"> <li> <p>the infusion of brentuximab vedotin (<a href="./references#CD008946-bbs2-0011" title="HorwitzS , WhittakerS , DuvicM , DummerR , KimYH , ScarisbrickJ , et al. Response by stage in CD30-positive (CD30+) cutaneous T cell lymphoma (CTCL) patients receiving brentuximab vedotin (BV) vs physician's choice (PC) in the phase 3 ALCANZA study. In: Hematological oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:245–7. [CENTRAL: CN-01408605] [DOI: 10.1002/hon.2438]HorwitzSM , AkilovOE , FisherD , KuzelTM , WangY , Palanca-WesselsMC , et al. Brentuximab vedotin or physician’s choice in CD30-positivecutaneous T-cell lymphoma (ALCANZA): an international,open-label, randomised, phase 3, multicentre trial. Lancet2017;390(10094):555-66. [CENTRAL: CN-01403731] HorwitzSM , ScarisbrickJJ , DummerR , DuvicM , KimYH , WalewskiJ , et al. Updated analyses of the international, open-label, randomized, phase 3 alcanza study: longer-term evidence for superiority of brentuximab vedotin versus methotrexate or bexarotene for CD30-positive cutaneous T-cell lymphoma (CTCL). In: Blood. Conference: 59th annual meeting of the american society of hematology, ASH 2017. United states. Vol. 130. 2017. [CENTRAL: CN-01450312] KimYH , PrinceHM , WhittakerS , HorwitzSM , DuvicM , ScarisbrickJ , et al. Brentuximab vedotin vs physician's choice in CTCL patients from the phase 3 ALCANZA study: analysis of outcomes by CD30 expression. In: Hematological Oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:77–8. [CENTRAL: CN-01408482] [DOI: 10.1002/hon.2437]KimYH , PrinceHM , WhittakerS , HorwitzSM , DuvicM , ScarisbrickJ , et al. Outcomes by CD30 expression in patients with CTCL receiving brentuximab vedotin (BV) vs physician's choice (PC) in the Phase 3 ALCANZA study. Journal of Clinical Oncology2017;35(15 Supplement 1):7517. [EMBASE: 617388795]KimYH , WhittakerS , DummerR , GeskinLJ , GauthierP , LittleM , et al. Phase 3 study of brentuximab vedotin versus physician's choice of methotrexate or bexarotene in patients (PTS) with CD30-positive (CD30+) cutaneous T-cell lymphoma (CTCL). The alcanza study. Hematological Oncology2013;31(Suppl 1):278. [CENTRAL: CN-01531598] [EMBASE: 71147875]KimYH , WhittakerS , HorwitzSM , DuvicM , DummerR , ScarisbrickJ , et al. Brentuximab vedotin demonstrates superior activity to standard therapy in CD30-expressing (CD30+) cutaneous T-cell lymphoma (CTCL) in the randomized phase 3 ALCANZA study. Journal of Investigative Dermatology2017;137(5 Suppl 1):S45. [CENTRAL: CN-01375469] [EMBASE: 616393777]KimYH , WhittakerS , HorwitzSM , DuvicM , DummerR , ScarisbrickJJ , et al. Brentuximab vedotin demonstrates significantly superior clinical outcomes in patients with CD30-expressing cutaneous T cell lymphoma versus physician's choice (Methotrexate or Bexarotene): the phase 3 alcanza study. In: Blood. Conference: 58th annual meeting of the american society of hematology, ASH 2016. United states. Conference start: 20161203. Conference end: 20161206. Vol. 128. 2016. [CENTRAL: CN-01303081] [EMBASE: 614225065]NCT01578499. A randomised, open-label, phase 3 trial of brentuximab vedotin (SGN-35) versus physician's choice (methotrexate or bexarotene) in patients with CD30-positive cutaneous T-cell lymphoma. clinicaltrials.gov/ct2/show/NCT01578499 (first received 17 April 2012). PrinceHM , DummerR , WhittakerS , HorwitzS , DuvicM , ScarisbrickJ , et al. Patient-reported outcomes and quality of life in patients with cutaneous T cell lymphoma: results from the phase 3 ALCANZA study. In: Hematological Oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:247–8. [CENTRAL: CN-01408603] [DOI: 10.1002/hon.2438]ZagadailovE , PrinceHM , WhittakerS , HorwitzS , DuvicM , KimY , et al. Phase 3 alcanza study of brentuximab vedotin (BV) or physician's choice (PC) of methotrexate (MTX) or bexarotene (BEX) in CD30-positive cutaneous T-cell lymphoma (CTCL): number needed to treat analysis. In: Haematologica. Conference: 22th congress of the european hematology association. Spain. Vol. 102. 2017:251. [CENTRAL: CN-01399195] ">Prince 2017</a>), denileukin diftitox (<a href="./references#CD008946-bbs2-0010" title="DuvicM , KuzelTM , OlsenEA , MartinAG , FossFM , KimYH , et al. Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK). Clinical Lymphoma2002;2(4):222-8. [CENTRAL: CN-00514479] [PMID: 11970761]KuzelT , OlsenE , MartinA , KimY , DuvicM , FrankelA , et al. Pivotal phase III trial of two dose levels of DAB389IL-2 (Ontak®) for the treatment of mycosis fungoides (MF). Blood1997;90(10 Suppl 1 (Pt 1)):586a. [CENTRAL: CN-00518069] NTC00050999. Study of ONTAK (Denileukin Diftitox) in cutaneous T-Cell lymphoma (CTCL) patients. clinicaltrials.gov/ct2/show/NCT00050999 (first received 3 January 2003). OlsenE , DuvicM , FrankelA , KimY , MartinA , VonderheidE , et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. Journal of Clinical Oncology2001;19(2):376-88. [CENTRAL: CN-00328506] [PMID: 11208829]OlsenE , DuvicM , MartinA . Pivotal phase III trial of two dose levels of DAB 389 IL-2 (ONTAK) for the treatment of cutaneous T-cell lymphoma (CTCL). Journal of Investigative Dermatology1998;110(4):678. [CENTRAL: CN-00353452] ">Olsen 2001</a>), and mogamulizumab (<a href="./references#CD008946-bbs2-0008" title="BagotM , DalleS , SokolL , TsianakasA , MusiekA , Ortiz-RomeroP , et al. Long-term clinical benefit to anti-CCR4 mogamulizumab: results from the phase 3 mavoric study in previously treated cutaneous t-cell lymphoma (CTCL). Blood2018;132(Supp 1):2901. [DOI: 10.1182/blood-2018-99-118473]CowanR , ScarisbrickJ , DwyerK , LeoniM , GrebennikD , MorrisS . Mogamulizumab demonstrates significant improvement in PFS compared to vorinostat in patients with previously treated cutaneous T-cell lymphoma (CTCL). British Journal of Haematology2018;181(S1):77–8. [DOI: 10.1111/bjh.15226]KimYH , BagotM , Pinter-BrownL , RookAH , PorcuP , HorwitzSM , et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncology2018;19(9):1192-1204. [PMID: 30100375]NCT01728805. Study of KW-0761 versus vorinostat in relapsed/refractory CTCL. clinicaltrials.gov/ct2/show/NCT01728805 (first received 20 November 2012). PorcuP , HudgensS , QuaglinoP , CowanR , FlodenL , LeoniM , et al. Quality of life in cutaneous T-cell lymphoma subjects treated with anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat: results from the phase 3 MAVORIC trial. Journal of Clinical Oncology2018;36(15):-. [DOI: 10.1097/HS9.0000000000000060]QuaglinoP , HudgensS , PorcuP , CowanR , FlodenL , TsianakasA , et al. Quality of life in cutaneous t-cell lymphoma subjects treated with the anti-ccr4 monoclonal antibody mogamulizumab versus vorinostat: results from the phase 3 mavoric trial. Hemasphere2018;2(S1):85. ScarisbrickJ , ZinzaniPL , HorwitzS , KimYH , MoskowitzAJ , PorcuP , et al. Efficacy of mogamulizumab by prior systemic therapy in patients with previously treated cutaneous T-cell lymphoma: Post hoc analysis from the phase 3 MAVORIC study. British Journal of Haematology2019;185(Suppl 1):94. TsianakasA , QuaglinoP , HudgensS , FlodenL , LeoniM , DaleS , et al. Quality of life in cutaneous T-cell lymphoma subjects treated with the anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat: Results from the phase 3 MAVORIC trial. Oncology Research and Treatment2018;41(Suppl 4):272. ZinzaniPL , HorwitzSM , KimYH , MoskowitzAJ , PorcuP , ScarisbrickJ , et al. Efficacy of mogamulizumab by prior systemic therapy in patients with previously treated cutaneous T-cell lymphoma: post hoc analysis from the phase 3 mavoric study. Blood2018;132(Suppl 1):1619. [DOI: 10.1182/blood-2018-99-114819]">Kim 2018</a>); </p> </li> <li> <p>the parenteral chemotherapy with cyclophosphamide, doxorubicin, etoposide, and vincristine (<a href="./references#CD008946-bbs2-0007" title="KayeF , EddyJ , IhdeDC , SteinbergS , FischmannAB , GlatsteinE , et al. Conservative vs. aggressive therapy in mycosis fungoides. Proceedings of the American Society of Clinical Oncology1989;8:257. [CENTRAL: CN-00694960] KayeF , IhdeD , FischmannA , GlatsteinE , MinnaJ , SchechterG , et al. A randomized trial comparing conservative and aggressive therapy in mycosis fungoides (MF). Proceedings of the American Society of Clinical Oncology1986;5:195. [CENTRAL: CN-00695166] KayeFJ , BunnPA , SteinbergSM , StockerJL , IhdeDC , FischmannAB , et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. New England Journal of Medicine1989;321(26):1784-90. [CENTRAL: CN-00064211] [PMID: 2594037]">Kaye 1989</a>); </p> </li> <li> <p>the subcutaneous injection of IFN‐α (intervention and comparator) (<a href="./references#CD008946-bbs2-0014" title="BohmeyerJ , OtteHG , StadlerR , LugerT , SterryW . Therapy of cutaneous T-cell lymphoma with PUVA versus interferon alfa plus PUVA: first results. Journal of the European Academy of Dermatology &amp; Venereology1999;12(Suppl 2):S268. [CENTRAL: CN-00478472] BohmeyerJ , StadlerR , LugerT , SterryW . Prospective randomized multicentre therapy optimizing protocol for therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α + PUVA [Prospectiv randomisiertes, multizentrisches Therapieoptimierungsprotokoll zur Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α + PUVA]. Zeitschrift für Hautkrankheiten2001;76(Suppl 1):S55. [CENTRAL: CN-01446038] KremerA , BohmeyerJ , StadlerR , LugerT , SterryW . Prospective randomized multicentre therapy optimizing protocol for therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α + PUVA [Prospectiv randomisiertes, multizentrisches Therapieoptimierungsprotokoll zur Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α + PUVA]. Journal der Deutschen Dermatologischen Gesellschaft2003;1(Suppl 1):S99. [CENTRAL: CN-01446037] OtteHG , StadlerR , LugerT , SterryW . Therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α plus PUVA: first results of a prospective randomized multicentre therapy optimizing protocol [Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α plus PUVA: Erste Ergebnisse des prospektiven randomisierten multizentrischen Therapieoptimierungsprotokolls]. Der Hautarzt1999;50(Suppl 1):S2. [CENTRAL: CN-01457423] OtteHG , StadlerR . Combination therapy of cutaneous t-cell-lymphoma with interferon alfa 2a and PUVA [Kombinationstherapie kutaner T-Zell-Lymphome mit Interferon Alfa 2a und PUVA]. Zentralblatt Haut- und Geschlechtskrankheiten1993;162(Suppl):P2.03.08. [CENTRAL: CN-01457422] StadlerM , KremerA , LugerT , SterryW . Prospective, randomized, multicentre clinical trial on the use of interferon a 2a plus PUVA versus PUVA monotherapy in patients with cutaneous T-cell lymphoma, stages I and II [Abstract 7541]. ASCO annual meeting proceedings. Journal of Clinical Oncology2006;24(18S Pt 1):432. [CENTRAL: CN-00625001] ">Stadler 2006</a>; <a href="./references#CD008946-bbs2-0013" title="OtteHG , KuhlS , StadlerR , LugerT , HenzB , SterryW . Treatment of cutaneous T-cell lymphoma with Interferon alpha and PUVA versus Interferon alpha and Acitretin - results of a prospective randomised multi-centre study [Behandlung des kutanen T-Zell-Lymphoms mit Interferon alpha und PUVA versus Interferon alpha und Acirentin - Ergebnisse einer prospektiv-randomisierten Multicenter-Studie]. Der Hautarzt1997;48(Suppl):S97. [CENTRAL: CN-00495120] OtteHG , StadierR , LugerT , HenzB , SterryW . Open controlled clinical trial on the use of interferon plus acitretin versus interferon plus PUVA in patients with cutaneous T-cell lymphoma (CTCL). Annals of Oncology1996;7(Suppl 3):66. [CENTRAL: CN-00308243] StadlerR , OtteHG , LugerT , HenzBM , KuhlP , ZwingersT , et al. Prospective randomized multicenter clinical trial on the use of interferon -2a plus acitretin versus interferon -2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood1998;92(10):3578-81. [CENTRAL: CN-00156682] [PMID: 9808550]">Stadler 1998</a>; <a href="./references#CD008946-bbs2-0020" title="WozniakMB , TraceyL , Ortiz-RomeroPL , MontesS , AlvarezM , FragaJ , et al. Psoralen plus ultraviolet A +/- interferon-alpha treatment resistance in mycosis fungoides: the role of tumour microenvironment, nuclear transcription factor-kappaB and T-cell receptor pathways. British Journal of Dermatology2008;160(1):92-102. [CENTRAL: CN-00668828] [PMID: 18945306]">Wozniak 2008</a>); and </p> </li> <li> <p>the intramuscular injections of active transfer factor (<a href="./references#CD008946-bbs2-0015" title="Thestrup-PedersenK , GrunnetE , ZachariaeH . Transfer factor therapy in mycosis fungoides: a double-blind study. Acta Dermato-Venereologica1982;62(1):47-53. [CENTRAL: CN-00027377] [PMID: 6175137]">Thestrup‐Pedersen 1982</a>). </p> </li> </ul> </p> <p>Finally, we assessed one RCT using electron beam therapy (<a href="./references#CD008946-bbs2-0007" title="KayeF , EddyJ , IhdeDC , SteinbergS , FischmannAB , GlatsteinE , et al. Conservative vs. aggressive therapy in mycosis fungoides. Proceedings of the American Society of Clinical Oncology1989;8:257. [CENTRAL: CN-00694960] KayeF , IhdeD , FischmannA , GlatsteinE , MinnaJ , SchechterG , et al. A randomized trial comparing conservative and aggressive therapy in mycosis fungoides (MF). Proceedings of the American Society of Clinical Oncology1986;5:195. [CENTRAL: CN-00695166] KayeFJ , BunnPA , SteinbergSM , StockerJL , IhdeDC , FischmannAB , et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. New England Journal of Medicine1989;321(26):1784-90. [CENTRAL: CN-00064211] [PMID: 2594037]">Kaye 1989</a>). </p> </section> <section id="CD008946-sec-0074"> <h5 class="title">Outcomes</h5> <p>Only three studies used standardised written questionnaires to assess quality of life (QoL) during treatment: <a href="./references#CD008946-bbs2-0004" title="DuvicM , MartinAG , KimY , OlsenE , WoodGS , CrowleyCA , et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Archives of Dermatology2001;137(5):581-93. [CENTRAL: CN-00347816] [PMID: 11346336]PrinceHM , McCormackC , RyanG , BakerC , RotsteinH , DavisonJ , et al. Bexarotene capsules and gel for previously treated patients with cutaneous T-cell lymphoma: results of the Australian patients treated on phase II trials. Australasian Journal of Dermatology2001;42(2):91-7. [CENTRAL: CN-00442169] [PMID: 11309029]">Duvic 2001</a> used the Spitzer QoL questionnaire validated for survivors in palliative care and hospice settings (<a href="./references#CD008946-bbs2-0169" title="SpitzerWO , DobsonAJ , HallJ , ChestermanE , LeviJ , ShepherdR , et al. Measuring the quality of life of cancer patients: a concise QL-index for use by physicians. Journal of Chronic Diseases1981;34(12):585-97. [PMID: 7309824]">Spitzer 1981</a>) and a non‐validated CTCL‐patient questionnaire. <a href="./references#CD008946-bbs2-0008" title="BagotM , DalleS , SokolL , TsianakasA , MusiekA , Ortiz-RomeroP , et al. Long-term clinical benefit to anti-CCR4 mogamulizumab: results from the phase 3 mavoric study in previously treated cutaneous t-cell lymphoma (CTCL). Blood2018;132(Supp 1):2901. [DOI: 10.1182/blood-2018-99-118473]CowanR , ScarisbrickJ , DwyerK , LeoniM , GrebennikD , MorrisS . Mogamulizumab demonstrates significant improvement in PFS compared to vorinostat in patients with previously treated cutaneous T-cell lymphoma (CTCL). British Journal of Haematology2018;181(S1):77–8. [DOI: 10.1111/bjh.15226]KimYH , BagotM , Pinter-BrownL , RookAH , PorcuP , HorwitzSM , et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncology2018;19(9):1192-1204. [PMID: 30100375]NCT01728805. Study of KW-0761 versus vorinostat in relapsed/refractory CTCL. clinicaltrials.gov/ct2/show/NCT01728805 (first received 20 November 2012). PorcuP , HudgensS , QuaglinoP , CowanR , FlodenL , LeoniM , et al. Quality of life in cutaneous T-cell lymphoma subjects treated with anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat: results from the phase 3 MAVORIC trial. Journal of Clinical Oncology2018;36(15):-. [DOI: 10.1097/HS9.0000000000000060]QuaglinoP , HudgensS , PorcuP , CowanR , FlodenL , TsianakasA , et al. Quality of life in cutaneous t-cell lymphoma subjects treated with the anti-ccr4 monoclonal antibody mogamulizumab versus vorinostat: results from the phase 3 mavoric trial. Hemasphere2018;2(S1):85. ScarisbrickJ , ZinzaniPL , HorwitzS , KimYH , MoskowitzAJ , PorcuP , et al. Efficacy of mogamulizumab by prior systemic therapy in patients with previously treated cutaneous T-cell lymphoma: Post hoc analysis from the phase 3 MAVORIC study. British Journal of Haematology2019;185(Suppl 1):94. TsianakasA , QuaglinoP , HudgensS , FlodenL , LeoniM , DaleS , et al. Quality of life in cutaneous T-cell lymphoma subjects treated with the anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat: Results from the phase 3 MAVORIC trial. Oncology Research and Treatment2018;41(Suppl 4):272. ZinzaniPL , HorwitzSM , KimYH , MoskowitzAJ , PorcuP , ScarisbrickJ , et al. Efficacy of mogamulizumab by prior systemic therapy in patients with previously treated cutaneous T-cell lymphoma: post hoc analysis from the phase 3 mavoric study. Blood2018;132(Suppl 1):1619. [DOI: 10.1182/blood-2018-99-114819]">Kim 2018</a>, <a href="./references#CD008946-bbs2-0010" title="DuvicM , KuzelTM , OlsenEA , MartinAG , FossFM , KimYH , et al. Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK). Clinical Lymphoma2002;2(4):222-8. [CENTRAL: CN-00514479] [PMID: 11970761]KuzelT , OlsenE , MartinA , KimY , DuvicM , FrankelA , et al. Pivotal phase III trial of two dose levels of DAB389IL-2 (Ontak®) for the treatment of mycosis fungoides (MF). Blood1997;90(10 Suppl 1 (Pt 1)):586a. [CENTRAL: CN-00518069] NTC00050999. Study of ONTAK (Denileukin Diftitox) in cutaneous T-Cell lymphoma (CTCL) patients. clinicaltrials.gov/ct2/show/NCT00050999 (first received 3 January 2003). OlsenE , DuvicM , FrankelA , KimY , MartinA , VonderheidE , et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. Journal of Clinical Oncology2001;19(2):376-88. [CENTRAL: CN-00328506] [PMID: 11208829]OlsenE , DuvicM , MartinA . Pivotal phase III trial of two dose levels of DAB 389 IL-2 (ONTAK) for the treatment of cutaneous T-cell lymphoma (CTCL). Journal of Investigative Dermatology1998;110(4):678. [CENTRAL: CN-00353452] ">Olsen 2001</a> and <a href="./references#CD008946-bbs2-0011" title="HorwitzS , WhittakerS , DuvicM , DummerR , KimYH , ScarisbrickJ , et al. Response by stage in CD30-positive (CD30+) cutaneous T cell lymphoma (CTCL) patients receiving brentuximab vedotin (BV) vs physician's choice (PC) in the phase 3 ALCANZA study. In: Hematological oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:245–7. [CENTRAL: CN-01408605] [DOI: 10.1002/hon.2438]HorwitzSM , AkilovOE , FisherD , KuzelTM , WangY , Palanca-WesselsMC , et al. Brentuximab vedotin or physician’s choice in CD30-positivecutaneous T-cell lymphoma (ALCANZA): an international,open-label, randomised, phase 3, multicentre trial. Lancet2017;390(10094):555-66. [CENTRAL: CN-01403731] HorwitzSM , ScarisbrickJJ , DummerR , DuvicM , KimYH , WalewskiJ , et al. Updated analyses of the international, open-label, randomized, phase 3 alcanza study: longer-term evidence for superiority of brentuximab vedotin versus methotrexate or bexarotene for CD30-positive cutaneous T-cell lymphoma (CTCL). In: Blood. Conference: 59th annual meeting of the american society of hematology, ASH 2017. United states. Vol. 130. 2017. [CENTRAL: CN-01450312] KimYH , PrinceHM , WhittakerS , HorwitzSM , DuvicM , ScarisbrickJ , et al. Brentuximab vedotin vs physician's choice in CTCL patients from the phase 3 ALCANZA study: analysis of outcomes by CD30 expression. In: Hematological Oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:77–8. [CENTRAL: CN-01408482] [DOI: 10.1002/hon.2437]KimYH , PrinceHM , WhittakerS , HorwitzSM , DuvicM , ScarisbrickJ , et al. Outcomes by CD30 expression in patients with CTCL receiving brentuximab vedotin (BV) vs physician's choice (PC) in the Phase 3 ALCANZA study. Journal of Clinical Oncology2017;35(15 Supplement 1):7517. [EMBASE: 617388795]KimYH , WhittakerS , DummerR , GeskinLJ , GauthierP , LittleM , et al. Phase 3 study of brentuximab vedotin versus physician's choice of methotrexate or bexarotene in patients (PTS) with CD30-positive (CD30+) cutaneous T-cell lymphoma (CTCL). The alcanza study. Hematological Oncology2013;31(Suppl 1):278. [CENTRAL: CN-01531598] [EMBASE: 71147875]KimYH , WhittakerS , HorwitzSM , DuvicM , DummerR , ScarisbrickJ , et al. Brentuximab vedotin demonstrates superior activity to standard therapy in CD30-expressing (CD30+) cutaneous T-cell lymphoma (CTCL) in the randomized phase 3 ALCANZA study. Journal of Investigative Dermatology2017;137(5 Suppl 1):S45. [CENTRAL: CN-01375469] [EMBASE: 616393777]KimYH , WhittakerS , HorwitzSM , DuvicM , DummerR , ScarisbrickJJ , et al. Brentuximab vedotin demonstrates significantly superior clinical outcomes in patients with CD30-expressing cutaneous T cell lymphoma versus physician's choice (Methotrexate or Bexarotene): the phase 3 alcanza study. In: Blood. Conference: 58th annual meeting of the american society of hematology, ASH 2016. United states. Conference start: 20161203. Conference end: 20161206. Vol. 128. 2016. [CENTRAL: CN-01303081] [EMBASE: 614225065]NCT01578499. A randomised, open-label, phase 3 trial of brentuximab vedotin (SGN-35) versus physician's choice (methotrexate or bexarotene) in patients with CD30-positive cutaneous T-cell lymphoma. clinicaltrials.gov/ct2/show/NCT01578499 (first received 17 April 2012). PrinceHM , DummerR , WhittakerS , HorwitzS , DuvicM , ScarisbrickJ , et al. Patient-reported outcomes and quality of life in patients with cutaneous T cell lymphoma: results from the phase 3 ALCANZA study. In: Hematological Oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:247–8. [CENTRAL: CN-01408603] [DOI: 10.1002/hon.2438]ZagadailovE , PrinceHM , WhittakerS , HorwitzS , DuvicM , KimY , et al. Phase 3 alcanza study of brentuximab vedotin (BV) or physician's choice (PC) of methotrexate (MTX) or bexarotene (BEX) in CD30-positive cutaneous T-cell lymphoma (CTCL): number needed to treat analysis. In: Haematologica. Conference: 22th congress of the european hematology association. Spain. Vol. 102. 2017:251. [CENTRAL: CN-01399195] ">Prince 2017</a> used the Functional Assessment in Cancer Therapy‐general (FACT‐G) questionnaire developed by <a href="./references#CD008946-bbs2-0100" title="CellaDF , TulskyDS , GrayG , SarafianB , LinnE , BonomiA , et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. Journal of Clinical Oncology1993;11(3):570-9. [PMID: 8445433]">Cella 1993</a>. </p> <p>Eighteen studies reported common adverse effects or their absence. This outcome was assessed by physicians (<a href="./references#CD008946-bbs2-0001" title="BagotM , HasanB , WhittakerS , Beylot-BarryM , KnoblerR , ShahE , et al. A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma - EORTC 21081 (NCT01098656): results and lessons learned for future trial designs. European Journal of Dermatology2017;27(3):286–94. [CENTRAL: CN-01395486] [PMID: 28468739]NCT01098656. A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-Cell lymphoma. clinicaltrials.gov/ct2/show/NCT01098656 (first received 5 April 2010). [NCT01098656]">Bagot 2017</a>; <a href="./references#CD008946-bbs2-0002" title="ChildFJ , MitchellTJ , WhittakerSJ , ScarisbrickJJ , SeedPT , Russel-JonesR . A randomized cross-over study to compare PUVA and extracorporeal photopheresis in the treatment of plaque stage (T2) mycosis fungoides. Clinical &amp; Experimental Dermatology2004;29(3):231-6. [CENTRAL: CN-00468455] [PMID: 15115499]ChildFJ , MitchellTJ , WhittakerSJ , WatkinsP , SeedP , Russell-JonesR . A randomised cross-over study to compare Puva and extracorporeal photopheresis (ECP) in the treatment of plaque stage (T2) mycosis fungoides. British Journal of Dermatology2001;145(Suppl 59):16. [CENTRAL: CN-00430854] ">Child 2004</a>; <a href="./references#CD008946-bbs2-0003" title="ChongA , LooWJ , BanneyL , GrantJW , NorrisPG . Imiquimod 5% cream in the treatment of mycosis fungoides - a pilot study. Journal of Dermatological Treatment2004;15(2):118-9. [CENTRAL: CN-00467258] [PMID: 15204164]">Chong 2004</a>; <a href="./references#CD008946-bbs2-0004" title="DuvicM , MartinAG , KimY , OlsenE , WoodGS , CrowleyCA , et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Archives of Dermatology2001;137(5):581-93. [CENTRAL: CN-00347816] [PMID: 11346336]PrinceHM , McCormackC , RyanG , BakerC , RotsteinH , DavisonJ , et al. Bexarotene capsules and gel for previously treated patients with cutaneous T-cell lymphoma: results of the Australian patients treated on phase II trials. Australasian Journal of Dermatology2001;42(2):91-7. [CENTRAL: CN-00442169] [PMID: 11309029]">Duvic 2001</a>; <a href="./references#CD008946-bbs2-0005" title="DuvicM , OlsenEA , OmuraGA , MaizeJC , VonderheidEC , et al. A phase III, randomized, double-blind, placebo-controlled study of peldesine (BCX-34) cream as topical therapy for cutaneous T-cell lymphoma. Journal of the American Academy of Dermatology2001;44(6):940-7. [CENTRAL: CN-00348073] [PMID: 11369904]">Duvic 2001a</a>; <a href="./references#CD008946-bbs2-0006" title="GuitartJ , TuckerR , StevensV . Low dose bexarotene (Targretin®) capsules and phototherapy for early stage cutaneous T-Cell lymphoma. Journal of Investigative Dermatology2002;119(1):241. [CENTRAL: CN-00794450] NCT00030589. A muliticenter, dose-randomized evaluation of Targretin capsules plus PUVA in patients with stage IB - IIA cutaneous T-Cell lymphoma. clinicaltrials.gov/ct/show/NCT00030589 (first received 27 Jaunry 2003). ">Guitart 2002</a>; <a href="./references#CD008946-bbs2-0007" title="KayeF , EddyJ , IhdeDC , SteinbergS , FischmannAB , GlatsteinE , et al. Conservative vs. aggressive therapy in mycosis fungoides. Proceedings of the American Society of Clinical Oncology1989;8:257. [CENTRAL: CN-00694960] KayeF , IhdeD , FischmannA , GlatsteinE , MinnaJ , SchechterG , et al. A randomized trial comparing conservative and aggressive therapy in mycosis fungoides (MF). Proceedings of the American Society of Clinical Oncology1986;5:195. [CENTRAL: CN-00695166] KayeFJ , BunnPA , SteinbergSM , StockerJL , IhdeDC , FischmannAB , et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. New England Journal of Medicine1989;321(26):1784-90. [CENTRAL: CN-00064211] [PMID: 2594037]">Kaye 1989</a>; <a href="./references#CD008946-bbs2-0008" title="BagotM , DalleS , SokolL , TsianakasA , MusiekA , Ortiz-RomeroP , et al. Long-term clinical benefit to anti-CCR4 mogamulizumab: results from the phase 3 mavoric study in previously treated cutaneous t-cell lymphoma (CTCL). Blood2018;132(Supp 1):2901. [DOI: 10.1182/blood-2018-99-118473]CowanR , ScarisbrickJ , DwyerK , LeoniM , GrebennikD , MorrisS . Mogamulizumab demonstrates significant improvement in PFS compared to vorinostat in patients with previously treated cutaneous T-cell lymphoma (CTCL). British Journal of Haematology2018;181(S1):77–8. [DOI: 10.1111/bjh.15226]KimYH , BagotM , Pinter-BrownL , RookAH , PorcuP , HorwitzSM , et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncology2018;19(9):1192-1204. [PMID: 30100375]NCT01728805. Study of KW-0761 versus vorinostat in relapsed/refractory CTCL. clinicaltrials.gov/ct2/show/NCT01728805 (first received 20 November 2012). PorcuP , HudgensS , QuaglinoP , CowanR , FlodenL , LeoniM , et al. Quality of life in cutaneous T-cell lymphoma subjects treated with anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat: results from the phase 3 MAVORIC trial. Journal of Clinical Oncology2018;36(15):-. [DOI: 10.1097/HS9.0000000000000060]QuaglinoP , HudgensS , PorcuP , CowanR , FlodenL , TsianakasA , et al. Quality of life in cutaneous t-cell lymphoma subjects treated with the anti-ccr4 monoclonal antibody mogamulizumab versus vorinostat: results from the phase 3 mavoric trial. Hemasphere2018;2(S1):85. ScarisbrickJ , ZinzaniPL , HorwitzS , KimYH , MoskowitzAJ , PorcuP , et al. Efficacy of mogamulizumab by prior systemic therapy in patients with previously treated cutaneous T-cell lymphoma: Post hoc analysis from the phase 3 MAVORIC study. British Journal of Haematology2019;185(Suppl 1):94. TsianakasA , QuaglinoP , HudgensS , FlodenL , LeoniM , DaleS , et al. Quality of life in cutaneous T-cell lymphoma subjects treated with the anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat: Results from the phase 3 MAVORIC trial. Oncology Research and Treatment2018;41(Suppl 4):272. ZinzaniPL , HorwitzSM , KimYH , MoskowitzAJ , PorcuP , ScarisbrickJ , et al. Efficacy of mogamulizumab by prior systemic therapy in patients with previously treated cutaneous T-cell lymphoma: post hoc analysis from the phase 3 mavoric study. Blood2018;132(Suppl 1):1619. [DOI: 10.1182/blood-2018-99-114819]">Kim 2018</a>; <a href="./references#CD008946-bbs2-0009" title="LessinS , DuvicM , GuitartJ , PandyaA , StroberB , OlsenE , et al. Positive results of a pivotal phase ii trial testing a manufactured 0.02% Mechlorethamine gel in mycosis fungoides (mf). Journal of Investigative Dermatology2011;131(Suppl 1):S84. [CENTRAL: CN-00843792] LessinSR , DuvicM , GuitartJ , PandyaAG , StroberBE , OlsenEA , et al. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatology2013;149(1):25-32. [CENTRAL: CN-00859487] [PMID: 23069814]NCT00168064. Safety and efficacy of nitrogen mustard in treatment of mycosis fungoides. clinicaltrials.gov/ct2/show/NCT00168064 (first received 14 September 2005). ">Lessin 2013</a>; <a href="./references#CD008946-bbs2-0010" title="DuvicM , KuzelTM , OlsenEA , MartinAG , FossFM , KimYH , et al. Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK). Clinical Lymphoma2002;2(4):222-8. [CENTRAL: CN-00514479] [PMID: 11970761]KuzelT , OlsenE , MartinA , KimY , DuvicM , FrankelA , et al. Pivotal phase III trial of two dose levels of DAB389IL-2 (Ontak®) for the treatment of mycosis fungoides (MF). Blood1997;90(10 Suppl 1 (Pt 1)):586a. [CENTRAL: CN-00518069] NTC00050999. Study of ONTAK (Denileukin Diftitox) in cutaneous T-Cell lymphoma (CTCL) patients. clinicaltrials.gov/ct2/show/NCT00050999 (first received 3 January 2003). OlsenE , DuvicM , FrankelA , KimY , MartinA , VonderheidE , et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. Journal of Clinical Oncology2001;19(2):376-88. [CENTRAL: CN-00328506] [PMID: 11208829]OlsenE , DuvicM , MartinA . Pivotal phase III trial of two dose levels of DAB 389 IL-2 (ONTAK) for the treatment of cutaneous T-cell lymphoma (CTCL). Journal of Investigative Dermatology1998;110(4):678. [CENTRAL: CN-00353452] ">Olsen 2001</a>; <a href="./references#CD008946-bbs2-0011" title="HorwitzS , WhittakerS , DuvicM , DummerR , KimYH , ScarisbrickJ , et al. Response by stage in CD30-positive (CD30+) cutaneous T cell lymphoma (CTCL) patients receiving brentuximab vedotin (BV) vs physician's choice (PC) in the phase 3 ALCANZA study. In: Hematological oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:245–7. [CENTRAL: CN-01408605] [DOI: 10.1002/hon.2438]HorwitzSM , AkilovOE , FisherD , KuzelTM , WangY , Palanca-WesselsMC , et al. Brentuximab vedotin or physician’s choice in CD30-positivecutaneous T-cell lymphoma (ALCANZA): an international,open-label, randomised, phase 3, multicentre trial. Lancet2017;390(10094):555-66. [CENTRAL: CN-01403731] HorwitzSM , ScarisbrickJJ , DummerR , DuvicM , KimYH , WalewskiJ , et al. Updated analyses of the international, open-label, randomized, phase 3 alcanza study: longer-term evidence for superiority of brentuximab vedotin versus methotrexate or bexarotene for CD30-positive cutaneous T-cell lymphoma (CTCL). In: Blood. Conference: 59th annual meeting of the american society of hematology, ASH 2017. United states. Vol. 130. 2017. [CENTRAL: CN-01450312] KimYH , PrinceHM , WhittakerS , HorwitzSM , DuvicM , ScarisbrickJ , et al. Brentuximab vedotin vs physician's choice in CTCL patients from the phase 3 ALCANZA study: analysis of outcomes by CD30 expression. In: Hematological Oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:77–8. [CENTRAL: CN-01408482] [DOI: 10.1002/hon.2437]KimYH , PrinceHM , WhittakerS , HorwitzSM , DuvicM , ScarisbrickJ , et al. Outcomes by CD30 expression in patients with CTCL receiving brentuximab vedotin (BV) vs physician's choice (PC) in the Phase 3 ALCANZA study. Journal of Clinical Oncology2017;35(15 Supplement 1):7517. [EMBASE: 617388795]KimYH , WhittakerS , DummerR , GeskinLJ , GauthierP , LittleM , et al. Phase 3 study of brentuximab vedotin versus physician's choice of methotrexate or bexarotene in patients (PTS) with CD30-positive (CD30+) cutaneous T-cell lymphoma (CTCL). The alcanza study. Hematological Oncology2013;31(Suppl 1):278. [CENTRAL: CN-01531598] [EMBASE: 71147875]KimYH , WhittakerS , HorwitzSM , DuvicM , DummerR , ScarisbrickJ , et al. Brentuximab vedotin demonstrates superior activity to standard therapy in CD30-expressing (CD30+) cutaneous T-cell lymphoma (CTCL) in the randomized phase 3 ALCANZA study. Journal of Investigative Dermatology2017;137(5 Suppl 1):S45. [CENTRAL: CN-01375469] [EMBASE: 616393777]KimYH , WhittakerS , HorwitzSM , DuvicM , DummerR , ScarisbrickJJ , et al. Brentuximab vedotin demonstrates significantly superior clinical outcomes in patients with CD30-expressing cutaneous T cell lymphoma versus physician's choice (Methotrexate or Bexarotene): the phase 3 alcanza study. In: Blood. Conference: 58th annual meeting of the american society of hematology, ASH 2016. United states. Conference start: 20161203. Conference end: 20161206. Vol. 128. 2016. [CENTRAL: CN-01303081] [EMBASE: 614225065]NCT01578499. A randomised, open-label, phase 3 trial of brentuximab vedotin (SGN-35) versus physician's choice (methotrexate or bexarotene) in patients with CD30-positive cutaneous T-cell lymphoma. clinicaltrials.gov/ct2/show/NCT01578499 (first received 17 April 2012). PrinceHM , DummerR , WhittakerS , HorwitzS , DuvicM , ScarisbrickJ , et al. Patient-reported outcomes and quality of life in patients with cutaneous T cell lymphoma: results from the phase 3 ALCANZA study. In: Hematological Oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:247–8. [CENTRAL: CN-01408603] [DOI: 10.1002/hon.2438]ZagadailovE , PrinceHM , WhittakerS , HorwitzS , DuvicM , KimY , et al. Phase 3 alcanza study of brentuximab vedotin (BV) or physician's choice (PC) of methotrexate (MTX) or bexarotene (BEX) in CD30-positive cutaneous T-cell lymphoma (CTCL): number needed to treat analysis. In: Haematologica. Conference: 22th congress of the european hematology association. Spain. Vol. 102. 2017:251. [CENTRAL: CN-01399195] ">Prince 2017</a>; <a href="./references#CD008946-bbs2-0012" title="RookAH , WoodGS , DuvicM , VonderheidEC , TobiaA , CabanaB . A phase II placebo-controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis. Journal of the American Academy of Dermatology2010;63(6):984-90. [CENTRAL: CN-00772559] [PMID: 20889234]">Rook 2010</a>; <a href="./references#CD008946-bbs2-0013" title="OtteHG , KuhlS , StadlerR , LugerT , HenzB , SterryW . Treatment of cutaneous T-cell lymphoma with Interferon alpha and PUVA versus Interferon alpha and Acitretin - results of a prospective randomised multi-centre study [Behandlung des kutanen T-Zell-Lymphoms mit Interferon alpha und PUVA versus Interferon alpha und Acirentin - Ergebnisse einer prospektiv-randomisierten Multicenter-Studie]. Der Hautarzt1997;48(Suppl):S97. [CENTRAL: CN-00495120] OtteHG , StadierR , LugerT , HenzB , SterryW . Open controlled clinical trial on the use of interferon plus acitretin versus interferon plus PUVA in patients with cutaneous T-cell lymphoma (CTCL). Annals of Oncology1996;7(Suppl 3):66. [CENTRAL: CN-00308243] StadlerR , OtteHG , LugerT , HenzBM , KuhlP , ZwingersT , et al. Prospective randomized multicenter clinical trial on the use of interferon -2a plus acitretin versus interferon -2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood1998;92(10):3578-81. [CENTRAL: CN-00156682] [PMID: 9808550]">Stadler 1998</a>; <a href="./references#CD008946-bbs2-0015" title="Thestrup-PedersenK , GrunnetE , ZachariaeH . Transfer factor therapy in mycosis fungoides: a double-blind study. Acta Dermato-Venereologica1982;62(1):47-53. [CENTRAL: CN-00027377] [PMID: 6175137]">Thestrup‐Pedersen 1982</a>; <a href="./references#CD008946-bbs2-0016" title="NCT01686594. A multi-center, randomized study on oral 8-methoxypsoralen plus UVA with or without maintenance therapy in mycosis fungoides EORTC/ISCL stage IA to IIB. clinicaltrials.gov/ct2/show/NCT01686594 (first received 18 September 2012). Vieyra-GarciaP , Fink-PuchesR , PorkertS , LangR , PöchlauerS , RatzingerG , et al. Evaluation of low-dose, low-frequency oral psoralen-UV-A treatment with or without maintenance on early-stage mycosis fungoides: A randomized clinical trial. JAMA Dermatology2019;155(5):538-47. [PMID: 30892603]">Vieyra‐Garcia 2019</a>; <a href="./references#CD008946-bbs2-0017" title="VonderheidEC , ThompsonR , SmilesKA , LattanandA . Recombinant interferon alfa-2b in plaque-phase mycosis fungoides. Intralesional and low-dose intramuscular therapy. Archives of Dermatology1987;123(6):757-63. [CENTRAL: CN-00047990] [PMID: 3579357]">Vonderheid 1987</a>; <a href="./references#CD008946-bbs2-0018" title="NCT00056056. Ultraviolet light therapy using methoxsalen with or without Bexarotene in treating patients with mycosis fungoides. clinicaltrials.gov/ct2/show/NCT00056056 (first received 7 March 2003). WhittakerS , OrtizP , DummerR , RankiA , HasanB , MeulemansB , et al. Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial 21011 (NCT00056056). British Journal of Dermatology2012;167(3):678-87. [CENTRAL: CN-00856432] [PMID: 22924950]WhittakerS , Ortiz-RomeroPL , DummerR , RankiA , HasanB , MeulemansB , et al. Efficacy and safety of bexarotene combined with psoralen/ultraviolet A light (PUVA) compared to PUVA treatment alone in stage IB-IIa mycosis fungoides (MF): Final results from EORTC cutaneous lymphoma task force (CLTF) phase III clinical trial 21011. Journal of Clinical Oncology2012;30(15 Suppl 1):8076. ">Whittaker 2012</a>; <a href="./references#CD008946-bbs2-0019" title="WolffJM , ZitelliJA , RabinBS , SmilesKA , AbellE . Intralesional interferon in the treatment of early mycosis fungoides. Journal of the American Academy of Dermatology1985;13(4):604-12. [CENTRAL: CN-00040943] [PMID: 2934438]">Wolff 1985</a>). </p> <p>All studies but <a href="./references#CD008946-bbs2-0001" title="BagotM , HasanB , WhittakerS , Beylot-BarryM , KnoblerR , ShahE , et al. A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma - EORTC 21081 (NCT01098656): results and lessons learned for future trial designs. European Journal of Dermatology2017;27(3):286–94. [CENTRAL: CN-01395486] [PMID: 28468739]NCT01098656. A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-Cell lymphoma. clinicaltrials.gov/ct2/show/NCT01098656 (first received 5 April 2010). [NCT01098656]">Bagot 2017</a> and <a href="./references#CD008946-bbs2-0012" title="RookAH , WoodGS , DuvicM , VonderheidEC , TobiaA , CabanaB . A phase II placebo-controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis. Journal of the American Academy of Dermatology2010;63(6):984-90. [CENTRAL: CN-00772559] [PMID: 20889234]">Rook 2010</a> assessed clearance (either directly or indirectly) in at least one of the following aspects of disease: lesion surfaces or lesion size of all lesions or target lesions only, blood tumour burden, or tumour size. In <a href="./references#CD008946-bbs2-0016" title="NCT01686594. A multi-center, randomized study on oral 8-methoxypsoralen plus UVA with or without maintenance therapy in mycosis fungoides EORTC/ISCL stage IA to IIB. clinicaltrials.gov/ct2/show/NCT01686594 (first received 18 September 2012). Vieyra-GarciaP , Fink-PuchesR , PorkertS , LangR , PöchlauerS , RatzingerG , et al. Evaluation of low-dose, low-frequency oral psoralen-UV-A treatment with or without maintenance on early-stage mycosis fungoides: A randomized clinical trial. JAMA Dermatology2019;155(5):538-47. [PMID: 30892603]">Vieyra‐Garcia 2019</a> CR was a condition for randomisation in one of the study arms (PUVA maintenance versus no maintenance) and could therefore not be attributed to one of the interventions. </p> <p>Relapse was investigated in seven studies (<a href="./references#CD008946-bbs2-0004" title="DuvicM , MartinAG , KimY , OlsenE , WoodGS , CrowleyCA , et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Archives of Dermatology2001;137(5):581-93. [CENTRAL: CN-00347816] [PMID: 11346336]PrinceHM , McCormackC , RyanG , BakerC , RotsteinH , DavisonJ , et al. Bexarotene capsules and gel for previously treated patients with cutaneous T-cell lymphoma: results of the Australian patients treated on phase II trials. Australasian Journal of Dermatology2001;42(2):91-7. [CENTRAL: CN-00442169] [PMID: 11309029]">Duvic 2001</a>; <a href="./references#CD008946-bbs2-0006" title="GuitartJ , TuckerR , StevensV . Low dose bexarotene (Targretin®) capsules and phototherapy for early stage cutaneous T-Cell lymphoma. Journal of Investigative Dermatology2002;119(1):241. [CENTRAL: CN-00794450] NCT00030589. A muliticenter, dose-randomized evaluation of Targretin capsules plus PUVA in patients with stage IB - IIA cutaneous T-Cell lymphoma. clinicaltrials.gov/ct/show/NCT00030589 (first received 27 Jaunry 2003). ">Guitart 2002</a>; <a href="./references#CD008946-bbs2-0007" title="KayeF , EddyJ , IhdeDC , SteinbergS , FischmannAB , GlatsteinE , et al. Conservative vs. aggressive therapy in mycosis fungoides. Proceedings of the American Society of Clinical Oncology1989;8:257. [CENTRAL: CN-00694960] KayeF , IhdeD , FischmannA , GlatsteinE , MinnaJ , SchechterG , et al. A randomized trial comparing conservative and aggressive therapy in mycosis fungoides (MF). Proceedings of the American Society of Clinical Oncology1986;5:195. [CENTRAL: CN-00695166] KayeFJ , BunnPA , SteinbergSM , StockerJL , IhdeDC , FischmannAB , et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. New England Journal of Medicine1989;321(26):1784-90. [CENTRAL: CN-00064211] [PMID: 2594037]">Kaye 1989</a>; <a href="./references#CD008946-bbs2-0008" title="BagotM , DalleS , SokolL , TsianakasA , MusiekA , Ortiz-RomeroP , et al. Long-term clinical benefit to anti-CCR4 mogamulizumab: results from the phase 3 mavoric study in previously treated cutaneous t-cell lymphoma (CTCL). Blood2018;132(Supp 1):2901. [DOI: 10.1182/blood-2018-99-118473]CowanR , ScarisbrickJ , DwyerK , LeoniM , GrebennikD , MorrisS . Mogamulizumab demonstrates significant improvement in PFS compared to vorinostat in patients with previously treated cutaneous T-cell lymphoma (CTCL). British Journal of Haematology2018;181(S1):77–8. [DOI: 10.1111/bjh.15226]KimYH , BagotM , Pinter-BrownL , RookAH , PorcuP , HorwitzSM , et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncology2018;19(9):1192-1204. [PMID: 30100375]NCT01728805. Study of KW-0761 versus vorinostat in relapsed/refractory CTCL. clinicaltrials.gov/ct2/show/NCT01728805 (first received 20 November 2012). PorcuP , HudgensS , QuaglinoP , CowanR , FlodenL , LeoniM , et al. Quality of life in cutaneous T-cell lymphoma subjects treated with anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat: results from the phase 3 MAVORIC trial. Journal of Clinical Oncology2018;36(15):-. [DOI: 10.1097/HS9.0000000000000060]QuaglinoP , HudgensS , PorcuP , CowanR , FlodenL , TsianakasA , et al. Quality of life in cutaneous t-cell lymphoma subjects treated with the anti-ccr4 monoclonal antibody mogamulizumab versus vorinostat: results from the phase 3 mavoric trial. Hemasphere2018;2(S1):85. ScarisbrickJ , ZinzaniPL , HorwitzS , KimYH , MoskowitzAJ , PorcuP , et al. Efficacy of mogamulizumab by prior systemic therapy in patients with previously treated cutaneous T-cell lymphoma: Post hoc analysis from the phase 3 MAVORIC study. British Journal of Haematology2019;185(Suppl 1):94. TsianakasA , QuaglinoP , HudgensS , FlodenL , LeoniM , DaleS , et al. Quality of life in cutaneous T-cell lymphoma subjects treated with the anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat: Results from the phase 3 MAVORIC trial. Oncology Research and Treatment2018;41(Suppl 4):272. ZinzaniPL , HorwitzSM , KimYH , MoskowitzAJ , PorcuP , ScarisbrickJ , et al. Efficacy of mogamulizumab by prior systemic therapy in patients with previously treated cutaneous T-cell lymphoma: post hoc analysis from the phase 3 mavoric study. Blood2018;132(Suppl 1):1619. [DOI: 10.1182/blood-2018-99-114819]">Kim 2018</a>; <a href="./references#CD008946-bbs2-0016" title="NCT01686594. A multi-center, randomized study on oral 8-methoxypsoralen plus UVA with or without maintenance therapy in mycosis fungoides EORTC/ISCL stage IA to IIB. clinicaltrials.gov/ct2/show/NCT01686594 (first received 18 September 2012). Vieyra-GarciaP , Fink-PuchesR , PorkertS , LangR , PöchlauerS , RatzingerG , et al. Evaluation of low-dose, low-frequency oral psoralen-UV-A treatment with or without maintenance on early-stage mycosis fungoides: A randomized clinical trial. JAMA Dermatology2019;155(5):538-47. [PMID: 30892603]">Vieyra‐Garcia 2019</a>; <a href="./references#CD008946-bbs2-0018" title="NCT00056056. Ultraviolet light therapy using methoxsalen with or without Bexarotene in treating patients with mycosis fungoides. clinicaltrials.gov/ct2/show/NCT00056056 (first received 7 March 2003). WhittakerS , OrtizP , DummerR , RankiA , HasanB , MeulemansB , et al. Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial 21011 (NCT00056056). British Journal of Dermatology2012;167(3):678-87. [CENTRAL: CN-00856432] [PMID: 22924950]WhittakerS , Ortiz-RomeroPL , DummerR , RankiA , HasanB , MeulemansB , et al. Efficacy and safety of bexarotene combined with psoralen/ultraviolet A light (PUVA) compared to PUVA treatment alone in stage IB-IIa mycosis fungoides (MF): Final results from EORTC cutaneous lymphoma task force (CLTF) phase III clinical trial 21011. Journal of Clinical Oncology2012;30(15 Suppl 1):8076. ">Whittaker 2012</a>; <a href="./references#CD008946-bbs2-0020" title="WozniakMB , TraceyL , Ortiz-RomeroPL , MontesS , AlvarezM , FragaJ , et al. Psoralen plus ultraviolet A +/- interferon-alpha treatment resistance in mycosis fungoides: the role of tumour microenvironment, nuclear transcription factor-kappaB and T-cell receptor pathways. British Journal of Dermatology2008;160(1):92-102. [CENTRAL: CN-00668828] [PMID: 18945306]">Wozniak 2008</a>). In two of those, relapse was not assessable (<a href="./references#CD008946-bbs2-0008" title="BagotM , DalleS , SokolL , TsianakasA , MusiekA , Ortiz-RomeroP , et al. Long-term clinical benefit to anti-CCR4 mogamulizumab: results from the phase 3 mavoric study in previously treated cutaneous t-cell lymphoma (CTCL). Blood2018;132(Supp 1):2901. [DOI: 10.1182/blood-2018-99-118473]CowanR , ScarisbrickJ , DwyerK , LeoniM , GrebennikD , MorrisS . Mogamulizumab demonstrates significant improvement in PFS compared to vorinostat in patients with previously treated cutaneous T-cell lymphoma (CTCL). British Journal of Haematology2018;181(S1):77–8. [DOI: 10.1111/bjh.15226]KimYH , BagotM , Pinter-BrownL , RookAH , PorcuP , HorwitzSM , et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncology2018;19(9):1192-1204. [PMID: 30100375]NCT01728805. Study of KW-0761 versus vorinostat in relapsed/refractory CTCL. clinicaltrials.gov/ct2/show/NCT01728805 (first received 20 November 2012). PorcuP , HudgensS , QuaglinoP , CowanR , FlodenL , LeoniM , et al. Quality of life in cutaneous T-cell lymphoma subjects treated with anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat: results from the phase 3 MAVORIC trial. Journal of Clinical Oncology2018;36(15):-. [DOI: 10.1097/HS9.0000000000000060]QuaglinoP , HudgensS , PorcuP , CowanR , FlodenL , TsianakasA , et al. Quality of life in cutaneous t-cell lymphoma subjects treated with the anti-ccr4 monoclonal antibody mogamulizumab versus vorinostat: results from the phase 3 mavoric trial. Hemasphere2018;2(S1):85. ScarisbrickJ , ZinzaniPL , HorwitzS , KimYH , MoskowitzAJ , PorcuP , et al. Efficacy of mogamulizumab by prior systemic therapy in patients with previously treated cutaneous T-cell lymphoma: Post hoc analysis from the phase 3 MAVORIC study. British Journal of Haematology2019;185(Suppl 1):94. TsianakasA , QuaglinoP , HudgensS , FlodenL , LeoniM , DaleS , et al. Quality of life in cutaneous T-cell lymphoma subjects treated with the anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat: Results from the phase 3 MAVORIC trial. Oncology Research and Treatment2018;41(Suppl 4):272. ZinzaniPL , HorwitzSM , KimYH , MoskowitzAJ , PorcuP , ScarisbrickJ , et al. Efficacy of mogamulizumab by prior systemic therapy in patients with previously treated cutaneous T-cell lymphoma: post hoc analysis from the phase 3 mavoric study. Blood2018;132(Suppl 1):1619. [DOI: 10.1182/blood-2018-99-114819]">Kim 2018</a>; <a href="./references#CD008946-bbs2-0018" title="NCT00056056. Ultraviolet light therapy using methoxsalen with or without Bexarotene in treating patients with mycosis fungoides. clinicaltrials.gov/ct2/show/NCT00056056 (first received 7 March 2003). WhittakerS , OrtizP , DummerR , RankiA , HasanB , MeulemansB , et al. Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial 21011 (NCT00056056). British Journal of Dermatology2012;167(3):678-87. [CENTRAL: CN-00856432] [PMID: 22924950]WhittakerS , Ortiz-RomeroPL , DummerR , RankiA , HasanB , MeulemansB , et al. Efficacy and safety of bexarotene combined with psoralen/ultraviolet A light (PUVA) compared to PUVA treatment alone in stage IB-IIa mycosis fungoides (MF): Final results from EORTC cutaneous lymphoma task force (CLTF) phase III clinical trial 21011. Journal of Clinical Oncology2012;30(15 Suppl 1):8076. ">Whittaker 2012</a>). Due to the special study design of <a href="./references#CD008946-bbs2-0016" title="NCT01686594. A multi-center, randomized study on oral 8-methoxypsoralen plus UVA with or without maintenance therapy in mycosis fungoides EORTC/ISCL stage IA to IIB. clinicaltrials.gov/ct2/show/NCT01686594 (first received 18 September 2012). Vieyra-GarciaP , Fink-PuchesR , PorkertS , LangR , PöchlauerS , RatzingerG , et al. Evaluation of low-dose, low-frequency oral psoralen-UV-A treatment with or without maintenance on early-stage mycosis fungoides: A randomized clinical trial. JAMA Dermatology2019;155(5):538-47. [PMID: 30892603]">Vieyra‐Garcia 2019</a>, relapse equates to disease‐free survival (see below). </p> <p><a href="./references#CD008946-bbs2-0007" title="KayeF , EddyJ , IhdeDC , SteinbergS , FischmannAB , GlatsteinE , et al. Conservative vs. aggressive therapy in mycosis fungoides. Proceedings of the American Society of Clinical Oncology1989;8:257. [CENTRAL: CN-00694960] KayeF , IhdeD , FischmannA , GlatsteinE , MinnaJ , SchechterG , et al. A randomized trial comparing conservative and aggressive therapy in mycosis fungoides (MF). Proceedings of the American Society of Clinical Oncology1986;5:195. [CENTRAL: CN-00695166] KayeFJ , BunnPA , SteinbergSM , StockerJL , IhdeDC , FischmannAB , et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. New England Journal of Medicine1989;321(26):1784-90. [CENTRAL: CN-00064211] [PMID: 2594037]">Kaye 1989</a>, <a href="./references#CD008946-bbs2-0016" title="NCT01686594. A multi-center, randomized study on oral 8-methoxypsoralen plus UVA with or without maintenance therapy in mycosis fungoides EORTC/ISCL stage IA to IIB. clinicaltrials.gov/ct2/show/NCT01686594 (first received 18 September 2012). Vieyra-GarciaP , Fink-PuchesR , PorkertS , LangR , PöchlauerS , RatzingerG , et al. Evaluation of low-dose, low-frequency oral psoralen-UV-A treatment with or without maintenance on early-stage mycosis fungoides: A randomized clinical trial. JAMA Dermatology2019;155(5):538-47. [PMID: 30892603]">Vieyra‐Garcia 2019</a> and <a href="./references#CD008946-bbs2-0020" title="WozniakMB , TraceyL , Ortiz-RomeroPL , MontesS , AlvarezM , FragaJ , et al. Psoralen plus ultraviolet A +/- interferon-alpha treatment resistance in mycosis fungoides: the role of tumour microenvironment, nuclear transcription factor-kappaB and T-cell receptor pathways. British Journal of Dermatology2008;160(1):92-102. [CENTRAL: CN-00668828] [PMID: 18945306]">Wozniak 2008</a> examined disease‐free survival. </p> <p>Survival rates were the subject of eight studies (<a href="./references#CD008946-bbs2-0002" title="ChildFJ , MitchellTJ , WhittakerSJ , ScarisbrickJJ , SeedPT , Russel-JonesR . A randomized cross-over study to compare PUVA and extracorporeal photopheresis in the treatment of plaque stage (T2) mycosis fungoides. Clinical &amp; Experimental Dermatology2004;29(3):231-6. [CENTRAL: CN-00468455] [PMID: 15115499]ChildFJ , MitchellTJ , WhittakerSJ , WatkinsP , SeedP , Russell-JonesR . A randomised cross-over study to compare Puva and extracorporeal photopheresis (ECP) in the treatment of plaque stage (T2) mycosis fungoides. British Journal of Dermatology2001;145(Suppl 59):16. [CENTRAL: CN-00430854] ">Child 2004</a>; <a href="./references#CD008946-bbs2-0005" title="DuvicM , OlsenEA , OmuraGA , MaizeJC , VonderheidEC , et al. A phase III, randomized, double-blind, placebo-controlled study of peldesine (BCX-34) cream as topical therapy for cutaneous T-cell lymphoma. Journal of the American Academy of Dermatology2001;44(6):940-7. [CENTRAL: CN-00348073] [PMID: 11369904]">Duvic 2001a</a>; <a href="./references#CD008946-bbs2-0006" title="GuitartJ , TuckerR , StevensV . Low dose bexarotene (Targretin®) capsules and phototherapy for early stage cutaneous T-Cell lymphoma. Journal of Investigative Dermatology2002;119(1):241. [CENTRAL: CN-00794450] NCT00030589. A muliticenter, dose-randomized evaluation of Targretin capsules plus PUVA in patients with stage IB - IIA cutaneous T-Cell lymphoma. clinicaltrials.gov/ct/show/NCT00030589 (first received 27 Jaunry 2003). ">Guitart 2002</a>; <a href="./references#CD008946-bbs2-0007" title="KayeF , EddyJ , IhdeDC , SteinbergS , FischmannAB , GlatsteinE , et al. Conservative vs. aggressive therapy in mycosis fungoides. Proceedings of the American Society of Clinical Oncology1989;8:257. [CENTRAL: CN-00694960] KayeF , IhdeD , FischmannA , GlatsteinE , MinnaJ , SchechterG , et al. A randomized trial comparing conservative and aggressive therapy in mycosis fungoides (MF). Proceedings of the American Society of Clinical Oncology1986;5:195. [CENTRAL: CN-00695166] KayeFJ , BunnPA , SteinbergSM , StockerJL , IhdeDC , FischmannAB , et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. New England Journal of Medicine1989;321(26):1784-90. [CENTRAL: CN-00064211] [PMID: 2594037]">Kaye 1989</a>; <a href="./references#CD008946-bbs2-0010" title="DuvicM , KuzelTM , OlsenEA , MartinAG , FossFM , KimYH , et al. Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK). Clinical Lymphoma2002;2(4):222-8. [CENTRAL: CN-00514479] [PMID: 11970761]KuzelT , OlsenE , MartinA , KimY , DuvicM , FrankelA , et al. Pivotal phase III trial of two dose levels of DAB389IL-2 (Ontak®) for the treatment of mycosis fungoides (MF). Blood1997;90(10 Suppl 1 (Pt 1)):586a. [CENTRAL: CN-00518069] NTC00050999. Study of ONTAK (Denileukin Diftitox) in cutaneous T-Cell lymphoma (CTCL) patients. clinicaltrials.gov/ct2/show/NCT00050999 (first received 3 January 2003). OlsenE , DuvicM , FrankelA , KimY , MartinA , VonderheidE , et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. Journal of Clinical Oncology2001;19(2):376-88. [CENTRAL: CN-00328506] [PMID: 11208829]OlsenE , DuvicM , MartinA . Pivotal phase III trial of two dose levels of DAB 389 IL-2 (ONTAK) for the treatment of cutaneous T-cell lymphoma (CTCL). Journal of Investigative Dermatology1998;110(4):678. [CENTRAL: CN-00353452] ">Olsen 2001</a>; <a href="./references#CD008946-bbs2-0012" title="RookAH , WoodGS , DuvicM , VonderheidEC , TobiaA , CabanaB . A phase II placebo-controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis. Journal of the American Academy of Dermatology2010;63(6):984-90. [CENTRAL: CN-00772559] [PMID: 20889234]">Rook 2010</a>; <a href="./references#CD008946-bbs2-0015" title="Thestrup-PedersenK , GrunnetE , ZachariaeH . Transfer factor therapy in mycosis fungoides: a double-blind study. Acta Dermato-Venereologica1982;62(1):47-53. [CENTRAL: CN-00027377] [PMID: 6175137]">Thestrup‐Pedersen 1982</a>; <a href="./references#CD008946-bbs2-0018" title="NCT00056056. Ultraviolet light therapy using methoxsalen with or without Bexarotene in treating patients with mycosis fungoides. clinicaltrials.gov/ct2/show/NCT00056056 (first received 7 March 2003). WhittakerS , OrtizP , DummerR , RankiA , HasanB , MeulemansB , et al. Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial 21011 (NCT00056056). British Journal of Dermatology2012;167(3):678-87. [CENTRAL: CN-00856432] [PMID: 22924950]WhittakerS , Ortiz-RomeroPL , DummerR , RankiA , HasanB , MeulemansB , et al. Efficacy and safety of bexarotene combined with psoralen/ultraviolet A light (PUVA) compared to PUVA treatment alone in stage IB-IIa mycosis fungoides (MF): Final results from EORTC cutaneous lymphoma task force (CLTF) phase III clinical trial 21011. Journal of Clinical Oncology2012;30(15 Suppl 1):8076. ">Whittaker 2012</a>). However, this outcome was not evaluable in <a href="./references#CD008946-bbs2-0018" title="NCT00056056. Ultraviolet light therapy using methoxsalen with or without Bexarotene in treating patients with mycosis fungoides. clinicaltrials.gov/ct2/show/NCT00056056 (first received 7 March 2003). WhittakerS , OrtizP , DummerR , RankiA , HasanB , MeulemansB , et al. Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial 21011 (NCT00056056). British Journal of Dermatology2012;167(3):678-87. [CENTRAL: CN-00856432] [PMID: 22924950]WhittakerS , Ortiz-RomeroPL , DummerR , RankiA , HasanB , MeulemansB , et al. Efficacy and safety of bexarotene combined with psoralen/ultraviolet A light (PUVA) compared to PUVA treatment alone in stage IB-IIa mycosis fungoides (MF): Final results from EORTC cutaneous lymphoma task force (CLTF) phase III clinical trial 21011. Journal of Clinical Oncology2012;30(15 Suppl 1):8076. ">Whittaker 2012</a>. </p> <p>Objective response rate (ORR) was measured in 13 studies (<a href="./references#CD008946-bbs2-0003" title="ChongA , LooWJ , BanneyL , GrantJW , NorrisPG . Imiquimod 5% cream in the treatment of mycosis fungoides - a pilot study. Journal of Dermatological Treatment2004;15(2):118-9. [CENTRAL: CN-00467258] [PMID: 15204164]">Chong 2004</a>; <a href="./references#CD008946-bbs2-0004" title="DuvicM , MartinAG , KimY , OlsenE , WoodGS , CrowleyCA , et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Archives of Dermatology2001;137(5):581-93. [CENTRAL: CN-00347816] [PMID: 11346336]PrinceHM , McCormackC , RyanG , BakerC , RotsteinH , DavisonJ , et al. Bexarotene capsules and gel for previously treated patients with cutaneous T-cell lymphoma: results of the Australian patients treated on phase II trials. Australasian Journal of Dermatology2001;42(2):91-7. [CENTRAL: CN-00442169] [PMID: 11309029]">Duvic 2001</a>; <a href="./references#CD008946-bbs2-0005" title="DuvicM , OlsenEA , OmuraGA , MaizeJC , VonderheidEC , et al. A phase III, randomized, double-blind, placebo-controlled study of peldesine (BCX-34) cream as topical therapy for cutaneous T-cell lymphoma. Journal of the American Academy of Dermatology2001;44(6):940-7. [CENTRAL: CN-00348073] [PMID: 11369904]">Duvic 2001a</a>; <a href="./references#CD008946-bbs2-0006" title="GuitartJ , TuckerR , StevensV . Low dose bexarotene (Targretin®) capsules and phototherapy for early stage cutaneous T-Cell lymphoma. Journal of Investigative Dermatology2002;119(1):241. [CENTRAL: CN-00794450] NCT00030589. A muliticenter, dose-randomized evaluation of Targretin capsules plus PUVA in patients with stage IB - IIA cutaneous T-Cell lymphoma. clinicaltrials.gov/ct/show/NCT00030589 (first received 27 Jaunry 2003). ">Guitart 2002</a>; <a href="./references#CD008946-bbs2-0007" title="KayeF , EddyJ , IhdeDC , SteinbergS , FischmannAB , GlatsteinE , et al. Conservative vs. aggressive therapy in mycosis fungoides. Proceedings of the American Society of Clinical Oncology1989;8:257. [CENTRAL: CN-00694960] KayeF , IhdeD , FischmannA , GlatsteinE , MinnaJ , SchechterG , et al. A randomized trial comparing conservative and aggressive therapy in mycosis fungoides (MF). Proceedings of the American Society of Clinical Oncology1986;5:195. [CENTRAL: CN-00695166] KayeFJ , BunnPA , SteinbergSM , StockerJL , IhdeDC , FischmannAB , et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. New England Journal of Medicine1989;321(26):1784-90. [CENTRAL: CN-00064211] [PMID: 2594037]">Kaye 1989</a>; <a href="./references#CD008946-bbs2-0008" title="BagotM , DalleS , SokolL , TsianakasA , MusiekA , Ortiz-RomeroP , et al. Long-term clinical benefit to anti-CCR4 mogamulizumab: results from the phase 3 mavoric study in previously treated cutaneous t-cell lymphoma (CTCL). Blood2018;132(Supp 1):2901. [DOI: 10.1182/blood-2018-99-118473]CowanR , ScarisbrickJ , DwyerK , LeoniM , GrebennikD , MorrisS . Mogamulizumab demonstrates significant improvement in PFS compared to vorinostat in patients with previously treated cutaneous T-cell lymphoma (CTCL). British Journal of Haematology2018;181(S1):77–8. [DOI: 10.1111/bjh.15226]KimYH , BagotM , Pinter-BrownL , RookAH , PorcuP , HorwitzSM , et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncology2018;19(9):1192-1204. [PMID: 30100375]NCT01728805. Study of KW-0761 versus vorinostat in relapsed/refractory CTCL. clinicaltrials.gov/ct2/show/NCT01728805 (first received 20 November 2012). PorcuP , HudgensS , QuaglinoP , CowanR , FlodenL , LeoniM , et al. Quality of life in cutaneous T-cell lymphoma subjects treated with anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat: results from the phase 3 MAVORIC trial. Journal of Clinical Oncology2018;36(15):-. [DOI: 10.1097/HS9.0000000000000060]QuaglinoP , HudgensS , PorcuP , CowanR , FlodenL , TsianakasA , et al. Quality of life in cutaneous t-cell lymphoma subjects treated with the anti-ccr4 monoclonal antibody mogamulizumab versus vorinostat: results from the phase 3 mavoric trial. Hemasphere2018;2(S1):85. ScarisbrickJ , ZinzaniPL , HorwitzS , KimYH , MoskowitzAJ , PorcuP , et al. Efficacy of mogamulizumab by prior systemic therapy in patients with previously treated cutaneous T-cell lymphoma: Post hoc analysis from the phase 3 MAVORIC study. British Journal of Haematology2019;185(Suppl 1):94. TsianakasA , QuaglinoP , HudgensS , FlodenL , LeoniM , DaleS , et al. Quality of life in cutaneous T-cell lymphoma subjects treated with the anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat: Results from the phase 3 MAVORIC trial. Oncology Research and Treatment2018;41(Suppl 4):272. ZinzaniPL , HorwitzSM , KimYH , MoskowitzAJ , PorcuP , ScarisbrickJ , et al. Efficacy of mogamulizumab by prior systemic therapy in patients with previously treated cutaneous T-cell lymphoma: post hoc analysis from the phase 3 mavoric study. Blood2018;132(Suppl 1):1619. [DOI: 10.1182/blood-2018-99-114819]">Kim 2018</a>; <a href="./references#CD008946-bbs2-0009" title="LessinS , DuvicM , GuitartJ , PandyaA , StroberB , OlsenE , et al. Positive results of a pivotal phase ii trial testing a manufactured 0.02% Mechlorethamine gel in mycosis fungoides (mf). Journal of Investigative Dermatology2011;131(Suppl 1):S84. [CENTRAL: CN-00843792] LessinSR , DuvicM , GuitartJ , PandyaAG , StroberBE , OlsenEA , et al. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatology2013;149(1):25-32. [CENTRAL: CN-00859487] [PMID: 23069814]NCT00168064. Safety and efficacy of nitrogen mustard in treatment of mycosis fungoides. clinicaltrials.gov/ct2/show/NCT00168064 (first received 14 September 2005). ">Lessin 2013</a>; <a href="./references#CD008946-bbs2-0010" title="DuvicM , KuzelTM , OlsenEA , MartinAG , FossFM , KimYH , et al. Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK). Clinical Lymphoma2002;2(4):222-8. [CENTRAL: CN-00514479] [PMID: 11970761]KuzelT , OlsenE , MartinA , KimY , DuvicM , FrankelA , et al. Pivotal phase III trial of two dose levels of DAB389IL-2 (Ontak®) for the treatment of mycosis fungoides (MF). Blood1997;90(10 Suppl 1 (Pt 1)):586a. [CENTRAL: CN-00518069] NTC00050999. Study of ONTAK (Denileukin Diftitox) in cutaneous T-Cell lymphoma (CTCL) patients. clinicaltrials.gov/ct2/show/NCT00050999 (first received 3 January 2003). OlsenE , DuvicM , FrankelA , KimY , MartinA , VonderheidE , et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. Journal of Clinical Oncology2001;19(2):376-88. [CENTRAL: CN-00328506] [PMID: 11208829]OlsenE , DuvicM , MartinA . Pivotal phase III trial of two dose levels of DAB 389 IL-2 (ONTAK) for the treatment of cutaneous T-cell lymphoma (CTCL). Journal of Investigative Dermatology1998;110(4):678. [CENTRAL: CN-00353452] ">Olsen 2001</a>; <a href="./references#CD008946-bbs2-0011" title="HorwitzS , WhittakerS , DuvicM , DummerR , KimYH , ScarisbrickJ , et al. Response by stage in CD30-positive (CD30+) cutaneous T cell lymphoma (CTCL) patients receiving brentuximab vedotin (BV) vs physician's choice (PC) in the phase 3 ALCANZA study. In: Hematological oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:245–7. [CENTRAL: CN-01408605] [DOI: 10.1002/hon.2438]HorwitzSM , AkilovOE , FisherD , KuzelTM , WangY , Palanca-WesselsMC , et al. Brentuximab vedotin or physician’s choice in CD30-positivecutaneous T-cell lymphoma (ALCANZA): an international,open-label, randomised, phase 3, multicentre trial. Lancet2017;390(10094):555-66. [CENTRAL: CN-01403731] HorwitzSM , ScarisbrickJJ , DummerR , DuvicM , KimYH , WalewskiJ , et al. Updated analyses of the international, open-label, randomized, phase 3 alcanza study: longer-term evidence for superiority of brentuximab vedotin versus methotrexate or bexarotene for CD30-positive cutaneous T-cell lymphoma (CTCL). In: Blood. Conference: 59th annual meeting of the american society of hematology, ASH 2017. United states. Vol. 130. 2017. [CENTRAL: CN-01450312] KimYH , PrinceHM , WhittakerS , HorwitzSM , DuvicM , ScarisbrickJ , et al. Brentuximab vedotin vs physician's choice in CTCL patients from the phase 3 ALCANZA study: analysis of outcomes by CD30 expression. In: Hematological Oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:77–8. [CENTRAL: CN-01408482] [DOI: 10.1002/hon.2437]KimYH , PrinceHM , WhittakerS , HorwitzSM , DuvicM , ScarisbrickJ , et al. Outcomes by CD30 expression in patients with CTCL receiving brentuximab vedotin (BV) vs physician's choice (PC) in the Phase 3 ALCANZA study. Journal of Clinical Oncology2017;35(15 Supplement 1):7517. [EMBASE: 617388795]KimYH , WhittakerS , DummerR , GeskinLJ , GauthierP , LittleM , et al. Phase 3 study of brentuximab vedotin versus physician's choice of methotrexate or bexarotene in patients (PTS) with CD30-positive (CD30+) cutaneous T-cell lymphoma (CTCL). The alcanza study. Hematological Oncology2013;31(Suppl 1):278. [CENTRAL: CN-01531598] [EMBASE: 71147875]KimYH , WhittakerS , HorwitzSM , DuvicM , DummerR , ScarisbrickJ , et al. Brentuximab vedotin demonstrates superior activity to standard therapy in CD30-expressing (CD30+) cutaneous T-cell lymphoma (CTCL) in the randomized phase 3 ALCANZA study. Journal of Investigative Dermatology2017;137(5 Suppl 1):S45. [CENTRAL: CN-01375469] [EMBASE: 616393777]KimYH , WhittakerS , HorwitzSM , DuvicM , DummerR , ScarisbrickJJ , et al. Brentuximab vedotin demonstrates significantly superior clinical outcomes in patients with CD30-expressing cutaneous T cell lymphoma versus physician's choice (Methotrexate or Bexarotene): the phase 3 alcanza study. In: Blood. Conference: 58th annual meeting of the american society of hematology, ASH 2016. United states. Conference start: 20161203. Conference end: 20161206. Vol. 128. 2016. [CENTRAL: CN-01303081] [EMBASE: 614225065]NCT01578499. A randomised, open-label, phase 3 trial of brentuximab vedotin (SGN-35) versus physician's choice (methotrexate or bexarotene) in patients with CD30-positive cutaneous T-cell lymphoma. clinicaltrials.gov/ct2/show/NCT01578499 (first received 17 April 2012). PrinceHM , DummerR , WhittakerS , HorwitzS , DuvicM , ScarisbrickJ , et al. Patient-reported outcomes and quality of life in patients with cutaneous T cell lymphoma: results from the phase 3 ALCANZA study. In: Hematological Oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:247–8. [CENTRAL: CN-01408603] [DOI: 10.1002/hon.2438]ZagadailovE , PrinceHM , WhittakerS , HorwitzS , DuvicM , KimY , et al. Phase 3 alcanza study of brentuximab vedotin (BV) or physician's choice (PC) of methotrexate (MTX) or bexarotene (BEX) in CD30-positive cutaneous T-cell lymphoma (CTCL): number needed to treat analysis. In: Haematologica. Conference: 22th congress of the european hematology association. Spain. Vol. 102. 2017:251. [CENTRAL: CN-01399195] ">Prince 2017</a>; <a href="./references#CD008946-bbs2-0012" title="RookAH , WoodGS , DuvicM , VonderheidEC , TobiaA , CabanaB . A phase II placebo-controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis. Journal of the American Academy of Dermatology2010;63(6):984-90. [CENTRAL: CN-00772559] [PMID: 20889234]">Rook 2010</a>; <a href="./references#CD008946-bbs2-0013" title="OtteHG , KuhlS , StadlerR , LugerT , HenzB , SterryW . Treatment of cutaneous T-cell lymphoma with Interferon alpha and PUVA versus Interferon alpha and Acitretin - results of a prospective randomised multi-centre study [Behandlung des kutanen T-Zell-Lymphoms mit Interferon alpha und PUVA versus Interferon alpha und Acirentin - Ergebnisse einer prospektiv-randomisierten Multicenter-Studie]. Der Hautarzt1997;48(Suppl):S97. [CENTRAL: CN-00495120] OtteHG , StadierR , LugerT , HenzB , SterryW . Open controlled clinical trial on the use of interferon plus acitretin versus interferon plus PUVA in patients with cutaneous T-cell lymphoma (CTCL). Annals of Oncology1996;7(Suppl 3):66. [CENTRAL: CN-00308243] StadlerR , OtteHG , LugerT , HenzBM , KuhlP , ZwingersT , et al. Prospective randomized multicenter clinical trial on the use of interferon -2a plus acitretin versus interferon -2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood1998;92(10):3578-81. [CENTRAL: CN-00156682] [PMID: 9808550]">Stadler 1998</a>; <a href="./references#CD008946-bbs2-0015" title="Thestrup-PedersenK , GrunnetE , ZachariaeH . Transfer factor therapy in mycosis fungoides: a double-blind study. Acta Dermato-Venereologica1982;62(1):47-53. [CENTRAL: CN-00027377] [PMID: 6175137]">Thestrup‐Pedersen 1982</a>; <a href="./references#CD008946-bbs2-0018" title="NCT00056056. Ultraviolet light therapy using methoxsalen with or without Bexarotene in treating patients with mycosis fungoides. clinicaltrials.gov/ct2/show/NCT00056056 (first received 7 March 2003). WhittakerS , OrtizP , DummerR , RankiA , HasanB , MeulemansB , et al. Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial 21011 (NCT00056056). British Journal of Dermatology2012;167(3):678-87. [CENTRAL: CN-00856432] [PMID: 22924950]WhittakerS , Ortiz-RomeroPL , DummerR , RankiA , HasanB , MeulemansB , et al. Efficacy and safety of bexarotene combined with psoralen/ultraviolet A light (PUVA) compared to PUVA treatment alone in stage IB-IIa mycosis fungoides (MF): Final results from EORTC cutaneous lymphoma task force (CLTF) phase III clinical trial 21011. Journal of Clinical Oncology2012;30(15 Suppl 1):8076. ">Whittaker 2012</a>). In <a href="./references#CD008946-bbs2-0013" title="OtteHG , KuhlS , StadlerR , LugerT , HenzB , SterryW . Treatment of cutaneous T-cell lymphoma with Interferon alpha and PUVA versus Interferon alpha and Acitretin - results of a prospective randomised multi-centre study [Behandlung des kutanen T-Zell-Lymphoms mit Interferon alpha und PUVA versus Interferon alpha und Acirentin - Ergebnisse einer prospektiv-randomisierten Multicenter-Studie]. Der Hautarzt1997;48(Suppl):S97. [CENTRAL: CN-00495120] OtteHG , StadierR , LugerT , HenzB , SterryW . Open controlled clinical trial on the use of interferon plus acitretin versus interferon plus PUVA in patients with cutaneous T-cell lymphoma (CTCL). Annals of Oncology1996;7(Suppl 3):66. [CENTRAL: CN-00308243] StadlerR , OtteHG , LugerT , HenzBM , KuhlP , ZwingersT , et al. Prospective randomized multicenter clinical trial on the use of interferon -2a plus acitretin versus interferon -2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood1998;92(10):3578-81. [CENTRAL: CN-00156682] [PMID: 9808550]">Stadler 1998</a>, this outcome was not assessable due to not fulfilling the criteria of <a href="./references#CD008946-bbs2-0157" title="OlsenEA , WhittakerS , KimYH , DuvicM , PrinceHM , LessinSR , et al. Clinical end points and response criteria in mycosis fungoides and Sezary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. Journal of Clinical Oncology2011;29(18):2598-607. [PMID: 21576639]">Olsen 2011</a>. </p> <p>Rare adverse effects were described in five studies (<a href="./references#CD008946-bbs2-0002" title="ChildFJ , MitchellTJ , WhittakerSJ , ScarisbrickJJ , SeedPT , Russel-JonesR . A randomized cross-over study to compare PUVA and extracorporeal photopheresis in the treatment of plaque stage (T2) mycosis fungoides. Clinical &amp; Experimental Dermatology2004;29(3):231-6. [CENTRAL: CN-00468455] [PMID: 15115499]ChildFJ , MitchellTJ , WhittakerSJ , WatkinsP , SeedP , Russell-JonesR . A randomised cross-over study to compare Puva and extracorporeal photopheresis (ECP) in the treatment of plaque stage (T2) mycosis fungoides. British Journal of Dermatology2001;145(Suppl 59):16. [CENTRAL: CN-00430854] ">Child 2004</a>; <a href="./references#CD008946-bbs2-0003" title="ChongA , LooWJ , BanneyL , GrantJW , NorrisPG . Imiquimod 5% cream in the treatment of mycosis fungoides - a pilot study. Journal of Dermatological Treatment2004;15(2):118-9. [CENTRAL: CN-00467258] [PMID: 15204164]">Chong 2004</a>; <a href="./references#CD008946-bbs2-0004" title="DuvicM , MartinAG , KimY , OlsenE , WoodGS , CrowleyCA , et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Archives of Dermatology2001;137(5):581-93. [CENTRAL: CN-00347816] [PMID: 11346336]PrinceHM , McCormackC , RyanG , BakerC , RotsteinH , DavisonJ , et al. Bexarotene capsules and gel for previously treated patients with cutaneous T-cell lymphoma: results of the Australian patients treated on phase II trials. Australasian Journal of Dermatology2001;42(2):91-7. [CENTRAL: CN-00442169] [PMID: 11309029]">Duvic 2001</a>; <a href="./references#CD008946-bbs2-0006" title="GuitartJ , TuckerR , StevensV . Low dose bexarotene (Targretin®) capsules and phototherapy for early stage cutaneous T-Cell lymphoma. Journal of Investigative Dermatology2002;119(1):241. [CENTRAL: CN-00794450] NCT00030589. A muliticenter, dose-randomized evaluation of Targretin capsules plus PUVA in patients with stage IB - IIA cutaneous T-Cell lymphoma. clinicaltrials.gov/ct/show/NCT00030589 (first received 27 Jaunry 2003). ">Guitart 2002</a>; <a href="./references#CD008946-bbs2-0010" title="DuvicM , KuzelTM , OlsenEA , MartinAG , FossFM , KimYH , et al. Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK). Clinical Lymphoma2002;2(4):222-8. [CENTRAL: CN-00514479] [PMID: 11970761]KuzelT , OlsenE , MartinA , KimY , DuvicM , FrankelA , et al. Pivotal phase III trial of two dose levels of DAB389IL-2 (Ontak®) for the treatment of mycosis fungoides (MF). Blood1997;90(10 Suppl 1 (Pt 1)):586a. [CENTRAL: CN-00518069] NTC00050999. Study of ONTAK (Denileukin Diftitox) in cutaneous T-Cell lymphoma (CTCL) patients. clinicaltrials.gov/ct2/show/NCT00050999 (first received 3 January 2003). OlsenE , DuvicM , FrankelA , KimY , MartinA , VonderheidE , et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. Journal of Clinical Oncology2001;19(2):376-88. [CENTRAL: CN-00328506] [PMID: 11208829]OlsenE , DuvicM , MartinA . Pivotal phase III trial of two dose levels of DAB 389 IL-2 (ONTAK) for the treatment of cutaneous T-cell lymphoma (CTCL). Journal of Investigative Dermatology1998;110(4):678. [CENTRAL: CN-00353452] ">Olsen 2001</a>). </p> <p>Definition of complete or partial response and quantitative assessment of clearance were very heterogeneous among the included studies. </p> <p>Outcomes were generally assessed by physicians. Improvement of quality of life was the only patient‐reported outcome. </p> <p>Time point of outcome assessment varied among the included studies due to the number and variety of interventions, their different administration routes as well as their different mechanisms of action. </p> </section> <section id="CD008946-sec-0075"> <h5 class="title">Study duration</h5> <p>The duration of the studies varied widely (four weeks to 12 months, except one study lasting more than six years). This was, in part, related to the clinical stage of disease and outcomes to be observed, for example, time to first response or survival. Some studies continued treatment until an optimal response was achieved. The longest study was <a href="./references#CD008946-bbs2-0007" title="KayeF , EddyJ , IhdeDC , SteinbergS , FischmannAB , GlatsteinE , et al. Conservative vs. aggressive therapy in mycosis fungoides. Proceedings of the American Society of Clinical Oncology1989;8:257. [CENTRAL: CN-00694960] KayeF , IhdeD , FischmannA , GlatsteinE , MinnaJ , SchechterG , et al. A randomized trial comparing conservative and aggressive therapy in mycosis fungoides (MF). Proceedings of the American Society of Clinical Oncology1986;5:195. [CENTRAL: CN-00695166] KayeFJ , BunnPA , SteinbergSM , StockerJL , IhdeDC , FischmannAB , et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. New England Journal of Medicine1989;321(26):1784-90. [CENTRAL: CN-00064211] [PMID: 2594037]">Kaye 1989</a>, with a median period from enrolment to analysis of 75.3 months (range 25.9 to 118.2 months). </p> </section> </section> <section id="CD008946-sec-0076"> <h4 class="title">Excluded studies</h4> <p>In the initial review we excluded 150 studies after reading the full text. These were mostly (122) excluded because they were not RCTs, which was identified in the full text (121) or after author contact (<a href="./references#CD008946-bbs2-0056" title="OlsenEA , DiabNG . Interferon alfa-2A in the treatment of cutaneous T cell lymphoma. Journal of Investigative Dermatology1986;86(4):498. ">Olsen 1986</a>). We excluded 15 studies as they enrolled &lt; 90% participants with Alibert‐Bazin type MF with no subgroup analysis available (<a href="./references#CD008946-bbs2-0027" title="CooperIA , WolfMM , RobertsonTI , FoxRM , MatthewsJP , StoneJM , et al. Randomized comparison of MACOP-B with CHOP in patients with intermediate-grade non-Hodgkin's lymphoma. The Australian and New Zealand Lymphoma Group. Journal of Clinical Oncology1994;12(4):769-78. ">Cooper 1994</a>; <a href="./references#CD008946-bbs2-0028" title="CurrieVE , KempinSJ , YoungCW . Phase I trial of metoprine in patients with advanced cancer. Cancer Treatment Reports1980;64(8-9):951-6. ">Currie 1980</a>; <a href="./references#CD008946-bbs2-0029" title="DangNH , ProB , HagemeisterFB , SamaniegoF , JonesD , SamuelsBI , et al. Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma. British Journal of Haematology2007;136(3):439-47. [PMID: 17233846]">Dang 2007</a>; <a href="./references#CD008946-bbs2-0030" title="DoanCA , WisemanBK , BouroncleBA . Clinical evaluation of CB 1348 in leukemias and lymphomas. Annals of the New York Academy of Sciences1958;68(3):979-95. ">Doan 1958</a>; <a href="./references#CD008946-bbs2-0031" title="DueckG , ChuaN , PrasadA , FinchD , StewartD , WhiteD , et al. Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma. Cancer2010;116(19):4541-8. ">Dueck 2010</a>; <a href="./references#CD008946-bbs2-0034" title="FisherRI , GaynorER , DahlbergS , OkenMM , GroganTM , MizeEM , et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. New England Journal of Medicine1993;328(14):1002-6. ">Fisher 1993</a>; <a href="./references#CD008946-bbs2-0039" title="KaungDT , WittingtonRM , SpencerH , PatnoME . Comparison of chlorambucil and streptonigrin (NSC-45383) in the treatment of malignant lymphomas. Cancer1969;23(6):1280-3. ">Kaung 1969</a>; <a href="./references#CD008946-bbs2-0041" title="KuzelT . Correlates of capillary leak syndrome (CLS) in patients with cutaneous T-cell lymphoma (CTCL) during treatment with denileukin diftitox (DD) in a placebo (PBO)-controlled phase III trial. Journal of Clinical Oncology2010;28(15 Suppl):e18509. ">Kuzel 2010</a>; <a href="./references#CD008946-bbs2-0053" title="NeeringH , KroonHV , van derRoeleveldCG . Treatment of localized skin lesions with betamethasone 17-valerate and triamcinolone acetonide in alcoholic solution under occlusive dressing. A double blind comparative study. Dermatologica1972;145(6):395-9. ">Neering 1972</a>; <a href="./references#CD008946-bbs2-0021" title="No authors listed. Comparison of the use of teniposide and vincristine in combination chemotherapy for non-Hodgkin's lymphoma. Cancer Treatment Reports1982;66(1):49-55. ">Anonymous 1982</a>; <a href="./references#CD008946-bbs2-0060" title="PrinceHM , DuvicM , MartinA , SterryW , AssafC , SunY , et al. Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. Journal of Clinical Oncology2010;28(11):1870-7. [PMID: 20212249]">Prince 2010</a>; <a href="./references#CD008946-bbs2-0064" title="SimonA , PeochM , CasassusP , DeconinckE , ColombatP , DesablensB , et al. Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95. British Journal of Haematology2010;151(2):159-66. [PMID: 20738307]">Simon 2010</a>; <a href="./references#CD008946-bbs2-0065" title="ThomsenK . Scandinavian mycosis fungoides study group. Bulletin du Cancer1977;64(2):287-90. [PMID: 912132]">Thomsen 1977</a>; <a href="./references#CD008946-bbs2-0070" title="WiernikPH , MooreDF , BennettJM , VoglSE , HarrisJE , LugerS , et al. Phase II study of mitoguazone, cyclophosphamide, doxorubicin, vincristine and prednisone for patients with diffuse histologic subtypes of non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group Study (PE481). Leukemia &amp; Lymphoma1998;30(5-6):601-7. ">Wiernik 1998</a>; <a href="./references#CD008946-bbs2-0072" title="ZubrodCG , SchneidermanM , FreiE , BrindleyC , GoldGL , ShniderB , et al. Appraisal of methods for the study of chemotherapy of cancer in man: Comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide. Journal of Chronic Diseases1960;11(1):7-33. ">Zubrod 1960</a>). We excluded four RCTs since they did not report any relevant outcome as set in the trial protocol (<a href="./references#CD008946-bbs2-0023" title="ArgyropoulosCL , LambergSI , ClendenningWE , FischmannAB , JegasothyB , ZackheimH , et al. Preliminary evaluation of 15 chemotherapeutic agents applied topically in the treatment of mycosis fungoides. Cancer Treatment Reports1979;63(4):619-21. ">Argyropoulos 1979</a>; <a href="./references#CD008946-bbs2-0026" title="BrenemanDL , NartkerAL , BallmanEA , PruemerJM , BlumsackRF , DavisM , et al. Topical mechlorethamine in the treatment of mycosis fungoides. Uniformity of application and potential for environmental contamination. Journal of the American Academy of Dermatology1991;25(6 Pt 1):1059-64. ">Breneman 1991</a>; <a href="./references#CD008946-bbs2-0043" title="LansiganF , FossFM . Rate of infection and immunosuppression in two phase III studies of denileukin diftitox (DD) in cutaneous T-cell lymphoma (CTCL). Journal of Clinical Oncology2010;28(15 Suppl):e18515. ">Lansigan 2010</a>; <a href="./references#CD008946-bbs2-0061" title="Schrag H-J, DippelE , GoerdtS , OrfanosCE . Extracorporal photophoresis (ECP) + Interferon-alpha 2a vs. ECP in patients with cutaneous T-cell lymphoma. Evaluation using a new score (CTCL-SI). Der Hautarzt1997;48(Suppl):S96. ">Schrag 1997</a>). We excluded eight studies after attempts to contact corresponding authors (because of insufficient data for abstraction) were unsuccessful (<a href="./references#CD008946-bbs2-0033" title="FawziM , El MoftyM , RamadanS , HegazyR , SayedS . Broadband UVA versus PUVA in the treatment of early stage mycosis fungoides: a comparative study. Melanoma Research2010;20:e85. [DOI: 10.1097/01.cmr.0000382933.41435.dc]">Fawzi 2010</a>; <a href="./references#CD008946-bbs2-0038" title="JapicCTI-050041. Post-marketing clinical study of Ogamma 100 in patients with mycosis fungoides. www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-050041 (first received 12 September 2005). ">JapicCTI‐050041</a>; <a href="./references#CD008946-bbs2-0040" title="KujawskaA , AbrouA , FivensonDP , LimHW . PUVA vs. PUVA and interferon alpha for treatment of mycosis fungoides. Journal of Investigative Dermatology2003;121(1):1185. ">Kujawska 2003</a>; <a href="./references#CD008946-bbs2-0047" title="NCT00054171. Photodynamic therapy in treating patients with lymphoma or chronic lymphocytic leukemia. clinicaltrials.gov/ct2/show/NCT00054171 (first received 6 February 2003). ">NCT00054171</a>; <a href="./references#CD008946-bbs2-0054" title="Negro-VilarA , DziewanowskaZ , GrovesES , StevensV , ZhangJK , PrinceM , et al. Efficacy and safety of denileukin diftitox (Dd) in a phase III, double-blind, placebo-controlled study of CD25+ patients with cutaneous T-cell lymphoma (CTCL). Journal of Clinical Oncology2007;25(18 Suppl):8026. ">Negro‐Vilar 2007</a>; <a href="./references#CD008946-bbs2-0057" title="PanY , PrinceHM , EllisL , CulverK . LBH589, a novel deacetylase inhibitor (DACi), in the treatment of cutaneous T-cell lymphoma (CTCL): changes in tumor gene expression profiles related to clinical response after therapy. In: 11th World Congress on Cancers of the Skin. 2007 June 8-11. Amsterdam, The Netherlands. 2007:Abstract 00172. ">Pan 2007</a>; <a href="./references#CD008946-bbs2-0059" title="PlettenbergH , StegeH , MegahedT , RuzickaT , HosokawaY , TsujiT , et al. UVA1-Phototherapie versus PUVA-Photochemotherapie in der Behandlung von Patienten mit kutanem T-Zell-Lymphom (CTCL). Zeitschrift für Hautkrankheiten2001;76(Suppl 1):S96. ">Plettenberg 2001</a>; <a href="./references#CD008946-bbs2-0069" title="WainEM , WhittakerSJ , Russell-JonesR . A randomized, open, crossover study to compare the efficacy of extracorporeal photopheresis with methotrexate in the treatment of erythrodermic primary cutaneous T-cell lymphoma. British Journal of Dermatology2005;153(Suppl 1):10. ">Wain 2005</a>). We excluded the RCT by <a href="./references#CD008946-bbs2-0058" title="PeugeotRL . Clinical efficacy of a novel purine nucleoside phosphorylase inhibitor (BCX-34) in the treatment of cutaneous T-cell lymphoma. Journal of Investigative Dermatology1995;104(4):563. ">Peugeot 1995</a> because of scientific fraud (<a href="./references#CD008946-bbs2-0121" title="GrantB . Biotech Baddies. The Scientist2009;23(4):48.">Grant 2009</a>). </p> <p>In this update we excluded 23 studies after reading the full text (<a href="#CD008946-fig-0002">Figure 2</a>). We excluded 18 studies because they were not RCTs (<a href="./references#CD008946-bbs2-0022" title="Anonymous. Bexarotene (Targretin) for cutaneous T-cell lymphoma. Medical Letter on Drugs and Therapeutics2000;42(1075):31-2. [PMID: 10788961]">Anonymous 2000</a>; <a href="./references#CD008946-bbs2-0024" title="AvilesA , NeriN , Fernandez-DiezJ , SilvaL , NamboMJ . Interferon and low doses of methotrexate versus interferon and retinoids in the treatment of refractory/relapsed cutaneous T-cell lymphoma. Hematology2015;20(9):538–42. [PMID: 25592781]">Aviles 2015</a>; <a href="./references#CD008946-bbs2-0025" title="BazexA , De MouzonJ , BazexJ . Not available [Expérimentation du Dipropionate de Bétaméthazone en application locale]. Revue de Medecine de Toulouse1975;11:1137-47. ">Bazex 1975</a>; <a href="./references#CD008946-bbs2-0032" title="DuvicM , MartinA , OlsenEA , FivensonD , PrinceM . Efficacy of denileukin diftitox retreatment in patients with cutaneous T-cell lymphoma who relapsed after initial response. Blood2010;116(21):2863. ">Duvic 2010</a>; <a href="./references#CD008946-bbs2-0035" title="FossF , DuvicM , OlsenEA . Predictors of complete responses with denileukin diftitox in cutaneous T-cell lymphoma. American Journal of Hematology2011;86(7):627-30. ">Foss 2011</a>; <a href="./references#CD008946-bbs2-0037" title="HealdP , MehlmauerM , MartinAG , CrowleyCA , YocumRC , ReichSD , et al. Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: Results of the phase III clinical trial. Journal of the American Academy of Dermatology2003;49(5):801–15. [DOI: 10.1067/S0190-9622(3)01475-0] [PMID: 14576658]">Heald 2003</a>; <a href="./references#CD008946-bbs2-0042" title="LambertD , BousserAM , DalacS , GodardW , LepinoyD , HoriotJC . Mycosis fungoides and radiotherapy. Value of combined total skin electron therapy and whole-body photon therapy. Annales de Dermatologie et de Venereologie1986;113(6-7):541–7. [PMID: 3545028]">Lambert 1986</a>; <a href="./references#CD008946-bbs2-0044" title="LoescherL , KesslerJ , JonesS , MeyskensF , LevineN , SauerK . 13-Cis retinoic acid as treatment for mycosis fungoides: Clinical results of a phase II trial. Federation Proceedings1984;43(4):3896. ">Loescher 1984</a>; <a href="./references#CD008946-bbs2-0045" title="MarsdenCW . Fluocinolone acetonide 0.2 per cent cream--a co-operative clinical trial. British Journal of Dermatology1968;80(9):614-7. [PMID: 4877599]">Marsden 1968</a>; <a href="./references#CD008946-bbs2-0046" title="MoogR . Therapeutic apheresis - Many ways to go. Transfusion Medicine and Hemotherapy2008;35(1):5-6. [PMID: 21547104]">Moog 2008</a>; <a href="./references#CD008946-bbs2-0048" title="NCT00091208. A phase I/II open label, multi-center study for the evaluation of Pf-3512676 (CPG 7909) in patients with stage Ib to Iva cutaneous T-Cell lymphoma. clinicaltrials.gov/ct2/show/NCT00091208 (first received 12 August 2002). [NCT00091208]">NCT00091208</a>; <a href="./references#CD008946-bbs2-0055" title="O'NeillB , GeskinL , StoryS . Novel combination therapy for the treatment of cutaneous T-cell lymphoma. Journal of the American Academy of Dermatology2013;68(4 Suppl 1):AB147. ">O'Neill 2013</a>; <a href="./references#CD008946-bbs2-0062" title="SerriF , De SimoneC , VenierA , RuscianiL , MarchettiF . Combination of retinoids and PUVA (Re-PUVA) in the treatment of cutaneous T cell lymphomas. Current Problems in Dermatology1990;19:252-7. [PMID: 2404681]">Serri 1990</a>; <a href="./references#CD008946-bbs2-0063" title="ShiY , DongM , ZhuJ , ZhouD , HuangH , TuP , et al. Phase II study of chidamide, a new subtype-selective oral histone deacetylase inhibitor, in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood2015;126(23):1513. ">Shi 2015</a>; <a href="./references#CD008946-bbs2-0066" title="ThomsenK . Scandinavian mycosis fungoides trial. Cancer Treatment Reports1979;63(4):709–11. [PMID: 445520]">Thomsen 1979</a>; <a href="./references#CD008946-bbs2-0067" title="ThomsenK , HammarH , MolinL , VoldenG . Retinoids plus PUVA (RePUVA) and PUVA in mycosis fungoides, plaque stage. Acta Dermato-Venereologica1989;69(6):536-8. ">Thomsen 1989</a>; <a href="./references#CD008946-bbs2-0068" title="TouraineR , RevuzJ . Topical chemotherapy in mycosis fungoides [Chimiotherapie locale du mycosis fongoide: Dermatologica]. Dermatologica1978;157(6):397-406. ">Touraine 1978</a>; <a href="./references#CD008946-bbs2-0071" title="WilsonLD , LicataAL , BravermanIM , EdelsonRL , HealdPW , FeldmanAM , et al. Systemic chemotherapy and extracorporeal photochemotherapy for T3 and T4 cutaneous T-cell lymphoma patients who have achieved a complete response to total skin electron beam therapy. International Journal of Radiation Oncology, Biology, Physics1995;32(4):987–95. [PMID: 7607973]">Wilson 1995</a>). We excluded one study (<a href="./references#CD008946-bbs2-0036" title="GrothO , MolinL , ThomsenK . Tumour stage of mycosis fungoides treated with bleomycin and methotrexate: report from the Scandinavian mycosis fungoides study group. Acta Dermato-Venereologica1979;59(1):59–63. [PMID: 84469]">Groth 1979</a>) as it enrolled &lt; 90% participants with Alibert‐Bazin type MF. From the ongoing trials in the initial review, one trial (<a href="./references#CD008946-bbs2-0050" title="NCT01187446. Low-dose (12 Gy) TSEBT+Vorinostat versus low-dose TSEBT monotherapy in mycosis fungoides. clinicaltrials.gov/ct2/show/NCT01187446 (first received 24 August 2010). ">NCT01187446</a>) was terminated with the following reason given: "business decision". We contacted the principal investigator for results of the trial but did not receive a reply. Another clinical trial (<a href="./references#CD008946-bbs2-0052" title="NCT01625455. Effect of Neurokinin-1 Receptor (NK1R) antagonism on pruritus in patients with Sezary syndrome. clinicaltrials.gov/ct2/show/NCT01625455 (first received 21 June 2012). ">NCT01625455</a>) was terminated due to difficulty recruiting. One trial was excluded due to being withdrawn prior to enrolment (<a href="./references#CD008946-bbs2-0051" title="NCT01386398. Vorinostat with or without Bortezomib in treating patients with refractory or recurrent stage IIB, stage III, or stage IV cutaneous T-Cell lymphoma. clinicaltrials.gov/ct2/show/NCT01386398 (first received 1 July 2011). ">NCT01386398</a>). We excluded <a href="./references#CD008946-bbs2-0049" title="NCT01007448. Study evaluating two dose levels of Targretin capsules in patients with refractory cutaneous T-cell lymphoma (CTCL). clinicaltrials.gov/ct2/show/NCT01007448 (first received 4 November 2009). ">NCT01007448</a> due to insufficient data as we contacted the authors but were unable to obtain any results. Further details are provided in the '<a href="./references#CD008946-sec-0234" title="">Characteristics of excluded studies</a>' tables. </p> <section id="CD008946-sec-0077"> <h5 class="title">Ongoing trials</h5> <p>Five of the ongoing trials identified in the initial review have been published in the meantime and were included in this update (NCT01098656 ➝ <a href="./references#CD008946-bbs2-0001" title="BagotM , HasanB , WhittakerS , Beylot-BarryM , KnoblerR , ShahE , et al. A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma - EORTC 21081 (NCT01098656): results and lessons learned for future trial designs. European Journal of Dermatology2017;27(3):286–94. [CENTRAL: CN-01395486] [PMID: 28468739]NCT01098656. A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-Cell lymphoma. clinicaltrials.gov/ct2/show/NCT01098656 (first received 5 April 2010). [NCT01098656]">Bagot 2017</a>; NCT01728805 ➝ <a href="./references#CD008946-bbs2-0008" title="BagotM , DalleS , SokolL , TsianakasA , MusiekA , Ortiz-RomeroP , et al. Long-term clinical benefit to anti-CCR4 mogamulizumab: results from the phase 3 mavoric study in previously treated cutaneous t-cell lymphoma (CTCL). Blood2018;132(Supp 1):2901. [DOI: 10.1182/blood-2018-99-118473]CowanR , ScarisbrickJ , DwyerK , LeoniM , GrebennikD , MorrisS . Mogamulizumab demonstrates significant improvement in PFS compared to vorinostat in patients with previously treated cutaneous T-cell lymphoma (CTCL). British Journal of Haematology2018;181(S1):77–8. [DOI: 10.1111/bjh.15226]KimYH , BagotM , Pinter-BrownL , RookAH , PorcuP , HorwitzSM , et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncology2018;19(9):1192-1204. [PMID: 30100375]NCT01728805. Study of KW-0761 versus vorinostat in relapsed/refractory CTCL. clinicaltrials.gov/ct2/show/NCT01728805 (first received 20 November 2012). PorcuP , HudgensS , QuaglinoP , CowanR , FlodenL , LeoniM , et al. Quality of life in cutaneous T-cell lymphoma subjects treated with anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat: results from the phase 3 MAVORIC trial. Journal of Clinical Oncology2018;36(15):-. [DOI: 10.1097/HS9.0000000000000060]QuaglinoP , HudgensS , PorcuP , CowanR , FlodenL , TsianakasA , et al. Quality of life in cutaneous t-cell lymphoma subjects treated with the anti-ccr4 monoclonal antibody mogamulizumab versus vorinostat: results from the phase 3 mavoric trial. Hemasphere2018;2(S1):85. ScarisbrickJ , ZinzaniPL , HorwitzS , KimYH , MoskowitzAJ , PorcuP , et al. Efficacy of mogamulizumab by prior systemic therapy in patients with previously treated cutaneous T-cell lymphoma: Post hoc analysis from the phase 3 MAVORIC study. British Journal of Haematology2019;185(Suppl 1):94. TsianakasA , QuaglinoP , HudgensS , FlodenL , LeoniM , DaleS , et al. Quality of life in cutaneous T-cell lymphoma subjects treated with the anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat: Results from the phase 3 MAVORIC trial. Oncology Research and Treatment2018;41(Suppl 4):272. ZinzaniPL , HorwitzSM , KimYH , MoskowitzAJ , PorcuP , ScarisbrickJ , et al. Efficacy of mogamulizumab by prior systemic therapy in patients with previously treated cutaneous T-cell lymphoma: post hoc analysis from the phase 3 mavoric study. Blood2018;132(Suppl 1):1619. [DOI: 10.1182/blood-2018-99-114819]">Kim 2018</a>; NCT00168064 ➝ <a href="./references#CD008946-bbs2-0009" title="LessinS , DuvicM , GuitartJ , PandyaA , StroberB , OlsenE , et al. Positive results of a pivotal phase ii trial testing a manufactured 0.02% Mechlorethamine gel in mycosis fungoides (mf). Journal of Investigative Dermatology2011;131(Suppl 1):S84. [CENTRAL: CN-00843792] LessinSR , DuvicM , GuitartJ , PandyaAG , StroberBE , OlsenEA , et al. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatology2013;149(1):25-32. [CENTRAL: CN-00859487] [PMID: 23069814]NCT00168064. Safety and efficacy of nitrogen mustard in treatment of mycosis fungoides. clinicaltrials.gov/ct2/show/NCT00168064 (first received 14 September 2005). ">Lessin 2013</a>; NCT01686594 ➝ <a href="./references#CD008946-bbs2-0016" title="NCT01686594. A multi-center, randomized study on oral 8-methoxypsoralen plus UVA with or without maintenance therapy in mycosis fungoides EORTC/ISCL stage IA to IIB. clinicaltrials.gov/ct2/show/NCT01686594 (first received 18 September 2012). Vieyra-GarciaP , Fink-PuchesR , PorkertS , LangR , PöchlauerS , RatzingerG , et al. Evaluation of low-dose, low-frequency oral psoralen-UV-A treatment with or without maintenance on early-stage mycosis fungoides: A randomized clinical trial. JAMA Dermatology2019;155(5):538-47. [PMID: 30892603]">Vieyra‐Garcia 2019</a>; NCT00056056 ➝ <a href="./references#CD008946-bbs2-0018" title="NCT00056056. Ultraviolet light therapy using methoxsalen with or without Bexarotene in treating patients with mycosis fungoides. clinicaltrials.gov/ct2/show/NCT00056056 (first received 7 March 2003). WhittakerS , OrtizP , DummerR , RankiA , HasanB , MeulemansB , et al. Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial 21011 (NCT00056056). British Journal of Dermatology2012;167(3):678-87. [CENTRAL: CN-00856432] [PMID: 22924950]WhittakerS , Ortiz-RomeroPL , DummerR , RankiA , HasanB , MeulemansB , et al. Efficacy and safety of bexarotene combined with psoralen/ultraviolet A light (PUVA) compared to PUVA treatment alone in stage IB-IIa mycosis fungoides (MF): Final results from EORTC cutaneous lymphoma task force (CLTF) phase III clinical trial 21011. Journal of Clinical Oncology2012;30(15 Suppl 1):8076. ">Whittaker 2012</a>). </p> <p>Furthermore, we were able to identify 13 new ongoing trials.</p> <p> <ul id="CD008946-list-0015"> <li> <p><a href="./references#CD008946-bbs2-0075" title="NCT01738594. Dose-escalation trial of carfilzomib with and without Romidepsin in cutaneous T-cell lymphoma. clinicaltrials.gov/ct2/show/NCT01738594 (first received 30 November 2012). ">NCT01738594</a> (carfilzomib IV versus carfilzomib IV and romidepsin IV) </p> </li> <li> <p><a href="./references#CD008946-bbs2-0076" title="DuvicM , KimYH , LeBoeufNR , PorcuP , HastingsJ , BassunerJ , et al. A phase 2 randomized study of SHAPE Gel (SHP-141) in patients with early-stage cutaneous T-cell lymphoma: Interim results. Journal of Clinical Oncology2016;34(15 Suppl):7562. [DOI: 10.1200/JCO.2016.34]NCT02213861. Efficacy, safety and tolerability study of SHAPE in IA, IB or IIA cutaneous T-cell lymphoma. clinicaltrials.gov/ct2/show/NCT02213861 (first received 12 August 2014). ">NCT02213861</a> (1.0% SHAPE gelled solution once daily versus 0.5% SHAPE gelled solution twice daily versus 1.0% SHAPE gelled solution twice daily) </p> </li> <li> <p><a href="./references#CD008946-bbs2-0077" title="NCT02301494. Effectiveness of imiquimod topical cream in early stage cutaneous T-cell lymphoma (CTCL). clinicaltrials.gov/ct2/show/NCT02301494 (first received 26 November 2014). ">NCT02301494</a> (fluocinonide (Vanos) cream 0.1% versus 3.75% imiquimod (Zyclara) cream) </p> </li> <li> <p><a href="./references#CD008946-bbs2-0078" title="NCT02323659. Comparison of methotrexate versus interferon-alfa 2b in patients with primary cutaneous T-cell lymphomas. clinicaltrials.gov/ct2/show/NCT02323659 (first received 23 December 2014). ">NCT02323659</a> (methotrexate versus interferon alfa‐2b) </p> </li> <li> <p><a href="./references#CD008946-bbs2-0079" title="NCT02448381. FLASH [Fluorescent Light Activated Synthetic Hypericin] clinical study: topical SGX301 (synthetic hypericin) for the treatment of cutaneous T-cell lymphoma (mycosis fungoides). clinicaltrials.gov/ct2/show/NCT02448381 (first received 19 May 2015). ">NCT02448381</a> (topical SGC301, a topical photosensitising agent, versus placebo) </p> </li> <li> <p><a href="./references#CD008946-bbs2-0080" title="NCT02811783. Naloxone hydrochloride study for relief of pruritus in patients with MF or SS forms of CTCL. clinicaltrials.gov/ct2/show/NCT02811783 (first received 23 June 2016). ">NCT02811783</a> (naloxone hydrochloride lotion 0.5% versus placebo) </p> </li> <li> <p><a href="./references#CD008946-bbs2-0081" title="NCT02943642. Safety and effectiveness of A-dmDT390-bisFv(UCHT1) fusion protein in subjects with mycosis fungoides (Resimmune®). clinicaltrials.gov/ct2/show/NCT02943642 (first received 25 October 2016). ">NCT02943642</a> (A‐dmDT390‐bisFv(UCHT1) versus vorinostat) </p> </li> <li> <p><a href="./references#CD008946-bbs2-0082" title="NCT02953301. Resminostat for maintenance treatment of patients with advanced stage mycosis fungoides (MF) or Sézary syndrome (SS) (RESMAIN). clinicaltrials.gov/ct2/show/NCT02953301 (first received 2 November 2016). StadlerR , ScarisbrickJ , KnoblerR , QuaglinoP , BorgmannM , OrloviusM , et al. A multicentre, double blind, randomised, placebo controlled, Phase II trial to evaluate Resminostat for maintenance treatment of patients with advanced stage (Stage IIB-IVB) mycosis fungoides (MF) or Sezary Syndrome (SS) that have achieved disease control with systemic therapy-the RESMAIN Study. Journal of the European Academy of Dermatology and Venereology2017;31(Suppl 3):50. StadlerR , ScarisbrickJ , KnoblerR , QuaglinoP , BorgmannM , OrloviusM , et al. A multicentre, double blind, randomised, placebo-controlled, Phase II trial to evaluate Resminostat for maintenance treatment of patients with advanced stage (Stage IIB-IVB) mycosis fungoides (MF) or Sezary Syndrome (SS) that have achieved disease control with systemic therapy: The RESMAIN Study. Journal der Deutschen Dermatologischen Gesellschaft [Journal of the German Society of Dermatology]2017;15(Suppl 3):74–5. [DOI: 10.1111/ddg.13300]">NCT02953301</a> (resminostat versus placebo) </p> </li> <li> <p><a href="./references#CD008946-bbs2-0083" title="NCT03011814. Durvalumab with or without lenalidomide in treating patients with relapsed or refractory cutaneous or peripheral T cell lymphoma. clinicaltrials.gov/ct2/show/NCT03011814 (first received 5 January 2017). ">NCT03011814</a> (durvalumab IV versus durvalumab IV plus lenalidomide) </p> </li> <li> <p><a href="./references#CD008946-bbs2-0084" title="NCT03292406. A safety, efficacy and pharmacokinetics study of CD11301 for the treatment of cutaneous T-cell lymphoma (CTCL) (CTCL). clinicaltrials.gov/ct2/show/NCT03292406 (first received 25 September 2017). ">NCT03292406</a> (placebo followed by CD11301 (0.03%) topical gel versus CD11301 (0.03%) topical gel versus CD11301 (0.06%) topical gel) </p> </li> <li> <p><a href="./references#CD008946-bbs2-0085" title="NCT03454945. Efficacy of doxycycline in the treatment of early stages of mycosis fungoides: A randomized controlled trial. clinicaltrials.gov/ct2/show/NCT03454945 (first received 6 March 2018). ">NCT03454945</a> (vibramycin versus UVA + psoralen) </p> </li> <li> <p><a href="./references#CD008946-bbs2-0086" title="NCT03713320. SOLAR: A phase 2, randomized, open-label, parallel-group, active comparator, multi-center study to investigate the efficacy and safety of cobomarsen (MRG-106) in subjects with cutaneous T-cell lymphoma (CTCL), mycosis fungoides (MF) subtype. clinicaltrials.gov/ct2/show/NCT03713320 (first received 17 October 2018). ">NCT03713320</a> (cobomarsen versus vorinostat) </p> </li> <li> <p><a href="./references#CD008946-bbs2-0087" title="UMIN000029537. Efficacy and safety of Targretin capsule 75-mg alone or in combination with phototherapy in Japanese patients with cutaneous T-cell lymphomas. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000033748 (date first received 16 October 2017). ">UMIN000029537</a> (bexarotene alone versus bexarotene plus phototherapy) </p> </li> </ul> </p> <p>Furher details are presented in the '<a href="./references#CD008946-sec-0236" title="">Characteristics of ongoing studies</a>' section. </p> </section> <section id="CD008946-sec-0078"> <h5 class="title">Studies awaiting classification</h5> <p>In the initial review, we identified two studies (<a href="./references#CD008946-bbs2-0035" title="FossF , DuvicM , OlsenEA . Predictors of complete responses with denileukin diftitox in cutaneous T-cell lymphoma. American Journal of Hematology2011;86(7):627-30. ">Foss 2011</a>; <a href="./references#CD008946-bbs2-0143" title="LessinS , DuvicM , GuitartJ , PandyaA , StroberB , OlsenE , et al. Positive results of a pivotal phase ii trial testing a manufactured 0.02% Mechlorethamine gel in mycosis fungoides (mf). Journal of Investigative Dermatology2011;131(Suppl 1):S84. [CENTRAL: CN-00843792]">Lessin 2011</a>), which were detailed in the <a href="./references#CD008946-sec-0235" title="">Characteristics of studies awaiting classification</a> table. Ultimately, we excluded <a href="./references#CD008946-bbs2-0035" title="FossF , DuvicM , OlsenEA . Predictors of complete responses with denileukin diftitox in cutaneous T-cell lymphoma. American Journal of Hematology2011;86(7):627-30. ">Foss 2011</a> because it did not have a RCT design. <a href="./references#CD008946-bbs2-0143" title="LessinS , DuvicM , GuitartJ , PandyaA , StroberB , OlsenE , et al. Positive results of a pivotal phase ii trial testing a manufactured 0.02% Mechlorethamine gel in mycosis fungoides (mf). Journal of Investigative Dermatology2011;131(Suppl 1):S84. [CENTRAL: CN-00843792]">Lessin 2011</a> is an excerpt from <a href="./references#CD008946-bbs2-0009" title="LessinS , DuvicM , GuitartJ , PandyaA , StroberB , OlsenE , et al. Positive results of a pivotal phase ii trial testing a manufactured 0.02% Mechlorethamine gel in mycosis fungoides (mf). Journal of Investigative Dermatology2011;131(Suppl 1):S84. [CENTRAL: CN-00843792] LessinSR , DuvicM , GuitartJ , PandyaAG , StroberBE , OlsenEA , et al. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatology2013;149(1):25-32. [CENTRAL: CN-00859487] [PMID: 23069814]NCT00168064. Safety and efficacy of nitrogen mustard in treatment of mycosis fungoides. clinicaltrials.gov/ct2/show/NCT00168064 (first received 14 September 2005). ">Lessin 2013</a>, which was included in this update. </p> <p>We identified three studies (<a href="./references#CD008946-bbs2-0073" title="BasheyS , TavallaeeM , DuvicM , DabajaB , TalpurR , WilsonL , et al. A multicenter, open-label, randomized, phase I/II study evaluating the safety and efficacy of low-dose (12 Gy) total skin electron beam therapy (TSEBT) combined with vorinostat versus low-dose TSEBT monotherapy in patients with mycosis fungoides. Journal of Investigative Dermatology2014;134(Suppl 1):S104. [DOI: doi.org/10.1038/jid.2014.109]">Bashey 2014</a>; <a href="./references#CD008946-bbs2-0074" title="KimYH , KrathenM , DuvicM , WongH , PorcuP , TacastacasJ , et al. A phase 1b study in cutaneous T-cell lymphoma (CTCL) with the novel topically applied skin-restricted histone deacteylase inhibitor (HDAC-i) SHP-141. Journal of Clinical Oncology2014;32(15 Suppl):8525. KimYH , KrathenMS , DuvicM , WongH , PorcuP , TacastacasJ , et al. Tolerability and encouraging clinical activity of SHP-141, a topical skin-restricted HDAC inhibitor, in a phase 1B study in cutaneous t-cell lymphoma. Journal of Investigative Dermatology2014;134(Suppl 1):S93. NCT01433731. Safety, pharmacodynamics (PD), pharmacokinetics (PK) study of SHP141 in 1A, 1B, or 2A cutaneous T-cell lymphoma (CTCL). clinicaltrials.gov/ct/show/NCT01433731 (first received 14 September 2011). ">Kim 2014</a>), which we detailed in the <a href="./references#CD008946-sec-0235" title="">Characteristics of studies awaiting classification</a> table. One study that we initially included in the ongoing trials section has been completed (<a href="./references#CD008946-bbs2-0074" title="KimYH , KrathenM , DuvicM , WongH , PorcuP , TacastacasJ , et al. A phase 1b study in cutaneous T-cell lymphoma (CTCL) with the novel topically applied skin-restricted histone deacteylase inhibitor (HDAC-i) SHP-141. Journal of Clinical Oncology2014;32(15 Suppl):8525. KimYH , KrathenMS , DuvicM , WongH , PorcuP , TacastacasJ , et al. Tolerability and encouraging clinical activity of SHP-141, a topical skin-restricted HDAC inhibitor, in a phase 1B study in cutaneous t-cell lymphoma. Journal of Investigative Dermatology2014;134(Suppl 1):S93. NCT01433731. Safety, pharmacodynamics (PD), pharmacokinetics (PK) study of SHP141 in 1A, 1B, or 2A cutaneous T-cell lymphoma (CTCL). clinicaltrials.gov/ct/show/NCT01433731 (first received 14 September 2011). ">Kim 2014</a>). The author stated that the results had not been published yet and that a further trial would be underway. Unpublished data were not provided. These studies will be assessed in the next update of this review. </p> </section> </section> </section> <section id="CD008946-sec-0079"> <h3 class="title">Risk of bias in included studies</h3> <p>Regarding the risk of bias in the included studies, we looked at the following seven possible sources of bias: generation of the randomisation sequence, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other source of bias. Further details are provided in the '<a href="./references#CD008946-sec-0233" title="">Characteristics of included studies</a>' tables and the 'Risk of bias' tables for each study. See also <a href="#CD008946-fig-0003">Figure 3</a> and <a href="#CD008946-fig-0004">Figure 4</a> for a graphical summary of the 'Risk of bias' components. </p> <div class="figure" id="CD008946-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD008946-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD008946-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study." data-id="CD008946-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study. </p> </div> </div> </div> <section id="CD008946-sec-0080"> <h4 class="title">Allocation</h4> <section id="CD008946-sec-0081"> <h5 class="title">Sequence generation and allocation concealment</h5> <p>We contacted the authors asking for further details about the random sequence generation and allocation concealment by the same contact procedure as when dealing with missing data, since procedures of randomisation and concealment were missing or incomplete in most included studies. In most cases we did not obtain any further information, which we classified according to the categories in the 'Risk of bias' table. The authors of one study stated that the randomisation list was generated by a statistician, who was provided by the sponsor and was not involved in the remainder of the trial (<a href="./references#CD008946-bbs2-0011" title="HorwitzS , WhittakerS , DuvicM , DummerR , KimYH , ScarisbrickJ , et al. Response by stage in CD30-positive (CD30+) cutaneous T cell lymphoma (CTCL) patients receiving brentuximab vedotin (BV) vs physician's choice (PC) in the phase 3 ALCANZA study. In: Hematological oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:245–7. [CENTRAL: CN-01408605] [DOI: 10.1002/hon.2438]HorwitzSM , AkilovOE , FisherD , KuzelTM , WangY , Palanca-WesselsMC , et al. Brentuximab vedotin or physician’s choice in CD30-positivecutaneous T-cell lymphoma (ALCANZA): an international,open-label, randomised, phase 3, multicentre trial. Lancet2017;390(10094):555-66. [CENTRAL: CN-01403731] HorwitzSM , ScarisbrickJJ , DummerR , DuvicM , KimYH , WalewskiJ , et al. Updated analyses of the international, open-label, randomized, phase 3 alcanza study: longer-term evidence for superiority of brentuximab vedotin versus methotrexate or bexarotene for CD30-positive cutaneous T-cell lymphoma (CTCL). In: Blood. Conference: 59th annual meeting of the american society of hematology, ASH 2017. United states. Vol. 130. 2017. [CENTRAL: CN-01450312] KimYH , PrinceHM , WhittakerS , HorwitzSM , DuvicM , ScarisbrickJ , et al. Brentuximab vedotin vs physician's choice in CTCL patients from the phase 3 ALCANZA study: analysis of outcomes by CD30 expression. In: Hematological Oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:77–8. [CENTRAL: CN-01408482] [DOI: 10.1002/hon.2437]KimYH , PrinceHM , WhittakerS , HorwitzSM , DuvicM , ScarisbrickJ , et al. Outcomes by CD30 expression in patients with CTCL receiving brentuximab vedotin (BV) vs physician's choice (PC) in the Phase 3 ALCANZA study. Journal of Clinical Oncology2017;35(15 Supplement 1):7517. [EMBASE: 617388795]KimYH , WhittakerS , DummerR , GeskinLJ , GauthierP , LittleM , et al. Phase 3 study of brentuximab vedotin versus physician's choice of methotrexate or bexarotene in patients (PTS) with CD30-positive (CD30+) cutaneous T-cell lymphoma (CTCL). The alcanza study. Hematological Oncology2013;31(Suppl 1):278. [CENTRAL: CN-01531598] [EMBASE: 71147875]KimYH , WhittakerS , HorwitzSM , DuvicM , DummerR , ScarisbrickJ , et al. Brentuximab vedotin demonstrates superior activity to standard therapy in CD30-expressing (CD30+) cutaneous T-cell lymphoma (CTCL) in the randomized phase 3 ALCANZA study. Journal of Investigative Dermatology2017;137(5 Suppl 1):S45. [CENTRAL: CN-01375469] [EMBASE: 616393777]KimYH , WhittakerS , HorwitzSM , DuvicM , DummerR , ScarisbrickJJ , et al. Brentuximab vedotin demonstrates significantly superior clinical outcomes in patients with CD30-expressing cutaneous T cell lymphoma versus physician's choice (Methotrexate or Bexarotene): the phase 3 alcanza study. In: Blood. Conference: 58th annual meeting of the american society of hematology, ASH 2016. United states. Conference start: 20161203. Conference end: 20161206. Vol. 128. 2016. [CENTRAL: CN-01303081] [EMBASE: 614225065]NCT01578499. A randomised, open-label, phase 3 trial of brentuximab vedotin (SGN-35) versus physician's choice (methotrexate or bexarotene) in patients with CD30-positive cutaneous T-cell lymphoma. clinicaltrials.gov/ct2/show/NCT01578499 (first received 17 April 2012). PrinceHM , DummerR , WhittakerS , HorwitzS , DuvicM , ScarisbrickJ , et al. Patient-reported outcomes and quality of life in patients with cutaneous T cell lymphoma: results from the phase 3 ALCANZA study. In: Hematological Oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:247–8. [CENTRAL: CN-01408603] [DOI: 10.1002/hon.2438]ZagadailovE , PrinceHM , WhittakerS , HorwitzS , DuvicM , KimY , et al. Phase 3 alcanza study of brentuximab vedotin (BV) or physician's choice (PC) of methotrexate (MTX) or bexarotene (BEX) in CD30-positive cutaneous T-cell lymphoma (CTCL): number needed to treat analysis. In: Haematologica. Conference: 22th congress of the european hematology association. Spain. Vol. 102. 2017:251. [CENTRAL: CN-01399195] ">Prince 2017</a>). </p> <p>The method of generation of the randomisation sequence was described in only eight of the studies. <a href="./references#CD008946-bbs2-0002" title="ChildFJ , MitchellTJ , WhittakerSJ , ScarisbrickJJ , SeedPT , Russel-JonesR . A randomized cross-over study to compare PUVA and extracorporeal photopheresis in the treatment of plaque stage (T2) mycosis fungoides. Clinical &amp; Experimental Dermatology2004;29(3):231-6. [CENTRAL: CN-00468455] [PMID: 15115499]ChildFJ , MitchellTJ , WhittakerSJ , WatkinsP , SeedP , Russell-JonesR . A randomised cross-over study to compare Puva and extracorporeal photopheresis (ECP) in the treatment of plaque stage (T2) mycosis fungoides. British Journal of Dermatology2001;145(Suppl 59):16. [CENTRAL: CN-00430854] ">Child 2004</a> used envelopes randomly allocating participants to treatment groups created by a statistician. However, regarding concealment of allocation, it was not stated whether those envelopes were sealed and opaque. <a href="./references#CD008946-bbs2-0007" title="KayeF , EddyJ , IhdeDC , SteinbergS , FischmannAB , GlatsteinE , et al. Conservative vs. aggressive therapy in mycosis fungoides. Proceedings of the American Society of Clinical Oncology1989;8:257. [CENTRAL: CN-00694960] KayeF , IhdeD , FischmannA , GlatsteinE , MinnaJ , SchechterG , et al. A randomized trial comparing conservative and aggressive therapy in mycosis fungoides (MF). Proceedings of the American Society of Clinical Oncology1986;5:195. [CENTRAL: CN-00695166] KayeFJ , BunnPA , SteinbergSM , StockerJL , IhdeDC , FischmannAB , et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. New England Journal of Medicine1989;321(26):1784-90. [CENTRAL: CN-00064211] [PMID: 2594037]">Kaye 1989</a> used stratified block randomisation without any information on concealment, while <a href="./references#CD008946-bbs2-0010" title="DuvicM , KuzelTM , OlsenEA , MartinAG , FossFM , KimYH , et al. Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK). Clinical Lymphoma2002;2(4):222-8. [CENTRAL: CN-00514479] [PMID: 11970761]KuzelT , OlsenE , MartinA , KimY , DuvicM , FrankelA , et al. Pivotal phase III trial of two dose levels of DAB389IL-2 (Ontak®) for the treatment of mycosis fungoides (MF). Blood1997;90(10 Suppl 1 (Pt 1)):586a. [CENTRAL: CN-00518069] NTC00050999. Study of ONTAK (Denileukin Diftitox) in cutaneous T-Cell lymphoma (CTCL) patients. clinicaltrials.gov/ct2/show/NCT00050999 (first received 3 January 2003). OlsenE , DuvicM , FrankelA , KimY , MartinA , VonderheidE , et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. Journal of Clinical Oncology2001;19(2):376-88. [CENTRAL: CN-00328506] [PMID: 11208829]OlsenE , DuvicM , MartinA . Pivotal phase III trial of two dose levels of DAB 389 IL-2 (ONTAK) for the treatment of cutaneous T-cell lymphoma (CTCL). Journal of Investigative Dermatology1998;110(4):678. [CENTRAL: CN-00353452] ">Olsen 2001</a> only mentioned stratification of participants by stage of CTCL for this multicentre trial. The statements that data management (<a href="./references#CD008946-bbs2-0005" title="DuvicM , OlsenEA , OmuraGA , MaizeJC , VonderheidEC , et al. A phase III, randomized, double-blind, placebo-controlled study of peldesine (BCX-34) cream as topical therapy for cutaneous T-cell lymphoma. Journal of the American Academy of Dermatology2001;44(6):940-7. [CENTRAL: CN-00348073] [PMID: 11369904]">Duvic 2001a</a>) or randomisation through a central institution stratified by pre‐treatment (<a href="./references#CD008946-bbs2-0013" title="OtteHG , KuhlS , StadlerR , LugerT , HenzB , SterryW . Treatment of cutaneous T-cell lymphoma with Interferon alpha and PUVA versus Interferon alpha and Acitretin - results of a prospective randomised multi-centre study [Behandlung des kutanen T-Zell-Lymphoms mit Interferon alpha und PUVA versus Interferon alpha und Acirentin - Ergebnisse einer prospektiv-randomisierten Multicenter-Studie]. Der Hautarzt1997;48(Suppl):S97. [CENTRAL: CN-00495120] OtteHG , StadierR , LugerT , HenzB , SterryW . Open controlled clinical trial on the use of interferon plus acitretin versus interferon plus PUVA in patients with cutaneous T-cell lymphoma (CTCL). Annals of Oncology1996;7(Suppl 3):66. [CENTRAL: CN-00308243] StadlerR , OtteHG , LugerT , HenzBM , KuhlP , ZwingersT , et al. Prospective randomized multicenter clinical trial on the use of interferon -2a plus acitretin versus interferon -2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood1998;92(10):3578-81. [CENTRAL: CN-00156682] [PMID: 9808550]">Stadler 1998</a>) were conducted by third parties led us to conclude that randomisation was concealed for these two studies. Two studies used an interactive voice response system for randomly assigning the patients into the treatment arms (<a href="./references#CD008946-bbs2-0008" title="BagotM , DalleS , SokolL , TsianakasA , MusiekA , Ortiz-RomeroP , et al. Long-term clinical benefit to anti-CCR4 mogamulizumab: results from the phase 3 mavoric study in previously treated cutaneous t-cell lymphoma (CTCL). Blood2018;132(Supp 1):2901. [DOI: 10.1182/blood-2018-99-118473]CowanR , ScarisbrickJ , DwyerK , LeoniM , GrebennikD , MorrisS . Mogamulizumab demonstrates significant improvement in PFS compared to vorinostat in patients with previously treated cutaneous T-cell lymphoma (CTCL). British Journal of Haematology2018;181(S1):77–8. [DOI: 10.1111/bjh.15226]KimYH , BagotM , Pinter-BrownL , RookAH , PorcuP , HorwitzSM , et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncology2018;19(9):1192-1204. [PMID: 30100375]NCT01728805. Study of KW-0761 versus vorinostat in relapsed/refractory CTCL. clinicaltrials.gov/ct2/show/NCT01728805 (first received 20 November 2012). PorcuP , HudgensS , QuaglinoP , CowanR , FlodenL , LeoniM , et al. Quality of life in cutaneous T-cell lymphoma subjects treated with anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat: results from the phase 3 MAVORIC trial. Journal of Clinical Oncology2018;36(15):-. [DOI: 10.1097/HS9.0000000000000060]QuaglinoP , HudgensS , PorcuP , CowanR , FlodenL , TsianakasA , et al. Quality of life in cutaneous t-cell lymphoma subjects treated with the anti-ccr4 monoclonal antibody mogamulizumab versus vorinostat: results from the phase 3 mavoric trial. Hemasphere2018;2(S1):85. ScarisbrickJ , ZinzaniPL , HorwitzS , KimYH , MoskowitzAJ , PorcuP , et al. Efficacy of mogamulizumab by prior systemic therapy in patients with previously treated cutaneous T-cell lymphoma: Post hoc analysis from the phase 3 MAVORIC study. British Journal of Haematology2019;185(Suppl 1):94. TsianakasA , QuaglinoP , HudgensS , FlodenL , LeoniM , DaleS , et al. Quality of life in cutaneous T-cell lymphoma subjects treated with the anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat: Results from the phase 3 MAVORIC trial. Oncology Research and Treatment2018;41(Suppl 4):272. ZinzaniPL , HorwitzSM , KimYH , MoskowitzAJ , PorcuP , ScarisbrickJ , et al. Efficacy of mogamulizumab by prior systemic therapy in patients with previously treated cutaneous T-cell lymphoma: post hoc analysis from the phase 3 mavoric study. Blood2018;132(Suppl 1):1619. [DOI: 10.1182/blood-2018-99-114819]">Kim 2018</a> and <a href="./references#CD008946-bbs2-0011" title="HorwitzS , WhittakerS , DuvicM , DummerR , KimYH , ScarisbrickJ , et al. Response by stage in CD30-positive (CD30+) cutaneous T cell lymphoma (CTCL) patients receiving brentuximab vedotin (BV) vs physician's choice (PC) in the phase 3 ALCANZA study. In: Hematological oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:245–7. [CENTRAL: CN-01408605] [DOI: 10.1002/hon.2438]HorwitzSM , AkilovOE , FisherD , KuzelTM , WangY , Palanca-WesselsMC , et al. Brentuximab vedotin or physician’s choice in CD30-positivecutaneous T-cell lymphoma (ALCANZA): an international,open-label, randomised, phase 3, multicentre trial. Lancet2017;390(10094):555-66. [CENTRAL: CN-01403731] HorwitzSM , ScarisbrickJJ , DummerR , DuvicM , KimYH , WalewskiJ , et al. Updated analyses of the international, open-label, randomized, phase 3 alcanza study: longer-term evidence for superiority of brentuximab vedotin versus methotrexate or bexarotene for CD30-positive cutaneous T-cell lymphoma (CTCL). In: Blood. Conference: 59th annual meeting of the american society of hematology, ASH 2017. United states. Vol. 130. 2017. [CENTRAL: CN-01450312] KimYH , PrinceHM , WhittakerS , HorwitzSM , DuvicM , ScarisbrickJ , et al. Brentuximab vedotin vs physician's choice in CTCL patients from the phase 3 ALCANZA study: analysis of outcomes by CD30 expression. In: Hematological Oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:77–8. [CENTRAL: CN-01408482] [DOI: 10.1002/hon.2437]KimYH , PrinceHM , WhittakerS , HorwitzSM , DuvicM , ScarisbrickJ , et al. Outcomes by CD30 expression in patients with CTCL receiving brentuximab vedotin (BV) vs physician's choice (PC) in the Phase 3 ALCANZA study. Journal of Clinical Oncology2017;35(15 Supplement 1):7517. [EMBASE: 617388795]KimYH , WhittakerS , DummerR , GeskinLJ , GauthierP , LittleM , et al. Phase 3 study of brentuximab vedotin versus physician's choice of methotrexate or bexarotene in patients (PTS) with CD30-positive (CD30+) cutaneous T-cell lymphoma (CTCL). The alcanza study. Hematological Oncology2013;31(Suppl 1):278. [CENTRAL: CN-01531598] [EMBASE: 71147875]KimYH , WhittakerS , HorwitzSM , DuvicM , DummerR , ScarisbrickJ , et al. Brentuximab vedotin demonstrates superior activity to standard therapy in CD30-expressing (CD30+) cutaneous T-cell lymphoma (CTCL) in the randomized phase 3 ALCANZA study. Journal of Investigative Dermatology2017;137(5 Suppl 1):S45. [CENTRAL: CN-01375469] [EMBASE: 616393777]KimYH , WhittakerS , HorwitzSM , DuvicM , DummerR , ScarisbrickJJ , et al. Brentuximab vedotin demonstrates significantly superior clinical outcomes in patients with CD30-expressing cutaneous T cell lymphoma versus physician's choice (Methotrexate or Bexarotene): the phase 3 alcanza study. In: Blood. Conference: 58th annual meeting of the american society of hematology, ASH 2016. United states. Conference start: 20161203. Conference end: 20161206. Vol. 128. 2016. [CENTRAL: CN-01303081] [EMBASE: 614225065]NCT01578499. A randomised, open-label, phase 3 trial of brentuximab vedotin (SGN-35) versus physician's choice (methotrexate or bexarotene) in patients with CD30-positive cutaneous T-cell lymphoma. clinicaltrials.gov/ct2/show/NCT01578499 (first received 17 April 2012). PrinceHM , DummerR , WhittakerS , HorwitzS , DuvicM , ScarisbrickJ , et al. Patient-reported outcomes and quality of life in patients with cutaneous T cell lymphoma: results from the phase 3 ALCANZA study. In: Hematological Oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:247–8. [CENTRAL: CN-01408603] [DOI: 10.1002/hon.2438]ZagadailovE , PrinceHM , WhittakerS , HorwitzS , DuvicM , KimY , et al. Phase 3 alcanza study of brentuximab vedotin (BV) or physician's choice (PC) of methotrexate (MTX) or bexarotene (BEX) in CD30-positive cutaneous T-cell lymphoma (CTCL): number needed to treat analysis. In: Haematologica. Conference: 22th congress of the european hematology association. Spain. Vol. 102. 2017:251. [CENTRAL: CN-01399195] ">Prince 2017</a>) and one study used a computerised randomisation service not otherwise specified (<a href="./references#CD008946-bbs2-0016" title="NCT01686594. A multi-center, randomized study on oral 8-methoxypsoralen plus UVA with or without maintenance therapy in mycosis fungoides EORTC/ISCL stage IA to IIB. clinicaltrials.gov/ct2/show/NCT01686594 (first received 18 September 2012). Vieyra-GarciaP , Fink-PuchesR , PorkertS , LangR , PöchlauerS , RatzingerG , et al. Evaluation of low-dose, low-frequency oral psoralen-UV-A treatment with or without maintenance on early-stage mycosis fungoides: A randomized clinical trial. JAMA Dermatology2019;155(5):538-47. [PMID: 30892603]">Vieyra‐Garcia 2019</a>), which we evaluated as a concealed allocation. </p> <p>In total, we assessed nine trials to be of low risk of selection bias (<a href="./references#CD008946-bbs2-0001" title="BagotM , HasanB , WhittakerS , Beylot-BarryM , KnoblerR , ShahE , et al. A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma - EORTC 21081 (NCT01098656): results and lessons learned for future trial designs. European Journal of Dermatology2017;27(3):286–94. [CENTRAL: CN-01395486] [PMID: 28468739]NCT01098656. A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-Cell lymphoma. clinicaltrials.gov/ct2/show/NCT01098656 (first received 5 April 2010). [NCT01098656]">Bagot 2017</a>; <a href="./references#CD008946-bbs2-0002" title="ChildFJ , MitchellTJ , WhittakerSJ , ScarisbrickJJ , SeedPT , Russel-JonesR . A randomized cross-over study to compare PUVA and extracorporeal photopheresis in the treatment of plaque stage (T2) mycosis fungoides. Clinical &amp; Experimental Dermatology2004;29(3):231-6. [CENTRAL: CN-00468455] [PMID: 15115499]ChildFJ , MitchellTJ , WhittakerSJ , WatkinsP , SeedP , Russell-JonesR . A randomised cross-over study to compare Puva and extracorporeal photopheresis (ECP) in the treatment of plaque stage (T2) mycosis fungoides. British Journal of Dermatology2001;145(Suppl 59):16. [CENTRAL: CN-00430854] ">Child 2004</a>; <a href="./references#CD008946-bbs2-0007" title="KayeF , EddyJ , IhdeDC , SteinbergS , FischmannAB , GlatsteinE , et al. Conservative vs. aggressive therapy in mycosis fungoides. Proceedings of the American Society of Clinical Oncology1989;8:257. [CENTRAL: CN-00694960] KayeF , IhdeD , FischmannA , GlatsteinE , MinnaJ , SchechterG , et al. A randomized trial comparing conservative and aggressive therapy in mycosis fungoides (MF). Proceedings of the American Society of Clinical Oncology1986;5:195. [CENTRAL: CN-00695166] KayeFJ , BunnPA , SteinbergSM , StockerJL , IhdeDC , FischmannAB , et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. New England Journal of Medicine1989;321(26):1784-90. [CENTRAL: CN-00064211] [PMID: 2594037]">Kaye 1989</a>; <a href="./references#CD008946-bbs2-0008" title="BagotM , DalleS , SokolL , TsianakasA , MusiekA , Ortiz-RomeroP , et al. Long-term clinical benefit to anti-CCR4 mogamulizumab: results from the phase 3 mavoric study in previously treated cutaneous t-cell lymphoma (CTCL). Blood2018;132(Supp 1):2901. [DOI: 10.1182/blood-2018-99-118473]CowanR , ScarisbrickJ , DwyerK , LeoniM , GrebennikD , MorrisS . Mogamulizumab demonstrates significant improvement in PFS compared to vorinostat in patients with previously treated cutaneous T-cell lymphoma (CTCL). British Journal of Haematology2018;181(S1):77–8. [DOI: 10.1111/bjh.15226]KimYH , BagotM , Pinter-BrownL , RookAH , PorcuP , HorwitzSM , et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncology2018;19(9):1192-1204. [PMID: 30100375]NCT01728805. Study of KW-0761 versus vorinostat in relapsed/refractory CTCL. clinicaltrials.gov/ct2/show/NCT01728805 (first received 20 November 2012). PorcuP , HudgensS , QuaglinoP , CowanR , FlodenL , LeoniM , et al. Quality of life in cutaneous T-cell lymphoma subjects treated with anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat: results from the phase 3 MAVORIC trial. Journal of Clinical Oncology2018;36(15):-. [DOI: 10.1097/HS9.0000000000000060]QuaglinoP , HudgensS , PorcuP , CowanR , FlodenL , TsianakasA , et al. Quality of life in cutaneous t-cell lymphoma subjects treated with the anti-ccr4 monoclonal antibody mogamulizumab versus vorinostat: results from the phase 3 mavoric trial. Hemasphere2018;2(S1):85. ScarisbrickJ , ZinzaniPL , HorwitzS , KimYH , MoskowitzAJ , PorcuP , et al. Efficacy of mogamulizumab by prior systemic therapy in patients with previously treated cutaneous T-cell lymphoma: Post hoc analysis from the phase 3 MAVORIC study. British Journal of Haematology2019;185(Suppl 1):94. TsianakasA , QuaglinoP , HudgensS , FlodenL , LeoniM , DaleS , et al. Quality of life in cutaneous T-cell lymphoma subjects treated with the anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat: Results from the phase 3 MAVORIC trial. Oncology Research and Treatment2018;41(Suppl 4):272. ZinzaniPL , HorwitzSM , KimYH , MoskowitzAJ , PorcuP , ScarisbrickJ , et al. Efficacy of mogamulizumab by prior systemic therapy in patients with previously treated cutaneous T-cell lymphoma: post hoc analysis from the phase 3 mavoric study. Blood2018;132(Suppl 1):1619. [DOI: 10.1182/blood-2018-99-114819]">Kim 2018</a>; <a href="./references#CD008946-bbs2-0010" title="DuvicM , KuzelTM , OlsenEA , MartinAG , FossFM , KimYH , et al. Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK). Clinical Lymphoma2002;2(4):222-8. [CENTRAL: CN-00514479] [PMID: 11970761]KuzelT , OlsenE , MartinA , KimY , DuvicM , FrankelA , et al. Pivotal phase III trial of two dose levels of DAB389IL-2 (Ontak®) for the treatment of mycosis fungoides (MF). Blood1997;90(10 Suppl 1 (Pt 1)):586a. [CENTRAL: CN-00518069] NTC00050999. Study of ONTAK (Denileukin Diftitox) in cutaneous T-Cell lymphoma (CTCL) patients. clinicaltrials.gov/ct2/show/NCT00050999 (first received 3 January 2003). OlsenE , DuvicM , FrankelA , KimY , MartinA , VonderheidE , et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. Journal of Clinical Oncology2001;19(2):376-88. [CENTRAL: CN-00328506] [PMID: 11208829]OlsenE , DuvicM , MartinA . Pivotal phase III trial of two dose levels of DAB 389 IL-2 (ONTAK) for the treatment of cutaneous T-cell lymphoma (CTCL). Journal of Investigative Dermatology1998;110(4):678. [CENTRAL: CN-00353452] ">Olsen 2001</a>; <a href="./references#CD008946-bbs2-0011" title="HorwitzS , WhittakerS , DuvicM , DummerR , KimYH , ScarisbrickJ , et al. Response by stage in CD30-positive (CD30+) cutaneous T cell lymphoma (CTCL) patients receiving brentuximab vedotin (BV) vs physician's choice (PC) in the phase 3 ALCANZA study. In: Hematological oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:245–7. [CENTRAL: CN-01408605] [DOI: 10.1002/hon.2438]HorwitzSM , AkilovOE , FisherD , KuzelTM , WangY , Palanca-WesselsMC , et al. Brentuximab vedotin or physician’s choice in CD30-positivecutaneous T-cell lymphoma (ALCANZA): an international,open-label, randomised, phase 3, multicentre trial. Lancet2017;390(10094):555-66. [CENTRAL: CN-01403731] HorwitzSM , ScarisbrickJJ , DummerR , DuvicM , KimYH , WalewskiJ , et al. Updated analyses of the international, open-label, randomized, phase 3 alcanza study: longer-term evidence for superiority of brentuximab vedotin versus methotrexate or bexarotene for CD30-positive cutaneous T-cell lymphoma (CTCL). In: Blood. Conference: 59th annual meeting of the american society of hematology, ASH 2017. United states. Vol. 130. 2017. [CENTRAL: CN-01450312] KimYH , PrinceHM , WhittakerS , HorwitzSM , DuvicM , ScarisbrickJ , et al. Brentuximab vedotin vs physician's choice in CTCL patients from the phase 3 ALCANZA study: analysis of outcomes by CD30 expression. In: Hematological Oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:77–8. [CENTRAL: CN-01408482] [DOI: 10.1002/hon.2437]KimYH , PrinceHM , WhittakerS , HorwitzSM , DuvicM , ScarisbrickJ , et al. Outcomes by CD30 expression in patients with CTCL receiving brentuximab vedotin (BV) vs physician's choice (PC) in the Phase 3 ALCANZA study. Journal of Clinical Oncology2017;35(15 Supplement 1):7517. [EMBASE: 617388795]KimYH , WhittakerS , DummerR , GeskinLJ , GauthierP , LittleM , et al. Phase 3 study of brentuximab vedotin versus physician's choice of methotrexate or bexarotene in patients (PTS) with CD30-positive (CD30+) cutaneous T-cell lymphoma (CTCL). The alcanza study. Hematological Oncology2013;31(Suppl 1):278. [CENTRAL: CN-01531598] [EMBASE: 71147875]KimYH , WhittakerS , HorwitzSM , DuvicM , DummerR , ScarisbrickJ , et al. Brentuximab vedotin demonstrates superior activity to standard therapy in CD30-expressing (CD30+) cutaneous T-cell lymphoma (CTCL) in the randomized phase 3 ALCANZA study. Journal of Investigative Dermatology2017;137(5 Suppl 1):S45. [CENTRAL: CN-01375469] [EMBASE: 616393777]KimYH , WhittakerS , HorwitzSM , DuvicM , DummerR , ScarisbrickJJ , et al. Brentuximab vedotin demonstrates significantly superior clinical outcomes in patients with CD30-expressing cutaneous T cell lymphoma versus physician's choice (Methotrexate or Bexarotene): the phase 3 alcanza study. In: Blood. Conference: 58th annual meeting of the american society of hematology, ASH 2016. United states. Conference start: 20161203. Conference end: 20161206. Vol. 128. 2016. [CENTRAL: CN-01303081] [EMBASE: 614225065]NCT01578499. A randomised, open-label, phase 3 trial of brentuximab vedotin (SGN-35) versus physician's choice (methotrexate or bexarotene) in patients with CD30-positive cutaneous T-cell lymphoma. clinicaltrials.gov/ct2/show/NCT01578499 (first received 17 April 2012). PrinceHM , DummerR , WhittakerS , HorwitzS , DuvicM , ScarisbrickJ , et al. Patient-reported outcomes and quality of life in patients with cutaneous T cell lymphoma: results from the phase 3 ALCANZA study. In: Hematological Oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:247–8. [CENTRAL: CN-01408603] [DOI: 10.1002/hon.2438]ZagadailovE , PrinceHM , WhittakerS , HorwitzS , DuvicM , KimY , et al. Phase 3 alcanza study of brentuximab vedotin (BV) or physician's choice (PC) of methotrexate (MTX) or bexarotene (BEX) in CD30-positive cutaneous T-cell lymphoma (CTCL): number needed to treat analysis. In: Haematologica. Conference: 22th congress of the european hematology association. Spain. Vol. 102. 2017:251. [CENTRAL: CN-01399195] ">Prince 2017</a>; <a href="./references#CD008946-bbs2-0013" title="OtteHG , KuhlS , StadlerR , LugerT , HenzB , SterryW . Treatment of cutaneous T-cell lymphoma with Interferon alpha and PUVA versus Interferon alpha and Acitretin - results of a prospective randomised multi-centre study [Behandlung des kutanen T-Zell-Lymphoms mit Interferon alpha und PUVA versus Interferon alpha und Acirentin - Ergebnisse einer prospektiv-randomisierten Multicenter-Studie]. Der Hautarzt1997;48(Suppl):S97. [CENTRAL: CN-00495120] OtteHG , StadierR , LugerT , HenzB , SterryW . Open controlled clinical trial on the use of interferon plus acitretin versus interferon plus PUVA in patients with cutaneous T-cell lymphoma (CTCL). Annals of Oncology1996;7(Suppl 3):66. [CENTRAL: CN-00308243] StadlerR , OtteHG , LugerT , HenzBM , KuhlP , ZwingersT , et al. Prospective randomized multicenter clinical trial on the use of interferon -2a plus acitretin versus interferon -2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood1998;92(10):3578-81. [CENTRAL: CN-00156682] [PMID: 9808550]">Stadler 1998</a>; <a href="./references#CD008946-bbs2-0016" title="NCT01686594. A multi-center, randomized study on oral 8-methoxypsoralen plus UVA with or without maintenance therapy in mycosis fungoides EORTC/ISCL stage IA to IIB. clinicaltrials.gov/ct2/show/NCT01686594 (first received 18 September 2012). Vieyra-GarciaP , Fink-PuchesR , PorkertS , LangR , PöchlauerS , RatzingerG , et al. Evaluation of low-dose, low-frequency oral psoralen-UV-A treatment with or without maintenance on early-stage mycosis fungoides: A randomized clinical trial. JAMA Dermatology2019;155(5):538-47. [PMID: 30892603]">Vieyra‐Garcia 2019</a>; <a href="./references#CD008946-bbs2-0018" title="NCT00056056. Ultraviolet light therapy using methoxsalen with or without Bexarotene in treating patients with mycosis fungoides. clinicaltrials.gov/ct2/show/NCT00056056 (first received 7 March 2003). WhittakerS , OrtizP , DummerR , RankiA , HasanB , MeulemansB , et al. Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial 21011 (NCT00056056). British Journal of Dermatology2012;167(3):678-87. [CENTRAL: CN-00856432] [PMID: 22924950]WhittakerS , Ortiz-RomeroPL , DummerR , RankiA , HasanB , MeulemansB , et al. Efficacy and safety of bexarotene combined with psoralen/ultraviolet A light (PUVA) compared to PUVA treatment alone in stage IB-IIa mycosis fungoides (MF): Final results from EORTC cutaneous lymphoma task force (CLTF) phase III clinical trial 21011. Journal of Clinical Oncology2012;30(15 Suppl 1):8076. ">Whittaker 2012</a>). The remaining 11 trials were considered to be of unclear risk (<a href="./references#CD008946-bbs2-0003" title="ChongA , LooWJ , BanneyL , GrantJW , NorrisPG . Imiquimod 5% cream in the treatment of mycosis fungoides - a pilot study. Journal of Dermatological Treatment2004;15(2):118-9. [CENTRAL: CN-00467258] [PMID: 15204164]">Chong 2004</a>; <a href="./references#CD008946-bbs2-0004" title="DuvicM , MartinAG , KimY , OlsenE , WoodGS , CrowleyCA , et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Archives of Dermatology2001;137(5):581-93. [CENTRAL: CN-00347816] [PMID: 11346336]PrinceHM , McCormackC , RyanG , BakerC , RotsteinH , DavisonJ , et al. Bexarotene capsules and gel for previously treated patients with cutaneous T-cell lymphoma: results of the Australian patients treated on phase II trials. Australasian Journal of Dermatology2001;42(2):91-7. [CENTRAL: CN-00442169] [PMID: 11309029]">Duvic 2001</a>; <a href="./references#CD008946-bbs2-0005" title="DuvicM , OlsenEA , OmuraGA , MaizeJC , VonderheidEC , et al. A phase III, randomized, double-blind, placebo-controlled study of peldesine (BCX-34) cream as topical therapy for cutaneous T-cell lymphoma. Journal of the American Academy of Dermatology2001;44(6):940-7. [CENTRAL: CN-00348073] [PMID: 11369904]">Duvic 2001a</a>; <a href="./references#CD008946-bbs2-0006" title="GuitartJ , TuckerR , StevensV . Low dose bexarotene (Targretin®) capsules and phototherapy for early stage cutaneous T-Cell lymphoma. Journal of Investigative Dermatology2002;119(1):241. [CENTRAL: CN-00794450] NCT00030589. A muliticenter, dose-randomized evaluation of Targretin capsules plus PUVA in patients with stage IB - IIA cutaneous T-Cell lymphoma. clinicaltrials.gov/ct/show/NCT00030589 (first received 27 Jaunry 2003). ">Guitart 2002</a>; <a href="./references#CD008946-bbs2-0009" title="LessinS , DuvicM , GuitartJ , PandyaA , StroberB , OlsenE , et al. Positive results of a pivotal phase ii trial testing a manufactured 0.02% Mechlorethamine gel in mycosis fungoides (mf). Journal of Investigative Dermatology2011;131(Suppl 1):S84. [CENTRAL: CN-00843792] LessinSR , DuvicM , GuitartJ , PandyaAG , StroberBE , OlsenEA , et al. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatology2013;149(1):25-32. [CENTRAL: CN-00859487] [PMID: 23069814]NCT00168064. Safety and efficacy of nitrogen mustard in treatment of mycosis fungoides. clinicaltrials.gov/ct2/show/NCT00168064 (first received 14 September 2005). ">Lessin 2013</a>; <a href="./references#CD008946-bbs2-0012" title="RookAH , WoodGS , DuvicM , VonderheidEC , TobiaA , CabanaB . A phase II placebo-controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis. Journal of the American Academy of Dermatology2010;63(6):984-90. [CENTRAL: CN-00772559] [PMID: 20889234]">Rook 2010</a>; <a href="./references#CD008946-bbs2-0014" title="BohmeyerJ , OtteHG , StadlerR , LugerT , SterryW . Therapy of cutaneous T-cell lymphoma with PUVA versus interferon alfa plus PUVA: first results. Journal of the European Academy of Dermatology &amp; Venereology1999;12(Suppl 2):S268. [CENTRAL: CN-00478472] BohmeyerJ , StadlerR , LugerT , SterryW . Prospective randomized multicentre therapy optimizing protocol for therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α + PUVA [Prospectiv randomisiertes, multizentrisches Therapieoptimierungsprotokoll zur Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α + PUVA]. Zeitschrift für Hautkrankheiten2001;76(Suppl 1):S55. [CENTRAL: CN-01446038] KremerA , BohmeyerJ , StadlerR , LugerT , SterryW . Prospective randomized multicentre therapy optimizing protocol for therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α + PUVA [Prospectiv randomisiertes, multizentrisches Therapieoptimierungsprotokoll zur Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α + PUVA]. Journal der Deutschen Dermatologischen Gesellschaft2003;1(Suppl 1):S99. [CENTRAL: CN-01446037] OtteHG , StadlerR , LugerT , SterryW . Therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α plus PUVA: first results of a prospective randomized multicentre therapy optimizing protocol [Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α plus PUVA: Erste Ergebnisse des prospektiven randomisierten multizentrischen Therapieoptimierungsprotokolls]. Der Hautarzt1999;50(Suppl 1):S2. [CENTRAL: CN-01457423] OtteHG , StadlerR . Combination therapy of cutaneous t-cell-lymphoma with interferon alfa 2a and PUVA [Kombinationstherapie kutaner T-Zell-Lymphome mit Interferon Alfa 2a und PUVA]. Zentralblatt Haut- und Geschlechtskrankheiten1993;162(Suppl):P2.03.08. [CENTRAL: CN-01457422] StadlerM , KremerA , LugerT , SterryW . Prospective, randomized, multicentre clinical trial on the use of interferon a 2a plus PUVA versus PUVA monotherapy in patients with cutaneous T-cell lymphoma, stages I and II [Abstract 7541]. ASCO annual meeting proceedings. Journal of Clinical Oncology2006;24(18S Pt 1):432. [CENTRAL: CN-00625001] ">Stadler 2006</a>; <a href="./references#CD008946-bbs2-0015" title="Thestrup-PedersenK , GrunnetE , ZachariaeH . Transfer factor therapy in mycosis fungoides: a double-blind study. Acta Dermato-Venereologica1982;62(1):47-53. [CENTRAL: CN-00027377] [PMID: 6175137]">Thestrup‐Pedersen 1982</a>; <a href="./references#CD008946-bbs2-0017" title="VonderheidEC , ThompsonR , SmilesKA , LattanandA . Recombinant interferon alfa-2b in plaque-phase mycosis fungoides. Intralesional and low-dose intramuscular therapy. Archives of Dermatology1987;123(6):757-63. [CENTRAL: CN-00047990] [PMID: 3579357]">Vonderheid 1987</a>; <a href="./references#CD008946-bbs2-0019" title="WolffJM , ZitelliJA , RabinBS , SmilesKA , AbellE . Intralesional interferon in the treatment of early mycosis fungoides. Journal of the American Academy of Dermatology1985;13(4):604-12. [CENTRAL: CN-00040943] [PMID: 2934438]">Wolff 1985</a>; <a href="./references#CD008946-bbs2-0020" title="WozniakMB , TraceyL , Ortiz-RomeroPL , MontesS , AlvarezM , FragaJ , et al. Psoralen plus ultraviolet A +/- interferon-alpha treatment resistance in mycosis fungoides: the role of tumour microenvironment, nuclear transcription factor-kappaB and T-cell receptor pathways. British Journal of Dermatology2008;160(1):92-102. [CENTRAL: CN-00668828] [PMID: 18945306]">Wozniak 2008</a>). No trial was rated to be of high risk of selection bias. </p> <p>In terms of allocation concealment, six studies were considered to be of low risk (<a href="./references#CD008946-bbs2-0001" title="BagotM , HasanB , WhittakerS , Beylot-BarryM , KnoblerR , ShahE , et al. A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma - EORTC 21081 (NCT01098656): results and lessons learned for future trial designs. European Journal of Dermatology2017;27(3):286–94. [CENTRAL: CN-01395486] [PMID: 28468739]NCT01098656. A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-Cell lymphoma. clinicaltrials.gov/ct2/show/NCT01098656 (first received 5 April 2010). [NCT01098656]">Bagot 2017</a>; <a href="./references#CD008946-bbs2-0005" title="DuvicM , OlsenEA , OmuraGA , MaizeJC , VonderheidEC , et al. A phase III, randomized, double-blind, placebo-controlled study of peldesine (BCX-34) cream as topical therapy for cutaneous T-cell lymphoma. Journal of the American Academy of Dermatology2001;44(6):940-7. [CENTRAL: CN-00348073] [PMID: 11369904]">Duvic 2001a</a>; <a href="./references#CD008946-bbs2-0008" title="BagotM , DalleS , SokolL , TsianakasA , MusiekA , Ortiz-RomeroP , et al. Long-term clinical benefit to anti-CCR4 mogamulizumab: results from the phase 3 mavoric study in previously treated cutaneous t-cell lymphoma (CTCL). Blood2018;132(Supp 1):2901. [DOI: 10.1182/blood-2018-99-118473]CowanR , ScarisbrickJ , DwyerK , LeoniM , GrebennikD , MorrisS . Mogamulizumab demonstrates significant improvement in PFS compared to vorinostat in patients with previously treated cutaneous T-cell lymphoma (CTCL). British Journal of Haematology2018;181(S1):77–8. [DOI: 10.1111/bjh.15226]KimYH , BagotM , Pinter-BrownL , RookAH , PorcuP , HorwitzSM , et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncology2018;19(9):1192-1204. [PMID: 30100375]NCT01728805. Study of KW-0761 versus vorinostat in relapsed/refractory CTCL. clinicaltrials.gov/ct2/show/NCT01728805 (first received 20 November 2012). PorcuP , HudgensS , QuaglinoP , CowanR , FlodenL , LeoniM , et al. Quality of life in cutaneous T-cell lymphoma subjects treated with anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat: results from the phase 3 MAVORIC trial. Journal of Clinical Oncology2018;36(15):-. [DOI: 10.1097/HS9.0000000000000060]QuaglinoP , HudgensS , PorcuP , CowanR , FlodenL , TsianakasA , et al. Quality of life in cutaneous t-cell lymphoma subjects treated with the anti-ccr4 monoclonal antibody mogamulizumab versus vorinostat: results from the phase 3 mavoric trial. Hemasphere2018;2(S1):85. ScarisbrickJ , ZinzaniPL , HorwitzS , KimYH , MoskowitzAJ , PorcuP , et al. Efficacy of mogamulizumab by prior systemic therapy in patients with previously treated cutaneous T-cell lymphoma: Post hoc analysis from the phase 3 MAVORIC study. British Journal of Haematology2019;185(Suppl 1):94. TsianakasA , QuaglinoP , HudgensS , FlodenL , LeoniM , DaleS , et al. Quality of life in cutaneous T-cell lymphoma subjects treated with the anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat: Results from the phase 3 MAVORIC trial. Oncology Research and Treatment2018;41(Suppl 4):272. ZinzaniPL , HorwitzSM , KimYH , MoskowitzAJ , PorcuP , ScarisbrickJ , et al. Efficacy of mogamulizumab by prior systemic therapy in patients with previously treated cutaneous T-cell lymphoma: post hoc analysis from the phase 3 mavoric study. Blood2018;132(Suppl 1):1619. [DOI: 10.1182/blood-2018-99-114819]">Kim 2018</a>; <a href="./references#CD008946-bbs2-0011" title="HorwitzS , WhittakerS , DuvicM , DummerR , KimYH , ScarisbrickJ , et al. Response by stage in CD30-positive (CD30+) cutaneous T cell lymphoma (CTCL) patients receiving brentuximab vedotin (BV) vs physician's choice (PC) in the phase 3 ALCANZA study. In: Hematological oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:245–7. [CENTRAL: CN-01408605] [DOI: 10.1002/hon.2438]HorwitzSM , AkilovOE , FisherD , KuzelTM , WangY , Palanca-WesselsMC , et al. Brentuximab vedotin or physician’s choice in CD30-positivecutaneous T-cell lymphoma (ALCANZA): an international,open-label, randomised, phase 3, multicentre trial. Lancet2017;390(10094):555-66. [CENTRAL: CN-01403731] HorwitzSM , ScarisbrickJJ , DummerR , DuvicM , KimYH , WalewskiJ , et al. Updated analyses of the international, open-label, randomized, phase 3 alcanza study: longer-term evidence for superiority of brentuximab vedotin versus methotrexate or bexarotene for CD30-positive cutaneous T-cell lymphoma (CTCL). In: Blood. Conference: 59th annual meeting of the american society of hematology, ASH 2017. United states. Vol. 130. 2017. [CENTRAL: CN-01450312] KimYH , PrinceHM , WhittakerS , HorwitzSM , DuvicM , ScarisbrickJ , et al. Brentuximab vedotin vs physician's choice in CTCL patients from the phase 3 ALCANZA study: analysis of outcomes by CD30 expression. In: Hematological Oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:77–8. [CENTRAL: CN-01408482] [DOI: 10.1002/hon.2437]KimYH , PrinceHM , WhittakerS , HorwitzSM , DuvicM , ScarisbrickJ , et al. Outcomes by CD30 expression in patients with CTCL receiving brentuximab vedotin (BV) vs physician's choice (PC) in the Phase 3 ALCANZA study. Journal of Clinical Oncology2017;35(15 Supplement 1):7517. [EMBASE: 617388795]KimYH , WhittakerS , DummerR , GeskinLJ , GauthierP , LittleM , et al. Phase 3 study of brentuximab vedotin versus physician's choice of methotrexate or bexarotene in patients (PTS) with CD30-positive (CD30+) cutaneous T-cell lymphoma (CTCL). The alcanza study. Hematological Oncology2013;31(Suppl 1):278. [CENTRAL: CN-01531598] [EMBASE: 71147875]KimYH , WhittakerS , HorwitzSM , DuvicM , DummerR , ScarisbrickJ , et al. Brentuximab vedotin demonstrates superior activity to standard therapy in CD30-expressing (CD30+) cutaneous T-cell lymphoma (CTCL) in the randomized phase 3 ALCANZA study. Journal of Investigative Dermatology2017;137(5 Suppl 1):S45. [CENTRAL: CN-01375469] [EMBASE: 616393777]KimYH , WhittakerS , HorwitzSM , DuvicM , DummerR , ScarisbrickJJ , et al. Brentuximab vedotin demonstrates significantly superior clinical outcomes in patients with CD30-expressing cutaneous T cell lymphoma versus physician's choice (Methotrexate or Bexarotene): the phase 3 alcanza study. In: Blood. Conference: 58th annual meeting of the american society of hematology, ASH 2016. United states. Conference start: 20161203. Conference end: 20161206. Vol. 128. 2016. [CENTRAL: CN-01303081] [EMBASE: 614225065]NCT01578499. A randomised, open-label, phase 3 trial of brentuximab vedotin (SGN-35) versus physician's choice (methotrexate or bexarotene) in patients with CD30-positive cutaneous T-cell lymphoma. clinicaltrials.gov/ct2/show/NCT01578499 (first received 17 April 2012). PrinceHM , DummerR , WhittakerS , HorwitzS , DuvicM , ScarisbrickJ , et al. Patient-reported outcomes and quality of life in patients with cutaneous T cell lymphoma: results from the phase 3 ALCANZA study. In: Hematological Oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:247–8. [CENTRAL: CN-01408603] [DOI: 10.1002/hon.2438]ZagadailovE , PrinceHM , WhittakerS , HorwitzS , DuvicM , KimY , et al. Phase 3 alcanza study of brentuximab vedotin (BV) or physician's choice (PC) of methotrexate (MTX) or bexarotene (BEX) in CD30-positive cutaneous T-cell lymphoma (CTCL): number needed to treat analysis. In: Haematologica. Conference: 22th congress of the european hematology association. Spain. Vol. 102. 2017:251. [CENTRAL: CN-01399195] ">Prince 2017</a>; <a href="./references#CD008946-bbs2-0013" title="OtteHG , KuhlS , StadlerR , LugerT , HenzB , SterryW . Treatment of cutaneous T-cell lymphoma with Interferon alpha and PUVA versus Interferon alpha and Acitretin - results of a prospective randomised multi-centre study [Behandlung des kutanen T-Zell-Lymphoms mit Interferon alpha und PUVA versus Interferon alpha und Acirentin - Ergebnisse einer prospektiv-randomisierten Multicenter-Studie]. Der Hautarzt1997;48(Suppl):S97. [CENTRAL: CN-00495120] OtteHG , StadierR , LugerT , HenzB , SterryW . Open controlled clinical trial on the use of interferon plus acitretin versus interferon plus PUVA in patients with cutaneous T-cell lymphoma (CTCL). Annals of Oncology1996;7(Suppl 3):66. [CENTRAL: CN-00308243] StadlerR , OtteHG , LugerT , HenzBM , KuhlP , ZwingersT , et al. Prospective randomized multicenter clinical trial on the use of interferon -2a plus acitretin versus interferon -2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood1998;92(10):3578-81. [CENTRAL: CN-00156682] [PMID: 9808550]">Stadler 1998</a>; <a href="./references#CD008946-bbs2-0016" title="NCT01686594. A multi-center, randomized study on oral 8-methoxypsoralen plus UVA with or without maintenance therapy in mycosis fungoides EORTC/ISCL stage IA to IIB. clinicaltrials.gov/ct2/show/NCT01686594 (first received 18 September 2012). Vieyra-GarciaP , Fink-PuchesR , PorkertS , LangR , PöchlauerS , RatzingerG , et al. Evaluation of low-dose, low-frequency oral psoralen-UV-A treatment with or without maintenance on early-stage mycosis fungoides: A randomized clinical trial. JAMA Dermatology2019;155(5):538-47. [PMID: 30892603]">Vieyra‐Garcia 2019</a>), 13 of unclear (<a href="./references#CD008946-bbs2-0002" title="ChildFJ , MitchellTJ , WhittakerSJ , ScarisbrickJJ , SeedPT , Russel-JonesR . A randomized cross-over study to compare PUVA and extracorporeal photopheresis in the treatment of plaque stage (T2) mycosis fungoides. Clinical &amp; Experimental Dermatology2004;29(3):231-6. [CENTRAL: CN-00468455] [PMID: 15115499]ChildFJ , MitchellTJ , WhittakerSJ , WatkinsP , SeedP , Russell-JonesR . A randomised cross-over study to compare Puva and extracorporeal photopheresis (ECP) in the treatment of plaque stage (T2) mycosis fungoides. British Journal of Dermatology2001;145(Suppl 59):16. [CENTRAL: CN-00430854] ">Child 2004</a>; <a href="./references#CD008946-bbs2-0003" title="ChongA , LooWJ , BanneyL , GrantJW , NorrisPG . Imiquimod 5% cream in the treatment of mycosis fungoides - a pilot study. Journal of Dermatological Treatment2004;15(2):118-9. [CENTRAL: CN-00467258] [PMID: 15204164]">Chong 2004</a>; <a href="./references#CD008946-bbs2-0004" title="DuvicM , MartinAG , KimY , OlsenE , WoodGS , CrowleyCA , et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Archives of Dermatology2001;137(5):581-93. [CENTRAL: CN-00347816] [PMID: 11346336]PrinceHM , McCormackC , RyanG , BakerC , RotsteinH , DavisonJ , et al. Bexarotene capsules and gel for previously treated patients with cutaneous T-cell lymphoma: results of the Australian patients treated on phase II trials. Australasian Journal of Dermatology2001;42(2):91-7. [CENTRAL: CN-00442169] [PMID: 11309029]">Duvic 2001</a>; <a href="./references#CD008946-bbs2-0006" title="GuitartJ , TuckerR , StevensV . Low dose bexarotene (Targretin®) capsules and phototherapy for early stage cutaneous T-Cell lymphoma. Journal of Investigative Dermatology2002;119(1):241. [CENTRAL: CN-00794450] NCT00030589. A muliticenter, dose-randomized evaluation of Targretin capsules plus PUVA in patients with stage IB - IIA cutaneous T-Cell lymphoma. clinicaltrials.gov/ct/show/NCT00030589 (first received 27 Jaunry 2003). ">Guitart 2002</a>; <a href="./references#CD008946-bbs2-0007" title="KayeF , EddyJ , IhdeDC , SteinbergS , FischmannAB , GlatsteinE , et al. Conservative vs. aggressive therapy in mycosis fungoides. Proceedings of the American Society of Clinical Oncology1989;8:257. [CENTRAL: CN-00694960] KayeF , IhdeD , FischmannA , GlatsteinE , MinnaJ , SchechterG , et al. A randomized trial comparing conservative and aggressive therapy in mycosis fungoides (MF). Proceedings of the American Society of Clinical Oncology1986;5:195. [CENTRAL: CN-00695166] KayeFJ , BunnPA , SteinbergSM , StockerJL , IhdeDC , FischmannAB , et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. New England Journal of Medicine1989;321(26):1784-90. [CENTRAL: CN-00064211] [PMID: 2594037]">Kaye 1989</a>; <a href="./references#CD008946-bbs2-0009" title="LessinS , DuvicM , GuitartJ , PandyaA , StroberB , OlsenE , et al. Positive results of a pivotal phase ii trial testing a manufactured 0.02% Mechlorethamine gel in mycosis fungoides (mf). Journal of Investigative Dermatology2011;131(Suppl 1):S84. [CENTRAL: CN-00843792] LessinSR , DuvicM , GuitartJ , PandyaAG , StroberBE , OlsenEA , et al. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatology2013;149(1):25-32. [CENTRAL: CN-00859487] [PMID: 23069814]NCT00168064. Safety and efficacy of nitrogen mustard in treatment of mycosis fungoides. clinicaltrials.gov/ct2/show/NCT00168064 (first received 14 September 2005). ">Lessin 2013</a>; <a href="./references#CD008946-bbs2-0010" title="DuvicM , KuzelTM , OlsenEA , MartinAG , FossFM , KimYH , et al. Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK). Clinical Lymphoma2002;2(4):222-8. [CENTRAL: CN-00514479] [PMID: 11970761]KuzelT , OlsenE , MartinA , KimY , DuvicM , FrankelA , et al. Pivotal phase III trial of two dose levels of DAB389IL-2 (Ontak®) for the treatment of mycosis fungoides (MF). Blood1997;90(10 Suppl 1 (Pt 1)):586a. [CENTRAL: CN-00518069] NTC00050999. Study of ONTAK (Denileukin Diftitox) in cutaneous T-Cell lymphoma (CTCL) patients. clinicaltrials.gov/ct2/show/NCT00050999 (first received 3 January 2003). OlsenE , DuvicM , FrankelA , KimY , MartinA , VonderheidE , et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. Journal of Clinical Oncology2001;19(2):376-88. [CENTRAL: CN-00328506] [PMID: 11208829]OlsenE , DuvicM , MartinA . Pivotal phase III trial of two dose levels of DAB 389 IL-2 (ONTAK) for the treatment of cutaneous T-cell lymphoma (CTCL). Journal of Investigative Dermatology1998;110(4):678. [CENTRAL: CN-00353452] ">Olsen 2001</a>; <a href="./references#CD008946-bbs2-0012" title="RookAH , WoodGS , DuvicM , VonderheidEC , TobiaA , CabanaB . A phase II placebo-controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis. Journal of the American Academy of Dermatology2010;63(6):984-90. [CENTRAL: CN-00772559] [PMID: 20889234]">Rook 2010</a>; <a href="./references#CD008946-bbs2-0014" title="BohmeyerJ , OtteHG , StadlerR , LugerT , SterryW . Therapy of cutaneous T-cell lymphoma with PUVA versus interferon alfa plus PUVA: first results. Journal of the European Academy of Dermatology &amp; Venereology1999;12(Suppl 2):S268. [CENTRAL: CN-00478472] BohmeyerJ , StadlerR , LugerT , SterryW . Prospective randomized multicentre therapy optimizing protocol for therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α + PUVA [Prospectiv randomisiertes, multizentrisches Therapieoptimierungsprotokoll zur Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α + PUVA]. Zeitschrift für Hautkrankheiten2001;76(Suppl 1):S55. [CENTRAL: CN-01446038] KremerA , BohmeyerJ , StadlerR , LugerT , SterryW . Prospective randomized multicentre therapy optimizing protocol for therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α + PUVA [Prospectiv randomisiertes, multizentrisches Therapieoptimierungsprotokoll zur Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α + PUVA]. Journal der Deutschen Dermatologischen Gesellschaft2003;1(Suppl 1):S99. [CENTRAL: CN-01446037] OtteHG , StadlerR , LugerT , SterryW . Therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α plus PUVA: first results of a prospective randomized multicentre therapy optimizing protocol [Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α plus PUVA: Erste Ergebnisse des prospektiven randomisierten multizentrischen Therapieoptimierungsprotokolls]. Der Hautarzt1999;50(Suppl 1):S2. [CENTRAL: CN-01457423] OtteHG , StadlerR . Combination therapy of cutaneous t-cell-lymphoma with interferon alfa 2a and PUVA [Kombinationstherapie kutaner T-Zell-Lymphome mit Interferon Alfa 2a und PUVA]. Zentralblatt Haut- und Geschlechtskrankheiten1993;162(Suppl):P2.03.08. [CENTRAL: CN-01457422] StadlerM , KremerA , LugerT , SterryW . Prospective, randomized, multicentre clinical trial on the use of interferon a 2a plus PUVA versus PUVA monotherapy in patients with cutaneous T-cell lymphoma, stages I and II [Abstract 7541]. ASCO annual meeting proceedings. Journal of Clinical Oncology2006;24(18S Pt 1):432. [CENTRAL: CN-00625001] ">Stadler 2006</a>; <a href="./references#CD008946-bbs2-0017" title="VonderheidEC , ThompsonR , SmilesKA , LattanandA . Recombinant interferon alfa-2b in plaque-phase mycosis fungoides. Intralesional and low-dose intramuscular therapy. Archives of Dermatology1987;123(6):757-63. [CENTRAL: CN-00047990] [PMID: 3579357]">Vonderheid 1987</a>; <a href="./references#CD008946-bbs2-0018" title="NCT00056056. Ultraviolet light therapy using methoxsalen with or without Bexarotene in treating patients with mycosis fungoides. clinicaltrials.gov/ct2/show/NCT00056056 (first received 7 March 2003). WhittakerS , OrtizP , DummerR , RankiA , HasanB , MeulemansB , et al. Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial 21011 (NCT00056056). British Journal of Dermatology2012;167(3):678-87. [CENTRAL: CN-00856432] [PMID: 22924950]WhittakerS , Ortiz-RomeroPL , DummerR , RankiA , HasanB , MeulemansB , et al. Efficacy and safety of bexarotene combined with psoralen/ultraviolet A light (PUVA) compared to PUVA treatment alone in stage IB-IIa mycosis fungoides (MF): Final results from EORTC cutaneous lymphoma task force (CLTF) phase III clinical trial 21011. Journal of Clinical Oncology2012;30(15 Suppl 1):8076. ">Whittaker 2012</a>; <a href="./references#CD008946-bbs2-0019" title="WolffJM , ZitelliJA , RabinBS , SmilesKA , AbellE . Intralesional interferon in the treatment of early mycosis fungoides. Journal of the American Academy of Dermatology1985;13(4):604-12. [CENTRAL: CN-00040943] [PMID: 2934438]">Wolff 1985</a>; <a href="./references#CD008946-bbs2-0020" title="WozniakMB , TraceyL , Ortiz-RomeroPL , MontesS , AlvarezM , FragaJ , et al. Psoralen plus ultraviolet A +/- interferon-alpha treatment resistance in mycosis fungoides: the role of tumour microenvironment, nuclear transcription factor-kappaB and T-cell receptor pathways. British Journal of Dermatology2008;160(1):92-102. [CENTRAL: CN-00668828] [PMID: 18945306]">Wozniak 2008</a>, and one study to be of high risk (<a href="./references#CD008946-bbs2-0015" title="Thestrup-PedersenK , GrunnetE , ZachariaeH . Transfer factor therapy in mycosis fungoides: a double-blind study. Acta Dermato-Venereologica1982;62(1):47-53. [CENTRAL: CN-00027377] [PMID: 6175137]">Thestrup‐Pedersen 1982</a>). Downgrading the validity of <a href="./references#CD008946-bbs2-0015" title="Thestrup-PedersenK , GrunnetE , ZachariaeH . Transfer factor therapy in mycosis fungoides: a double-blind study. Acta Dermato-Venereologica1982;62(1):47-53. [CENTRAL: CN-00027377] [PMID: 6175137]">Thestrup‐Pedersen 1982</a> is due to the trial author confirming that the randomisation list was open, which we rated as high risk. </p> <p>Further details are provided in the 'Risk of bias' tables in the <a href="./references#CD008946-sec-0233" title="">Characteristics of included studies</a> section. </p> </section> </section> <section id="CD008946-sec-0082"> <h4 class="title">Blinding</h4> <p>Although six studies (<a href="./references#CD008946-bbs2-0003" title="ChongA , LooWJ , BanneyL , GrantJW , NorrisPG . Imiquimod 5% cream in the treatment of mycosis fungoides - a pilot study. Journal of Dermatological Treatment2004;15(2):118-9. [CENTRAL: CN-00467258] [PMID: 15204164]">Chong 2004</a>; <a href="./references#CD008946-bbs2-0005" title="DuvicM , OlsenEA , OmuraGA , MaizeJC , VonderheidEC , et al. A phase III, randomized, double-blind, placebo-controlled study of peldesine (BCX-34) cream as topical therapy for cutaneous T-cell lymphoma. Journal of the American Academy of Dermatology2001;44(6):940-7. [CENTRAL: CN-00348073] [PMID: 11369904]">Duvic 2001a</a>; <a href="./references#CD008946-bbs2-0012" title="RookAH , WoodGS , DuvicM , VonderheidEC , TobiaA , CabanaB . A phase II placebo-controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis. Journal of the American Academy of Dermatology2010;63(6):984-90. [CENTRAL: CN-00772559] [PMID: 20889234]">Rook 2010</a>; <a href="./references#CD008946-bbs2-0015" title="Thestrup-PedersenK , GrunnetE , ZachariaeH . Transfer factor therapy in mycosis fungoides: a double-blind study. Acta Dermato-Venereologica1982;62(1):47-53. [CENTRAL: CN-00027377] [PMID: 6175137]">Thestrup‐Pedersen 1982</a>; <a href="./references#CD008946-bbs2-0017" title="VonderheidEC , ThompsonR , SmilesKA , LattanandA . Recombinant interferon alfa-2b in plaque-phase mycosis fungoides. Intralesional and low-dose intramuscular therapy. Archives of Dermatology1987;123(6):757-63. [CENTRAL: CN-00047990] [PMID: 3579357]">Vonderheid 1987</a>; <a href="./references#CD008946-bbs2-0019" title="WolffJM , ZitelliJA , RabinBS , SmilesKA , AbellE . Intralesional interferon in the treatment of early mycosis fungoides. Journal of the American Academy of Dermatology1985;13(4):604-12. [CENTRAL: CN-00040943] [PMID: 2934438]">Wolff 1985</a>) were described as 'double‐blind' or implied double‐blinding, only one of them (<a href="./references#CD008946-bbs2-0005" title="DuvicM , OlsenEA , OmuraGA , MaizeJC , VonderheidEC , et al. A phase III, randomized, double-blind, placebo-controlled study of peldesine (BCX-34) cream as topical therapy for cutaneous T-cell lymphoma. Journal of the American Academy of Dermatology2001;44(6):940-7. [CENTRAL: CN-00348073] [PMID: 11369904]">Duvic 2001a</a>) provided details about how double‐blinding of e.g. participants, investigators, statisticians and other study personnel was maintained. If studies used different modalities (e.g. PUVA versus capsules) and blinding participants or clinicians was hardly possible, we judged lack of blinding to be an unclear risk (<a href="./references#CD008946-bbs2-0002" title="ChildFJ , MitchellTJ , WhittakerSJ , ScarisbrickJJ , SeedPT , Russel-JonesR . A randomized cross-over study to compare PUVA and extracorporeal photopheresis in the treatment of plaque stage (T2) mycosis fungoides. Clinical &amp; Experimental Dermatology2004;29(3):231-6. [CENTRAL: CN-00468455] [PMID: 15115499]ChildFJ , MitchellTJ , WhittakerSJ , WatkinsP , SeedP , Russell-JonesR . A randomised cross-over study to compare Puva and extracorporeal photopheresis (ECP) in the treatment of plaque stage (T2) mycosis fungoides. British Journal of Dermatology2001;145(Suppl 59):16. [CENTRAL: CN-00430854] ">Child 2004</a>; <a href="./references#CD008946-bbs2-0007" title="KayeF , EddyJ , IhdeDC , SteinbergS , FischmannAB , GlatsteinE , et al. Conservative vs. aggressive therapy in mycosis fungoides. Proceedings of the American Society of Clinical Oncology1989;8:257. [CENTRAL: CN-00694960] KayeF , IhdeD , FischmannA , GlatsteinE , MinnaJ , SchechterG , et al. A randomized trial comparing conservative and aggressive therapy in mycosis fungoides (MF). Proceedings of the American Society of Clinical Oncology1986;5:195. [CENTRAL: CN-00695166] KayeFJ , BunnPA , SteinbergSM , StockerJL , IhdeDC , FischmannAB , et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. New England Journal of Medicine1989;321(26):1784-90. [CENTRAL: CN-00064211] [PMID: 2594037]">Kaye 1989</a>; <a href="./references#CD008946-bbs2-0009" title="LessinS , DuvicM , GuitartJ , PandyaA , StroberB , OlsenE , et al. Positive results of a pivotal phase ii trial testing a manufactured 0.02% Mechlorethamine gel in mycosis fungoides (mf). Journal of Investigative Dermatology2011;131(Suppl 1):S84. [CENTRAL: CN-00843792] LessinSR , DuvicM , GuitartJ , PandyaAG , StroberBE , OlsenEA , et al. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatology2013;149(1):25-32. [CENTRAL: CN-00859487] [PMID: 23069814]NCT00168064. Safety and efficacy of nitrogen mustard in treatment of mycosis fungoides. clinicaltrials.gov/ct2/show/NCT00168064 (first received 14 September 2005). ">Lessin 2013</a>; <a href="./references#CD008946-bbs2-0011" title="HorwitzS , WhittakerS , DuvicM , DummerR , KimYH , ScarisbrickJ , et al. Response by stage in CD30-positive (CD30+) cutaneous T cell lymphoma (CTCL) patients receiving brentuximab vedotin (BV) vs physician's choice (PC) in the phase 3 ALCANZA study. In: Hematological oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:245–7. [CENTRAL: CN-01408605] [DOI: 10.1002/hon.2438]HorwitzSM , AkilovOE , FisherD , KuzelTM , WangY , Palanca-WesselsMC , et al. Brentuximab vedotin or physician’s choice in CD30-positivecutaneous T-cell lymphoma (ALCANZA): an international,open-label, randomised, phase 3, multicentre trial. Lancet2017;390(10094):555-66. [CENTRAL: CN-01403731] HorwitzSM , ScarisbrickJJ , DummerR , DuvicM , KimYH , WalewskiJ , et al. Updated analyses of the international, open-label, randomized, phase 3 alcanza study: longer-term evidence for superiority of brentuximab vedotin versus methotrexate or bexarotene for CD30-positive cutaneous T-cell lymphoma (CTCL). In: Blood. Conference: 59th annual meeting of the american society of hematology, ASH 2017. United states. Vol. 130. 2017. [CENTRAL: CN-01450312] KimYH , PrinceHM , WhittakerS , HorwitzSM , DuvicM , ScarisbrickJ , et al. Brentuximab vedotin vs physician's choice in CTCL patients from the phase 3 ALCANZA study: analysis of outcomes by CD30 expression. In: Hematological Oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:77–8. [CENTRAL: CN-01408482] [DOI: 10.1002/hon.2437]KimYH , PrinceHM , WhittakerS , HorwitzSM , DuvicM , ScarisbrickJ , et al. Outcomes by CD30 expression in patients with CTCL receiving brentuximab vedotin (BV) vs physician's choice (PC) in the Phase 3 ALCANZA study. Journal of Clinical Oncology2017;35(15 Supplement 1):7517. [EMBASE: 617388795]KimYH , WhittakerS , DummerR , GeskinLJ , GauthierP , LittleM , et al. Phase 3 study of brentuximab vedotin versus physician's choice of methotrexate or bexarotene in patients (PTS) with CD30-positive (CD30+) cutaneous T-cell lymphoma (CTCL). The alcanza study. Hematological Oncology2013;31(Suppl 1):278. [CENTRAL: CN-01531598] [EMBASE: 71147875]KimYH , WhittakerS , HorwitzSM , DuvicM , DummerR , ScarisbrickJ , et al. Brentuximab vedotin demonstrates superior activity to standard therapy in CD30-expressing (CD30+) cutaneous T-cell lymphoma (CTCL) in the randomized phase 3 ALCANZA study. Journal of Investigative Dermatology2017;137(5 Suppl 1):S45. [CENTRAL: CN-01375469] [EMBASE: 616393777]KimYH , WhittakerS , HorwitzSM , DuvicM , DummerR , ScarisbrickJJ , et al. Brentuximab vedotin demonstrates significantly superior clinical outcomes in patients with CD30-expressing cutaneous T cell lymphoma versus physician's choice (Methotrexate or Bexarotene): the phase 3 alcanza study. In: Blood. Conference: 58th annual meeting of the american society of hematology, ASH 2016. United states. Conference start: 20161203. Conference end: 20161206. Vol. 128. 2016. [CENTRAL: CN-01303081] [EMBASE: 614225065]NCT01578499. A randomised, open-label, phase 3 trial of brentuximab vedotin (SGN-35) versus physician's choice (methotrexate or bexarotene) in patients with CD30-positive cutaneous T-cell lymphoma. clinicaltrials.gov/ct2/show/NCT01578499 (first received 17 April 2012). PrinceHM , DummerR , WhittakerS , HorwitzS , DuvicM , ScarisbrickJ , et al. Patient-reported outcomes and quality of life in patients with cutaneous T cell lymphoma: results from the phase 3 ALCANZA study. In: Hematological Oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:247–8. [CENTRAL: CN-01408603] [DOI: 10.1002/hon.2438]ZagadailovE , PrinceHM , WhittakerS , HorwitzS , DuvicM , KimY , et al. Phase 3 alcanza study of brentuximab vedotin (BV) or physician's choice (PC) of methotrexate (MTX) or bexarotene (BEX) in CD30-positive cutaneous T-cell lymphoma (CTCL): number needed to treat analysis. In: Haematologica. Conference: 22th congress of the european hematology association. Spain. Vol. 102. 2017:251. [CENTRAL: CN-01399195] ">Prince 2017</a>; <a href="./references#CD008946-bbs2-0013" title="OtteHG , KuhlS , StadlerR , LugerT , HenzB , SterryW . Treatment of cutaneous T-cell lymphoma with Interferon alpha and PUVA versus Interferon alpha and Acitretin - results of a prospective randomised multi-centre study [Behandlung des kutanen T-Zell-Lymphoms mit Interferon alpha und PUVA versus Interferon alpha und Acirentin - Ergebnisse einer prospektiv-randomisierten Multicenter-Studie]. Der Hautarzt1997;48(Suppl):S97. [CENTRAL: CN-00495120] OtteHG , StadierR , LugerT , HenzB , SterryW . Open controlled clinical trial on the use of interferon plus acitretin versus interferon plus PUVA in patients with cutaneous T-cell lymphoma (CTCL). Annals of Oncology1996;7(Suppl 3):66. [CENTRAL: CN-00308243] StadlerR , OtteHG , LugerT , HenzBM , KuhlP , ZwingersT , et al. Prospective randomized multicenter clinical trial on the use of interferon -2a plus acitretin versus interferon -2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood1998;92(10):3578-81. [CENTRAL: CN-00156682] [PMID: 9808550]">Stadler 1998</a>; <a href="./references#CD008946-bbs2-0016" title="NCT01686594. A multi-center, randomized study on oral 8-methoxypsoralen plus UVA with or without maintenance therapy in mycosis fungoides EORTC/ISCL stage IA to IIB. clinicaltrials.gov/ct2/show/NCT01686594 (first received 18 September 2012). Vieyra-GarciaP , Fink-PuchesR , PorkertS , LangR , PöchlauerS , RatzingerG , et al. Evaluation of low-dose, low-frequency oral psoralen-UV-A treatment with or without maintenance on early-stage mycosis fungoides: A randomized clinical trial. JAMA Dermatology2019;155(5):538-47. [PMID: 30892603]">Vieyra‐Garcia 2019</a>). If studies used different treatment intervals (e.g. once‐weekly injection versus twice‐weekly injections) and blinding was not provided by placebo treatment (e.g. placebo injections), we judged lack of blinding, which was described or assumed by the description of the study, to represent a high risk of performance bias (<a href="./references#CD008946-bbs2-0004" title="DuvicM , MartinAG , KimY , OlsenE , WoodGS , CrowleyCA , et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Archives of Dermatology2001;137(5):581-93. [CENTRAL: CN-00347816] [PMID: 11346336]PrinceHM , McCormackC , RyanG , BakerC , RotsteinH , DavisonJ , et al. Bexarotene capsules and gel for previously treated patients with cutaneous T-cell lymphoma: results of the Australian patients treated on phase II trials. Australasian Journal of Dermatology2001;42(2):91-7. [CENTRAL: CN-00442169] [PMID: 11309029]">Duvic 2001</a>; <a href="./references#CD008946-bbs2-0006" title="GuitartJ , TuckerR , StevensV . Low dose bexarotene (Targretin®) capsules and phototherapy for early stage cutaneous T-Cell lymphoma. Journal of Investigative Dermatology2002;119(1):241. [CENTRAL: CN-00794450] NCT00030589. A muliticenter, dose-randomized evaluation of Targretin capsules plus PUVA in patients with stage IB - IIA cutaneous T-Cell lymphoma. clinicaltrials.gov/ct/show/NCT00030589 (first received 27 Jaunry 2003). ">Guitart 2002</a>; <a href="./references#CD008946-bbs2-0010" title="DuvicM , KuzelTM , OlsenEA , MartinAG , FossFM , KimYH , et al. Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK). Clinical Lymphoma2002;2(4):222-8. [CENTRAL: CN-00514479] [PMID: 11970761]KuzelT , OlsenE , MartinA , KimY , DuvicM , FrankelA , et al. Pivotal phase III trial of two dose levels of DAB389IL-2 (Ontak®) for the treatment of mycosis fungoides (MF). Blood1997;90(10 Suppl 1 (Pt 1)):586a. [CENTRAL: CN-00518069] NTC00050999. Study of ONTAK (Denileukin Diftitox) in cutaneous T-Cell lymphoma (CTCL) patients. clinicaltrials.gov/ct2/show/NCT00050999 (first received 3 January 2003). OlsenE , DuvicM , FrankelA , KimY , MartinA , VonderheidE , et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. Journal of Clinical Oncology2001;19(2):376-88. [CENTRAL: CN-00328506] [PMID: 11208829]OlsenE , DuvicM , MartinA . Pivotal phase III trial of two dose levels of DAB 389 IL-2 (ONTAK) for the treatment of cutaneous T-cell lymphoma (CTCL). Journal of Investigative Dermatology1998;110(4):678. [CENTRAL: CN-00353452] ">Olsen 2001</a>; <a href="./references#CD008946-bbs2-0014" title="BohmeyerJ , OtteHG , StadlerR , LugerT , SterryW . Therapy of cutaneous T-cell lymphoma with PUVA versus interferon alfa plus PUVA: first results. Journal of the European Academy of Dermatology &amp; Venereology1999;12(Suppl 2):S268. [CENTRAL: CN-00478472] BohmeyerJ , StadlerR , LugerT , SterryW . Prospective randomized multicentre therapy optimizing protocol for therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α + PUVA [Prospectiv randomisiertes, multizentrisches Therapieoptimierungsprotokoll zur Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α + PUVA]. Zeitschrift für Hautkrankheiten2001;76(Suppl 1):S55. [CENTRAL: CN-01446038] KremerA , BohmeyerJ , StadlerR , LugerT , SterryW . Prospective randomized multicentre therapy optimizing protocol for therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α + PUVA [Prospectiv randomisiertes, multizentrisches Therapieoptimierungsprotokoll zur Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α + PUVA]. Journal der Deutschen Dermatologischen Gesellschaft2003;1(Suppl 1):S99. [CENTRAL: CN-01446037] OtteHG , StadlerR , LugerT , SterryW . Therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α plus PUVA: first results of a prospective randomized multicentre therapy optimizing protocol [Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α plus PUVA: Erste Ergebnisse des prospektiven randomisierten multizentrischen Therapieoptimierungsprotokolls]. Der Hautarzt1999;50(Suppl 1):S2. [CENTRAL: CN-01457423] OtteHG , StadlerR . Combination therapy of cutaneous t-cell-lymphoma with interferon alfa 2a and PUVA [Kombinationstherapie kutaner T-Zell-Lymphome mit Interferon Alfa 2a und PUVA]. Zentralblatt Haut- und Geschlechtskrankheiten1993;162(Suppl):P2.03.08. [CENTRAL: CN-01457422] StadlerM , KremerA , LugerT , SterryW . Prospective, randomized, multicentre clinical trial on the use of interferon a 2a plus PUVA versus PUVA monotherapy in patients with cutaneous T-cell lymphoma, stages I and II [Abstract 7541]. ASCO annual meeting proceedings. Journal of Clinical Oncology2006;24(18S Pt 1):432. [CENTRAL: CN-00625001] ">Stadler 2006</a>; <a href="./references#CD008946-bbs2-0020" title="WozniakMB , TraceyL , Ortiz-RomeroPL , MontesS , AlvarezM , FragaJ , et al. Psoralen plus ultraviolet A +/- interferon-alpha treatment resistance in mycosis fungoides: the role of tumour microenvironment, nuclear transcription factor-kappaB and T-cell receptor pathways. British Journal of Dermatology2008;160(1):92-102. [CENTRAL: CN-00668828] [PMID: 18945306]">Wozniak 2008</a>). <a href="./references#CD008946-bbs2-0008" title="BagotM , DalleS , SokolL , TsianakasA , MusiekA , Ortiz-RomeroP , et al. Long-term clinical benefit to anti-CCR4 mogamulizumab: results from the phase 3 mavoric study in previously treated cutaneous t-cell lymphoma (CTCL). Blood2018;132(Supp 1):2901. [DOI: 10.1182/blood-2018-99-118473]CowanR , ScarisbrickJ , DwyerK , LeoniM , GrebennikD , MorrisS . Mogamulizumab demonstrates significant improvement in PFS compared to vorinostat in patients with previously treated cutaneous T-cell lymphoma (CTCL). British Journal of Haematology2018;181(S1):77–8. [DOI: 10.1111/bjh.15226]KimYH , BagotM , Pinter-BrownL , RookAH , PorcuP , HorwitzSM , et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncology2018;19(9):1192-1204. [PMID: 30100375]NCT01728805. Study of KW-0761 versus vorinostat in relapsed/refractory CTCL. clinicaltrials.gov/ct2/show/NCT01728805 (first received 20 November 2012). PorcuP , HudgensS , QuaglinoP , CowanR , FlodenL , LeoniM , et al. Quality of life in cutaneous T-cell lymphoma subjects treated with anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat: results from the phase 3 MAVORIC trial. Journal of Clinical Oncology2018;36(15):-. [DOI: 10.1097/HS9.0000000000000060]QuaglinoP , HudgensS , PorcuP , CowanR , FlodenL , TsianakasA , et al. Quality of life in cutaneous t-cell lymphoma subjects treated with the anti-ccr4 monoclonal antibody mogamulizumab versus vorinostat: results from the phase 3 mavoric trial. Hemasphere2018;2(S1):85. ScarisbrickJ , ZinzaniPL , HorwitzS , KimYH , MoskowitzAJ , PorcuP , et al. Efficacy of mogamulizumab by prior systemic therapy in patients with previously treated cutaneous T-cell lymphoma: Post hoc analysis from the phase 3 MAVORIC study. British Journal of Haematology2019;185(Suppl 1):94. TsianakasA , QuaglinoP , HudgensS , FlodenL , LeoniM , DaleS , et al. Quality of life in cutaneous T-cell lymphoma subjects treated with the anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat: Results from the phase 3 MAVORIC trial. Oncology Research and Treatment2018;41(Suppl 4):272. ZinzaniPL , HorwitzSM , KimYH , MoskowitzAJ , PorcuP , ScarisbrickJ , et al. Efficacy of mogamulizumab by prior systemic therapy in patients with previously treated cutaneous T-cell lymphoma: post hoc analysis from the phase 3 mavoric study. Blood2018;132(Suppl 1):1619. [DOI: 10.1182/blood-2018-99-114819]">Kim 2018</a> was an open‐label study. The authors of one study comparing PUVA + bexarotene versus PUVA alone (<a href="./references#CD008946-bbs2-0018" title="NCT00056056. Ultraviolet light therapy using methoxsalen with or without Bexarotene in treating patients with mycosis fungoides. clinicaltrials.gov/ct2/show/NCT00056056 (first received 7 March 2003). WhittakerS , OrtizP , DummerR , RankiA , HasanB , MeulemansB , et al. Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial 21011 (NCT00056056). British Journal of Dermatology2012;167(3):678-87. [CENTRAL: CN-00856432] [PMID: 22924950]WhittakerS , Ortiz-RomeroPL , DummerR , RankiA , HasanB , MeulemansB , et al. Efficacy and safety of bexarotene combined with psoralen/ultraviolet A light (PUVA) compared to PUVA treatment alone in stage IB-IIa mycosis fungoides (MF): Final results from EORTC cutaneous lymphoma task force (CLTF) phase III clinical trial 21011. Journal of Clinical Oncology2012;30(15 Suppl 1):8076. ">Whittaker 2012</a>) described that study personnel were not blinded to the treatment arms, which we ranked as a high risk of performance bias, since a placebo pill in the control arm could have been easily administered. </p> <p>Outcome assessors were described as blinded in eight studies (<a href="./references#CD008946-bbs2-0004" title="DuvicM , MartinAG , KimY , OlsenE , WoodGS , CrowleyCA , et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Archives of Dermatology2001;137(5):581-93. [CENTRAL: CN-00347816] [PMID: 11346336]PrinceHM , McCormackC , RyanG , BakerC , RotsteinH , DavisonJ , et al. Bexarotene capsules and gel for previously treated patients with cutaneous T-cell lymphoma: results of the Australian patients treated on phase II trials. Australasian Journal of Dermatology2001;42(2):91-7. [CENTRAL: CN-00442169] [PMID: 11309029]">Duvic 2001</a>; <a href="./references#CD008946-bbs2-0005" title="DuvicM , OlsenEA , OmuraGA , MaizeJC , VonderheidEC , et al. A phase III, randomized, double-blind, placebo-controlled study of peldesine (BCX-34) cream as topical therapy for cutaneous T-cell lymphoma. Journal of the American Academy of Dermatology2001;44(6):940-7. [CENTRAL: CN-00348073] [PMID: 11369904]">Duvic 2001a</a>; <a href="./references#CD008946-bbs2-0008" title="BagotM , DalleS , SokolL , TsianakasA , MusiekA , Ortiz-RomeroP , et al. Long-term clinical benefit to anti-CCR4 mogamulizumab: results from the phase 3 mavoric study in previously treated cutaneous t-cell lymphoma (CTCL). Blood2018;132(Supp 1):2901. [DOI: 10.1182/blood-2018-99-118473]CowanR , ScarisbrickJ , DwyerK , LeoniM , GrebennikD , MorrisS . Mogamulizumab demonstrates significant improvement in PFS compared to vorinostat in patients with previously treated cutaneous T-cell lymphoma (CTCL). British Journal of Haematology2018;181(S1):77–8. [DOI: 10.1111/bjh.15226]KimYH , BagotM , Pinter-BrownL , RookAH , PorcuP , HorwitzSM , et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncology2018;19(9):1192-1204. [PMID: 30100375]NCT01728805. Study of KW-0761 versus vorinostat in relapsed/refractory CTCL. clinicaltrials.gov/ct2/show/NCT01728805 (first received 20 November 2012). PorcuP , HudgensS , QuaglinoP , CowanR , FlodenL , LeoniM , et al. Quality of life in cutaneous T-cell lymphoma subjects treated with anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat: results from the phase 3 MAVORIC trial. Journal of Clinical Oncology2018;36(15):-. [DOI: 10.1097/HS9.0000000000000060]QuaglinoP , HudgensS , PorcuP , CowanR , FlodenL , TsianakasA , et al. Quality of life in cutaneous t-cell lymphoma subjects treated with the anti-ccr4 monoclonal antibody mogamulizumab versus vorinostat: results from the phase 3 mavoric trial. Hemasphere2018;2(S1):85. ScarisbrickJ , ZinzaniPL , HorwitzS , KimYH , MoskowitzAJ , PorcuP , et al. Efficacy of mogamulizumab by prior systemic therapy in patients with previously treated cutaneous T-cell lymphoma: Post hoc analysis from the phase 3 MAVORIC study. British Journal of Haematology2019;185(Suppl 1):94. TsianakasA , QuaglinoP , HudgensS , FlodenL , LeoniM , DaleS , et al. Quality of life in cutaneous T-cell lymphoma subjects treated with the anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat: Results from the phase 3 MAVORIC trial. Oncology Research and Treatment2018;41(Suppl 4):272. ZinzaniPL , HorwitzSM , KimYH , MoskowitzAJ , PorcuP , ScarisbrickJ , et al. Efficacy of mogamulizumab by prior systemic therapy in patients with previously treated cutaneous T-cell lymphoma: post hoc analysis from the phase 3 mavoric study. Blood2018;132(Suppl 1):1619. [DOI: 10.1182/blood-2018-99-114819]">Kim 2018</a>; <a href="./references#CD008946-bbs2-0009" title="LessinS , DuvicM , GuitartJ , PandyaA , StroberB , OlsenE , et al. Positive results of a pivotal phase ii trial testing a manufactured 0.02% Mechlorethamine gel in mycosis fungoides (mf). Journal of Investigative Dermatology2011;131(Suppl 1):S84. [CENTRAL: CN-00843792] LessinSR , DuvicM , GuitartJ , PandyaAG , StroberBE , OlsenEA , et al. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatology2013;149(1):25-32. [CENTRAL: CN-00859487] [PMID: 23069814]NCT00168064. Safety and efficacy of nitrogen mustard in treatment of mycosis fungoides. clinicaltrials.gov/ct2/show/NCT00168064 (first received 14 September 2005). ">Lessin 2013</a>; <a href="./references#CD008946-bbs2-0010" title="DuvicM , KuzelTM , OlsenEA , MartinAG , FossFM , KimYH , et al. Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK). Clinical Lymphoma2002;2(4):222-8. [CENTRAL: CN-00514479] [PMID: 11970761]KuzelT , OlsenE , MartinA , KimY , DuvicM , FrankelA , et al. Pivotal phase III trial of two dose levels of DAB389IL-2 (Ontak®) for the treatment of mycosis fungoides (MF). Blood1997;90(10 Suppl 1 (Pt 1)):586a. [CENTRAL: CN-00518069] NTC00050999. Study of ONTAK (Denileukin Diftitox) in cutaneous T-Cell lymphoma (CTCL) patients. clinicaltrials.gov/ct2/show/NCT00050999 (first received 3 January 2003). OlsenE , DuvicM , FrankelA , KimY , MartinA , VonderheidE , et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. Journal of Clinical Oncology2001;19(2):376-88. [CENTRAL: CN-00328506] [PMID: 11208829]OlsenE , DuvicM , MartinA . Pivotal phase III trial of two dose levels of DAB 389 IL-2 (ONTAK) for the treatment of cutaneous T-cell lymphoma (CTCL). Journal of Investigative Dermatology1998;110(4):678. [CENTRAL: CN-00353452] ">Olsen 2001</a>; <a href="./references#CD008946-bbs2-0011" title="HorwitzS , WhittakerS , DuvicM , DummerR , KimYH , ScarisbrickJ , et al. Response by stage in CD30-positive (CD30+) cutaneous T cell lymphoma (CTCL) patients receiving brentuximab vedotin (BV) vs physician's choice (PC) in the phase 3 ALCANZA study. In: Hematological oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:245–7. [CENTRAL: CN-01408605] [DOI: 10.1002/hon.2438]HorwitzSM , AkilovOE , FisherD , KuzelTM , WangY , Palanca-WesselsMC , et al. Brentuximab vedotin or physician’s choice in CD30-positivecutaneous T-cell lymphoma (ALCANZA): an international,open-label, randomised, phase 3, multicentre trial. Lancet2017;390(10094):555-66. [CENTRAL: CN-01403731] HorwitzSM , ScarisbrickJJ , DummerR , DuvicM , KimYH , WalewskiJ , et al. Updated analyses of the international, open-label, randomized, phase 3 alcanza study: longer-term evidence for superiority of brentuximab vedotin versus methotrexate or bexarotene for CD30-positive cutaneous T-cell lymphoma (CTCL). In: Blood. Conference: 59th annual meeting of the american society of hematology, ASH 2017. United states. Vol. 130. 2017. [CENTRAL: CN-01450312] KimYH , PrinceHM , WhittakerS , HorwitzSM , DuvicM , ScarisbrickJ , et al. Brentuximab vedotin vs physician's choice in CTCL patients from the phase 3 ALCANZA study: analysis of outcomes by CD30 expression. In: Hematological Oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:77–8. [CENTRAL: CN-01408482] [DOI: 10.1002/hon.2437]KimYH , PrinceHM , WhittakerS , HorwitzSM , DuvicM , ScarisbrickJ , et al. Outcomes by CD30 expression in patients with CTCL receiving brentuximab vedotin (BV) vs physician's choice (PC) in the Phase 3 ALCANZA study. Journal of Clinical Oncology2017;35(15 Supplement 1):7517. [EMBASE: 617388795]KimYH , WhittakerS , DummerR , GeskinLJ , GauthierP , LittleM , et al. Phase 3 study of brentuximab vedotin versus physician's choice of methotrexate or bexarotene in patients (PTS) with CD30-positive (CD30+) cutaneous T-cell lymphoma (CTCL). The alcanza study. Hematological Oncology2013;31(Suppl 1):278. [CENTRAL: CN-01531598] [EMBASE: 71147875]KimYH , WhittakerS , HorwitzSM , DuvicM , DummerR , ScarisbrickJ , et al. Brentuximab vedotin demonstrates superior activity to standard therapy in CD30-expressing (CD30+) cutaneous T-cell lymphoma (CTCL) in the randomized phase 3 ALCANZA study. Journal of Investigative Dermatology2017;137(5 Suppl 1):S45. [CENTRAL: CN-01375469] [EMBASE: 616393777]KimYH , WhittakerS , HorwitzSM , DuvicM , DummerR , ScarisbrickJJ , et al. Brentuximab vedotin demonstrates significantly superior clinical outcomes in patients with CD30-expressing cutaneous T cell lymphoma versus physician's choice (Methotrexate or Bexarotene): the phase 3 alcanza study. In: Blood. Conference: 58th annual meeting of the american society of hematology, ASH 2016. United states. Conference start: 20161203. Conference end: 20161206. Vol. 128. 2016. [CENTRAL: CN-01303081] [EMBASE: 614225065]NCT01578499. A randomised, open-label, phase 3 trial of brentuximab vedotin (SGN-35) versus physician's choice (methotrexate or bexarotene) in patients with CD30-positive cutaneous T-cell lymphoma. clinicaltrials.gov/ct2/show/NCT01578499 (first received 17 April 2012). PrinceHM , DummerR , WhittakerS , HorwitzS , DuvicM , ScarisbrickJ , et al. Patient-reported outcomes and quality of life in patients with cutaneous T cell lymphoma: results from the phase 3 ALCANZA study. In: Hematological Oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:247–8. [CENTRAL: CN-01408603] [DOI: 10.1002/hon.2438]ZagadailovE , PrinceHM , WhittakerS , HorwitzS , DuvicM , KimY , et al. Phase 3 alcanza study of brentuximab vedotin (BV) or physician's choice (PC) of methotrexate (MTX) or bexarotene (BEX) in CD30-positive cutaneous T-cell lymphoma (CTCL): number needed to treat analysis. In: Haematologica. Conference: 22th congress of the european hematology association. Spain. Vol. 102. 2017:251. [CENTRAL: CN-01399195] ">Prince 2017</a>; <a href="./references#CD008946-bbs2-0015" title="Thestrup-PedersenK , GrunnetE , ZachariaeH . Transfer factor therapy in mycosis fungoides: a double-blind study. Acta Dermato-Venereologica1982;62(1):47-53. [CENTRAL: CN-00027377] [PMID: 6175137]">Thestrup‐Pedersen 1982</a>; <a href="./references#CD008946-bbs2-0019" title="WolffJM , ZitelliJA , RabinBS , SmilesKA , AbellE . Intralesional interferon in the treatment of early mycosis fungoides. Journal of the American Academy of Dermatology1985;13(4):604-12. [CENTRAL: CN-00040943] [PMID: 2934438]">Wolff 1985</a>). In all other studies (<a href="./references#CD008946-bbs2-0001" title="BagotM , HasanB , WhittakerS , Beylot-BarryM , KnoblerR , ShahE , et al. A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma - EORTC 21081 (NCT01098656): results and lessons learned for future trial designs. European Journal of Dermatology2017;27(3):286–94. [CENTRAL: CN-01395486] [PMID: 28468739]NCT01098656. A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-Cell lymphoma. clinicaltrials.gov/ct2/show/NCT01098656 (first received 5 April 2010). [NCT01098656]">Bagot 2017</a>; <a href="./references#CD008946-bbs2-0002" title="ChildFJ , MitchellTJ , WhittakerSJ , ScarisbrickJJ , SeedPT , Russel-JonesR . A randomized cross-over study to compare PUVA and extracorporeal photopheresis in the treatment of plaque stage (T2) mycosis fungoides. Clinical &amp; Experimental Dermatology2004;29(3):231-6. [CENTRAL: CN-00468455] [PMID: 15115499]ChildFJ , MitchellTJ , WhittakerSJ , WatkinsP , SeedP , Russell-JonesR . A randomised cross-over study to compare Puva and extracorporeal photopheresis (ECP) in the treatment of plaque stage (T2) mycosis fungoides. British Journal of Dermatology2001;145(Suppl 59):16. [CENTRAL: CN-00430854] ">Child 2004</a>; <a href="./references#CD008946-bbs2-0003" title="ChongA , LooWJ , BanneyL , GrantJW , NorrisPG . Imiquimod 5% cream in the treatment of mycosis fungoides - a pilot study. Journal of Dermatological Treatment2004;15(2):118-9. [CENTRAL: CN-00467258] [PMID: 15204164]">Chong 2004</a>; <a href="./references#CD008946-bbs2-0006" title="GuitartJ , TuckerR , StevensV . Low dose bexarotene (Targretin®) capsules and phototherapy for early stage cutaneous T-Cell lymphoma. Journal of Investigative Dermatology2002;119(1):241. [CENTRAL: CN-00794450] NCT00030589. A muliticenter, dose-randomized evaluation of Targretin capsules plus PUVA in patients with stage IB - IIA cutaneous T-Cell lymphoma. clinicaltrials.gov/ct/show/NCT00030589 (first received 27 Jaunry 2003). ">Guitart 2002</a>; <a href="./references#CD008946-bbs2-0007" title="KayeF , EddyJ , IhdeDC , SteinbergS , FischmannAB , GlatsteinE , et al. Conservative vs. aggressive therapy in mycosis fungoides. Proceedings of the American Society of Clinical Oncology1989;8:257. [CENTRAL: CN-00694960] KayeF , IhdeD , FischmannA , GlatsteinE , MinnaJ , SchechterG , et al. A randomized trial comparing conservative and aggressive therapy in mycosis fungoides (MF). Proceedings of the American Society of Clinical Oncology1986;5:195. [CENTRAL: CN-00695166] KayeFJ , BunnPA , SteinbergSM , StockerJL , IhdeDC , FischmannAB , et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. New England Journal of Medicine1989;321(26):1784-90. [CENTRAL: CN-00064211] [PMID: 2594037]">Kaye 1989</a>; <a href="./references#CD008946-bbs2-0012" title="RookAH , WoodGS , DuvicM , VonderheidEC , TobiaA , CabanaB . A phase II placebo-controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis. Journal of the American Academy of Dermatology2010;63(6):984-90. [CENTRAL: CN-00772559] [PMID: 20889234]">Rook 2010</a>; <a href="./references#CD008946-bbs2-0013" title="OtteHG , KuhlS , StadlerR , LugerT , HenzB , SterryW . Treatment of cutaneous T-cell lymphoma with Interferon alpha and PUVA versus Interferon alpha and Acitretin - results of a prospective randomised multi-centre study [Behandlung des kutanen T-Zell-Lymphoms mit Interferon alpha und PUVA versus Interferon alpha und Acirentin - Ergebnisse einer prospektiv-randomisierten Multicenter-Studie]. Der Hautarzt1997;48(Suppl):S97. [CENTRAL: CN-00495120] OtteHG , StadierR , LugerT , HenzB , SterryW . Open controlled clinical trial on the use of interferon plus acitretin versus interferon plus PUVA in patients with cutaneous T-cell lymphoma (CTCL). Annals of Oncology1996;7(Suppl 3):66. [CENTRAL: CN-00308243] StadlerR , OtteHG , LugerT , HenzBM , KuhlP , ZwingersT , et al. Prospective randomized multicenter clinical trial on the use of interferon -2a plus acitretin versus interferon -2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood1998;92(10):3578-81. [CENTRAL: CN-00156682] [PMID: 9808550]">Stadler 1998</a>; <a href="./references#CD008946-bbs2-0014" title="BohmeyerJ , OtteHG , StadlerR , LugerT , SterryW . Therapy of cutaneous T-cell lymphoma with PUVA versus interferon alfa plus PUVA: first results. Journal of the European Academy of Dermatology &amp; Venereology1999;12(Suppl 2):S268. [CENTRAL: CN-00478472] BohmeyerJ , StadlerR , LugerT , SterryW . Prospective randomized multicentre therapy optimizing protocol for therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α + PUVA [Prospectiv randomisiertes, multizentrisches Therapieoptimierungsprotokoll zur Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α + PUVA]. Zeitschrift für Hautkrankheiten2001;76(Suppl 1):S55. [CENTRAL: CN-01446038] KremerA , BohmeyerJ , StadlerR , LugerT , SterryW . Prospective randomized multicentre therapy optimizing protocol for therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α + PUVA [Prospectiv randomisiertes, multizentrisches Therapieoptimierungsprotokoll zur Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α + PUVA]. Journal der Deutschen Dermatologischen Gesellschaft2003;1(Suppl 1):S99. [CENTRAL: CN-01446037] OtteHG , StadlerR , LugerT , SterryW . Therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α plus PUVA: first results of a prospective randomized multicentre therapy optimizing protocol [Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α plus PUVA: Erste Ergebnisse des prospektiven randomisierten multizentrischen Therapieoptimierungsprotokolls]. Der Hautarzt1999;50(Suppl 1):S2. [CENTRAL: CN-01457423] OtteHG , StadlerR . Combination therapy of cutaneous t-cell-lymphoma with interferon alfa 2a and PUVA [Kombinationstherapie kutaner T-Zell-Lymphome mit Interferon Alfa 2a und PUVA]. Zentralblatt Haut- und Geschlechtskrankheiten1993;162(Suppl):P2.03.08. [CENTRAL: CN-01457422] StadlerM , KremerA , LugerT , SterryW . Prospective, randomized, multicentre clinical trial on the use of interferon a 2a plus PUVA versus PUVA monotherapy in patients with cutaneous T-cell lymphoma, stages I and II [Abstract 7541]. ASCO annual meeting proceedings. Journal of Clinical Oncology2006;24(18S Pt 1):432. [CENTRAL: CN-00625001] ">Stadler 2006</a>; <a href="./references#CD008946-bbs2-0017" title="VonderheidEC , ThompsonR , SmilesKA , LattanandA . Recombinant interferon alfa-2b in plaque-phase mycosis fungoides. Intralesional and low-dose intramuscular therapy. Archives of Dermatology1987;123(6):757-63. [CENTRAL: CN-00047990] [PMID: 3579357]">Vonderheid 1987</a>; <a href="./references#CD008946-bbs2-0018" title="NCT00056056. Ultraviolet light therapy using methoxsalen with or without Bexarotene in treating patients with mycosis fungoides. clinicaltrials.gov/ct2/show/NCT00056056 (first received 7 March 2003). WhittakerS , OrtizP , DummerR , RankiA , HasanB , MeulemansB , et al. Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial 21011 (NCT00056056). British Journal of Dermatology2012;167(3):678-87. [CENTRAL: CN-00856432] [PMID: 22924950]WhittakerS , Ortiz-RomeroPL , DummerR , RankiA , HasanB , MeulemansB , et al. Efficacy and safety of bexarotene combined with psoralen/ultraviolet A light (PUVA) compared to PUVA treatment alone in stage IB-IIa mycosis fungoides (MF): Final results from EORTC cutaneous lymphoma task force (CLTF) phase III clinical trial 21011. Journal of Clinical Oncology2012;30(15 Suppl 1):8076. ">Whittaker 2012</a>; <a href="./references#CD008946-bbs2-0020" title="WozniakMB , TraceyL , Ortiz-RomeroPL , MontesS , AlvarezM , FragaJ , et al. Psoralen plus ultraviolet A +/- interferon-alpha treatment resistance in mycosis fungoides: the role of tumour microenvironment, nuclear transcription factor-kappaB and T-cell receptor pathways. British Journal of Dermatology2008;160(1):92-102. [CENTRAL: CN-00668828] [PMID: 18945306]">Wozniak 2008</a>), it remained unclear whether assessors were blinded or not. Final assessment of <a href="./references#CD008946-bbs2-0011" title="HorwitzS , WhittakerS , DuvicM , DummerR , KimYH , ScarisbrickJ , et al. Response by stage in CD30-positive (CD30+) cutaneous T cell lymphoma (CTCL) patients receiving brentuximab vedotin (BV) vs physician's choice (PC) in the phase 3 ALCANZA study. In: Hematological oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:245–7. [CENTRAL: CN-01408605] [DOI: 10.1002/hon.2438]HorwitzSM , AkilovOE , FisherD , KuzelTM , WangY , Palanca-WesselsMC , et al. Brentuximab vedotin or physician’s choice in CD30-positivecutaneous T-cell lymphoma (ALCANZA): an international,open-label, randomised, phase 3, multicentre trial. Lancet2017;390(10094):555-66. [CENTRAL: CN-01403731] HorwitzSM , ScarisbrickJJ , DummerR , DuvicM , KimYH , WalewskiJ , et al. Updated analyses of the international, open-label, randomized, phase 3 alcanza study: longer-term evidence for superiority of brentuximab vedotin versus methotrexate or bexarotene for CD30-positive cutaneous T-cell lymphoma (CTCL). In: Blood. Conference: 59th annual meeting of the american society of hematology, ASH 2017. United states. Vol. 130. 2017. [CENTRAL: CN-01450312] KimYH , PrinceHM , WhittakerS , HorwitzSM , DuvicM , ScarisbrickJ , et al. Brentuximab vedotin vs physician's choice in CTCL patients from the phase 3 ALCANZA study: analysis of outcomes by CD30 expression. In: Hematological Oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:77–8. [CENTRAL: CN-01408482] [DOI: 10.1002/hon.2437]KimYH , PrinceHM , WhittakerS , HorwitzSM , DuvicM , ScarisbrickJ , et al. Outcomes by CD30 expression in patients with CTCL receiving brentuximab vedotin (BV) vs physician's choice (PC) in the Phase 3 ALCANZA study. Journal of Clinical Oncology2017;35(15 Supplement 1):7517. [EMBASE: 617388795]KimYH , WhittakerS , DummerR , GeskinLJ , GauthierP , LittleM , et al. Phase 3 study of brentuximab vedotin versus physician's choice of methotrexate or bexarotene in patients (PTS) with CD30-positive (CD30+) cutaneous T-cell lymphoma (CTCL). The alcanza study. Hematological Oncology2013;31(Suppl 1):278. [CENTRAL: CN-01531598] [EMBASE: 71147875]KimYH , WhittakerS , HorwitzSM , DuvicM , DummerR , ScarisbrickJ , et al. Brentuximab vedotin demonstrates superior activity to standard therapy in CD30-expressing (CD30+) cutaneous T-cell lymphoma (CTCL) in the randomized phase 3 ALCANZA study. Journal of Investigative Dermatology2017;137(5 Suppl 1):S45. [CENTRAL: CN-01375469] [EMBASE: 616393777]KimYH , WhittakerS , HorwitzSM , DuvicM , DummerR , ScarisbrickJJ , et al. Brentuximab vedotin demonstrates significantly superior clinical outcomes in patients with CD30-expressing cutaneous T cell lymphoma versus physician's choice (Methotrexate or Bexarotene): the phase 3 alcanza study. In: Blood. Conference: 58th annual meeting of the american society of hematology, ASH 2016. United states. Conference start: 20161203. Conference end: 20161206. Vol. 128. 2016. [CENTRAL: CN-01303081] [EMBASE: 614225065]NCT01578499. A randomised, open-label, phase 3 trial of brentuximab vedotin (SGN-35) versus physician's choice (methotrexate or bexarotene) in patients with CD30-positive cutaneous T-cell lymphoma. clinicaltrials.gov/ct2/show/NCT01578499 (first received 17 April 2012). PrinceHM , DummerR , WhittakerS , HorwitzS , DuvicM , ScarisbrickJ , et al. Patient-reported outcomes and quality of life in patients with cutaneous T cell lymphoma: results from the phase 3 ALCANZA study. In: Hematological Oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:247–8. [CENTRAL: CN-01408603] [DOI: 10.1002/hon.2438]ZagadailovE , PrinceHM , WhittakerS , HorwitzS , DuvicM , KimY , et al. Phase 3 alcanza study of brentuximab vedotin (BV) or physician's choice (PC) of methotrexate (MTX) or bexarotene (BEX) in CD30-positive cutaneous T-cell lymphoma (CTCL): number needed to treat analysis. In: Haematologica. Conference: 22th congress of the european hematology association. Spain. Vol. 102. 2017:251. [CENTRAL: CN-01399195] ">Prince 2017</a> and <a href="./references#CD008946-bbs2-0001" title="BagotM , HasanB , WhittakerS , Beylot-BarryM , KnoblerR , ShahE , et al. A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma - EORTC 21081 (NCT01098656): results and lessons learned for future trial designs. European Journal of Dermatology2017;27(3):286–94. [CENTRAL: CN-01395486] [PMID: 28468739]NCT01098656. A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-Cell lymphoma. clinicaltrials.gov/ct2/show/NCT01098656 (first received 5 April 2010). [NCT01098656]">Bagot 2017</a> was performed after contacting the respective author teams. </p> <p>Further details are provided in the 'Risk of bias' tables in the <a href="./references#CD008946-sec-0233" title="">Characteristics of included studies</a> section. </p> </section> <section id="CD008946-sec-0083"> <h4 class="title">Incomplete outcome data</h4> <p>The overall number of participants lost to follow‐up was 185/1369 (13.5%) of the total number of study participants included in the review. Dropout rates varied from 0% to 72.4%. Eighteen of the included studies analysed data on an intention‐to‐treat (ITT) basis. We regarded studies to have a low risk of bias if either analyses were ITT analyses with complete outcome data for the participants analysed in the randomised group (<a href="./references#CD008946-bbs2-0003" title="ChongA , LooWJ , BanneyL , GrantJW , NorrisPG . Imiquimod 5% cream in the treatment of mycosis fungoides - a pilot study. Journal of Dermatological Treatment2004;15(2):118-9. [CENTRAL: CN-00467258] [PMID: 15204164]">Chong 2004</a>; <a href="./references#CD008946-bbs2-0008" title="BagotM , DalleS , SokolL , TsianakasA , MusiekA , Ortiz-RomeroP , et al. Long-term clinical benefit to anti-CCR4 mogamulizumab: results from the phase 3 mavoric study in previously treated cutaneous t-cell lymphoma (CTCL). Blood2018;132(Supp 1):2901. [DOI: 10.1182/blood-2018-99-118473]CowanR , ScarisbrickJ , DwyerK , LeoniM , GrebennikD , MorrisS . Mogamulizumab demonstrates significant improvement in PFS compared to vorinostat in patients with previously treated cutaneous T-cell lymphoma (CTCL). British Journal of Haematology2018;181(S1):77–8. [DOI: 10.1111/bjh.15226]KimYH , BagotM , Pinter-BrownL , RookAH , PorcuP , HorwitzSM , et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncology2018;19(9):1192-1204. [PMID: 30100375]NCT01728805. Study of KW-0761 versus vorinostat in relapsed/refractory CTCL. clinicaltrials.gov/ct2/show/NCT01728805 (first received 20 November 2012). PorcuP , HudgensS , QuaglinoP , CowanR , FlodenL , LeoniM , et al. Quality of life in cutaneous T-cell lymphoma subjects treated with anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat: results from the phase 3 MAVORIC trial. Journal of Clinical Oncology2018;36(15):-. [DOI: 10.1097/HS9.0000000000000060]QuaglinoP , HudgensS , PorcuP , CowanR , FlodenL , TsianakasA , et al. Quality of life in cutaneous t-cell lymphoma subjects treated with the anti-ccr4 monoclonal antibody mogamulizumab versus vorinostat: results from the phase 3 mavoric trial. Hemasphere2018;2(S1):85. ScarisbrickJ , ZinzaniPL , HorwitzS , KimYH , MoskowitzAJ , PorcuP , et al. Efficacy of mogamulizumab by prior systemic therapy in patients with previously treated cutaneous T-cell lymphoma: Post hoc analysis from the phase 3 MAVORIC study. British Journal of Haematology2019;185(Suppl 1):94. TsianakasA , QuaglinoP , HudgensS , FlodenL , LeoniM , DaleS , et al. Quality of life in cutaneous T-cell lymphoma subjects treated with the anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat: Results from the phase 3 MAVORIC trial. Oncology Research and Treatment2018;41(Suppl 4):272. ZinzaniPL , HorwitzSM , KimYH , MoskowitzAJ , PorcuP , ScarisbrickJ , et al. Efficacy of mogamulizumab by prior systemic therapy in patients with previously treated cutaneous T-cell lymphoma: post hoc analysis from the phase 3 mavoric study. Blood2018;132(Suppl 1):1619. [DOI: 10.1182/blood-2018-99-114819]">Kim 2018</a>; <a href="./references#CD008946-bbs2-0011" title="HorwitzS , WhittakerS , DuvicM , DummerR , KimYH , ScarisbrickJ , et al. Response by stage in CD30-positive (CD30+) cutaneous T cell lymphoma (CTCL) patients receiving brentuximab vedotin (BV) vs physician's choice (PC) in the phase 3 ALCANZA study. In: Hematological oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:245–7. [CENTRAL: CN-01408605] [DOI: 10.1002/hon.2438]HorwitzSM , AkilovOE , FisherD , KuzelTM , WangY , Palanca-WesselsMC , et al. Brentuximab vedotin or physician’s choice in CD30-positivecutaneous T-cell lymphoma (ALCANZA): an international,open-label, randomised, phase 3, multicentre trial. Lancet2017;390(10094):555-66. [CENTRAL: CN-01403731] HorwitzSM , ScarisbrickJJ , DummerR , DuvicM , KimYH , WalewskiJ , et al. Updated analyses of the international, open-label, randomized, phase 3 alcanza study: longer-term evidence for superiority of brentuximab vedotin versus methotrexate or bexarotene for CD30-positive cutaneous T-cell lymphoma (CTCL). In: Blood. Conference: 59th annual meeting of the american society of hematology, ASH 2017. United states. Vol. 130. 2017. [CENTRAL: CN-01450312] KimYH , PrinceHM , WhittakerS , HorwitzSM , DuvicM , ScarisbrickJ , et al. Brentuximab vedotin vs physician's choice in CTCL patients from the phase 3 ALCANZA study: analysis of outcomes by CD30 expression. In: Hematological Oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:77–8. [CENTRAL: CN-01408482] [DOI: 10.1002/hon.2437]KimYH , PrinceHM , WhittakerS , HorwitzSM , DuvicM , ScarisbrickJ , et al. Outcomes by CD30 expression in patients with CTCL receiving brentuximab vedotin (BV) vs physician's choice (PC) in the Phase 3 ALCANZA study. Journal of Clinical Oncology2017;35(15 Supplement 1):7517. [EMBASE: 617388795]KimYH , WhittakerS , DummerR , GeskinLJ , GauthierP , LittleM , et al. Phase 3 study of brentuximab vedotin versus physician's choice of methotrexate or bexarotene in patients (PTS) with CD30-positive (CD30+) cutaneous T-cell lymphoma (CTCL). The alcanza study. Hematological Oncology2013;31(Suppl 1):278. [CENTRAL: CN-01531598] [EMBASE: 71147875]KimYH , WhittakerS , HorwitzSM , DuvicM , DummerR , ScarisbrickJ , et al. Brentuximab vedotin demonstrates superior activity to standard therapy in CD30-expressing (CD30+) cutaneous T-cell lymphoma (CTCL) in the randomized phase 3 ALCANZA study. Journal of Investigative Dermatology2017;137(5 Suppl 1):S45. [CENTRAL: CN-01375469] [EMBASE: 616393777]KimYH , WhittakerS , HorwitzSM , DuvicM , DummerR , ScarisbrickJJ , et al. Brentuximab vedotin demonstrates significantly superior clinical outcomes in patients with CD30-expressing cutaneous T cell lymphoma versus physician's choice (Methotrexate or Bexarotene): the phase 3 alcanza study. In: Blood. Conference: 58th annual meeting of the american society of hematology, ASH 2016. United states. Conference start: 20161203. Conference end: 20161206. Vol. 128. 2016. [CENTRAL: CN-01303081] [EMBASE: 614225065]NCT01578499. A randomised, open-label, phase 3 trial of brentuximab vedotin (SGN-35) versus physician's choice (methotrexate or bexarotene) in patients with CD30-positive cutaneous T-cell lymphoma. clinicaltrials.gov/ct2/show/NCT01578499 (first received 17 April 2012). PrinceHM , DummerR , WhittakerS , HorwitzS , DuvicM , ScarisbrickJ , et al. Patient-reported outcomes and quality of life in patients with cutaneous T cell lymphoma: results from the phase 3 ALCANZA study. In: Hematological Oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:247–8. [CENTRAL: CN-01408603] [DOI: 10.1002/hon.2438]ZagadailovE , PrinceHM , WhittakerS , HorwitzS , DuvicM , KimY , et al. Phase 3 alcanza study of brentuximab vedotin (BV) or physician's choice (PC) of methotrexate (MTX) or bexarotene (BEX) in CD30-positive cutaneous T-cell lymphoma (CTCL): number needed to treat analysis. In: Haematologica. Conference: 22th congress of the european hematology association. Spain. Vol. 102. 2017:251. [CENTRAL: CN-01399195] ">Prince 2017</a>; <a href="./references#CD008946-bbs2-0012" title="RookAH , WoodGS , DuvicM , VonderheidEC , TobiaA , CabanaB . A phase II placebo-controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis. Journal of the American Academy of Dermatology2010;63(6):984-90. [CENTRAL: CN-00772559] [PMID: 20889234]">Rook 2010</a>; <a href="./references#CD008946-bbs2-0016" title="NCT01686594. A multi-center, randomized study on oral 8-methoxypsoralen plus UVA with or without maintenance therapy in mycosis fungoides EORTC/ISCL stage IA to IIB. clinicaltrials.gov/ct2/show/NCT01686594 (first received 18 September 2012). Vieyra-GarciaP , Fink-PuchesR , PorkertS , LangR , PöchlauerS , RatzingerG , et al. Evaluation of low-dose, low-frequency oral psoralen-UV-A treatment with or without maintenance on early-stage mycosis fungoides: A randomized clinical trial. JAMA Dermatology2019;155(5):538-47. [PMID: 30892603]">Vieyra‐Garcia 2019</a>; <a href="./references#CD008946-bbs2-0017" title="VonderheidEC , ThompsonR , SmilesKA , LattanandA . Recombinant interferon alfa-2b in plaque-phase mycosis fungoides. Intralesional and low-dose intramuscular therapy. Archives of Dermatology1987;123(6):757-63. [CENTRAL: CN-00047990] [PMID: 3579357]">Vonderheid 1987</a>; <a href="./references#CD008946-bbs2-0019" title="WolffJM , ZitelliJA , RabinBS , SmilesKA , AbellE . Intralesional interferon in the treatment of early mycosis fungoides. Journal of the American Academy of Dermatology1985;13(4):604-12. [CENTRAL: CN-00040943] [PMID: 2934438]">Wolff 1985</a>; <a href="./references#CD008946-bbs2-0020" title="WozniakMB , TraceyL , Ortiz-RomeroPL , MontesS , AlvarezM , FragaJ , et al. Psoralen plus ultraviolet A +/- interferon-alpha treatment resistance in mycosis fungoides: the role of tumour microenvironment, nuclear transcription factor-kappaB and T-cell receptor pathways. British Journal of Dermatology2008;160(1):92-102. [CENTRAL: CN-00668828] [PMID: 18945306]">Wozniak 2008</a>) or dropout rates were &lt; 10% and data from dropouts were explicitly included in the ITT analysis (<a href="./references#CD008946-bbs2-0006" title="GuitartJ , TuckerR , StevensV . Low dose bexarotene (Targretin®) capsules and phototherapy for early stage cutaneous T-Cell lymphoma. Journal of Investigative Dermatology2002;119(1):241. [CENTRAL: CN-00794450] NCT00030589. A muliticenter, dose-randomized evaluation of Targretin capsules plus PUVA in patients with stage IB - IIA cutaneous T-Cell lymphoma. clinicaltrials.gov/ct/show/NCT00030589 (first received 27 Jaunry 2003). ">Guitart 2002</a>; <a href="./references#CD008946-bbs2-0009" title="LessinS , DuvicM , GuitartJ , PandyaA , StroberB , OlsenE , et al. Positive results of a pivotal phase ii trial testing a manufactured 0.02% Mechlorethamine gel in mycosis fungoides (mf). Journal of Investigative Dermatology2011;131(Suppl 1):S84. [CENTRAL: CN-00843792] LessinSR , DuvicM , GuitartJ , PandyaAG , StroberBE , OlsenEA , et al. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatology2013;149(1):25-32. [CENTRAL: CN-00859487] [PMID: 23069814]NCT00168064. Safety and efficacy of nitrogen mustard in treatment of mycosis fungoides. clinicaltrials.gov/ct2/show/NCT00168064 (first received 14 September 2005). ">Lessin 2013</a>; <a href="./references#CD008946-bbs2-0018" title="NCT00056056. Ultraviolet light therapy using methoxsalen with or without Bexarotene in treating patients with mycosis fungoides. clinicaltrials.gov/ct2/show/NCT00056056 (first received 7 March 2003). WhittakerS , OrtizP , DummerR , RankiA , HasanB , MeulemansB , et al. Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial 21011 (NCT00056056). British Journal of Dermatology2012;167(3):678-87. [CENTRAL: CN-00856432] [PMID: 22924950]WhittakerS , Ortiz-RomeroPL , DummerR , RankiA , HasanB , MeulemansB , et al. Efficacy and safety of bexarotene combined with psoralen/ultraviolet A light (PUVA) compared to PUVA treatment alone in stage IB-IIa mycosis fungoides (MF): Final results from EORTC cutaneous lymphoma task force (CLTF) phase III clinical trial 21011. Journal of Clinical Oncology2012;30(15 Suppl 1):8076. ">Whittaker 2012</a>). We judged studies to have an unclear risk of bias if dropouts were 10% to 20% and data were analysed on an ITT basis (<a href="./references#CD008946-bbs2-0007" title="KayeF , EddyJ , IhdeDC , SteinbergS , FischmannAB , GlatsteinE , et al. Conservative vs. aggressive therapy in mycosis fungoides. Proceedings of the American Society of Clinical Oncology1989;8:257. [CENTRAL: CN-00694960] KayeF , IhdeD , FischmannA , GlatsteinE , MinnaJ , SchechterG , et al. A randomized trial comparing conservative and aggressive therapy in mycosis fungoides (MF). Proceedings of the American Society of Clinical Oncology1986;5:195. [CENTRAL: CN-00695166] KayeFJ , BunnPA , SteinbergSM , StockerJL , IhdeDC , FischmannAB , et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. New England Journal of Medicine1989;321(26):1784-90. [CENTRAL: CN-00064211] [PMID: 2594037]">Kaye 1989</a>), or if the number of participants randomised was unclear (<a href="./references#CD008946-bbs2-0015" title="Thestrup-PedersenK , GrunnetE , ZachariaeH . Transfer factor therapy in mycosis fungoides: a double-blind study. Acta Dermato-Venereologica1982;62(1):47-53. [CENTRAL: CN-00027377] [PMID: 6175137]">Thestrup‐Pedersen 1982</a>). Studies with dropouts &gt; 10% that were analysed by per‐protocol analysis (<a href="./references#CD008946-bbs2-0013" title="OtteHG , KuhlS , StadlerR , LugerT , HenzB , SterryW . Treatment of cutaneous T-cell lymphoma with Interferon alpha and PUVA versus Interferon alpha and Acitretin - results of a prospective randomised multi-centre study [Behandlung des kutanen T-Zell-Lymphoms mit Interferon alpha und PUVA versus Interferon alpha und Acirentin - Ergebnisse einer prospektiv-randomisierten Multicenter-Studie]. Der Hautarzt1997;48(Suppl):S97. [CENTRAL: CN-00495120] OtteHG , StadierR , LugerT , HenzB , SterryW . Open controlled clinical trial on the use of interferon plus acitretin versus interferon plus PUVA in patients with cutaneous T-cell lymphoma (CTCL). Annals of Oncology1996;7(Suppl 3):66. [CENTRAL: CN-00308243] StadlerR , OtteHG , LugerT , HenzBM , KuhlP , ZwingersT , et al. Prospective randomized multicenter clinical trial on the use of interferon -2a plus acitretin versus interferon -2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood1998;92(10):3578-81. [CENTRAL: CN-00156682] [PMID: 9808550]">Stadler 1998</a>) or with dropouts &gt; 20% that were analysed by ITT (<a href="./references#CD008946-bbs2-0001" title="BagotM , HasanB , WhittakerS , Beylot-BarryM , KnoblerR , ShahE , et al. A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma - EORTC 21081 (NCT01098656): results and lessons learned for future trial designs. European Journal of Dermatology2017;27(3):286–94. [CENTRAL: CN-01395486] [PMID: 28468739]NCT01098656. A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-Cell lymphoma. clinicaltrials.gov/ct2/show/NCT01098656 (first received 5 April 2010). [NCT01098656]">Bagot 2017</a>; <a href="./references#CD008946-bbs2-0002" title="ChildFJ , MitchellTJ , WhittakerSJ , ScarisbrickJJ , SeedPT , Russel-JonesR . A randomized cross-over study to compare PUVA and extracorporeal photopheresis in the treatment of plaque stage (T2) mycosis fungoides. Clinical &amp; Experimental Dermatology2004;29(3):231-6. [CENTRAL: CN-00468455] [PMID: 15115499]ChildFJ , MitchellTJ , WhittakerSJ , WatkinsP , SeedP , Russell-JonesR . A randomised cross-over study to compare Puva and extracorporeal photopheresis (ECP) in the treatment of plaque stage (T2) mycosis fungoides. British Journal of Dermatology2001;145(Suppl 59):16. [CENTRAL: CN-00430854] ">Child 2004</a>; <a href="./references#CD008946-bbs2-0004" title="DuvicM , MartinAG , KimY , OlsenE , WoodGS , CrowleyCA , et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Archives of Dermatology2001;137(5):581-93. [CENTRAL: CN-00347816] [PMID: 11346336]PrinceHM , McCormackC , RyanG , BakerC , RotsteinH , DavisonJ , et al. Bexarotene capsules and gel for previously treated patients with cutaneous T-cell lymphoma: results of the Australian patients treated on phase II trials. Australasian Journal of Dermatology2001;42(2):91-7. [CENTRAL: CN-00442169] [PMID: 11309029]">Duvic 2001</a>; <a href="./references#CD008946-bbs2-0005" title="DuvicM , OlsenEA , OmuraGA , MaizeJC , VonderheidEC , et al. A phase III, randomized, double-blind, placebo-controlled study of peldesine (BCX-34) cream as topical therapy for cutaneous T-cell lymphoma. Journal of the American Academy of Dermatology2001;44(6):940-7. [CENTRAL: CN-00348073] [PMID: 11369904]">Duvic 2001a</a>; <a href="./references#CD008946-bbs2-0010" title="DuvicM , KuzelTM , OlsenEA , MartinAG , FossFM , KimYH , et al. Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK). Clinical Lymphoma2002;2(4):222-8. [CENTRAL: CN-00514479] [PMID: 11970761]KuzelT , OlsenE , MartinA , KimY , DuvicM , FrankelA , et al. Pivotal phase III trial of two dose levels of DAB389IL-2 (Ontak®) for the treatment of mycosis fungoides (MF). Blood1997;90(10 Suppl 1 (Pt 1)):586a. [CENTRAL: CN-00518069] NTC00050999. Study of ONTAK (Denileukin Diftitox) in cutaneous T-Cell lymphoma (CTCL) patients. clinicaltrials.gov/ct2/show/NCT00050999 (first received 3 January 2003). OlsenE , DuvicM , FrankelA , KimY , MartinA , VonderheidE , et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. Journal of Clinical Oncology2001;19(2):376-88. [CENTRAL: CN-00328506] [PMID: 11208829]OlsenE , DuvicM , MartinA . Pivotal phase III trial of two dose levels of DAB 389 IL-2 (ONTAK) for the treatment of cutaneous T-cell lymphoma (CTCL). Journal of Investigative Dermatology1998;110(4):678. [CENTRAL: CN-00353452] ">Olsen 2001</a>; <a href="./references#CD008946-bbs2-0014" title="BohmeyerJ , OtteHG , StadlerR , LugerT , SterryW . Therapy of cutaneous T-cell lymphoma with PUVA versus interferon alfa plus PUVA: first results. Journal of the European Academy of Dermatology &amp; Venereology1999;12(Suppl 2):S268. [CENTRAL: CN-00478472] BohmeyerJ , StadlerR , LugerT , SterryW . Prospective randomized multicentre therapy optimizing protocol for therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α + PUVA [Prospectiv randomisiertes, multizentrisches Therapieoptimierungsprotokoll zur Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α + PUVA]. Zeitschrift für Hautkrankheiten2001;76(Suppl 1):S55. [CENTRAL: CN-01446038] KremerA , BohmeyerJ , StadlerR , LugerT , SterryW . Prospective randomized multicentre therapy optimizing protocol for therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α + PUVA [Prospectiv randomisiertes, multizentrisches Therapieoptimierungsprotokoll zur Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α + PUVA]. Journal der Deutschen Dermatologischen Gesellschaft2003;1(Suppl 1):S99. [CENTRAL: CN-01446037] OtteHG , StadlerR , LugerT , SterryW . Therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α plus PUVA: first results of a prospective randomized multicentre therapy optimizing protocol [Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α plus PUVA: Erste Ergebnisse des prospektiven randomisierten multizentrischen Therapieoptimierungsprotokolls]. Der Hautarzt1999;50(Suppl 1):S2. [CENTRAL: CN-01457423] OtteHG , StadlerR . Combination therapy of cutaneous t-cell-lymphoma with interferon alfa 2a and PUVA [Kombinationstherapie kutaner T-Zell-Lymphome mit Interferon Alfa 2a und PUVA]. Zentralblatt Haut- und Geschlechtskrankheiten1993;162(Suppl):P2.03.08. [CENTRAL: CN-01457422] StadlerM , KremerA , LugerT , SterryW . Prospective, randomized, multicentre clinical trial on the use of interferon a 2a plus PUVA versus PUVA monotherapy in patients with cutaneous T-cell lymphoma, stages I and II [Abstract 7541]. ASCO annual meeting proceedings. Journal of Clinical Oncology2006;24(18S Pt 1):432. [CENTRAL: CN-00625001] ">Stadler 2006</a>) were regarded as having a high risk of bias. In particular, the high dropout rate of 72.4% in the trial of <a href="./references#CD008946-bbs2-0004" title="DuvicM , MartinAG , KimY , OlsenE , WoodGS , CrowleyCA , et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Archives of Dermatology2001;137(5):581-93. [CENTRAL: CN-00347816] [PMID: 11346336]PrinceHM , McCormackC , RyanG , BakerC , RotsteinH , DavisonJ , et al. Bexarotene capsules and gel for previously treated patients with cutaneous T-cell lymphoma: results of the Australian patients treated on phase II trials. Australasian Journal of Dermatology2001;42(2):91-7. [CENTRAL: CN-00442169] [PMID: 11309029]">Duvic 2001</a> made it difficult to draw reasonable conclusions. </p> <p>Further details are provided in the 'Risk of bias' tables in the <a href="./references#CD008946-sec-0233" title="">Characteristics of included studies</a> section. </p> </section> <section id="CD008946-sec-0084"> <h4 class="title">Selective reporting</h4> <p>We contacted the corresponding authors of included studies to provide data about outcomes not reported in their publications, although this method has methodological limitations (<a href="./references#CD008946-bbs2-0102" title="ChanAW , HróbjartssonA , HaahrMT , GøtzschePC , AltmanDG . Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA2004;291(20):2457-65.">Chan 2004</a>). With regard to selective reporting, if an included study was previously registered in a screened database of ongoing trials, we compared all stages of the published with the reported outcomes. </p> <p>Three authors responded and stated that all of the outcomes within their studies were reported (<a href="./references#CD008946-bbs2-0001" title="BagotM , HasanB , WhittakerS , Beylot-BarryM , KnoblerR , ShahE , et al. A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma - EORTC 21081 (NCT01098656): results and lessons learned for future trial designs. European Journal of Dermatology2017;27(3):286–94. [CENTRAL: CN-01395486] [PMID: 28468739]NCT01098656. A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-Cell lymphoma. clinicaltrials.gov/ct2/show/NCT01098656 (first received 5 April 2010). [NCT01098656]">Bagot 2017</a>; <a href="./references#CD008946-bbs2-0006" title="GuitartJ , TuckerR , StevensV . Low dose bexarotene (Targretin®) capsules and phototherapy for early stage cutaneous T-Cell lymphoma. Journal of Investigative Dermatology2002;119(1):241. [CENTRAL: CN-00794450] NCT00030589. A muliticenter, dose-randomized evaluation of Targretin capsules plus PUVA in patients with stage IB - IIA cutaneous T-Cell lymphoma. clinicaltrials.gov/ct/show/NCT00030589 (first received 27 Jaunry 2003). ">Guitart 2002</a>; <a href="./references#CD008946-bbs2-0015" title="Thestrup-PedersenK , GrunnetE , ZachariaeH . Transfer factor therapy in mycosis fungoides: a double-blind study. Acta Dermato-Venereologica1982;62(1):47-53. [CENTRAL: CN-00027377] [PMID: 6175137]">Thestrup‐Pedersen 1982</a>). These studies were judged to have a low risk of reporting bias. Since some studies reported results for some end points for responders and non‐responders instead of comparisons between treatment groups (<a href="./references#CD008946-bbs2-0010" title="DuvicM , KuzelTM , OlsenEA , MartinAG , FossFM , KimYH , et al. Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK). Clinical Lymphoma2002;2(4):222-8. [CENTRAL: CN-00514479] [PMID: 11970761]KuzelT , OlsenE , MartinA , KimY , DuvicM , FrankelA , et al. Pivotal phase III trial of two dose levels of DAB389IL-2 (Ontak®) for the treatment of mycosis fungoides (MF). Blood1997;90(10 Suppl 1 (Pt 1)):586a. [CENTRAL: CN-00518069] NTC00050999. Study of ONTAK (Denileukin Diftitox) in cutaneous T-Cell lymphoma (CTCL) patients. clinicaltrials.gov/ct2/show/NCT00050999 (first received 3 January 2003). OlsenE , DuvicM , FrankelA , KimY , MartinA , VonderheidE , et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. Journal of Clinical Oncology2001;19(2):376-88. [CENTRAL: CN-00328506] [PMID: 11208829]OlsenE , DuvicM , MartinA . Pivotal phase III trial of two dose levels of DAB 389 IL-2 (ONTAK) for the treatment of cutaneous T-cell lymphoma (CTCL). Journal of Investigative Dermatology1998;110(4):678. [CENTRAL: CN-00353452] ">Olsen 2001</a>; <a href="./references#CD008946-bbs2-0020" title="WozniakMB , TraceyL , Ortiz-RomeroPL , MontesS , AlvarezM , FragaJ , et al. Psoralen plus ultraviolet A +/- interferon-alpha treatment resistance in mycosis fungoides: the role of tumour microenvironment, nuclear transcription factor-kappaB and T-cell receptor pathways. British Journal of Dermatology2008;160(1):92-102. [CENTRAL: CN-00668828] [PMID: 18945306]">Wozniak 2008</a>), only reported on a single end point (<a href="./references#CD008946-bbs2-0014" title="BohmeyerJ , OtteHG , StadlerR , LugerT , SterryW . Therapy of cutaneous T-cell lymphoma with PUVA versus interferon alfa plus PUVA: first results. Journal of the European Academy of Dermatology &amp; Venereology1999;12(Suppl 2):S268. [CENTRAL: CN-00478472] BohmeyerJ , StadlerR , LugerT , SterryW . Prospective randomized multicentre therapy optimizing protocol for therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α + PUVA [Prospectiv randomisiertes, multizentrisches Therapieoptimierungsprotokoll zur Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α + PUVA]. Zeitschrift für Hautkrankheiten2001;76(Suppl 1):S55. [CENTRAL: CN-01446038] KremerA , BohmeyerJ , StadlerR , LugerT , SterryW . Prospective randomized multicentre therapy optimizing protocol for therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α + PUVA [Prospectiv randomisiertes, multizentrisches Therapieoptimierungsprotokoll zur Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α + PUVA]. Journal der Deutschen Dermatologischen Gesellschaft2003;1(Suppl 1):S99. [CENTRAL: CN-01446037] OtteHG , StadlerR , LugerT , SterryW . Therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α plus PUVA: first results of a prospective randomized multicentre therapy optimizing protocol [Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α plus PUVA: Erste Ergebnisse des prospektiven randomisierten multizentrischen Therapieoptimierungsprotokolls]. Der Hautarzt1999;50(Suppl 1):S2. [CENTRAL: CN-01457423] OtteHG , StadlerR . Combination therapy of cutaneous t-cell-lymphoma with interferon alfa 2a and PUVA [Kombinationstherapie kutaner T-Zell-Lymphome mit Interferon Alfa 2a und PUVA]. Zentralblatt Haut- und Geschlechtskrankheiten1993;162(Suppl):P2.03.08. [CENTRAL: CN-01457422] StadlerM , KremerA , LugerT , SterryW . Prospective, randomized, multicentre clinical trial on the use of interferon a 2a plus PUVA versus PUVA monotherapy in patients with cutaneous T-cell lymphoma, stages I and II [Abstract 7541]. ASCO annual meeting proceedings. Journal of Clinical Oncology2006;24(18S Pt 1):432. [CENTRAL: CN-00625001] ">Stadler 2006</a>), or used mean differences instead of absolute results (<a href="./references#CD008946-bbs2-0019" title="WolffJM , ZitelliJA , RabinBS , SmilesKA , AbellE . Intralesional interferon in the treatment of early mycosis fungoides. Journal of the American Academy of Dermatology1985;13(4):604-12. [CENTRAL: CN-00040943] [PMID: 2934438]">Wolff 1985</a>), we regarded these studies to have a high risk of bias for selective reporting. In <a href="./references#CD008946-bbs2-0008" title="BagotM , DalleS , SokolL , TsianakasA , MusiekA , Ortiz-RomeroP , et al. Long-term clinical benefit to anti-CCR4 mogamulizumab: results from the phase 3 mavoric study in previously treated cutaneous t-cell lymphoma (CTCL). Blood2018;132(Supp 1):2901. [DOI: 10.1182/blood-2018-99-118473]CowanR , ScarisbrickJ , DwyerK , LeoniM , GrebennikD , MorrisS . Mogamulizumab demonstrates significant improvement in PFS compared to vorinostat in patients with previously treated cutaneous T-cell lymphoma (CTCL). British Journal of Haematology2018;181(S1):77–8. [DOI: 10.1111/bjh.15226]KimYH , BagotM , Pinter-BrownL , RookAH , PorcuP , HorwitzSM , et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncology2018;19(9):1192-1204. [PMID: 30100375]NCT01728805. Study of KW-0761 versus vorinostat in relapsed/refractory CTCL. clinicaltrials.gov/ct2/show/NCT01728805 (first received 20 November 2012). PorcuP , HudgensS , QuaglinoP , CowanR , FlodenL , LeoniM , et al. Quality of life in cutaneous T-cell lymphoma subjects treated with anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat: results from the phase 3 MAVORIC trial. Journal of Clinical Oncology2018;36(15):-. [DOI: 10.1097/HS9.0000000000000060]QuaglinoP , HudgensS , PorcuP , CowanR , FlodenL , TsianakasA , et al. Quality of life in cutaneous t-cell lymphoma subjects treated with the anti-ccr4 monoclonal antibody mogamulizumab versus vorinostat: results from the phase 3 mavoric trial. Hemasphere2018;2(S1):85. ScarisbrickJ , ZinzaniPL , HorwitzS , KimYH , MoskowitzAJ , PorcuP , et al. Efficacy of mogamulizumab by prior systemic therapy in patients with previously treated cutaneous T-cell lymphoma: Post hoc analysis from the phase 3 MAVORIC study. British Journal of Haematology2019;185(Suppl 1):94. TsianakasA , QuaglinoP , HudgensS , FlodenL , LeoniM , DaleS , et al. Quality of life in cutaneous T-cell lymphoma subjects treated with the anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat: Results from the phase 3 MAVORIC trial. Oncology Research and Treatment2018;41(Suppl 4):272. ZinzaniPL , HorwitzSM , KimYH , MoskowitzAJ , PorcuP , ScarisbrickJ , et al. Efficacy of mogamulizumab by prior systemic therapy in patients with previously treated cutaneous T-cell lymphoma: post hoc analysis from the phase 3 mavoric study. Blood2018;132(Suppl 1):1619. [DOI: 10.1182/blood-2018-99-114819]">Kim 2018</a> and <a href="./references#CD008946-bbs2-0011" title="HorwitzS , WhittakerS , DuvicM , DummerR , KimYH , ScarisbrickJ , et al. Response by stage in CD30-positive (CD30+) cutaneous T cell lymphoma (CTCL) patients receiving brentuximab vedotin (BV) vs physician's choice (PC) in the phase 3 ALCANZA study. In: Hematological oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:245–7. [CENTRAL: CN-01408605] [DOI: 10.1002/hon.2438]HorwitzSM , AkilovOE , FisherD , KuzelTM , WangY , Palanca-WesselsMC , et al. Brentuximab vedotin or physician’s choice in CD30-positivecutaneous T-cell lymphoma (ALCANZA): an international,open-label, randomised, phase 3, multicentre trial. Lancet2017;390(10094):555-66. [CENTRAL: CN-01403731] HorwitzSM , ScarisbrickJJ , DummerR , DuvicM , KimYH , WalewskiJ , et al. Updated analyses of the international, open-label, randomized, phase 3 alcanza study: longer-term evidence for superiority of brentuximab vedotin versus methotrexate or bexarotene for CD30-positive cutaneous T-cell lymphoma (CTCL). In: Blood. Conference: 59th annual meeting of the american society of hematology, ASH 2017. United states. Vol. 130. 2017. [CENTRAL: CN-01450312] KimYH , PrinceHM , WhittakerS , HorwitzSM , DuvicM , ScarisbrickJ , et al. Brentuximab vedotin vs physician's choice in CTCL patients from the phase 3 ALCANZA study: analysis of outcomes by CD30 expression. In: Hematological Oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:77–8. [CENTRAL: CN-01408482] [DOI: 10.1002/hon.2437]KimYH , PrinceHM , WhittakerS , HorwitzSM , DuvicM , ScarisbrickJ , et al. Outcomes by CD30 expression in patients with CTCL receiving brentuximab vedotin (BV) vs physician's choice (PC) in the Phase 3 ALCANZA study. Journal of Clinical Oncology2017;35(15 Supplement 1):7517. [EMBASE: 617388795]KimYH , WhittakerS , DummerR , GeskinLJ , GauthierP , LittleM , et al. Phase 3 study of brentuximab vedotin versus physician's choice of methotrexate or bexarotene in patients (PTS) with CD30-positive (CD30+) cutaneous T-cell lymphoma (CTCL). The alcanza study. Hematological Oncology2013;31(Suppl 1):278. [CENTRAL: CN-01531598] [EMBASE: 71147875]KimYH , WhittakerS , HorwitzSM , DuvicM , DummerR , ScarisbrickJ , et al. Brentuximab vedotin demonstrates superior activity to standard therapy in CD30-expressing (CD30+) cutaneous T-cell lymphoma (CTCL) in the randomized phase 3 ALCANZA study. Journal of Investigative Dermatology2017;137(5 Suppl 1):S45. [CENTRAL: CN-01375469] [EMBASE: 616393777]KimYH , WhittakerS , HorwitzSM , DuvicM , DummerR , ScarisbrickJJ , et al. Brentuximab vedotin demonstrates significantly superior clinical outcomes in patients with CD30-expressing cutaneous T cell lymphoma versus physician's choice (Methotrexate or Bexarotene): the phase 3 alcanza study. In: Blood. Conference: 58th annual meeting of the american society of hematology, ASH 2016. United states. Conference start: 20161203. Conference end: 20161206. Vol. 128. 2016. [CENTRAL: CN-01303081] [EMBASE: 614225065]NCT01578499. A randomised, open-label, phase 3 trial of brentuximab vedotin (SGN-35) versus physician's choice (methotrexate or bexarotene) in patients with CD30-positive cutaneous T-cell lymphoma. clinicaltrials.gov/ct2/show/NCT01578499 (first received 17 April 2012). PrinceHM , DummerR , WhittakerS , HorwitzS , DuvicM , ScarisbrickJ , et al. Patient-reported outcomes and quality of life in patients with cutaneous T cell lymphoma: results from the phase 3 ALCANZA study. In: Hematological Oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:247–8. [CENTRAL: CN-01408603] [DOI: 10.1002/hon.2438]ZagadailovE , PrinceHM , WhittakerS , HorwitzS , DuvicM , KimY , et al. Phase 3 alcanza study of brentuximab vedotin (BV) or physician's choice (PC) of methotrexate (MTX) or bexarotene (BEX) in CD30-positive cutaneous T-cell lymphoma (CTCL): number needed to treat analysis. In: Haematologica. Conference: 22th congress of the european hematology association. Spain. Vol. 102. 2017:251. [CENTRAL: CN-01399195] ">Prince 2017</a>, only a proportion of the outcomes were reported, therefore we rated these trials to be of high risk of reporting bias as well. Furthermore, we identified two studies which did not report the prespecified secondary outcomes listed in the trials registry (<a href="./references#CD008946-bbs2-0009" title="LessinS , DuvicM , GuitartJ , PandyaA , StroberB , OlsenE , et al. Positive results of a pivotal phase ii trial testing a manufactured 0.02% Mechlorethamine gel in mycosis fungoides (mf). Journal of Investigative Dermatology2011;131(Suppl 1):S84. [CENTRAL: CN-00843792] LessinSR , DuvicM , GuitartJ , PandyaAG , StroberBE , OlsenEA , et al. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatology2013;149(1):25-32. [CENTRAL: CN-00859487] [PMID: 23069814]NCT00168064. Safety and efficacy of nitrogen mustard in treatment of mycosis fungoides. clinicaltrials.gov/ct2/show/NCT00168064 (first received 14 September 2005). ">Lessin 2013</a>; <a href="./references#CD008946-bbs2-0016" title="NCT01686594. A multi-center, randomized study on oral 8-methoxypsoralen plus UVA with or without maintenance therapy in mycosis fungoides EORTC/ISCL stage IA to IIB. clinicaltrials.gov/ct2/show/NCT01686594 (first received 18 September 2012). Vieyra-GarciaP , Fink-PuchesR , PorkertS , LangR , PöchlauerS , RatzingerG , et al. Evaluation of low-dose, low-frequency oral psoralen-UV-A treatment with or without maintenance on early-stage mycosis fungoides: A randomized clinical trial. JAMA Dermatology2019;155(5):538-47. [PMID: 30892603]">Vieyra‐Garcia 2019</a>). Hence, we judged these studies to be at high risk of reporting bias. </p> <p>Further details are provided in the 'Risk of bias' tables in the <a href="./references#CD008946-sec-0233" title="">Characteristics of included studies</a> section. </p> </section> <section id="CD008946-sec-0085"> <h4 class="title">Other potential sources of bias</h4> <p>Details of other aspects that are likely to have impact on validity or may be sources of other bias are mentioned in the 'Risk of bias' tables in the <a href="./references#CD008946-sec-0233" title="">Characteristics of included studies</a> section. Only four studies were considered free of other sources of bias (<a href="./references#CD008946-bbs2-0003" title="ChongA , LooWJ , BanneyL , GrantJW , NorrisPG . Imiquimod 5% cream in the treatment of mycosis fungoides - a pilot study. Journal of Dermatological Treatment2004;15(2):118-9. [CENTRAL: CN-00467258] [PMID: 15204164]">Chong 2004</a>; <a href="./references#CD008946-bbs2-0005" title="DuvicM , OlsenEA , OmuraGA , MaizeJC , VonderheidEC , et al. A phase III, randomized, double-blind, placebo-controlled study of peldesine (BCX-34) cream as topical therapy for cutaneous T-cell lymphoma. Journal of the American Academy of Dermatology2001;44(6):940-7. [CENTRAL: CN-00348073] [PMID: 11369904]">Duvic 2001a</a><a href="./references#CD008946-bbs2-0009" title="LessinS , DuvicM , GuitartJ , PandyaA , StroberB , OlsenE , et al. Positive results of a pivotal phase ii trial testing a manufactured 0.02% Mechlorethamine gel in mycosis fungoides (mf). Journal of Investigative Dermatology2011;131(Suppl 1):S84. [CENTRAL: CN-00843792] LessinSR , DuvicM , GuitartJ , PandyaAG , StroberBE , OlsenEA , et al. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatology2013;149(1):25-32. [CENTRAL: CN-00859487] [PMID: 23069814]NCT00168064. Safety and efficacy of nitrogen mustard in treatment of mycosis fungoides. clinicaltrials.gov/ct2/show/NCT00168064 (first received 14 September 2005). ">Lessin 2013</a>; <a href="./references#CD008946-bbs2-0011" title="HorwitzS , WhittakerS , DuvicM , DummerR , KimYH , ScarisbrickJ , et al. Response by stage in CD30-positive (CD30+) cutaneous T cell lymphoma (CTCL) patients receiving brentuximab vedotin (BV) vs physician's choice (PC) in the phase 3 ALCANZA study. In: Hematological oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:245–7. [CENTRAL: CN-01408605] [DOI: 10.1002/hon.2438]HorwitzSM , AkilovOE , FisherD , KuzelTM , WangY , Palanca-WesselsMC , et al. Brentuximab vedotin or physician’s choice in CD30-positivecutaneous T-cell lymphoma (ALCANZA): an international,open-label, randomised, phase 3, multicentre trial. Lancet2017;390(10094):555-66. [CENTRAL: CN-01403731] HorwitzSM , ScarisbrickJJ , DummerR , DuvicM , KimYH , WalewskiJ , et al. Updated analyses of the international, open-label, randomized, phase 3 alcanza study: longer-term evidence for superiority of brentuximab vedotin versus methotrexate or bexarotene for CD30-positive cutaneous T-cell lymphoma (CTCL). In: Blood. Conference: 59th annual meeting of the american society of hematology, ASH 2017. United states. Vol. 130. 2017. [CENTRAL: CN-01450312] KimYH , PrinceHM , WhittakerS , HorwitzSM , DuvicM , ScarisbrickJ , et al. Brentuximab vedotin vs physician's choice in CTCL patients from the phase 3 ALCANZA study: analysis of outcomes by CD30 expression. In: Hematological Oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:77–8. [CENTRAL: CN-01408482] [DOI: 10.1002/hon.2437]KimYH , PrinceHM , WhittakerS , HorwitzSM , DuvicM , ScarisbrickJ , et al. Outcomes by CD30 expression in patients with CTCL receiving brentuximab vedotin (BV) vs physician's choice (PC) in the Phase 3 ALCANZA study. Journal of Clinical Oncology2017;35(15 Supplement 1):7517. [EMBASE: 617388795]KimYH , WhittakerS , DummerR , GeskinLJ , GauthierP , LittleM , et al. Phase 3 study of brentuximab vedotin versus physician's choice of methotrexate or bexarotene in patients (PTS) with CD30-positive (CD30+) cutaneous T-cell lymphoma (CTCL). The alcanza study. Hematological Oncology2013;31(Suppl 1):278. [CENTRAL: CN-01531598] [EMBASE: 71147875]KimYH , WhittakerS , HorwitzSM , DuvicM , DummerR , ScarisbrickJ , et al. Brentuximab vedotin demonstrates superior activity to standard therapy in CD30-expressing (CD30+) cutaneous T-cell lymphoma (CTCL) in the randomized phase 3 ALCANZA study. Journal of Investigative Dermatology2017;137(5 Suppl 1):S45. [CENTRAL: CN-01375469] [EMBASE: 616393777]KimYH , WhittakerS , HorwitzSM , DuvicM , DummerR , ScarisbrickJJ , et al. Brentuximab vedotin demonstrates significantly superior clinical outcomes in patients with CD30-expressing cutaneous T cell lymphoma versus physician's choice (Methotrexate or Bexarotene): the phase 3 alcanza study. In: Blood. Conference: 58th annual meeting of the american society of hematology, ASH 2016. United states. Conference start: 20161203. Conference end: 20161206. Vol. 128. 2016. [CENTRAL: CN-01303081] [EMBASE: 614225065]NCT01578499. A randomised, open-label, phase 3 trial of brentuximab vedotin (SGN-35) versus physician's choice (methotrexate or bexarotene) in patients with CD30-positive cutaneous T-cell lymphoma. clinicaltrials.gov/ct2/show/NCT01578499 (first received 17 April 2012). PrinceHM , DummerR , WhittakerS , HorwitzS , DuvicM , ScarisbrickJ , et al. Patient-reported outcomes and quality of life in patients with cutaneous T cell lymphoma: results from the phase 3 ALCANZA study. In: Hematological Oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:247–8. [CENTRAL: CN-01408603] [DOI: 10.1002/hon.2438]ZagadailovE , PrinceHM , WhittakerS , HorwitzS , DuvicM , KimY , et al. Phase 3 alcanza study of brentuximab vedotin (BV) or physician's choice (PC) of methotrexate (MTX) or bexarotene (BEX) in CD30-positive cutaneous T-cell lymphoma (CTCL): number needed to treat analysis. In: Haematologica. Conference: 22th congress of the european hematology association. Spain. Vol. 102. 2017:251. [CENTRAL: CN-01399195] ">Prince 2017</a>). Ten studies were considered high risk of other biases (<a href="./references#CD008946-bbs2-0001" title="BagotM , HasanB , WhittakerS , Beylot-BarryM , KnoblerR , ShahE , et al. A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma - EORTC 21081 (NCT01098656): results and lessons learned for future trial designs. European Journal of Dermatology2017;27(3):286–94. [CENTRAL: CN-01395486] [PMID: 28468739]NCT01098656. A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-Cell lymphoma. clinicaltrials.gov/ct2/show/NCT01098656 (first received 5 April 2010). [NCT01098656]">Bagot 2017</a>; <a href="./references#CD008946-bbs2-0002" title="ChildFJ , MitchellTJ , WhittakerSJ , ScarisbrickJJ , SeedPT , Russel-JonesR . A randomized cross-over study to compare PUVA and extracorporeal photopheresis in the treatment of plaque stage (T2) mycosis fungoides. Clinical &amp; Experimental Dermatology2004;29(3):231-6. [CENTRAL: CN-00468455] [PMID: 15115499]ChildFJ , MitchellTJ , WhittakerSJ , WatkinsP , SeedP , Russell-JonesR . A randomised cross-over study to compare Puva and extracorporeal photopheresis (ECP) in the treatment of plaque stage (T2) mycosis fungoides. British Journal of Dermatology2001;145(Suppl 59):16. [CENTRAL: CN-00430854] ">Child 2004</a>; <a href="./references#CD008946-bbs2-0004" title="DuvicM , MartinAG , KimY , OlsenE , WoodGS , CrowleyCA , et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Archives of Dermatology2001;137(5):581-93. [CENTRAL: CN-00347816] [PMID: 11346336]PrinceHM , McCormackC , RyanG , BakerC , RotsteinH , DavisonJ , et al. Bexarotene capsules and gel for previously treated patients with cutaneous T-cell lymphoma: results of the Australian patients treated on phase II trials. Australasian Journal of Dermatology2001;42(2):91-7. [CENTRAL: CN-00442169] [PMID: 11309029]">Duvic 2001</a>; <a href="./references#CD008946-bbs2-0006" title="GuitartJ , TuckerR , StevensV . Low dose bexarotene (Targretin®) capsules and phototherapy for early stage cutaneous T-Cell lymphoma. Journal of Investigative Dermatology2002;119(1):241. [CENTRAL: CN-00794450] NCT00030589. A muliticenter, dose-randomized evaluation of Targretin capsules plus PUVA in patients with stage IB - IIA cutaneous T-Cell lymphoma. clinicaltrials.gov/ct/show/NCT00030589 (first received 27 Jaunry 2003). ">Guitart 2002</a>; <a href="./references#CD008946-bbs2-0008" title="BagotM , DalleS , SokolL , TsianakasA , MusiekA , Ortiz-RomeroP , et al. Long-term clinical benefit to anti-CCR4 mogamulizumab: results from the phase 3 mavoric study in previously treated cutaneous t-cell lymphoma (CTCL). Blood2018;132(Supp 1):2901. [DOI: 10.1182/blood-2018-99-118473]CowanR , ScarisbrickJ , DwyerK , LeoniM , GrebennikD , MorrisS . Mogamulizumab demonstrates significant improvement in PFS compared to vorinostat in patients with previously treated cutaneous T-cell lymphoma (CTCL). British Journal of Haematology2018;181(S1):77–8. [DOI: 10.1111/bjh.15226]KimYH , BagotM , Pinter-BrownL , RookAH , PorcuP , HorwitzSM , et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncology2018;19(9):1192-1204. [PMID: 30100375]NCT01728805. Study of KW-0761 versus vorinostat in relapsed/refractory CTCL. clinicaltrials.gov/ct2/show/NCT01728805 (first received 20 November 2012). PorcuP , HudgensS , QuaglinoP , CowanR , FlodenL , LeoniM , et al. Quality of life in cutaneous T-cell lymphoma subjects treated with anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat: results from the phase 3 MAVORIC trial. Journal of Clinical Oncology2018;36(15):-. [DOI: 10.1097/HS9.0000000000000060]QuaglinoP , HudgensS , PorcuP , CowanR , FlodenL , TsianakasA , et al. Quality of life in cutaneous t-cell lymphoma subjects treated with the anti-ccr4 monoclonal antibody mogamulizumab versus vorinostat: results from the phase 3 mavoric trial. Hemasphere2018;2(S1):85. ScarisbrickJ , ZinzaniPL , HorwitzS , KimYH , MoskowitzAJ , PorcuP , et al. Efficacy of mogamulizumab by prior systemic therapy in patients with previously treated cutaneous T-cell lymphoma: Post hoc analysis from the phase 3 MAVORIC study. British Journal of Haematology2019;185(Suppl 1):94. TsianakasA , QuaglinoP , HudgensS , FlodenL , LeoniM , DaleS , et al. Quality of life in cutaneous T-cell lymphoma subjects treated with the anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat: Results from the phase 3 MAVORIC trial. Oncology Research and Treatment2018;41(Suppl 4):272. ZinzaniPL , HorwitzSM , KimYH , MoskowitzAJ , PorcuP , ScarisbrickJ , et al. Efficacy of mogamulizumab by prior systemic therapy in patients with previously treated cutaneous T-cell lymphoma: post hoc analysis from the phase 3 mavoric study. Blood2018;132(Suppl 1):1619. [DOI: 10.1182/blood-2018-99-114819]">Kim 2018</a>; <a href="./references#CD008946-bbs2-0015" title="Thestrup-PedersenK , GrunnetE , ZachariaeH . Transfer factor therapy in mycosis fungoides: a double-blind study. Acta Dermato-Venereologica1982;62(1):47-53. [CENTRAL: CN-00027377] [PMID: 6175137]">Thestrup‐Pedersen 1982</a>; <a href="./references#CD008946-bbs2-0016" title="NCT01686594. A multi-center, randomized study on oral 8-methoxypsoralen plus UVA with or without maintenance therapy in mycosis fungoides EORTC/ISCL stage IA to IIB. clinicaltrials.gov/ct2/show/NCT01686594 (first received 18 September 2012). Vieyra-GarciaP , Fink-PuchesR , PorkertS , LangR , PöchlauerS , RatzingerG , et al. Evaluation of low-dose, low-frequency oral psoralen-UV-A treatment with or without maintenance on early-stage mycosis fungoides: A randomized clinical trial. JAMA Dermatology2019;155(5):538-47. [PMID: 30892603]">Vieyra‐Garcia 2019</a>; <a href="./references#CD008946-bbs2-0018" title="NCT00056056. Ultraviolet light therapy using methoxsalen with or without Bexarotene in treating patients with mycosis fungoides. clinicaltrials.gov/ct2/show/NCT00056056 (first received 7 March 2003). WhittakerS , OrtizP , DummerR , RankiA , HasanB , MeulemansB , et al. Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial 21011 (NCT00056056). British Journal of Dermatology2012;167(3):678-87. [CENTRAL: CN-00856432] [PMID: 22924950]WhittakerS , Ortiz-RomeroPL , DummerR , RankiA , HasanB , MeulemansB , et al. Efficacy and safety of bexarotene combined with psoralen/ultraviolet A light (PUVA) compared to PUVA treatment alone in stage IB-IIa mycosis fungoides (MF): Final results from EORTC cutaneous lymphoma task force (CLTF) phase III clinical trial 21011. Journal of Clinical Oncology2012;30(15 Suppl 1):8076. ">Whittaker 2012</a>; <a href="./references#CD008946-bbs2-0019" title="WolffJM , ZitelliJA , RabinBS , SmilesKA , AbellE . Intralesional interferon in the treatment of early mycosis fungoides. Journal of the American Academy of Dermatology1985;13(4):604-12. [CENTRAL: CN-00040943] [PMID: 2934438]">Wolff 1985</a>; <a href="./references#CD008946-bbs2-0020" title="WozniakMB , TraceyL , Ortiz-RomeroPL , MontesS , AlvarezM , FragaJ , et al. Psoralen plus ultraviolet A +/- interferon-alpha treatment resistance in mycosis fungoides: the role of tumour microenvironment, nuclear transcription factor-kappaB and T-cell receptor pathways. British Journal of Dermatology2008;160(1):92-102. [CENTRAL: CN-00668828] [PMID: 18945306]">Wozniak 2008</a>); reasons included that the study was prematurely closed, discontinued randomisation, and use of a concomitant treatment. In the remaining six studies it was unclear whether other biases were presented. Unclear risk was assigned to six studies (<a href="./references#CD008946-bbs2-0007" title="KayeF , EddyJ , IhdeDC , SteinbergS , FischmannAB , GlatsteinE , et al. Conservative vs. aggressive therapy in mycosis fungoides. Proceedings of the American Society of Clinical Oncology1989;8:257. [CENTRAL: CN-00694960] KayeF , IhdeD , FischmannA , GlatsteinE , MinnaJ , SchechterG , et al. A randomized trial comparing conservative and aggressive therapy in mycosis fungoides (MF). Proceedings of the American Society of Clinical Oncology1986;5:195. [CENTRAL: CN-00695166] KayeFJ , BunnPA , SteinbergSM , StockerJL , IhdeDC , FischmannAB , et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. New England Journal of Medicine1989;321(26):1784-90. [CENTRAL: CN-00064211] [PMID: 2594037]">Kaye 1989</a>; <a href="./references#CD008946-bbs2-0010" title="DuvicM , KuzelTM , OlsenEA , MartinAG , FossFM , KimYH , et al. Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK). Clinical Lymphoma2002;2(4):222-8. [CENTRAL: CN-00514479] [PMID: 11970761]KuzelT , OlsenE , MartinA , KimY , DuvicM , FrankelA , et al. Pivotal phase III trial of two dose levels of DAB389IL-2 (Ontak®) for the treatment of mycosis fungoides (MF). Blood1997;90(10 Suppl 1 (Pt 1)):586a. [CENTRAL: CN-00518069] NTC00050999. Study of ONTAK (Denileukin Diftitox) in cutaneous T-Cell lymphoma (CTCL) patients. clinicaltrials.gov/ct2/show/NCT00050999 (first received 3 January 2003). OlsenE , DuvicM , FrankelA , KimY , MartinA , VonderheidE , et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. Journal of Clinical Oncology2001;19(2):376-88. [CENTRAL: CN-00328506] [PMID: 11208829]OlsenE , DuvicM , MartinA . Pivotal phase III trial of two dose levels of DAB 389 IL-2 (ONTAK) for the treatment of cutaneous T-cell lymphoma (CTCL). Journal of Investigative Dermatology1998;110(4):678. [CENTRAL: CN-00353452] ">Olsen 2001</a>; <a href="./references#CD008946-bbs2-0012" title="RookAH , WoodGS , DuvicM , VonderheidEC , TobiaA , CabanaB . A phase II placebo-controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis. Journal of the American Academy of Dermatology2010;63(6):984-90. [CENTRAL: CN-00772559] [PMID: 20889234]">Rook 2010</a>; <a href="./references#CD008946-bbs2-0013" title="OtteHG , KuhlS , StadlerR , LugerT , HenzB , SterryW . Treatment of cutaneous T-cell lymphoma with Interferon alpha and PUVA versus Interferon alpha and Acitretin - results of a prospective randomised multi-centre study [Behandlung des kutanen T-Zell-Lymphoms mit Interferon alpha und PUVA versus Interferon alpha und Acirentin - Ergebnisse einer prospektiv-randomisierten Multicenter-Studie]. Der Hautarzt1997;48(Suppl):S97. [CENTRAL: CN-00495120] OtteHG , StadierR , LugerT , HenzB , SterryW . Open controlled clinical trial on the use of interferon plus acitretin versus interferon plus PUVA in patients with cutaneous T-cell lymphoma (CTCL). Annals of Oncology1996;7(Suppl 3):66. [CENTRAL: CN-00308243] StadlerR , OtteHG , LugerT , HenzBM , KuhlP , ZwingersT , et al. Prospective randomized multicenter clinical trial on the use of interferon -2a plus acitretin versus interferon -2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood1998;92(10):3578-81. [CENTRAL: CN-00156682] [PMID: 9808550]">Stadler 1998</a>; <a href="./references#CD008946-bbs2-0014" title="BohmeyerJ , OtteHG , StadlerR , LugerT , SterryW . Therapy of cutaneous T-cell lymphoma with PUVA versus interferon alfa plus PUVA: first results. Journal of the European Academy of Dermatology &amp; Venereology1999;12(Suppl 2):S268. [CENTRAL: CN-00478472] BohmeyerJ , StadlerR , LugerT , SterryW . Prospective randomized multicentre therapy optimizing protocol for therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α + PUVA [Prospectiv randomisiertes, multizentrisches Therapieoptimierungsprotokoll zur Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α + PUVA]. Zeitschrift für Hautkrankheiten2001;76(Suppl 1):S55. [CENTRAL: CN-01446038] KremerA , BohmeyerJ , StadlerR , LugerT , SterryW . Prospective randomized multicentre therapy optimizing protocol for therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α + PUVA [Prospectiv randomisiertes, multizentrisches Therapieoptimierungsprotokoll zur Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α + PUVA]. Journal der Deutschen Dermatologischen Gesellschaft2003;1(Suppl 1):S99. [CENTRAL: CN-01446037] OtteHG , StadlerR , LugerT , SterryW . Therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α plus PUVA: first results of a prospective randomized multicentre therapy optimizing protocol [Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α plus PUVA: Erste Ergebnisse des prospektiven randomisierten multizentrischen Therapieoptimierungsprotokolls]. Der Hautarzt1999;50(Suppl 1):S2. [CENTRAL: CN-01457423] OtteHG , StadlerR . Combination therapy of cutaneous t-cell-lymphoma with interferon alfa 2a and PUVA [Kombinationstherapie kutaner T-Zell-Lymphome mit Interferon Alfa 2a und PUVA]. Zentralblatt Haut- und Geschlechtskrankheiten1993;162(Suppl):P2.03.08. [CENTRAL: CN-01457422] StadlerM , KremerA , LugerT , SterryW . Prospective, randomized, multicentre clinical trial on the use of interferon a 2a plus PUVA versus PUVA monotherapy in patients with cutaneous T-cell lymphoma, stages I and II [Abstract 7541]. ASCO annual meeting proceedings. Journal of Clinical Oncology2006;24(18S Pt 1):432. [CENTRAL: CN-00625001] ">Stadler 2006</a>; <a href="./references#CD008946-bbs2-0017" title="VonderheidEC , ThompsonR , SmilesKA , LattanandA . Recombinant interferon alfa-2b in plaque-phase mycosis fungoides. Intralesional and low-dose intramuscular therapy. Archives of Dermatology1987;123(6):757-63. [CENTRAL: CN-00047990] [PMID: 3579357]">Vonderheid 1987</a>). </p> <section id="CD008946-sec-0086"> <h5 class="title">Assessment of external validity</h5> <p><a href="./appendices#CD008946-sec-0217">Appendix 7</a> shows the checklist we used to assess external validity. After careful consideration, no major limitations for the external validity could be observed. Since MF is a rare disease which is normally treated in specialised medical centres (tertiary care setting), the results of the studies were considered applicable to daily practice. </p> </section> </section> </section> <section id="CD008946-sec-0087"> <h3 class="title" id="CD008946-sec-0087">Effects of interventions</h3> <p>See: <a href="./full#CD008946-tbl-0001"><b>Summary of findings 1</b> IFN‐α + PUVA compared to PUVA alone for mycosis fungoides</a>; <a href="./full#CD008946-tbl-0002"><b>Summary of findings 2</b> Extracorporeal photopheresis compared to PUVA for mycosis fungoides</a>; <a href="./full#CD008946-tbl-0003"><b>Summary of findings 3</b> Bexarotene + PUVA compared to PUVA alone for mycosis fungoides</a>; <a href="./full#CD008946-tbl-0004"><b>Summary of findings 4</b> IFN‐α + acitretin compared to IFN‐α + PUVA for mycosis fungoides</a>; <a href="./full#CD008946-tbl-0005"><b>Summary of findings 5</b> PUVA maintenance compared to no maintenance for mycosis fungoides</a> </p> <p>In this section, we have presented the results for the effects of interventions for included studies that examined at least one primary or secondary outcome of interest in this review. Only two studies (<a href="./references#CD008946-bbs2-0014" title="BohmeyerJ , OtteHG , StadlerR , LugerT , SterryW . Therapy of cutaneous T-cell lymphoma with PUVA versus interferon alfa plus PUVA: first results. Journal of the European Academy of Dermatology &amp; Venereology1999;12(Suppl 2):S268. [CENTRAL: CN-00478472] BohmeyerJ , StadlerR , LugerT , SterryW . Prospective randomized multicentre therapy optimizing protocol for therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α + PUVA [Prospectiv randomisiertes, multizentrisches Therapieoptimierungsprotokoll zur Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α + PUVA]. Zeitschrift für Hautkrankheiten2001;76(Suppl 1):S55. [CENTRAL: CN-01446038] KremerA , BohmeyerJ , StadlerR , LugerT , SterryW . Prospective randomized multicentre therapy optimizing protocol for therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α + PUVA [Prospectiv randomisiertes, multizentrisches Therapieoptimierungsprotokoll zur Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α + PUVA]. Journal der Deutschen Dermatologischen Gesellschaft2003;1(Suppl 1):S99. [CENTRAL: CN-01446037] OtteHG , StadlerR , LugerT , SterryW . Therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α plus PUVA: first results of a prospective randomized multicentre therapy optimizing protocol [Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α plus PUVA: Erste Ergebnisse des prospektiven randomisierten multizentrischen Therapieoptimierungsprotokolls]. Der Hautarzt1999;50(Suppl 1):S2. [CENTRAL: CN-01457423] OtteHG , StadlerR . Combination therapy of cutaneous t-cell-lymphoma with interferon alfa 2a and PUVA [Kombinationstherapie kutaner T-Zell-Lymphome mit Interferon Alfa 2a und PUVA]. Zentralblatt Haut- und Geschlechtskrankheiten1993;162(Suppl):P2.03.08. [CENTRAL: CN-01457422] StadlerM , KremerA , LugerT , SterryW . Prospective, randomized, multicentre clinical trial on the use of interferon a 2a plus PUVA versus PUVA monotherapy in patients with cutaneous T-cell lymphoma, stages I and II [Abstract 7541]. ASCO annual meeting proceedings. Journal of Clinical Oncology2006;24(18S Pt 1):432. [CENTRAL: CN-00625001] ">Stadler 2006</a>; <a href="./references#CD008946-bbs2-0020" title="WozniakMB , TraceyL , Ortiz-RomeroPL , MontesS , AlvarezM , FragaJ , et al. Psoralen plus ultraviolet A +/- interferon-alpha treatment resistance in mycosis fungoides: the role of tumour microenvironment, nuclear transcription factor-kappaB and T-cell receptor pathways. British Journal of Dermatology2008;160(1):92-102. [CENTRAL: CN-00668828] [PMID: 18945306]">Wozniak 2008</a>) were similar enough to allow meta‐analysis. We have presented all included studies using the PICO scheme to describe included <b>P</b> articipants, <b>I</b> nterventions, <b>C</b> ontrols, and <b>O</b>utcomes. The outcomes are displayed separately for each reported primary and secondary outcome of interest below the PICO description. For each intervention, we mention the relevant studies, and the study itself is presented in full only once, in the section where the treatment under investigation fits best. This is primarily the treatment for which it was randomised. If a study was randomised to two different treatments, we chose the section for reporting the trial data according to the newer treatment. The following treatment modalities are sorted by their level of invasiveness, starting from least to most, and differ from their sequence of appearance in the <a href="./references#CD008946-sec-0209" title="">Data and analyses</a> section. </p> <p>This section is laid out as follows.</p> <p>I. Topical therapies</p> <p> <ul id="CD008946-list-0016"> <li> <p>I.1. Topical peldesine versus placebo</p> </li> <li> <p>I.2. Topical Imiquimod versus placebo</p> </li> <li> <p>I.3. Topical hypericin versus placebo</p> </li> <li> <p>I.4. Interferon‐α (intralesionally‐injected) versus placebo</p> </li> <li> <p>I.5. Mechlorethamine gel versus mechlorethamine ointment</p> </li> </ul> </p> <p>II. Skin‐directed phototherapies</p> <p> <ul id="CD008946-list-0017"> <li> <p>II.1. PUVA maintenance versus no maintenance</p> </li> </ul> </p> <p>III. Total skin electron beam</p> <p>IV. Radiotherapy</p> <p>V. Chemotherapies and biological response modifiers</p> <p> <ul id="CD008946-list-0018"> <li> <p>V.1. IFN‐α + PUVA versus PUVA alone</p> </li> <li> <p>V.2. Denileukin diftitox high versus low dose</p> </li> <li> <p>V.3. Bexarotene</p> </li> <li> <p>V.4. Lenalidomide maintenance versus observation</p> </li> <li> <p>V.5. Brentuximab vedotin versus physician's choice (oral methotrexate or bexarotene)</p> </li> <li> <p>V.6. Mogamulizumab versus vorinostat</p> </li> </ul> </p> <p>VI. Extracorporeal photochemotherapy</p> <p> <ul id="CD008946-list-0019"> <li> <p>VI.1. Extracorporeal photopheresis</p> </li> </ul> </p> <p>VII. Combination therapies</p> <p> <ul id="CD008946-list-0020"> <li> <p>VII.1. Electron‐beam radiation and parenteral chemotherapy compared to topical treatment</p> </li> <li> <p>VII.2. IFN‐α (subcutaneously‐injected) combined with either PUVA or acitretin capsules</p> </li> <li> <p>VII.3. Active or inactivated transfer factor (injected intramuscularly) under concomitant therapy with topically‐applied nitrogen mustard </p> </li> </ul> </p> <p>Results from separate rare or serious adverse effects search in non‐randomised studies</p> <section id="CD008946-sec-0088"> <h4 class="title">I. Topical therapies</h4> <p>Three included studies (<a href="./references#CD008946-bbs2-0007" title="KayeF , EddyJ , IhdeDC , SteinbergS , FischmannAB , GlatsteinE , et al. Conservative vs. aggressive therapy in mycosis fungoides. Proceedings of the American Society of Clinical Oncology1989;8:257. [CENTRAL: CN-00694960] KayeF , IhdeD , FischmannA , GlatsteinE , MinnaJ , SchechterG , et al. A randomized trial comparing conservative and aggressive therapy in mycosis fungoides (MF). Proceedings of the American Society of Clinical Oncology1986;5:195. [CENTRAL: CN-00695166] KayeFJ , BunnPA , SteinbergSM , StockerJL , IhdeDC , FischmannAB , et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. New England Journal of Medicine1989;321(26):1784-90. [CENTRAL: CN-00064211] [PMID: 2594037]">Kaye 1989</a>; <a href="./references#CD008946-bbs2-0009" title="LessinS , DuvicM , GuitartJ , PandyaA , StroberB , OlsenE , et al. Positive results of a pivotal phase ii trial testing a manufactured 0.02% Mechlorethamine gel in mycosis fungoides (mf). Journal of Investigative Dermatology2011;131(Suppl 1):S84. [CENTRAL: CN-00843792] LessinSR , DuvicM , GuitartJ , PandyaAG , StroberBE , OlsenEA , et al. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatology2013;149(1):25-32. [CENTRAL: CN-00859487] [PMID: 23069814]NCT00168064. Safety and efficacy of nitrogen mustard in treatment of mycosis fungoides. clinicaltrials.gov/ct2/show/NCT00168064 (first received 14 September 2005). ">Lessin 2013</a>; <a href="./references#CD008946-bbs2-0015" title="Thestrup-PedersenK , GrunnetE , ZachariaeH . Transfer factor therapy in mycosis fungoides: a double-blind study. Acta Dermato-Venereologica1982;62(1):47-53. [CENTRAL: CN-00027377] [PMID: 6175137]">Thestrup‐Pedersen 1982</a>) examined the effect of topical nitrogen mustard, either as monotherapy or in combination with other interventions. <a href="./references#CD008946-bbs2-0007" title="KayeF , EddyJ , IhdeDC , SteinbergS , FischmannAB , GlatsteinE , et al. Conservative vs. aggressive therapy in mycosis fungoides. Proceedings of the American Society of Clinical Oncology1989;8:257. [CENTRAL: CN-00694960] KayeF , IhdeD , FischmannA , GlatsteinE , MinnaJ , SchechterG , et al. A randomized trial comparing conservative and aggressive therapy in mycosis fungoides (MF). Proceedings of the American Society of Clinical Oncology1986;5:195. [CENTRAL: CN-00695166] KayeFJ , BunnPA , SteinbergSM , StockerJL , IhdeDC , FischmannAB , et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. New England Journal of Medicine1989;321(26):1784-90. [CENTRAL: CN-00064211] [PMID: 2594037]">Kaye 1989</a> compared nitrogen mustard and a series of four sequential escape therapies (an escape therapy (see also escape medication) is a therapy that may be taken by a participant in the event of a treatment failure of the investigational therapy during the trial) to a combination of electron‐beam radiation and parenteral chemotherapy. <a href="./references#CD008946-bbs2-0009" title="LessinS , DuvicM , GuitartJ , PandyaA , StroberB , OlsenE , et al. Positive results of a pivotal phase ii trial testing a manufactured 0.02% Mechlorethamine gel in mycosis fungoides (mf). Journal of Investigative Dermatology2011;131(Suppl 1):S84. [CENTRAL: CN-00843792] LessinSR , DuvicM , GuitartJ , PandyaAG , StroberBE , OlsenEA , et al. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatology2013;149(1):25-32. [CENTRAL: CN-00859487] [PMID: 23069814]NCT00168064. Safety and efficacy of nitrogen mustard in treatment of mycosis fungoides. clinicaltrials.gov/ct2/show/NCT00168064 (first received 14 September 2005). ">Lessin 2013</a> contrasted two different base formulations for mechlorethamine, gel versus compounded ointment. The results are described in this section. <a href="./references#CD008946-bbs2-0015" title="Thestrup-PedersenK , GrunnetE , ZachariaeH . Transfer factor therapy in mycosis fungoides: a double-blind study. Acta Dermato-Venereologica1982;62(1):47-53. [CENTRAL: CN-00027377] [PMID: 6175137]">Thestrup‐Pedersen 1982</a> assessed the effect of active or inactivated transfer factor (injected intramuscularly) under concomitant therapy with nitrogen mustard. PUVA was administered instead of nitrogen mustard in participants with severe hypersensitivity to nitrogen mustard or relapse after treatment. The trials, in which topical nitrogen mustard is not used as monotherapy, are described in section 'VIII. Combination therapies'. </p> <p>Other included studies examined the effect of topical peldesine 1% (<a href="./references#CD008946-bbs2-0005" title="DuvicM , OlsenEA , OmuraGA , MaizeJC , VonderheidEC , et al. A phase III, randomized, double-blind, placebo-controlled study of peldesine (BCX-34) cream as topical therapy for cutaneous T-cell lymphoma. Journal of the American Academy of Dermatology2001;44(6):940-7. [CENTRAL: CN-00348073] [PMID: 11369904]">Duvic 2001a</a>), topical imiquimod 5% (<a href="./references#CD008946-bbs2-0003" title="ChongA , LooWJ , BanneyL , GrantJW , NorrisPG . Imiquimod 5% cream in the treatment of mycosis fungoides - a pilot study. Journal of Dermatological Treatment2004;15(2):118-9. [CENTRAL: CN-00467258] [PMID: 15204164]">Chong 2004</a>), hypericin 0.05% to 0.25%, in combination with visible light (<a href="./references#CD008946-bbs2-0012" title="RookAH , WoodGS , DuvicM , VonderheidEC , TobiaA , CabanaB . A phase II placebo-controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis. Journal of the American Academy of Dermatology2010;63(6):984-90. [CENTRAL: CN-00772559] [PMID: 20889234]">Rook 2010</a>), or the effect of intralesionally‐injected IFN‐α (<a href="./references#CD008946-bbs2-0017" title="VonderheidEC , ThompsonR , SmilesKA , LattanandA . Recombinant interferon alfa-2b in plaque-phase mycosis fungoides. Intralesional and low-dose intramuscular therapy. Archives of Dermatology1987;123(6):757-63. [CENTRAL: CN-00047990] [PMID: 3579357]">Vonderheid 1987</a>; <a href="./references#CD008946-bbs2-0019" title="WolffJM , ZitelliJA , RabinBS , SmilesKA , AbellE . Intralesional interferon in the treatment of early mycosis fungoides. Journal of the American Academy of Dermatology1985;13(4):604-12. [CENTRAL: CN-00040943] [PMID: 2934438]">Wolff 1985</a>). </p> <p><a href="./references#CD008946-bbs2-0012" title="RookAH , WoodGS , DuvicM , VonderheidEC , TobiaA , CabanaB . A phase II placebo-controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis. Journal of the American Academy of Dermatology2010;63(6):984-90. [CENTRAL: CN-00772559] [PMID: 20889234]">Rook 2010</a> and <a href="./references#CD008946-bbs2-0017" title="VonderheidEC , ThompsonR , SmilesKA , LattanandA . Recombinant interferon alfa-2b in plaque-phase mycosis fungoides. Intralesional and low-dose intramuscular therapy. Archives of Dermatology1987;123(6):757-63. [CENTRAL: CN-00047990] [PMID: 3579357]">Vonderheid 1987</a> have a within‐participant design. We extracted the data as reported and did not adjust for unit of analysis issues. </p> <section id="CD008946-sec-0089"> <h5 class="title">I.1. Topical peldesine (one trial)</h5> <p>PICO: In participants with MF Stage I (patches with or without plaques), <a href="./references#CD008946-bbs2-0005" title="DuvicM , OlsenEA , OmuraGA , MaizeJC , VonderheidEC , et al. A phase III, randomized, double-blind, placebo-controlled study of peldesine (BCX-34) cream as topical therapy for cutaneous T-cell lymphoma. Journal of the American Academy of Dermatology2001;44(6):940-7. [CENTRAL: CN-00348073] [PMID: 11369904]">Duvic 2001a</a> investigated the effect of topical peldesine 1% compared to placebo cream given for 24 weeks. End points were evaluated at the end of this period. </p> <section id="CD008946-sec-0090"> <h6 class="title">Primary outcomes</h6> <section id="CD008946-sec-0091"> <p><b>Common adverse effects of the treatments</b></p> <p>In <a href="./references#CD008946-bbs2-0005" title="DuvicM , OlsenEA , OmuraGA , MaizeJC , VonderheidEC , et al. A phase III, randomized, double-blind, placebo-controlled study of peldesine (BCX-34) cream as topical therapy for cutaneous T-cell lymphoma. Journal of the American Academy of Dermatology2001;44(6):940-7. [CENTRAL: CN-00348073] [PMID: 11369904]">Duvic 2001a</a>, no differences between peldesine and placebo were seen for pruritus, albeit there is imprecision of the result due to the small sample size. There were nine cases of pruritus in the topical peldesine group and six cases in the placebo group risk ratio ((RR) 1.81, 95% confidence intervals (Cs)I 0.73 to 4.49, 64 participants, <a href="./references#CD008946-fig-0006" title="">Analysis 1.1</a>, Fisher test P = 0.24). </p> <p>In <a href="./references#CD008946-bbs2-0005" title="DuvicM , OlsenEA , OmuraGA , MaizeJC , VonderheidEC , et al. A phase III, randomized, double-blind, placebo-controlled study of peldesine (BCX-34) cream as topical therapy for cutaneous T-cell lymphoma. Journal of the American Academy of Dermatology2001;44(6):940-7. [CENTRAL: CN-00348073] [PMID: 11369904]">Duvic 2001a</a>, there were differences between peldesine and placebo for rash. There were six cases of rash in the peldesine group and one case in the placebo group (RR 7.24, 95% CI 0.92 to 56.76 (95% CI according to Miettinen: 1.22 to 45.1), 64 participants, <a href="./references#CD008946-fig-0006" title="">Analysis 1.1</a>). Although the number of events was low resulting in wide 95% CIs, the risk ratio showed a higher risk for peldesine (Fisher test P = 0.041). </p> </section> </section> <section id="CD008946-sec-0092"> <h6 class="title">Secondary outcomes</h6> <section id="CD008946-sec-0093"> <p><b>Complete response (CR)</b></p> <p>Defined as complete disappearance of all clinical evidence of disease<i>.</i> </p> <p>In <a href="./references#CD008946-bbs2-0005" title="DuvicM , OlsenEA , OmuraGA , MaizeJC , VonderheidEC , et al. A phase III, randomized, double-blind, placebo-controlled study of peldesine (BCX-34) cream as topical therapy for cutaneous T-cell lymphoma. Journal of the American Academy of Dermatology2001;44(6):940-7. [CENTRAL: CN-00348073] [PMID: 11369904]">Duvic 2001a</a>, there were no differences between the peldesine and placebo groups for complete response. Each group reported 1 CR (RR 1.21, 95% CI 0.08 to 18.46, 64 participants, <a href="./references#CD008946-fig-0007" title="">Analysis 1.2</a>, Fisher test P = 1.00). </p> </section> <section id="CD008946-sec-0094"> <p><b>Overall survival</b></p> <p>In <a href="./references#CD008946-bbs2-0005" title="DuvicM , OlsenEA , OmuraGA , MaizeJC , VonderheidEC , et al. A phase III, randomized, double-blind, placebo-controlled study of peldesine (BCX-34) cream as topical therapy for cutaneous T-cell lymphoma. Journal of the American Academy of Dermatology2001;44(6):940-7. [CENTRAL: CN-00348073] [PMID: 11369904]">Duvic 2001a</a>, no deaths were reported (the follow‐up period was not reported). </p> <p>Objective response rate (ORR) (defined as proportion of patients with CR or partial response (PR). A PR is considered as a regression of measurable disease of at least 50% in one of the categories T, N, M and B without any progression of disease.) </p> <p>In <a href="./references#CD008946-bbs2-0005" title="DuvicM , OlsenEA , OmuraGA , MaizeJC , VonderheidEC , et al. A phase III, randomized, double-blind, placebo-controlled study of peldesine (BCX-34) cream as topical therapy for cutaneous T-cell lymphoma. Journal of the American Academy of Dermatology2001;44(6):940-7. [CENTRAL: CN-00348073] [PMID: 11369904]">Duvic 2001a</a>, the ORR was not different between peldesine and placebo. Each group reported 11 ORRs (RR 1.21, 95% CI 0.61 to 2.37, 64 participants, <a href="./references#CD008946-fig-0008" title="">Analysis 1.3</a>, Fisher test P = 0.61). </p> </section> </section> </section> <section id="CD008946-sec-0095"> <h5 class="title">I.2. Topical Imiquimod (one trial)</h5> <p>PICO: In participants with MF plaque stage 1B MF (T<sub>2</sub>N<sub>0</sub>M<sub>0</sub>), <a href="./references#CD008946-bbs2-0003" title="ChongA , LooWJ , BanneyL , GrantJW , NorrisPG . Imiquimod 5% cream in the treatment of mycosis fungoides - a pilot study. Journal of Dermatological Treatment2004;15(2):118-9. [CENTRAL: CN-00467258] [PMID: 15204164]">Chong 2004</a> investigated the effect of topical imiquimod 5% compared to placebo cream administered for 16 weeks. End points were evaluated at the end of this period. </p> <section id="CD008946-sec-0096"> <h6 class="title">Primary outcomes</h6> <section id="CD008946-sec-0097"> <p><b>Common adverse effects of the treatments</b></p> <p>The only adverse effect reported by <a href="./references#CD008946-bbs2-0003" title="ChongA , LooWJ , BanneyL , GrantJW , NorrisPG . Imiquimod 5% cream in the treatment of mycosis fungoides - a pilot study. Journal of Dermatological Treatment2004;15(2):118-9. [CENTRAL: CN-00467258] [PMID: 15204164]">Chong 2004</a> was mild lesional irritation in the imiquimod group (numbers were not reported). No participant discontinued the study because of adverse effects. </p> </section> </section> <section id="CD008946-sec-0098"> <h6 class="title">Secondary outcomes</h6> <section id="CD008946-sec-0099"> <p><b>Complete response (CR)</b></p> <p>In <a href="./references#CD008946-bbs2-0003" title="ChongA , LooWJ , BanneyL , GrantJW , NorrisPG . Imiquimod 5% cream in the treatment of mycosis fungoides - a pilot study. Journal of Dermatological Treatment2004;15(2):118-9. [CENTRAL: CN-00467258] [PMID: 15204164]">Chong 2004</a>, none of the four participants treated with either imiquimod or placebo showed CR (assessment was at 16 weeks after the end of the intervention). </p> </section> <section id="CD008946-sec-0100"> <p><b>Objective response rate (ORR)</b></p> <p>In <a href="./references#CD008946-bbs2-0003" title="ChongA , LooWJ , BanneyL , GrantJW , NorrisPG . Imiquimod 5% cream in the treatment of mycosis fungoides - a pilot study. Journal of Dermatological Treatment2004;15(2):118-9. [CENTRAL: CN-00467258] [PMID: 15204164]">Chong 2004</a>, none of the four participants treated with either imiquimod or placebo showed ORR (assessment was at 16 weeks after the end of the intervention). </p> </section> <section id="CD008946-sec-0101"> <p><b>Rare adverse effects</b></p> <p><a href="./references#CD008946-bbs2-0003" title="ChongA , LooWJ , BanneyL , GrantJW , NorrisPG . Imiquimod 5% cream in the treatment of mycosis fungoides - a pilot study. Journal of Dermatological Treatment2004;15(2):118-9. [CENTRAL: CN-00467258] [PMID: 15204164]">Chong 2004</a> explicitly stated that no rare adverse events occurred. </p> </section> </section> </section> <section id="CD008946-sec-0102"> <h5 class="title">I.3. Topical hypericin (one trial)</h5> <p>PICO: In participants with stable patch or plaque phase CTCL, <a href="./references#CD008946-bbs2-0012" title="RookAH , WoodGS , DuvicM , VonderheidEC , TobiaA , CabanaB . A phase II placebo-controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis. Journal of the American Academy of Dermatology2010;63(6):984-90. [CENTRAL: CN-00772559] [PMID: 20889234]">Rook 2010</a> investigated the effect of hypericin 0.05% to 0.25% compared to placebo cream, both in combination with visible light administered for six weeks. End points were evaluated at the end of this period. </p> <section id="CD008946-sec-0103"> <h6 class="title">Primary outcomes</h6> <section id="CD008946-sec-0104"> <p><b>Common adverse effects of the treatments</b></p> <p><a href="./references#CD008946-bbs2-0012" title="RookAH , WoodGS , DuvicM , VonderheidEC , TobiaA , CabanaB . A phase II placebo-controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis. Journal of the American Academy of Dermatology2010;63(6):984-90. [CENTRAL: CN-00772559] [PMID: 20889234]">Rook 2010</a> described mild to moderate burning, itching, erythema, and pruritus at the application site, which are typical phototoxic reactions expected from the study drug (numbers not reported). </p> </section> </section> <section id="CD008946-sec-0105"> <h6 class="title">Secondary outcomes</h6> <section id="CD008946-sec-0106"> <p><b>Overall survival (OS)</b></p> <p>In <a href="./references#CD008946-bbs2-0012" title="RookAH , WoodGS , DuvicM , VonderheidEC , TobiaA , CabanaB . A phase II placebo-controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis. Journal of the American Academy of Dermatology2010;63(6):984-90. [CENTRAL: CN-00772559] [PMID: 20889234]">Rook 2010</a>, no deaths were reported (information about follow‐up was not reported). </p> </section> <section id="CD008946-sec-0107"> <p><b>Objective response rate (ORR)</b></p> <p>In <a href="./references#CD008946-bbs2-0012" title="RookAH , WoodGS , DuvicM , VonderheidEC , TobiaA , CabanaB . A phase II placebo-controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis. Journal of the American Academy of Dermatology2010;63(6):984-90. [CENTRAL: CN-00772559] [PMID: 20889234]">Rook 2010</a>, the ORR is better in the topical hypericin 0.05% to 0.25% group compared to the placebo cream group. There were seven cases of ORR in the topical hypericin group and one in the placebo group (RR 7.00, 95% CI 1.01 to 48.54, 24 lesions, <a href="./references#CD008946-fig-0009" title="">Analysis 2.1</a>; Fisher test P = 0.028). </p> </section> </section> </section> <section id="CD008946-sec-0108"> <h5 class="title">I.4. Interferon‐α (intralesionally‐injected) (two trials)</h5> <p>PICO: In participants with MF stages IA to IIA, <a href="./references#CD008946-bbs2-0017" title="VonderheidEC , ThompsonR , SmilesKA , LattanandA . Recombinant interferon alfa-2b in plaque-phase mycosis fungoides. Intralesional and low-dose intramuscular therapy. Archives of Dermatology1987;123(6):757-63. [CENTRAL: CN-00047990] [PMID: 3579357]">Vonderheid 1987</a> investigated the effect of injections of 1 million units of IFN‐α 2b three times weekly compared to injections of isotonic sterile water administered for four weeks. End points for this study were evaluated at different time points. </p> <p>PICO: In participants with histologically‐proven MF stages IA to IB, <a href="./references#CD008946-bbs2-0019" title="WolffJM , ZitelliJA , RabinBS , SmilesKA , AbellE . Intralesional interferon in the treatment of early mycosis fungoides. Journal of the American Academy of Dermatology1985;13(4):604-12. [CENTRAL: CN-00040943] [PMID: 2934438]">Wolff 1985</a> investigated the effect of intralesional injections of two million units of IFN‐α in the superficial dermis three times weekly compared to intralesional injections of buffered glycine serum human albumin in the superficial dermis given for four weeks. End points were evaluated at the end of this period. </p> <section id="CD008946-sec-0109"> <h6 class="title">Primary outcomes</h6> <section id="CD008946-sec-0110"> <p><b>Common adverse effects of the treatments</b></p> <p><a href="./references#CD008946-bbs2-0017" title="VonderheidEC , ThompsonR , SmilesKA , LattanandA . Recombinant interferon alfa-2b in plaque-phase mycosis fungoides. Intralesional and low-dose intramuscular therapy. Archives of Dermatology1987;123(6):757-63. [CENTRAL: CN-00047990] [PMID: 3579357]">Vonderheid 1987</a> described systemic adverse effects probably due to the injection of IFN‐α: five of six participants had mild fatigue; four of six had low grade fever; three of six had chills or headaches or generalised myalgias. Since this was a within‐participant trial, differences with regard to systemic effects were not detectable between treatment groups. Locally, there were differences between IFN‐α and sterile water for lesional mild erythema. There were five cases of erythema in the IFN‐α group and zero in the placebo group (RR 11.00, 95% CI 0.74 to 163.49 (95% CI according to Miettinen: 1.83 to not estimable), 12 lesions, <a href="./references#CD008946-fig-0010" title="">Analysis 3.1</a>, assessed after three weeks of intervention). The risk ratio showed a higher risk for IFN‐α (Fisher test P = 0.016). </p> <p>In <a href="./references#CD008946-bbs2-0019" title="WolffJM , ZitelliJA , RabinBS , SmilesKA , AbellE . Intralesional interferon in the treatment of early mycosis fungoides. Journal of the American Academy of Dermatology1985;13(4):604-12. [CENTRAL: CN-00040943] [PMID: 2934438]">Wolff 1985</a>, there were differences between IFN‐α and placebo injections for mild and transient fevers. There were five cases of fever in the IFN‐α group and zero in the placebo group (RR 11.00, 95% CI 0.70 to 173.66 (95% CI according to Miettinen: 1.59 to not estimable), 18 participants, <a href="./references#CD008946-fig-0010" title="">Analysis 3.1</a>). The risk ratio showed a higher risk for IFN‐α (Fisher test P = 0.03). </p> <p>For the other reported adverse effects in <a href="./references#CD008946-bbs2-0019" title="WolffJM , ZitelliJA , RabinBS , SmilesKA , AbellE . Intralesional interferon in the treatment of early mycosis fungoides. Journal of the American Academy of Dermatology1985;13(4):604-12. [CENTRAL: CN-00040943] [PMID: 2934438]">Wolff 1985</a>, there were no differences between IFN‐α and placebo injections (18 participants each) in terms of myalgia. There were three cases of myalgia in the IFN‐α group and zero cases in the placebo group (RR 7.00, 95% CI 0.41 to 118.69, <a href="./references#CD008946-fig-0010" title="">Analysis 3.1</a>, Fisher test P = 0.21). Due to low number of events, the result was very imprecise with a wide 95% CI. <a href="./references#CD008946-bbs2-0019" title="WolffJM , ZitelliJA , RabinBS , SmilesKA , AbellE . Intralesional interferon in the treatment of early mycosis fungoides. Journal of the American Academy of Dermatology1985;13(4):604-12. [CENTRAL: CN-00040943] [PMID: 2934438]">Wolff 1985</a> reported on two cases of chills or weakness in the IFN‐α group and zero in the control group (RR 5.00, 95% CI 0.27 to 91.52, <a href="./references#CD008946-fig-0010" title="">Analysis 3.1</a>, Fisher test P =0.47); for nausea, arthralgia, and malaise there was one case in IFN‐α group and zero in the placebo group (RR 3.00, 95% CI 0.14 to 65.16, <a href="./references#CD008946-fig-0010" title="">Analysis 3.1</a>, Fisher test P = 1.00). </p> </section> </section> <section id="CD008946-sec-0111"> <h6 class="title">Secondary outcomes</h6> <section id="CD008946-sec-0112"> <p><b>Complete response (CR)</b></p> <p>In <a href="./references#CD008946-bbs2-0017" title="VonderheidEC , ThompsonR , SmilesKA , LattanandA . Recombinant interferon alfa-2b in plaque-phase mycosis fungoides. Intralesional and low-dose intramuscular therapy. Archives of Dermatology1987;123(6):757-63. [CENTRAL: CN-00047990] [PMID: 3579357]">Vonderheid 1987</a>, there were differences between intralesional IFN‐α and intralesional placebo for CR assessed 4 weeks after the end of the intervention. There were 10 cases of CR in the IFN‐α group and one in the placebo group (RR 10.00, 95% CI 1.51 to 66.43, 24 lesions, <a href="./references#CD008946-fig-0011" title="">Analysis 3.2</a>). Although the 95% confidence interval was very wide, the risk ratio favoured IFN‐α (Fisher test P = 0.001). </p> <p>In <a href="./references#CD008946-bbs2-0019" title="WolffJM , ZitelliJA , RabinBS , SmilesKA , AbellE . Intralesional interferon in the treatment of early mycosis fungoides. Journal of the American Academy of Dermatology1985;13(4):604-12. [CENTRAL: CN-00040943] [PMID: 2934438]">Wolff 1985</a>, the CR did not differ between intralesional IFN‐α and intralesional placebo. There were three cases of CR in the IFN‐α group and zero in the placebo group (RR 2.80, 95% CI 0.18 to 42.80, 12 participants, <a href="./references#CD008946-fig-0011" title="">Analysis 3.2</a>, Fisher test P = 0.51). Due to the low number of events, the result was very imprecise with a wide 95%CI including 1. </p> <p>Since <a href="./references#CD008946-bbs2-0017" title="VonderheidEC , ThompsonR , SmilesKA , LattanandA . Recombinant interferon alfa-2b in plaque-phase mycosis fungoides. Intralesional and low-dose intramuscular therapy. Archives of Dermatology1987;123(6):757-63. [CENTRAL: CN-00047990] [PMID: 3579357]">Vonderheid 1987</a> was a within‐participant trial and <a href="./references#CD008946-bbs2-0019" title="WolffJM , ZitelliJA , RabinBS , SmilesKA , AbellE . Intralesional interferon in the treatment of early mycosis fungoides. Journal of the American Academy of Dermatology1985;13(4):604-12. [CENTRAL: CN-00040943] [PMID: 2934438]">Wolff 1985</a> had a parallel‐group design with intralesional injections, we did not perform a meta‐analysis of these results. </p> </section> </section> </section> <section id="CD008946-sec-0113"> <h5 class="title">I.5. Topical Mechlorethamine (one trial)</h5> <p>PICO: In participants with MF stage IA to IIA, <a href="./references#CD008946-bbs2-0009" title="LessinS , DuvicM , GuitartJ , PandyaA , StroberB , OlsenE , et al. Positive results of a pivotal phase ii trial testing a manufactured 0.02% Mechlorethamine gel in mycosis fungoides (mf). Journal of Investigative Dermatology2011;131(Suppl 1):S84. [CENTRAL: CN-00843792] LessinSR , DuvicM , GuitartJ , PandyaAG , StroberBE , OlsenEA , et al. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatology2013;149(1):25-32. [CENTRAL: CN-00859487] [PMID: 23069814]NCT00168064. Safety and efficacy of nitrogen mustard in treatment of mycosis fungoides. clinicaltrials.gov/ct2/show/NCT00168064 (first received 14 September 2005). ">Lessin 2013</a> investigated the effect of topical mechlorethamine 0.02% gel compared to 0.02% mechlorethamine ointment administered for up to 12 months. </p> <section id="CD008946-sec-0114"> <h6 class="title">Primary outcomes</h6> <section id="CD008946-sec-0115"> <p><b>Common adverse effects of the treatments</b></p> <p><a href="./references#CD008946-bbs2-0009" title="LessinS , DuvicM , GuitartJ , PandyaA , StroberB , OlsenE , et al. Positive results of a pivotal phase ii trial testing a manufactured 0.02% Mechlorethamine gel in mycosis fungoides (mf). Journal of Investigative Dermatology2011;131(Suppl 1):S84. [CENTRAL: CN-00843792] LessinSR , DuvicM , GuitartJ , PandyaAG , StroberBE , OlsenEA , et al. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatology2013;149(1):25-32. [CENTRAL: CN-00859487] [PMID: 23069814]NCT00168064. Safety and efficacy of nitrogen mustard in treatment of mycosis fungoides. clinicaltrials.gov/ct2/show/NCT00168064 (first received 14 September 2005). ">Lessin 2013</a> described skin irritation, pruritus, erythema, contact dermatitis, skin hyperpigmentation and folliculitis as common adverse effects. There were more skin irritations in the mechlorethamine gel arm. The authors reported on 32 cases of skin irritation in the mechlorethamine gel arm and 18 cases in the ointment arm (RR 1.78, 95% CI 1.05 to 3.00, 260 participants, <a href="./references#CD008946-fig-0012" title="">Analysis 4.1</a>, Fisher test P = 0.04). No difference was found in the other categories: </p> <p> <ul id="CD008946-list-0021"> <li> <p>pruritus: gel 25 cases, ointment 20 cases (RR 1.25, 95% CI 0.73 to 2.14, <a href="./references#CD008946-fig-0012" title="">Analysis 4.1</a>, Fisher test P = 0.51) </p> </li> <li> <p>erythema: gel 22 cases, ointment 18 cases (RR 1.22, 95% CI 0.69 to 2.17, <a href="./references#CD008946-fig-0012" title="">Analysis 4.1</a>, Fisher test P = 0.61) </p> </li> <li> <p>contact dermatitis: each group 19 cases (RR 1.00, 95% CI 0.56 to 1.80, <a href="./references#CD008946-fig-0012" title="">Analysis 4.1</a>, Fisher test P = 1.00) </p> </li> <li> <p>skin hyperpigmentation: gel seven cases, ointment nine cases (RR 0.78, 95% CI 0.30 to 2.03, <a href="./references#CD008946-fig-0012" title="">Analysis 4.1</a>, Fisher test P = 0.80) </p> </li> <li> <p>folliculitis: gel seven cases, ointment five cases (RR 1.40, 95% CI 0.46 to 4.30, <a href="./references#CD008946-fig-0012" title="">Analysis 4.1</a>, Fisher test P = 0.77) </p> </li> </ul> </p> </section> </section> <section id="CD008946-sec-0116"> <h6 class="title">Secondary outcomes</h6> <section id="CD008946-sec-0117"> <p><b>Complete response (CR)</b></p> <p>In <a href="./references#CD008946-bbs2-0009" title="LessinS , DuvicM , GuitartJ , PandyaA , StroberB , OlsenE , et al. Positive results of a pivotal phase ii trial testing a manufactured 0.02% Mechlorethamine gel in mycosis fungoides (mf). Journal of Investigative Dermatology2011;131(Suppl 1):S84. [CENTRAL: CN-00843792] LessinSR , DuvicM , GuitartJ , PandyaAG , StroberBE , OlsenEA , et al. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatology2013;149(1):25-32. [CENTRAL: CN-00859487] [PMID: 23069814]NCT00168064. Safety and efficacy of nitrogen mustard in treatment of mycosis fungoides. clinicaltrials.gov/ct2/show/NCT00168064 (first received 14 September 2005). ">Lessin 2013</a>, CR did not differ between mechlorethamine gel versus mechlorethamine ointment (18 and 15 cases, respectively, RR 1.20, 95% CI 0.63 to 2.28, 260 participants, <a href="./references#CD008946-fig-0013" title="">Analysis 4.2</a>, Fisher test P = 0.71). </p> </section> <section id="CD008946-sec-0118"> <p><b>Objective response rate (ORR)</b></p> <p>In <a href="./references#CD008946-bbs2-0009" title="LessinS , DuvicM , GuitartJ , PandyaA , StroberB , OlsenE , et al. Positive results of a pivotal phase ii trial testing a manufactured 0.02% Mechlorethamine gel in mycosis fungoides (mf). Journal of Investigative Dermatology2011;131(Suppl 1):S84. [CENTRAL: CN-00843792] LessinSR , DuvicM , GuitartJ , PandyaAG , StroberBE , OlsenEA , et al. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatology2013;149(1):25-32. [CENTRAL: CN-00859487] [PMID: 23069814]NCT00168064. Safety and efficacy of nitrogen mustard in treatment of mycosis fungoides. clinicaltrials.gov/ct2/show/NCT00168064 (first received 14 September 2005). ">Lessin 2013</a>, the ORR did not differ between both study arms (58 and 47 cases, respectively, RR 1.23, 95% CI 0.92 to 1.66, 260 participants, <a href="./references#CD008946-fig-0014" title="">Analysis 4.3</a>, Fisher test P = 0.21). </p> </section> </section> </section> </section> <section id="CD008946-sec-0119"> <h4 class="title">II. Skin‐directed phototherapies</h4> <p>Eight studies (<a href="./references#CD008946-bbs2-0002" title="ChildFJ , MitchellTJ , WhittakerSJ , ScarisbrickJJ , SeedPT , Russel-JonesR . A randomized cross-over study to compare PUVA and extracorporeal photopheresis in the treatment of plaque stage (T2) mycosis fungoides. Clinical &amp; Experimental Dermatology2004;29(3):231-6. [CENTRAL: CN-00468455] [PMID: 15115499]ChildFJ , MitchellTJ , WhittakerSJ , WatkinsP , SeedP , Russell-JonesR . A randomised cross-over study to compare Puva and extracorporeal photopheresis (ECP) in the treatment of plaque stage (T2) mycosis fungoides. British Journal of Dermatology2001;145(Suppl 59):16. [CENTRAL: CN-00430854] ">Child 2004</a>; <a href="./references#CD008946-bbs2-0006" title="GuitartJ , TuckerR , StevensV . Low dose bexarotene (Targretin®) capsules and phototherapy for early stage cutaneous T-Cell lymphoma. Journal of Investigative Dermatology2002;119(1):241. [CENTRAL: CN-00794450] NCT00030589. A muliticenter, dose-randomized evaluation of Targretin capsules plus PUVA in patients with stage IB - IIA cutaneous T-Cell lymphoma. clinicaltrials.gov/ct/show/NCT00030589 (first received 27 Jaunry 2003). ">Guitart 2002</a>; <a href="./references#CD008946-bbs2-0007" title="KayeF , EddyJ , IhdeDC , SteinbergS , FischmannAB , GlatsteinE , et al. Conservative vs. aggressive therapy in mycosis fungoides. Proceedings of the American Society of Clinical Oncology1989;8:257. [CENTRAL: CN-00694960] KayeF , IhdeD , FischmannA , GlatsteinE , MinnaJ , SchechterG , et al. A randomized trial comparing conservative and aggressive therapy in mycosis fungoides (MF). Proceedings of the American Society of Clinical Oncology1986;5:195. [CENTRAL: CN-00695166] KayeFJ , BunnPA , SteinbergSM , StockerJL , IhdeDC , FischmannAB , et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. New England Journal of Medicine1989;321(26):1784-90. [CENTRAL: CN-00064211] [PMID: 2594037]">Kaye 1989</a>; <a href="./references#CD008946-bbs2-0013" title="OtteHG , KuhlS , StadlerR , LugerT , HenzB , SterryW . Treatment of cutaneous T-cell lymphoma with Interferon alpha and PUVA versus Interferon alpha and Acitretin - results of a prospective randomised multi-centre study [Behandlung des kutanen T-Zell-Lymphoms mit Interferon alpha und PUVA versus Interferon alpha und Acirentin - Ergebnisse einer prospektiv-randomisierten Multicenter-Studie]. Der Hautarzt1997;48(Suppl):S97. [CENTRAL: CN-00495120] OtteHG , StadierR , LugerT , HenzB , SterryW . Open controlled clinical trial on the use of interferon plus acitretin versus interferon plus PUVA in patients with cutaneous T-cell lymphoma (CTCL). Annals of Oncology1996;7(Suppl 3):66. [CENTRAL: CN-00308243] StadlerR , OtteHG , LugerT , HenzBM , KuhlP , ZwingersT , et al. Prospective randomized multicenter clinical trial on the use of interferon -2a plus acitretin versus interferon -2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood1998;92(10):3578-81. [CENTRAL: CN-00156682] [PMID: 9808550]">Stadler 1998</a>; <a href="./references#CD008946-bbs2-0014" title="BohmeyerJ , OtteHG , StadlerR , LugerT , SterryW . Therapy of cutaneous T-cell lymphoma with PUVA versus interferon alfa plus PUVA: first results. Journal of the European Academy of Dermatology &amp; Venereology1999;12(Suppl 2):S268. [CENTRAL: CN-00478472] BohmeyerJ , StadlerR , LugerT , SterryW . Prospective randomized multicentre therapy optimizing protocol for therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α + PUVA [Prospectiv randomisiertes, multizentrisches Therapieoptimierungsprotokoll zur Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α + PUVA]. Zeitschrift für Hautkrankheiten2001;76(Suppl 1):S55. [CENTRAL: CN-01446038] KremerA , BohmeyerJ , StadlerR , LugerT , SterryW . Prospective randomized multicentre therapy optimizing protocol for therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α + PUVA [Prospectiv randomisiertes, multizentrisches Therapieoptimierungsprotokoll zur Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α + PUVA]. Journal der Deutschen Dermatologischen Gesellschaft2003;1(Suppl 1):S99. [CENTRAL: CN-01446037] OtteHG , StadlerR , LugerT , SterryW . Therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α plus PUVA: first results of a prospective randomized multicentre therapy optimizing protocol [Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α plus PUVA: Erste Ergebnisse des prospektiven randomisierten multizentrischen Therapieoptimierungsprotokolls]. Der Hautarzt1999;50(Suppl 1):S2. [CENTRAL: CN-01457423] OtteHG , StadlerR . Combination therapy of cutaneous t-cell-lymphoma with interferon alfa 2a and PUVA [Kombinationstherapie kutaner T-Zell-Lymphome mit Interferon Alfa 2a und PUVA]. Zentralblatt Haut- und Geschlechtskrankheiten1993;162(Suppl):P2.03.08. [CENTRAL: CN-01457422] StadlerM , KremerA , LugerT , SterryW . Prospective, randomized, multicentre clinical trial on the use of interferon a 2a plus PUVA versus PUVA monotherapy in patients with cutaneous T-cell lymphoma, stages I and II [Abstract 7541]. ASCO annual meeting proceedings. Journal of Clinical Oncology2006;24(18S Pt 1):432. [CENTRAL: CN-00625001] ">Stadler 2006</a>; <a href="./references#CD008946-bbs2-0015" title="Thestrup-PedersenK , GrunnetE , ZachariaeH . Transfer factor therapy in mycosis fungoides: a double-blind study. Acta Dermato-Venereologica1982;62(1):47-53. [CENTRAL: CN-00027377] [PMID: 6175137]">Thestrup‐Pedersen 1982</a>; <a href="./references#CD008946-bbs2-0018" title="NCT00056056. Ultraviolet light therapy using methoxsalen with or without Bexarotene in treating patients with mycosis fungoides. clinicaltrials.gov/ct2/show/NCT00056056 (first received 7 March 2003). WhittakerS , OrtizP , DummerR , RankiA , HasanB , MeulemansB , et al. Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial 21011 (NCT00056056). British Journal of Dermatology2012;167(3):678-87. [CENTRAL: CN-00856432] [PMID: 22924950]WhittakerS , Ortiz-RomeroPL , DummerR , RankiA , HasanB , MeulemansB , et al. Efficacy and safety of bexarotene combined with psoralen/ultraviolet A light (PUVA) compared to PUVA treatment alone in stage IB-IIa mycosis fungoides (MF): Final results from EORTC cutaneous lymphoma task force (CLTF) phase III clinical trial 21011. Journal of Clinical Oncology2012;30(15 Suppl 1):8076. ">Whittaker 2012</a>: <a href="./references#CD008946-bbs2-0020" title="WozniakMB , TraceyL , Ortiz-RomeroPL , MontesS , AlvarezM , FragaJ , et al. Psoralen plus ultraviolet A +/- interferon-alpha treatment resistance in mycosis fungoides: the role of tumour microenvironment, nuclear transcription factor-kappaB and T-cell receptor pathways. British Journal of Dermatology2008;160(1):92-102. [CENTRAL: CN-00668828] [PMID: 18945306]">Wozniak 2008</a>) investigated the effect of psoralen plus ultraviolet A light (PUVA) in combination with other therapies. <a href="./references#CD008946-bbs2-0002" title="ChildFJ , MitchellTJ , WhittakerSJ , ScarisbrickJJ , SeedPT , Russel-JonesR . A randomized cross-over study to compare PUVA and extracorporeal photopheresis in the treatment of plaque stage (T2) mycosis fungoides. Clinical &amp; Experimental Dermatology2004;29(3):231-6. [CENTRAL: CN-00468455] [PMID: 15115499]ChildFJ , MitchellTJ , WhittakerSJ , WatkinsP , SeedP , Russell-JonesR . A randomised cross-over study to compare Puva and extracorporeal photopheresis (ECP) in the treatment of plaque stage (T2) mycosis fungoides. British Journal of Dermatology2001;145(Suppl 59):16. [CENTRAL: CN-00430854] ">Child 2004</a> compared extracorporeal photopheresis (ECP) to PUVA in a cross‐over design randomising participants either to start with three months of PUVA or six months of extracorporeal photopheresis. This trial is described in section 'VI. Extracorporeal photochemotherapy'. While <a href="./references#CD008946-bbs2-0006" title="GuitartJ , TuckerR , StevensV . Low dose bexarotene (Targretin®) capsules and phototherapy for early stage cutaneous T-Cell lymphoma. Journal of Investigative Dermatology2002;119(1):241. [CENTRAL: CN-00794450] NCT00030589. A muliticenter, dose-randomized evaluation of Targretin capsules plus PUVA in patients with stage IB - IIA cutaneous T-Cell lymphoma. clinicaltrials.gov/ct/show/NCT00030589 (first received 27 Jaunry 2003). ">Guitart 2002</a> assessed the effect of two‐dose regimens of bexarotene in combination with PUVA, <a href="./references#CD008946-bbs2-0018" title="NCT00056056. Ultraviolet light therapy using methoxsalen with or without Bexarotene in treating patients with mycosis fungoides. clinicaltrials.gov/ct2/show/NCT00056056 (first received 7 March 2003). WhittakerS , OrtizP , DummerR , RankiA , HasanB , MeulemansB , et al. Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial 21011 (NCT00056056). British Journal of Dermatology2012;167(3):678-87. [CENTRAL: CN-00856432] [PMID: 22924950]WhittakerS , Ortiz-RomeroPL , DummerR , RankiA , HasanB , MeulemansB , et al. Efficacy and safety of bexarotene combined with psoralen/ultraviolet A light (PUVA) compared to PUVA treatment alone in stage IB-IIa mycosis fungoides (MF): Final results from EORTC cutaneous lymphoma task force (CLTF) phase III clinical trial 21011. Journal of Clinical Oncology2012;30(15 Suppl 1):8076. ">Whittaker 2012</a> compared bexarotene in combination with PUVA to PUVA alone. The results of these trials are described in section 'V. chemotherapy'. <a href="./references#CD008946-bbs2-0007" title="KayeF , EddyJ , IhdeDC , SteinbergS , FischmannAB , GlatsteinE , et al. Conservative vs. aggressive therapy in mycosis fungoides. Proceedings of the American Society of Clinical Oncology1989;8:257. [CENTRAL: CN-00694960] KayeF , IhdeD , FischmannA , GlatsteinE , MinnaJ , SchechterG , et al. A randomized trial comparing conservative and aggressive therapy in mycosis fungoides (MF). Proceedings of the American Society of Clinical Oncology1986;5:195. [CENTRAL: CN-00695166] KayeFJ , BunnPA , SteinbergSM , StockerJL , IhdeDC , FischmannAB , et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. New England Journal of Medicine1989;321(26):1784-90. [CENTRAL: CN-00064211] [PMID: 2594037]">Kaye 1989</a> used PUVA as one of four sequential escape therapies, while comparing electron‐beam radiation and parenteral chemotherapy to topical treatment. This trial is described in section 'VIII. Combination therapies'. <a href="./references#CD008946-bbs2-0013" title="OtteHG , KuhlS , StadlerR , LugerT , HenzB , SterryW . Treatment of cutaneous T-cell lymphoma with Interferon alpha and PUVA versus Interferon alpha and Acitretin - results of a prospective randomised multi-centre study [Behandlung des kutanen T-Zell-Lymphoms mit Interferon alpha und PUVA versus Interferon alpha und Acirentin - Ergebnisse einer prospektiv-randomisierten Multicenter-Studie]. Der Hautarzt1997;48(Suppl):S97. [CENTRAL: CN-00495120] OtteHG , StadierR , LugerT , HenzB , SterryW . Open controlled clinical trial on the use of interferon plus acitretin versus interferon plus PUVA in patients with cutaneous T-cell lymphoma (CTCL). Annals of Oncology1996;7(Suppl 3):66. [CENTRAL: CN-00308243] StadlerR , OtteHG , LugerT , HenzBM , KuhlP , ZwingersT , et al. Prospective randomized multicenter clinical trial on the use of interferon -2a plus acitretin versus interferon -2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood1998;92(10):3578-81. [CENTRAL: CN-00156682] [PMID: 9808550]">Stadler 1998</a> investigated the effect of IFN‐α (subcutaneously‐injected) combined with either acitretin capsules or PUVA. This trial is described in section 'VIII. Combination therapies'. <a href="./references#CD008946-bbs2-0015" title="Thestrup-PedersenK , GrunnetE , ZachariaeH . Transfer factor therapy in mycosis fungoides: a double-blind study. Acta Dermato-Venereologica1982;62(1):47-53. [CENTRAL: CN-00027377] [PMID: 6175137]">Thestrup‐Pedersen 1982</a> assessed the effect of active or inactivated transfer factor (injected intramuscularly) under concomitant therapy with either nitrogen mustard or PUVA in combination. This trial is described in section 'VIII. Combination therapies'. </p> <p><a href="./references#CD008946-bbs2-0014" title="BohmeyerJ , OtteHG , StadlerR , LugerT , SterryW . Therapy of cutaneous T-cell lymphoma with PUVA versus interferon alfa plus PUVA: first results. Journal of the European Academy of Dermatology &amp; Venereology1999;12(Suppl 2):S268. [CENTRAL: CN-00478472] BohmeyerJ , StadlerR , LugerT , SterryW . Prospective randomized multicentre therapy optimizing protocol for therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α + PUVA [Prospectiv randomisiertes, multizentrisches Therapieoptimierungsprotokoll zur Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α + PUVA]. Zeitschrift für Hautkrankheiten2001;76(Suppl 1):S55. [CENTRAL: CN-01446038] KremerA , BohmeyerJ , StadlerR , LugerT , SterryW . Prospective randomized multicentre therapy optimizing protocol for therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α + PUVA [Prospectiv randomisiertes, multizentrisches Therapieoptimierungsprotokoll zur Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α + PUVA]. Journal der Deutschen Dermatologischen Gesellschaft2003;1(Suppl 1):S99. [CENTRAL: CN-01446037] OtteHG , StadlerR , LugerT , SterryW . Therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α plus PUVA: first results of a prospective randomized multicentre therapy optimizing protocol [Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α plus PUVA: Erste Ergebnisse des prospektiven randomisierten multizentrischen Therapieoptimierungsprotokolls]. Der Hautarzt1999;50(Suppl 1):S2. [CENTRAL: CN-01457423] OtteHG , StadlerR . Combination therapy of cutaneous t-cell-lymphoma with interferon alfa 2a and PUVA [Kombinationstherapie kutaner T-Zell-Lymphome mit Interferon Alfa 2a und PUVA]. Zentralblatt Haut- und Geschlechtskrankheiten1993;162(Suppl):P2.03.08. [CENTRAL: CN-01457422] StadlerM , KremerA , LugerT , SterryW . Prospective, randomized, multicentre clinical trial on the use of interferon a 2a plus PUVA versus PUVA monotherapy in patients with cutaneous T-cell lymphoma, stages I and II [Abstract 7541]. ASCO annual meeting proceedings. Journal of Clinical Oncology2006;24(18S Pt 1):432. [CENTRAL: CN-00625001] ">Stadler 2006</a> and <a href="./references#CD008946-bbs2-0020" title="WozniakMB , TraceyL , Ortiz-RomeroPL , MontesS , AlvarezM , FragaJ , et al. Psoralen plus ultraviolet A +/- interferon-alpha treatment resistance in mycosis fungoides: the role of tumour microenvironment, nuclear transcription factor-kappaB and T-cell receptor pathways. British Journal of Dermatology2008;160(1):92-102. [CENTRAL: CN-00668828] [PMID: 18945306]">Wozniak 2008</a> compared IFN‐α (subcutaneously‐injected) to placebo under concomitant therapy with PUVA. These studies are described in section 'V. Chemotherapy' of this section. </p> <p>One study (<a href="./references#CD008946-bbs2-0012" title="RookAH , WoodGS , DuvicM , VonderheidEC , TobiaA , CabanaB . A phase II placebo-controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis. Journal of the American Academy of Dermatology2010;63(6):984-90. [CENTRAL: CN-00772559] [PMID: 20889234]">Rook 2010</a>) assessing the effect of visible light in combination with topical hypericin is described in section 'I. Topical therapies'. </p> <p>Another study (<a href="./references#CD008946-bbs2-0016" title="NCT01686594. A multi-center, randomized study on oral 8-methoxypsoralen plus UVA with or without maintenance therapy in mycosis fungoides EORTC/ISCL stage IA to IIB. clinicaltrials.gov/ct2/show/NCT01686594 (first received 18 September 2012). Vieyra-GarciaP , Fink-PuchesR , PorkertS , LangR , PöchlauerS , RatzingerG , et al. Evaluation of low-dose, low-frequency oral psoralen-UV-A treatment with or without maintenance on early-stage mycosis fungoides: A randomized clinical trial. JAMA Dermatology2019;155(5):538-47. [PMID: 30892603]">Vieyra‐Garcia 2019</a>) compared PUVA maintenance therapy to no maintenance after having achieved a complete response to PUVA. </p> <section id="CD008946-sec-0120"> <h5 class="title">II.1 PUVA maintenance (one trial)</h5> <p>PICO: In participants with MF CTCL stages IA to IIB, <a href="./references#CD008946-bbs2-0016" title="NCT01686594. A multi-center, randomized study on oral 8-methoxypsoralen plus UVA with or without maintenance therapy in mycosis fungoides EORTC/ISCL stage IA to IIB. clinicaltrials.gov/ct2/show/NCT01686594 (first received 18 September 2012). Vieyra-GarciaP , Fink-PuchesR , PorkertS , LangR , PöchlauerS , RatzingerG , et al. Evaluation of low-dose, low-frequency oral psoralen-UV-A treatment with or without maintenance on early-stage mycosis fungoides: A randomized clinical trial. JAMA Dermatology2019;155(5):538-47. [PMID: 30892603]">Vieyra‐Garcia 2019</a> investigated the effect of PUVA maintenance therapy compared to no maintenance after achieving a complete response with PUVA therapy. Patients were treated or observed for up to nine months. </p> <p>Please see <a href="./full#CD008946-tbl-0005">summary of findings Table 5</a>. </p> <section id="CD008946-sec-0121"> <h6 class="title">Primary outcomes</h6> <section id="CD008946-sec-0122"> <p><b>Common adverse effects of the treatments</b></p> <p><a href="./references#CD008946-bbs2-0016" title="NCT01686594. A multi-center, randomized study on oral 8-methoxypsoralen plus UVA with or without maintenance therapy in mycosis fungoides EORTC/ISCL stage IA to IIB. clinicaltrials.gov/ct2/show/NCT01686594 (first received 18 September 2012). Vieyra-GarciaP , Fink-PuchesR , PorkertS , LangR , PöchlauerS , RatzingerG , et al. Evaluation of low-dose, low-frequency oral psoralen-UV-A treatment with or without maintenance on early-stage mycosis fungoides: A randomized clinical trial. JAMA Dermatology2019;155(5):538-47. [PMID: 30892603]">Vieyra‐Garcia 2019</a> measured adverse effects but the distribution in the treatment arms was not reported. </p> </section> </section> <section id="CD008946-sec-0123"> <h6 class="title">Secondary outcomes</h6> <section id="CD008946-sec-0124"> <p><b>Relapse</b></p> <p>Since all randomised patients started with a complete response, relapse automatically equates to disease‐free survival. We present the data for disease‐free survival (see below). </p> </section> <section id="CD008946-sec-0125"> <p><b>Disease‐free survival</b></p> <p>In <a href="./references#CD008946-bbs2-0016" title="NCT01686594. A multi-center, randomized study on oral 8-methoxypsoralen plus UVA with or without maintenance therapy in mycosis fungoides EORTC/ISCL stage IA to IIB. clinicaltrials.gov/ct2/show/NCT01686594 (first received 18 September 2012). Vieyra-GarciaP , Fink-PuchesR , PorkertS , LangR , PöchlauerS , RatzingerG , et al. Evaluation of low-dose, low-frequency oral psoralen-UV-A treatment with or without maintenance on early-stage mycosis fungoides: A randomized clinical trial. JAMA Dermatology2019;155(5):538-47. [PMID: 30892603]">Vieyra‐Garcia 2019</a>, the hazard ratio (HR) for recurrence when comparing patients with PUVA maintenance with those without maintenance indicated that the chance of extending the duration of disease‐free survival is approximately three times higher in the PUVA maintenance group (HR = 3.25, CI: 1.14 ‐ 9.29, 8 participants, <a href="./references#CD008946-fig-0042" title="">Analysis 16.1</a>). Maximum follow‐up time was 60 months. The certainty of evidence is moderate as we downgraded once due to low sample size (imprecision). </p> </section> </section> </section> </section> <section id="CD008946-sec-0126"> <h4 class="title">III. Total skin electron beam</h4> <p>One study (<a href="./references#CD008946-bbs2-0007" title="KayeF , EddyJ , IhdeDC , SteinbergS , FischmannAB , GlatsteinE , et al. Conservative vs. aggressive therapy in mycosis fungoides. Proceedings of the American Society of Clinical Oncology1989;8:257. [CENTRAL: CN-00694960] KayeF , IhdeD , FischmannA , GlatsteinE , MinnaJ , SchechterG , et al. A randomized trial comparing conservative and aggressive therapy in mycosis fungoides (MF). Proceedings of the American Society of Clinical Oncology1986;5:195. [CENTRAL: CN-00695166] KayeFJ , BunnPA , SteinbergSM , StockerJL , IhdeDC , FischmannAB , et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. New England Journal of Medicine1989;321(26):1784-90. [CENTRAL: CN-00064211] [PMID: 2594037]">Kaye 1989</a>) compared a combination of electron‐beam radiation and parenteral chemotherapy to topical treatment and a series of four sequential escape therapies. This trial is described in section 'VIII. Combination therapies'. </p> </section> <section id="CD008946-sec-0127"> <h4 class="title">IV. Radiotherapy</h4> <p>We did not identify any RCTs assessing the effect of radiotherapy other than total skin electron beam for participants with mycosis fungoides. </p> </section> <section id="CD008946-sec-0128"> <h4 class="title">V. Chemotherapies and biological response modifiers</h4> <p>Ten studies examined the effect of chemotherapy. <a href="./references#CD008946-bbs2-0007" title="KayeF , EddyJ , IhdeDC , SteinbergS , FischmannAB , GlatsteinE , et al. Conservative vs. aggressive therapy in mycosis fungoides. Proceedings of the American Society of Clinical Oncology1989;8:257. [CENTRAL: CN-00694960] KayeF , IhdeD , FischmannA , GlatsteinE , MinnaJ , SchechterG , et al. A randomized trial comparing conservative and aggressive therapy in mycosis fungoides (MF). Proceedings of the American Society of Clinical Oncology1986;5:195. [CENTRAL: CN-00695166] KayeFJ , BunnPA , SteinbergSM , StockerJL , IhdeDC , FischmannAB , et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. New England Journal of Medicine1989;321(26):1784-90. [CENTRAL: CN-00064211] [PMID: 2594037]">Kaye 1989</a> assessed parenteral chemotherapy with cyclophosphamide, doxorubicin, etoposide, and vincristine in combination with total skin electron‐beam radiation to topical treatment. This trial is described in section 'VIII. Combination therapies'. </p> <p><a href="./references#CD008946-bbs2-0014" title="BohmeyerJ , OtteHG , StadlerR , LugerT , SterryW . Therapy of cutaneous T-cell lymphoma with PUVA versus interferon alfa plus PUVA: first results. Journal of the European Academy of Dermatology &amp; Venereology1999;12(Suppl 2):S268. [CENTRAL: CN-00478472] BohmeyerJ , StadlerR , LugerT , SterryW . Prospective randomized multicentre therapy optimizing protocol for therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α + PUVA [Prospectiv randomisiertes, multizentrisches Therapieoptimierungsprotokoll zur Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α + PUVA]. Zeitschrift für Hautkrankheiten2001;76(Suppl 1):S55. [CENTRAL: CN-01446038] KremerA , BohmeyerJ , StadlerR , LugerT , SterryW . Prospective randomized multicentre therapy optimizing protocol for therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α + PUVA [Prospectiv randomisiertes, multizentrisches Therapieoptimierungsprotokoll zur Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α + PUVA]. Journal der Deutschen Dermatologischen Gesellschaft2003;1(Suppl 1):S99. [CENTRAL: CN-01446037] OtteHG , StadlerR , LugerT , SterryW . Therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α plus PUVA: first results of a prospective randomized multicentre therapy optimizing protocol [Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α plus PUVA: Erste Ergebnisse des prospektiven randomisierten multizentrischen Therapieoptimierungsprotokolls]. Der Hautarzt1999;50(Suppl 1):S2. [CENTRAL: CN-01457423] OtteHG , StadlerR . Combination therapy of cutaneous t-cell-lymphoma with interferon alfa 2a and PUVA [Kombinationstherapie kutaner T-Zell-Lymphome mit Interferon Alfa 2a und PUVA]. Zentralblatt Haut- und Geschlechtskrankheiten1993;162(Suppl):P2.03.08. [CENTRAL: CN-01457422] StadlerM , KremerA , LugerT , SterryW . Prospective, randomized, multicentre clinical trial on the use of interferon a 2a plus PUVA versus PUVA monotherapy in patients with cutaneous T-cell lymphoma, stages I and II [Abstract 7541]. ASCO annual meeting proceedings. Journal of Clinical Oncology2006;24(18S Pt 1):432. [CENTRAL: CN-00625001] ">Stadler 2006</a> and <a href="./references#CD008946-bbs2-0020" title="WozniakMB , TraceyL , Ortiz-RomeroPL , MontesS , AlvarezM , FragaJ , et al. Psoralen plus ultraviolet A +/- interferon-alpha treatment resistance in mycosis fungoides: the role of tumour microenvironment, nuclear transcription factor-kappaB and T-cell receptor pathways. British Journal of Dermatology2008;160(1):92-102. [CENTRAL: CN-00668828] [PMID: 18945306]">Wozniak 2008</a> compared IFN‐α (subcutaneously‐injected) to placebo under concomitant therapy with PUVA. </p> <p>Treatment with parenteral systemic agents, such as brentuximab vedotin (<a href="./references#CD008946-bbs2-0011" title="HorwitzS , WhittakerS , DuvicM , DummerR , KimYH , ScarisbrickJ , et al. Response by stage in CD30-positive (CD30+) cutaneous T cell lymphoma (CTCL) patients receiving brentuximab vedotin (BV) vs physician's choice (PC) in the phase 3 ALCANZA study. In: Hematological oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:245–7. [CENTRAL: CN-01408605] [DOI: 10.1002/hon.2438]HorwitzSM , AkilovOE , FisherD , KuzelTM , WangY , Palanca-WesselsMC , et al. Brentuximab vedotin or physician’s choice in CD30-positivecutaneous T-cell lymphoma (ALCANZA): an international,open-label, randomised, phase 3, multicentre trial. Lancet2017;390(10094):555-66. [CENTRAL: CN-01403731] HorwitzSM , ScarisbrickJJ , DummerR , DuvicM , KimYH , WalewskiJ , et al. Updated analyses of the international, open-label, randomized, phase 3 alcanza study: longer-term evidence for superiority of brentuximab vedotin versus methotrexate or bexarotene for CD30-positive cutaneous T-cell lymphoma (CTCL). In: Blood. Conference: 59th annual meeting of the american society of hematology, ASH 2017. United states. Vol. 130. 2017. [CENTRAL: CN-01450312] KimYH , PrinceHM , WhittakerS , HorwitzSM , DuvicM , ScarisbrickJ , et al. Brentuximab vedotin vs physician's choice in CTCL patients from the phase 3 ALCANZA study: analysis of outcomes by CD30 expression. In: Hematological Oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:77–8. [CENTRAL: CN-01408482] [DOI: 10.1002/hon.2437]KimYH , PrinceHM , WhittakerS , HorwitzSM , DuvicM , ScarisbrickJ , et al. Outcomes by CD30 expression in patients with CTCL receiving brentuximab vedotin (BV) vs physician's choice (PC) in the Phase 3 ALCANZA study. Journal of Clinical Oncology2017;35(15 Supplement 1):7517. [EMBASE: 617388795]KimYH , WhittakerS , DummerR , GeskinLJ , GauthierP , LittleM , et al. Phase 3 study of brentuximab vedotin versus physician's choice of methotrexate or bexarotene in patients (PTS) with CD30-positive (CD30+) cutaneous T-cell lymphoma (CTCL). The alcanza study. Hematological Oncology2013;31(Suppl 1):278. [CENTRAL: CN-01531598] [EMBASE: 71147875]KimYH , WhittakerS , HorwitzSM , DuvicM , DummerR , ScarisbrickJ , et al. Brentuximab vedotin demonstrates superior activity to standard therapy in CD30-expressing (CD30+) cutaneous T-cell lymphoma (CTCL) in the randomized phase 3 ALCANZA study. Journal of Investigative Dermatology2017;137(5 Suppl 1):S45. [CENTRAL: CN-01375469] [EMBASE: 616393777]KimYH , WhittakerS , HorwitzSM , DuvicM , DummerR , ScarisbrickJJ , et al. Brentuximab vedotin demonstrates significantly superior clinical outcomes in patients with CD30-expressing cutaneous T cell lymphoma versus physician's choice (Methotrexate or Bexarotene): the phase 3 alcanza study. In: Blood. Conference: 58th annual meeting of the american society of hematology, ASH 2016. United states. Conference start: 20161203. Conference end: 20161206. Vol. 128. 2016. [CENTRAL: CN-01303081] [EMBASE: 614225065]NCT01578499. A randomised, open-label, phase 3 trial of brentuximab vedotin (SGN-35) versus physician's choice (methotrexate or bexarotene) in patients with CD30-positive cutaneous T-cell lymphoma. clinicaltrials.gov/ct2/show/NCT01578499 (first received 17 April 2012). PrinceHM , DummerR , WhittakerS , HorwitzS , DuvicM , ScarisbrickJ , et al. Patient-reported outcomes and quality of life in patients with cutaneous T cell lymphoma: results from the phase 3 ALCANZA study. In: Hematological Oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:247–8. [CENTRAL: CN-01408603] [DOI: 10.1002/hon.2438]ZagadailovE , PrinceHM , WhittakerS , HorwitzS , DuvicM , KimY , et al. Phase 3 alcanza study of brentuximab vedotin (BV) or physician's choice (PC) of methotrexate (MTX) or bexarotene (BEX) in CD30-positive cutaneous T-cell lymphoma (CTCL): number needed to treat analysis. In: Haematologica. Conference: 22th congress of the european hematology association. Spain. Vol. 102. 2017:251. [CENTRAL: CN-01399195] ">Prince 2017</a>), denileukin diftitox (<a href="./references#CD008946-bbs2-0010" title="DuvicM , KuzelTM , OlsenEA , MartinAG , FossFM , KimYH , et al. Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK). Clinical Lymphoma2002;2(4):222-8. [CENTRAL: CN-00514479] [PMID: 11970761]KuzelT , OlsenE , MartinA , KimY , DuvicM , FrankelA , et al. Pivotal phase III trial of two dose levels of DAB389IL-2 (Ontak®) for the treatment of mycosis fungoides (MF). Blood1997;90(10 Suppl 1 (Pt 1)):586a. [CENTRAL: CN-00518069] NTC00050999. Study of ONTAK (Denileukin Diftitox) in cutaneous T-Cell lymphoma (CTCL) patients. clinicaltrials.gov/ct2/show/NCT00050999 (first received 3 January 2003). OlsenE , DuvicM , FrankelA , KimY , MartinA , VonderheidE , et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. Journal of Clinical Oncology2001;19(2):376-88. [CENTRAL: CN-00328506] [PMID: 11208829]OlsenE , DuvicM , MartinA . Pivotal phase III trial of two dose levels of DAB 389 IL-2 (ONTAK) for the treatment of cutaneous T-cell lymphoma (CTCL). Journal of Investigative Dermatology1998;110(4):678. [CENTRAL: CN-00353452] ">Olsen 2001</a>) or oral systemic agents like bexarotene (<a href="./references#CD008946-bbs2-0004" title="DuvicM , MartinAG , KimY , OlsenE , WoodGS , CrowleyCA , et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Archives of Dermatology2001;137(5):581-93. [CENTRAL: CN-00347816] [PMID: 11346336]PrinceHM , McCormackC , RyanG , BakerC , RotsteinH , DavisonJ , et al. Bexarotene capsules and gel for previously treated patients with cutaneous T-cell lymphoma: results of the Australian patients treated on phase II trials. Australasian Journal of Dermatology2001;42(2):91-7. [CENTRAL: CN-00442169] [PMID: 11309029]">Duvic 2001</a>; Guitart 2002; <a href="./references#CD008946-bbs2-0018" title="NCT00056056. Ultraviolet light therapy using methoxsalen with or without Bexarotene in treating patients with mycosis fungoides. clinicaltrials.gov/ct2/show/NCT00056056 (first received 7 March 2003). WhittakerS , OrtizP , DummerR , RankiA , HasanB , MeulemansB , et al. Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial 21011 (NCT00056056). British Journal of Dermatology2012;167(3):678-87. [CENTRAL: CN-00856432] [PMID: 22924950]WhittakerS , Ortiz-RomeroPL , DummerR , RankiA , HasanB , MeulemansB , et al. Efficacy and safety of bexarotene combined with psoralen/ultraviolet A light (PUVA) compared to PUVA treatment alone in stage IB-IIa mycosis fungoides (MF): Final results from EORTC cutaneous lymphoma task force (CLTF) phase III clinical trial 21011. Journal of Clinical Oncology2012;30(15 Suppl 1):8076. ">Whittaker 2012</a>) and lenalidomide (<a href="./references#CD008946-bbs2-0001" title="BagotM , HasanB , WhittakerS , Beylot-BarryM , KnoblerR , ShahE , et al. A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma - EORTC 21081 (NCT01098656): results and lessons learned for future trial designs. European Journal of Dermatology2017;27(3):286–94. [CENTRAL: CN-01395486] [PMID: 28468739]NCT01098656. A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-Cell lymphoma. clinicaltrials.gov/ct2/show/NCT01098656 (first received 5 April 2010). [NCT01098656]">Bagot 2017</a>), are also described in this section. Topical mechlorethamine treatment (<a href="./references#CD008946-bbs2-0009" title="LessinS , DuvicM , GuitartJ , PandyaA , StroberB , OlsenE , et al. Positive results of a pivotal phase ii trial testing a manufactured 0.02% Mechlorethamine gel in mycosis fungoides (mf). Journal of Investigative Dermatology2011;131(Suppl 1):S84. [CENTRAL: CN-00843792] LessinSR , DuvicM , GuitartJ , PandyaAG , StroberBE , OlsenEA , et al. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatology2013;149(1):25-32. [CENTRAL: CN-00859487] [PMID: 23069814]NCT00168064. Safety and efficacy of nitrogen mustard in treatment of mycosis fungoides. clinicaltrials.gov/ct2/show/NCT00168064 (first received 14 September 2005). ">Lessin 2013</a>) is described in the topical treatment section. </p> <section id="CD008946-sec-0129"> <h5 class="title">V.1. IFN‐α + PUVA (two trials)</h5> <p>PICO: In participants with MF (CTCL stages lA to IIA), <a href="./references#CD008946-bbs2-0014" title="BohmeyerJ , OtteHG , StadlerR , LugerT , SterryW . Therapy of cutaneous T-cell lymphoma with PUVA versus interferon alfa plus PUVA: first results. Journal of the European Academy of Dermatology &amp; Venereology1999;12(Suppl 2):S268. [CENTRAL: CN-00478472] BohmeyerJ , StadlerR , LugerT , SterryW . Prospective randomized multicentre therapy optimizing protocol for therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α + PUVA [Prospectiv randomisiertes, multizentrisches Therapieoptimierungsprotokoll zur Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α + PUVA]. Zeitschrift für Hautkrankheiten2001;76(Suppl 1):S55. [CENTRAL: CN-01446038] KremerA , BohmeyerJ , StadlerR , LugerT , SterryW . Prospective randomized multicentre therapy optimizing protocol for therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α + PUVA [Prospectiv randomisiertes, multizentrisches Therapieoptimierungsprotokoll zur Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α + PUVA]. Journal der Deutschen Dermatologischen Gesellschaft2003;1(Suppl 1):S99. [CENTRAL: CN-01446037] OtteHG , StadlerR , LugerT , SterryW . Therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α plus PUVA: first results of a prospective randomized multicentre therapy optimizing protocol [Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α plus PUVA: Erste Ergebnisse des prospektiven randomisierten multizentrischen Therapieoptimierungsprotokolls]. Der Hautarzt1999;50(Suppl 1):S2. [CENTRAL: CN-01457423] OtteHG , StadlerR . Combination therapy of cutaneous t-cell-lymphoma with interferon alfa 2a and PUVA [Kombinationstherapie kutaner T-Zell-Lymphome mit Interferon Alfa 2a und PUVA]. Zentralblatt Haut- und Geschlechtskrankheiten1993;162(Suppl):P2.03.08. [CENTRAL: CN-01457422] StadlerM , KremerA , LugerT , SterryW . Prospective, randomized, multicentre clinical trial on the use of interferon a 2a plus PUVA versus PUVA monotherapy in patients with cutaneous T-cell lymphoma, stages I and II [Abstract 7541]. ASCO annual meeting proceedings. Journal of Clinical Oncology2006;24(18S Pt 1):432. [CENTRAL: CN-00625001] ">Stadler 2006</a> investigated the effect of subcutaneous injections of IFN‐α in combination with PUVA compared to treatment with PUVA alone given for up to 52 weeks or until complete response. End points were evaluated at the end of this timeframe. </p> <p>PICO: In participants with histologically‐proven MF (CTCL stages lA to IIA), <a href="./references#CD008946-bbs2-0020" title="WozniakMB , TraceyL , Ortiz-RomeroPL , MontesS , AlvarezM , FragaJ , et al. Psoralen plus ultraviolet A +/- interferon-alpha treatment resistance in mycosis fungoides: the role of tumour microenvironment, nuclear transcription factor-kappaB and T-cell receptor pathways. British Journal of Dermatology2008;160(1):92-102. [CENTRAL: CN-00668828] [PMID: 18945306]">Wozniak 2008</a> investigated the effect of subcutaneous injections of IFN‐α in combination with PUVA compared to treatment with PUVA alone administered for 24 weeks. End points were evaluated at the end of this period. </p> <p>The studies were similar enough to perform a meta‐analysis ‐ see <a href="./full#CD008946-tbl-0001">summary of findings Table 1</a>. </p> <section id="CD008946-sec-0130"> <h6 class="title">Secondary outcomes</h6> <section id="CD008946-sec-0131"> <p><b>Complete response (CR)</b></p> <p>Combining <a href="./references#CD008946-bbs2-0014" title="BohmeyerJ , OtteHG , StadlerR , LugerT , SterryW . Therapy of cutaneous T-cell lymphoma with PUVA versus interferon alfa plus PUVA: first results. Journal of the European Academy of Dermatology &amp; Venereology1999;12(Suppl 2):S268. [CENTRAL: CN-00478472] BohmeyerJ , StadlerR , LugerT , SterryW . Prospective randomized multicentre therapy optimizing protocol for therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α + PUVA [Prospectiv randomisiertes, multizentrisches Therapieoptimierungsprotokoll zur Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α + PUVA]. Zeitschrift für Hautkrankheiten2001;76(Suppl 1):S55. [CENTRAL: CN-01446038] KremerA , BohmeyerJ , StadlerR , LugerT , SterryW . Prospective randomized multicentre therapy optimizing protocol for therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α + PUVA [Prospectiv randomisiertes, multizentrisches Therapieoptimierungsprotokoll zur Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α + PUVA]. Journal der Deutschen Dermatologischen Gesellschaft2003;1(Suppl 1):S99. [CENTRAL: CN-01446037] OtteHG , StadlerR , LugerT , SterryW . Therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α plus PUVA: first results of a prospective randomized multicentre therapy optimizing protocol [Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α plus PUVA: Erste Ergebnisse des prospektiven randomisierten multizentrischen Therapieoptimierungsprotokolls]. Der Hautarzt1999;50(Suppl 1):S2. [CENTRAL: CN-01457423] OtteHG , StadlerR . Combination therapy of cutaneous t-cell-lymphoma with interferon alfa 2a and PUVA [Kombinationstherapie kutaner T-Zell-Lymphome mit Interferon Alfa 2a und PUVA]. Zentralblatt Haut- und Geschlechtskrankheiten1993;162(Suppl):P2.03.08. [CENTRAL: CN-01457422] StadlerM , KremerA , LugerT , SterryW . Prospective, randomized, multicentre clinical trial on the use of interferon a 2a plus PUVA versus PUVA monotherapy in patients with cutaneous T-cell lymphoma, stages I and II [Abstract 7541]. ASCO annual meeting proceedings. Journal of Clinical Oncology2006;24(18S Pt 1):432. [CENTRAL: CN-00625001] ">Stadler 2006</a> and <a href="./references#CD008946-bbs2-0020" title="WozniakMB , TraceyL , Ortiz-RomeroPL , MontesS , AlvarezM , FragaJ , et al. Psoralen plus ultraviolet A +/- interferon-alpha treatment resistance in mycosis fungoides: the role of tumour microenvironment, nuclear transcription factor-kappaB and T-cell receptor pathways. British Journal of Dermatology2008;160(1):92-102. [CENTRAL: CN-00668828] [PMID: 18945306]">Wozniak 2008</a> in a meta‐analysis indicated no difference between the groups for CR (43 and 49 cases, respectively, RR 1.07, 95% CI 0.87 to 1.31, 122 participants, <a href="./references#CD008946-fig-0015" title="">Analysis 5.1</a>, <a href="#CD008946-fig-0005">Figure 5</a>, Z‐test P = 0.51). Statistical heterogeneity I² statistic was 0%; no clinical heterogeneity could be observed in the two trials. The certainty of evidence is low. We downgraded by two levels to low‐certainty evidence: one level due to low internal validity (risk of bias ‐ performance bias in both studies, attrition bias in <a href="./references#CD008946-bbs2-0014" title="BohmeyerJ , OtteHG , StadlerR , LugerT , SterryW . Therapy of cutaneous T-cell lymphoma with PUVA versus interferon alfa plus PUVA: first results. Journal of the European Academy of Dermatology &amp; Venereology1999;12(Suppl 2):S268. [CENTRAL: CN-00478472] BohmeyerJ , StadlerR , LugerT , SterryW . Prospective randomized multicentre therapy optimizing protocol for therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α + PUVA [Prospectiv randomisiertes, multizentrisches Therapieoptimierungsprotokoll zur Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α + PUVA]. Zeitschrift für Hautkrankheiten2001;76(Suppl 1):S55. [CENTRAL: CN-01446038] KremerA , BohmeyerJ , StadlerR , LugerT , SterryW . Prospective randomized multicentre therapy optimizing protocol for therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α + PUVA [Prospectiv randomisiertes, multizentrisches Therapieoptimierungsprotokoll zur Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α + PUVA]. Journal der Deutschen Dermatologischen Gesellschaft2003;1(Suppl 1):S99. [CENTRAL: CN-01446037] OtteHG , StadlerR , LugerT , SterryW . Therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α plus PUVA: first results of a prospective randomized multicentre therapy optimizing protocol [Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α plus PUVA: Erste Ergebnisse des prospektiven randomisierten multizentrischen Therapieoptimierungsprotokolls]. Der Hautarzt1999;50(Suppl 1):S2. [CENTRAL: CN-01457423] OtteHG , StadlerR . Combination therapy of cutaneous t-cell-lymphoma with interferon alfa 2a and PUVA [Kombinationstherapie kutaner T-Zell-Lymphome mit Interferon Alfa 2a und PUVA]. Zentralblatt Haut- und Geschlechtskrankheiten1993;162(Suppl):P2.03.08. [CENTRAL: CN-01457422] StadlerM , KremerA , LugerT , SterryW . Prospective, randomized, multicentre clinical trial on the use of interferon a 2a plus PUVA versus PUVA monotherapy in patients with cutaneous T-cell lymphoma, stages I and II [Abstract 7541]. ASCO annual meeting proceedings. Journal of Clinical Oncology2006;24(18S Pt 1):432. [CENTRAL: CN-00625001] ">Stadler 2006</a>) and one level due to low sample size (imprecision). </p> <div class="figure" id="CD008946-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 6 IFN‐α + PUVA versus PUVA alone, outcome: 6.1 Complete response." data-id="CD008946-fig-0005" src="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-FIG-05.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 6 IFN‐α + PUVA versus PUVA alone, outcome: 6.1 Complete response. </p> </div> </div> </div> </section> <section id="CD008946-sec-0132"> <p><b>Relapse</b></p> <p>In <a href="./references#CD008946-bbs2-0020" title="WozniakMB , TraceyL , Ortiz-RomeroPL , MontesS , AlvarezM , FragaJ , et al. Psoralen plus ultraviolet A +/- interferon-alpha treatment resistance in mycosis fungoides: the role of tumour microenvironment, nuclear transcription factor-kappaB and T-cell receptor pathways. British Journal of Dermatology2008;160(1):92-102. [CENTRAL: CN-00668828] [PMID: 18945306]">Wozniak 2008</a>, 20 of 22 participants who obtained CR experienced a relapse (the median duration of complete response was 66 weeks). However, no distribution between treatment groups were reported. </p> <p><a href="./references#CD008946-bbs2-0014" title="BohmeyerJ , OtteHG , StadlerR , LugerT , SterryW . Therapy of cutaneous T-cell lymphoma with PUVA versus interferon alfa plus PUVA: first results. Journal of the European Academy of Dermatology &amp; Venereology1999;12(Suppl 2):S268. [CENTRAL: CN-00478472] BohmeyerJ , StadlerR , LugerT , SterryW . Prospective randomized multicentre therapy optimizing protocol for therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α + PUVA [Prospectiv randomisiertes, multizentrisches Therapieoptimierungsprotokoll zur Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α + PUVA]. Zeitschrift für Hautkrankheiten2001;76(Suppl 1):S55. [CENTRAL: CN-01446038] KremerA , BohmeyerJ , StadlerR , LugerT , SterryW . Prospective randomized multicentre therapy optimizing protocol for therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α + PUVA [Prospectiv randomisiertes, multizentrisches Therapieoptimierungsprotokoll zur Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α + PUVA]. Journal der Deutschen Dermatologischen Gesellschaft2003;1(Suppl 1):S99. [CENTRAL: CN-01446037] OtteHG , StadlerR , LugerT , SterryW . Therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α plus PUVA: first results of a prospective randomized multicentre therapy optimizing protocol [Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α plus PUVA: Erste Ergebnisse des prospektiven randomisierten multizentrischen Therapieoptimierungsprotokolls]. Der Hautarzt1999;50(Suppl 1):S2. [CENTRAL: CN-01457423] OtteHG , StadlerR . Combination therapy of cutaneous t-cell-lymphoma with interferon alfa 2a and PUVA [Kombinationstherapie kutaner T-Zell-Lymphome mit Interferon Alfa 2a und PUVA]. Zentralblatt Haut- und Geschlechtskrankheiten1993;162(Suppl):P2.03.08. [CENTRAL: CN-01457422] StadlerM , KremerA , LugerT , SterryW . Prospective, randomized, multicentre clinical trial on the use of interferon a 2a plus PUVA versus PUVA monotherapy in patients with cutaneous T-cell lymphoma, stages I and II [Abstract 7541]. ASCO annual meeting proceedings. Journal of Clinical Oncology2006;24(18S Pt 1):432. [CENTRAL: CN-00625001] ">Stadler 2006</a> did not assess this outcome. </p> </section> <section id="CD008946-sec-0133"> <p><b>Disease‐free survival</b></p> <p>In <a href="./references#CD008946-bbs2-0020" title="WozniakMB , TraceyL , Ortiz-RomeroPL , MontesS , AlvarezM , FragaJ , et al. Psoralen plus ultraviolet A +/- interferon-alpha treatment resistance in mycosis fungoides: the role of tumour microenvironment, nuclear transcription factor-kappaB and T-cell receptor pathways. British Journal of Dermatology2008;160(1):92-102. [CENTRAL: CN-00668828] [PMID: 18945306]">Wozniak 2008</a>, median duration of complete response was reported to be 93 weeks among all participants. However, no distribution between treatment groups were reported. </p> <p><a href="./references#CD008946-bbs2-0014" title="BohmeyerJ , OtteHG , StadlerR , LugerT , SterryW . Therapy of cutaneous T-cell lymphoma with PUVA versus interferon alfa plus PUVA: first results. Journal of the European Academy of Dermatology &amp; Venereology1999;12(Suppl 2):S268. [CENTRAL: CN-00478472] BohmeyerJ , StadlerR , LugerT , SterryW . Prospective randomized multicentre therapy optimizing protocol for therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α + PUVA [Prospectiv randomisiertes, multizentrisches Therapieoptimierungsprotokoll zur Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α + PUVA]. Zeitschrift für Hautkrankheiten2001;76(Suppl 1):S55. [CENTRAL: CN-01446038] KremerA , BohmeyerJ , StadlerR , LugerT , SterryW . Prospective randomized multicentre therapy optimizing protocol for therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α + PUVA [Prospectiv randomisiertes, multizentrisches Therapieoptimierungsprotokoll zur Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α + PUVA]. Journal der Deutschen Dermatologischen Gesellschaft2003;1(Suppl 1):S99. [CENTRAL: CN-01446037] OtteHG , StadlerR , LugerT , SterryW . Therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α plus PUVA: first results of a prospective randomized multicentre therapy optimizing protocol [Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α plus PUVA: Erste Ergebnisse des prospektiven randomisierten multizentrischen Therapieoptimierungsprotokolls]. Der Hautarzt1999;50(Suppl 1):S2. [CENTRAL: CN-01457423] OtteHG , StadlerR . Combination therapy of cutaneous t-cell-lymphoma with interferon alfa 2a and PUVA [Kombinationstherapie kutaner T-Zell-Lymphome mit Interferon Alfa 2a und PUVA]. Zentralblatt Haut- und Geschlechtskrankheiten1993;162(Suppl):P2.03.08. [CENTRAL: CN-01457422] StadlerM , KremerA , LugerT , SterryW . Prospective, randomized, multicentre clinical trial on the use of interferon a 2a plus PUVA versus PUVA monotherapy in patients with cutaneous T-cell lymphoma, stages I and II [Abstract 7541]. ASCO annual meeting proceedings. Journal of Clinical Oncology2006;24(18S Pt 1):432. [CENTRAL: CN-00625001] ">Stadler 2006</a> did not assess this outcome. </p> </section> </section> </section> <section id="CD008946-sec-0134"> <h5 class="title">V.2. Denileukin diftitox (one trial)</h5> <p>PICO: In participants with MF with ≥ 20% of lymphocytes within the skin biopsy stain positively for CD25 by immunohistochemistry stages IB‐IVA, <a href="./references#CD008946-bbs2-0010" title="DuvicM , KuzelTM , OlsenEA , MartinAG , FossFM , KimYH , et al. Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK). Clinical Lymphoma2002;2(4):222-8. [CENTRAL: CN-00514479] [PMID: 11970761]KuzelT , OlsenE , MartinA , KimY , DuvicM , FrankelA , et al. Pivotal phase III trial of two dose levels of DAB389IL-2 (Ontak®) for the treatment of mycosis fungoides (MF). Blood1997;90(10 Suppl 1 (Pt 1)):586a. [CENTRAL: CN-00518069] NTC00050999. Study of ONTAK (Denileukin Diftitox) in cutaneous T-Cell lymphoma (CTCL) patients. clinicaltrials.gov/ct2/show/NCT00050999 (first received 3 January 2003). OlsenE , DuvicM , FrankelA , KimY , MartinA , VonderheidE , et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. Journal of Clinical Oncology2001;19(2):376-88. [CENTRAL: CN-00328506] [PMID: 11208829]OlsenE , DuvicM , MartinA . Pivotal phase III trial of two dose levels of DAB 389 IL-2 (ONTAK) for the treatment of cutaneous T-cell lymphoma (CTCL). Journal of Investigative Dermatology1998;110(4):678. [CENTRAL: CN-00353452] ">Olsen 2001</a> investigated the effect of denileukin diftitox intravenous infusions of 9 µg/kg/day (low‐dose group) compared to denileukin diftitox intravenous infusions of 18 µg/kg/day (high‐dose group) given for up to six months. End points were evaluated at the end of this period. </p> <section id="CD008946-sec-0135"> <h6 class="title">Primary outcomes</h6> <section id="CD008946-sec-0136"> <p><b>Improvement in quality of life as defined by participant questionnaires</b></p> <p>The study of <a href="./references#CD008946-bbs2-0010" title="DuvicM , KuzelTM , OlsenEA , MartinAG , FossFM , KimYH , et al. Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK). Clinical Lymphoma2002;2(4):222-8. [CENTRAL: CN-00514479] [PMID: 11970761]KuzelT , OlsenE , MartinA , KimY , DuvicM , FrankelA , et al. Pivotal phase III trial of two dose levels of DAB389IL-2 (Ontak®) for the treatment of mycosis fungoides (MF). Blood1997;90(10 Suppl 1 (Pt 1)):586a. [CENTRAL: CN-00518069] NTC00050999. Study of ONTAK (Denileukin Diftitox) in cutaneous T-Cell lymphoma (CTCL) patients. clinicaltrials.gov/ct2/show/NCT00050999 (first received 3 January 2003). OlsenE , DuvicM , FrankelA , KimY , MartinA , VonderheidE , et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. Journal of Clinical Oncology2001;19(2):376-88. [CENTRAL: CN-00328506] [PMID: 11208829]OlsenE , DuvicM , MartinA . Pivotal phase III trial of two dose levels of DAB 389 IL-2 (ONTAK) for the treatment of cutaneous T-cell lymphoma (CTCL). Journal of Investigative Dermatology1998;110(4):678. [CENTRAL: CN-00353452] ">Olsen 2001</a> investigated quality of life using the Functional Assessment in Cancer Therapy‐general (FACT‐G) questionnaire (version 3), as completed by participants at baseline, before the start of each treatment cycle, and when the study was discontinued. Participants were excluded from the end point FACT‐G analyses if they did not complete a post‐baseline FACT‐G questionnaire or answer a sufficient number of questions for calculation of their post‐baseline FACT‐G composite and subscale scores. </p> <p>Sixty participants completed a FACT‐G questionnaire (scale 0 to 112 points, higher scores indicating better quality of life) at the end point of the study. Changes in the FACT‐G composite score were only given for 42 participants from baseline to the end of treatment. The mean difference for the 23 participants receiving the low dose was +7 points and for the 19 participants in the high‐dose group, +4 points. </p> <p>However, the results were sub‐divided into responders and non‐responders. The mean difference from baseline for eight responders receiving the low dose was +14 points compared to a difference of +2 points in 13 responders in the high‐dose group. Among non‐responders, for the 15 participants receiving the low dose the mean difference from baseline was +3 points compared to +7 points in the six non‐responders in the high‐dose group. The study did not provide data on variability. </p> </section> <section id="CD008946-sec-0137"> <p><b>Common adverse effects of the treatments</b></p> <p>The study of <a href="./references#CD008946-bbs2-0010" title="DuvicM , KuzelTM , OlsenEA , MartinAG , FossFM , KimYH , et al. Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK). Clinical Lymphoma2002;2(4):222-8. [CENTRAL: CN-00514479] [PMID: 11970761]KuzelT , OlsenE , MartinA , KimY , DuvicM , FrankelA , et al. Pivotal phase III trial of two dose levels of DAB389IL-2 (Ontak®) for the treatment of mycosis fungoides (MF). Blood1997;90(10 Suppl 1 (Pt 1)):586a. [CENTRAL: CN-00518069] NTC00050999. Study of ONTAK (Denileukin Diftitox) in cutaneous T-Cell lymphoma (CTCL) patients. clinicaltrials.gov/ct2/show/NCT00050999 (first received 3 January 2003). OlsenE , DuvicM , FrankelA , KimY , MartinA , VonderheidE , et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. Journal of Clinical Oncology2001;19(2):376-88. [CENTRAL: CN-00328506] [PMID: 11208829]OlsenE , DuvicM , MartinA . Pivotal phase III trial of two dose levels of DAB 389 IL-2 (ONTAK) for the treatment of cutaneous T-cell lymphoma (CTCL). Journal of Investigative Dermatology1998;110(4):678. [CENTRAL: CN-00353452] ">Olsen 2001</a> reported on common adverse effects, such as acute infusion events, constitutional symptoms, gastrointestinal syndromes, vascular leak syndrome, thrombotic events, cardiopulmonary and central nervous system (CNS) syndromes, as well as laboratory abnormalities. Of all adverse events, 87% occurred for the first time during the first cycle. </p> <p>The most common adverse effects were constitutional symptoms like chills, fever, asthenia, arthralgia, myalgia; headaches followed by infections; gastrointestinal and CNS syndromes; as well as rash and vascular leak syndrome. </p> <p>A spectrum of adverse effects and higher‐grade adverse effects (grade 3 or 4) have been reported, but we found no difference between the low‐ and high‐dose groups (71 participants): </p> <p> <ul id="CD008946-list-0022"> <li> <p>constitutional symptoms and grade 3 to 4 constitutional symptoms: RR 0.85, 95% CI 0.70 to 1.04, <a href="./references#CD008946-fig-0016" title="">Analysis 6.1</a>, Fisher test P = 0.19; and RR 1.27, 95% CI 0.73 to 2.21, <a href="./references#CD008946-fig-0016" title="">Analysis 6.1</a>, Fisher test P = 0.47, respectively; </p> </li> <li> <p>infections and grade 3 to 4 infections: RR 0.80, 95% CI 0.53 to 1.20, <a href="./references#CD008946-fig-0016" title="">Analysis 6.1</a>, Fisher test P = 0.34; and RR 0.78, 95% CI 0.43 to 1.42, <a href="./references#CD008946-fig-0016" title="">Analysis 6.1</a>, Fisher test P = 0.47, respectively; </p> </li> <li> <p>gastrointestinal syndromes and grade 3 or 4 syndromes: RR 1.05, 95% CI 0.81 to 1.36, <a href="./references#CD008946-fig-0016" title="">Analysis 6.1</a>, Fisher test P = 0.79; and RR 0.63, 95% CI 0.38 to 1.06, <a href="./references#CD008946-fig-0016" title="">Analysis 6.1</a>, Fisher test P = 0.10, respectively; </p> </li> <li> <p>CNS syndromes and grade 3 or 4 CNS syndromes: RR 1.14, 95% CI 0.73 to 1.79, <a href="./references#CD008946-fig-0016" title="">Analysis 6.1</a>, Fisher test P = 0.64; and RR 1.46, 95% CI 0.58 to 3.67, <a href="./references#CD008946-fig-0016" title="">Analysis 6.1</a>, Fisher test P = 0.56, respectively; </p> </li> <li> <p>rash and grade 3 or 4 rashes: RR 0.76, 95% CI 0.40 to 1.45, <a href="./references#CD008946-fig-0016" title="">Analysis 6.1</a>, Fisher test P = 0.46; and RR 0.85, 95% CI 0.35 to 2.10, <a href="./references#CD008946-fig-0016" title="">Analysis 6.1</a>, Fisher test P = 0.78, respectively; </p> </li> <li> <p>vascular leak syndrome and grade 3 to 4 vascular leak syndrome: RR 0.97, 95% CI 0.44 to 2.16, <a href="./references#CD008946-fig-0016" title="">Analysis 6.1</a>, Fisher test P = 1.00; and RR 1.46, 95% CI 0.58 to 3.67, <a href="./references#CD008946-fig-0016" title="">Analysis 6.1</a>, Fisher test P = 0.56, respectively; </p> </li> <li> <p>thrombotic events and grade 3 to 4 thrombotic events: RR 0.97, 95% CI 0.26 to 3.59, <a href="./references#CD008946-fig-0016" title="">Analysis 6.1</a>, Fisher test P = 1.00; and RR 2.92, 95% CI 0.32 to 26.72, <a href="./references#CD008946-fig-0016" title="">Analysis 6.1</a>, Fisher test P = 0.61, respectively; </p> </li> <li> <p>cardiopulmonary events, such as increased cough or right heart failure, and grade 3 or 4 cardiopulmonary events: RR 0.52, 95% CI 0.24 to 1.16, <a href="./references#CD008946-fig-0016" title="">Analysis 6.1</a>, Fisher test P = 0.12; and RR 0.65, 95% CI 0.12 to 3.65, <a href="./references#CD008946-fig-0016" title="">Analysis 6.1</a>, Fisher test P = 0.67, respectively; </p> </li> <li> <p>acute infusion‐related events, such as back pain, chest pain, hypotension, pruritus, vasodilatation or dyspnoea and grade 3 or 4 acute infusion‐related events: RR 0.92, 95% CI 0.80 to 1.04, <a href="./references#CD008946-fig-0016" title="">Analysis 6.1</a>, Fisher test P = 0.36; and RR 1.13, 95% CI 0.61 to 2.10, <a href="./references#CD008946-fig-0016" title="">Analysis 6.1</a>, Fisher test P = 0.81, respectively; </p> </li> <li> <p>grade 3 to 4 laboratory abnormalities: RR 1.25, 95% CI 0.74 to 2.10, <a href="./references#CD008946-fig-0016" title="">Analysis 6.1</a>, Fisher test P = 0.48. </p> </li> </ul> </p> </section> </section> <section id="CD008946-sec-0138"> <h6 class="title">Secondary outcomes</h6> <section id="CD008946-sec-0139"> <p><b>Complete response (CR)</b></p> <p>In <a href="./references#CD008946-bbs2-0010" title="DuvicM , KuzelTM , OlsenEA , MartinAG , FossFM , KimYH , et al. Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK). Clinical Lymphoma2002;2(4):222-8. [CENTRAL: CN-00514479] [PMID: 11970761]KuzelT , OlsenE , MartinA , KimY , DuvicM , FrankelA , et al. Pivotal phase III trial of two dose levels of DAB389IL-2 (Ontak®) for the treatment of mycosis fungoides (MF). Blood1997;90(10 Suppl 1 (Pt 1)):586a. [CENTRAL: CN-00518069] NTC00050999. Study of ONTAK (Denileukin Diftitox) in cutaneous T-Cell lymphoma (CTCL) patients. clinicaltrials.gov/ct2/show/NCT00050999 (first received 3 January 2003). OlsenE , DuvicM , FrankelA , KimY , MartinA , VonderheidE , et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. Journal of Clinical Oncology2001;19(2):376-88. [CENTRAL: CN-00328506] [PMID: 11208829]OlsenE , DuvicM , MartinA . Pivotal phase III trial of two dose levels of DAB 389 IL-2 (ONTAK) for the treatment of cutaneous T-cell lymphoma (CTCL). Journal of Investigative Dermatology1998;110(4):678. [CENTRAL: CN-00353452] ">Olsen 2001</a>, no differences were observed between the low‐ and high‐dose group for CR: RR 1.30, 95% CI 0.31 to 5.38, 71 participants, <a href="./references#CD008946-fig-0017" title="">Analysis 6.2</a>, Fisher test P = 1.00. All responders in the low‐dose group had stage IB disease, whereas responders in the high‐dose group had stage IB (1), IIB (2), or IVA (1) disease. </p> </section> <section id="CD008946-sec-0140"> <p><b>Overall survival <i>(</i>OS)</b></p> <p>There were two deaths reported within 90 days of the last study drug administration in the 18 µg/kg/day group: One participant died of sepsis at day 58 after the last study drug. One participant died of myocardial infarction at day 26. </p> </section> <section id="CD008946-sec-0141"> <p><b>Objective response rate (ORR)</b></p> <p>In <a href="./references#CD008946-bbs2-0010" title="DuvicM , KuzelTM , OlsenEA , MartinAG , FossFM , KimYH , et al. Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK). Clinical Lymphoma2002;2(4):222-8. [CENTRAL: CN-00514479] [PMID: 11970761]KuzelT , OlsenE , MartinA , KimY , DuvicM , FrankelA , et al. Pivotal phase III trial of two dose levels of DAB389IL-2 (Ontak®) for the treatment of mycosis fungoides (MF). Blood1997;90(10 Suppl 1 (Pt 1)):586a. [CENTRAL: CN-00518069] NTC00050999. Study of ONTAK (Denileukin Diftitox) in cutaneous T-Cell lymphoma (CTCL) patients. clinicaltrials.gov/ct2/show/NCT00050999 (first received 3 January 2003). OlsenE , DuvicM , FrankelA , KimY , MartinA , VonderheidE , et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. Journal of Clinical Oncology2001;19(2):376-88. [CENTRAL: CN-00328506] [PMID: 11208829]OlsenE , DuvicM , MartinA . Pivotal phase III trial of two dose levels of DAB 389 IL-2 (ONTAK) for the treatment of cutaneous T-cell lymphoma (CTCL). Journal of Investigative Dermatology1998;110(4):678. [CENTRAL: CN-00353452] ">Olsen 2001</a>, ORR was did not differ between the low‐ and high‐dose group: RR 1.58, 95% CI 0.75 to 3.34, 71 participants, <a href="./references#CD008946-fig-0018" title="">Analysis 6.3</a>, Fisher test P = 0.30. Responders in the low‐dose group had stage IB (1), IIA (2), IIB (1), or IVA (1) disease, whereas responders in the high‐dose group had stage IB (2), IIA (1), IIB (3), III (2), or IVA (1) disease. </p> </section> <section id="CD008946-sec-0142"> <p><b>Rare adverse effects</b></p> <p><a href="./references#CD008946-bbs2-0010" title="DuvicM , KuzelTM , OlsenEA , MartinAG , FossFM , KimYH , et al. Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK). Clinical Lymphoma2002;2(4):222-8. [CENTRAL: CN-00514479] [PMID: 11970761]KuzelT , OlsenE , MartinA , KimY , DuvicM , FrankelA , et al. Pivotal phase III trial of two dose levels of DAB389IL-2 (Ontak®) for the treatment of mycosis fungoides (MF). Blood1997;90(10 Suppl 1 (Pt 1)):586a. [CENTRAL: CN-00518069] NTC00050999. Study of ONTAK (Denileukin Diftitox) in cutaneous T-Cell lymphoma (CTCL) patients. clinicaltrials.gov/ct2/show/NCT00050999 (first received 3 January 2003). OlsenE , DuvicM , FrankelA , KimY , MartinA , VonderheidE , et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. Journal of Clinical Oncology2001;19(2):376-88. [CENTRAL: CN-00328506] [PMID: 11208829]OlsenE , DuvicM , MartinA . Pivotal phase III trial of two dose levels of DAB 389 IL-2 (ONTAK) for the treatment of cutaneous T-cell lymphoma (CTCL). Journal of Investigative Dermatology1998;110(4):678. [CENTRAL: CN-00353452] ">Olsen 2001</a> reported one case of thyrotoxicosis. However, the authors did not state to which group this participant was allocated. </p> </section> </section> </section> <section id="CD008946-sec-0143"> <h5 class="title">V.3. Bexarotene (three trials)</h5> <p>PICO: In participants with MF CTCL stages I to IIA, <a href="./references#CD008946-bbs2-0004" title="DuvicM , MartinAG , KimY , OlsenE , WoodGS , CrowleyCA , et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Archives of Dermatology2001;137(5):581-93. [CENTRAL: CN-00347816] [PMID: 11346336]PrinceHM , McCormackC , RyanG , BakerC , RotsteinH , DavisonJ , et al. Bexarotene capsules and gel for previously treated patients with cutaneous T-cell lymphoma: results of the Australian patients treated on phase II trials. Australasian Journal of Dermatology2001;42(2):91-7. [CENTRAL: CN-00442169] [PMID: 11309029]">Duvic 2001</a> investigated the effect of bexarotene capsules dosed 300 mg/m²/day to 650 mg/m²/day versus bexarotene capsules dosed 6.5 mg/m²/day given for 16 weeks. End points were evaluated at the end of this period. The study of <a href="./references#CD008946-bbs2-0004" title="DuvicM , MartinAG , KimY , OlsenE , WoodGS , CrowleyCA , et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Archives of Dermatology2001;137(5):581-93. [CENTRAL: CN-00347816] [PMID: 11346336]PrinceHM , McCormackC , RyanG , BakerC , RotsteinH , DavisonJ , et al. Bexarotene capsules and gel for previously treated patients with cutaneous T-cell lymphoma: results of the Australian patients treated on phase II trials. Australasian Journal of Dermatology2001;42(2):91-7. [CENTRAL: CN-00442169] [PMID: 11309029]">Duvic 2001</a> reduced the dose of bexarotene twice during the study and partly discontinued randomisation for an uncertain period of time in the middle of the study; the dropout rate was 72.4%. Therefore, the results of this study are only presented qualitatively. </p> <p>PICO: In participants with MF CTCL stages IB and IIA, <a href="./references#CD008946-bbs2-0006" title="GuitartJ , TuckerR , StevensV . Low dose bexarotene (Targretin®) capsules and phototherapy for early stage cutaneous T-Cell lymphoma. Journal of Investigative Dermatology2002;119(1):241. [CENTRAL: CN-00794450] NCT00030589. A muliticenter, dose-randomized evaluation of Targretin capsules plus PUVA in patients with stage IB - IIA cutaneous T-Cell lymphoma. clinicaltrials.gov/ct/show/NCT00030589 (first received 27 Jaunry 2003). ">Guitart 2002</a> investigated the effect of 300 mg/day bexarotene in combination with PUVA and 54 mg/day fenofibrate to 150 mg/day bexarotene in combination with PUVA and 54 mg/day fenofibrate given for 24 weeks. End points were evaluated at the end of this period. </p> <p>PICO: In participants with MF CTCL stages IB to IIA, <a href="./references#CD008946-bbs2-0018" title="NCT00056056. Ultraviolet light therapy using methoxsalen with or without Bexarotene in treating patients with mycosis fungoides. clinicaltrials.gov/ct2/show/NCT00056056 (first received 7 March 2003). WhittakerS , OrtizP , DummerR , RankiA , HasanB , MeulemansB , et al. Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial 21011 (NCT00056056). British Journal of Dermatology2012;167(3):678-87. [CENTRAL: CN-00856432] [PMID: 22924950]WhittakerS , Ortiz-RomeroPL , DummerR , RankiA , HasanB , MeulemansB , et al. Efficacy and safety of bexarotene combined with psoralen/ultraviolet A light (PUVA) compared to PUVA treatment alone in stage IB-IIa mycosis fungoides (MF): Final results from EORTC cutaneous lymphoma task force (CLTF) phase III clinical trial 21011. Journal of Clinical Oncology2012;30(15 Suppl 1):8076. ">Whittaker 2012</a> investigated the effect of bexarotene in combination with PUVA to PUVA alone for up to 16 weeks. Treatment continued until a patient achieved complete response, there was progressive disease or unacceptable toxicity. Therefore, end points were evaluated individually. Please see <a href="./full#CD008946-tbl-0003">summary of findings Table 3</a>. </p> <section id="CD008946-sec-0144"> <h6 class="title">Primary outcomes</h6> <section id="CD008946-sec-0145"> <p><b>Improvement in quality of life as defined by participant questionnaires</b></p> <p><a href="./references#CD008946-bbs2-0004" title="DuvicM , MartinAG , KimY , OlsenE , WoodGS , CrowleyCA , et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Archives of Dermatology2001;137(5):581-93. [CENTRAL: CN-00347816] [PMID: 11346336]PrinceHM , McCormackC , RyanG , BakerC , RotsteinH , DavisonJ , et al. Bexarotene capsules and gel for previously treated patients with cutaneous T-cell lymphoma: results of the Australian patients treated on phase II trials. Australasian Journal of Dermatology2001;42(2):91-7. [CENTRAL: CN-00442169] [PMID: 11309029]">Duvic 2001</a> investigated quality of life using a non‐validated CTCL quality of life questionnaire and the Spitzer quality of life questionnaire (six items) at baseline and each month. However, results were divided into responders and non‐responders rather than treatment groups. </p> <p><a href="./references#CD008946-bbs2-0006" title="GuitartJ , TuckerR , StevensV . Low dose bexarotene (Targretin®) capsules and phototherapy for early stage cutaneous T-Cell lymphoma. Journal of Investigative Dermatology2002;119(1):241. [CENTRAL: CN-00794450] NCT00030589. A muliticenter, dose-randomized evaluation of Targretin capsules plus PUVA in patients with stage IB - IIA cutaneous T-Cell lymphoma. clinicaltrials.gov/ct/show/NCT00030589 (first received 27 Jaunry 2003). ">Guitart 2002</a> did not assess this outcome. </p> <p><a href="./references#CD008946-bbs2-0018" title="NCT00056056. Ultraviolet light therapy using methoxsalen with or without Bexarotene in treating patients with mycosis fungoides. clinicaltrials.gov/ct2/show/NCT00056056 (first received 7 March 2003). WhittakerS , OrtizP , DummerR , RankiA , HasanB , MeulemansB , et al. Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial 21011 (NCT00056056). British Journal of Dermatology2012;167(3):678-87. [CENTRAL: CN-00856432] [PMID: 22924950]WhittakerS , Ortiz-RomeroPL , DummerR , RankiA , HasanB , MeulemansB , et al. Efficacy and safety of bexarotene combined with psoralen/ultraviolet A light (PUVA) compared to PUVA treatment alone in stage IB-IIa mycosis fungoides (MF): Final results from EORTC cutaneous lymphoma task force (CLTF) phase III clinical trial 21011. Journal of Clinical Oncology2012;30(15 Suppl 1):8076. ">Whittaker 2012</a> did not assess this outcome. </p> </section> <section id="CD008946-sec-0146"> <p><b>Common adverse effects of the treatments</b></p> <p><a href="./references#CD008946-bbs2-0004" title="DuvicM , MartinAG , KimY , OlsenE , WoodGS , CrowleyCA , et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Archives of Dermatology2001;137(5):581-93. [CENTRAL: CN-00347816] [PMID: 11346336]PrinceHM , McCormackC , RyanG , BakerC , RotsteinH , DavisonJ , et al. Bexarotene capsules and gel for previously treated patients with cutaneous T-cell lymphoma: results of the Australian patients treated on phase II trials. Australasian Journal of Dermatology2001;42(2):91-7. [CENTRAL: CN-00442169] [PMID: 11309029]">Duvic 2001</a> reported on adverse effects in the body as a whole, the digestive and endocrine systems, the skin and appendages as well as laboratory abnormalities of the haematological and metabolic systems. Adverse effects were compared between the low‐dose group before cross‐over (L1) and after the cross‐over period (L1‐&gt;H1) as well as with the high‐dose groups taking 300 mg/m²/day of bexarotene (H1) and the replaced high‐dose group taking 650 mg/m²/day (H2). In the low‐dose group, 11 of 15 participants crossed over to the high‐dose therapy group resulting in increased incidences of almost every adverse event. </p> <p>Common adverse effects including systemic reactions: affection of digestive, endocrine, haematological/lymphatic, and metabolic systems; and skin reactions are shown in the <a href="#CD008946-tbl-0011">Table 6</a>. </p> <div class="table" id="CD008946-tbl-0011"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Common adverse events from Duvic 2001</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Body as a whole </b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Altered hormone level, asthenia, chills, headache, infection, pain, abdominal pain</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Digestive system </b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diarrhoea, nausea</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Endocrine system </b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypothyroidism</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Haematological and lymphatic system </b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anaemia, hypochromic anaemia, leukopenia</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Metabolic and nutritional system </b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypercholesterolaemia, hyperlipidaemia, lactate dehydrogenase (LDH) increase, aspartate aminotransferase (AST) increase, alanine aminotransferase (ALT) increase </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Skin and appendages </b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dermatitis exfoliation, pruritus, rash, skin disorder</p> </td> </tr> </tbody> </table> </div> <p><a href="./references#CD008946-bbs2-0006" title="GuitartJ , TuckerR , StevensV . Low dose bexarotene (Targretin®) capsules and phototherapy for early stage cutaneous T-Cell lymphoma. Journal of Investigative Dermatology2002;119(1):241. [CENTRAL: CN-00794450] NCT00030589. A muliticenter, dose-randomized evaluation of Targretin capsules plus PUVA in patients with stage IB - IIA cutaneous T-Cell lymphoma. clinicaltrials.gov/ct/show/NCT00030589 (first received 27 Jaunry 2003). ">Guitart 2002</a> reported on the following common adverse effects: photosensitivity, nausea, constipation, fatigue, pruritus, arthralgias, nasopharyngitis, headaches, and insomnia for which there was no difference between the low‐ and the high‐dose group (39 participants each): </p> <p> <ul id="CD008946-list-0023"> <li> <p>photosensitivity: RR 1.40, 95% CI 0.36 to 5.46, <a href="./references#CD008946-fig-0019" title="">Analysis 7.1</a>, Fisher test P = 0.69; </p> </li> <li> <p>nausea: RR 0.82, 95% CI 0.38 to 1.75, <a href="./references#CD008946-fig-0019" title="">Analysis 7.1</a>, Fisher test P = 0.75; </p> </li> <li> <p>constipation: RR 3.16, 95% CI 0.36 to 27.78, <a href="./references#CD008946-fig-0019" title="">Analysis 7.1</a>, Fisher test P = 0.34; </p> </li> <li> <p>fatigue: RR 1.20, 95% CI 0.54 to 2.67, <a href="./references#CD008946-fig-0019" title="">Analysis 7.1</a>, Fisher test P = 0.75; </p> </li> <li> <p>pruritus: RR 0.70, 95% CI 0.31 to 1.59, <a href="./references#CD008946-fig-0019" title="">Analysis 7.1</a>, Fisher test P = 0.51; </p> </li> <li> <p>arthralgias: RR 1.40, 95% CI 0.36 to 5.46, <a href="./references#CD008946-fig-0019" title="">Analysis 7.1</a>, Fisher test P = 0.69; </p> </li> <li> <p>nasopharyngitis: RR 0.53, 95% CI 0.11 to 2.55, <a href="./references#CD008946-fig-0019" title="">Analysis 7.1</a>, Fisher test P = 0.66; </p> </li> <li> <p>headaches: RR 0.84, 95% CI 0.27 to 2.67, <a href="./references#CD008946-fig-0019" title="">Analysis 7.1</a>, Fisher test P = 1.00; </p> </li> <li> <p>insomnia: RR 1.05, 95% CI 0.16 to 6.74, <a href="./references#CD008946-fig-0019" title="">Analysis 7.1</a>, Fisher test P = 1.00. </p> </li> </ul> </p> <p>There were differences in laboratory abnormalities for free T4, cholesterol, triglycerides, and liver enzymes SGOT/SGPT between low‐ and high‐dose groups. The results of <a href="./references#CD008946-bbs2-0006" title="GuitartJ , TuckerR , StevensV . Low dose bexarotene (Targretin®) capsules and phototherapy for early stage cutaneous T-Cell lymphoma. Journal of Investigative Dermatology2002;119(1):241. [CENTRAL: CN-00794450] NCT00030589. A muliticenter, dose-randomized evaluation of Targretin capsules plus PUVA in patients with stage IB - IIA cutaneous T-Cell lymphoma. clinicaltrials.gov/ct/show/NCT00030589 (first received 27 Jaunry 2003). ">Guitart 2002</a> indicate that cholesterol and triglyceride levels were higher in the high‐dose group (39 participants each): </p> <p> <ul id="CD008946-list-0024"> <li> <p>free T4 abnormalities: RR 1.26, 95% CI 0.46 to 3.46, <a href="./references#CD008946-fig-0019" title="">Analysis 7.1</a>, Fisher test P = 0.73; </p> </li> <li> <p>cholesterol abnormalities: 13 cases in high‐dose arm, three cases in low‐dose arm, RR 4.56, 95% CI 1.54 to 13.53, <a href="./references#CD008946-fig-0019" title="">Analysis 7.1</a>. The risk ratio showed a higher risk for the high‐dose group (Fisher test P = 0.002); </p> </li> <li> <p>triglyceride abnormalities: 15 cases in high‐dose arm, five cases in low‐dose arm, RR 3.16, 95% CI 1.43 to 6.98, <a href="./references#CD008946-fig-0019" title="">Analysis 7.1</a>. The risk ratio showed a higher risk for the high‐dose group (Fisher test P = 0.002); </p> </li> <li> <p>abnormalities of SGOT/SGPT: RR 5.25, 95% CI 0.27 to 102.74, <a href="./references#CD008946-fig-0019" title="">Analysis 7.1</a>, Fisher test P = 0.23. </p> </li> </ul> </p> <p><a href="./references#CD008946-bbs2-0018" title="NCT00056056. Ultraviolet light therapy using methoxsalen with or without Bexarotene in treating patients with mycosis fungoides. clinicaltrials.gov/ct2/show/NCT00056056 (first received 7 March 2003). WhittakerS , OrtizP , DummerR , RankiA , HasanB , MeulemansB , et al. Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial 21011 (NCT00056056). British Journal of Dermatology2012;167(3):678-87. [CENTRAL: CN-00856432] [PMID: 22924950]WhittakerS , Ortiz-RomeroPL , DummerR , RankiA , HasanB , MeulemansB , et al. Efficacy and safety of bexarotene combined with psoralen/ultraviolet A light (PUVA) compared to PUVA treatment alone in stage IB-IIa mycosis fungoides (MF): Final results from EORTC cutaneous lymphoma task force (CLTF) phase III clinical trial 21011. Journal of Clinical Oncology2012;30(15 Suppl 1):8076. ">Whittaker 2012</a> reported on the following adverse effects: liver toxicities, renal toxicities, haematological toxicities, increased fasting cholesterol, photosensitivity, pruritus, rash and hypertriglyceridaemia. Bexarotene and PUVA lead to a increase of liver toxicities and fasting cholesterol (87 participants): </p> <p> <ul id="CD008946-list-0025"> <li> <p>liver toxicities: six cases in combination arm, zero cases in PUVA alone arm, RR 11.62, 95% CI 0.7 to 200.07 (95% CI according to Miettinen: 1.46 to not estimable), <a href="./references#CD008946-fig-0023" title="">Analysis 8.1</a>, Fisher test P = 0.03; </p> </li> <li> <p>Increased fasting cholesterol: six cases combination arm, zero cases in PUVA‐alone arm, RR 11.62, 95% CI 0.67 to 200.07 (95% CI according to Miettinen: 1.46 to not estimable), <a href="./references#CD008946-fig-0023" title="">Analysis 8.1</a>, Fisher test P = 0.03. </p> </li> </ul> </p> <p>For all the other adverse effects, no differences could be observed:</p> <p> <ul id="CD008946-list-0026"> <li> <p>renal toxicities: RR 0.30, 95% CI 0.01 to 7.12, <a href="./references#CD008946-fig-0023" title="">Analysis 8.1</a>, Fisher test P = 0.47; </p> </li> <li> <p>haematological toxicities: five cases combination arm, zero cases PUVA‐alone arm, RR 9.83, 95% CI 0.56 to 172.50, <a href="./references#CD008946-fig-0023" title="">Analysis 8.1</a>, Fisher test P = 0.06; </p> </li> <li> <p>photosensitivity: RR 2.68, 95% CI 0.11 to 64.04, <a href="./references#CD008946-fig-0023" title="">Analysis 8.1</a>, Fisher test P = 1.00. The certainty of evidence is low as we downgraded twice: once due to low internal validity (risk of bias ‐ high risk of performance bias) and once due to low sample size (imprecision); </p> </li> <li> <p>pruritus: RR 0.30, 95% CI 0.01 to 7.12, <a href="./references#CD008946-fig-0023" title="">Analysis 8.1</a>, Fisher test P = 0.47; </p> </li> <li> <p>rash: RR 2.68, 95% CI 0.11 to 64.04, <a href="./references#CD008946-fig-0023" title="">Analysis 8.1</a>, Fisher test P = 1.00; </p> </li> <li> <p>hypertriglyceridaemia: RR 4.47, 95% CI 0.22 to 90.44, <a href="./references#CD008946-fig-0023" title="">Analysis 8.1</a>, Fisher test P = 0.50. </p> </li> </ul> </p> </section> </section> <section id="CD008946-sec-0147"> <h6 class="title">Secondary outcomes</h6> <section id="CD008946-sec-0148"> <p><b>Complete response (CR)</b></p> <p>In <a href="./references#CD008946-bbs2-0004" title="DuvicM , MartinAG , KimY , OlsenE , WoodGS , CrowleyCA , et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Archives of Dermatology2001;137(5):581-93. [CENTRAL: CN-00347816] [PMID: 11346336]PrinceHM , McCormackC , RyanG , BakerC , RotsteinH , DavisonJ , et al. Bexarotene capsules and gel for previously treated patients with cutaneous T-cell lymphoma: results of the Australian patients treated on phase II trials. Australasian Journal of Dermatology2001;42(2):91-7. [CENTRAL: CN-00442169] [PMID: 11309029]">Duvic 2001</a>, zero of 15 participants (0%) in the low‐dose group showed CR compared to six of 43 participants (14%) in the high‐dose therapy arm ‐ but the trial had a high dropout rate of 72.4%, which made it difficult to draw reasonable conclusions from these data. </p> <p><a href="./references#CD008946-bbs2-0006" title="GuitartJ , TuckerR , StevensV . Low dose bexarotene (Targretin®) capsules and phototherapy for early stage cutaneous T-Cell lymphoma. Journal of Investigative Dermatology2002;119(1):241. [CENTRAL: CN-00794450] NCT00030589. A muliticenter, dose-randomized evaluation of Targretin capsules plus PUVA in patients with stage IB - IIA cutaneous T-Cell lymphoma. clinicaltrials.gov/ct/show/NCT00030589 (first received 27 Jaunry 2003). ">Guitart 2002</a> found no differences in CR between the low‐ and high‐dose groups: RR 0.86, 95% CI 0.46 to 1.60, 39 participants, <a href="./references#CD008946-fig-0020" title="">Analysis 7.2</a>, Fisher test P = 0.75. </p> <p>In <a href="./references#CD008946-bbs2-0018" title="NCT00056056. Ultraviolet light therapy using methoxsalen with or without Bexarotene in treating patients with mycosis fungoides. clinicaltrials.gov/ct2/show/NCT00056056 (first received 7 March 2003). WhittakerS , OrtizP , DummerR , RankiA , HasanB , MeulemansB , et al. Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial 21011 (NCT00056056). British Journal of Dermatology2012;167(3):678-87. [CENTRAL: CN-00856432] [PMID: 22924950]WhittakerS , Ortiz-RomeroPL , DummerR , RankiA , HasanB , MeulemansB , et al. Efficacy and safety of bexarotene combined with psoralen/ultraviolet A light (PUVA) compared to PUVA treatment alone in stage IB-IIa mycosis fungoides (MF): Final results from EORTC cutaneous lymphoma task force (CLTF) phase III clinical trial 21011. Journal of Clinical Oncology2012;30(15 Suppl 1):8076. ">Whittaker 2012</a>, no difference could be observed between bexarotene in combination with PUVA versus PUVA alone for CR: RR 1.41, 95% CI 0.71 to 2.80, 93 participants, <a href="./references#CD008946-fig-0024" title="">Analysis 8.2</a>, Fisher test P = 0.36. The certainty of evidence is low as we downgraded twice: once due to low internal validity (risk of bias ‐ high risk of performance bias) and once due to low sample size (imprecision). </p> </section> <section id="CD008946-sec-0149"> <p><b>Relapse</b></p> <p>In <a href="./references#CD008946-bbs2-0004" title="DuvicM , MartinAG , KimY , OlsenE , WoodGS , CrowleyCA , et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Archives of Dermatology2001;137(5):581-93. [CENTRAL: CN-00347816] [PMID: 11346336]PrinceHM , McCormackC , RyanG , BakerC , RotsteinH , DavisonJ , et al. Bexarotene capsules and gel for previously treated patients with cutaneous T-cell lymphoma: results of the Australian patients treated on phase II trials. Australasian Journal of Dermatology2001;42(2):91-7. [CENTRAL: CN-00442169] [PMID: 11309029]">Duvic 2001</a>, zero of three participants achieving partial remission in the low‐dose group relapsed compared to seven of 25 participants achieving complete or partial remission in the high‐dose therapy arms. No time to event data were provided. </p> <p>In <a href="./references#CD008946-bbs2-0006" title="GuitartJ , TuckerR , StevensV . Low dose bexarotene (Targretin®) capsules and phototherapy for early stage cutaneous T-Cell lymphoma. Journal of Investigative Dermatology2002;119(1):241. [CENTRAL: CN-00794450] NCT00030589. A muliticenter, dose-randomized evaluation of Targretin capsules plus PUVA in patients with stage IB - IIA cutaneous T-Cell lymphoma. clinicaltrials.gov/ct/show/NCT00030589 (first received 27 Jaunry 2003). ">Guitart 2002</a>, no differences between the low‐ and high‐dose groups were seen six months after treatment: four cases in high‐dose arm, eight cases in low‐dose arm (RR 0.53, 95% CI 0.19 to 1.46, 39 participants, <a href="./references#CD008946-fig-0021" title="">Analysis 7.3</a>, Fisher test P = 0.30). </p> <p><a href="./references#CD008946-bbs2-0018" title="NCT00056056. Ultraviolet light therapy using methoxsalen with or without Bexarotene in treating patients with mycosis fungoides. clinicaltrials.gov/ct2/show/NCT00056056 (first received 7 March 2003). WhittakerS , OrtizP , DummerR , RankiA , HasanB , MeulemansB , et al. Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial 21011 (NCT00056056). British Journal of Dermatology2012;167(3):678-87. [CENTRAL: CN-00856432] [PMID: 22924950]WhittakerS , Ortiz-RomeroPL , DummerR , RankiA , HasanB , MeulemansB , et al. Efficacy and safety of bexarotene combined with psoralen/ultraviolet A light (PUVA) compared to PUVA treatment alone in stage IB-IIa mycosis fungoides (MF): Final results from EORTC cutaneous lymphoma task force (CLTF) phase III clinical trial 21011. Journal of Clinical Oncology2012;30(15 Suppl 1):8076. ">Whittaker 2012</a> did not allow assessment of this outcome, since relapse and progression were summarised in one category. </p> </section> <section id="CD008946-sec-0150"> <p><b>Disease‐free survival</b></p> <p>In <a href="./references#CD008946-bbs2-0006" title="GuitartJ , TuckerR , StevensV . Low dose bexarotene (Targretin®) capsules and phototherapy for early stage cutaneous T-Cell lymphoma. Journal of Investigative Dermatology2002;119(1):241. [CENTRAL: CN-00794450] NCT00030589. A muliticenter, dose-randomized evaluation of Targretin capsules plus PUVA in patients with stage IB - IIA cutaneous T-Cell lymphoma. clinicaltrials.gov/ct/show/NCT00030589 (first received 27 Jaunry 2003). ">Guitart 2002</a>, the median disease‐free survival was 155 days for the low‐dose group and 103 days for the high‐dose group (assessed six months after the end of the intervention). </p> <p>No distribution measure was given for relapse.</p> <p><a href="./references#CD008946-bbs2-0004" title="DuvicM , MartinAG , KimY , OlsenE , WoodGS , CrowleyCA , et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Archives of Dermatology2001;137(5):581-93. [CENTRAL: CN-00347816] [PMID: 11346336]PrinceHM , McCormackC , RyanG , BakerC , RotsteinH , DavisonJ , et al. Bexarotene capsules and gel for previously treated patients with cutaneous T-cell lymphoma: results of the Australian patients treated on phase II trials. Australasian Journal of Dermatology2001;42(2):91-7. [CENTRAL: CN-00442169] [PMID: 11309029]">Duvic 2001</a> did not assess this outcome. </p> <p><a href="./references#CD008946-bbs2-0018" title="NCT00056056. Ultraviolet light therapy using methoxsalen with or without Bexarotene in treating patients with mycosis fungoides. clinicaltrials.gov/ct2/show/NCT00056056 (first received 7 March 2003). WhittakerS , OrtizP , DummerR , RankiA , HasanB , MeulemansB , et al. Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial 21011 (NCT00056056). British Journal of Dermatology2012;167(3):678-87. [CENTRAL: CN-00856432] [PMID: 22924950]WhittakerS , Ortiz-RomeroPL , DummerR , RankiA , HasanB , MeulemansB , et al. Efficacy and safety of bexarotene combined with psoralen/ultraviolet A light (PUVA) compared to PUVA treatment alone in stage IB-IIa mycosis fungoides (MF): Final results from EORTC cutaneous lymphoma task force (CLTF) phase III clinical trial 21011. Journal of Clinical Oncology2012;30(15 Suppl 1):8076. ">Whittaker 2012</a> did not allow assessment of this outcome. </p> </section> <section id="CD008946-sec-0151"> <p><b>Overall survival (OS)</b></p> <p>In <a href="./references#CD008946-bbs2-0004" title="DuvicM , MartinAG , KimY , OlsenE , WoodGS , CrowleyCA , et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Archives of Dermatology2001;137(5):581-93. [CENTRAL: CN-00347816] [PMID: 11346336]PrinceHM , McCormackC , RyanG , BakerC , RotsteinH , DavisonJ , et al. Bexarotene capsules and gel for previously treated patients with cutaneous T-cell lymphoma: results of the Australian patients treated on phase II trials. Australasian Journal of Dermatology2001;42(2):91-7. [CENTRAL: CN-00442169] [PMID: 11309029]">Duvic 2001</a>, no participant died during the study or within four weeks time after therapy discontinuation, but three participants died within three months of discontinuation of therapy, which was attributed to infection or progressive disease by the study authors. No allocation to one of the treatment groups was reported. </p> <p>In <a href="./references#CD008946-bbs2-0006" title="GuitartJ , TuckerR , StevensV . Low dose bexarotene (Targretin®) capsules and phototherapy for early stage cutaneous T-Cell lymphoma. Journal of Investigative Dermatology2002;119(1):241. [CENTRAL: CN-00794450] NCT00030589. A muliticenter, dose-randomized evaluation of Targretin capsules plus PUVA in patients with stage IB - IIA cutaneous T-Cell lymphoma. clinicaltrials.gov/ct/show/NCT00030589 (first received 27 Jaunry 2003). ">Guitart 2002</a>, no deaths reported. </p> <p><a href="./references#CD008946-bbs2-0018" title="NCT00056056. Ultraviolet light therapy using methoxsalen with or without Bexarotene in treating patients with mycosis fungoides. clinicaltrials.gov/ct2/show/NCT00056056 (first received 7 March 2003). WhittakerS , OrtizP , DummerR , RankiA , HasanB , MeulemansB , et al. Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial 21011 (NCT00056056). British Journal of Dermatology2012;167(3):678-87. [CENTRAL: CN-00856432] [PMID: 22924950]WhittakerS , Ortiz-RomeroPL , DummerR , RankiA , HasanB , MeulemansB , et al. Efficacy and safety of bexarotene combined with psoralen/ultraviolet A light (PUVA) compared to PUVA treatment alone in stage IB-IIa mycosis fungoides (MF): Final results from EORTC cutaneous lymphoma task force (CLTF) phase III clinical trial 21011. Journal of Clinical Oncology2012;30(15 Suppl 1):8076. ">Whittaker 2012</a> did not provide overall survival rates. </p> </section> <section id="CD008946-sec-0152"> <p><b>Objective response rate (ORR)</b></p> <p>In <a href="./references#CD008946-bbs2-0004" title="DuvicM , MartinAG , KimY , OlsenE , WoodGS , CrowleyCA , et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Archives of Dermatology2001;137(5):581-93. [CENTRAL: CN-00347816] [PMID: 11346336]PrinceHM , McCormackC , RyanG , BakerC , RotsteinH , DavisonJ , et al. Bexarotene capsules and gel for previously treated patients with cutaneous T-cell lymphoma: results of the Australian patients treated on phase II trials. Australasian Journal of Dermatology2001;42(2):91-7. [CENTRAL: CN-00442169] [PMID: 11309029]">Duvic 2001</a>, three of 15 participants (20%) showed ORR as defined above compared to 25 of 43 participants (58%) in the high‐dose therapy arms. </p> <p>In <a href="./references#CD008946-bbs2-0006" title="GuitartJ , TuckerR , StevensV . Low dose bexarotene (Targretin®) capsules and phototherapy for early stage cutaneous T-Cell lymphoma. Journal of Investigative Dermatology2002;119(1):241. [CENTRAL: CN-00794450] NCT00030589. A muliticenter, dose-randomized evaluation of Targretin capsules plus PUVA in patients with stage IB - IIA cutaneous T-Cell lymphoma. clinicaltrials.gov/ct/show/NCT00030589 (first received 27 Jaunry 2003). ">Guitart 2002</a>, there were no differences between the low‐ and high‐dose group for ORR: RR 0.93, 95% CI 0.69 to 1.25, 39 participants, <a href="./references#CD008946-fig-0022" title="">Analysis 7.4</a>, Fisher test P = 0.69. </p> <p>In <a href="./references#CD008946-bbs2-0018" title="NCT00056056. Ultraviolet light therapy using methoxsalen with or without Bexarotene in treating patients with mycosis fungoides. clinicaltrials.gov/ct2/show/NCT00056056 (first received 7 March 2003). WhittakerS , OrtizP , DummerR , RankiA , HasanB , MeulemansB , et al. Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial 21011 (NCT00056056). British Journal of Dermatology2012;167(3):678-87. [CENTRAL: CN-00856432] [PMID: 22924950]WhittakerS , Ortiz-RomeroPL , DummerR , RankiA , HasanB , MeulemansB , et al. Efficacy and safety of bexarotene combined with psoralen/ultraviolet A light (PUVA) compared to PUVA treatment alone in stage IB-IIa mycosis fungoides (MF): Final results from EORTC cutaneous lymphoma task force (CLTF) phase III clinical trial 21011. Journal of Clinical Oncology2012;30(15 Suppl 1):8076. ">Whittaker 2012</a>, there were no differences between bexarotene combined with PUVA vs PUVA alone for ORR: RR 0.94, 95% CI 0.61 to 1.44, 93 participants, <a href="./references#CD008946-fig-0025" title="">Analysis 8.3</a>, Fisher test P = 0.84. The certainty of evidence is low as we downgraded twice: once due to low internal validity (risk of bias ‐ high risk of performance bias) and once due to low sample size (imprecision). </p> </section> <section id="CD008946-sec-0153"> <p><b>Rare adverse effects</b></p> <p><a href="./references#CD008946-bbs2-0004" title="DuvicM , MartinAG , KimY , OlsenE , WoodGS , CrowleyCA , et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Archives of Dermatology2001;137(5):581-93. [CENTRAL: CN-00347816] [PMID: 11346336]PrinceHM , McCormackC , RyanG , BakerC , RotsteinH , DavisonJ , et al. Bexarotene capsules and gel for previously treated patients with cutaneous T-cell lymphoma: results of the Australian patients treated on phase II trials. Australasian Journal of Dermatology2001;42(2):91-7. [CENTRAL: CN-00442169] [PMID: 11309029]">Duvic 2001</a> reported three cases of acute pancreatitis due to massive hyperlipidaemia in the high‐dose therapy arms. Furthermore, lens opacity without loss of visual acuity was detected in 2 of 58 participants (3%) in the study. However, the distribution within the therapy arms was not reported. </p> </section> </section> </section> <section id="CD008946-sec-0154"> <h5 class="title">V.4. Lenalidomide (one trial)</h5> <p>PICO: In participants with MF CTCL stages I to IV, <a href="./references#CD008946-bbs2-0001" title="BagotM , HasanB , WhittakerS , Beylot-BarryM , KnoblerR , ShahE , et al. A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma - EORTC 21081 (NCT01098656): results and lessons learned for future trial designs. European Journal of Dermatology2017;27(3):286–94. [CENTRAL: CN-01395486] [PMID: 28468739]NCT01098656. A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-Cell lymphoma. clinicaltrials.gov/ct2/show/NCT01098656 (first received 5 April 2010). [NCT01098656]">Bagot 2017</a> investigated the effect of lenalidomide maintenance therapy compared to observation after debulking therapy. Patients were treated or observed until disease progression. Therefore end points were evaluated individually. </p> <section id="CD008946-sec-0155"> <h6 class="title">Primary outcomes</h6> <section id="CD008946-sec-0156"> <p><b>Common adverse effects of the treatments</b></p> <p>In <a href="./references#CD008946-bbs2-0001" title="BagotM , HasanB , WhittakerS , Beylot-BarryM , KnoblerR , ShahE , et al. A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma - EORTC 21081 (NCT01098656): results and lessons learned for future trial designs. European Journal of Dermatology2017;27(3):286–94. [CENTRAL: CN-01395486] [PMID: 28468739]NCT01098656. A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-Cell lymphoma. clinicaltrials.gov/ct2/show/NCT01098656 (first received 5 April 2010). [NCT01098656]">Bagot 2017</a>, the following adverse events were documented: </p> <p> <ul id="CD008946-list-0027"> <li> <p>neutropenia: one case in lenalidomide arm, zero cases in observation arm, RR 4.33, 95% CI 0.20 to 94.83, 20 participants, <a href="./references#CD008946-fig-0026" title="">Analysis 9.1</a>, Fisher test P = 0.40; </p> </li> <li> <p>hyperbilirubinaemia: one case in lenalidomide arm, zero cases in observation arm, RR 4.33, 95% CI 0.20 to 94.83, 20 participants, <a href="./references#CD008946-fig-0026" title="">Analysis 9.1</a>, Fisher test P = 0.40; </p> </li> <li> <p>hypercalcaemia: one case in lenalidomide arm, zero cases in observation arm, RR 4.33, 95% CI 0.20 to 94.83, 20 participants, <a href="./references#CD008946-fig-0026" title="">Analysis 9.1</a>, Fisher test P = 0.40; </p> </li> <li> <p>hypokalaemia: one case in lenalidomide arm, zero cases in observation arm, RR 4.33, 95% CI 0.20 to 94.83, 20 participants, <a href="./references#CD008946-fig-0026" title="">Analysis 9.1</a>, Fisher test P = 0.40; </p> </li> <li> <p>hypophosphataemia: 2 cases in lenalidomide arm, zero cases in observation arm RR 7.22, 95% CI 0.39 to 133.24, 20 participants, <a href="./references#CD008946-fig-0026" title="">Analysis 9.1</a>, Fisher test P = 0.15; </p> </li> <li> <p>erythema multiforme: one case in lenalidomide arm,zero cases in observation arm, RR 4.33, 95% CI 0.20 to 94.83, 20 participants, <a href="./references#CD008946-fig-0026" title="">Analysis 9.1</a>, Fisher test P = 0.40; </p> </li> <li> <p>periorbital oedema: one case in lenalidomide arm, zero cases in observation arm, RR 4.33, 95% CI 0.20 to 94.83, 20 participants, <a href="./references#CD008946-fig-0026" title="">Analysis 9.1</a>, Fisher test P = 0.40; </p> </li> <li> <p>pruritus: RR 1.50, 95% CI 0.11 to 20.68, 20 participants, <a href="./references#CD008946-fig-0026" title="">Analysis 9.1</a>, Fisher test P = 1.00; </p> </li> <li> <p>other adverse effects: 2 cases in lenalidomide arm, zero cases in observation arm, RR 7.22, 95% CI 0.39 to 133.24, 20 participants, <a href="./references#CD008946-fig-0026" title="">Analysis 9.1</a>, Fisher test P = 0.15. </p> </li> </ul> </p> </section> </section> <section id="CD008946-sec-0157"> <h6 class="title">Secondary outcomes</h6> <p>Assessment of overall survival was intended by the investigators but ultimately not measured. </p> </section> </section> <section id="CD008946-sec-0158"> <h5 class="title">V.5. Brentuximab vedotin (one trial)</h5> <p>PICO: In participants with CD30+ MF CTCL stages IA ‐ IVB or CD30+ primary cutaneous anaplastic large‐cell lymphoma, <a href="./references#CD008946-bbs2-0011" title="HorwitzS , WhittakerS , DuvicM , DummerR , KimYH , ScarisbrickJ , et al. Response by stage in CD30-positive (CD30+) cutaneous T cell lymphoma (CTCL) patients receiving brentuximab vedotin (BV) vs physician's choice (PC) in the phase 3 ALCANZA study. In: Hematological oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:245–7. [CENTRAL: CN-01408605] [DOI: 10.1002/hon.2438]HorwitzSM , AkilovOE , FisherD , KuzelTM , WangY , Palanca-WesselsMC , et al. Brentuximab vedotin or physician’s choice in CD30-positivecutaneous T-cell lymphoma (ALCANZA): an international,open-label, randomised, phase 3, multicentre trial. Lancet2017;390(10094):555-66. [CENTRAL: CN-01403731] HorwitzSM , ScarisbrickJJ , DummerR , DuvicM , KimYH , WalewskiJ , et al. Updated analyses of the international, open-label, randomized, phase 3 alcanza study: longer-term evidence for superiority of brentuximab vedotin versus methotrexate or bexarotene for CD30-positive cutaneous T-cell lymphoma (CTCL). In: Blood. Conference: 59th annual meeting of the american society of hematology, ASH 2017. United states. Vol. 130. 2017. [CENTRAL: CN-01450312] KimYH , PrinceHM , WhittakerS , HorwitzSM , DuvicM , ScarisbrickJ , et al. Brentuximab vedotin vs physician's choice in CTCL patients from the phase 3 ALCANZA study: analysis of outcomes by CD30 expression. In: Hematological Oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:77–8. [CENTRAL: CN-01408482] [DOI: 10.1002/hon.2437]KimYH , PrinceHM , WhittakerS , HorwitzSM , DuvicM , ScarisbrickJ , et al. Outcomes by CD30 expression in patients with CTCL receiving brentuximab vedotin (BV) vs physician's choice (PC) in the Phase 3 ALCANZA study. Journal of Clinical Oncology2017;35(15 Supplement 1):7517. [EMBASE: 617388795]KimYH , WhittakerS , DummerR , GeskinLJ , GauthierP , LittleM , et al. Phase 3 study of brentuximab vedotin versus physician's choice of methotrexate or bexarotene in patients (PTS) with CD30-positive (CD30+) cutaneous T-cell lymphoma (CTCL). The alcanza study. Hematological Oncology2013;31(Suppl 1):278. [CENTRAL: CN-01531598] [EMBASE: 71147875]KimYH , WhittakerS , HorwitzSM , DuvicM , DummerR , ScarisbrickJ , et al. Brentuximab vedotin demonstrates superior activity to standard therapy in CD30-expressing (CD30+) cutaneous T-cell lymphoma (CTCL) in the randomized phase 3 ALCANZA study. Journal of Investigative Dermatology2017;137(5 Suppl 1):S45. [CENTRAL: CN-01375469] [EMBASE: 616393777]KimYH , WhittakerS , HorwitzSM , DuvicM , DummerR , ScarisbrickJJ , et al. Brentuximab vedotin demonstrates significantly superior clinical outcomes in patients with CD30-expressing cutaneous T cell lymphoma versus physician's choice (Methotrexate or Bexarotene): the phase 3 alcanza study. In: Blood. Conference: 58th annual meeting of the american society of hematology, ASH 2016. United states. Conference start: 20161203. Conference end: 20161206. Vol. 128. 2016. [CENTRAL: CN-01303081] [EMBASE: 614225065]NCT01578499. A randomised, open-label, phase 3 trial of brentuximab vedotin (SGN-35) versus physician's choice (methotrexate or bexarotene) in patients with CD30-positive cutaneous T-cell lymphoma. clinicaltrials.gov/ct2/show/NCT01578499 (first received 17 April 2012). PrinceHM , DummerR , WhittakerS , HorwitzS , DuvicM , ScarisbrickJ , et al. Patient-reported outcomes and quality of life in patients with cutaneous T cell lymphoma: results from the phase 3 ALCANZA study. In: Hematological Oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:247–8. [CENTRAL: CN-01408603] [DOI: 10.1002/hon.2438]ZagadailovE , PrinceHM , WhittakerS , HorwitzS , DuvicM , KimY , et al. Phase 3 alcanza study of brentuximab vedotin (BV) or physician's choice (PC) of methotrexate (MTX) or bexarotene (BEX) in CD30-positive cutaneous T-cell lymphoma (CTCL): number needed to treat analysis. In: Haematologica. Conference: 22th congress of the european hematology association. Spain. Vol. 102. 2017:251. [CENTRAL: CN-01399195] ">Prince 2017</a> investigated the effect of brentuximab vedotin compared to physician's choice (methotrexate or bexarotene) for up to 48 weeks. The end points were evaluated individually. </p> <section id="CD008946-sec-0159"> <h6 class="title">Primary outcomes</h6> <section id="CD008946-sec-0160"> <p><b>Common adverse effects of the treatments</b></p> <p>In <a href="./references#CD008946-bbs2-0011" title="HorwitzS , WhittakerS , DuvicM , DummerR , KimYH , ScarisbrickJ , et al. Response by stage in CD30-positive (CD30+) cutaneous T cell lymphoma (CTCL) patients receiving brentuximab vedotin (BV) vs physician's choice (PC) in the phase 3 ALCANZA study. In: Hematological oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:245–7. [CENTRAL: CN-01408605] [DOI: 10.1002/hon.2438]HorwitzSM , AkilovOE , FisherD , KuzelTM , WangY , Palanca-WesselsMC , et al. Brentuximab vedotin or physician’s choice in CD30-positivecutaneous T-cell lymphoma (ALCANZA): an international,open-label, randomised, phase 3, multicentre trial. Lancet2017;390(10094):555-66. [CENTRAL: CN-01403731] HorwitzSM , ScarisbrickJJ , DummerR , DuvicM , KimYH , WalewskiJ , et al. Updated analyses of the international, open-label, randomized, phase 3 alcanza study: longer-term evidence for superiority of brentuximab vedotin versus methotrexate or bexarotene for CD30-positive cutaneous T-cell lymphoma (CTCL). In: Blood. Conference: 59th annual meeting of the american society of hematology, ASH 2017. United states. Vol. 130. 2017. [CENTRAL: CN-01450312] KimYH , PrinceHM , WhittakerS , HorwitzSM , DuvicM , ScarisbrickJ , et al. Brentuximab vedotin vs physician's choice in CTCL patients from the phase 3 ALCANZA study: analysis of outcomes by CD30 expression. In: Hematological Oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:77–8. [CENTRAL: CN-01408482] [DOI: 10.1002/hon.2437]KimYH , PrinceHM , WhittakerS , HorwitzSM , DuvicM , ScarisbrickJ , et al. Outcomes by CD30 expression in patients with CTCL receiving brentuximab vedotin (BV) vs physician's choice (PC) in the Phase 3 ALCANZA study. Journal of Clinical Oncology2017;35(15 Supplement 1):7517. [EMBASE: 617388795]KimYH , WhittakerS , DummerR , GeskinLJ , GauthierP , LittleM , et al. Phase 3 study of brentuximab vedotin versus physician's choice of methotrexate or bexarotene in patients (PTS) with CD30-positive (CD30+) cutaneous T-cell lymphoma (CTCL). The alcanza study. Hematological Oncology2013;31(Suppl 1):278. [CENTRAL: CN-01531598] [EMBASE: 71147875]KimYH , WhittakerS , HorwitzSM , DuvicM , DummerR , ScarisbrickJ , et al. Brentuximab vedotin demonstrates superior activity to standard therapy in CD30-expressing (CD30+) cutaneous T-cell lymphoma (CTCL) in the randomized phase 3 ALCANZA study. Journal of Investigative Dermatology2017;137(5 Suppl 1):S45. [CENTRAL: CN-01375469] [EMBASE: 616393777]KimYH , WhittakerS , HorwitzSM , DuvicM , DummerR , ScarisbrickJJ , et al. Brentuximab vedotin demonstrates significantly superior clinical outcomes in patients with CD30-expressing cutaneous T cell lymphoma versus physician's choice (Methotrexate or Bexarotene): the phase 3 alcanza study. In: Blood. Conference: 58th annual meeting of the american society of hematology, ASH 2016. United states. Conference start: 20161203. Conference end: 20161206. Vol. 128. 2016. [CENTRAL: CN-01303081] [EMBASE: 614225065]NCT01578499. A randomised, open-label, phase 3 trial of brentuximab vedotin (SGN-35) versus physician's choice (methotrexate or bexarotene) in patients with CD30-positive cutaneous T-cell lymphoma. clinicaltrials.gov/ct2/show/NCT01578499 (first received 17 April 2012). PrinceHM , DummerR , WhittakerS , HorwitzS , DuvicM , ScarisbrickJ , et al. Patient-reported outcomes and quality of life in patients with cutaneous T cell lymphoma: results from the phase 3 ALCANZA study. In: Hematological Oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:247–8. [CENTRAL: CN-01408603] [DOI: 10.1002/hon.2438]ZagadailovE , PrinceHM , WhittakerS , HorwitzS , DuvicM , KimY , et al. Phase 3 alcanza study of brentuximab vedotin (BV) or physician's choice (PC) of methotrexate (MTX) or bexarotene (BEX) in CD30-positive cutaneous T-cell lymphoma (CTCL): number needed to treat analysis. In: Haematologica. Conference: 22th congress of the european hematology association. Spain. Vol. 102. 2017:251. [CENTRAL: CN-01399195] ">Prince 2017</a>, common adverse effects were assessed but could not be retraced to the patients with CD30‐positive mycosis fungoides, since the adverse effects were summarised for all patients according to their allocated treatment. </p> </section> </section> <section id="CD008946-sec-0161"> <h6 class="title">Secondary outcomes</h6> <section id="CD008946-sec-0162"> <p><b>Complete response (CR)</b></p> <p>In <a href="./references#CD008946-bbs2-0011" title="HorwitzS , WhittakerS , DuvicM , DummerR , KimYH , ScarisbrickJ , et al. Response by stage in CD30-positive (CD30+) cutaneous T cell lymphoma (CTCL) patients receiving brentuximab vedotin (BV) vs physician's choice (PC) in the phase 3 ALCANZA study. In: Hematological oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:245–7. [CENTRAL: CN-01408605] [DOI: 10.1002/hon.2438]HorwitzSM , AkilovOE , FisherD , KuzelTM , WangY , Palanca-WesselsMC , et al. Brentuximab vedotin or physician’s choice in CD30-positivecutaneous T-cell lymphoma (ALCANZA): an international,open-label, randomised, phase 3, multicentre trial. Lancet2017;390(10094):555-66. [CENTRAL: CN-01403731] HorwitzSM , ScarisbrickJJ , DummerR , DuvicM , KimYH , WalewskiJ , et al. Updated analyses of the international, open-label, randomized, phase 3 alcanza study: longer-term evidence for superiority of brentuximab vedotin versus methotrexate or bexarotene for CD30-positive cutaneous T-cell lymphoma (CTCL). In: Blood. Conference: 59th annual meeting of the american society of hematology, ASH 2017. United states. Vol. 130. 2017. [CENTRAL: CN-01450312] KimYH , PrinceHM , WhittakerS , HorwitzSM , DuvicM , ScarisbrickJ , et al. Brentuximab vedotin vs physician's choice in CTCL patients from the phase 3 ALCANZA study: analysis of outcomes by CD30 expression. In: Hematological Oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:77–8. [CENTRAL: CN-01408482] [DOI: 10.1002/hon.2437]KimYH , PrinceHM , WhittakerS , HorwitzSM , DuvicM , ScarisbrickJ , et al. Outcomes by CD30 expression in patients with CTCL receiving brentuximab vedotin (BV) vs physician's choice (PC) in the Phase 3 ALCANZA study. Journal of Clinical Oncology2017;35(15 Supplement 1):7517. [EMBASE: 617388795]KimYH , WhittakerS , DummerR , GeskinLJ , GauthierP , LittleM , et al. Phase 3 study of brentuximab vedotin versus physician's choice of methotrexate or bexarotene in patients (PTS) with CD30-positive (CD30+) cutaneous T-cell lymphoma (CTCL). The alcanza study. Hematological Oncology2013;31(Suppl 1):278. [CENTRAL: CN-01531598] [EMBASE: 71147875]KimYH , WhittakerS , HorwitzSM , DuvicM , DummerR , ScarisbrickJ , et al. Brentuximab vedotin demonstrates superior activity to standard therapy in CD30-expressing (CD30+) cutaneous T-cell lymphoma (CTCL) in the randomized phase 3 ALCANZA study. Journal of Investigative Dermatology2017;137(5 Suppl 1):S45. [CENTRAL: CN-01375469] [EMBASE: 616393777]KimYH , WhittakerS , HorwitzSM , DuvicM , DummerR , ScarisbrickJJ , et al. Brentuximab vedotin demonstrates significantly superior clinical outcomes in patients with CD30-expressing cutaneous T cell lymphoma versus physician's choice (Methotrexate or Bexarotene): the phase 3 alcanza study. In: Blood. Conference: 58th annual meeting of the american society of hematology, ASH 2016. United states. Conference start: 20161203. Conference end: 20161206. Vol. 128. 2016. [CENTRAL: CN-01303081] [EMBASE: 614225065]NCT01578499. A randomised, open-label, phase 3 trial of brentuximab vedotin (SGN-35) versus physician's choice (methotrexate or bexarotene) in patients with CD30-positive cutaneous T-cell lymphoma. clinicaltrials.gov/ct2/show/NCT01578499 (first received 17 April 2012). PrinceHM , DummerR , WhittakerS , HorwitzS , DuvicM , ScarisbrickJ , et al. Patient-reported outcomes and quality of life in patients with cutaneous T cell lymphoma: results from the phase 3 ALCANZA study. In: Hematological Oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:247–8. [CENTRAL: CN-01408603] [DOI: 10.1002/hon.2438]ZagadailovE , PrinceHM , WhittakerS , HorwitzS , DuvicM , KimY , et al. Phase 3 alcanza study of brentuximab vedotin (BV) or physician's choice (PC) of methotrexate (MTX) or bexarotene (BEX) in CD30-positive cutaneous T-cell lymphoma (CTCL): number needed to treat analysis. In: Haematologica. Conference: 22th congress of the european hematology association. Spain. Vol. 102. 2017:251. [CENTRAL: CN-01399195] ">Prince 2017</a>, differences were seen between brentuximab vedotin and physician's choice for CR. There were five cases in the brentuximab vedotin arm and zero cases in the physician's choice arm (RR 11.22, 95% CI 0.64 to 197.60 (95% CI according to Miettinen: 1.36 to not estimable), 97 participants, <a href="./references#CD008946-fig-0027" title="">Analysis 10.1</a>). The risk ratio favoured brentuximab vedotin (Fisher test P = 0.03). </p> </section> <section id="CD008946-sec-0163"> <p><b>Objective response rate (ORR)</b></p> <p>In <a href="./references#CD008946-bbs2-0011" title="HorwitzS , WhittakerS , DuvicM , DummerR , KimYH , ScarisbrickJ , et al. Response by stage in CD30-positive (CD30+) cutaneous T cell lymphoma (CTCL) patients receiving brentuximab vedotin (BV) vs physician's choice (PC) in the phase 3 ALCANZA study. In: Hematological oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:245–7. [CENTRAL: CN-01408605] [DOI: 10.1002/hon.2438]HorwitzSM , AkilovOE , FisherD , KuzelTM , WangY , Palanca-WesselsMC , et al. Brentuximab vedotin or physician’s choice in CD30-positivecutaneous T-cell lymphoma (ALCANZA): an international,open-label, randomised, phase 3, multicentre trial. Lancet2017;390(10094):555-66. [CENTRAL: CN-01403731] HorwitzSM , ScarisbrickJJ , DummerR , DuvicM , KimYH , WalewskiJ , et al. Updated analyses of the international, open-label, randomized, phase 3 alcanza study: longer-term evidence for superiority of brentuximab vedotin versus methotrexate or bexarotene for CD30-positive cutaneous T-cell lymphoma (CTCL). In: Blood. Conference: 59th annual meeting of the american society of hematology, ASH 2017. United states. Vol. 130. 2017. [CENTRAL: CN-01450312] KimYH , PrinceHM , WhittakerS , HorwitzSM , DuvicM , ScarisbrickJ , et al. Brentuximab vedotin vs physician's choice in CTCL patients from the phase 3 ALCANZA study: analysis of outcomes by CD30 expression. In: Hematological Oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:77–8. [CENTRAL: CN-01408482] [DOI: 10.1002/hon.2437]KimYH , PrinceHM , WhittakerS , HorwitzSM , DuvicM , ScarisbrickJ , et al. Outcomes by CD30 expression in patients with CTCL receiving brentuximab vedotin (BV) vs physician's choice (PC) in the Phase 3 ALCANZA study. Journal of Clinical Oncology2017;35(15 Supplement 1):7517. [EMBASE: 617388795]KimYH , WhittakerS , DummerR , GeskinLJ , GauthierP , LittleM , et al. Phase 3 study of brentuximab vedotin versus physician's choice of methotrexate or bexarotene in patients (PTS) with CD30-positive (CD30+) cutaneous T-cell lymphoma (CTCL). The alcanza study. Hematological Oncology2013;31(Suppl 1):278. [CENTRAL: CN-01531598] [EMBASE: 71147875]KimYH , WhittakerS , HorwitzSM , DuvicM , DummerR , ScarisbrickJ , et al. Brentuximab vedotin demonstrates superior activity to standard therapy in CD30-expressing (CD30+) cutaneous T-cell lymphoma (CTCL) in the randomized phase 3 ALCANZA study. Journal of Investigative Dermatology2017;137(5 Suppl 1):S45. [CENTRAL: CN-01375469] [EMBASE: 616393777]KimYH , WhittakerS , HorwitzSM , DuvicM , DummerR , ScarisbrickJJ , et al. Brentuximab vedotin demonstrates significantly superior clinical outcomes in patients with CD30-expressing cutaneous T cell lymphoma versus physician's choice (Methotrexate or Bexarotene): the phase 3 alcanza study. In: Blood. Conference: 58th annual meeting of the american society of hematology, ASH 2016. United states. Conference start: 20161203. Conference end: 20161206. Vol. 128. 2016. [CENTRAL: CN-01303081] [EMBASE: 614225065]NCT01578499. A randomised, open-label, phase 3 trial of brentuximab vedotin (SGN-35) versus physician's choice (methotrexate or bexarotene) in patients with CD30-positive cutaneous T-cell lymphoma. clinicaltrials.gov/ct2/show/NCT01578499 (first received 17 April 2012). PrinceHM , DummerR , WhittakerS , HorwitzS , DuvicM , ScarisbrickJ , et al. Patient-reported outcomes and quality of life in patients with cutaneous T cell lymphoma: results from the phase 3 ALCANZA study. In: Hematological Oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:247–8. [CENTRAL: CN-01408603] [DOI: 10.1002/hon.2438]ZagadailovE , PrinceHM , WhittakerS , HorwitzS , DuvicM , KimY , et al. Phase 3 alcanza study of brentuximab vedotin (BV) or physician's choice (PC) of methotrexate (MTX) or bexarotene (BEX) in CD30-positive cutaneous T-cell lymphoma (CTCL): number needed to treat analysis. In: Haematologica. Conference: 22th congress of the european hematology association. Spain. Vol. 102. 2017:251. [CENTRAL: CN-01399195] ">Prince 2017</a>, ORR was different between brentuximab vedotin and physician's choice. The authors reported on 31 cases in the brentuximab vedotin arm and eight cases in the control group (RR 3.96, 95% CI 2.03 to 7.71, 97 participants, <a href="./references#CD008946-fig-0028" title="">Analysis 10.2</a>). The risk ratio favoured brentuximab vedotin (Fisher test P &lt; 0.001). </p> </section> </section> </section> <section id="CD008946-sec-0164"> <h5 class="title">V.6. Mogamulizumab (one trial)</h5> <p>PICO: In participants with MF stages IB ‐ IVB, <a href="./references#CD008946-bbs2-0008" title="BagotM , DalleS , SokolL , TsianakasA , MusiekA , Ortiz-RomeroP , et al. Long-term clinical benefit to anti-CCR4 mogamulizumab: results from the phase 3 mavoric study in previously treated cutaneous t-cell lymphoma (CTCL). Blood2018;132(Supp 1):2901. [DOI: 10.1182/blood-2018-99-118473]CowanR , ScarisbrickJ , DwyerK , LeoniM , GrebennikD , MorrisS . Mogamulizumab demonstrates significant improvement in PFS compared to vorinostat in patients with previously treated cutaneous T-cell lymphoma (CTCL). British Journal of Haematology2018;181(S1):77–8. [DOI: 10.1111/bjh.15226]KimYH , BagotM , Pinter-BrownL , RookAH , PorcuP , HorwitzSM , et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncology2018;19(9):1192-1204. [PMID: 30100375]NCT01728805. Study of KW-0761 versus vorinostat in relapsed/refractory CTCL. clinicaltrials.gov/ct2/show/NCT01728805 (first received 20 November 2012). PorcuP , HudgensS , QuaglinoP , CowanR , FlodenL , LeoniM , et al. Quality of life in cutaneous T-cell lymphoma subjects treated with anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat: results from the phase 3 MAVORIC trial. Journal of Clinical Oncology2018;36(15):-. [DOI: 10.1097/HS9.0000000000000060]QuaglinoP , HudgensS , PorcuP , CowanR , FlodenL , TsianakasA , et al. Quality of life in cutaneous t-cell lymphoma subjects treated with the anti-ccr4 monoclonal antibody mogamulizumab versus vorinostat: results from the phase 3 mavoric trial. Hemasphere2018;2(S1):85. ScarisbrickJ , ZinzaniPL , HorwitzS , KimYH , MoskowitzAJ , PorcuP , et al. Efficacy of mogamulizumab by prior systemic therapy in patients with previously treated cutaneous T-cell lymphoma: Post hoc analysis from the phase 3 MAVORIC study. British Journal of Haematology2019;185(Suppl 1):94. TsianakasA , QuaglinoP , HudgensS , FlodenL , LeoniM , DaleS , et al. Quality of life in cutaneous T-cell lymphoma subjects treated with the anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat: Results from the phase 3 MAVORIC trial. Oncology Research and Treatment2018;41(Suppl 4):272. ZinzaniPL , HorwitzSM , KimYH , MoskowitzAJ , PorcuP , ScarisbrickJ , et al. Efficacy of mogamulizumab by prior systemic therapy in patients with previously treated cutaneous T-cell lymphoma: post hoc analysis from the phase 3 mavoric study. Blood2018;132(Suppl 1):1619. [DOI: 10.1182/blood-2018-99-114819]">Kim 2018</a> investigated the effect of Mogamulizumab compared to vorinostat for up to 12 months. The end points were evaluated individually. </p> <section id="CD008946-sec-0165"> <h6 class="title">Primary outcomes</h6> <section id="CD008946-sec-0166"> <p><b>Common adverse effects of the treatments</b></p> <p><a href="./references#CD008946-bbs2-0008" title="BagotM , DalleS , SokolL , TsianakasA , MusiekA , Ortiz-RomeroP , et al. Long-term clinical benefit to anti-CCR4 mogamulizumab: results from the phase 3 mavoric study in previously treated cutaneous t-cell lymphoma (CTCL). Blood2018;132(Supp 1):2901. [DOI: 10.1182/blood-2018-99-118473]CowanR , ScarisbrickJ , DwyerK , LeoniM , GrebennikD , MorrisS . Mogamulizumab demonstrates significant improvement in PFS compared to vorinostat in patients with previously treated cutaneous T-cell lymphoma (CTCL). British Journal of Haematology2018;181(S1):77–8. [DOI: 10.1111/bjh.15226]KimYH , BagotM , Pinter-BrownL , RookAH , PorcuP , HorwitzSM , et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncology2018;19(9):1192-1204. [PMID: 30100375]NCT01728805. Study of KW-0761 versus vorinostat in relapsed/refractory CTCL. clinicaltrials.gov/ct2/show/NCT01728805 (first received 20 November 2012). PorcuP , HudgensS , QuaglinoP , CowanR , FlodenL , LeoniM , et al. Quality of life in cutaneous T-cell lymphoma subjects treated with anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat: results from the phase 3 MAVORIC trial. Journal of Clinical Oncology2018;36(15):-. [DOI: 10.1097/HS9.0000000000000060]QuaglinoP , HudgensS , PorcuP , CowanR , FlodenL , TsianakasA , et al. Quality of life in cutaneous t-cell lymphoma subjects treated with the anti-ccr4 monoclonal antibody mogamulizumab versus vorinostat: results from the phase 3 mavoric trial. Hemasphere2018;2(S1):85. ScarisbrickJ , ZinzaniPL , HorwitzS , KimYH , MoskowitzAJ , PorcuP , et al. Efficacy of mogamulizumab by prior systemic therapy in patients with previously treated cutaneous T-cell lymphoma: Post hoc analysis from the phase 3 MAVORIC study. British Journal of Haematology2019;185(Suppl 1):94. TsianakasA , QuaglinoP , HudgensS , FlodenL , LeoniM , DaleS , et al. Quality of life in cutaneous T-cell lymphoma subjects treated with the anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat: Results from the phase 3 MAVORIC trial. Oncology Research and Treatment2018;41(Suppl 4):272. ZinzaniPL , HorwitzSM , KimYH , MoskowitzAJ , PorcuP , ScarisbrickJ , et al. Efficacy of mogamulizumab by prior systemic therapy in patients with previously treated cutaneous T-cell lymphoma: post hoc analysis from the phase 3 mavoric study. Blood2018;132(Suppl 1):1619. [DOI: 10.1182/blood-2018-99-114819]">Kim 2018</a> measured adverse effects but the distribution in the treatment arms was not reported. </p> </section> <section id="CD008946-sec-0167"> <p><b>Objective response rate (ORR)</b></p> <p>In <a href="./references#CD008946-bbs2-0008" title="BagotM , DalleS , SokolL , TsianakasA , MusiekA , Ortiz-RomeroP , et al. Long-term clinical benefit to anti-CCR4 mogamulizumab: results from the phase 3 mavoric study in previously treated cutaneous t-cell lymphoma (CTCL). Blood2018;132(Supp 1):2901. [DOI: 10.1182/blood-2018-99-118473]CowanR , ScarisbrickJ , DwyerK , LeoniM , GrebennikD , MorrisS . Mogamulizumab demonstrates significant improvement in PFS compared to vorinostat in patients with previously treated cutaneous T-cell lymphoma (CTCL). British Journal of Haematology2018;181(S1):77–8. [DOI: 10.1111/bjh.15226]KimYH , BagotM , Pinter-BrownL , RookAH , PorcuP , HorwitzSM , et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncology2018;19(9):1192-1204. [PMID: 30100375]NCT01728805. Study of KW-0761 versus vorinostat in relapsed/refractory CTCL. clinicaltrials.gov/ct2/show/NCT01728805 (first received 20 November 2012). PorcuP , HudgensS , QuaglinoP , CowanR , FlodenL , LeoniM , et al. Quality of life in cutaneous T-cell lymphoma subjects treated with anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat: results from the phase 3 MAVORIC trial. Journal of Clinical Oncology2018;36(15):-. [DOI: 10.1097/HS9.0000000000000060]QuaglinoP , HudgensS , PorcuP , CowanR , FlodenL , TsianakasA , et al. Quality of life in cutaneous t-cell lymphoma subjects treated with the anti-ccr4 monoclonal antibody mogamulizumab versus vorinostat: results from the phase 3 mavoric trial. Hemasphere2018;2(S1):85. ScarisbrickJ , ZinzaniPL , HorwitzS , KimYH , MoskowitzAJ , PorcuP , et al. Efficacy of mogamulizumab by prior systemic therapy in patients with previously treated cutaneous T-cell lymphoma: Post hoc analysis from the phase 3 MAVORIC study. British Journal of Haematology2019;185(Suppl 1):94. TsianakasA , QuaglinoP , HudgensS , FlodenL , LeoniM , DaleS , et al. Quality of life in cutaneous T-cell lymphoma subjects treated with the anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat: Results from the phase 3 MAVORIC trial. Oncology Research and Treatment2018;41(Suppl 4):272. ZinzaniPL , HorwitzSM , KimYH , MoskowitzAJ , PorcuP , ScarisbrickJ , et al. Efficacy of mogamulizumab by prior systemic therapy in patients with previously treated cutaneous T-cell lymphoma: post hoc analysis from the phase 3 mavoric study. Blood2018;132(Suppl 1):1619. [DOI: 10.1182/blood-2018-99-114819]">Kim 2018</a>, there were differences between mogamulizumab and vorinostat for ORR. There were 22 cases of ORR in the mogamuizumab group and 7 in the placebo group (RR 2.96, 95% CI 1.32 to 6.63 (95% CI according to Miettinen: 1.37 to 6.56), 204 participants, <a href="./references#CD008946-fig-0041" title="">Analysis 15.1</a>). The risk ratio favoured mogamulizumab (Fisher test P = 0.005). </p> </section> </section> </section> </section> <section id="CD008946-sec-0168"> <h4 class="title">VI. Extracorporeal photochemotherapy</h4> <p>One study (<a href="./references#CD008946-bbs2-0002" title="ChildFJ , MitchellTJ , WhittakerSJ , ScarisbrickJJ , SeedPT , Russel-JonesR . A randomized cross-over study to compare PUVA and extracorporeal photopheresis in the treatment of plaque stage (T2) mycosis fungoides. Clinical &amp; Experimental Dermatology2004;29(3):231-6. [CENTRAL: CN-00468455] [PMID: 15115499]ChildFJ , MitchellTJ , WhittakerSJ , WatkinsP , SeedP , Russell-JonesR . A randomised cross-over study to compare Puva and extracorporeal photopheresis (ECP) in the treatment of plaque stage (T2) mycosis fungoides. British Journal of Dermatology2001;145(Suppl 59):16. [CENTRAL: CN-00430854] ">Child 2004</a>) investigated the effect of extracorporeal photopheresis compared to other therapies in a cross‐over design. We extracted the data as reported and did not adjust for unit of analysis issues. </p> <section id="CD008946-sec-0169"> <h5 class="title">VI.1. Extracorporeal photopheresis (one trial)</h5> <p>PICO: In participants with plaque stage (Bunn Lamberg stage 1B) MF and a peripheral blood T‐cell clone, <a href="./references#CD008946-bbs2-0002" title="ChildFJ , MitchellTJ , WhittakerSJ , ScarisbrickJJ , SeedPT , Russel-JonesR . A randomized cross-over study to compare PUVA and extracorporeal photopheresis in the treatment of plaque stage (T2) mycosis fungoides. Clinical &amp; Experimental Dermatology2004;29(3):231-6. [CENTRAL: CN-00468455] [PMID: 15115499]ChildFJ , MitchellTJ , WhittakerSJ , WatkinsP , SeedP , Russell-JonesR . A randomised cross-over study to compare Puva and extracorporeal photopheresis (ECP) in the treatment of plaque stage (T2) mycosis fungoides. British Journal of Dermatology2001;145(Suppl 59):16. [CENTRAL: CN-00430854] ">Child 2004</a> investigated the effect of extracorporeal photopheresis compared to PUVA in a cross‐over design randomising participants either to start with three months of PUVA or six months of ECP. End points were evaluated at the end of these periods. </p> <p>Please see <a href="./full#CD008946-tbl-0002">summary of findings Table 2</a>. </p> <section id="CD008946-sec-0170"> <h6 class="title">Primary outcomes</h6> <section id="CD008946-sec-0171"> <p><b>Common adverse effects of the treatments</b></p> <p>The study of <a href="./references#CD008946-bbs2-0002" title="ChildFJ , MitchellTJ , WhittakerSJ , ScarisbrickJJ , SeedPT , Russel-JonesR . A randomized cross-over study to compare PUVA and extracorporeal photopheresis in the treatment of plaque stage (T2) mycosis fungoides. Clinical &amp; Experimental Dermatology2004;29(3):231-6. [CENTRAL: CN-00468455] [PMID: 15115499]ChildFJ , MitchellTJ , WhittakerSJ , WatkinsP , SeedP , Russell-JonesR . A randomised cross-over study to compare Puva and extracorporeal photopheresis (ECP) in the treatment of plaque stage (T2) mycosis fungoides. British Journal of Dermatology2001;145(Suppl 59):16. [CENTRAL: CN-00430854] ">Child 2004</a> reported that some participants reported mild nausea after PUVA. However, incidences and time points were not stated. One participant starting in the ECP group had hypotension leading to withdrawal from the study. The certainty of evidence is very low as we downgraded thrice: once due to low internal validity (risk of bias ‐ high risk of attrition bias) and twice due to very low sample size (imprecision). </p> </section> </section> <section id="CD008946-sec-0172"> <h6 class="title">Secondary outcomes</h6> <section id="CD008946-sec-0173"> <p><b>Complete response (CR)</b></p> <p>In <a href="./references#CD008946-bbs2-0002" title="ChildFJ , MitchellTJ , WhittakerSJ , ScarisbrickJJ , SeedPT , Russel-JonesR . A randomized cross-over study to compare PUVA and extracorporeal photopheresis in the treatment of plaque stage (T2) mycosis fungoides. Clinical &amp; Experimental Dermatology2004;29(3):231-6. [CENTRAL: CN-00468455] [PMID: 15115499]ChildFJ , MitchellTJ , WhittakerSJ , WatkinsP , SeedP , Russell-JonesR . A randomised cross-over study to compare Puva and extracorporeal photopheresis (ECP) in the treatment of plaque stage (T2) mycosis fungoides. British Journal of Dermatology2001;145(Suppl 59):16. [CENTRAL: CN-00430854] ">Child 2004</a>, there were no differences between ECP and PUVA for complete response. There were zero cases in the ECP arm and two cases in the PUVA arm (RR 0.20, 95% CI 0.01 to 3.61, 16 participants, <a href="./references#CD008946-fig-0029" title="">Analysis 11.1</a>, Fisher test P = 0.47). The certainty of evidence is very low as we downgraded thrice: once due to low internal validity (risk of bias ‐ high risk of attrition bias) and twice due to very low sample size (imprecision). </p> </section> <section id="CD008946-sec-0174"> <p><b>Overall survival (OR)</b></p> <p>Of the eight evaluable participants completing the cross‐over study of <a href="./references#CD008946-bbs2-0002" title="ChildFJ , MitchellTJ , WhittakerSJ , ScarisbrickJJ , SeedPT , Russel-JonesR . A randomized cross-over study to compare PUVA and extracorporeal photopheresis in the treatment of plaque stage (T2) mycosis fungoides. Clinical &amp; Experimental Dermatology2004;29(3):231-6. [CENTRAL: CN-00468455] [PMID: 15115499]ChildFJ , MitchellTJ , WhittakerSJ , WatkinsP , SeedP , Russell-JonesR . A randomised cross-over study to compare Puva and extracorporeal photopheresis (ECP) in the treatment of plaque stage (T2) mycosis fungoides. British Journal of Dermatology2001;145(Suppl 59):16. [CENTRAL: CN-00430854] ">Child 2004</a>, one participant was lost to follow‐up. All other participants were alive at the end of follow‐up, which lasted two to 21 months. </p> </section> <section id="CD008946-sec-0175"> <p><b>Objective response rate (ORR)</b></p> <p>In <a href="./references#CD008946-bbs2-0002" title="ChildFJ , MitchellTJ , WhittakerSJ , ScarisbrickJJ , SeedPT , Russel-JonesR . A randomized cross-over study to compare PUVA and extracorporeal photopheresis in the treatment of plaque stage (T2) mycosis fungoides. Clinical &amp; Experimental Dermatology2004;29(3):231-6. [CENTRAL: CN-00468455] [PMID: 15115499]ChildFJ , MitchellTJ , WhittakerSJ , WatkinsP , SeedP , Russell-JonesR . A randomised cross-over study to compare Puva and extracorporeal photopheresis (ECP) in the treatment of plaque stage (T2) mycosis fungoides. British Journal of Dermatology2001;145(Suppl 59):16. [CENTRAL: CN-00430854] ">Child 2004</a>, differences were seen between ECP and PUVA for ORR. There were zero cases of ORR in the ECP arm and six cases in the PUVA arm (RR 0.08, 95% CI 0.01 to 1.17 (95% CI according to Miettinen: 0.00 to 0.40), eight participants, <a href="./references#CD008946-fig-0030" title="">Analysis 11.2</a>). The risk ratio favoured PUVA (Fisher test P = 0.01). The certainty of evidence is very low as we downgraded thrice: once due to low internal validity (risk of bias ‐ high risk of attrition bias) and twice due to very low sample size (imprecision). </p> </section> </section> </section> </section> <section id="CD008946-sec-0176"> <h4 class="title">VII. Combination therapies</h4> <p>Eight studies (<a href="./references#CD008946-bbs2-0002" title="ChildFJ , MitchellTJ , WhittakerSJ , ScarisbrickJJ , SeedPT , Russel-JonesR . A randomized cross-over study to compare PUVA and extracorporeal photopheresis in the treatment of plaque stage (T2) mycosis fungoides. Clinical &amp; Experimental Dermatology2004;29(3):231-6. [CENTRAL: CN-00468455] [PMID: 15115499]ChildFJ , MitchellTJ , WhittakerSJ , WatkinsP , SeedP , Russell-JonesR . A randomised cross-over study to compare Puva and extracorporeal photopheresis (ECP) in the treatment of plaque stage (T2) mycosis fungoides. British Journal of Dermatology2001;145(Suppl 59):16. [CENTRAL: CN-00430854] ">Child 2004</a>; <a href="./references#CD008946-bbs2-0006" title="GuitartJ , TuckerR , StevensV . Low dose bexarotene (Targretin®) capsules and phototherapy for early stage cutaneous T-Cell lymphoma. Journal of Investigative Dermatology2002;119(1):241. [CENTRAL: CN-00794450] NCT00030589. A muliticenter, dose-randomized evaluation of Targretin capsules plus PUVA in patients with stage IB - IIA cutaneous T-Cell lymphoma. clinicaltrials.gov/ct/show/NCT00030589 (first received 27 Jaunry 2003). ">Guitart 2002</a>; <a href="./references#CD008946-bbs2-0007" title="KayeF , EddyJ , IhdeDC , SteinbergS , FischmannAB , GlatsteinE , et al. Conservative vs. aggressive therapy in mycosis fungoides. Proceedings of the American Society of Clinical Oncology1989;8:257. [CENTRAL: CN-00694960] KayeF , IhdeD , FischmannA , GlatsteinE , MinnaJ , SchechterG , et al. A randomized trial comparing conservative and aggressive therapy in mycosis fungoides (MF). Proceedings of the American Society of Clinical Oncology1986;5:195. [CENTRAL: CN-00695166] KayeFJ , BunnPA , SteinbergSM , StockerJL , IhdeDC , FischmannAB , et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. New England Journal of Medicine1989;321(26):1784-90. [CENTRAL: CN-00064211] [PMID: 2594037]">Kaye 1989</a>; <a href="./references#CD008946-bbs2-0013" title="OtteHG , KuhlS , StadlerR , LugerT , HenzB , SterryW . Treatment of cutaneous T-cell lymphoma with Interferon alpha and PUVA versus Interferon alpha and Acitretin - results of a prospective randomised multi-centre study [Behandlung des kutanen T-Zell-Lymphoms mit Interferon alpha und PUVA versus Interferon alpha und Acirentin - Ergebnisse einer prospektiv-randomisierten Multicenter-Studie]. Der Hautarzt1997;48(Suppl):S97. [CENTRAL: CN-00495120] OtteHG , StadierR , LugerT , HenzB , SterryW . Open controlled clinical trial on the use of interferon plus acitretin versus interferon plus PUVA in patients with cutaneous T-cell lymphoma (CTCL). Annals of Oncology1996;7(Suppl 3):66. [CENTRAL: CN-00308243] StadlerR , OtteHG , LugerT , HenzBM , KuhlP , ZwingersT , et al. Prospective randomized multicenter clinical trial on the use of interferon -2a plus acitretin versus interferon -2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood1998;92(10):3578-81. [CENTRAL: CN-00156682] [PMID: 9808550]">Stadler 1998</a>; <a href="./references#CD008946-bbs2-0014" title="BohmeyerJ , OtteHG , StadlerR , LugerT , SterryW . Therapy of cutaneous T-cell lymphoma with PUVA versus interferon alfa plus PUVA: first results. Journal of the European Academy of Dermatology &amp; Venereology1999;12(Suppl 2):S268. [CENTRAL: CN-00478472] BohmeyerJ , StadlerR , LugerT , SterryW . Prospective randomized multicentre therapy optimizing protocol for therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α + PUVA [Prospectiv randomisiertes, multizentrisches Therapieoptimierungsprotokoll zur Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α + PUVA]. Zeitschrift für Hautkrankheiten2001;76(Suppl 1):S55. [CENTRAL: CN-01446038] KremerA , BohmeyerJ , StadlerR , LugerT , SterryW . Prospective randomized multicentre therapy optimizing protocol for therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α + PUVA [Prospectiv randomisiertes, multizentrisches Therapieoptimierungsprotokoll zur Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α + PUVA]. Journal der Deutschen Dermatologischen Gesellschaft2003;1(Suppl 1):S99. [CENTRAL: CN-01446037] OtteHG , StadlerR , LugerT , SterryW . Therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α plus PUVA: first results of a prospective randomized multicentre therapy optimizing protocol [Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α plus PUVA: Erste Ergebnisse des prospektiven randomisierten multizentrischen Therapieoptimierungsprotokolls]. Der Hautarzt1999;50(Suppl 1):S2. [CENTRAL: CN-01457423] OtteHG , StadlerR . Combination therapy of cutaneous t-cell-lymphoma with interferon alfa 2a and PUVA [Kombinationstherapie kutaner T-Zell-Lymphome mit Interferon Alfa 2a und PUVA]. Zentralblatt Haut- und Geschlechtskrankheiten1993;162(Suppl):P2.03.08. [CENTRAL: CN-01457422] StadlerM , KremerA , LugerT , SterryW . Prospective, randomized, multicentre clinical trial on the use of interferon a 2a plus PUVA versus PUVA monotherapy in patients with cutaneous T-cell lymphoma, stages I and II [Abstract 7541]. ASCO annual meeting proceedings. Journal of Clinical Oncology2006;24(18S Pt 1):432. [CENTRAL: CN-00625001] ">Stadler 2006</a>; <a href="./references#CD008946-bbs2-0015" title="Thestrup-PedersenK , GrunnetE , ZachariaeH . Transfer factor therapy in mycosis fungoides: a double-blind study. Acta Dermato-Venereologica1982;62(1):47-53. [CENTRAL: CN-00027377] [PMID: 6175137]">Thestrup‐Pedersen 1982</a>; <a href="./references#CD008946-bbs2-0018" title="NCT00056056. Ultraviolet light therapy using methoxsalen with or without Bexarotene in treating patients with mycosis fungoides. clinicaltrials.gov/ct2/show/NCT00056056 (first received 7 March 2003). WhittakerS , OrtizP , DummerR , RankiA , HasanB , MeulemansB , et al. Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial 21011 (NCT00056056). British Journal of Dermatology2012;167(3):678-87. [CENTRAL: CN-00856432] [PMID: 22924950]WhittakerS , Ortiz-RomeroPL , DummerR , RankiA , HasanB , MeulemansB , et al. Efficacy and safety of bexarotene combined with psoralen/ultraviolet A light (PUVA) compared to PUVA treatment alone in stage IB-IIa mycosis fungoides (MF): Final results from EORTC cutaneous lymphoma task force (CLTF) phase III clinical trial 21011. Journal of Clinical Oncology2012;30(15 Suppl 1):8076. ">Whittaker 2012</a>; <a href="./references#CD008946-bbs2-0020" title="WozniakMB , TraceyL , Ortiz-RomeroPL , MontesS , AlvarezM , FragaJ , et al. Psoralen plus ultraviolet A +/- interferon-alpha treatment resistance in mycosis fungoides: the role of tumour microenvironment, nuclear transcription factor-kappaB and T-cell receptor pathways. British Journal of Dermatology2008;160(1):92-102. [CENTRAL: CN-00668828] [PMID: 18945306]">Wozniak 2008</a>) investigated the effect of combination therapies. <a href="./references#CD008946-bbs2-0002" title="ChildFJ , MitchellTJ , WhittakerSJ , ScarisbrickJJ , SeedPT , Russel-JonesR . A randomized cross-over study to compare PUVA and extracorporeal photopheresis in the treatment of plaque stage (T2) mycosis fungoides. Clinical &amp; Experimental Dermatology2004;29(3):231-6. [CENTRAL: CN-00468455] [PMID: 15115499]ChildFJ , MitchellTJ , WhittakerSJ , WatkinsP , SeedP , Russell-JonesR . A randomised cross-over study to compare Puva and extracorporeal photopheresis (ECP) in the treatment of plaque stage (T2) mycosis fungoides. British Journal of Dermatology2001;145(Suppl 59):16. [CENTRAL: CN-00430854] ">Child 2004</a> compared PUVA with extracorporeal photopheresis in a cross‐over design randomising participants either to start with three months of PUVA or six months of ECP. This trial is described in section 'VI. Extracorporeal photochemotherapy'. <a href="./references#CD008946-bbs2-0006" title="GuitartJ , TuckerR , StevensV . Low dose bexarotene (Targretin®) capsules and phototherapy for early stage cutaneous T-Cell lymphoma. Journal of Investigative Dermatology2002;119(1):241. [CENTRAL: CN-00794450] NCT00030589. A muliticenter, dose-randomized evaluation of Targretin capsules plus PUVA in patients with stage IB - IIA cutaneous T-Cell lymphoma. clinicaltrials.gov/ct/show/NCT00030589 (first received 27 Jaunry 2003). ">Guitart 2002</a> assessed the effect of two low‐dose regimens of bexarotene in combination with PUVA. The results of this trial are described in section 'V. Chemotherapy'. <a href="./references#CD008946-bbs2-0014" title="BohmeyerJ , OtteHG , StadlerR , LugerT , SterryW . Therapy of cutaneous T-cell lymphoma with PUVA versus interferon alfa plus PUVA: first results. Journal of the European Academy of Dermatology &amp; Venereology1999;12(Suppl 2):S268. [CENTRAL: CN-00478472] BohmeyerJ , StadlerR , LugerT , SterryW . Prospective randomized multicentre therapy optimizing protocol for therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α + PUVA [Prospectiv randomisiertes, multizentrisches Therapieoptimierungsprotokoll zur Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α + PUVA]. Zeitschrift für Hautkrankheiten2001;76(Suppl 1):S55. [CENTRAL: CN-01446038] KremerA , BohmeyerJ , StadlerR , LugerT , SterryW . Prospective randomized multicentre therapy optimizing protocol for therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α + PUVA [Prospectiv randomisiertes, multizentrisches Therapieoptimierungsprotokoll zur Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α + PUVA]. Journal der Deutschen Dermatologischen Gesellschaft2003;1(Suppl 1):S99. [CENTRAL: CN-01446037] OtteHG , StadlerR , LugerT , SterryW . Therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α plus PUVA: first results of a prospective randomized multicentre therapy optimizing protocol [Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α plus PUVA: Erste Ergebnisse des prospektiven randomisierten multizentrischen Therapieoptimierungsprotokolls]. Der Hautarzt1999;50(Suppl 1):S2. [CENTRAL: CN-01457423] OtteHG , StadlerR . Combination therapy of cutaneous t-cell-lymphoma with interferon alfa 2a and PUVA [Kombinationstherapie kutaner T-Zell-Lymphome mit Interferon Alfa 2a und PUVA]. Zentralblatt Haut- und Geschlechtskrankheiten1993;162(Suppl):P2.03.08. [CENTRAL: CN-01457422] StadlerM , KremerA , LugerT , SterryW . Prospective, randomized, multicentre clinical trial on the use of interferon a 2a plus PUVA versus PUVA monotherapy in patients with cutaneous T-cell lymphoma, stages I and II [Abstract 7541]. ASCO annual meeting proceedings. Journal of Clinical Oncology2006;24(18S Pt 1):432. [CENTRAL: CN-00625001] ">Stadler 2006</a> and <a href="./references#CD008946-bbs2-0020" title="WozniakMB , TraceyL , Ortiz-RomeroPL , MontesS , AlvarezM , FragaJ , et al. Psoralen plus ultraviolet A +/- interferon-alpha treatment resistance in mycosis fungoides: the role of tumour microenvironment, nuclear transcription factor-kappaB and T-cell receptor pathways. British Journal of Dermatology2008;160(1):92-102. [CENTRAL: CN-00668828] [PMID: 18945306]">Wozniak 2008</a> compared IFN‐α (subcutaneously‐injected) to placebo under concomitant therapy with PUVA. These trials are described in section 'V. Chemotherapy'. </p> <p><a href="./references#CD008946-bbs2-0007" title="KayeF , EddyJ , IhdeDC , SteinbergS , FischmannAB , GlatsteinE , et al. Conservative vs. aggressive therapy in mycosis fungoides. Proceedings of the American Society of Clinical Oncology1989;8:257. [CENTRAL: CN-00694960] KayeF , IhdeD , FischmannA , GlatsteinE , MinnaJ , SchechterG , et al. A randomized trial comparing conservative and aggressive therapy in mycosis fungoides (MF). Proceedings of the American Society of Clinical Oncology1986;5:195. [CENTRAL: CN-00695166] KayeFJ , BunnPA , SteinbergSM , StockerJL , IhdeDC , FischmannAB , et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. New England Journal of Medicine1989;321(26):1784-90. [CENTRAL: CN-00064211] [PMID: 2594037]">Kaye 1989</a> investigated electron‐beam radiation and parenteral chemotherapy compared to topical treatment supported by four sequential escape therapies. <a href="./references#CD008946-bbs2-0013" title="OtteHG , KuhlS , StadlerR , LugerT , HenzB , SterryW . Treatment of cutaneous T-cell lymphoma with Interferon alpha and PUVA versus Interferon alpha and Acitretin - results of a prospective randomised multi-centre study [Behandlung des kutanen T-Zell-Lymphoms mit Interferon alpha und PUVA versus Interferon alpha und Acirentin - Ergebnisse einer prospektiv-randomisierten Multicenter-Studie]. Der Hautarzt1997;48(Suppl):S97. [CENTRAL: CN-00495120] OtteHG , StadierR , LugerT , HenzB , SterryW . Open controlled clinical trial on the use of interferon plus acitretin versus interferon plus PUVA in patients with cutaneous T-cell lymphoma (CTCL). Annals of Oncology1996;7(Suppl 3):66. [CENTRAL: CN-00308243] StadlerR , OtteHG , LugerT , HenzBM , KuhlP , ZwingersT , et al. Prospective randomized multicenter clinical trial on the use of interferon -2a plus acitretin versus interferon -2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood1998;92(10):3578-81. [CENTRAL: CN-00156682] [PMID: 9808550]">Stadler 1998</a> investigated the effect of IFN‐α (subcutaneously‐injected) combined with either acitretin capsules or PUVA. <a href="./references#CD008946-bbs2-0015" title="Thestrup-PedersenK , GrunnetE , ZachariaeH . Transfer factor therapy in mycosis fungoides: a double-blind study. Acta Dermato-Venereologica1982;62(1):47-53. [CENTRAL: CN-00027377] [PMID: 6175137]">Thestrup‐Pedersen 1982</a> assessed the effect of active or inactivated transfer factor (injected intramuscularly) under concomitant therapy with nitrogen mustard. PUVA was administered instead of nitrogen mustard in participants with severe hypersensitivity to nitrogen mustard or relapse after treatment. <a href="./references#CD008946-bbs2-0018" title="NCT00056056. Ultraviolet light therapy using methoxsalen with or without Bexarotene in treating patients with mycosis fungoides. clinicaltrials.gov/ct2/show/NCT00056056 (first received 7 March 2003). WhittakerS , OrtizP , DummerR , RankiA , HasanB , MeulemansB , et al. Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial 21011 (NCT00056056). British Journal of Dermatology2012;167(3):678-87. [CENTRAL: CN-00856432] [PMID: 22924950]WhittakerS , Ortiz-RomeroPL , DummerR , RankiA , HasanB , MeulemansB , et al. Efficacy and safety of bexarotene combined with psoralen/ultraviolet A light (PUVA) compared to PUVA treatment alone in stage IB-IIa mycosis fungoides (MF): Final results from EORTC cutaneous lymphoma task force (CLTF) phase III clinical trial 21011. Journal of Clinical Oncology2012;30(15 Suppl 1):8076. ">Whittaker 2012</a> assessed the effect of bexarotene combined with PUVA versus PUVA alone. The results of this trial are presented in the skin‐directed phototherapies section. At least one outcome of interest is reported in the three studies (<a href="./references#CD008946-bbs2-0007" title="KayeF , EddyJ , IhdeDC , SteinbergS , FischmannAB , GlatsteinE , et al. Conservative vs. aggressive therapy in mycosis fungoides. Proceedings of the American Society of Clinical Oncology1989;8:257. [CENTRAL: CN-00694960] KayeF , IhdeD , FischmannA , GlatsteinE , MinnaJ , SchechterG , et al. A randomized trial comparing conservative and aggressive therapy in mycosis fungoides (MF). Proceedings of the American Society of Clinical Oncology1986;5:195. [CENTRAL: CN-00695166] KayeFJ , BunnPA , SteinbergSM , StockerJL , IhdeDC , FischmannAB , et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. New England Journal of Medicine1989;321(26):1784-90. [CENTRAL: CN-00064211] [PMID: 2594037]">Kaye 1989</a>; <a href="./references#CD008946-bbs2-0013" title="OtteHG , KuhlS , StadlerR , LugerT , HenzB , SterryW . Treatment of cutaneous T-cell lymphoma with Interferon alpha and PUVA versus Interferon alpha and Acitretin - results of a prospective randomised multi-centre study [Behandlung des kutanen T-Zell-Lymphoms mit Interferon alpha und PUVA versus Interferon alpha und Acirentin - Ergebnisse einer prospektiv-randomisierten Multicenter-Studie]. Der Hautarzt1997;48(Suppl):S97. [CENTRAL: CN-00495120] OtteHG , StadierR , LugerT , HenzB , SterryW . Open controlled clinical trial on the use of interferon plus acitretin versus interferon plus PUVA in patients with cutaneous T-cell lymphoma (CTCL). Annals of Oncology1996;7(Suppl 3):66. [CENTRAL: CN-00308243] StadlerR , OtteHG , LugerT , HenzBM , KuhlP , ZwingersT , et al. Prospective randomized multicenter clinical trial on the use of interferon -2a plus acitretin versus interferon -2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood1998;92(10):3578-81. [CENTRAL: CN-00156682] [PMID: 9808550]">Stadler 1998</a>; <a href="./references#CD008946-bbs2-0015" title="Thestrup-PedersenK , GrunnetE , ZachariaeH . Transfer factor therapy in mycosis fungoides: a double-blind study. Acta Dermato-Venereologica1982;62(1):47-53. [CENTRAL: CN-00027377] [PMID: 6175137]">Thestrup‐Pedersen 1982</a>) included in this section. </p> <section id="CD008946-sec-0177"> <h5 class="title">VII.1. Electron‐beam radiation and parenteral chemotherapy (one trial)</h5> <p>PICO: In participants with MF of all stages, <a href="./references#CD008946-bbs2-0007" title="KayeF , EddyJ , IhdeDC , SteinbergS , FischmannAB , GlatsteinE , et al. Conservative vs. aggressive therapy in mycosis fungoides. Proceedings of the American Society of Clinical Oncology1989;8:257. [CENTRAL: CN-00694960] KayeF , IhdeD , FischmannA , GlatsteinE , MinnaJ , SchechterG , et al. A randomized trial comparing conservative and aggressive therapy in mycosis fungoides (MF). Proceedings of the American Society of Clinical Oncology1986;5:195. [CENTRAL: CN-00695166] KayeFJ , BunnPA , SteinbergSM , StockerJL , IhdeDC , FischmannAB , et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. New England Journal of Medicine1989;321(26):1784-90. [CENTRAL: CN-00064211] [PMID: 2594037]">Kaye 1989</a> investigated the effect of a "combined therapy" consisting of electron‐beam radiation and parenteral chemotherapy with cyclophosphamide, doxorubicin, etoposide, and vincristine, given for eight to 12 weeks, versus a "conservative treatment" consisting of topical treatment with mechlorethamine supported by a stepwise escalation of the therapy according to the stage of the disease. End points were evaluated at the end of this timeframe. </p> <section id="CD008946-sec-0178"> <h6 class="title">Primary outcomes</h6> <section id="CD008946-sec-0179"> <p><b>Common adverse effects of the treatments</b></p> <p><a href="./references#CD008946-bbs2-0007" title="KayeF , EddyJ , IhdeDC , SteinbergS , FischmannAB , GlatsteinE , et al. Conservative vs. aggressive therapy in mycosis fungoides. Proceedings of the American Society of Clinical Oncology1989;8:257. [CENTRAL: CN-00694960] KayeF , IhdeD , FischmannA , GlatsteinE , MinnaJ , SchechterG , et al. A randomized trial comparing conservative and aggressive therapy in mycosis fungoides (MF). Proceedings of the American Society of Clinical Oncology1986;5:195. [CENTRAL: CN-00695166] KayeFJ , BunnPA , SteinbergSM , StockerJL , IhdeDC , FischmannAB , et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. New England Journal of Medicine1989;321(26):1784-90. [CENTRAL: CN-00064211] [PMID: 2594037]">Kaye 1989</a> reported on common fatal and non‐fatal adverse events. Because of the variety of different therapies in the conservative group, some procedure‐specific adverse effects only occurred in one treatment arm. In others words, e.g. not every patient in the control arm received electron beam radiation therapy. These adverse effects are presented qualitatively. </p> <p>Adverse effects assessable in both treatment groups were hospitalisation, fatal acute myocardial infarction, cutaneous toxicity from electron beam radiotherapy, acute non‐lymphatic leukaemia, non‐melanoma skin cancer, and occurrence of other cancers not specified more closely by <a href="./references#CD008946-bbs2-0007" title="KayeF , EddyJ , IhdeDC , SteinbergS , FischmannAB , GlatsteinE , et al. Conservative vs. aggressive therapy in mycosis fungoides. Proceedings of the American Society of Clinical Oncology1989;8:257. [CENTRAL: CN-00694960] KayeF , IhdeD , FischmannA , GlatsteinE , MinnaJ , SchechterG , et al. A randomized trial comparing conservative and aggressive therapy in mycosis fungoides (MF). Proceedings of the American Society of Clinical Oncology1986;5:195. [CENTRAL: CN-00695166] KayeFJ , BunnPA , SteinbergSM , StockerJL , IhdeDC , FischmannAB , et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. New England Journal of Medicine1989;321(26):1784-90. [CENTRAL: CN-00064211] [PMID: 2594037]">Kaye 1989</a>. These were compared for the participants of the combined‐therapy groups versus those participants of the conservative group receiving the same treatment: </p> <p> <ul id="CD008946-list-0028"> <li> <p>hospitalisation (due to myelosuppression or radiodermatitis): RR 33.65, 95% CI 2.07 to 546.09, 101 participants, <a href="./references#CD008946-fig-0031" title="">Analysis 12.1</a>. In absolute numbers, there were 16 cases of hospitalisation in the combination arm and zero cases in the conservative arm (Fisher test: P &lt; 0.001); </p> </li> <li> <p>fatal myocardial infarction: RR 1.02, 95% CI 0.07 to 15.86, 101 participants, <a href="./references#CD008946-fig-0031" title="">Analysis 12.1</a>, Fisher test P = 1.00; </p> </li> <li> <p>cutaneous toxicity from electron beam therapy: 13 cases in combination arm, one case conservative arm, RR 3.38, 95% CI 0.49 to 23.53, 63 participants, <a href="./references#CD008946-fig-0031" title="">Analysis 12.1</a>, Fisher test P = 0.26; </p> </li> <li> <p>acute non‐lymphocytic leukaemia: RR 2.04, 95% CI 0.19 to 21.79, 101 participants, <a href="./references#CD008946-fig-0031" title="">Analysis 12.1</a>, Fisher test P = 0.62; </p> </li> <li> <p>non‐melanoma skin cancer: RR 0.20, 95% CI 0.01 to 4.14, 101 participants, <a href="./references#CD008946-fig-0031" title="">Analysis 12.1</a>, Fisher test P = 0.50; </p> </li> <li> <p>unspecified other cancers: RR 0.11, 95% CI 0.01 to 2.05, 101 participants, <a href="./references#CD008946-fig-0031" title="">Analysis 12.1</a>, Fisher test P =0.12. </p> </li> </ul> </p> <p>Adverse effects that were only reported for the combined‐therapy group included leucopenia (white cell count &lt; 1.000 cells per microlitre of blood) [7/50 (14%) participants], thrombopenia (platelets &lt; 50.000 per microlitre of blood) [1/50 (2%) participants], neuropathy [8/50 (16%) participants], and cardiomyopathy [5/50 (10%) participants]. </p> <p>Adverse effects that were only reported for the conservative‐treatment group included cutaneous hypersensitivity to mechlorethamine [15/51 (29%) participants], cutaneous toxicity to methoxsalen and UVA [3/26 (12%) participants], reversible hepatotoxicity due to oral methotrexate [1/16 (6%) participants], and mucositis due to oral methotrexate [3/16 (19%) participants]. </p> </section> </section> <section id="CD008946-sec-0180"> <h6 class="title">Secondary outcomes</h6> <section id="CD008946-sec-0181"> <p><b>Complete response (CR)</b></p> <p>In <a href="./references#CD008946-bbs2-0007" title="KayeF , EddyJ , IhdeDC , SteinbergS , FischmannAB , GlatsteinE , et al. Conservative vs. aggressive therapy in mycosis fungoides. Proceedings of the American Society of Clinical Oncology1989;8:257. [CENTRAL: CN-00694960] KayeF , IhdeD , FischmannA , GlatsteinE , MinnaJ , SchechterG , et al. A randomized trial comparing conservative and aggressive therapy in mycosis fungoides (MF). Proceedings of the American Society of Clinical Oncology1986;5:195. [CENTRAL: CN-00695166] KayeFJ , BunnPA , SteinbergSM , StockerJL , IhdeDC , FischmannAB , et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. New England Journal of Medicine1989;321(26):1784-90. [CENTRAL: CN-00064211] [PMID: 2594037]">Kaye 1989</a>, differences were seen between the combined‐therapy group and the conservative‐treatment group for CR: 20 cases in the combination arm and nine cases in the conservative arm, RR 2.18, 95% CI 1.10 to 4.33, 103 participants, <a href="./references#CD008946-fig-0032" title="">Analysis 12.2</a>. The risk ratio favoured the combined‐therapy group (Fisher test P = 0.03). Responders in the combined‐therapy group had stage IA (2), IB (5), IIA (2), IIB (2) IVA (7), or IVB (2) disease, whereas responders in the conservative‐treatment group had stage IA (2), IB (3), IIA (1), or IVA (3) disease. </p> </section> <section id="CD008946-sec-0182"> <p><b>Relapse</b></p> <p>In <a href="./references#CD008946-bbs2-0007" title="KayeF , EddyJ , IhdeDC , SteinbergS , FischmannAB , GlatsteinE , et al. Conservative vs. aggressive therapy in mycosis fungoides. Proceedings of the American Society of Clinical Oncology1989;8:257. [CENTRAL: CN-00694960] KayeF , IhdeD , FischmannA , GlatsteinE , MinnaJ , SchechterG , et al. A randomized trial comparing conservative and aggressive therapy in mycosis fungoides (MF). Proceedings of the American Society of Clinical Oncology1986;5:195. [CENTRAL: CN-00695166] KayeFJ , BunnPA , SteinbergSM , StockerJL , IhdeDC , FischmannAB , et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. New England Journal of Medicine1989;321(26):1784-90. [CENTRAL: CN-00064211] [PMID: 2594037]">Kaye 1989</a>, no differences were seen in relapse after 48 months between the combined‐therapy group and the conservative‐treatment group: RR 0.98, CI 0.88 to 1.09, 103 participants, <a href="./references#CD008946-fig-0033" title="">Analysis 12.3</a>, Fisher test P = 1.00. </p> </section> <section id="CD008946-sec-0183"> <p><b>Disease‐free survival</b></p> <p>The median disease‐free survival in <a href="./references#CD008946-bbs2-0007" title="KayeF , EddyJ , IhdeDC , SteinbergS , FischmannAB , GlatsteinE , et al. Conservative vs. aggressive therapy in mycosis fungoides. Proceedings of the American Society of Clinical Oncology1989;8:257. [CENTRAL: CN-00694960] KayeF , IhdeD , FischmannA , GlatsteinE , MinnaJ , SchechterG , et al. A randomized trial comparing conservative and aggressive therapy in mycosis fungoides (MF). Proceedings of the American Society of Clinical Oncology1986;5:195. [CENTRAL: CN-00695166] KayeFJ , BunnPA , SteinbergSM , StockerJL , IhdeDC , FischmannAB , et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. New England Journal of Medicine1989;321(26):1784-90. [CENTRAL: CN-00064211] [PMID: 2594037]">Kaye 1989</a> was 12.9 months in the combined‐therapy group compared to 21.3 months in the conservative‐treatment group. No distribution measure was reported for this outcome. </p> </section> <section id="CD008946-sec-0184"> <p><b>Overall survival (OS)</b></p> <p>In <a href="./references#CD008946-bbs2-0007" title="KayeF , EddyJ , IhdeDC , SteinbergS , FischmannAB , GlatsteinE , et al. Conservative vs. aggressive therapy in mycosis fungoides. Proceedings of the American Society of Clinical Oncology1989;8:257. [CENTRAL: CN-00694960] KayeF , IhdeD , FischmannA , GlatsteinE , MinnaJ , SchechterG , et al. A randomized trial comparing conservative and aggressive therapy in mycosis fungoides (MF). Proceedings of the American Society of Clinical Oncology1986;5:195. [CENTRAL: CN-00695166] KayeFJ , BunnPA , SteinbergSM , StockerJL , IhdeDC , FischmannAB , et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. New England Journal of Medicine1989;321(26):1784-90. [CENTRAL: CN-00064211] [PMID: 2594037]">Kaye 1989</a>, the median follow‐up was 68 months (range = 19 to 111 months). Within the follow‐up period no differences between the combined‐therapy group and the conservative‐treatment group were seen for overall survival: RR 0.95, 95% CI 0.68 to 1.32, 103 participants, <a href="./references#CD008946-fig-0034" title="">Analysis 12.4</a>, Fisher test P = 0.15. For stages I and II, overall survival was longer than five years for more than 80% of the participants in both groups; for stage III no data were provided with only few participants belonging to this group, and for stage IV the median length of overall survival was 49 months in the combined group and 68 months in the conservative group. </p> </section> <section id="CD008946-sec-0185"> <p><b>Objective response rate (ORR)</b></p> <p>In <a href="./references#CD008946-bbs2-0007" title="KayeF , EddyJ , IhdeDC , SteinbergS , FischmannAB , GlatsteinE , et al. Conservative vs. aggressive therapy in mycosis fungoides. Proceedings of the American Society of Clinical Oncology1989;8:257. [CENTRAL: CN-00694960] KayeF , IhdeD , FischmannA , GlatsteinE , MinnaJ , SchechterG , et al. A randomized trial comparing conservative and aggressive therapy in mycosis fungoides (MF). Proceedings of the American Society of Clinical Oncology1986;5:195. [CENTRAL: CN-00695166] KayeFJ , BunnPA , SteinbergSM , StockerJL , IhdeDC , FischmannAB , et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. New England Journal of Medicine1989;321(26):1784-90. [CENTRAL: CN-00064211] [PMID: 2594037]">Kaye 1989</a>, there were differences between the combined‐therapy group and the conservative‐treatment group for ORR: RR 1.40, 95% CI 1.12 to 1.74, 103 participants, <a href="./references#CD008946-fig-0035" title="">Analysis 12.5</a>. This risk ratio favoured the combined‐therapy (Fisher test P = 0.003). Responders in the combined‐therapy group had stage IA (2), IB (8), IIA (5), IIB (5), IVA (20), or IVB (7) disease, whereas responders in the conservative‐treatment group had stage IA (2), IB (6), IIA (3), IIB (4), III (1), IVA (12), or IVB (5) disease. </p> </section> </section> </section> <section id="CD008946-sec-0186"> <h5 class="title">VII.2. IFN‐α (subcutaneously‐injected) combined with either PUVA or acitretin capsules (one trial) </h5> <p>PICO: In participants with MF Bunn Lamberg stages I and II, <a href="./references#CD008946-bbs2-0013" title="OtteHG , KuhlS , StadlerR , LugerT , HenzB , SterryW . Treatment of cutaneous T-cell lymphoma with Interferon alpha and PUVA versus Interferon alpha and Acitretin - results of a prospective randomised multi-centre study [Behandlung des kutanen T-Zell-Lymphoms mit Interferon alpha und PUVA versus Interferon alpha und Acirentin - Ergebnisse einer prospektiv-randomisierten Multicenter-Studie]. Der Hautarzt1997;48(Suppl):S97. [CENTRAL: CN-00495120] OtteHG , StadierR , LugerT , HenzB , SterryW . Open controlled clinical trial on the use of interferon plus acitretin versus interferon plus PUVA in patients with cutaneous T-cell lymphoma (CTCL). Annals of Oncology1996;7(Suppl 3):66. [CENTRAL: CN-00308243] StadlerR , OtteHG , LugerT , HenzBM , KuhlP , ZwingersT , et al. Prospective randomized multicenter clinical trial on the use of interferon -2a plus acitretin versus interferon -2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood1998;92(10):3578-81. [CENTRAL: CN-00156682] [PMID: 9808550]">Stadler 1998</a> investigated the effect of IFN‐α subcutaneously‐injected acitretin to IFN‐α subcutaneously injected + PUVA administered for up to 48 weeks or until complete response. End points were evaluated at the end of this period. </p> <p>Please see <a href="./full#CD008946-tbl-0004">summary of findings Table 4</a>. </p> <section id="CD008946-sec-0187"> <h6 class="title">Primary outcomes</h6> <section id="CD008946-sec-0188"> <p><b>Common adverse effects of the treatments</b></p> <p><a href="./references#CD008946-bbs2-0013" title="OtteHG , KuhlS , StadlerR , LugerT , HenzB , SterryW . Treatment of cutaneous T-cell lymphoma with Interferon alpha and PUVA versus Interferon alpha and Acitretin - results of a prospective randomised multi-centre study [Behandlung des kutanen T-Zell-Lymphoms mit Interferon alpha und PUVA versus Interferon alpha und Acirentin - Ergebnisse einer prospektiv-randomisierten Multicenter-Studie]. Der Hautarzt1997;48(Suppl):S97. [CENTRAL: CN-00495120] OtteHG , StadierR , LugerT , HenzB , SterryW . Open controlled clinical trial on the use of interferon plus acitretin versus interferon plus PUVA in patients with cutaneous T-cell lymphoma (CTCL). Annals of Oncology1996;7(Suppl 3):66. [CENTRAL: CN-00308243] StadlerR , OtteHG , LugerT , HenzBM , KuhlP , ZwingersT , et al. Prospective randomized multicenter clinical trial on the use of interferon -2a plus acitretin versus interferon -2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood1998;92(10):3578-81. [CENTRAL: CN-00156682] [PMID: 9808550]">Stadler 1998</a> reported common adverse effects divided into grades of severity (I = mild, II = moderate, III = severe). </p> <p>Adverse effects of grade I or II were not different between the IFN‐α + acitretin group and the IFN‐α + PUVA group: RR 0.95, 95% CI 0.64 to 1.42, 82 participants, <a href="./references#CD008946-fig-0036" title="">Analysis 13.1</a>, Fisher test P = 0.83. </p> <p>There was a difference in adverse effects of grade III between IFN‐α + acitretin, and between IFN‐α + PUVA: RR 3.10, 95% CI 1.10 to 8.70, 82 participants, <a href="./references#CD008946-fig-0036" title="">Analysis 13.1</a>. The risk ratio for adverse events grade III showed a higher risk for the IFN‐α + acitretin group (Fisher test P = 0.03). </p> <p>Adverse effects requiring discontinuation of the study differed between IFN‐α + acitretin and IFN‐α + PUVA: nine cases in the IFN‐α + acitretin arm and two cases in the IFN‐α + PUVA arm, RR 4.29, 95% CI 0.99 to 18.63 (95% CI according to Miettinen: 1.13 to 17.1), 82 participants, <a href="./references#CD008946-fig-0036" title="">Analysis 13.1</a>. The risk ratio indicated a higher risk for the IFN‐α + acitretin group (Fisher test P = 0.049). </p> <p>Side‐effects being compared for the treatment with IFN‐α + acitretin and IFN‐α + PUVA were flu‐like symptoms; dryness/redness of the skin, hair loss, or both; neurological disorders; psychiatric disorders; gastrointestinal disorders; elevated liver or biliary tract enzymes; elevated triglycerides; anaemia; leukopenia; impotentia and redness; and infiltration at application site, but differences were only found for neurological disorders (82 participants): </p> <p> <ul id="CD008946-list-0029"> <li> <p>flu‐like symptoms: 29 cases in the IFN‐α + acitretin and 21 cases in the IFN‐α + PUVA, RR 1.32, 95% CI 0.92 to 1.88, <a href="./references#CD008946-fig-0036" title="">Analysis 13.1</a>, Fisher test P = 0.17. The certainty of evidence is low as we downgraded twice: once due to low internal validity (risk of bias ‐ high risk of attrition bias) and once due to low sample size (imprecision); </p> </li> <li> <p>dryness/redness of the skin, hair loss, or both: RR 1.48, 95% CI 0.72 to 3.03, <a href="./references#CD008946-fig-0036" title="">Analysis 13.1</a>, Fisher test P = 0.33; </p> </li> <li> <p>neurological disorders: 11 cases in the IFN‐α + acitretin arm and three in the IFN‐α + PUVA arm, RR 3.49, 95% CI 1.05 to 11.60, <a href="./references#CD008946-fig-0036" title="">Analysis 13.1</a>. The risk ratio showed a higher risk for the acitretin group (Fisher test P = 0.04); </p> </li> <li> <p>psychiatric disorders: RR 1.43, 95% CI 0.25 to 8.11, <a href="./references#CD008946-fig-0036" title="">Analysis 13.1</a>, Fisher test P = 1.00; </p> </li> <li> <p>gastrointestinal disorders: RR 0.76, 95% CI 0.33 to 1.73, <a href="./references#CD008946-fig-0036" title="">Analysis 13.1</a>, Fisher test P = 0.60; </p> </li> <li> <p>elevated liver or biliary tract enzymes: RR 2.38, 95% CI 0.49 to 11.58, <a href="./references#CD008946-fig-0036" title="">Analysis 13.1</a>, Fisher test P = 0.43; </p> </li> <li> <p>elevated triglycerides: five cases in the IFN‐α + acitretin arm and zero cases in the IFN‐α + PUVA arm, RR 10.49, 95% CI 0.60 to 183.74, <a href="./references#CD008946-fig-0036" title="">Analysis 13.1</a>, Fisher test P = 0.55; </p> </li> <li> <p>anaemia: RR 0.95, 95% CI 0.14 to 6.44, <a href="./references#CD008946-fig-0036" title="">Analysis 13.1</a>, Fisher test P = 1.00; </p> </li> <li> <p>leukopenia: RR 0.95, 95% CI 0.42 to 2.15, <a href="./references#CD008946-fig-0036" title="">Analysis 13.1</a>, Fisher test P = 1.00; </p> </li> <li> <p>impotentia: RR 0.48, 95% CI 0.04 to 5.05, <a href="./references#CD008946-fig-0036" title="">Analysis 13.1</a>, Fisher test P = 0.61; </p> </li> <li> <p>redness and infiltration at application site: RR 0.14, 95% CI 0.01 to 2.56, <a href="./references#CD008946-fig-0036" title="">Analysis 13.1</a>, Fisher test P = 0.11. </p> </li> </ul> </p> </section> </section> <section id="CD008946-sec-0189"> <h6 class="title">Secondary outcomes</h6> <section id="CD008946-sec-0190"> <p><b>Complete response (CR)</b></p> <p>In <a href="./references#CD008946-bbs2-0013" title="OtteHG , KuhlS , StadlerR , LugerT , HenzB , SterryW . Treatment of cutaneous T-cell lymphoma with Interferon alpha and PUVA versus Interferon alpha and Acitretin - results of a prospective randomised multi-centre study [Behandlung des kutanen T-Zell-Lymphoms mit Interferon alpha und PUVA versus Interferon alpha und Acirentin - Ergebnisse einer prospektiv-randomisierten Multicenter-Studie]. Der Hautarzt1997;48(Suppl):S97. [CENTRAL: CN-00495120] OtteHG , StadierR , LugerT , HenzB , SterryW . Open controlled clinical trial on the use of interferon plus acitretin versus interferon plus PUVA in patients with cutaneous T-cell lymphoma (CTCL). Annals of Oncology1996;7(Suppl 3):66. [CENTRAL: CN-00308243] StadlerR , OtteHG , LugerT , HenzBM , KuhlP , ZwingersT , et al. Prospective randomized multicenter clinical trial on the use of interferon -2a plus acitretin versus interferon -2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood1998;92(10):3578-81. [CENTRAL: CN-00156682] [PMID: 9808550]">Stadler 1998</a>, differences were observed between the IFN‐α + acitretin and the IFN‐α + PUVA groups for CR: 16 cases in the IFN‐α + acitretin arm and 28 in the IFN‐α + PUVA arm (RR 0.54, 95% CI 0.35 to 0.84, 82 participants, <a href="./references#CD008946-fig-0037" title="">Analysis 13.2</a>). The risk ratio favoured the IFN‐α + PUVA group (Fisher test P = 0.005). The certainty of evidence is low as we downgraded twice: once due to low internal validity (risk of bias ‐ high risk of attrition bias) and once due to low sample size (imprecision). </p> </section> <section id="CD008946-sec-0191"> <p><b>Objective response rate (ORR)</b></p> <p><a href="./references#CD008946-bbs2-0013" title="OtteHG , KuhlS , StadlerR , LugerT , HenzB , SterryW . Treatment of cutaneous T-cell lymphoma with Interferon alpha and PUVA versus Interferon alpha and Acitretin - results of a prospective randomised multi-centre study [Behandlung des kutanen T-Zell-Lymphoms mit Interferon alpha und PUVA versus Interferon alpha und Acirentin - Ergebnisse einer prospektiv-randomisierten Multicenter-Studie]. Der Hautarzt1997;48(Suppl):S97. [CENTRAL: CN-00495120] OtteHG , StadierR , LugerT , HenzB , SterryW . Open controlled clinical trial on the use of interferon plus acitretin versus interferon plus PUVA in patients with cutaneous T-cell lymphoma (CTCL). Annals of Oncology1996;7(Suppl 3):66. [CENTRAL: CN-00308243] StadlerR , OtteHG , LugerT , HenzBM , KuhlP , ZwingersT , et al. Prospective randomized multicenter clinical trial on the use of interferon -2a plus acitretin versus interferon -2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood1998;92(10):3578-81. [CENTRAL: CN-00156682] [PMID: 9808550]">Stadler 1998</a> did not provide ORR. </p> </section> </section> </section> <section id="CD008946-sec-0192"> <h5 class="title">VII.3. Active or inactivated transfer factor (injected intramuscularly) under concomitant therapy with topically‐applied nitrogen mustard (one trial) </h5> <p>PICO: In participants with MF van Scott stage II‐IV (<a href="./references#CD008946-bbs2-0175" title="Van ScottEJ , KalmansonJD . Complete remissions of mycosis fungoides lymphoma induced by topical nitrogen mustard (HN2). Control of delayed hypersensitivity to HN2 by desensitization and by induction of specific immunologic tolerance. Cancer1973;32(1):18-30. [PMID: 4577503]">van Scott 1973</a>), <a href="./references#CD008946-bbs2-0015" title="Thestrup-PedersenK , GrunnetE , ZachariaeH . Transfer factor therapy in mycosis fungoides: a double-blind study. Acta Dermato-Venereologica1982;62(1):47-53. [CENTRAL: CN-00027377] [PMID: 6175137]">Thestrup‐Pedersen 1982</a> investigated the effect of topically‐applied nitrogen mustard with active transfer factor to topically‐applied nitrogen mustard with inactivated transfer factor given for one year. PUVA was administered instead of nitrogen mustard in participants with severe hypersensitivity to nitrogen mustard or relapse after treatment. Van Scott stage II‐IV is best transferred to clinical stage I‐III according to <a href="#CD008946-tbl-0006">Table 1</a>. </p> <section id="CD008946-sec-0193"> <h6 class="title">Primary outcomes</h6> <section id="CD008946-sec-0194"> <p><b>Common adverse effects of the treatments</b></p> <p><a href="./references#CD008946-bbs2-0015" title="Thestrup-PedersenK , GrunnetE , ZachariaeH . Transfer factor therapy in mycosis fungoides: a double-blind study. Acta Dermato-Venereologica1982;62(1):47-53. [CENTRAL: CN-00027377] [PMID: 6175137]">Thestrup‐Pedersen 1982</a> reported that some participants reported slight or moderate pain at the site of injection, which according to the study author, was probably due to the hyperosmolarity of the solution. Furthermore, fatigue and unrest for two to four hours in one participant and fever and malaise in three participants was observed. However, allocation to treatment groups and time points were not stated. </p> </section> </section> <section id="CD008946-sec-0195"> <h6 class="title">Secondary outcomes</h6> <section id="CD008946-sec-0196"> <p><b>Complete response (CR)</b></p> <p>In <a href="./references#CD008946-bbs2-0015" title="Thestrup-PedersenK , GrunnetE , ZachariaeH . Transfer factor therapy in mycosis fungoides: a double-blind study. Acta Dermato-Venereologica1982;62(1):47-53. [CENTRAL: CN-00027377] [PMID: 6175137]">Thestrup‐Pedersen 1982</a>, differences were seen between the active transfer factor group and the inactivated transfer factor group for CR: zero cases of CR in the active transfer factor group and five cases in the inactive transfer factor group, RR 0.09, 95% CI 0.01 to 1.41 (95% CI according to Miettinen: 0.00 to 0.61), 16 participants, <a href="./references#CD008946-fig-0038" title="">Analysis 14.1</a> (assessed one year after the end of the intervention). The risk ratio favoured the inactivated transfer factor group (Fisher test P = 0.03). The authors of this study speculate that the participants in the inactivated transfer factor group may have had a better prognosis initially. </p> </section> <section id="CD008946-sec-0197"> <p><b>Overall survival (OS)</b></p> <p>In <a href="./references#CD008946-bbs2-0015" title="Thestrup-PedersenK , GrunnetE , ZachariaeH . Transfer factor therapy in mycosis fungoides: a double-blind study. Acta Dermato-Venereologica1982;62(1):47-53. [CENTRAL: CN-00027377] [PMID: 6175137]">Thestrup‐Pedersen 1982</a>, the overall survival at the end of the two‐year follow‐up did not differ between the active transfer factor group and the inactivated transfer factor group: RR 1.00, 95% CI 0.69 to 1.45, 16 participants, <a href="./references#CD008946-fig-0039" title="">Analysis 14.2</a>, Fisher test P = 1.00 (assessed one year after the end of the intervention). </p> </section> <section id="CD008946-sec-0198"> <p><b>Objective response rate (ORR)</b></p> <p>In <a href="./references#CD008946-bbs2-0015" title="Thestrup-PedersenK , GrunnetE , ZachariaeH . Transfer factor therapy in mycosis fungoides: a double-blind study. Acta Dermato-Venereologica1982;62(1):47-53. [CENTRAL: CN-00027377] [PMID: 6175137]">Thestrup‐Pedersen 1982</a>, no differences were seen between the active transfer factor group and the inactivated transfer factor for ORR: four cases in the active transfer factor group and seven cases in the inactive transfer factor arm, RR 0.57, 95% CI 0.27 to 1.20, 16 participants, <a href="./references#CD008946-fig-0040" title="">Analysis 14.3</a>, Fisher test P = 0.28 (assessed one year after the end of the intervention). </p> <p>Results from separate adverse effects search in non‐randomised studies</p> <p>In addition to rare adverse effects found in the included studies, we were able to extract information on severe rare adverse effects from a separate adverse effect search. Most of the rare adverse effects, which are listed in <a href="#CD008946-tbl-0010">Table 5</a>, were reported in case reports and other non‐randomised trials. Due to the large spectrum of different treatment options, rare adverse effects consequently occurred in a variety of organs. </p> </section> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD008946-sec-0199" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD008946-sec-0199"></div> <section id="CD008946-sec-0200"> <h3 class="title" id="CD008946-sec-0200">Summary of main results</h3> <p>This review identified 20 studies that met the inclusion criteria. Although these studies assessed a wide range of interventions, we were only able to meta‐analyse two studies. Most interventions were evaluated by only one study, which limits the evidence base. </p> <p>Topical treatments included an immune response modifier (imiquimod), a photosensitising agent (hypericin), an inhibitor of purine nucleoside phosphorylase (BCX‐34 dermal cream), and the cytotoxin nitrogen mustard. Oral treatments included an immunomodulatory drug (lenalidomide) and the chemotherapy drug bexarotene, which was assessed by three studies. Electron beam radiation combined with chemotherapy was assessed by one study. Parenteral systemic agents included the monoclonal antibody mogamulizumab, the cytotoxin denileukin diftitox intravenous infusion, the targeted therapy brentuximab vedotin, and transfer factor. Light therapies included extracorporeal photopheresis (ECP) and psoralen plus ultraviolet A) (PUVA); PUVA was the intervention that was most often a part of study interventions, but no single trial investigated the effect of PUVA versus placebo, and only five studies assessed PUVA given alone or in combination. However, interferon‐α (IFN‐α, given alone or combined with additional therapy, was assessed by 30% of the studies. Only one trial investigated the effect of topical steroids, despite its widespread recommended use (<a href="./references#CD008946-bbs2-0019" title="WolffJM , ZitelliJA , RabinBS , SmilesKA , AbellE . Intralesional interferon in the treatment of early mycosis fungoides. Journal of the American Academy of Dermatology1985;13(4):604-12. [CENTRAL: CN-00040943] [PMID: 2934438]">Wolff 1985</a>). </p> <p>Our primary end point improvement of quality of life was only measured in four studies. Eighteen out of 20 studies reported common adverse effects. Complete response (CR) and common adverse effects were the most frequently reported outcomes. Objective response rate (ORR) was measured in 13 studies (although we could only assess the outcome in 12 studies). Other outcomes of interest were poorly addressed. </p> <p>We created 'Summary of findings tables' for our main comparisons.</p> <p> <ul id="CD008946-list-0030"> <li> <p>IFN‐α + PUVA compared to PUVA alone (<a href="./full#CD008946-tbl-0001">summary of findings Table 1</a>) </p> </li> <li> <p>ECP compared to PUVA (<a href="./full#CD008946-tbl-0002">summary of findings Table 2</a>) </p> </li> <li> <p>Bexarotene + PUVA compared to PUVA alone (<a href="./full#CD008946-tbl-0003">summary of findings Table 3</a>) </p> </li> <li> <p>IFN‐α + acitretin compared to IFN‐α + PUVA (<a href="./full#CD008946-tbl-0004">summary of findings Table 4</a>) </p> </li> <li> <p>PUVA maintenance compared to no maintenance (<a href="./full#CD008946-tbl-0005">summary of findings Table 5</a>) </p> </li> </ul> </p> <p>In terms of our outcomes of interest, our primary outcome quality of life was not assessed by any of our key comparisons, and of the two studies that did report it, results were divided into responders and non‐responders rather than treatment groups. Ninety per cent of all studies reported on common or rare serious adverse effects or their absence. The studies reported a wide range of adverse effects, from mild symptoms to potentially lethal complications. Severity of the common adverse effects was mostly dependent on the invasiveness of the intervention, with local therapies generally resulting in less severe adverse effects. </p> <p>Eighty per cent of the trials included in our key comparisons reported on our secondary outcome CR, whereas only 33% addressed ORR. Only one of five studies comprising our key comparisons investigated disease‐free survival. Other secondary outcomes were not assessed in the trials comprising our key comparisons. </p> <p>The studies assessing PUVA alone versus PUVA plus interferon‐α did not measure common adverse events or ORR. For CR, there may be little to no difference between groups (low‐certainty evidence). </p> <p>We found very low‐certainty evidence for the comparison of ECP versus PUVA. Although the study in this comparison did report ORR and CR in some participants treated with PUVA and none treated with ECP, and common adverse events with each treatment (some participants reported mild nausea after PUVA, and one participant in the ECP group withdrew due to hypotension), due to the certainty of the evidence, we cannot be sure of the results. </p> <p>There may be little to no difference in CR and ORR in participants given bexarotene in combination with PUVA compared to PUVA alone (low‐certainty‐evidence). In the bexarotene plus PUVA group, one participant reported photosensitivity compared to no participants in the PUVA‐alone group (low‐certainty evidence). </p> <p>The comparison of IFN‐α combined with either acitretin capsules or PUVA indicated there may be little to no difference in flu‐like symptoms (low‐certainty evidence). However, IFN‐α + PUVA may lead to a higher CR rate than IFN‐α + acitretin (low‐certainty evidence). ORR was not measured. </p> <p>Another trial compared common adverse effects of PUVA maintenance versus no maintenance in participants with CR. However, the distribution between study arms was not provided. CR and OR were, by study design, not assessable. </p> <p>We found low‐certainty evidence, so could not draw conclusions from the studies included in this review. </p> </section> <section id="CD008946-sec-0201"> <h3 class="title" id="CD008946-sec-0201">Overall completeness and applicability of evidence</h3> <p>We were only able to include studies for a limited number of commonly‐used types of treatment for mycosis fungoides (MF) because of the low number of randomised controlled trials (RCTS) found. </p> <p>Included trials investigated participants with all stages of disease. The more recent trials were conducted as multicentre and multinational studies, facilitating the application of the study results. </p> <p>We did not find any RCTs exclusively assessing the effect of topical steroids compared to placebo. Most of the trials used an active comparator instead of placebo or watchful waiting. This may limit the certainty of therapeutic value as overall survival or quality of life might have been equal or even worse for some treatments compared to placebo or watchful waiting. </p> <p>Treatments like carmustine (BCNU) for the early stages of MF or stem cell transplantation for stage IV participants have not been evaluated in RCTs so far. </p> <p>Most of the included studies did not assess our primary outcome patient‐reported quality of life, and when reported, the data was not usable; this hindered our conclusions in terms of this outcome. However, another primary outcome, common adverse effects, was widely assessed. </p> <p>The applicability of the complete response (CR) and objective response rate (ORR) outcome was limited by the heterogeneous measures of assessment. Relapse, disease‐free survival, survival rates and rare adverse effects were poorly reported in the included studies. Drawing applicable conclusions was limited. </p> <p>A separate rare adverse effects search highlighted important, but in the case of RCTs rarely reported, adverse effects. </p> <p>Study duration was variable and reflected the types of outcomes assessed by different trials (e.g. first response outcomes will require shorter follow‐up than survival outcomes). Very few studies provided a long enough follow‐up. Due to small sample sizes, reliable survival analysis was not possible. Long‐term benefit (i.e. clearance of all symptoms of disease lasting at least two years) was not widely assessed. </p> <p>After decades of discussions about different classifications of cutaneous lymphoma, the joint publication of the WHO‐EORTC classification in 2005 established defined disease entities. This helps both clinicians and researchers in the management and the exploration of MF. For the first time, commonly‐accepted criteria exist that define cutaneous lymphoma not only by means of histological findings but also by giving information on management, treatment and prognosis. Accordingly, diagnosis can only be made when clinical and histological findings are available. The classification was updated in 2018 (<a href="./references#CD008946-bbs2-0116" title="ElderDE , MassiD , ScolyerRA , WillemzeR . WHO Classification of Skin Tumours (4th edition). IARC Press, 2018. [ISBN-13 9789283224402]">Elder 2018</a>; <a href="./references#CD008946-bbs2-0185" title="WillemzeR , CerroniL , KempfW , BertiE , FacchettiF , SwerdlowSH , et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood 2019 Jan 11 [Epub ahead of print]. [DOI: 10.1182/blood-2018-11-881268]">Willemze 2019</a>). Several risk factors for the development of MF have been established, amongst them ethnicity, which might imply a genetic predisposition, since incidences differ between Hispanic, Asian, Black and White populations. </p> <p>The review does not have any major limitations regarding external validity; since MF is a rare disease which is normally treated in specialised medical centres (tertiary care setting), we consider the results of the studies applicable to daily practice. </p> </section> <section id="CD008946-sec-0202"> <h3 class="title" id="CD008946-sec-0202">Quality of the evidence</h3> <p>The quality of the included studies was very variable. All results expressed regarding the interventions, except the comparison of PUVA with or without IFN‐α, were based on single, often underpowered studies limiting the robustness of the findings. </p> <p>In all the included studies, the risk of bias concerning random sequence generation was low or unclear. Only one study (<a href="./references#CD008946-bbs2-0015" title="Thestrup-PedersenK , GrunnetE , ZachariaeH . Transfer factor therapy in mycosis fungoides: a double-blind study. Acta Dermato-Venereologica1982;62(1):47-53. [CENTRAL: CN-00027377] [PMID: 6175137]">Thestrup‐Pedersen 1982</a>) had a high risk of selection bias for allocation concealment due to an open‐list randomisation procedure, and risk of bias was unclear for many of the other included studies. </p> <p>We considered seven studies to be at high risk of bias concerning incomplete outcome data (<a href="./references#CD008946-bbs2-0001" title="BagotM , HasanB , WhittakerS , Beylot-BarryM , KnoblerR , ShahE , et al. A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma - EORTC 21081 (NCT01098656): results and lessons learned for future trial designs. European Journal of Dermatology2017;27(3):286–94. [CENTRAL: CN-01395486] [PMID: 28468739]NCT01098656. A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-Cell lymphoma. clinicaltrials.gov/ct2/show/NCT01098656 (first received 5 April 2010). [NCT01098656]">Bagot 2017</a>; <a href="./references#CD008946-bbs2-0002" title="ChildFJ , MitchellTJ , WhittakerSJ , ScarisbrickJJ , SeedPT , Russel-JonesR . A randomized cross-over study to compare PUVA and extracorporeal photopheresis in the treatment of plaque stage (T2) mycosis fungoides. Clinical &amp; Experimental Dermatology2004;29(3):231-6. [CENTRAL: CN-00468455] [PMID: 15115499]ChildFJ , MitchellTJ , WhittakerSJ , WatkinsP , SeedP , Russell-JonesR . A randomised cross-over study to compare Puva and extracorporeal photopheresis (ECP) in the treatment of plaque stage (T2) mycosis fungoides. British Journal of Dermatology2001;145(Suppl 59):16. [CENTRAL: CN-00430854] ">Child 2004</a>; <a href="./references#CD008946-bbs2-0004" title="DuvicM , MartinAG , KimY , OlsenE , WoodGS , CrowleyCA , et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Archives of Dermatology2001;137(5):581-93. [CENTRAL: CN-00347816] [PMID: 11346336]PrinceHM , McCormackC , RyanG , BakerC , RotsteinH , DavisonJ , et al. Bexarotene capsules and gel for previously treated patients with cutaneous T-cell lymphoma: results of the Australian patients treated on phase II trials. Australasian Journal of Dermatology2001;42(2):91-7. [CENTRAL: CN-00442169] [PMID: 11309029]">Duvic 2001</a>; <a href="./references#CD008946-bbs2-0005" title="DuvicM , OlsenEA , OmuraGA , MaizeJC , VonderheidEC , et al. A phase III, randomized, double-blind, placebo-controlled study of peldesine (BCX-34) cream as topical therapy for cutaneous T-cell lymphoma. Journal of the American Academy of Dermatology2001;44(6):940-7. [CENTRAL: CN-00348073] [PMID: 11369904]">Duvic 2001a</a>; <a href="./references#CD008946-bbs2-0010" title="DuvicM , KuzelTM , OlsenEA , MartinAG , FossFM , KimYH , et al. Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK). Clinical Lymphoma2002;2(4):222-8. [CENTRAL: CN-00514479] [PMID: 11970761]KuzelT , OlsenE , MartinA , KimY , DuvicM , FrankelA , et al. Pivotal phase III trial of two dose levels of DAB389IL-2 (Ontak®) for the treatment of mycosis fungoides (MF). Blood1997;90(10 Suppl 1 (Pt 1)):586a. [CENTRAL: CN-00518069] NTC00050999. Study of ONTAK (Denileukin Diftitox) in cutaneous T-Cell lymphoma (CTCL) patients. clinicaltrials.gov/ct2/show/NCT00050999 (first received 3 January 2003). OlsenE , DuvicM , FrankelA , KimY , MartinA , VonderheidE , et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. Journal of Clinical Oncology2001;19(2):376-88. [CENTRAL: CN-00328506] [PMID: 11208829]OlsenE , DuvicM , MartinA . Pivotal phase III trial of two dose levels of DAB 389 IL-2 (ONTAK) for the treatment of cutaneous T-cell lymphoma (CTCL). Journal of Investigative Dermatology1998;110(4):678. [CENTRAL: CN-00353452] ">Olsen 2001</a>; <a href="./references#CD008946-bbs2-0013" title="OtteHG , KuhlS , StadlerR , LugerT , HenzB , SterryW . Treatment of cutaneous T-cell lymphoma with Interferon alpha and PUVA versus Interferon alpha and Acitretin - results of a prospective randomised multi-centre study [Behandlung des kutanen T-Zell-Lymphoms mit Interferon alpha und PUVA versus Interferon alpha und Acirentin - Ergebnisse einer prospektiv-randomisierten Multicenter-Studie]. Der Hautarzt1997;48(Suppl):S97. [CENTRAL: CN-00495120] OtteHG , StadierR , LugerT , HenzB , SterryW . Open controlled clinical trial on the use of interferon plus acitretin versus interferon plus PUVA in patients with cutaneous T-cell lymphoma (CTCL). Annals of Oncology1996;7(Suppl 3):66. [CENTRAL: CN-00308243] StadlerR , OtteHG , LugerT , HenzBM , KuhlP , ZwingersT , et al. Prospective randomized multicenter clinical trial on the use of interferon -2a plus acitretin versus interferon -2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood1998;92(10):3578-81. [CENTRAL: CN-00156682] [PMID: 9808550]">Stadler 1998</a>; <a href="./references#CD008946-bbs2-0014" title="BohmeyerJ , OtteHG , StadlerR , LugerT , SterryW . Therapy of cutaneous T-cell lymphoma with PUVA versus interferon alfa plus PUVA: first results. Journal of the European Academy of Dermatology &amp; Venereology1999;12(Suppl 2):S268. [CENTRAL: CN-00478472] BohmeyerJ , StadlerR , LugerT , SterryW . Prospective randomized multicentre therapy optimizing protocol for therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α + PUVA [Prospectiv randomisiertes, multizentrisches Therapieoptimierungsprotokoll zur Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α + PUVA]. Zeitschrift für Hautkrankheiten2001;76(Suppl 1):S55. [CENTRAL: CN-01446038] KremerA , BohmeyerJ , StadlerR , LugerT , SterryW . Prospective randomized multicentre therapy optimizing protocol for therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α + PUVA [Prospectiv randomisiertes, multizentrisches Therapieoptimierungsprotokoll zur Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α + PUVA]. Journal der Deutschen Dermatologischen Gesellschaft2003;1(Suppl 1):S99. [CENTRAL: CN-01446037] OtteHG , StadlerR , LugerT , SterryW . Therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α plus PUVA: first results of a prospective randomized multicentre therapy optimizing protocol [Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α plus PUVA: Erste Ergebnisse des prospektiven randomisierten multizentrischen Therapieoptimierungsprotokolls]. Der Hautarzt1999;50(Suppl 1):S2. [CENTRAL: CN-01457423] OtteHG , StadlerR . Combination therapy of cutaneous t-cell-lymphoma with interferon alfa 2a and PUVA [Kombinationstherapie kutaner T-Zell-Lymphome mit Interferon Alfa 2a und PUVA]. Zentralblatt Haut- und Geschlechtskrankheiten1993;162(Suppl):P2.03.08. [CENTRAL: CN-01457422] StadlerM , KremerA , LugerT , SterryW . Prospective, randomized, multicentre clinical trial on the use of interferon a 2a plus PUVA versus PUVA monotherapy in patients with cutaneous T-cell lymphoma, stages I and II [Abstract 7541]. ASCO annual meeting proceedings. Journal of Clinical Oncology2006;24(18S Pt 1):432. [CENTRAL: CN-00625001] ">Stadler 2006</a>). A common reason for assigning a high risk were high dropout rates. Other studies with small sample sizes did not report dropouts at all, so we had to assume dropout rates were zero, which may be untrue. </p> <p>We rated the evidence of the studies displayed in the 'Summary of findings' tables as low certainty due to low internal validity and imprecision. This was based on a high risk of bias and a low event rate. We downgraded the results in <a href="./full#CD008946-tbl-0002">summary of findings Table 2</a> further to very low certainty due to very low sample size. </p> </section> <section id="CD008946-sec-0203"> <h3 class="title" id="CD008946-sec-0203">Potential biases in the review process</h3> <p>We consider our search strategy to be comprehensive and sensitive enough to identify relevant trials regarding our efficacy outcomes as we did not apply any language restrictions. Despite not applying any language restrictions, synonyms for mycosis fungoides in other languages can differ, which can lead to the omission of potential relevant trials published in other languages. Allthough we followed <i>Cochrane Handbook for Systematic Reviews of Interventions</i>, potential biases in the review may have occurred. The fact that two studies have not yet been incorporated may be a source of potential bias. In order to confirm inclusion criteria for studies retrieved by our search strategy, when necessary, we asked the corresponding authors how many of their included participants actually had MF of the Alibert‐Bazin type. Some authors answered that all participants included in their publications had this type of MF, although they defined cutaneous T‐cell lymphomas (CTCL) as inclusion criteria. Furthermore, missing efficacy data may be a possible source for bias as we were not able to obtain all relevant data of the included studies (e.g. improvement in quality of life in <a href="./references#CD008946-bbs2-0011" title="HorwitzS , WhittakerS , DuvicM , DummerR , KimYH , ScarisbrickJ , et al. Response by stage in CD30-positive (CD30+) cutaneous T cell lymphoma (CTCL) patients receiving brentuximab vedotin (BV) vs physician's choice (PC) in the phase 3 ALCANZA study. In: Hematological oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:245–7. [CENTRAL: CN-01408605] [DOI: 10.1002/hon.2438]HorwitzSM , AkilovOE , FisherD , KuzelTM , WangY , Palanca-WesselsMC , et al. Brentuximab vedotin or physician’s choice in CD30-positivecutaneous T-cell lymphoma (ALCANZA): an international,open-label, randomised, phase 3, multicentre trial. Lancet2017;390(10094):555-66. [CENTRAL: CN-01403731] HorwitzSM , ScarisbrickJJ , DummerR , DuvicM , KimYH , WalewskiJ , et al. Updated analyses of the international, open-label, randomized, phase 3 alcanza study: longer-term evidence for superiority of brentuximab vedotin versus methotrexate or bexarotene for CD30-positive cutaneous T-cell lymphoma (CTCL). In: Blood. Conference: 59th annual meeting of the american society of hematology, ASH 2017. United states. Vol. 130. 2017. [CENTRAL: CN-01450312] KimYH , PrinceHM , WhittakerS , HorwitzSM , DuvicM , ScarisbrickJ , et al. Brentuximab vedotin vs physician's choice in CTCL patients from the phase 3 ALCANZA study: analysis of outcomes by CD30 expression. In: Hematological Oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:77–8. [CENTRAL: CN-01408482] [DOI: 10.1002/hon.2437]KimYH , PrinceHM , WhittakerS , HorwitzSM , DuvicM , ScarisbrickJ , et al. Outcomes by CD30 expression in patients with CTCL receiving brentuximab vedotin (BV) vs physician's choice (PC) in the Phase 3 ALCANZA study. Journal of Clinical Oncology2017;35(15 Supplement 1):7517. [EMBASE: 617388795]KimYH , WhittakerS , DummerR , GeskinLJ , GauthierP , LittleM , et al. Phase 3 study of brentuximab vedotin versus physician's choice of methotrexate or bexarotene in patients (PTS) with CD30-positive (CD30+) cutaneous T-cell lymphoma (CTCL). The alcanza study. Hematological Oncology2013;31(Suppl 1):278. [CENTRAL: CN-01531598] [EMBASE: 71147875]KimYH , WhittakerS , HorwitzSM , DuvicM , DummerR , ScarisbrickJ , et al. Brentuximab vedotin demonstrates superior activity to standard therapy in CD30-expressing (CD30+) cutaneous T-cell lymphoma (CTCL) in the randomized phase 3 ALCANZA study. Journal of Investigative Dermatology2017;137(5 Suppl 1):S45. [CENTRAL: CN-01375469] [EMBASE: 616393777]KimYH , WhittakerS , HorwitzSM , DuvicM , DummerR , ScarisbrickJJ , et al. Brentuximab vedotin demonstrates significantly superior clinical outcomes in patients with CD30-expressing cutaneous T cell lymphoma versus physician's choice (Methotrexate or Bexarotene): the phase 3 alcanza study. In: Blood. Conference: 58th annual meeting of the american society of hematology, ASH 2016. United states. Conference start: 20161203. Conference end: 20161206. Vol. 128. 2016. [CENTRAL: CN-01303081] [EMBASE: 614225065]NCT01578499. A randomised, open-label, phase 3 trial of brentuximab vedotin (SGN-35) versus physician's choice (methotrexate or bexarotene) in patients with CD30-positive cutaneous T-cell lymphoma. clinicaltrials.gov/ct2/show/NCT01578499 (first received 17 April 2012). PrinceHM , DummerR , WhittakerS , HorwitzS , DuvicM , ScarisbrickJ , et al. Patient-reported outcomes and quality of life in patients with cutaneous T cell lymphoma: results from the phase 3 ALCANZA study. In: Hematological Oncology. Conference: 14th international conference on malignant lymphoma palazzo dei congressi. Switzerland. Vol. 35. 2017:247–8. [CENTRAL: CN-01408603] [DOI: 10.1002/hon.2438]ZagadailovE , PrinceHM , WhittakerS , HorwitzS , DuvicM , KimY , et al. Phase 3 alcanza study of brentuximab vedotin (BV) or physician's choice (PC) of methotrexate (MTX) or bexarotene (BEX) in CD30-positive cutaneous T-cell lymphoma (CTCL): number needed to treat analysis. In: Haematologica. Conference: 22th congress of the european hematology association. Spain. Vol. 102. 2017:251. [CENTRAL: CN-01399195] ">Prince 2017</a>) by contacting the authors. In order to detect all dropouts, even those occurring during the study, we contacted the authors for further information. In case of no reply within four weeks of contact, we assumed there were no dropouts during the study, which probably does not reflect the truth. Data from cross‐over and within‐participant trials were presented without adjustments. A limitation of this approach is the possibility of a carry‐over effect and the proneness to over‐ or underestimation of the precision of results. </p> </section> <section id="CD008946-sec-0204"> <h3 class="title" id="CD008946-sec-0204">Agreements and disagreements with other studies or reviews</h3> <p>The evidence‐based Joint British Association of Dermatologists and UK Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T‐cell lymphomas of 2018 (<a href="./references#CD008946-bbs2-0118" title="GilsonD , WhittakerSJ , ChildFJ , ScarisbrickJJ , IllidgeTM , ParryEJ , et al. British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018. British Journal of Dermatology2019;180(3):496-526. [PMID: 30561020]">Gilson 2019</a>) concluded that skin‐directed treatments represent a fundamental treatment option for all stages of MF. Skin‐directed therapies including phototherapy, local radiotherapy as well as topical treatments with steroids, carmustine, mechlorethamine or bexarotene are recommended in the early stages of disease (IA‐IIA). The use of PUVA is recommended by <a href="./references#CD008946-bbs2-0118" title="GilsonD , WhittakerSJ , ChildFJ , ScarisbrickJJ , IllidgeTM , ParryEJ , et al. British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018. British Journal of Dermatology2019;180(3):496-526. [PMID: 30561020]">Gilson 2019</a> for early‐stage disease to obtain complete remission, but not for maintenance therapy, although it is unclear whether disease‐specific survival is affected. The authors state that Total Skin Electron Beam (TSEB) causes short‐term complete response (up to 50 months) and should be reserved for those people for whom topical treatments and phototherapy have failed (stage IB) or as a first‐line treatment in patients with extensive cutaneous disease (stage T2b). The use of IFN‐α is not recommended for early stages as there is no evidence that IFN‐α positively influences long‐term outcome. The combination of IFN‐α and PUVA is considered superior to the combination of IFN‐α and acitretin based on <a href="./references#CD008946-bbs2-0013" title="OtteHG , KuhlS , StadlerR , LugerT , HenzB , SterryW . Treatment of cutaneous T-cell lymphoma with Interferon alpha and PUVA versus Interferon alpha and Acitretin - results of a prospective randomised multi-centre study [Behandlung des kutanen T-Zell-Lymphoms mit Interferon alpha und PUVA versus Interferon alpha und Acirentin - Ergebnisse einer prospektiv-randomisierten Multicenter-Studie]. Der Hautarzt1997;48(Suppl):S97. [CENTRAL: CN-00495120] OtteHG , StadierR , LugerT , HenzB , SterryW . Open controlled clinical trial on the use of interferon plus acitretin versus interferon plus PUVA in patients with cutaneous T-cell lymphoma (CTCL). Annals of Oncology1996;7(Suppl 3):66. [CENTRAL: CN-00308243] StadlerR , OtteHG , LugerT , HenzBM , KuhlP , ZwingersT , et al. Prospective randomized multicenter clinical trial on the use of interferon -2a plus acitretin versus interferon -2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood1998;92(10):3578-81. [CENTRAL: CN-00156682] [PMID: 9808550]">Stadler 1998</a> for therapy‐resistant early stages or those people with thick plaques. Chemotherapies are recommended for advanced stages of the disease. </p> <p>Concordant with <a href="./references#CD008946-bbs2-0118" title="GilsonD , WhittakerSJ , ChildFJ , ScarisbrickJJ , IllidgeTM , ParryEJ , et al. British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018. British Journal of Dermatology2019;180(3):496-526. [PMID: 30561020]">Gilson 2019</a>, we were not able to identify any curative intervention for MF even for participants with early‐stage disease. According to <a href="./references#CD008946-bbs2-0118" title="GilsonD , WhittakerSJ , ChildFJ , ScarisbrickJJ , IllidgeTM , ParryEJ , et al. British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018. British Journal of Dermatology2019;180(3):496-526. [PMID: 30561020]">Gilson 2019</a>, PUVA in combination with additional IFN‐α may be beneficial. However, our meta‐analysis of the data of <a href="./references#CD008946-bbs2-0014" title="BohmeyerJ , OtteHG , StadlerR , LugerT , SterryW . Therapy of cutaneous T-cell lymphoma with PUVA versus interferon alfa plus PUVA: first results. Journal of the European Academy of Dermatology &amp; Venereology1999;12(Suppl 2):S268. [CENTRAL: CN-00478472] BohmeyerJ , StadlerR , LugerT , SterryW . Prospective randomized multicentre therapy optimizing protocol for therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α + PUVA [Prospectiv randomisiertes, multizentrisches Therapieoptimierungsprotokoll zur Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α + PUVA]. Zeitschrift für Hautkrankheiten2001;76(Suppl 1):S55. [CENTRAL: CN-01446038] KremerA , BohmeyerJ , StadlerR , LugerT , SterryW . Prospective randomized multicentre therapy optimizing protocol for therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α + PUVA [Prospectiv randomisiertes, multizentrisches Therapieoptimierungsprotokoll zur Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α + PUVA]. Journal der Deutschen Dermatologischen Gesellschaft2003;1(Suppl 1):S99. [CENTRAL: CN-01446037] OtteHG , StadlerR , LugerT , SterryW . Therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α plus PUVA: first results of a prospective randomized multicentre therapy optimizing protocol [Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α plus PUVA: Erste Ergebnisse des prospektiven randomisierten multizentrischen Therapieoptimierungsprotokolls]. Der Hautarzt1999;50(Suppl 1):S2. [CENTRAL: CN-01457423] OtteHG , StadlerR . Combination therapy of cutaneous t-cell-lymphoma with interferon alfa 2a and PUVA [Kombinationstherapie kutaner T-Zell-Lymphome mit Interferon Alfa 2a und PUVA]. Zentralblatt Haut- und Geschlechtskrankheiten1993;162(Suppl):P2.03.08. [CENTRAL: CN-01457422] StadlerM , KremerA , LugerT , SterryW . Prospective, randomized, multicentre clinical trial on the use of interferon a 2a plus PUVA versus PUVA monotherapy in patients with cutaneous T-cell lymphoma, stages I and II [Abstract 7541]. ASCO annual meeting proceedings. Journal of Clinical Oncology2006;24(18S Pt 1):432. [CENTRAL: CN-00625001] ">Stadler 2006</a> and <a href="./references#CD008946-bbs2-0020" title="WozniakMB , TraceyL , Ortiz-RomeroPL , MontesS , AlvarezM , FragaJ , et al. Psoralen plus ultraviolet A +/- interferon-alpha treatment resistance in mycosis fungoides: the role of tumour microenvironment, nuclear transcription factor-kappaB and T-cell receptor pathways. British Journal of Dermatology2008;160(1):92-102. [CENTRAL: CN-00668828] [PMID: 18945306]">Wozniak 2008</a> did not support a high grade of evidence. </p> <p>The EORTC Cutaneous Lymphoma Task Force consensus workshop summarised recommendations for the treatment of mycosis fungoides/Sézary syndrome based on the best practice of each national group that was involved (<a href="./references#CD008946-bbs2-0173" title="TrautingerF , EderJ , AssafC , BagotM , CozzioA , DummerR , et al. European organisation for research and treatment of cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017. European Journal of Cancer2017;77:57-74. [DOI: 10.1016/j.ejca.2017.02.027] [PMID: 28365528]">Trautinger 2017</a>). Recommendations for treatment of each stage of MF were given. </p> <p> <ul id="CD008946-list-0031"> <li> <p>Based on limited evidence, recommendations for first‐line treatment of early stage disease (IA, IB, and IIA) include expectant policy and skin‐directed therapies like PUVA, UVB, topical corticosteroids, localised radiotherapy, or mechlorethamine. </p> </li> <li> <p>Second‐line treatments for these stages include systemic therapies like retinoids, IFN‐α, TSEB and low dose methotrexate (MTX). </p> </li> <li> <p>Recommendations for first‐line treatment of stage IIB patients include systemic therapies such as retinoids and IFN‐α, TSEB, monochemotherapy (gemcitabine, pegylated liposomal doxorubicin), low‐dose MTX or localised radiotherapy. </p> </li> <li> <p>Second‐line treatments for stage IIB include polychemotherapy (CHOP is the most widely used regimen<b>:</b> it is a specific regimen of chemotherapy, including the drugs cyclophosphamide, doxorubicin hydrochloride (hydroxydaunorubicin), vincristine sulphate and prednisone) and allogeneic stem cell transplantation. </p> </li> <li> <p>Treatment recommendations for stage III disease include systemic therapies (retinoids, IFN‐α), ECP, low‐dose MTX and TSEB. </p> </li> <li> <p>Second‐line treatments for stage III include monochemotherapy (gemcitabine, pegylated liposomal doxorubicin) and allogeneic stem cell transplantation. </p> </li> <li> <p><a href="./references#CD008946-bbs2-0173" title="TrautingerF , EderJ , AssafC , BagotM , CozzioA , DummerR , et al. European organisation for research and treatment of cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017. European Journal of Cancer2017;77:57-74. [DOI: 10.1016/j.ejca.2017.02.027] [PMID: 28365528]">Trautinger 2017</a> state that stage IV patients should be treated with chemotherapy (gemcitabine, pegylated liposomal doxorubicin, CHOP and CHOP‐like polychemotherapy), radiotherapy (TSEB and localised), alemtuzumab or allogeneic stem cell transplantation. </p> </li> </ul> </p> <p>Since these guidelines are determined with all levels of evidence, we cannot comment on most of the recommendations made as we identified only a comparatively small number of RCTs. As noted in the previously‐mentioned guidelines, we agree with the authors that focus should be on quality of life‐targeted skin‐directed therapy for the early stages of disease to avoid the severe adverse effects caused by systemic treatments. </p> <p>The ESMO clinical recommendations for diagnosis, treatment, and follow‐up of MF (<a href="./references#CD008946-bbs2-0110" title="DummerR , DreylingM . Primary cutaneous lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Annals of Oncology2008;19(Suppl 2):ii72-6. [PMID: 18456777]">Dummer 2008</a>) also suggest a wait‐and‐see policy or a skin‐directed therapeutic approach for early‐stage disease, followed by PUVA and IFN‐α or extracorporeal photopheresis for stages II to IV as first‐line treatments. TSEB, oral bexarotene, denileukin diftitox and chemotherapy are suggested as second‐line therapy according to the stage of the disease. </p> <p>For the treatment of MF by stem cell transplantation, this review could not identify a single RCT. This is in accordance with the findings of two other reviews addressing this issue by <a href="./references#CD008946-bbs2-0186" title="WuPA , KimYH , LavoriPW , HoppeRT , Stockerl-GoldsteinKE . A meta-analysis of patients receiving allogeneic or autologous hematopoietic stem cell transplant in mycosis fungoides and Sezary syndrome. Biology of Blood &amp; Marrow Transplantation2009;15(8):982-90.">Wu 2009</a> for mycosis fungoides and Sézary syndrome and more thoroughly investigated by <a href="./references#CD008946-bbs2-0164" title="SchlaakM , PickenhainJ , TheurichS , SkoetzN , vonBergwelt-BaildonM , KurschatP . Allogeneic stem cell transplantation versus conventional therapy for advanced primary cutaneous T-cell lymphoma. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD008908.pub3]">Schlaak 2013</a> for cutaneous T‐cell lymphoma. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD008946-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/urn:x-wiley:14651858:media:CD008946:CD008946-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Skin changes in mycosis fungoides. Left: Patch; Middle: Plaque; Right: TumourCopyright © 2018. Department of Dermatology, University Hospital Frankfurt am Main: reproduced with permission." data-id="CD008946-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-FIG-01.jpg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_t/tCD008946-FIG-01.jpg" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Skin changes in mycosis fungoides. Left: Patch; Middle: Plaque; Right: Tumour</p> <p>Copyright © 2018. Department of Dermatology, University Hospital Frankfurt am Main: reproduced with permission. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/full#CD008946-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-FIG-01.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008946-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/urn:x-wiley:14651858:media:CD008946:CD008946-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD008946-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-FIG-02.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_t/tCD008946-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/full#CD008946-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-FIG-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008946-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/urn:x-wiley:14651858:media:CD008946:CD008946-FIG-03" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD008946-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_t/tCD008946-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/full#CD008946-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008946-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/urn:x-wiley:14651858:media:CD008946:CD008946-FIG-04" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study." data-id="CD008946-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_t/tCD008946-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/full#CD008946-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008946-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/urn:x-wiley:14651858:media:CD008946:CD008946-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 6 IFN‐α + PUVA versus PUVA alone, outcome: 6.1 Complete response." data-id="CD008946-fig-0005" src="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-FIG-05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_t/tCD008946-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 6 IFN‐α + PUVA versus PUVA alone, outcome: 6.1 Complete response. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/full#CD008946-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-FIG-05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008946-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/urn:x-wiley:14651858:media:CD008946:CD008946-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Topical peldesine versus placebo, Outcome 1: Common adverse effects" data-id="CD008946-fig-0006" src="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_t/tCD008946-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Topical peldesine versus placebo, Outcome 1: Common adverse effects</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/references#CD008946-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008946-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/urn:x-wiley:14651858:media:CD008946:CD008946-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Topical peldesine versus placebo, Outcome 2: Complete response" data-id="CD008946-fig-0007" src="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_t/tCD008946-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Topical peldesine versus placebo, Outcome 2: Complete response</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/references#CD008946-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008946-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/urn:x-wiley:14651858:media:CD008946:CD008946-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Topical peldesine versus placebo, Outcome 3: Objective response rate" data-id="CD008946-fig-0008" src="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_t/tCD008946-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Topical peldesine versus placebo, Outcome 3: Objective response rate</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/references#CD008946-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008946-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/urn:x-wiley:14651858:media:CD008946:CD008946-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Topical hypericin versus placebo, Outcome 1: Objective response rate" data-id="CD008946-fig-0009" src="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_t/tCD008946-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Topical hypericin versus placebo, Outcome 1: Objective response rate</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/references#CD008946-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008946-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/urn:x-wiley:14651858:media:CD008946:CD008946-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: IFN‐α versus placebo, Outcome 1: Common adverse effects" data-id="CD008946-fig-0010" src="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_t/tCD008946-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: IFN‐α versus placebo, Outcome 1: Common adverse effects</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/references#CD008946-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008946-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/urn:x-wiley:14651858:media:CD008946:CD008946-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: IFN‐α versus placebo, Outcome 2: Complete response" data-id="CD008946-fig-0011" src="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_t/tCD008946-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: IFN‐α versus placebo, Outcome 2: Complete response</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/references#CD008946-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008946-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/urn:x-wiley:14651858:media:CD008946:CD008946-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Mechlorethamine gel vs mechlorethamine ointment, Outcome 1: Common adverse event" data-id="CD008946-fig-0012" src="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_t/tCD008946-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Mechlorethamine gel vs mechlorethamine ointment, Outcome 1: Common adverse event </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/references#CD008946-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008946-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/urn:x-wiley:14651858:media:CD008946:CD008946-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Mechlorethamine gel vs mechlorethamine ointment, Outcome 2: Complete response" data-id="CD008946-fig-0013" src="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_t/tCD008946-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Mechlorethamine gel vs mechlorethamine ointment, Outcome 2: Complete response </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/references#CD008946-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008946-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/urn:x-wiley:14651858:media:CD008946:CD008946-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Mechlorethamine gel vs mechlorethamine ointment, Outcome 3: Objective response rate" data-id="CD008946-fig-0014" src="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_t/tCD008946-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: Mechlorethamine gel vs mechlorethamine ointment, Outcome 3: Objective response rate </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/references#CD008946-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008946-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/urn:x-wiley:14651858:media:CD008946:CD008946-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: IFN‐α + PUVA versus PUVA alone, Outcome 1: Complete response" data-id="CD008946-fig-0015" src="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_t/tCD008946-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: IFN‐α + PUVA versus PUVA alone, Outcome 1: Complete response</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/references#CD008946-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008946-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/urn:x-wiley:14651858:media:CD008946:CD008946-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Denileukin diftitox high versus low dose, Outcome 1: Common adverse effects" data-id="CD008946-fig-0016" src="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_t/tCD008946-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: Denileukin diftitox high versus low dose, Outcome 1: Common adverse effects </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/references#CD008946-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008946-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/urn:x-wiley:14651858:media:CD008946:CD008946-CMP-006.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Denileukin diftitox high versus low dose, Outcome 2: Complete response" data-id="CD008946-fig-0017" src="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-CMP-006.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_t/tCD008946-CMP-006.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6: Denileukin diftitox high versus low dose, Outcome 2: Complete response</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/references#CD008946-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-CMP-006.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008946-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/urn:x-wiley:14651858:media:CD008946:CD008946-CMP-006.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Denileukin diftitox high versus low dose, Outcome 3: Objective response rate" data-id="CD008946-fig-0018" src="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-CMP-006.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_t/tCD008946-CMP-006.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6: Denileukin diftitox high versus low dose, Outcome 3: Objective response rate </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/references#CD008946-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-CMP-006.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008946-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/urn:x-wiley:14651858:media:CD008946:CD008946-CMP-007.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Bexarotene high versus low dose, Outcome 1: Common adverse effects" data-id="CD008946-fig-0019" src="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-CMP-007.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_t/tCD008946-CMP-007.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7: Bexarotene high versus low dose, Outcome 1: Common adverse effects</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/references#CD008946-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-CMP-007.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008946-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/urn:x-wiley:14651858:media:CD008946:CD008946-CMP-007.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Bexarotene high versus low dose, Outcome 2: Complete response" data-id="CD008946-fig-0020" src="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-CMP-007.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_t/tCD008946-CMP-007.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7: Bexarotene high versus low dose, Outcome 2: Complete response</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/references#CD008946-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-CMP-007.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008946-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/urn:x-wiley:14651858:media:CD008946:CD008946-CMP-007.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Bexarotene high versus low dose, Outcome 3: Relapse" data-id="CD008946-fig-0021" src="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-CMP-007.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_t/tCD008946-CMP-007.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7: Bexarotene high versus low dose, Outcome 3: Relapse</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/references#CD008946-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-CMP-007.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008946-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/urn:x-wiley:14651858:media:CD008946:CD008946-CMP-007.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Bexarotene high versus low dose, Outcome 4: Objective response rate" data-id="CD008946-fig-0022" src="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-CMP-007.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_t/tCD008946-CMP-007.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.4</div> <div class="figure-caption"> <p>Comparison 7: Bexarotene high versus low dose, Outcome 4: Objective response rate</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/references#CD008946-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-CMP-007.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008946-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/urn:x-wiley:14651858:media:CD008946:CD008946-CMP-008.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Bexarotene + PUVA vs PUVA alone, Outcome 1: Common adverse events" data-id="CD008946-fig-0023" src="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-CMP-008.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_t/tCD008946-CMP-008.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8: Bexarotene + PUVA vs PUVA alone, Outcome 1: Common adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/references#CD008946-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-CMP-008.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008946-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/urn:x-wiley:14651858:media:CD008946:CD008946-CMP-008.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Bexarotene + PUVA vs PUVA alone, Outcome 2: Complete response" data-id="CD008946-fig-0024" src="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-CMP-008.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_t/tCD008946-CMP-008.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8: Bexarotene + PUVA vs PUVA alone, Outcome 2: Complete response</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/references#CD008946-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-CMP-008.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008946-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/urn:x-wiley:14651858:media:CD008946:CD008946-CMP-008.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Bexarotene + PUVA vs PUVA alone, Outcome 3: Objective response rate" data-id="CD008946-fig-0025" src="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-CMP-008.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_t/tCD008946-CMP-008.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.3</div> <div class="figure-caption"> <p>Comparison 8: Bexarotene + PUVA vs PUVA alone, Outcome 3: Objective response rate</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/references#CD008946-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-CMP-008.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008946-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/urn:x-wiley:14651858:media:CD008946:CD008946-CMP-009.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Lenalidomide maintenance versus observation after debulking therapy, Outcome 1: Common adverse effects" data-id="CD008946-fig-0026" src="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-CMP-009.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_t/tCD008946-CMP-009.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9: Lenalidomide maintenance versus observation after debulking therapy, Outcome 1: Common adverse effects </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/references#CD008946-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-CMP-009.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008946-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/urn:x-wiley:14651858:media:CD008946:CD008946-CMP-010.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Brentuximab vedotin vs. physician's choice (MTX or bexarotene), Outcome 1: Complete response" data-id="CD008946-fig-0027" src="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-CMP-010.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_t/tCD008946-CMP-010.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10: Brentuximab vedotin vs. physician's choice (MTX or bexarotene), Outcome 1: Complete response </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/references#CD008946-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-CMP-010.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008946-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/urn:x-wiley:14651858:media:CD008946:CD008946-CMP-010.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Brentuximab vedotin vs. physician's choice (MTX or bexarotene), Outcome 2: Objective response rate" data-id="CD008946-fig-0028" src="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-CMP-010.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_t/tCD008946-CMP-010.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.2</div> <div class="figure-caption"> <p>Comparison 10: Brentuximab vedotin vs. physician's choice (MTX or bexarotene), Outcome 2: Objective response rate </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/references#CD008946-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-CMP-010.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008946-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/urn:x-wiley:14651858:media:CD008946:CD008946-CMP-011.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Extracorporeal photopheresis versus PUVA, Outcome 1: Complete response" data-id="CD008946-fig-0029" src="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-CMP-011.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_t/tCD008946-CMP-011.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.1</div> <div class="figure-caption"> <p>Comparison 11: Extracorporeal photopheresis versus PUVA, Outcome 1: Complete response</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/references#CD008946-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-CMP-011.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008946-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/urn:x-wiley:14651858:media:CD008946:CD008946-CMP-011.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Extracorporeal photopheresis versus PUVA, Outcome 2: Objective response rate" data-id="CD008946-fig-0030" src="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-CMP-011.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_t/tCD008946-CMP-011.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.2</div> <div class="figure-caption"> <p>Comparison 11: Extracorporeal photopheresis versus PUVA, Outcome 2: Objective response rate </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/references#CD008946-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-CMP-011.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008946-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/urn:x-wiley:14651858:media:CD008946:CD008946-CMP-012.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Combined therapy versus conservative therapy, Outcome 1: Common adverse effects" data-id="CD008946-fig-0031" src="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-CMP-012.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_t/tCD008946-CMP-012.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.1</div> <div class="figure-caption"> <p>Comparison 12: Combined therapy versus conservative therapy, Outcome 1: Common adverse effects </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/references#CD008946-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-CMP-012.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008946-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/urn:x-wiley:14651858:media:CD008946:CD008946-CMP-012.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Combined therapy versus conservative therapy, Outcome 2: Complete response" data-id="CD008946-fig-0032" src="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-CMP-012.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_t/tCD008946-CMP-012.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.2</div> <div class="figure-caption"> <p>Comparison 12: Combined therapy versus conservative therapy, Outcome 2: Complete response</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/references#CD008946-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-CMP-012.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008946-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/urn:x-wiley:14651858:media:CD008946:CD008946-CMP-012.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Combined therapy versus conservative therapy, Outcome 3: Relapse" data-id="CD008946-fig-0033" src="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-CMP-012.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_t/tCD008946-CMP-012.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.3</div> <div class="figure-caption"> <p>Comparison 12: Combined therapy versus conservative therapy, Outcome 3: Relapse</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/references#CD008946-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-CMP-012.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008946-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/urn:x-wiley:14651858:media:CD008946:CD008946-CMP-012.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Combined therapy versus conservative therapy, Outcome 4: Overall survival" data-id="CD008946-fig-0034" src="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-CMP-012.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_t/tCD008946-CMP-012.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.4</div> <div class="figure-caption"> <p>Comparison 12: Combined therapy versus conservative therapy, Outcome 4: Overall survival</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/references#CD008946-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-CMP-012.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008946-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/urn:x-wiley:14651858:media:CD008946:CD008946-CMP-012.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Combined therapy versus conservative therapy, Outcome 5: Objective response rate" data-id="CD008946-fig-0035" src="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-CMP-012.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_t/tCD008946-CMP-012.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.5</div> <div class="figure-caption"> <p>Comparison 12: Combined therapy versus conservative therapy, Outcome 5: Objective response rate </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/references#CD008946-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-CMP-012.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008946-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/urn:x-wiley:14651858:media:CD008946:CD008946-CMP-013.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: IFN‐α + acitretin versus IFN‐α + PUVA, Outcome 1: Common adverse effects" data-id="CD008946-fig-0036" src="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-CMP-013.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_t/tCD008946-CMP-013.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.1</div> <div class="figure-caption"> <p>Comparison 13: IFN‐α + acitretin versus IFN‐α + PUVA, Outcome 1: Common adverse effects</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/references#CD008946-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-CMP-013.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008946-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/urn:x-wiley:14651858:media:CD008946:CD008946-CMP-013.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: IFN‐α + acitretin versus IFN‐α + PUVA, Outcome 2: Complete response" data-id="CD008946-fig-0037" src="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-CMP-013.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_t/tCD008946-CMP-013.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.2</div> <div class="figure-caption"> <p>Comparison 13: IFN‐α + acitretin versus IFN‐α + PUVA, Outcome 2: Complete response</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/references#CD008946-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-CMP-013.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008946-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/urn:x-wiley:14651858:media:CD008946:CD008946-CMP-014.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Topical nitrogen mustard with active transfer factor versus topical nitrogen mustard with inactivated transfer factor, Outcome 1: Complete response" data-id="CD008946-fig-0038" src="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-CMP-014.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_t/tCD008946-CMP-014.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.1</div> <div class="figure-caption"> <p>Comparison 14: Topical nitrogen mustard with active transfer factor versus topical nitrogen mustard with inactivated transfer factor, Outcome 1: Complete response </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/references#CD008946-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-CMP-014.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008946-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/urn:x-wiley:14651858:media:CD008946:CD008946-CMP-014.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Topical nitrogen mustard with active transfer factor versus topical nitrogen mustard with inactivated transfer factor, Outcome 2: Overall survival" data-id="CD008946-fig-0039" src="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-CMP-014.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_t/tCD008946-CMP-014.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.2</div> <div class="figure-caption"> <p>Comparison 14: Topical nitrogen mustard with active transfer factor versus topical nitrogen mustard with inactivated transfer factor, Outcome 2: Overall survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/references#CD008946-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-CMP-014.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008946-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/urn:x-wiley:14651858:media:CD008946:CD008946-CMP-014.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Topical nitrogen mustard with active transfer factor versus topical nitrogen mustard with inactivated transfer factor, Outcome 3: Objective response rate" data-id="CD008946-fig-0040" src="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-CMP-014.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_t/tCD008946-CMP-014.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.3</div> <div class="figure-caption"> <p>Comparison 14: Topical nitrogen mustard with active transfer factor versus topical nitrogen mustard with inactivated transfer factor, Outcome 3: Objective response rate </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/references#CD008946-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-CMP-014.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008946-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/urn:x-wiley:14651858:media:CD008946:CD008946-CMP-015.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: Mogamulizumab vs. Vorinostat, Outcome 1: Objective response rate" data-id="CD008946-fig-0041" src="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-CMP-015.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_t/tCD008946-CMP-015.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.1</div> <div class="figure-caption"> <p>Comparison 15: Mogamulizumab vs. Vorinostat, Outcome 1: Objective response rate</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/references#CD008946-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-CMP-015.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008946-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/urn:x-wiley:14651858:media:CD008946:CD008946-CMP-016.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 16: PUVA maintenance vs. no maintenance, Outcome 1: Disease‐free survival" data-id="CD008946-fig-0042" src="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-CMP-016.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_t/tCD008946-CMP-016.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.1</div> <div class="figure-caption"> <p>Comparison 16: PUVA maintenance vs. no maintenance, Outcome 1: Disease‐free survival</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/references#CD008946-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/media/CDSR/CD008946/image_n/nCD008946-CMP-016.01.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD008946-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">IFN‐α + PUVA compared to PUVA alone for mycosis fungoides</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>IFN‐α + PUVA compared to PUVA alone for mycosis fungoides</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with mycosis fungoides<br/><b>Setting:</b> tertiary care setting<br/><b>Intervention:</b> IFN‐α + PUVA<br/><b>Comparison:</b> PUVA alone </p> <p><b>Number of trials included:</b> 2 (<a href="./references#CD008946-bbs2-0014" title="BohmeyerJ , OtteHG , StadlerR , LugerT , SterryW . Therapy of cutaneous T-cell lymphoma with PUVA versus interferon alfa plus PUVA: first results. Journal of the European Academy of Dermatology &amp; Venereology1999;12(Suppl 2):S268. [CENTRAL: CN-00478472] BohmeyerJ , StadlerR , LugerT , SterryW . Prospective randomized multicentre therapy optimizing protocol for therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α + PUVA [Prospectiv randomisiertes, multizentrisches Therapieoptimierungsprotokoll zur Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α + PUVA]. Zeitschrift für Hautkrankheiten2001;76(Suppl 1):S55. [CENTRAL: CN-01446038] KremerA , BohmeyerJ , StadlerR , LugerT , SterryW . Prospective randomized multicentre therapy optimizing protocol for therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α + PUVA [Prospectiv randomisiertes, multizentrisches Therapieoptimierungsprotokoll zur Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α + PUVA]. Journal der Deutschen Dermatologischen Gesellschaft2003;1(Suppl 1):S99. [CENTRAL: CN-01446037] OtteHG , StadlerR , LugerT , SterryW . Therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α plus PUVA: first results of a prospective randomized multicentre therapy optimizing protocol [Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α plus PUVA: Erste Ergebnisse des prospektiven randomisierten multizentrischen Therapieoptimierungsprotokolls]. Der Hautarzt1999;50(Suppl 1):S2. [CENTRAL: CN-01457423] OtteHG , StadlerR . Combination therapy of cutaneous t-cell-lymphoma with interferon alfa 2a and PUVA [Kombinationstherapie kutaner T-Zell-Lymphome mit Interferon Alfa 2a und PUVA]. Zentralblatt Haut- und Geschlechtskrankheiten1993;162(Suppl):P2.03.08. [CENTRAL: CN-01457422] StadlerM , KremerA , LugerT , SterryW . Prospective, randomized, multicentre clinical trial on the use of interferon a 2a plus PUVA versus PUVA monotherapy in patients with cutaneous T-cell lymphoma, stages I and II [Abstract 7541]. ASCO annual meeting proceedings. Journal of Clinical Oncology2006;24(18S Pt 1):432. [CENTRAL: CN-00625001] ">Stadler 2006</a>; <a href="./references#CD008946-bbs2-0020" title="WozniakMB , TraceyL , Ortiz-RomeroPL , MontesS , AlvarezM , FragaJ , et al. Psoralen plus ultraviolet A +/- interferon-alpha treatment resistance in mycosis fungoides: the role of tumour microenvironment, nuclear transcription factor-kappaB and T-cell receptor pathways. British Journal of Dermatology2008;160(1):92-102. [CENTRAL: CN-00668828] [PMID: 18945306]">Wozniak 2008</a>) </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with PUVA alone</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with IFN‐α + PUVA</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement of quality of life</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Common adverse effects</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Complete response (CR)<br/>assessed with: outcome assessment not described </p> <p>Time point of measurement</p> <p><a href="./references#CD008946-bbs2-0014" title="BohmeyerJ , OtteHG , StadlerR , LugerT , SterryW . Therapy of cutaneous T-cell lymphoma with PUVA versus interferon alfa plus PUVA: first results. Journal of the European Academy of Dermatology &amp; Venereology1999;12(Suppl 2):S268. [CENTRAL: CN-00478472] BohmeyerJ , StadlerR , LugerT , SterryW . Prospective randomized multicentre therapy optimizing protocol for therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α + PUVA [Prospectiv randomisiertes, multizentrisches Therapieoptimierungsprotokoll zur Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α + PUVA]. Zeitschrift für Hautkrankheiten2001;76(Suppl 1):S55. [CENTRAL: CN-01446038] KremerA , BohmeyerJ , StadlerR , LugerT , SterryW . Prospective randomized multicentre therapy optimizing protocol for therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α + PUVA [Prospectiv randomisiertes, multizentrisches Therapieoptimierungsprotokoll zur Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α + PUVA]. Journal der Deutschen Dermatologischen Gesellschaft2003;1(Suppl 1):S99. [CENTRAL: CN-01446037] OtteHG , StadlerR , LugerT , SterryW . Therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α plus PUVA: first results of a prospective randomized multicentre therapy optimizing protocol [Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α plus PUVA: Erste Ergebnisse des prospektiven randomisierten multizentrischen Therapieoptimierungsprotokolls]. Der Hautarzt1999;50(Suppl 1):S2. [CENTRAL: CN-01457423] OtteHG , StadlerR . Combination therapy of cutaneous t-cell-lymphoma with interferon alfa 2a and PUVA [Kombinationstherapie kutaner T-Zell-Lymphome mit Interferon Alfa 2a und PUVA]. Zentralblatt Haut- und Geschlechtskrankheiten1993;162(Suppl):P2.03.08. [CENTRAL: CN-01457422] StadlerM , KremerA , LugerT , SterryW . Prospective, randomized, multicentre clinical trial on the use of interferon a 2a plus PUVA versus PUVA monotherapy in patients with cutaneous T-cell lymphoma, stages I and II [Abstract 7541]. ASCO annual meeting proceedings. Journal of Clinical Oncology2006;24(18S Pt 1):432. [CENTRAL: CN-00625001] ">Stadler 2006</a>: up to week 52 </p> <p><a href="./references#CD008946-bbs2-0020" title="WozniakMB , TraceyL , Ortiz-RomeroPL , MontesS , AlvarezM , FragaJ , et al. Psoralen plus ultraviolet A +/- interferon-alpha treatment resistance in mycosis fungoides: the role of tumour microenvironment, nuclear transcription factor-kappaB and T-cell receptor pathways. British Journal of Dermatology2008;160(1):92-102. [CENTRAL: CN-00668828] [PMID: 18945306]">Wozniak 2008</a>: up to week 24 </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.07<br/>(0.87 to 1.31) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>122<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low <sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>731 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>783 per 1000<br/>(636 to 958) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Objective response rate (ORR)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The assumed risk is based on the number of events/number of participants in the control groups in <a href="./references#CD008946-fig-0015" title="">Analysis 5.1</a>.<br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded by two levels to low‐certainty evidence. One level because of low internal validity (risk of bias ‐ performance bias in both studies, attrition bias in <a href="./references#CD008946-bbs2-0014" title="BohmeyerJ , OtteHG , StadlerR , LugerT , SterryW . Therapy of cutaneous T-cell lymphoma with PUVA versus interferon alfa plus PUVA: first results. Journal of the European Academy of Dermatology &amp; Venereology1999;12(Suppl 2):S268. [CENTRAL: CN-00478472] BohmeyerJ , StadlerR , LugerT , SterryW . Prospective randomized multicentre therapy optimizing protocol for therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α + PUVA [Prospectiv randomisiertes, multizentrisches Therapieoptimierungsprotokoll zur Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α + PUVA]. Zeitschrift für Hautkrankheiten2001;76(Suppl 1):S55. [CENTRAL: CN-01446038] KremerA , BohmeyerJ , StadlerR , LugerT , SterryW . Prospective randomized multicentre therapy optimizing protocol for therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α + PUVA [Prospectiv randomisiertes, multizentrisches Therapieoptimierungsprotokoll zur Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α + PUVA]. Journal der Deutschen Dermatologischen Gesellschaft2003;1(Suppl 1):S99. [CENTRAL: CN-01446037] OtteHG , StadlerR , LugerT , SterryW . Therapy of cutaneous t-cell-lymphoma with PUVA versus Interferon α plus PUVA: first results of a prospective randomized multicentre therapy optimizing protocol [Therapie kutaner T-Zell-Lymphome mit PUVA versus Interferon α plus PUVA: Erste Ergebnisse des prospektiven randomisierten multizentrischen Therapieoptimierungsprotokolls]. Der Hautarzt1999;50(Suppl 1):S2. [CENTRAL: CN-01457423] OtteHG , StadlerR . Combination therapy of cutaneous t-cell-lymphoma with interferon alfa 2a and PUVA [Kombinationstherapie kutaner T-Zell-Lymphome mit Interferon Alfa 2a und PUVA]. Zentralblatt Haut- und Geschlechtskrankheiten1993;162(Suppl):P2.03.08. [CENTRAL: CN-01457422] StadlerM , KremerA , LugerT , SterryW . Prospective, randomized, multicentre clinical trial on the use of interferon a 2a plus PUVA versus PUVA monotherapy in patients with cutaneous T-cell lymphoma, stages I and II [Abstract 7541]. ASCO annual meeting proceedings. Journal of Clinical Oncology2006;24(18S Pt 1):432. [CENTRAL: CN-00625001] ">Stadler 2006</a>) and one level because of low sample size (imprecision) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">IFN‐α + PUVA compared to PUVA alone for mycosis fungoides</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/full#CD008946-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008946-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Extracorporeal photopheresis compared to PUVA for mycosis fungoides</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Extracorporeal photopheresis compared to PUVA for mycosis fungoides</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with mycosis fungoides<br/><b>Setting:</b> tertiary care setting<br/><b>Intervention:</b> Extracorporeal photopheresis (ECP)<br/><b>Comparison:</b> PUVA </p> <p><b>Number of trials included:</b> 1 (<a href="./references#CD008946-bbs2-0002" title="ChildFJ , MitchellTJ , WhittakerSJ , ScarisbrickJJ , SeedPT , Russel-JonesR . A randomized cross-over study to compare PUVA and extracorporeal photopheresis in the treatment of plaque stage (T2) mycosis fungoides. Clinical &amp; Experimental Dermatology2004;29(3):231-6. [CENTRAL: CN-00468455] [PMID: 15115499]ChildFJ , MitchellTJ , WhittakerSJ , WatkinsP , SeedP , Russell-JonesR . A randomised cross-over study to compare Puva and extracorporeal photopheresis (ECP) in the treatment of plaque stage (T2) mycosis fungoides. British Journal of Dermatology2001;145(Suppl 59):16. [CENTRAL: CN-00430854] ">Child 2004</a>) </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with PUVA</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with Extracorporeal photopheresis</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement of quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Common adverse effects</p> <p>(Time point of measurement:</p> <p>three months of PUVA or six months of ECP<sup>c</sup>) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Some participants reported mild nausea after PUVA. However, incidences and time points were not stated. One participant starting in the ECP group had hypotension leading to withdrawal from the study. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16<br/>(1 RCT) <sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low <sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Complete response</p> <p>(Time point of measurement: three months of PUVA or six months of ECP<sup>c</sup>) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.20<br/>(0.01 to 3.61) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>16<br/>(1 RCT) <sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low <sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>250 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>50 per 1000<br/>(3 to 903) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Objective response rate</p> <p>(Time point of measurement: three months of PUVA or six months of ECP<sup>c</sup>) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.08<br/>(0.01 to 1.17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>16<br/>(1 RCT) <sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low <sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Additionally computed 95% CI by the use of the method described by Miettinen 1985 (adverse effects requiring discontinuation): 95% CI by Miettinen 0.00 to 0.40, Fisher test P = 0.002 </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>750 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>53 per 1000<br/>(0 to 750) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded by three levels to very low‐certainty evidence. One level because of low internal validity (risk of bias ‐ high risk of attrition bias) and two levels because of very low sample size (imprecision) </p> <p><sup>b</sup> Cross‐over design, no carry‐over effect suspected due to long washout phase of three months </p> <p><sup>c</sup> The PUVA‐first group was given PUVA twice a week for 3 months followed by ECP once monthly for 6 months (doses not reported). The ECP‐first group was given ECP once monthly for 6 months followed by PUVA twice a week for 3 months (doses not reported). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Extracorporeal photopheresis compared to PUVA for mycosis fungoides</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/full#CD008946-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008946-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Bexarotene + PUVA compared to PUVA alone for mycosis fungoides</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Bexarotene + PUVA compared to PUVA alone for mycosis fungoides</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with mycosis fungoides<br/><b>Setting:</b> tertiary care setting<br/><b>Intervention:</b> Bexarotene + PUVA<br/><b>Comparison:</b> PUVA alone </p> <p><b>Number of trials included:</b> 1 (<a href="./references#CD008946-bbs2-0018" title="NCT00056056. Ultraviolet light therapy using methoxsalen with or without Bexarotene in treating patients with mycosis fungoides. clinicaltrials.gov/ct2/show/NCT00056056 (first received 7 March 2003). WhittakerS , OrtizP , DummerR , RankiA , HasanB , MeulemansB , et al. Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial 21011 (NCT00056056). British Journal of Dermatology2012;167(3):678-87. [CENTRAL: CN-00856432] [PMID: 22924950]WhittakerS , Ortiz-RomeroPL , DummerR , RankiA , HasanB , MeulemansB , et al. Efficacy and safety of bexarotene combined with psoralen/ultraviolet A light (PUVA) compared to PUVA treatment alone in stage IB-IIa mycosis fungoides (MF): Final results from EORTC cutaneous lymphoma task force (CLTF) phase III clinical trial 21011. Journal of Clinical Oncology2012;30(15 Suppl 1):8076. ">Whittaker 2012</a>) </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with PUVA alone</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with Bexarotene + PUVA</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement of quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Common adverse effects ‐ Photosensitivity (Time point of measurement: up to 16 weeks)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Zero events in with PUVA alone, so unable to calculate absolute effects.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.68<br/>(0.11 to 64.04) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low <sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Complete response (Time point of measurement: up to 16 weeks)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.41<br/>(0.71 to 2.80) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>93<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low <sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>222 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>313 per 1000<br/>(158 to 622) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Objective response rate (Time point of measurement: up to 16 weeks)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.94<br/>(0.61 to 1.44) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>93<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low <sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>489 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>460 per 1000<br/>(298 to 704) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded by two levels to low‐certainty evidence. One level because of low internal validity (risk of bias ‐ high risk of performance bias) and one level because of low sample size (imprecision) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Bexarotene + PUVA compared to PUVA alone for mycosis fungoides</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/full#CD008946-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008946-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">IFN‐α + acitretin compared to IFN‐α + PUVA for mycosis fungoides</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>IFN‐α + acitretin compared to</b> <b>IFN‐α + PUVA for mycosis fungoides</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with mycosis fungoides<br/><b>Setting:</b> tertiary care setting<br/><b>Intervention:</b> IFN‐α + acitretin<br/><b>Comparison:</b> IFN‐α + PUVA </p> <p><b>Number of trials included:</b> 1 (<a href="./references#CD008946-bbs2-0013" title="OtteHG , KuhlS , StadlerR , LugerT , HenzB , SterryW . Treatment of cutaneous T-cell lymphoma with Interferon alpha and PUVA versus Interferon alpha and Acitretin - results of a prospective randomised multi-centre study [Behandlung des kutanen T-Zell-Lymphoms mit Interferon alpha und PUVA versus Interferon alpha und Acirentin - Ergebnisse einer prospektiv-randomisierten Multicenter-Studie]. Der Hautarzt1997;48(Suppl):S97. [CENTRAL: CN-00495120] OtteHG , StadierR , LugerT , HenzB , SterryW . Open controlled clinical trial on the use of interferon plus acitretin versus interferon plus PUVA in patients with cutaneous T-cell lymphoma (CTCL). Annals of Oncology1996;7(Suppl 3):66. [CENTRAL: CN-00308243] StadlerR , OtteHG , LugerT , HenzBM , KuhlP , ZwingersT , et al. Prospective randomized multicenter clinical trial on the use of interferon -2a plus acitretin versus interferon -2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood1998;92(10):3578-81. [CENTRAL: CN-00156682] [PMID: 9808550]">Stadler 1998</a>) </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with IFN‐α + PUVA</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with IFN‐α + acitretin</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement of quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Common adverse effects ‐ Flu‐like symptoms</p> <p>(Time point of measurement: up to 48 weeks or until complete response)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.32<br/>(0.92 to 1.88) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>82<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low <sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>525 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>693 per 1000<br/>(483 to 987) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Complete response</p> <p>(Time point of measurement: up to 48 weeks or until complete response)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.54<br/>(0.35 to 0.84) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>82<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low <sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>700 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>378 per 1000<br/>(245 to 588) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Objective response rate</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate;the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded by two levels to low‐certainty evidence. One level because of low internal validity (risk of bias ‐ high risk of attrition bias) and one level because of low sample size (imprecision) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">IFN‐α + acitretin compared to IFN‐α + PUVA for mycosis fungoides</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/full#CD008946-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008946-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">PUVA maintenance compared to no maintenance for mycosis fungoides</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>PUVA maintenance compared to no maintenance for mycosis fungoides</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> mycosis fungoides<br/><b>Setting:</b> tertiary care setting<br/><b>Intervention:</b> PUVA maintenance<br/><b>Comparison:</b> no maintenance </p> <p><b>Number of trials included:</b> 1 (<a href="./references#CD008946-bbs2-0016" title="NCT01686594. A multi-center, randomized study on oral 8-methoxypsoralen plus UVA with or without maintenance therapy in mycosis fungoides EORTC/ISCL stage IA to IIB. clinicaltrials.gov/ct2/show/NCT01686594 (first received 18 September 2012). Vieyra-GarciaP , Fink-PuchesR , PorkertS , LangR , PöchlauerS , RatzingerG , et al. Evaluation of low-dose, low-frequency oral psoralen-UV-A treatment with or without maintenance on early-stage mycosis fungoides: A randomized clinical trial. JAMA Dermatology2019;155(5):538-47. [PMID: 30892603]">Vieyra‐Garcia 2019</a>) </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with no maintenance</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with PUVA maintenance</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Improvement of quality of life</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1.000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Common adverse effects</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Measured but distribution in treatment arms was not reported</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1.000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Complete response</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Complete response was a condition for randomisation and not an outcome</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0 per 1.000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0 per 1.000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Objective response rate</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0 per 1.000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0 per 1.000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">PUVA maintenance compared to no maintenance for mycosis fungoides</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/full#CD008946-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008946-tbl-0006"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Clinical staging system</span></div> <tbody> <tr> <th align="center" class="headercell" colspan="2" rowspan="2" scope="col" valign="middle"> <p><b>2007</b> </p> <p><b>MF and Sézary syndrome</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="2" scope="col" valign="middle"> <p><b>1979</b> </p> <p><b>CTCL</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="middle"> <p><b>Disease‐specific survival rates in % (</b><a href="./references#CD008946-bbs2-0089" title="AgarNS , WedgeworthE , CrichtonS , MitchellTJ , CoxM , FerreiraS , et al. Survival outcomes and prognostic factors in mycosis fungoides/Sezary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. Journal of Clinical Oncology2010;28(31):4730-9. [PMID: 20855822]">Agar 2010</a>) </p> </th> </tr> <tr> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="middle"> <p><b>5 year</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="middle"> <p><b>10 year</b> </p> </th> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="middle"> <p><b>IA</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>T1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="middle"> <p><b>IA</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>T1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="middle"> <p>98</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="middle"> <p>95</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>N0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>N0</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>M0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>M0</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>B0‐1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>‐</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="middle"> <p><b>IB</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>T2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="middle"> <p><b>IB</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>T2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="middle"> <p>89</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="middle"> <p>77</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>N0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>N0</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>M0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>M0</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>0‐1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>‐</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="middle"> <p><b>IIA</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>T1‐2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="middle"> <p><b>IIA</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>T1‐2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="middle"> <p>89</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="middle"> <p>67</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>N1‐2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>N1</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>M0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>M0</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>B0‐1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>‐</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="middle"> <p><b>IIB</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>T3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="middle"> <p><b>IIB</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>T3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="middle"> <p>56</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="middle"> <p>42</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>N0‐2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>N0,1</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>M0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>M0</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>B0‐1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>‐</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="middle"> <p><b>III</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>T4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="middle"> <p><b>III</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>T4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="middle"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="middle"></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>N0‐2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>N0,1</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>M0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>M0</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>B0‐1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>‐</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="middle"> <p><b>IIIA</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>T4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="middle"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="middle"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="middle"> <p>54</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="middle"> <p>45</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>N0‐2</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>M0</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>B0</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="middle"> <p><b>IIIB</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>T4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="middle"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="middle"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="middle"> <p>48</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="middle"> <p>45</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>N0‐2</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>M0</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>B1</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="middle"> <p><b>IVA1</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>T1‐4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="8" valign="middle"> <p><b>IVA</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="middle"> <p>T1‐4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="middle"> <p>41</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="middle"> <p>20</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>N0‐2</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>M0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="middle"> <p>N2‐3</p> <p>‐</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>B2</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="middle"> <p><b>IVA2</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>T1‐4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="middle"> <p>M0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>23</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>20</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>N3</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>M0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="middle"> <p>‐</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>B0‐2</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="middle"> <p><b>IVB</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>T1‐4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="middle"> <p><b>IVB</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>T1‐4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>18</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>not reached</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>N0‐3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>N0‐3</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>M1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>M1</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>B0‐2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>‐</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Clinical staging system</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/full#CD008946-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008946-tbl-0007"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Glossary of terms</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>General medical terms</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Explanation</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Apoptosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Programmed cell death</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cutaneous T‐cell lymphoma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group of skin‐directed T‐cell neoplasms with diverse clinical and histological features and prognosis </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cutaneous B‐cell lymphoma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group of skin‐directed B‐cell neoplasms with diverse clinical and histological features and prognosis </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lesional skin atrophy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death of the cells in the damaged area of skin</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lymph nodes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Small organs in the human body which are part of the immune system</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Neoplasm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Any new and abnormal growth</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NK‐cell lymphoma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group of neoplasms derived from the natural killer cells (NK‐cells) with diverse clinical and histological features and prognosis </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Plaques</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A solid elevated area on the skin that is more broad than it is high</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pleomorphic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Variability in size and shape</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Poikiloderma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Skin that demonstrates adjacent hyper‐ and hypopigmented areas with widened capillaries (telangiectasia) in the affected area </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Precursor haematologic neoplasm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Clinically‐aggressive neoplasm with a high incidence of cutaneous involvement and risk of leukaemic dissemination </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Primary cutaneous lymphoma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Cutaneous T‐ and B‐cell lymphoma that primarily affect the skin</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>T‐cell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>A type of lymphocyte (white cell)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Adverse effects</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Explanation</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Acute myocardial infarction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Death of myocardial tissue due to blocked blood supply</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Acute non‐lymphatic leukaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>A quickly progressive malignant disease of too many immature non‐lymphatic leucocytes cells in the blood and bone marrow </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>ALT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>The alanine transaminase is a liver enzyme (SGPT)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Anaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Low count of red blood cells</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Anaemia hypochromic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Low count of red blood cells with low amount of haemoglobin, the red molecule that transports oxygen within the blood vessels </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Anaphylactoid reactions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Very acute systemic allergic reaction often accompanied with flushing, angioedema,urticaria, difficulty breathing, lowered blood pressure, nausea </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Arthralgia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Joint pain</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>AST</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>The aspartate transaminase is an enzyme mainly present in the liver but also in the blood, muscle cells, and bones (SGOT) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Asthenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Lack of energy or physical weakness or both</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Cardiomyopathy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Structural or functional disease of the cardiac muscle</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Cardiopulmonary syndrome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Adverse effect where the heart and the lung are involved</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Chill</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Feeling of cold, resulting in shivering</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>CNS syndrome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Adverse effect where the central nervous system (brain, spinal cord) is involved</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Cutaneous hypersensitivity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Altered reactivity to a specific antigen leading to cutaneous alterations</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Cutaneous toxicity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Cutaneous adverse effect of an agent used in therapeutic dosages</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Constipation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Hard and/or difficult bowel movements</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Dermatitis exfoliation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Inflammation and detachment of the skin</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Many fluid stools</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Dyspnea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Bad breathing</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Erythema</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Redness of the skin</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>To be exhausted</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Flu‐like symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Symptoms which are often seen with influenza, such as fever, chills, and muscular pain </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Gastrointestinal syndromes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Adverse effects affecting the digestive system (oesophagus, stomach, bowel)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Hair loss</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Pathological increased loss of hair</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Hepatotoxicity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Capacity of a substance to have damaging effects on the liver</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Hospitalisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Admission of a patient in a hospital</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Hypercholesterolaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Elevated levels of cholesterol in the blood</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Hyperlipidaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Elevated levels of lipids in the blood</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Hypotension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Low blood pressure</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Hypothyroidism</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Low function of thyroid gland</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Impotentia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Inability to engage in sexual intercourse</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Not being able to sleep</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>LDH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Lactate dehydrogenase, an enzyme which helps to produce energy in the body when oxygen is absent </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Leukopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Low count of white blood cells</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Malaise</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>To feel ill</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Mucositis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Inflammation of mucosa</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Myalgia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Muscle pain</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Nasopharyngitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Inflammation of the inner nose and the throat</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>An unpleasant sensation associated with the feeling one is going to vomit</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Neuropathy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>A problem of the nervous system or nerves, which can result in abnormal sensations, pain, or muscle weakness </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Non‐melanoma skin cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Skin cancer which does not originate from melanocytes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Photosensitivity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Enhanced responsibility to light or ultraviolet light</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Pruritus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Itching of the skin</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Radiodermatitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Dermatitis resulting from overexposure to sources of radiant energy</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>An abnormal change in the skin often affecting colour (increased redness), texture, and/or sensation </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>SGOT/SGPT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Liver enzymes, see also AST and ALT</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>T4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Enzyme of the thyroid gland</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Thrombopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Low count of thrombocytes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Thrombotic syndrome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Blood coagulation and clotting within blood vessels, obstructing blood flow</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Triglycerid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Lipid</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Vascular leak syndrome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>When the blood vessels dilate and become more porous, allowing blood components to leak into the surrounding tissue </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Vasodilatation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Widening of the blood vessels</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Glossary of terms</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/full#CD008946-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008946-tbl-0008"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">List of abbreviations and acronyms</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Acronym</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Description (letters used for acronym in capitals)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ADF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Arbeitsgemeinschaft Dermatologische Forschung</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BCNU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Carmustine, a nitrogen mustard related alkylating agent</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CENTRAL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cochrane Central Register of Controlled Trials</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Confidence interval</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CTCL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cutaneous T‐Cell Lymphoma</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DDG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>German Dermatologic Society</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EORTC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>European Organization of Research and Treatment of Cancer</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ISCL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>International Society for Cutaneous Lymphoma (ISCL)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ITT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intention‐to‐treat</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LILACS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Latin American and Caribbean Health Science Information database</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mycosis Fungoides</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PICOS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants, Interventions, Controls, Outcomes and Study</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PRISMA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Preferred Reporting Items of Systematic Reviews and Meta‐Analyses</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Randomised‐Controlled Trial</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk Ratio</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TSEB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total Skin Electron Beam</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TNMB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tumour, lymph Node, Metastasis and Blood</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>United Kingdom</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>United States of America</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USCLC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>United States Cutaneous Lymphoma Consortium</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WHO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>World Health Organization</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">List of abbreviations and acronyms</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/full#CD008946-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008946-tbl-0009"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">TNMB classifications</span></div> <tbody> <tr> <td align="center" class="headercell" colspan="2" rowspan="1" valign="middle"></td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="middle"> <p><b>Modified ISCL/EORTC classification of MF and Sézary Syndrome according to</b><a href="./references#CD008946-bbs2-0157" title="OlsenEA , WhittakerS , KimYH , DuvicM , PrinceHM , LessinSR , et al. Clinical end points and response criteria in mycosis fungoides and Sezary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. Journal of Clinical Oncology2011;29(18):2598-607. [PMID: 21576639]"><b>Olsen 2011</b> </a> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="middle"> <p><b>CTCL 1979</b> </p> </th> </tr> <tr> <th align="center" class="headercell" colspan="4" rowspan="1" scope="col" valign="middle"> <p><b>T: Skin<sup>1</sup> </b> </p> </th> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>T<sub>0</sub> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>N.E.</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Clinically and/or histopathologically suspicious lesions</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>T<sub>1</sub> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Limited patches, papules, and/or plaques covering &lt; 10% of the skin surface; may further stratify into T1a (patch only) vs. T1b (plaque ± patch) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Limited plaques, papules, or eczematous patches<br/>covering &lt; 10% of the skin surface </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>T<sub>2</sub> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Patches, papules, or plaques covering ≥ 10% of the skin surface; may further stratify into T2a (patch only) vs. T2b (plaque patch) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Generalised plaques, papules, or erythematous<br/>patches covering ≥ 10% of the skin surface </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>T<sub>3</sub> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>One or more tumours (≥ 1 cm diameter)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Tumours, 1 or more</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>T<sub>4</sub> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Confluence of erythema covering ≥ 80% body surface area</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Generalised erythroderma</p> </td> </tr> <tr> <th align="center" class="headercell" colspan="4" rowspan="1" scope="col" valign="middle"> <p><b>N: Node<sup>2</sup> </b> </p> </th> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>N<sub>0</sub> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>No clinically abnormal peripheral lymph nodes; biopsy not required</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>No clinically abnormal peripheral lymph nodes palpable,<br/>histopathology negative for CTCL </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>N<sub>1</sub> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Clinically abnormal lymph nodes; histopathology Dutch grade 1 or NCI LN<sub>0-2</sub> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Palpable Clinically abnormal peripheral lymph nodes, histopathology<br/>negative for CTCL </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>N<sub>1a</sub> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Clone negative</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>‐</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>N<sub>1b</sub> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Clone positive</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>‐</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>N<sub>2</sub> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Clinically abnormal peripheral lymph nodes, histopathology Dutch grade 2 or NCI LN<sub>3</sub> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>No clinically abnormal peripheral lymph nodes,<br/>histopathology positive for CTCL </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>N<sub>2a</sub> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Clone negative</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>‐</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>N<sub>2b</sub> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Clone positive</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>‐</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>N<sub>3</sub> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Clinically abnormal lymph nodes; histopathology Dutch grade 3‐4 or NCI LN<sub>4</sub>; </p> <p>clone positive or negative</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Palpable clinically abnormal peripheral lymph nodes, pathology<br/>positive for CTCL </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>N<sub>x</sub> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Clinically abnormal lymph nodes without histologic confirmation or inability to fully characterize the histologic subcategories </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>‐</p> </td> </tr> <tr> <th align="center" class="headercell" colspan="4" rowspan="1" scope="col" valign="middle"> <p><b>M: Visceral</b> </p> </th> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>M<sub>0</sub> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>No visceral organ involvement</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>No visceral organ involvement</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>M<sub>1</sub> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Visceral involvement (must have pathology confirmation and organ involved should be specified) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Visceral involvement (must have pathology<br/>confirmation and organ involved should be<br/>specified) </p> </td> </tr> <tr> <th align="center" class="headercell" colspan="4" rowspan="1" scope="col" valign="middle"> <p><b>B: Blood</b> </p> </th> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>B<sub>0</sub> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Absence of significant blood involvement: ≤ 5% of peripheral blood lymphocytes are atypical (Sézary) cells </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Atypical circulating cells not present (less than 5%)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>B<sub>0a</sub> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Clone negative</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>‐</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>B<sub>0b</sub> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Clone positive</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>‐</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>B<sub>1</sub> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Low blood tumour burden: &gt; 5% of peripheral blood lymphocytes are atypical (Sézary) cells but does not meet the criteria of B<sub>2</sub> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Atypical circulating cells present (more than 5%), record total<br/>white blood count and total lymphocyte counts, and<br/>number of atypical cells/100 lymphocytes </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>B<sub>1a</sub> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Clone negative</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>‐</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>B<sub>1b</sub> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Clone positive</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>‐</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>B<sub>2</sub> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>High blood tumour burden: ≥ 1,000/L Sézary cells with positive clone<sup>3</sup>; one of the following can be substituted for Sézary cells: CD4/CD8 ≥ 10,<br/>CD4CD7‐ cells ≥ 40% or CD4CD26‐ cells ≥ 30% </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>‐</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p><sup>1</sup> Patch any size lesion without induration or significant elevation above the surrounding uninvolved skin: poikiloderma may be present. Plaque any size lesion that is elevated or indurated: crusting or poikiloderma may be present. Tumour any solid or nodular lesion ≥ 1 cm in diameter with evidence of deep infiltration in the skin and/or vertical growth. </p> <p><sup>2</sup> Lymph node classification has been modified from 2007 ISCL/EORTC consensus revisions1 to include central nodes. Lymph nodes are qualified as abnormal if ≥ 1.5 cm in diameter. </p> <p><sup>3</sup> The clone in the blood should match that of the skin. The relevance of an isolated clone in the blood or a clone in the blood that does not match the clone in the skin remains to be determined. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">TNMB classifications</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/full#CD008946-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008946-tbl-0010"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Rare adverse effects detected by separate adverse event search</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Intervention</b>  </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Rare severe adverse effects</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PUVA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>transient lymphomatoid papulosis (<a href="./references#CD008946-bbs2-0091" title="AronssonA , JonssonN , TegnerE . Transient lymphomatoid papulosis in mycosis fungoides. Acta Dermato-Venereologica1982;62(6):529-31.">Aronsson 1982</a>)<br/>basal cell carcinoma/squamous cell carcinoma (<a href="./references#CD008946-bbs2-0126" title="HerrmannJJ , Roenigk HH Jr, HurriaA , KuzelTM , SamuelsonE , RademakerAW , et al. Treatment of mycosis fungoides with photochemotherapy (PUVA): long-term follow-up. Journal of the American Academy of Dermatology1995;33(2 Pt 1):234-42.">Herrmann 1995</a>)<br/>squamous cell carcinoma (<a href="./references#CD008946-bbs2-0152" title="MolinL , ThomsenK , VoldenG , GrothO . Photochemotherapy (PUVA) in the pretumour stage of mycosis fungoides: a report from the Scandinavian Mycosis Fungoides Study Group. Acta Dermatovenereologica (Stockholm)1981;61(1):47-51.">Molin 1981</a>)<br/>cataract (<a href="./references#CD008946-bbs2-0160" title="RupoliS , GoteriG , PuliniS , FilosaA , TassettiA , OffidaniM , et al. Long-term experience with low-dose interferon-alpha and PUVA in the management of early mycosis fungoides. European Journal of Haematology2005;75(2):136-45.">Rupoli 2005</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>extracorporeal photopheresis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>sarcoma (<a href="./references#CD008946-bbs2-0140" title="KorpusikD , HomeyB , StegeH , Bruch-GerharzD , SchulteKW . Mycosis fungoides: Complications of long-term treatment with PUVA and ECP [Mycosis fungoides: Komplikationen einer Langzeitbehandlung mit PUVA und ECP]. Hautarzt2007;58(4):298-9. [EMBASE: 46623430]">Korpusik 2007</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>imiquimod</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no reported SAEs found</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>electron beam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total epilation (<a href="./references#CD008946-bbs2-0096" title="BravermanIM , YagerNB , ChenM , CadmanEC , HaitWN , MaynardT . Combined total body electron beam irradiation and chemotherapy for mycosis fungoides. Journal of the American Academy of Dermatology1987;16(1 Pt 1):45-60.">Braverman 1987</a>, <a href="./references#CD008946-bbs2-0107" title="DesaiKR , PeznerRD , LipsettJA , VoraNL , LukKH , WongJY , et al. Total skin electron irradiation for mycosis fungoides: relationship between acute toxicities and measured dose at different anatomic sites. International Journal of Radiation Oncology, Biology, Physics1988;15(3):641-5.">Desai 1988</a>),<br/>nail dystrophy/oedema of hands and feet/bullae dorsum and feet/conjunctivitis/hospitalisation due to skin ulcers (<a href="./references#CD008946-bbs2-0107" title="DesaiKR , PeznerRD , LipsettJA , VoraNL , LukKH , WongJY , et al. Total skin electron irradiation for mycosis fungoides: relationship between acute toxicities and measured dose at different anatomic sites. International Journal of Radiation Oncology, Biology, Physics1988;15(3):641-5.">Desai 1988</a>)<br/>diffuse permanent telangiectasia/linear sclerosis/Ischaemic ulceration of finger tips (<a href="./references#CD008946-bbs2-0146" title="MicailyB , VonderheidEC , BradyLW . Combined moderate dose electron beam radiotherapy and topical chemotherapy for cutaneous T-Cell lymphoma. International Journal of Radiation Oncology, Biology, Physics1983;9(4):475-9.">Micaily 1983</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>cyclophosphamide, doxorubicin, etoposide, vincristine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>haematological toxicity: febrile neutropenia/staphylococcal bacteraemia/disseminated herpes infection/pneumocystis carinii pneumonia/neurologic toxicity grade 3/decreased left ventricular ejection fraction (<a href="./references#CD008946-bbs2-0090" title="AkpekG , KohHK , BogenS , O'HaraC , FossFM . Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma. Cancer1999;86(7):1368-76.">Akpek 1999</a>) </p> <p>pulmonary embolism and death due to drug‐related cardiac infarction reported for doxorubicin monotherapy (<a href="./references#CD008946-bbs2-0111" title="DummerR , QuaglinoP , BeckerJC , HasanB , KarraschM , WhittakerS , et al. Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012. Journal of Clinical Oncology2012;30(33):4091-7.">Dummer 2012</a>) </p> <p>nephrotic syndrome (<a href="./references#CD008946-bbs2-0135" title="KairouaniM , SekkateS , IsmailiN , AbahssainH , ErrihaniH . A rare case of nephrotic syndrome revealing mycosis fungoide managed successfully with chemotherapy. Pan African Medical Journal2012;12:67.">Kairouani 2012</a>) </p> <p>acute nonlymphocytic leukaemia reported for combination of CHOP with TSEBT (<a href="./references#CD008946-bbs2-0007" title="KayeF , EddyJ , IhdeDC , SteinbergS , FischmannAB , GlatsteinE , et al. Conservative vs. aggressive therapy in mycosis fungoides. Proceedings of the American Society of Clinical Oncology1989;8:257. [CENTRAL: CN-00694960] KayeF , IhdeD , FischmannA , GlatsteinE , MinnaJ , SchechterG , et al. A randomized trial comparing conservative and aggressive therapy in mycosis fungoides (MF). Proceedings of the American Society of Clinical Oncology1986;5:195. [CENTRAL: CN-00695166] KayeFJ , BunnPA , SteinbergSM , StockerJL , IhdeDC , FischmannAB , et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. New England Journal of Medicine1989;321(26):1784-90. [CENTRAL: CN-00064211] [PMID: 2594037]">Kaye 1989</a>) </p> <p>reticulated generalised skin pigmentation reported for combination of cyclophosphamide with prednisone (<a href="./references#CD008946-bbs2-0188" title="YoussefM , MokniS , BelhadjaliH , AouemK , MoussaA , LaatiriA , et al. Cyclophosphamide-induced generalised reticulated skin pigmentation: a rare presentation. International Journal of Clinical Pharmacy2013;35(3):309-12.">Youssef 2013</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>active transfer factor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no reported SAEs found</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>methotrexate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>severe oedematous erythroderma/denudation on the trunk and extremities/Interstitial pulmonary fibrosis (<a href="./references#CD008946-bbs2-0189" title="ZackheimHS , Kashani-SabetM , HwangST . Low-dose methotrexate to treat erythrodermic cutaneous T-cell lymphoma: results in twenty-nine patients. Journal of the American Academy of Dermatology1996;34(4):626-31.">Zackheim 1996</a>) </p> <p>epidermal necrosis (<a href="./references#CD008946-bbs2-0148" title="MnaAB , SouissiA , HalouaniS , El EuchD , ZahaniA , KchirN , et al. Methotrexate-induced necrolysis in tumoral-stage mycosis fungoides: a challenging diagnosis. Dermatology Online Journal2016;22(1):16.">Mna 2016</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>interferon‐alpha</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>acrocyanosis (<a href="./references#CD008946-bbs2-0098" title="Campo-VoegeliA , EstrachT , MartiRM , CorominasN , TusetM , MascaróJM . Acrocyanosis induced by interferon alpha(2a). Dermatology1998;196(3):361-3.">Campo‐Voegeli 1998</a>)<br/>oropharyngeal lichen planus (<a href="./references#CD008946-bbs2-0141" title="KüttingB , BöhmM , LugerTA , BonsmannG . Oropharyngeal lichen planus associated with interferon-alpha treatment for mycosis fungoides: a rare side-effect in the therapy of cutaneous lymphomas. British Journal of Dermatology1997;137(5):836-7.">Kütting 1997</a>)<br/>seizures (<a href="./references#CD008946-bbs2-0142" title="Legroux-CrespelE , LafayeS , MahéE , Picard-DahanC , CrickxB , SassolasB , et al. Seizures during interferon alpha therapy: three cases in dermatology. Annales de Dermatologie et de Venereologie2003;130(2 Pt 1):202-4.">Legroux‐Crespel 2003</a>)<br/>fatal neutropenia and sepsis (<a href="./references#CD008946-bbs2-0176" title="VegnaML , PapaG , DefazioD , PisaniF , CoppolaG , De PitàO , et al. Interferon alpha-2a in cutaneous T-cell lymphoma. European Journal of Haematology. Supplementum1990;52:32-5.">Vegna 1990</a>)<br/>liver toxicity (<a href="./references#CD008946-bbs2-0160" title="RupoliS , GoteriG , PuliniS , FilosaA , TassettiA , OffidaniM , et al. Long-term experience with low-dose interferon-alpha and PUVA in the management of early mycosis fungoides. European Journal of Haematology2005;75(2):136-45.">Rupoli 2005</a>, <a href="./references#CD008946-bbs2-0166" title="SimoniR , CavalieriR , CoppolaG , RicciottiL , De PitàO , CriscuoloD , et al. Recombinant leukocyte interferon alfa-2a in the treatment of mycosis fungoides. Journal of Biological Regulators and Homeostatic Agents1987;1(2):93-9.">Simoni 1987</a>, <a href="./references#CD008946-bbs2-0176" title="VegnaML , PapaG , DefazioD , PisaniF , CoppolaG , De PitàO , et al. Interferon alpha-2a in cutaneous T-cell lymphoma. European Journal of Haematology. Supplementum1990;52:32-5.">Vegna 1990</a>) </p> <p>generalised urticaria in association with angio‐oedema (<a href="./references#CD008946-bbs2-0132" title="HüskenAC , TsianakasA , HensenP , NashanD , LoquaiC , BeissertS , et al. Comparison of pegylated interferon α-2b plus psoralen PUVA versus standard interferon α-2a plus PUVA in patients with cutaneous T-cell lymphoma. Journal of the European Academy of Dermatology and Venereology : JEADV2012;26(1):71-8.">Hüsken 2012</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>bexarotene</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>neutropenia/non‐ST‐elevation myocardial infarction/elevated liver enzymes (<a href="./references#CD008946-bbs2-0088" title="AbbottRA , WhittakerSJ , MorrisSL , Russell-JonesR , HungT , BashirSJ , et al. Bexarotene therapy for mycosis fungoides and Sézary syndrome. British Journal of Dermatology2009;160(6):1299-307.">Abbott 2009</a>)<br/>lethal sepsis (<a href="./references#CD008946-bbs2-0094" title="BohmeyerJ , StadlerR , KremerA , NashanD , MucheM , GellrichS , et al. Bexarotene--an alternative therapy for progressive cutaneous T-cell lymphoma? First experiences. Journal der Deutschen Dermatologischen Gesellschaft [Journal of the German Society of Dermatology]2003;1(10):785-9.">Bohmeyer 2003</a>) </p> <p>pancreatitis (<a href="./references#CD008946-bbs2-0112" title="DuvicM , HymesK , HealdP , BrenemanD , MartinAG , MyskowskiP , et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. Journal of Clinical Oncology2001;19(9):2456-71.">Duvic 2001b</a>) </p> <p>bleeding gastric ulcer (<a href="./references#CD008946-bbs2-0167" title="Sokolowska-WojdyloM , FlorekA , ZauchaJM , ChmielowskaE , GizaA , Knopinska-PoslusznyW , et al. Polish lymphoma research group experience with bexarotene in the treatment of cutaneous T-cell lymphoma. American Journal of Therapeutics2016;23(3):e749-56.">Sokolowska‐Wojdylo 2016</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>peldesine (BCX‐34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no reported SAEs found</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>denileukin diftitox (ONTAK)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>capillary leak syndrome (<a href="./references#CD008946-bbs2-0113" title="DuvicM , KuzelTM , OlsenEA , MartinAG , FossFM , KimYH , et al. Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK). Clinical Lymphoma2002;2(4):222-8.">Duvic 2002</a> and <a href="./references#CD008946-bbs2-0114" title="DuvicM , MartinAG , OlsenEA , FivensonDP , PrinceHM . Efficacy and safety of denileukin diftitox retreatment in patients with relapsed cutaneous T-cell lymphoma. Leukemia &amp; Lymphoma2013;54(3):514-9.">Duvic 2013</a>, <a href="./references#CD008946-bbs2-0170" title="TalpurR , DuvicM . Pilot study of denileukin diftitox alternate dosing regimen in patients with cutaneous peripheral T-cell lymphomas. Clinical Lymphoma, Myeloma &amp; Leukemia2012;12(3):180-5.">Talpur 2012</a>) </p> <p>lethal vascular leak syndrome with rhabdomyolysis (<a href="./references#CD008946-bbs2-0092" title="AvarbockAB , LorenAW , ParkJY , Junkins-HopkinsJM , ChoiJ , LitzkyLA , et al. Lethal vascular leak syndrome after denileukin diftitox administration to a patient with cutaneous gamma/delta T-cell lymphoma and occult cirrhosis. American Journal of Hematology2008;83(7):593-5.">Avarbock 2008</a>)<br/>grade 4 infusion event (<a href="./references#CD008946-bbs2-0117" title="FossFM , BachaP , OsannKE , DemierreMF , BellT , KuzelT . Biological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication. Clinical Lymphoma2001;1(4):298-302.">Foss 2001</a>) </p> <p>visual changes (<a href="./references#CD008946-bbs2-0145" title="McCannS , AkilovOE , GeskinL . Adverse effects of denileukin diftitox and their management in patients with cutaneous T-cell lymphoma. Clinical Journal of Oncology Nursing2012;16(5):E164-72.">McCann 2012</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nitrogen mustard</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>urticaria and anaphylactoid reaction (<a href="./references#CD008946-bbs2-0105" title="DaughtersD , ZackheimH , MaibachH . Urticaria and anaphylactoid reactions after topical application of mechlorethamine. Archives of Dermatology1973;107(3):429-30.">Daughters 1973</a>, <a href="./references#CD008946-bbs2-0122" title="GrunnetE . Contact urticaria and anaphylactoid reaction induced by topical application of nitrogen mustard. British Journal of Dermatology1976;94(1):101-3.">Grunnet 1976</a>, <a href="./references#CD008946-bbs2-0161" title="Sánchez YusE , Surárez MartínE . Contact urticaria and anaphylactic reactions induced by topical application of nitrogen mustard. Actas Dermo-Sifiliograficas1977;68(12):39-44.">Sanchez 1977</a>)<br/>local bullous reaction (<a href="./references#CD008946-bbs2-0119" title="GodayJJ , AguirreA , RatónJA , Díaz-PérezJL . Local bullous reaction to topical mechlorethamine (mustine). Contact Dermatitis1990;22(5):306-7.">Goday 1990</a>)<br/>perforating follicular mucinosis (<a href="./references#CD008946-bbs2-0123" title="GuilhouJJ , BarnéonG , MalbosS , PeyronJL , MichelB , MeynadierJ . Perforating follicular mucinosis and immediate hypersensitivity to mechlorethamine in a patient with mycosis fungoides. Annales de Dermatologie et de Venereologie1980;107(1-2):59-62.">Guilhou 1980</a>)<br/>Stevens‐Johnson‐Syndrome (<a href="./references#CD008946-bbs2-0155" title="NewmanJM , RindlerJM , BergfeldWF , BrydonJK . Stevens-Johnson syndrome associated with topical nitrogen mustard therapy. Journal of the American Academy of Dermatology1997;36(1):112-4.">Newman 1997</a>)<br/>cutaneous squamous/basal cell carcinoma (<a href="./references#CD008946-bbs2-0129" title="HoppeRT , AbelEA , DeneauDG , PriceNM . Mycosis fungoides: management with topical nitrogen mustard. Journal of Clinical Oncology1987;5(11):1796-803.">Hoppe 1987</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>brentuximab vedotin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>peripheral neuropathy (<a href="./references#CD008946-bbs2-0115" title="DuvicM , TetzlaffMT , GangarP , ClosAL , SuiD , TalpurR . Results of a phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis. Journal of Clinical Oncology2015;33(32):3759-65.">Duvic 2015</a>, <a href="./references#CD008946-bbs2-0103" title="CorbinZA , Nguyen-LinA , LiS , RahbarZ , TavallaeeM , VogelH , et al. Characterization of the peripheral neuropathy associated with brentuximab vedotin treatment of Mycosis Fungoides and Sézary Syndrome. Journal of Neuro-oncology2017;132(3):439-46.">Corbin 2017</a>) </p> <p>unstable angina or myocardial infarction, pulmonary embolism (<a href="./references#CD008946-bbs2-0115" title="DuvicM , TetzlaffMT , GangarP , ClosAL , SuiD , TalpurR . Results of a phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis. Journal of Clinical Oncology2015;33(32):3759-65.">Duvic 2015</a>) </p> <p>progressive multifocal leukoencephalopathy (<a href="./references#CD008946-bbs2-0099" title="CarsonKR , NewsomeSD , KimEJ , Wagner-JohnstonND , vonGeldernG , MoskowitzCH , et al. Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project. Cancer2014;120(16):2464-71.">Carson 2014</a>) </p> <p>acute renal failure (<a href="./references#CD008946-bbs2-0138" title="KimYH , TavallaeeM , SundramU , SalvaKA , WoodGS , LiS , et al. Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and Sézary syndrome with variable CD30 expression level: a multi-institution collaborative project. Journal of Clinical Oncology2015;33(32):3750–8.">Kim 2015</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>lenalidomide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>thrombocytopenia, pneumonitis, fatigue, dyspnoea, cognitive disturbance, respiratory failure, seizure (<a href="./references#CD008946-bbs2-0109" title="DueckG , ChuaN , PrasadA , FinchD , StewartD , WhiteD , et al. Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma. Cancer2010;116(19):4541-8.">Dueck 2010a</a>) </p> <p>anaemia, lymphopenia, neutropenia, cardiac ischaemia/infarction‐acute myocardial infarction, hypoxia‐respiratory failure, rash, supraventricular arrhythmia (<a href="./references#CD008946-bbs2-0171" title="ToumisheyE , PrasadA , DueckG , ChuaN , FinchD , JohnstonJ , et al. Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma. Cancer2015;121(5):716-23.">Toumishey 2015</a>) </p> <p>pneumonitis, fatigue, cognitive disturbance, dyspnoea (<a href="./references#CD008946-bbs2-0109" title="DueckG , ChuaN , PrasadA , FinchD , StewartD , WhiteD , et al. Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma. Cancer2010;116(19):4541-8.">Dueck 2010a</a>, <a href="./references#CD008946-bbs2-0171" title="ToumisheyE , PrasadA , DueckG , ChuaN , FinchD , JohnstonJ , et al. Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma. Cancer2015;121(5):716-23.">Toumishey 2015</a>) </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Rare adverse effects detected by separate adverse event search</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/full#CD008946-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008946-tbl-0011"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Common adverse events from Duvic 2001</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Body as a whole </b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Altered hormone level, asthenia, chills, headache, infection, pain, abdominal pain</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Digestive system </b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diarrhoea, nausea</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Endocrine system </b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypothyroidism</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Haematological and lymphatic system </b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anaemia, hypochromic anaemia, leukopenia</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Metabolic and nutritional system </b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypercholesterolaemia, hyperlipidaemia, lactate dehydrogenase (LDH) increase, aspartate aminotransferase (AST) increase, alanine aminotransferase (ALT) increase </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Skin and appendages </b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dermatitis exfoliation, pruritus, rash, skin disorder</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Common adverse events from Duvic 2001</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/full#CD008946-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008946-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Topical peldesine versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Common adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Pruritus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 Rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Complete response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Objective response rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Topical peldesine versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/references#CD008946-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008946-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Topical hypericin versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Objective response rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Topical hypericin versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/references#CD008946-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008946-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">IFN‐α versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Common adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.1 Erythema</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.2 Fever</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.3 Myalgia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.4 Chills or weakness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.5 Nausea, arthralgia, and malaise</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Complete response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.00 [1.56, 31.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">IFN‐α versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/references#CD008946-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008946-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Mechlorethamine gel vs mechlorethamine ointment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Common adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.1 Skin irritation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.2 Pruritus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.3 Erythema</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.4 Contact dermatitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.5 Skin hyperpigmentation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.6 Folliculitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Complete response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 Objective response rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Mechlorethamine gel vs mechlorethamine ointment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/references#CD008946-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008946-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">IFN‐α + PUVA versus PUVA alone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Complete response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.87, 1.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">IFN‐α + PUVA versus PUVA alone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/references#CD008946-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008946-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Denileukin diftitox high versus low dose</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 Common adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.1 Constitutional symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.2 Grade 3 to 4 constitutional symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.3 Infections</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.4 Grade 3 to 4 infections</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.5 Gastrointestinal syndromes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.6 Grade 3 to 4 gastrointestinal syndromes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.7 CNS syndromes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.8 Grade 3 to 4 CNS syndromes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.9 Rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.10 Grade 3 to 4 rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.11 Vascular leak syndrome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.12 Grade 3 to 4 vascular leak syndrome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.13 Thrombotic events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.14 Grade 3 to 4 thrombotic events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.15 Cardiopulmonary events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.16 Grade 3 to 4 cardiopulmonary events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.17 Acute infusion related events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.18 Grade 3 to 4 acute infusion related events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.19 Grade 3 to 4 laboratory abnormalities</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.2 Complete response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.3 Objective response rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Denileukin diftitox high versus low dose</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/references#CD008946-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008946-tbl-0018"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Bexarotene high versus low dose</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.1 Common adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.1 Photosensitivity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.2 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.3 Constipation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.4 Fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.5 Pruritus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.6 Arthralgia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.7 Nasopharyngitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.8 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.9 Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.10 Free T4 abnormalities</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.11 Cholesterol abnormalities</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.12 Triglycerid abnormalities</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.13 SGOT/SGPT abnormalities</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.2 Complete response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.3 Relapse <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.4 Objective response rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Bexarotene high versus low dose</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/references#CD008946-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008946-tbl-0019"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Bexarotene + PUVA vs PUVA alone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.1 Common adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.1 Liver toxicities</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.2 Renal toxicity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.3 Haematological toxicities</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.4 Increased fasting cholesterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.5 Photosensitivity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.6 Pruritus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.7 Rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.8 Hypertriglyceridaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.2 Complete response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.3 Objective response rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Bexarotene + PUVA vs PUVA alone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/references#CD008946-tbl-0019">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008946-tbl-0020"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Lenalidomide maintenance versus observation after debulking therapy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.1 Common adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1.1 Neutropenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1.2 Hyperbilirubinaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1.3 Hypercalcaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1.4 Hypokalaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1.5 Hypophosphataemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1.6 Erythema multiforme</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1.7 Periorbital oedema</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1.8 Pruritus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1.9 Other AE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Lenalidomide maintenance versus observation after debulking therapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/references#CD008946-tbl-0020">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008946-tbl-0021"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Brentuximab vedotin vs. physician's choice (MTX or bexarotene)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.1 Complete response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.2 Objective response rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Brentuximab vedotin vs. physician's choice (MTX or bexarotene)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/references#CD008946-tbl-0021">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008946-tbl-0022"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Extracorporeal photopheresis versus PUVA</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.1 Complete response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.2 Objective response rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Extracorporeal photopheresis versus PUVA</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/references#CD008946-tbl-0022">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008946-tbl-0023"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Combined therapy versus conservative therapy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.1 Common adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1.1 Hospitalization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1.2 Fatal myocardial infarction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1.3 Cutaneous toxicity from electron beam therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1.4 Acute non‐lymphocytic leukaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1.5 Non‐melanoma skin cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1.6 Unspecified</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.2 Complete response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.3 Relapse <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.4 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.5 Objective response rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Combined therapy versus conservative therapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/references#CD008946-tbl-0023">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008946-tbl-0024"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">IFN‐α + acitretin versus IFN‐α + PUVA</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.1 Common adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1.1 Grade I to II adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1.2 Grade III adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1.3 Adverse events requiring treatment discontinuation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1.4 Flu‐like symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1.5 Dryness/redness of skin or hair loss</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1.6 Neurological disorders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1.7 Psychiatric disorders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1.8 Gastrointestinal disorders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1.9 Elevated liver or biliary tract enzymes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1.10 Elevated triglycerides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1.11 Anemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1.12 Leukopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1.13 Impotentia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1.14 Redness and infiltration at application site</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.2 Complete response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">IFN‐α + acitretin versus IFN‐α + PUVA</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/references#CD008946-tbl-0024">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008946-tbl-0025"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">Topical nitrogen mustard with active transfer factor versus topical nitrogen mustard with inactivated transfer factor</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.1 Complete response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.2 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.3 Objective response rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">Topical nitrogen mustard with active transfer factor versus topical nitrogen mustard with inactivated transfer factor</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/references#CD008946-tbl-0025">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008946-tbl-0026"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">Mogamulizumab vs. Vorinostat</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.1 Objective response rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">Mogamulizumab vs. Vorinostat</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/references#CD008946-tbl-0026">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008946-tbl-0027"> <div class="table-heading"><span class="table-label">Comparison 16.</span> <span class="table-title">PUVA maintenance vs. no maintenance</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16.1 Disease‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 16.</span> <span class="table-title">PUVA maintenance vs. no maintenance</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008946.pub3/references#CD008946-tbl-0027">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD008946.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD008946-note-0018">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD008946-note-0016">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD008946-note-0017">Français</a> </li> <li class="section-language"> <a class="" href="ja#CD008946-note-0015">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD008946-note-0011">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD008946-note-0012">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD008946-note-0010">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008946\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008946\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008946\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008946\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008946\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008946\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008946\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008946\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008946\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008946\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008946\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008946\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008946\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008946\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008946\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008946\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008946\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008946\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=z6k50IFd&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008946.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008946.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD008946.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD008946.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008946.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740714929237"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008946.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740714929241"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008946.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d7aa3c9439368',t:'MTc0MDcxNDkyOS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 